TW202421790A - 工程化dna結合蛋白 - Google Patents
工程化dna結合蛋白 Download PDFInfo
- Publication number
- TW202421790A TW202421790A TW113105374A TW113105374A TW202421790A TW 202421790 A TW202421790 A TW 202421790A TW 113105374 A TW113105374 A TW 113105374A TW 113105374 A TW113105374 A TW 113105374A TW 202421790 A TW202421790 A TW 202421790A
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- fold
- sequence
- etf
- expression
- Prior art date
Links
- 102000052510 DNA-Binding Proteins Human genes 0.000 title description 27
- 108700020911 DNA-Binding Proteins Proteins 0.000 title 1
- 230000014509 gene expression Effects 0.000 description 317
- 108090000623 proteins and genes Proteins 0.000 description 316
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 293
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 270
- 210000004027 cell Anatomy 0.000 description 262
- 102000004169 proteins and genes Human genes 0.000 description 166
- 235000018102 proteins Nutrition 0.000 description 160
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 142
- 229910052725 zinc Inorganic materials 0.000 description 142
- 239000011701 zinc Substances 0.000 description 142
- 108010012809 Progranulins Proteins 0.000 description 135
- 102000019204 Progranulins Human genes 0.000 description 132
- 150000007523 nucleic acids Chemical class 0.000 description 122
- 230000027455 binding Effects 0.000 description 113
- 108090000144 Human Proteins Proteins 0.000 description 108
- 102000003839 Human Proteins Human genes 0.000 description 108
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 103
- 102000040430 polynucleotide Human genes 0.000 description 101
- 108091033319 polynucleotide Proteins 0.000 description 101
- 239000002157 polynucleotide Substances 0.000 description 101
- 108020005004 Guide RNA Proteins 0.000 description 98
- 230000001105 regulatory effect Effects 0.000 description 92
- 108060005874 Parvalbumin Proteins 0.000 description 87
- 102000001675 Parvalbumin Human genes 0.000 description 87
- 238000000034 method Methods 0.000 description 84
- 239000012634 fragment Substances 0.000 description 83
- 102000039446 nucleic acids Human genes 0.000 description 73
- 108020004707 nucleic acids Proteins 0.000 description 73
- 241000282414 Homo sapiens Species 0.000 description 70
- 230000004568 DNA-binding Effects 0.000 description 69
- 101000944074 Homo sapiens Cbp/p300-interacting transactivator 4 Proteins 0.000 description 65
- 101001049697 Homo sapiens Early growth response protein 1 Proteins 0.000 description 65
- 101000944098 Homo sapiens Cbp/p300-interacting transactivator 2 Proteins 0.000 description 61
- 101000896450 Homo sapiens Early growth response protein 3 Proteins 0.000 description 60
- 201000010099 disease Diseases 0.000 description 60
- 239000002245 particle Substances 0.000 description 60
- 102100033487 Cbp/p300-interacting transactivator 4 Human genes 0.000 description 58
- 102100033471 Cbp/p300-interacting transactivator 2 Human genes 0.000 description 56
- 230000003612 virological effect Effects 0.000 description 55
- 108091028043 Nucleic acid sequence Proteins 0.000 description 53
- 102100021717 Early growth response protein 3 Human genes 0.000 description 50
- 239000013604 expression vector Substances 0.000 description 49
- 102100023226 Early growth response protein 1 Human genes 0.000 description 48
- 102000040945 Transcription factor Human genes 0.000 description 43
- 108091023040 Transcription factor Proteins 0.000 description 43
- 241000700605 Viruses Species 0.000 description 43
- 208000035475 disorder Diseases 0.000 description 43
- 239000013598 vector Substances 0.000 description 42
- 230000035772 mutation Effects 0.000 description 40
- 101710149136 Protein Vpr Proteins 0.000 description 37
- 230000005847 immunogenicity Effects 0.000 description 37
- 238000004519 manufacturing process Methods 0.000 description 35
- 239000013612 plasmid Substances 0.000 description 34
- 210000000349 chromosome Anatomy 0.000 description 33
- 230000006870 function Effects 0.000 description 33
- 208000024891 symptom Diseases 0.000 description 31
- 238000013518 transcription Methods 0.000 description 31
- 230000035897 transcription Effects 0.000 description 31
- 238000011282 treatment Methods 0.000 description 31
- 210000003169 central nervous system Anatomy 0.000 description 30
- 206010015037 epilepsy Diseases 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 28
- 201000007547 Dravet syndrome Diseases 0.000 description 28
- 210000002569 neuron Anatomy 0.000 description 27
- 101710096438 DNA-binding protein Proteins 0.000 description 26
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 26
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 26
- 102100037632 Progranulin Human genes 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 25
- 210000002845 virion Anatomy 0.000 description 25
- 206010010904 Convulsion Diseases 0.000 description 23
- 235000001014 amino acid Nutrition 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 23
- 239000013603 viral vector Substances 0.000 description 23
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 22
- 108700019146 Transgenes Proteins 0.000 description 22
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 230000009467 reduction Effects 0.000 description 22
- 208000024827 Alzheimer disease Diseases 0.000 description 21
- 101710185494 Zinc finger protein Proteins 0.000 description 21
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 21
- 230000001965 increasing effect Effects 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 208000018737 Parkinson disease Diseases 0.000 description 20
- 125000000539 amino acid group Chemical group 0.000 description 20
- 238000003556 assay Methods 0.000 description 20
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- 238000001415 gene therapy Methods 0.000 description 19
- 239000013607 AAV vector Substances 0.000 description 18
- 208000015114 central nervous system disease Diseases 0.000 description 18
- 230000007812 deficiency Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 238000004806 packaging method and process Methods 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 17
- 108091033409 CRISPR Proteins 0.000 description 16
- 101001027324 Homo sapiens Progranulin Proteins 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 238000003018 immunoassay Methods 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 16
- 125000003729 nucleotide group Chemical group 0.000 description 16
- 230000002103 transcriptional effect Effects 0.000 description 16
- 108091026890 Coding region Proteins 0.000 description 15
- 201000011240 Frontotemporal dementia Diseases 0.000 description 15
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 15
- -1 VP64 Proteins 0.000 description 15
- 201000001320 Atherosclerosis Diseases 0.000 description 14
- 208000012902 Nervous system disease Diseases 0.000 description 14
- 238000005094 computer simulation Methods 0.000 description 14
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 14
- 108090000565 Capsid Proteins Proteins 0.000 description 13
- 102100023321 Ceruloplasmin Human genes 0.000 description 13
- 210000000234 capsid Anatomy 0.000 description 13
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 108091006106 transcriptional activators Proteins 0.000 description 13
- 241000701161 unidentified adenovirus Species 0.000 description 13
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 12
- 208000009869 Neu-Laxova syndrome Diseases 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 238000011144 upstream manufacturing Methods 0.000 description 12
- 108010067390 Viral Proteins Proteins 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 230000009437 off-target effect Effects 0.000 description 11
- 230000010076 replication Effects 0.000 description 11
- 241000702421 Dependoparvovirus Species 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 208000030159 metabolic disease Diseases 0.000 description 10
- 208000015122 neurodegenerative disease Diseases 0.000 description 10
- 230000001177 retroviral effect Effects 0.000 description 10
- 241001430294 unidentified retrovirus Species 0.000 description 10
- 230000003827 upregulation Effects 0.000 description 10
- 241000124008 Mammalia Species 0.000 description 9
- 101710114165 Progranulin Proteins 0.000 description 9
- 238000010459 TALEN Methods 0.000 description 9
- 108700009124 Transcription Initiation Site Proteins 0.000 description 9
- 206010044565 Tremor Diseases 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 8
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 8
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 8
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 8
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 8
- 238000004422 calculation algorithm Methods 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 230000004770 neurodegeneration Effects 0.000 description 8
- 239000013608 rAAV vector Substances 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 101150024624 GRN gene Proteins 0.000 description 7
- 101710163270 Nuclease Proteins 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000003623 enhancer Substances 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000010362 genome editing Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 208000000044 Amnesia Diseases 0.000 description 6
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 6
- 241000271566 Aves Species 0.000 description 6
- 241000282693 Cercopithecidae Species 0.000 description 6
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 241000713666 Lentivirus Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000006735 deficit Effects 0.000 description 6
- 230000007850 degeneration Effects 0.000 description 6
- 102000052687 human CITED4 Human genes 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 241001529453 unidentified herpesvirus Species 0.000 description 6
- 108010053770 Deoxyribonucleases Proteins 0.000 description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 description 5
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 5
- 241000238631 Hexapoda Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000026139 Memory disease Diseases 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 108010052164 Sodium Channels Proteins 0.000 description 5
- 102000018674 Sodium Channels Human genes 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000003542 behavioural effect Effects 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 208000016097 disease of metabolism Diseases 0.000 description 5
- 230000003828 downregulation Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 210000001222 gaba-ergic neuron Anatomy 0.000 description 5
- 230000003371 gabaergic effect Effects 0.000 description 5
- 238000001476 gene delivery Methods 0.000 description 5
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 5
- 208000013403 hyperactivity Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000006984 memory degeneration Effects 0.000 description 5
- 208000023060 memory loss Diseases 0.000 description 5
- 230000004973 motor coordination Effects 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 108010054624 red fluorescent protein Proteins 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 4
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 4
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 4
- 241000649045 Adeno-associated virus 10 Species 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 108091006146 Channels Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102100023227 E3 SUMO-protein ligase EGR2 Human genes 0.000 description 4
- 102100021720 Early growth response protein 4 Human genes 0.000 description 4
- 102100035857 Glutamate decarboxylase 2 Human genes 0.000 description 4
- 108060003393 Granulin Proteins 0.000 description 4
- 101001049692 Homo sapiens E3 SUMO-protein ligase EGR2 Proteins 0.000 description 4
- 101000896533 Homo sapiens Early growth response protein 4 Proteins 0.000 description 4
- 101000873786 Homo sapiens Glutamate decarboxylase 2 Proteins 0.000 description 4
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 4
- 101000658648 Homo sapiens Tetratricopeptide repeat protein 21B Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 208000010291 Primary Progressive Nonfluent Aphasia Diseases 0.000 description 4
- 101150022529 Scn1a gene Proteins 0.000 description 4
- 208000018642 Semantic dementia Diseases 0.000 description 4
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 4
- 102100034908 Tetratricopeptide repeat protein 21B Human genes 0.000 description 4
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 4
- 101150063416 add gene Proteins 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 210000005013 brain tissue Anatomy 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 102000017941 granulin Human genes 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000007913 intrathecal administration Methods 0.000 description 4
- 238000007914 intraventricular administration Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000002132 lysosomal effect Effects 0.000 description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000000626 neurodegenerative effect Effects 0.000 description 4
- 210000004498 neuroglial cell Anatomy 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 3
- 241000649046 Adeno-associated virus 11 Species 0.000 description 3
- 241000649047 Adeno-associated virus 12 Species 0.000 description 3
- 241000272525 Anas platyrhynchos Species 0.000 description 3
- 241000304886 Bacilli Species 0.000 description 3
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 3
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000645320 Homo sapiens Titin Proteins 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- 208000025966 Neurological disease Diseases 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 238000011530 RNeasy Mini Kit Methods 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 3
- 108010034546 Serratia marcescens nuclease Proteins 0.000 description 3
- 102100026260 Titin Human genes 0.000 description 3
- 108010075653 Utrophin Proteins 0.000 description 3
- 102100029092 Utrophin Human genes 0.000 description 3
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000005110 dorsal hippocampus Anatomy 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 201000008186 generalized epilepsy with febrile seizures plus Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000002977 hyperthermial effect Effects 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000004558 lewy body Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 239000003094 microcapsule Substances 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 230000037434 nonsense mutation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000003151 transfection method Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 210000005111 ventral hippocampus Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000537222 Betabaculovirus Species 0.000 description 2
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241001269524 Dura Species 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000713730 Equine infectious anemia virus Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 206010016173 Fall Diseases 0.000 description 2
- 241000713800 Feline immunodeficiency virus Species 0.000 description 2
- 108010008945 General Transcription Factors Proteins 0.000 description 2
- 102000006580 General Transcription Factors Human genes 0.000 description 2
- 102100035902 Glutamate decarboxylase 1 Human genes 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 102100030087 Homeobox protein DLX-1 Human genes 0.000 description 2
- 102100022373 Homeobox protein DLX-5 Human genes 0.000 description 2
- 101000873546 Homo sapiens Glutamate decarboxylase 1 Proteins 0.000 description 2
- 101000864690 Homo sapiens Homeobox protein DLX-1 Proteins 0.000 description 2
- 101000901627 Homo sapiens Homeobox protein DLX-5 Proteins 0.000 description 2
- 101000788669 Homo sapiens Zinc finger MYM-type protein 2 Proteins 0.000 description 2
- 101000788739 Homo sapiens Zinc finger MYM-type protein 3 Proteins 0.000 description 2
- 101000788741 Homo sapiens Zinc finger MYM-type protein 4 Proteins 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 101150111110 NKX2-1 gene Proteins 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000009572 RNA Polymerase II Human genes 0.000 description 2
- 108010009460 RNA Polymerase II Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108700005077 Viral Genes Proteins 0.000 description 2
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 2
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 2
- 102000019374 Zinc finger C2H2-type Human genes 0.000 description 2
- 108050006929 Zinc finger C2H2-type Proteins 0.000 description 2
- 102100025085 Zinc finger MYM-type protein 2 Human genes 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 201000008181 benign familial infantile epilepsy Diseases 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000009295 crossflow filtration Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013230 female C57BL/6J mice Methods 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 210000001652 frontal lobe Anatomy 0.000 description 2
- 108700004026 gag Genes Proteins 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 230000010005 growth-factor like effect Effects 0.000 description 2
- 210000000688 human artificial chromosome Anatomy 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 230000013016 learning Effects 0.000 description 2
- 230000006372 lipid accumulation Effects 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 231100000590 oncogenic Toxicity 0.000 description 2
- 230000002246 oncogenic effect Effects 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108020001580 protein domains Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 101150066583 rep gene Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000037436 splice-site mutation Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000037314 wound repair Effects 0.000 description 2
- JARGNLJYKBUKSJ-KGZKBUQUSA-N (2r)-2-amino-5-[[(2r)-1-(carboxymethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]-5-oxopentanoic acid;hydrobromide Chemical compound Br.OC(=O)[C@H](N)CCC(=O)N[C@H](CO)C(=O)NCC(O)=O JARGNLJYKBUKSJ-KGZKBUQUSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- YFKITBPVZJDOKG-NPULLEENSA-N 1-butyl-n-(2,6-dimethylphenyl)piperidine-2-carboxamide;4-[(1r)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1.CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C YFKITBPVZJDOKG-NPULLEENSA-N 0.000 description 1
- 102100038028 1-phosphatidylinositol 3-phosphate 5-kinase Human genes 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 102100032282 26S proteasome non-ATPase regulatory subunit 14 Human genes 0.000 description 1
- 102100040799 AN1-type zinc finger protein 3 Human genes 0.000 description 1
- 102100036605 AN1-type zinc finger protein 6 Human genes 0.000 description 1
- 102100022385 Activity-dependent neuroprotector homeobox protein Human genes 0.000 description 1
- 241000300529 Adeno-associated virus 13 Species 0.000 description 1
- 102000014777 Adipokines Human genes 0.000 description 1
- 108010078606 Adipokines Proteins 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 102100027878 Bardet-Biedl syndrome 5 protein Human genes 0.000 description 1
- 208000030169 Benign childhood occipital epilepsy, Panayiotopoulos type Diseases 0.000 description 1
- 102100032438 Beta-1,3-galactosyltransferase 1 Human genes 0.000 description 1
- 102100028282 Bile salt export pump Human genes 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000007774 Broca Aphasia Diseases 0.000 description 1
- 206010059027 Brugada syndrome Diseases 0.000 description 1
- 201000009707 Brugada syndrome 1 Diseases 0.000 description 1
- 208000005079 Brugada syndrome 5 Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
- 102100033849 CCHC-type zinc finger nucleic acid binding protein Human genes 0.000 description 1
- 101710116319 CCHC-type zinc finger nucleic acid binding protein Proteins 0.000 description 1
- 101150061077 CERS6 gene Proteins 0.000 description 1
- 102100021975 CREB-binding protein Human genes 0.000 description 1
- 238000010454 CRISPR gRNA design Methods 0.000 description 1
- 101710172824 CRISPR-associated endonuclease Cas9 Proteins 0.000 description 1
- 238000010453 CRISPR/Cas method Methods 0.000 description 1
- 102100036168 CXXC-type zinc finger protein 1 Human genes 0.000 description 1
- 102100036167 CXXC-type zinc finger protein 5 Human genes 0.000 description 1
- 101100011365 Caenorhabditis elegans egl-13 gene Proteins 0.000 description 1
- 101150044789 Cap gene Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 101710182302 Cbp/p300-interacting transactivator 2 Proteins 0.000 description 1
- 101710182300 Cbp/p300-interacting transactivator 4 Proteins 0.000 description 1
- 102100035434 Ceramide synthase 6 Human genes 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102100029653 Cordon-bleu protein-like 1 Human genes 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 1
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 1
- 102100031061 Cysteine/serine-rich nuclear protein 3 Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102100023586 DBF4-type zinc finger-containing protein 2 Human genes 0.000 description 1
- 101150026402 DBP gene Proteins 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 230000003682 DNA packaging effect Effects 0.000 description 1
- 101710179497 DNA replication helicase Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100040401 DNA topoisomerase 3-alpha Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102100038694 DNA-binding protein SMUBP-2 Human genes 0.000 description 1
- 102100036504 Dehydrogenase/reductase SDR family member 9 Human genes 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100321435 Dictyostelium discoideum zfand gene Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- 102100035989 E3 SUMO-protein ligase PIAS1 Human genes 0.000 description 1
- 102100030837 E3 SUMO-protein ligase PIAS3 Human genes 0.000 description 1
- 102100030987 E3 SUMO-protein ligase PIAS4 Human genes 0.000 description 1
- 102100025800 E3 SUMO-protein ligase ZBED1 Human genes 0.000 description 1
- 102100034745 E3 ubiquitin-protein ligase HERC2 Human genes 0.000 description 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 1
- 102100037237 E3 ubiquitin-protein ligase UBR3 Human genes 0.000 description 1
- 108010051542 Early Growth Response Protein 1 Proteins 0.000 description 1
- 102100023078 Early endosome antigen 1 Human genes 0.000 description 1
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 1
- 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 102100028773 Endonuclease 8-like 3 Human genes 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102100038595 Estrogen receptor Human genes 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- 102100037789 FAST kinase domain-containing protein 1, mitochondrial Human genes 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 102100037010 Fidgetin Human genes 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000003078 Generalized Epilepsy Diseases 0.000 description 1
- 229940123611 Genome editing Drugs 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100023911 Growth factor receptor-bound protein 14 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102100022557 Hepatocyte growth factor-regulated tyrosine kinase substrate Human genes 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 102100032801 Histone-lysine N-methyltransferase SMYD1 Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108700005087 Homeobox Genes Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000590281 Homo sapiens 26S proteasome non-ATPase regulatory subunit 14 Proteins 0.000 description 1
- 101000964568 Homo sapiens AN1-type zinc finger protein 3 Proteins 0.000 description 1
- 101000782083 Homo sapiens AN1-type zinc finger protein 6 Proteins 0.000 description 1
- 101000755474 Homo sapiens Activity-dependent neuroprotector homeobox protein Proteins 0.000 description 1
- 101000697666 Homo sapiens Bardet-Biedl syndrome 5 protein Proteins 0.000 description 1
- 101000798380 Homo sapiens Beta-1,3-galactosyltransferase 1 Proteins 0.000 description 1
- 101000896987 Homo sapiens CREB-binding protein Proteins 0.000 description 1
- 101000947157 Homo sapiens CXXC-type zinc finger protein 1 Proteins 0.000 description 1
- 101000947154 Homo sapiens CXXC-type zinc finger protein 5 Proteins 0.000 description 1
- 101000939779 Homo sapiens Cordon-bleu protein-like 1 Proteins 0.000 description 1
- 101000922013 Homo sapiens Cysteine/serine-rich nuclear protein 3 Proteins 0.000 description 1
- 101000976560 Homo sapiens DBF4-type zinc finger-containing protein 2 Proteins 0.000 description 1
- 101000927847 Homo sapiens DNA ligase 3 Proteins 0.000 description 1
- 101000611068 Homo sapiens DNA topoisomerase 3-alpha Proteins 0.000 description 1
- 101000665135 Homo sapiens DNA-binding protein SMUBP-2 Proteins 0.000 description 1
- 101000928746 Homo sapiens Dehydrogenase/reductase SDR family member 9 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101000583444 Homo sapiens E3 SUMO-protein ligase PIAS3 Proteins 0.000 description 1
- 101000583450 Homo sapiens E3 SUMO-protein ligase PIAS4 Proteins 0.000 description 1
- 101000786317 Homo sapiens E3 SUMO-protein ligase ZBED1 Proteins 0.000 description 1
- 101000872516 Homo sapiens E3 ubiquitin-protein ligase HERC2 Proteins 0.000 description 1
- 101001050162 Homo sapiens Early endosome antigen 1 Proteins 0.000 description 1
- 101001123819 Homo sapiens Endonuclease 8-like 3 Proteins 0.000 description 1
- 101000882584 Homo sapiens Estrogen receptor Proteins 0.000 description 1
- 101000878541 Homo sapiens FAST kinase domain-containing protein 1, mitochondrial Proteins 0.000 description 1
- 101000878296 Homo sapiens Fidgetin Proteins 0.000 description 1
- 101000904875 Homo sapiens Growth factor receptor-bound protein 14 Proteins 0.000 description 1
- 101001045469 Homo sapiens Hepatocyte growth factor-regulated tyrosine kinase substrate Proteins 0.000 description 1
- 101000708638 Homo sapiens Histone-lysine N-methyltransferase SMYD1 Proteins 0.000 description 1
- 101000998494 Homo sapiens INO80 complex subunit B Proteins 0.000 description 1
- 101001015064 Homo sapiens Integrin beta-6 Proteins 0.000 description 1
- 101001006875 Homo sapiens Kelch-like protein 23 Proteins 0.000 description 1
- 101001027192 Homo sapiens Kelch-like protein 41 Proteins 0.000 description 1
- 101000711455 Homo sapiens Kinetochore protein Spc25 Proteins 0.000 description 1
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 1
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 description 1
- 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 1
- 101000613958 Homo sapiens Lysine-specific demethylase 2A Proteins 0.000 description 1
- 101000613960 Homo sapiens Lysine-specific histone demethylase 1B Proteins 0.000 description 1
- 101001028659 Homo sapiens MORC family CW-type zinc finger protein 1 Proteins 0.000 description 1
- 101000687968 Homo sapiens Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Proteins 0.000 description 1
- 101001027925 Homo sapiens Metastasis-associated protein MTA1 Proteins 0.000 description 1
- 101000581507 Homo sapiens Methyl-CpG-binding domain protein 1 Proteins 0.000 description 1
- 101000957437 Homo sapiens Mitochondrial carnitine/acylcarnitine carrier protein Proteins 0.000 description 1
- 101000583839 Homo sapiens Muscleblind-like protein 1 Proteins 0.000 description 1
- 101000583016 Homo sapiens Myosin-IIIb Proteins 0.000 description 1
- 101000708645 Homo sapiens N-lysine methyltransferase SMYD2 Proteins 0.000 description 1
- 101000973618 Homo sapiens NF-kappa-B essential modulator Proteins 0.000 description 1
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 1
- 101001109700 Homo sapiens Nuclear receptor subfamily 4 group A member 1 Proteins 0.000 description 1
- 101001071233 Homo sapiens PHD finger protein 1 Proteins 0.000 description 1
- 101100174573 Homo sapiens PIKFYVE gene Proteins 0.000 description 1
- 101000915562 Homo sapiens Palmitoyltransferase ZDHHC2 Proteins 0.000 description 1
- 101000976669 Homo sapiens Palmitoyltransferase ZDHHC8 Proteins 0.000 description 1
- 101001098517 Homo sapiens Paxillin Proteins 0.000 description 1
- 101001091194 Homo sapiens Peptidyl-prolyl cis-trans isomerase G Proteins 0.000 description 1
- 101001131990 Homo sapiens Peroxidasin homolog Proteins 0.000 description 1
- 101000890327 Homo sapiens Peroxynitrite isomerase THAP4 Proteins 0.000 description 1
- 101000886179 Homo sapiens Polypeptide N-acetylgalactosaminyltransferase 3 Proteins 0.000 description 1
- 101001067140 Homo sapiens Porphobilinogen deaminase Proteins 0.000 description 1
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- 101000952097 Homo sapiens Probable ATP-dependent RNA helicase DDX59 Proteins 0.000 description 1
- 101001083769 Homo sapiens Probable helicase with zinc finger domain Proteins 0.000 description 1
- 101000611939 Homo sapiens Programmed cell death protein 2 Proteins 0.000 description 1
- 101000884614 Homo sapiens Protein CFAP210 Proteins 0.000 description 1
- 101000721172 Homo sapiens Protein DBF4 homolog A Proteins 0.000 description 1
- 101000721176 Homo sapiens Protein DBF4 homolog B Proteins 0.000 description 1
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 1
- 101001071164 Homo sapiens Pyridoxal phosphate phosphatase PHOSPHO2 Proteins 0.000 description 1
- 101001079872 Homo sapiens RING finger protein 112 Proteins 0.000 description 1
- 101000668165 Homo sapiens RNA-binding motif, single-stranded-interacting protein 1 Proteins 0.000 description 1
- 101100078258 Homo sapiens RUNX1T1 gene Proteins 0.000 description 1
- 101000857634 Homo sapiens Receptor-transporting protein 1 Proteins 0.000 description 1
- 101000635777 Homo sapiens Receptor-transporting protein 4 Proteins 0.000 description 1
- 101000742854 Homo sapiens Roquin-1 Proteins 0.000 description 1
- 101000701497 Homo sapiens STE20/SPS1-related proline-alanine-rich protein kinase Proteins 0.000 description 1
- 101001126009 Homo sapiens Secretory phospholipase A2 receptor Proteins 0.000 description 1
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 description 1
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 description 1
- 101000694025 Homo sapiens Sodium channel protein type 7 subunit alpha Proteins 0.000 description 1
- 101000864761 Homo sapiens Splicing factor 1 Proteins 0.000 description 1
- 101000585255 Homo sapiens Steroidogenic factor 1 Proteins 0.000 description 1
- 101000661816 Homo sapiens Suppression of tumorigenicity 18 protein Proteins 0.000 description 1
- 101000595526 Homo sapiens T-box brain protein 1 Proteins 0.000 description 1
- 101000890301 Homo sapiens THAP domain-containing protein 1 Proteins 0.000 description 1
- 101000596543 Homo sapiens THAP domain-containing protein 11 Proteins 0.000 description 1
- 101000819074 Homo sapiens Transcription factor GATA-4 Proteins 0.000 description 1
- 101000819088 Homo sapiens Transcription factor GATA-6 Proteins 0.000 description 1
- 101000845264 Homo sapiens Transcription termination factor 2 Proteins 0.000 description 1
- 101000791652 Homo sapiens YY1-associated factor 2 Proteins 0.000 description 1
- 101000786321 Homo sapiens Zinc finger BED domain-containing protein 4 Proteins 0.000 description 1
- 101000786335 Homo sapiens Zinc finger BED domain-containing protein 6 Proteins 0.000 description 1
- 101000788823 Homo sapiens Zinc finger CW-type PWWP domain protein 1 Proteins 0.000 description 1
- 101000785626 Homo sapiens Zinc finger E-box-binding homeobox 1 Proteins 0.000 description 1
- 101000915578 Homo sapiens Zinc finger HIT domain-containing protein 3 Proteins 0.000 description 1
- 101000802348 Homo sapiens Zinc finger SWIM domain-containing protein 5 Proteins 0.000 description 1
- 101000802350 Homo sapiens Zinc finger SWIM domain-containing protein 6 Proteins 0.000 description 1
- 101000723887 Homo sapiens Zinc finger matrin-type protein 1 Proteins 0.000 description 1
- 101000723893 Homo sapiens Zinc finger matrin-type protein 3 Proteins 0.000 description 1
- 101000915491 Homo sapiens Zinc finger matrin-type protein 5 Proteins 0.000 description 1
- 101000744882 Homo sapiens Zinc finger protein 185 Proteins 0.000 description 1
- 101000785710 Homo sapiens Zinc finger protein 281 Proteins 0.000 description 1
- 101000760284 Homo sapiens Zinc finger protein 32 Proteins 0.000 description 1
- 101000782294 Homo sapiens Zinc finger protein 638 Proteins 0.000 description 1
- 101000760275 Homo sapiens Zinc finger protein 746 Proteins 0.000 description 1
- 101000802329 Homo sapiens Zinc finger protein 750 Proteins 0.000 description 1
- 101000857270 Homo sapiens Zinc finger protein GLIS1 Proteins 0.000 description 1
- 101000857276 Homo sapiens Zinc finger protein GLIS3 Proteins 0.000 description 1
- 101000633054 Homo sapiens Zinc finger protein SNAI2 Proteins 0.000 description 1
- 101000788690 Homo sapiens Zinc fingers and homeoboxes protein 1 Proteins 0.000 description 1
- 101000744862 Homo sapiens Zygote arrest protein 1 Proteins 0.000 description 1
- 101000795753 Homo sapiens mRNA decay activator protein ZFP36 Proteins 0.000 description 1
- 101000802094 Homo sapiens mRNA decay activator protein ZFP36L1 Proteins 0.000 description 1
- 101001012529 Homo sapiens rRNA N6-adenosine-methyltransferase METTL5 Proteins 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000714192 Human spumaretrovirus Species 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 108010044240 IFIH1 Interferon-Induced Helicase Proteins 0.000 description 1
- 102100033278 INO80 complex subunit B Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003781 Inhibitor of growth protein 1 Human genes 0.000 description 1
- 108090000191 Inhibitor of growth protein 1 Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100033011 Integrin beta-6 Human genes 0.000 description 1
- 102100027353 Interferon-induced helicase C domain-containing protein 1 Human genes 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 1
- 102100027795 Kelch-like protein 23 Human genes 0.000 description 1
- 102100037644 Kelch-like protein 41 Human genes 0.000 description 1
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 1
- 102100020680 Krueppel-like factor 5 Human genes 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102100026023 LIM domain kinase 1 Human genes 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 102100030657 Lethal(3)malignant brain tumor-like protein 1 Human genes 0.000 description 1
- 101710173086 Lethal(3)malignant brain tumor-like protein 1 Proteins 0.000 description 1
- 102100033284 Leucine-rich repeats and immunoglobulin-like domains protein 3 Human genes 0.000 description 1
- 102100022742 Lupus La protein Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102100040598 Lysine-specific demethylase 2A Human genes 0.000 description 1
- 102100040596 Lysine-specific histone demethylase 1B Human genes 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 102100037200 MORC family CW-type zinc finger protein 1 Human genes 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- NLSTZAFFNDSJGQ-UHFFFAOYSA-N Matrin Natural products O=C1CCCN2CC3CCNC4CCCC(C34)C12 NLSTZAFFNDSJGQ-UHFFFAOYSA-N 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 108010093662 Member 11 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 102100024262 Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Human genes 0.000 description 1
- 102100037517 Metastasis-associated protein MTA1 Human genes 0.000 description 1
- 102100027383 Methyl-CpG-binding domain protein 1 Human genes 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 102100038738 Mitochondrial carnitine/acylcarnitine carrier protein Human genes 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 102100030965 Muscleblind-like protein 1 Human genes 0.000 description 1
- 102100031623 Myelin transcription factor 1-like protein Human genes 0.000 description 1
- 102100030369 Myosin-IIIb Human genes 0.000 description 1
- 101150059596 Myt1l gene Proteins 0.000 description 1
- 102100032806 N-lysine methyltransferase SMYD2 Human genes 0.000 description 1
- 102100022219 NF-kappa-B essential modulator Human genes 0.000 description 1
- 101150011840 NOSTRIN gene Proteins 0.000 description 1
- 102100037001 Next to BRCA1 gene 1 protein Human genes 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 102100039030 Nostrin Human genes 0.000 description 1
- 102100022679 Nuclear receptor subfamily 4 group A member 1 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102100036879 PHD finger protein 1 Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 102100028614 Palmitoyltransferase ZDHHC2 Human genes 0.000 description 1
- 102100023491 Palmitoyltransferase ZDHHC8 Human genes 0.000 description 1
- 102100023498 Palmitoyltransferase ZDHHC9 Human genes 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000032461 Panayiotopoulos type benign childhood occipital epilepsy Diseases 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 206010061334 Partial seizures Diseases 0.000 description 1
- 102100034850 Peptidyl-prolyl cis-trans isomerase G Human genes 0.000 description 1
- 102100034601 Peroxidasin homolog Human genes 0.000 description 1
- 102100040041 Peroxynitrite isomerase THAP4 Human genes 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 101710093976 Plasmid-derived single-stranded DNA-binding protein Proteins 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 102100039685 Polypeptide N-acetylgalactosaminyltransferase 3 Human genes 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 1
- 102100037436 Probable ATP-dependent RNA helicase DDX59 Human genes 0.000 description 1
- 102100031018 Probable helicase with zinc finger domain Human genes 0.000 description 1
- 102100040676 Programmed cell death protein 2 Human genes 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 102100024952 Protein CBFA2T1 Human genes 0.000 description 1
- 102100038136 Protein CFAP210 Human genes 0.000 description 1
- 102100025198 Protein DBF4 homolog A Human genes 0.000 description 1
- 102100025199 Protein DBF4 homolog B Human genes 0.000 description 1
- 108010038241 Protein Inhibitors of Activated STAT Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037213 Psychomotor retardation Diseases 0.000 description 1
- 102100025793 Putative sodium-coupled neutral amino acid transporter 11 Human genes 0.000 description 1
- 102100036843 Pyridoxal phosphate phosphatase PHOSPHO2 Human genes 0.000 description 1
- 102100028089 RING finger protein 112 Human genes 0.000 description 1
- 230000007022 RNA scission Effects 0.000 description 1
- 102100039692 RNA-binding motif, single-stranded-interacting protein 1 Human genes 0.000 description 1
- 102000004229 RNA-binding protein EWS Human genes 0.000 description 1
- 108090000740 RNA-binding protein EWS Proteins 0.000 description 1
- 108700040655 RUNX1 Translocation Partner 1 Proteins 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 102100025426 Receptor-transporting protein 1 Human genes 0.000 description 1
- 102100030854 Receptor-transporting protein 4 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 102100038043 Roquin-1 Human genes 0.000 description 1
- 101150057235 SCN1B gene Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 108091006931 SLC38A11 Proteins 0.000 description 1
- 108091006265 SLC4A10 Proteins 0.000 description 1
- 102100030491 STE20/SPS1-related proline-alanine-rich protein kinase Human genes 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102100029392 Secretory phospholipase A2 receptor Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100022332 Sharpin Human genes 0.000 description 1
- 102100023776 Signal peptidase complex subunit 2 Human genes 0.000 description 1
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 description 1
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 description 1
- 102100027190 Sodium channel protein type 7 subunit alpha Human genes 0.000 description 1
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 101100166144 Staphylococcus aureus cas9 gene Proteins 0.000 description 1
- 102100029856 Steroidogenic factor 1 Human genes 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102100037943 Suppression of tumorigenicity 18 protein Human genes 0.000 description 1
- 206010042602 Supraventricular extrasystoles Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- 102000001435 Synapsin Human genes 0.000 description 1
- 102100036083 T-box brain protein 1 Human genes 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 102100040045 THAP domain-containing protein 1 Human genes 0.000 description 1
- 102100035063 THAP domain-containing protein 11 Human genes 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100021380 Transcription factor GATA-4 Human genes 0.000 description 1
- 102100021382 Transcription factor GATA-6 Human genes 0.000 description 1
- 102100031080 Transcription termination factor 2 Human genes 0.000 description 1
- 101150008036 UL29 gene Proteins 0.000 description 1
- 101150011902 UL52 gene Proteins 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 108091034131 VA RNA Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000713325 Visna/maedi virus Species 0.000 description 1
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 102100027644 YY1-associated factor 2 Human genes 0.000 description 1
- 108091009220 ZDHHC9 Proteins 0.000 description 1
- 101150069236 ZNF148 gene Proteins 0.000 description 1
- 102100025788 Zinc finger BED domain-containing protein 4 Human genes 0.000 description 1
- 102100025792 Zinc finger BED domain-containing protein 6 Human genes 0.000 description 1
- 102100025363 Zinc finger CW-type PWWP domain protein 1 Human genes 0.000 description 1
- 102100026457 Zinc finger E-box-binding homeobox 1 Human genes 0.000 description 1
- 102100028598 Zinc finger HIT domain-containing protein 3 Human genes 0.000 description 1
- 102100025417 Zinc finger MYM-type protein 3 Human genes 0.000 description 1
- 102100025418 Zinc finger MYM-type protein 4 Human genes 0.000 description 1
- 102100034655 Zinc finger SWIM domain-containing protein 5 Human genes 0.000 description 1
- 102100034685 Zinc finger SWIM domain-containing protein 6 Human genes 0.000 description 1
- 102100028499 Zinc finger matrin-type protein 1 Human genes 0.000 description 1
- 102100028482 Zinc finger matrin-type protein 3 Human genes 0.000 description 1
- 102100028542 Zinc finger matrin-type protein 5 Human genes 0.000 description 1
- 102100023442 Zinc finger protein 148 Human genes 0.000 description 1
- 102100040032 Zinc finger protein 185 Human genes 0.000 description 1
- 102100026316 Zinc finger protein 281 Human genes 0.000 description 1
- 102100024703 Zinc finger protein 32 Human genes 0.000 description 1
- 102100035806 Zinc finger protein 638 Human genes 0.000 description 1
- 102100024714 Zinc finger protein 746 Human genes 0.000 description 1
- 102100034644 Zinc finger protein 750 Human genes 0.000 description 1
- 102100025883 Zinc finger protein GLIS1 Human genes 0.000 description 1
- 102100025879 Zinc finger protein GLIS3 Human genes 0.000 description 1
- 102100029570 Zinc finger protein SNAI2 Human genes 0.000 description 1
- 102100025105 Zinc fingers and homeoboxes protein 1 Human genes 0.000 description 1
- 102100040034 Zygote arrest protein 1 Human genes 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000478 adipokine Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229940120606 bupivacaine / epinephrine Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 231100000870 cognitive problem Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 208000021723 developmental and epileptic encephalopathy 11 Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000026502 entry into host cell Effects 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000007830 familial atrial fibrillation Diseases 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 108010044804 gamma-glutamyl-seryl-glycine Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 208000013069 generalized epilepsy with febrile seizures plus 1 Diseases 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000005099 host tropism Effects 0.000 description 1
- 102000049589 human SCN1A Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 101150111214 lin-28 gene Proteins 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 102100031622 mRNA decay activator protein ZFP36 Human genes 0.000 description 1
- 102100034702 mRNA decay activator protein ZFP36L1 Human genes 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 208000024191 minimally invasive lung adenocarcinoma Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- YIEDSISPYKQADU-UHFFFAOYSA-N n-acetyl-n-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]acetamide Chemical compound C1=C(C)C(N(C(C)=O)C(=O)C)=CC=C1N=NC1=CC=CC=C1C YIEDSISPYKQADU-UHFFFAOYSA-N 0.000 description 1
- 238000001728 nano-filtration Methods 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000012223 nuclear import Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 229920000724 poly(L-arginine) polymer Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 210000002763 pyramidal cell Anatomy 0.000 description 1
- 102100029739 rRNA N6-adenosine-methyltransferase METTL5 Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000005912 ran GTP Binding Protein Human genes 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000037425 regulation of transcription Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 102220032656 rs63749817 Human genes 0.000 description 1
- 102220032637 rs63749844 Human genes 0.000 description 1
- 102220032688 rs63749908 Human genes 0.000 description 1
- 102220005585 rs63750077 Human genes 0.000 description 1
- 102220032677 rs63750118 Human genes 0.000 description 1
- 102220005587 rs63750331 Human genes 0.000 description 1
- 102220032667 rs63750707 Human genes 0.000 description 1
- 102220032668 rs63750926 Human genes 0.000 description 1
- 102220005586 rs63751006 Human genes 0.000 description 1
- 102220032666 rs63751177 Human genes 0.000 description 1
- 102220032681 rs63751180 Human genes 0.000 description 1
- 102220032675 rs63751213 Human genes 0.000 description 1
- 102220005591 rs63751294 Human genes 0.000 description 1
- 102220057738 rs730881360 Human genes 0.000 description 1
- 102220285550 rs730881360 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 108010088972 sharpin Proteins 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 125000004436 sodium atom Chemical group 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000027765 speech disease Diseases 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 208000028325 tonic-clonic seizure Diseases 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 108091008023 transcriptional regulators Proteins 0.000 description 1
- 230000037426 transcriptional repression Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 101150113424 ubr3 gene Proteins 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 102000009310 vitamin D receptors Human genes 0.000 description 1
- 108050000156 vitamin D receptors Proteins 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本文提供包含調節內源性基因之表現之非天然存在之DNA結合蛋白的組合物及其使用方法。
Description
大範圍之人類疾病與基因之異常表現相關。在一些情況下,基因中之基因突變使其失調、下調或根本不表現,導致單倍不足。在一些情況下,基因中之基因突變使其上調,導致基因之過度表現。治療遺傳病症或疾病中存在許多挑戰。一種方法為基因療法,其涉及將核酸治療性遞送至患者之細胞中。然而,與基因療法相關之各種挑戰仍未解決,諸如由基因療法引發之非所需免疫反應、脫靶效應、基因療法媒劑(例如病毒)之選殖容量限制、經較長時段維持治療效應等。中樞神經系統(CNS)為開發解決基因及/或蛋白質表現之潛在障礙的療法帶來許多獨特挑戰。儘管存在幫助管理CNS疾病/病症之症狀的藥物,但許多CNS疾病/病症(例如德拉韋症候群(Dravet syndrome)或額顳葉型癡呆)仍缺乏特定治療或治癒。因此,需要能夠調節任何內源性基因之表現以幫助逆轉疾病或病症之效應的新穎組合物及方法,特定言之,具有降低之免疫原性、減少之脫靶效應、增加之針對靶基因之特異性及/或增加之治療功效的療法。
在一個態樣中,本申請提供包含編碼非天然存在之轉錄因子之序列的表現卡匣,該轉錄因子增加SCN1A基因在細胞中之表現。在某些實施例中,增加SCN1A之表現的轉錄因子結合至能夠在轉錄活化分析中增加SCN1A表現至少20%之標靶位點。在某些實施例中,增加SCN1A之表現的轉錄因子能夠在高熱癲癇分析中降低德拉韋症候群小鼠模型之癲癇頻率至少20%。在某些實施例中,增加SCN1A之表現的轉錄因子結合至能夠在轉錄活化分析中增加SCN1A表現至少20%之標靶位點且轉錄因子能夠在高熱癲癇分析中降低德拉韋症候群小鼠模型之癲癇頻率至少20%。
在某些實施例中,增加SCN1A之表現的轉錄因子結合至染色體2上之基因組位置。在某些實施例中,增加SCN1A之表現的轉錄因子結合至在SCN1A基因之轉錄起始位點上游或下游110 kb內的染色體2上之基因組位置。在某些實施例中,增加SCN1A之表現的轉錄因子結合至在位置166179652-165989571 (參看GRCh38.p12)內的染色體2上之基因組位置。在某些實施例中,增加SCN1A之表現的轉錄因子結合至在位置166128050-166127958 (參看GRCh38.p12)內的染色體2上之基因組位置。在某些實施例中,增加SCN1A之表現的轉錄因子結合至在位置166155414-166140590 (參看GRCh38.p12)內的染色體2上之基因組位置。在某些實施例中,增加SCN1A之表現的轉錄因子結合至在位置166179652-1661777272 (參看GRCh38.p12)內的染色體2上之基因組位置。在某些實施例中,增加SCN1A之表現的轉錄因子結合至在位置1659990246-165989592 (參看GRCh38.p12)內的染色體2上之基因組位置。在某些實施例中,增加SCN1A之表現的轉錄因子結合至在具有SEQ ID NO: 35-37、105-111、136、195-211、224-238、240-267中之任一者之序列之基因組位置之200 bp內的基因組區域。在某些實施例中,增加SCN1A之表現的轉錄因子結合至與具有SEQ ID NO: 35-37、105-111、136、195-211、224-238、240-267中之任一者之序列的基因組位置至少部分重疊之基因組區域。在某些實施例中,增加SCN1A之表現的轉錄因子結合至具有SEQ ID NO: 35-37、105-111、136、195-211、224-238、240-267中之任一者之序列的基因組區域。在某些實施例中,增加SCN1A之表現的轉錄因子結合至具有18-27個核苷酸(例如至少12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29或30個核苷酸)之基因組區域。
在某些實施例中,增加SCN1A之表現的轉錄因子包含DNA結合域。在某些實施例中,增加SCN1A之表現的轉錄因子包含DNA結合域及轉錄活化域。在某些實施例中,DNA結合域包含與其最接近人類對應物之至少80%序列一致性。在某些實施例中,DNA結合域包含與其最接近人類對應物之至少90%序列一致性。在某些實施例中,DNA結合域及轉錄活化域均包含與其最接近人類對應物之至少80%序列一致性。在某些實施例中,DNA結合域及轉錄活化域均包含與其最接近人類對應物之至少90%序列一致性。在某些實施例中,DNA結合域包含嚮導RNA及核酸酶不活化Cas蛋白。在某些實施例中,核酸酶不活化Cas蛋白為核酸酶不活化Cas9。在某些實施例中,DNA結合域包含鋅指域。在某些實施例中,DNA結合域包含六至九個鋅指域。在某些實施例中,DNA結合域包含六個鋅指。在某些實施例中,包含六個指之DNA結合域結合至具有18個核苷酸之基因組區域。在某些實施例中,DNA結合域包含九個鋅指。在某些實施例中,包含九個鋅指之DNA結合域結合至具有27個核苷酸之基因組區域。在某些實施例中,DNA結合域包含與SEQ ID NO: 135、371、372或376中之任一者具有至少95%序列一致性之序列。在某些實施例中,DNA結合域包含具有SEQ ID NO: 135、371、372或376中之任一者之序列。在某些實施例中,DNA結合域衍生自人類EGR1或人類EGR3。在某些實施例中,轉錄活化域包含VPR、VP64、CITED2或CITED4序列,或其功能片段。在某些實施例中,轉錄活化域包含人類CITED2或CITED4序列,或其功能片段。
在某些實施例中,編碼增加SCN1A之表現之轉錄因子的表現卡匣進一步包含相比於在其他細胞類型中,在PV神經元中以更高水準驅動轉錄因子表現之調節元件。在某些實施例中,調節元件包含具有SEQ ID NO: 183、184、185或417中之任一者的序列。在某些實施例中,調節元件包含具有SEQ ID NO: 183或185之序列。
在某些實施例中,編碼增加SCN1A之表現之轉錄因子的表現卡匣為病毒載體之一部分。在某些實施例中,病毒載體為AAV病毒。在某些實施例中,AAV病毒為AAV9病毒或scAAV9病毒。
在另一態樣中,本申請案提供增加SCN1A於細胞中之表現的方法,其藉由投與編碼增加SCN1A之表現之轉錄因子的本文所述之表現卡匣中之任一者。在某些實施例中,細胞為PV神經元。在某些實施例中,細胞在個體內。在某些實施例中,個體為哺乳動物。在某些實施例中,個體為人類。在某些實施例中,增加SCN1A之表現治療疾病、病症或症狀。在某些實施例中,病症為中樞神經系統病症。在某些實施例中,病症為德拉韋症候群。在某些實施例中,中樞神經系統病症為神經元機能亢進。在某些實施例中,治療中樞神經系統病症包含降低神經元機能亢進。在某些實施例中,中樞神經系統病症之症狀為癲癇。在某些實施例中,治療中樞神經系統病症包含降低癲癇頻率。在某些實施例中,治療中樞神經系統病症包含降低癲癇嚴重度。在某些實施例中,治療中樞神經系統病症包含降低癲癇嚴重度及頻率。
在另一態樣中,本申請提供包含編碼非天然存在之轉錄因子之序列的表現卡匣,該轉錄因子增加GRN基因在細胞中之表現。
在某些實施例中,增加GRN之表現的轉錄因子結合至具有18-27個核苷酸之基因組區域。
在某些實施例中,增加GRN之表現的轉錄因子包含DNA結合域。在某些實施例中,增加GRN之表現的轉錄因子包含DNA結合域及轉錄活化域。在某些實施例中,DNA結合域包含嚮導RNA及核酸酶不活化Cas蛋白。在某些實施例中,核酸酶不活化Cas蛋白為核酸酶不活化Cas9。在某些實施例中,DNA結合域包含鋅指域。在某些實施例中,DNA結合域包含六至九個鋅指域。在某些實施例中,DNA結合域包含六個鋅指。在某些實施例中,包含六個鋅指之DNA結合域結合至具有18個核苷酸之基因組區域。在某些實施例中,DNA結合域包含九個鋅指。在某些實施例中,包含九個鋅指之DNA結合域結合至具有27個核苷酸之基因組區域。在某些實施例中,DNA結合域包含與SEQ ID NO: 171或412-416中之任一者具有至少95%序列一致性之序列。在某些實施例中,DNA結合域包含具有SEQ ID NO: 171或412-416中之任一者之序列。在某些實施例中,DNA結合域衍生自人類EGR1或人類EGR3。在某些實施例中,轉錄活化域包含VPR、VP64、CITED2或CITED4序列,或其功能片段。
在某些實施例中,編碼增加GRN之表現之轉錄因子的表現卡匣進一步包含驅動非天然存在之轉錄調節子之表現的調節元件。在某些實施例中,調節元件為細胞類型選擇性調節元件。
在某些實施例中,編碼增加GRN之表現之轉錄因子的表現卡匣為病毒載體之一部分。在某些實施例中,病毒載體為AAV病毒。在某些實施例中,AAV病毒為AAV9病毒或scAAV9病毒。
在另一態樣中,本申請提供增加GRN於細胞中之表現的方法,其藉由投與編碼增加GRN之表現之轉錄因子的本文所述之表現卡匣中之任一者。在某些實施例中,增加GRN之表現治療疾病、病症或症狀。在某些實施例中,細胞在個體內。在某些實施例中,個體為哺乳動物。在某些實施例中,個體為人類。在某些實施例中,細胞選自由以下組成之群:中樞神經系統細胞、額葉皮層細胞、神經膠細胞、微神經膠細胞及紋狀體細胞。在某些實施例中,調節GRN之表現治療疾病或病症。在某些實施例中,病症為中樞神經系統病症。在某些實施例中,病症為額顳葉型變性(FTD)、帕金森氏病(Parkinson's disease)、阿茲海默氏症(Alzheimer's disease)或動脈粥樣硬化。在某些實施例中,中樞神經系統病症之症狀為路易體(Lewy body)之存在、顆粒蛋白前體(GRN)單倍不足、社交缺陷、溶酶體異常、記憶喪失、運動協調喪失或肌震顫。在某些實施例中,治療中樞神經系統病症包含降低肌震顫頻率及/或減輕肌震顫之嚴重度。
在另一態樣中,本申請案提供編碼非天然存在之DNA結合蛋白之表現卡匣,該DNA結合蛋白包含有包含三個或超過三個DNA結合域之DNA結合域,其中DNA結合蛋白以至少5倍之因數增加或抑制內源性基因之表現,且其中DNA結合蛋白與其最接近人類對應物具有90%或更大序列一致性。在例示性實施例中,DNA結合域包含三個或超過三個鋅指域。
在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白結合至人類對應物蛋白質不天然地結合之人類基因組中之標靶位點。在某些實施例中,人類對應物為EGR1。在某些實施例中,人類對應物為EGR3。在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白包含至少6個鋅指域。在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白包含9個鋅指域。在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合域包含一或多個鋅指域之識別螺旋之位置-1、2、3或6處之至少一個胺基酸取代。在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白包含一或多個衍生自EGR1或EGR3之鋅指域。
在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白進一步包含轉錄效應子域。在某些實施例中,轉錄效應子域衍生自CITED2或CITED4。在某些實施例中,轉錄效應子域安置於DNA結合蛋白中之DNA結合域之C端。在某些實施例中,效應子域安置於DNA結合蛋白中之DNA結合域之N端。在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白包含安置於DNA結合蛋白中之DNA結合域之N端的效應子域及安置於DNA結合蛋白中之DNA結合域之C端的效應子域。
在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白識別18 bp或更長的標靶結合位點。在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白識別27 bp之標靶結合位點。
在某些實施例中,編碼與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白的表現卡匣進一步包含細胞類型選擇性調節元件。在某些實施例中,編碼與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白的表現卡匣進一步包含相比於在其他細胞類型中,在PV神經元中以更高水準驅動DNA結合蛋白表現之調節元件。在某些實施例中,調節元件包含具有SEQ ID NO: 183、184、185或417中之任一者的序列。在某些實施例中,調節元件包含具有SEQ ID NO: 183或185之序列。
在某些實施例中,編碼與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白的表現卡匣在病毒載體中。在某些實施例中,病毒載體為AAV。在某些實施例中,AAV為AAV9或scAAV9。
在另一態樣中,本申請案提供治療疾病或病況之方法,該方法包含投與基因療法,該基因療法包含編碼與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白的本文提供之任何表現卡匣。在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白當表現於細胞中或活體內時引發減小或極小的免疫反應。在某些實施例中,細胞在個體內。在某些實施例中,個體為哺乳動物。在某些實施例中,個體為人類。在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白增加內源性SCN1A之表現。在某些實施例中,細胞為PV神經元。在某些實施例中,增加SCN1A之表現治療疾病、病症或症狀。在某些實施例中,病症為中樞神經系統病症。在某些實施例中,病症為德拉韋症候群。在某些實施例中,中樞神經系統病症為神經元機能亢進。在某些實施例中,治療中樞神經系統病症包含降低神經元機能亢進。在某些實施例中,中樞神經系統病症之症狀為癲癇。在某些實施例中,治療中樞神經系統病症包含降低癲癇頻率。在某些實施例中,治療中樞神經系統病症包含降低癲癇嚴重度。在某些實施例中,治療中樞神經系統病症包含降低癲癇嚴重度及頻率。在某些實施例中,與其最接近人類對應物具有90%或更大序列一致性之DNA結合蛋白增加內源性GRN之表現。在某些實施例中,細胞選自由以下組成之群:中樞神經系統細胞、額葉皮層細胞、神經膠細胞、微神經膠細胞及紋狀體細胞。在某些實施例中,調節GRN之表現治療疾病或病症。在某些實施例中,病症為中樞神經系統病症。在某些實施例中,病症為額顳葉型變性(FTD)、帕金森氏病、阿茲海默氏症或動脈粥樣硬化。在某些實施例中,中樞神經系統病症之症狀為路易體之存在、顆粒蛋白前體(GRN)單倍不足、社交缺陷、溶酶體異常、記憶喪失、運動協調喪失或肌震顫。在某些實施例中,治療中樞神經系統病症包含降低肌震顫頻率及/或減輕肌震顫之嚴重度。
以引用的方式併入
本說明書中所提及之所有公開案、專利及專利申請案均以引用的方式併入本文中,其引用的程度如各個別公開案、專利或專利申請案經特定及個別地指示以引用的方式併入一般。
交叉引用
本申請案主張2017年12月1日申請之美國臨時專利申請案第62/593,824號;2017年12月22日申請之美國臨時專利申請案第62/610,014號;2018年3月21日申請之美國臨時專利申請案第62/646,198號;2018年1月18日申請之美國臨時專利申請案第62/618,966號;2018年3月12日申請之美國臨時專利申請案第62/641,806號;2018年4月30日申請之美國臨時專利申請案第62/664,814號;及2018年4月30日申請之美國臨時專利申請案第62/664,817號之權益,其各自以全文引用的方式併入本文中。
序列表
本申請案含有序列表,該序列表已以ASCII格式、以電子方式提交且以全文引用的方式併入本文中。該ASCII複本於2018年11月29日創建,命名為46482-711_851_SL.txt且大小為858,523個位元組。
本文提供工程化轉錄因子,或eTF,其為非天然存在的且已經設計以結合至基因組標靶位點且調節所關注之內源性基因之表現。此類eTF可經設計以上調或下調所關注之基因之表現(RNA及/或蛋白質表現)。
在一個態樣中,本申請案提供能夠上調鈉電壓門控通道α次單位1 (SCN1A)基因之表現及增加其對應蛋白質產物Nav1.1之表現的eTF及其用於治療與Nav1.1缺乏相關之疾病或病症(諸如德拉韋症候群)的使用方法。
在另一態樣中,本申請案提供能夠上調顆粒蛋白前體(GRN)基因之表現及增加GRN蛋白質之表現的eTF及其用於治療與GRN缺乏相關之疾病或病症(諸如額顳葉型癡呆(FTD))的使用方法。
在另一態樣中,本申請案提供與人類蛋白質具有高序列一致性百分比之eTF,其可經設計以結合至基因組標靶位點且調節任何所關注之基因(包括例如SCN1A或GRN)之表現(上調或下調)。此類eTF當向個體投與時具有極小至無免疫原性或相比於與人類蛋白質序列具有較低百分比一致性之eTF具有降低的免疫原性。
定義
如本文所使用,除非上下文另外清楚地指示,否則單數形式「一(a/an)」及「該」意欲亦包括複數形式。此外,就實施方式及/或申請專利範圍中使用術語「包括(including)」、「包括(includes)」、「具有(having)」、「具有(has)」、「具有(with)」或其變化形式之程度而言,此類術語意欲以類似於術語「包含」之方式為包括性的。
術語「約」或「大致」意謂在如藉由一般熟習此項技術者所測定的對於特定值可接受之誤差範圍內,其將部分取決於如何量測或測定該值,亦即量測系統之限度。舉例而言,根據此項技術中之實踐,「約」可意謂在1或大於1個標準偏差內。或者,「約」可意謂既定值之至多20%、至多15%、至多10%、至多5%或至多1%之範圍。
術語「測定」、「量測」、「評估(evaluating)」、「評估(assessing)」、「分析(assaying)」、「分析(analyzing)」及其文法等效物可在本文中互換地使用以指任何量測形式,且包括確定要素是否存在(例如偵測)。此等術語可包括定量及/或定性測定兩者。評估可為相對或絕對的。
術語「表現」係指核酸序列或聚核苷酸自DNA模板轉錄(諸如轉錄為mRNA或其他RNA轉錄物)之方法及/或經轉錄之mRNA隨後轉譯為肽、多肽或蛋白質之方法。轉錄物及編碼多肽可統稱為「基因產物」。若聚核苷酸衍生自基因組DNA,則表現可包括真核細胞中mRNA之剪接。
如本文所用,「可操作地連接(operably linked)」、「可操作連接(operable linkage)」、「以可操作方式連接(operatively linked)」或其文法等效物係指基因元件,例如啟動子、增強子、聚腺苷酸化序列等的併接,其中元件呈允許其以預期方式操作之關係。舉例而言,若調節元件幫助起始編碼序列轉錄,則調節元件(其可包含啟動子及/或增強子序列)以可操作方式連接於編碼區。在調節元件與編碼區之間可存在中間殘基,只要維持此功能關係即可。
如本文所用之「載體」係指包含聚核苷酸或與聚核苷酸締合且可用於介導將聚核苷酸遞送至細胞之大分子或大分子締合物。載體之實例包括質體、病毒載體、脂質體及其他基因遞送媒劑。載體一般包含基因元件,例如調節元件,其以可操作方式連接於基因以促進基因於標靶中之表現。
如本文所用,「表現卡匣」及「核酸卡匣」可互換使用以指共同地表現或可操作地連接用於表現之核酸序列或元件之組合。在一些情況下,表現卡匣係指調節元件及其可操作地連接用於表現之一或多個基因之組合。
術語「AAV」為腺相關病毒之縮寫,且可用於指代病毒自身或其衍生物。除非另有要求,否則該術語覆蓋所有血清型、亞型以及天然存在及重組之形式兩者。縮寫「rAAV」係指重組腺相關病毒,亦稱為重組AAV載體(或「rAAV載體」)。術語「AAV」包括AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、AAV12、rh10及其雜種,禽類AAV、牛類AAV、犬類AAV、馬類AAV、靈長類AAV、非靈長類AAV及綿羊類AAV。各種血清型之AAV的基因組序列,以及自然末端重複序列(TR)、Rep蛋白質及衣殼次單位之序列為此項技術中已知的。此類序列可發現於文獻中或諸如GenBank之公共資料庫中。如本文所用之「rAAV載體」係指包含不屬於AAV來源之聚核苷酸序列(亦即,與AAV異源之聚核苷酸)的AAV載體,通常為用於細胞之遺傳轉化的所關注之序列。一般而言,異源聚核苷酸係藉由至少一個,且一般藉由兩個AAV反向末端重複序列(ITR)側接。rAAV載體可為單股(ssAAV)或自補的(scAAV)。「AAV病毒」或「AAV病毒粒子」係指由至少一個AAV衣殼蛋白及衣殼化聚核苷酸rAAV載體構成之病毒粒子。若粒子包含異源聚核苷酸(亦即除野生型AAV基因組,諸如待遞送至哺乳動物細胞之轉殖基因以外的聚核苷酸),則其通常稱為「rAAV載體粒子」或簡稱為「rAAV粒子」。因此,rAAV粒子之製造必定包括rAAV載體之製造,因此載體內含於rAAV粒子。
如本文所用,術語「治療(treat/treatment)」、「療法」及其類似者係指緩解疾病或病症、延緩或減緩其進展、預防疾病或病症、減弱疾病或病症、減少其效應或症狀、預防其發病、抑制疾病或病症或改善其發病。本發明之方法可用於任何哺乳動物。例示性哺乳動物包括但不限於大鼠、貓、狗、馬、母牛、綿羊、豬,且更佳為人類。治療效益包括根除或改善所治療之潛在病症。另外,經由根除或改善與潛在病症相關之一或多種生理症狀來達成治療效益,從而觀測到個體之改善,儘管該個體仍可能罹患潛在病症。在一些情況下,出於預防效益,治療劑可向處於罹患特定疾病之風險下的個體投與,或向報導具有疾病之生理症狀中之一或多者的個體投與,儘管可能尚未診斷患有此疾病。本發明之方法可用於任何哺乳動物。在一些情況下,治療可導致症狀之減輕或中止(例如癲癇頻率、持續時間及/或嚴重度之降低)。預防作用包括延遲或消除疾病或病況之出現、延遲或消除疾病或病況之症狀發作、減緩、阻止或逆轉疾病或病況之進展,或其任何組合。
術語「有效量」或「治療有效量」係指足以影響如下文所定義之預期應用,包括但不限於疾病治療的本文所述之組合物之量。治療有效量可視而預期治療應用(活體內),或治療之個體及疾病狀況,例如個體之體重及年齡、疾病狀況之嚴重度、投與方式及其類似者而變化,其可由一般熟習此項技術者容易地測定。該術語亦適用於將在靶細胞中誘導特定反應之劑量。特定劑量將取決於選擇之特定組合物、遵循之給藥方案、其是否與其他化合物組合投與、投與時序、其所投與之組織及承載其之物理遞送系統而變化。
核苷酸或肽序列之「片段」係指比參考或「全長」序列短之序列。
分子之「變異體」係指此類序列之對偶基因變化形式,亦即結構及生物活性基本上類似於整個分子或其片段之序列。
DNA或蛋白質序列之「功能片段」係指保留與全長DNA或蛋白質序列之生物活性基本上類似之生物活性(功能或結構)的片段。DNA序列之生物活性可為其以已知歸於全長序列之方式影響表現的能力。
術語「個體(subject)」及「個體(individual)」在本文中可互換使用以指脊椎動物,較佳為哺乳動物,更佳為人類。本文所描述之方法可適用於人類治療學、獸醫學應用及/或疾病或病況之動物模型臨床前研究。
術語「活體內」係指發生於個體體內之事件。
術語「活體外」係指發生於個體體外之事件。舉例而言,活體外分析涵蓋個體體外之任何分析操作。活體外分析涵蓋基於細胞之分析,其中採用存活或死亡細胞。活體外分析亦涵蓋無細胞分析,其中不採用完整細胞。
一般而言,「序列一致性」或「序列同源性」可互換地使用,分別指兩個聚核苷酸或多肽序列之精確核苷酸:核苷酸或胺基酸:胺基酸對應關係。通常,測定序列一致性之技術包括比較兩個核苷酸或胺基酸序列及測定其百分比一致性。序列比較(諸如出於評估一致性之目的)可藉由任何適合之比對算法進行,包括但不限於尼德曼-翁施算法(Needleman-Wunsch algorithm)(參見例如www.ebi.ac.uk/Tools/psa/emboss_needle/處可用的EMBOSS Needle比對器,視情況具有預設設定)、BLAST算法(參見例如blast.ncbi.nlm.nih.gov/Blast.cgi處可用的BLAST比對工具,視情況具有預設設定)及史密斯-沃特曼算法(Smith-Waterman algorithm)(參見例如www.ebi.ac.uk/Tools/psa/emboss_water/處可用的EMBOSS Water比對器,視情況具有預設設定)。最佳比對可使用所選算法之任何適合之參數,包括預設參數來評估。兩個序列之間的「百分比一致性」(亦稱為「百分比同源性」)可計算為兩個最佳比對序列之間的精確匹配之數目除以參考序列之長度且乘以100。百分比一致性亦可例如藉由使用先進BLAST電腦程式,包括購自美國國家衛生研究院之版本2.2.9比較序列資訊來測定。BLAST程式係基於Karlin及Altschul, Proc. Natl. Acad. Sci. USA 87:2264-2268 (1990)及如Altschul等人, J. Mol. Biol. 215:403-410 (1990);Karlin及Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5877 (1993);及Altschul等人, Nucleic Acids Res. 25:3389-3402 (1997)中所論述之比對方法。簡言之,BLAST程式將一致性定義為相同比對符號(亦即核苷酸或胺基酸)之數目除以兩個序列中之較短序列之符號的總數目。程式可用於測定比較之序列之整個長度上的百分比一致性。提供預設參數以藉由短查詢序列,例如藉由blastp程式使檢索最佳化。程式亦允許使用SEG濾波器來屏蔽查詢序列之片段,如藉由Wootton及Federhen, Computers and Chemistry 17: 149-163 (1993)之SEG程式所測定。高序列一致性一般包括大致80%至100%及在其之間的整數值之序列一致性範圍。
如本文所用,參考蛋白質之「工程化」係指非天然存在之蛋白質,包括但不限於衍生自天然存在之蛋白質的蛋白質,或其中天然存在之蛋白質已經修飾或再程式化以具有某一特性。
如本文所用,「合成」及「人工」可互換使用以指與天然存在之人類蛋白質具有低序列一致性(例如小於50%序列一致性)之蛋白質或其域。舉例而言,VPR及VP64域為合成轉活化域。
如本文所用,「工程化轉錄因子」或「eTF」係指非天然存在之DNA結合蛋白或非天然存在之轉錄調節子,其已經修飾或再程式化以結合至特定標靶結合位點及/或包括經修飾或置換之轉錄效應子域。
如本文所用,「DNA結合域」可用於指一或多個DNA結合基元,諸如鋅指或鹼性螺旋-環-螺旋(bHLH)基元,其單獨或共同地作為DNA結合蛋白之一部分。
術語「轉錄活化域(transcription activation domain/transcriptional activation domain」、「轉活化域(transactivation domain/trans-activating domain)」及「TAD」在本文中可互換使用且係指與DNA結合域結合之蛋白質域,其可藉由直接或經由稱為共活化子之其他蛋白質與轉錄機構(例如一般轉錄因子及/或RNA聚合酶)接觸而活化自啟動子之轉錄。
術語「轉錄抑制子域(transcriptional repressor domain/transcription repressor domain)」及「TRD」在本文中可互換使用且係指與DNA結合域結合之蛋白質域,其可藉由直接或經由稱為共抑制子之其他蛋白質與轉錄機構(例如一般轉錄因子及/或RNA聚合酶)接觸而抑制自啟動子之轉錄。
術語「GRCh38.p12」係指具有GenBank Assembly寄存編號GCA_000001405.27且日期為2017/12/21之Genome Reference Consortium Human Build 38 patch release 12 (GRCh38.p12)。
除非另外規定,否則本文所用之所有術語具有其對於熟習此項技術者所意味之相同含義且本發明之實踐將採用分子生物學、微生物學及重組DNA技術之習知技術,其在熟習此項技術者之知識內。
工程化轉錄因子 ( eTF )
轉錄因子(TF)為結合基因組中之特定序列且控制基因表現之蛋白質。本文提供之工程化轉錄因子或eTF為非天然存在之蛋白質,其包含DNA結合域(DBD)及至少一個為轉錄調節子之域,例如轉錄活化域(TAD)或轉錄抑制域(TRD)。在一個實施例中,eTF可包含DBD及TAD (例如TAD-DBD或DBD-TAD),其中DBD及TAD可衍生自相同蛋白質或不同蛋白質。在另一實施例中,eTF可包含一個DBD及兩個TAD,其中DBD及TAD衍生自相同蛋白質,DBD衍生自第一蛋白質且兩個TAD均衍生自第二蛋白質,DBD及一個TAD衍生自第一蛋白質且第二TAD衍生自第二蛋白質,或DBD衍生自第一蛋白質,一個TAD衍生自第二蛋白質,且第二TAD衍生自第三蛋白質(例如TAD1-DBD-TAD1或TAD1-DBD-TAD2)。在一個實施例中,eTF可包含DBD及TRD (例如TRD-DBD或DBD-TRD),其中DBD及TRD可衍生自相同蛋白質或不同蛋白質。在另一實施例中,eTF可包含一個DBD及兩個TRD,其中DBD及TRD衍生自相同蛋白質,DBD衍生自第一蛋白質且兩個TRD均衍生自第二蛋白質,DBD及一個TRD衍生自第一蛋白質且第二TRD衍生自第二蛋白質,或DBD衍生自第一蛋白質,一個TRD衍生自第二蛋白質,且第二TRD衍生自第三蛋白質(例如TRD1-DBD-TRD1或TRD1-DBD-TRD2)。在某些實施例中,DBD可為含有來自多個蛋白質之域的合成構築體。
在某些實施例中,DBD及TAD可直接結合,例如不具有中間胺基酸序列。在其他實施例中,DBD及TAD可使用肽連接子結合。在某些實施例中,DBD經由具有1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、25、30、35、40、50、60、70、75、80、90或100個胺基酸,或1-5、1-10、1-20、1-30、1-40、1-50、1-75、1-100、5-10、5-20、5-30、5-40、5-50、5-75、5-100、10-20、10-30、10-40、10-50、10-75、10-100、20-30、20-40、20-50、20-75或20-100個胺基酸之連接子與TAD結合。在一些情況下,DBD及TAD係經由衍生該等域之天然存在之蛋白質中發現之天然存在之中間殘基結合。在其他實施例中,DBD及TAD係經由合成或外源連接子序列結合。適合之連接子可為可撓性、可裂解、不可裂解、親水性及/或疏水性的。在某些實施例中,DBD及TAD可經由包含複數個甘胺酸及/或絲胺酸殘基之連接子融合在一起。甘胺酸/絲胺酸肽連接子之實例包括[GS]n、[GGGS]n (SEQ ID NO: 436)、[GGGGS]n (SEQ ID NO: 437)、[GGSG]n (SEQ ID NO: 438),其中n為等於或大於1之整數。在某些實施例中,適用於結合DBD及TAD之連接子為GGSGGGSG (SEQ ID NO: 410)。在某些實施例中,當DBD與兩個TAD結合時,第一及第二TAD可藉由相同或不同連接子與DBD結合,或一個TAD可藉由連接子與DBD結合且另一TAD直接與DBD結合(例如無中間連接序列),或兩個TAD可直接與DBD結合(例如無中間連接序列)。
本文提供之eTF具有與天然存在之轉錄因子不同的特性。在某些實施例中,本文提供之eTF包含衍生自天然存在之蛋白質的DBD,其已經修飾以使得DBD結合至相比於衍生其之天然存在之蛋白質不同的標靶位點,包含此類經修飾DBD之eTF自相比於衍生DBD之天然存在之蛋白質不同的基因調節表現,及/或包含此類經修飾DBD之eTF相比於衍生DBD之天然存在之蛋白質不同地調節靶基因表現(例如上調相對於下調)。在其他實施例中,本文提供之eTF包含衍生自天然存在之蛋白質的TAD,其已經修飾以使得包含此類經修飾TAD之eTF自相比於衍生TAD之天然存在之蛋白質不同的基因調節表現,及/或包含此類經修飾TAD之eTF相比於衍生TAD之天然存在之蛋白質不同地調節靶基因表現(例如上調相對於下調)。在某些實施例中,本文提供之eTF包含衍生自天然存在之蛋白質之DBD及衍生自天然存在之蛋白質(相同或不同蛋白質)之TAD,其中DBD及TAD均已經修飾。在此類實施例中,DBD可結合至相比於衍生其之天然存在之蛋白質不同的標靶位點,包含此類經修飾DBD及TAD之eTF自相比於衍生該等域之天然存在之蛋白質不同的基因調節表現,及/或包含此類經修飾DBD及TAD之eTF相比於衍生DBD及TAD域之天然存在之蛋白質不同地調節靶基因表現(例如上調相對於下調)。
DNA 結合域 ( DBD )
本文提供之eTF可包含結合至所關注之標靶位點的任何適合之DBD。在某些實施例中,DBD可為以合成方式設計之DBD。在其他實施例中,DBD可衍生自天然存在之蛋白質。DBD家族包括鹼性螺旋-環-螺旋(bHLH)(例如c-Myc)、鹼性-白胺酸拉鏈(例如C/EBP)、螺旋-轉角-螺旋(例如Oct-1)及鋅指(例如EGR3)。此等家族展現大範圍之DNA結合特異性及基因靶向。如本文中所預期,已知人類轉錄因子蛋白質中之任一者可充當蛋白質平台,用於工程化及/或再程式化DBD以識別導致調節所關注之內源性基因之表現的特定標靶位點。在例示性實施例中,本文提供之DBD包含鋅指域、TALEN結合域或gRNA/Cas複合物。
本文提供之DBD可經設計以識別任何所關注之標靶位點。在例示性實施例中,DBD經工程化以識別能夠在與eTF結合時自所關注之基因調節(例如上調或下調)表現的標靶位點。在例示性實施例中,DBD經設計以識別基因組位置及在與eTF結合時調節內源性基因之表現。能夠在與eTF結合時調節所關注之內源性基因之表現的結合位點可位於導致調節靶基因之基因表現的基因組中之任何位置。在各種實施例中,結合位點可位於與所關注之基因不同的染色體上、與所關注之基因相同的染色體上、所關注之基因之轉錄起始位點(TSS)上游、所關注之基因之TSS下游、靠近所關注之基因之TSS、遠離所關注之基因、所關注之基因之編碼區內、所關注之基因之內含子內、所關注之基因之polyA尾下游、調節所關注之基因之啟動子序列內、調節所關注之基因之增強子序列內或調節所關注之基因之抑制子序列內。
DBD可經設計以結合至任何長度之標靶結合位點,只要其藉由DBD特異性識別標靶結合位點序列,例如在極小或無脫靶結合之情況下。在某些實施例中,標靶結合位點可在與eTF結合時以相比於所有其他基因至少2倍、5倍、10倍、20倍、50倍、75倍、100倍、150倍、200倍、250倍、500倍或更大之水準調節所關注之內源性基因之表現。在某些實施例中,標靶結合位點可在與eTF結合時以相比於40個最近鄰基因(例如在所關注之基因之編碼序列上游或下游之染色體上位於最接近處之40個基因)至少2倍、5倍、10倍、20倍、50倍、75倍、100倍、150倍、200倍、250倍、500倍或更大之水準調節所關注之內源性基因之表現。在某些實施例中,標靶結合位點可為至少5 bp、10 bp、15 bp、20 bp、25 bp、30 bp、35 bp、40 bp、45 bp或50 bp或更大。結合位點之特定長度將由eTF中DBD之類型告知。一般而言,結合位點之長度愈長,結合特異性及基因表現調節愈大(例如較長結合位點具有較少脫靶效應)。在某些實施例中,相對於在具有結合至較短標靶位點之DBD之eTF的情況下觀測之脫靶效應,具有識別較長標靶結合位點之DBD的eTF具有較少與非特異性結合相關之脫靶效應(諸如調節脫靶基因或除所關注之基因以外的基因之表現)。在一些情況下,相比於具有識別較短標靶結合位點之DBD的類似eTF,脫靶結合之減少低至少1.2、1.3、1.4、1.5、2、3、4、5、6、7、8、9或10倍。
在某些實施例中,本文提供之DBD可經修飾以具有增加之結合親和力,使得其結合至標靶結合位點較長時間,使得與DBD結合之TAD能夠募集更多轉錄因子及/或募集此類轉錄因子較長時段以對所關注之內源性基因之表現量施加較大影響。在某些實施例中,eTF可經工程化以使得DBD穩定結合至標靶結合位點且阻斷表現內源性基因必需之轉錄或轉錄機構。在某些實施例中,DBD可經修飾以增加其與所需標靶位點之特異性結合(或中靶結合)及/或經修飾以減少其非特異性或脫靶結合。
在各種實施例中,DBD或eTF與標靶結合位點之間的結合可使用各種方法測定。在某些實施例中,DBD或eTF與標靶結合位點之間的特異性結合可使用遷移率變動分析、DNA酶保護分析或此項技術中已知用於分析蛋白質-DNA結合之任何其他活體外方法來測定。在其他實施例中,eTF與標靶結合位點之間的特異性結合可使用功能分析測定,例如藉由量測基因在標靶結合位點與eTF結合時之表現(RNA或蛋白質)。舉例而言,標靶結合位點可安置於載體上之報導基因(諸如eGFP)或所關注之靶基因上游,該載體包含於細胞中或整合至細胞之基因組中,其中細胞表現eTF。相比於對照(例如無eTF或識別不同標靶位點之eTF),在eTF存在下較大之報導基因(或所關注之靶基因)表現量指示eTF之DBD結合至標靶位點。適合之活體外(例如非基於細胞)轉錄及轉譯系統亦可以類似方式使用。在某些實施例中,結合至標靶位點之eTF可具有相比於對照(例如無eTF或識別不同標靶位點之eTF)至少2倍、3倍、5倍、10倍、15倍、20倍、30倍、50倍、75倍、100倍、150倍或更大的報導基因或所關注之靶基因之表現。
在其他實施例中,本文提供之eTF可包含DBD,其來自鋅指蛋白、衍生自鋅指蛋白或為作為不活化鋅指蛋白之核酸酶。鋅指為較小蛋白質結構性基元,其特徵在於對一或多個鋅離子(Zn
2 +)進行配位以使摺疊穩定化。鋅指(Znf)域為相對較小蛋白質基元,其含有多個與DNA標靶位點進行串聯接觸之指狀突出部分。鋅指基元之模組性質允許大多數DNA序列組合以較高程度之親和力及特異性結合,且因此理想地適合於工程化可靶向及結合特定DNA序列之蛋白質。許多工程化鋅指陣列係基於鼠類轉錄因子Zif268之鋅指域。Zif268具有三個個別鋅指基元,其共同地以高親和力結合9 bp序列。多種鋅指蛋白質已經鑑定且基於結構表徵為不同類型(如本文進一步描述)。任何此類鋅指蛋白可與本文所述之DBD結合使用。
各種設計鋅指蛋白之方法為可用的。舉例而言,描述設計鋅指蛋白以結合至所關注之靶DNA序列的方法,參見例如Liu Q等人, Design of polydactyl zinc-finger proteins for unique addressing within complex genomes, Proc Natl Acad Sci USA. 94 (11): 5525-30 (1997);Wright DA等人, Standardized reagents and protocols for engineering zinc finger nucleases by modular assembly, Nat Protoc . Nat Protoc. 2006;1(3):1637-52;及CA Gersbach及T Gaj, Synthetic Zinc Finger Proteins: The Advent of Targeted Gene Regulation and Genome Modification Technologies, Am Chem Soc 47: 2309-2318 (2014)。另外,各種設計鋅指蛋白以結合至所關注之DNA靶序列之基於網路之工具為公開可用的,參見例如來自OmicX之Zinc Finger Nuclease Design Software Tools及Genome Engineering Data Analysis網站,在全球資訊網、omictools.com/zfns-category處可用;及來自Scripps之Zinc Finger Tools design網站,在全球資訊網、scripps.edu/barbas/zfdesign/zfdesignhome.php處可用。另外,各種設計鋅指蛋白以結合至所關注之DNA靶序列之市售服務為可用的,參見例如由Creative Biolabs提供之市售服務或套組(全球資訊網、creative-biolabs.com/Design-and-Synthesis-of-Artificial-Zinc-Finger-Proteins.html)、購自Addgene之Zinc Finger Consortium Modular Assembly Kit (全球資訊網、addgene.org/kits/zfc-modular-assembly/)或購自Sigma Aldrich之CompoZr Custom ZFN Service (全球資訊網、sigmaaldrich.com/life-science/zinc-finger-nuclease-technology/custom-zfn.html)。
在某些實施例中,本文提供之eTF包含有包含一或多個鋅指之DBD或衍生自鋅指蛋白之DBD。在一些情況下,DBD包含多個鋅指,其中各鋅指在其N端或C端,或均經由胺基酸連接子連接至另一鋅指或另一域。在一些情況下,本文提供之DBD包含一或多個來自
表 5中所述之一或多種鋅指類型的鋅指。在一些情況下,本文提供之DBD包含複數個鋅指結構或基元,或複數個具有SEQ ID NO: 115-130或141-164中之一或多者之鋅指,或其任何組合。在某些實施例中,DBD包含X-[ZF-X]n及/或[X-ZF]n-X,其中ZF為具有表5中所列基元中之任一者(例如SEQ ID NO: 39-49中之任一者)之鋅指域,X為包含1-50個胺基酸之胺基酸連接子,且n為1-15之整數,例如1、2、3、4、5、6、7、8、9、10、11、12、13、14或15,其中各ZF可獨立地具有與DBD中之其他ZF序列相同之序列或不同之序列,且其中各連接子X可獨立地具有與DBD中之其他X序列相同之序列或不同之序列。各鋅指可在其C端、N端或兩端連接至另一序列、鋅指或域。在DBD中,各連接子X可在序列、長度及/或特性(例如可撓性或電荷)中相同,或在序列、長度及/或特性中不同。在一些情況下,兩個或更多個連接子可相同,而其他連接子不同。在例示性實施例中,連接子可獲自或衍生自連接
表 5中提供之一或多種天然存在之鋅指蛋白中發現之鋅指的序列。在其他實施例中,適合之連接序列包括例如長度為5個或更多個胺基酸之連接子。關於長度為6個或更多個胺基酸之例示性連接序列,亦參見美國專利第6,479,626號;第6,903,185號;及第7,153,949號,其各自全文併入本文中。本文提供之DBD蛋白質可在蛋白質之個別鋅指之間包括適合之連接子之任何組合。本文所述之DBD蛋白質可在蛋白質之個別鋅指之間包括適合之連接子之任何組合。
在某些實施例中,本文提供之DBD包含一或多個典型鋅指。經典C2H2鋅指在一條鏈中具有兩個半胱胺酸且在另一條鏈中具有兩個組胺酸殘基,藉由鋅離子配位。經典鋅指域具有兩個β-摺疊及一個α-螺旋,其中α-螺旋與DNA分子相互作用且形成DBD結合至標靶位點之基礎且可稱為「識別螺旋」。在例示性實施例中,鋅指之識別螺旋包含位置-1、2、3或6處之至少一個胺基酸取代,進而改變鋅指域之結合特異性。在其他實施例中,本文提供之DBD包含一或多個非經典鋅指,例如C2-H2、C2-CH及C2-C2。
在另一實施例中,本文提供之DBD域包含具有以下結構之鋅指基元:LEPGEKP - [YKCPECGKSFS X HQRTH TGEKP]n - YKCPECGKSFS X HQRTH - TGKKTS (SEQ ID NO: 421),其中n為1-15之整數,例如1、2、3、4、5、6、7、8、9、10、11、12、13、14或15,且各X獨立地為能夠結合至3 bp靶序列之識別序列(例如識別螺旋)。在例示性實施例中,n為3、6或9。在一尤佳實施例中,n為6。在各種實施例中,各X可獨立地具有相比於DBD中之其他X序列相同之胺基酸序列或不同之胺基酸序列。在例示性實施例中,各X為包含7個胺基酸之序列,其已使用來自Scripps之Zinger Finger Design Tool (位於全球資訊網、scripps.edu/barbas/zfdesign/zfdesignhome.php處)設計以與3 bp所關注之標靶結合位點相互作用。
由於DBD內之各鋅指識別3 bp,包括於DBD中之鋅指的數目告知藉由DBD識別之結合位點的長度,例如具有1個鋅指之DBD將識別具有3 bp之標靶結合位點,具有2個鋅指之DBD將識別具有6 bp之標靶結合位點,具有3個鋅指之DBD將識別具有9 bp之標靶結合位點,具有4個鋅指之DBD將識別具有12 bp之標靶結合位點,具有5個鋅指之DBD將識別具有15 bp之標靶結合位點,具有6個鋅指之DBD將識別具有18 bp之標靶結合位點,具有9個鋅指之DBD將識別具有27 bp之標靶結合位點等。一般而言,識別較長標靶結合位點之DBD將展現較大結合特異性(例如較少脫靶或非特異性結合)。
在其他實施例中,本文提供之DBD藉由在鋅指域之一或多個識別螺旋中進行一或多個胺基酸取代以改變DBD之結合特異性(例如改變藉由DBD識別之標靶位點)而衍生自天然存在之鋅指蛋白。本文提供之DBD可衍生自任何天然存在之鋅指蛋白。在各種實施例中,此類DBD可衍生自任何物種,例如小鼠、大鼠、人類等的鋅指蛋白。在例示性實施例中,本文提供之DBD衍生自人類鋅指蛋白。在某些實施例中,本文提供之DBD衍生自
表 5中所列之天然存在之蛋白質。在例示性實施例中,本文提供之DBD蛋白質衍生自人類EGR鋅指蛋白,例如EGR1、EGR2、EGR3或EGR4。
在某些實施例中,本文提供之DBD藉由在天然存在之蛋白質之DBD內重複一或多個鋅指來修飾DBD以提高DBD蛋白質自組鋅指域的數目而衍生自天然存在之蛋白質。在某些實施例中,此類修飾包括鋅指在天然存在之蛋白質之DBD內的複製、三倍化複製、四倍化複製或另外多倍化複製。在一些情況下,來自人類蛋白質之DBD的一個鋅指經倍增,例如相同鋅指基元之2、3、4、5、6、7、8、9、10、11、12或更多個複本在eTF之DBD中重複。在一些情況下,來自天然存在之蛋白質之DBD的一組鋅指經倍增,例如來自天然存在之蛋白質之DBD的一組3個鋅指經複製以產生具有6個鋅指之DBD的eTF,經三倍化複製以產生具有9個鋅指之eTF的DBD,或經四倍化複製以產生具有12個鋅指之eTF的DBD等。在一些情況下,來自天然存在之蛋白質之DBD的一組鋅指經部分複製以形成具有較大數目之鋅指之eTF的DBD,例如eTF之DBD包含四個鋅指,其中鋅指表示第一鋅指之一個複本、第二鋅指之一個複本及第三鋅指之兩個複本,其來自天然存在之蛋白質,總共為eTF之DBD中之四個鋅指。此類DBD接著藉由在鋅指域之一或多個識別螺旋中進行一或多個胺基酸取代以改變DBD之結合特異性(例如改變由DBD識別之標靶位點)而進一步修飾。在例示性實施例中,DBD衍生自天然存在之人類蛋白質,諸如人類EGR鋅指蛋白,例如EGR1、EGR2、EGR3或EGR4。
人類EGR1及EGR3係藉由三指C2H2鋅指DBD表徵。鋅指之一般結合規則規定全部三個指與其具有類似幾何結構之同源DNA序列相互作用,使用各鋅指之α螺旋中之相同胺基酸測定標靶結合位點序列之特異性或識別。此類結合規則允許吾人修飾EGR1或EGR3之DBD一工程化識別所需標靶結合位點之DBD。在一些情況下,EGR1或EGR3之鋅指基元中之7-胺基酸DNA識別螺旋根據公佈之鋅指設計規則進行修飾。在某些實施例中,EGR1或EGR3之三指DBD中之各鋅指經修飾,例如藉由更改一或多個識別螺旋之序列及/或藉由增加DBD中鋅指之數目。在某些實施例中,EGR1或EGR3經再程式化以識別所需標靶位點處之至少9、12、15、18、21、24、27、30、33、36或更多個鹼基對的標靶結合位點。在某些實施例中,衍生自ERG1或EGR3之此類DBD包含至少3、4、5、6、7、8、9、10、11、12或更多個鋅指。在例示性實施例中,DBD中之一或多個鋅指包含識別螺旋之位置-1、2、3或6處之至少一個胺基酸取代。
在各種實施例中,包含衍生自EGR1或EGR3之DBD的eTF具有不同於天然存在之EGR1或EGR3之結合特異性的DNA結合特異性,例如DBD識別標靶結合位點,該標靶結合位點具有不同於藉由未經修飾的EGR1或EGR3識別之結合位點之序列的序列:(GCG(T/G)GGGCG) (SEQ ID NO: 373)。
在其他實施例中,本文提供之eTF包含DBD,其為gRNA/Cas複合物。CRISPR (成簇規律間隔短回文重複序列)/Cas9為允許位點特異性基因組靶向之基因組編輯工具。II型CRISPR/Cas系統為使用非編碼RNA來引導Cas9核酸酶以誘導位點特異性DNA裂解之原核適應性免疫反應。CRISPR/Cas9系統已用於建立簡單的RNA可程式化方法來介導哺乳動物細胞自組基因組編輯。可產生單一嚮導RNA (sgRNA)以將Cas9核酸酶導引至接著與gRNA/Cas9複合物結合之特定基因組位置。gRNA可使用各種方法及工具設計以結合至所關注之標靶位點。舉例而言,設計gRNA以結合至所關注之靶DNA序列之方法描述於Aach等人 Flexible algorithm for identifying specific Cas9 targets in genomes. BioRxiv, Cold Spring Harbor Labs. doi: http://dx.doi.org/10.1101/005074 (2014);Bae等人 Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases. Bioinformatics. 30(10):1473-1475 (2014);Doench, J. G.等人 Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotech 34, 184-191 (2016);Gratz等人 Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila. Genetics. 196(4):961-971 (2014);Heigwer等人 E-CRISP: fast CRISPR target site identification. Nat Methods. 11(2):122-123 (2014);Ma等人 A guide RNA sequence design platform for the CRISPR/Cas9 system for model organism genomes. Biomed Res Int. doi:http://doi.org/10.1155/2013/270805 (2013);Montague等人 CHOPCHOP: a CRISPR/Cas9 and TALEN web tool for genome editing. Nucleic Acids Res. 42(W1):W401-W407 (2014);Liu等人 CRISPR-ERA: a comprehensive design tool for CRISPR-mediated gene editing, repression and activation. Bioinformatics. 31(22):3676-3678 (2015);Ran等人
In vivogenome editing using Staphylococcus aureus Cas9. Nature. 520(7546):186-191 (2015);Wu等人 Target specificity of the CRISPR-Cas9 system. Quant Biol. 2(2):59-70 (2015);Xiao等人 CasOT: a genome-wide Cas9/gRNA off-target searching tool. Bioinformatics. 30(8):1180-1182 (2014);Zetsche等人 Cpf1 is a single RNA-guided endonuclease of a Class 2 CRISPR-Cas System. Cell. 163(3):759-771 (2015)中。另外,設計gRNA以結合至所關注之DNA靶序列之各種基於網路之工具為公開可用的,參見例如在全球資訊網、atum.bio/eCommerce/cas9/input?multipleContacts=false購自AUTM之CRISPR gRNA Design工具;在全球資訊網、portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design-crisprai購自Broad Institute之CRISPRa/i gRNA設計工具;在全球資訊網、e-crisp.org/E-CRISP/可用的購自DKFZ German Cancer Research Center之E-CRISP設計工具;及在全球資訊網、design.synthego.com/#/購自Synthego之Knockout Guide Design工具。另外,設計gRNA以結合至所關注之DNA靶序列之各種市售服務為可用的,參見例如由IDT (全球資訊網、idtdna.com/site/order/designtool/index/CRISPR_SEQUENCE)、ThermoFisher (全球資訊網、thermofisher.com/order/custom-oligo/crispr)及GenScript (全球資訊網、genscript.com/gRNA-design-tool.html)提供之市售服務。
在例示性實施例中,為gRNA/Cas複合物之DBD包含核酸酶去活化Cas蛋白或dCas,諸如dCas9,諸如核酸酶去活化金黃色葡萄球菌(
Staphylococcus aureus)(dSaCas9)或核酸酶去活化釀膿鏈球菌(
Streptococcus pyogenes)Cas9 (dSpCas9)。gRNA提供為序列,該序列包含靶向區,其將gRNA/Cas複合物靶向至所需標靶位點,及骨架區,其促進與Cas蛋白之相互作用。任何適合之gRNA骨架可與本文提供之gRNA結合使用。在例示性實施例中,gRNA為單一gRNA或sgRNA且包含以下骨架序列:5'-GTTTTAGTACTCTGGAAACAGAATCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTCAACTTGTTGGCGAGA-3' (SEQ ID NO: 102)。嚮導RNA之靶向區連接至骨架序列之5'端以形成完全sgRNA。在某些實施例中,gRNA及dCas蛋白質可自相同表現卡匣表現。在某些實施例中,U6啟動子用於表現gRNA。在其他實施例中,gRNA可表現於已經工程化以穩定表現dCas-TAD蛋白質之細胞中,例如藉由將dCas穩定整合至基因組中或在染色體外穩定維持之質體上。
在其他實施例中,本文提供之eTF可包含DBD,其來自TALEN、衍生自TALEN或為作為不活化TALEN之核酸酶。轉錄活化子樣效應物核酸酶(TALEN)為限制酶,其含有DBD及可經工程化以切割DNA之特定序列的核酸酶域。TALEN係藉由將TAL效應DNA結合域結合至DNA裂解域(例如核酸酶)而產生。轉錄活化子樣效應子(TALE)可經工程化以結合至所需靶DNA序列,進而將核酸酶域導引至特定位置。
TAL效應子為來自黃單胞菌屬細菌之細菌蛋白質。DNA結合域含有重複的高度保守之33-34胺基酸序列,其具有發散的第12及第13胺基酸。此兩個位置稱為重複可變二殘基(RVD),為高度可變的且與特異性核苷酸識別顯示強相關性。胺基酸序列與DNA識別之間的此直接關係允許藉由選擇含有適當RVD之重複片段組合而工程化特異性靶向所需序列之DBD。
設計TALE之各種方法為可用的。舉例而言,設計TALE以結合至所關注之靶DNA序列之方法描述於T. Cermak等人,
Nucleic Acids Research.
39(12): e82 (2011);F. Zhang F等人,
Nature Biotechnology.
29(2): 149-53 (2011);R. Morbitzer等人,
Nucleic Acids Research.
39(13): 5790-9 (2011);T. Li等人,
Nucleic Acids Research.
39(14): 6315-25 (2011);R. Geissler等人,
PLOS One.
6(5): e19509 (2011);及E. Weber等人,
PLOS One.
6(5): e19722 (2011)中。另外,設計TALE以結合至所關注之DNA靶序列之各種基於網路之工具為公開可用的,參見例如在全球資訊網、e-talen.org/E-TALEN/TAL可用的E-Talen及在全球資訊網、tale-nt.cac.cornell.edu/node/add/single-tale可用的Effector Nucleotide Targeter 2.0工具。另外,設計TALE以結合至所關注之DNA靶序列之各種市售服務為可用的,參見例如由OmicX (全球資訊網、omictools.com/)、Addgene (全球資訊網、addgene.org/talen/guide/)或ThermoFisher (全球資訊網、thermofisher.com/us/en/home/life-science/genome-editing/geneart-tals/tal-design-tool.html)提供之市售服務。另外,公開可用的軟體程式(DNAWorks)可用於設計適合於TALE裝配的寡核苷酸,參見例如D. Hoover D
Methods in Molecular Biology.
852: 215-23 (2012)。
轉錄調節域
本文提供之eTF可包含任何適合之域,其能夠募集可在eTF經由DBD (例如鋅指DBD、gRNA/Cas DBD或TALE DBD)結合至標靶位點時自所關注之基因調節轉錄(例如RNA聚合酶II、CBP/p300、CREB或KRAB)或基因表現量的一或多個蛋白因子。在某些實施例中,此類域募集增加所關注之基因之轉錄水準或基因表現量的蛋白因子且為轉錄活化域(TAD)。在其他實施例中,此類域募集減少所關注之基因之轉錄水準或基因表現量的蛋白因子且為轉錄抑制域(TRD)。在某些實施例中,轉錄調節域(TAD或TRD)可為以合成方式設計之域。在其他實施例中,轉錄調節域(TAD或TRD)可衍生自天然存在之蛋白質,例如轉錄因子、轉錄共活化子、轉錄共抑制子或靜止子蛋白質。在各種實施例中,轉錄調節域(TAD或TRD)可衍生自任何物種,例如小鼠、大鼠、猴、病毒或人類之蛋白質。
在一例示性實施例中,適用於本文提供之eTF的TAD衍生自病毒蛋白質。衍生自病毒蛋白質之例示性TAD包括例如VP64 (SEQ ID NO: 95)、VPR (SEQ ID NO: 114)、VP16、VP128、p65、p300或其任何功能片段或變異體,或與其具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列的TAD域。
在另一例示性實施例中,適用於本文提供之eTF的TAD衍生自人類蛋白質。衍生自人類蛋白質之例示性TAD包括例如CBP/p300相互作用轉活化子2 (CITED2)(SEQ ID NO: 96或98)、CBP/p300相互作用轉活化子4 (CITED4)(SEQ ID NO: 97或100)、EGR1 (SEQ ID NO: 1)或EGR3 (SEQ ID NO: 422),或其任何功能片段或變異體,或與其具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列的TAD域。
在另一實施例中,適用於本文提供之eTF的TRD包含KRAB域,該域可募集抑制轉錄之蛋白質,或其任何功能片段或變異體,或與其具有至少80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列。
在某些實施例中,鋅指DBD與如下文進一步描述之轉錄調節域,諸如TAD或TRD結合。在各種實施例中,鋅指DBD可與來自病毒蛋白質之TAD (諸如VP64或VPR),或來自人類蛋白質之TAD (諸如CITED2或CITED4)結合。在某些實施例中,衍生自人類蛋白質之鋅指DBD (例如EGR1或EGR3)與衍生自人類蛋白質之TAD (例如CITED2或CITED4)結合。在某些實施例中,衍生自人類蛋白質之鋅指DBD (例如EGR1或EGR3)與VP64或VPR TAD結合。在某些實施例中,與人類蛋白質具有小於75%序列一致性之合成鋅指DBD或鋅指DBD (例如EGR1或EGR3)與衍生自人類蛋白質之TAD (例如CITED2或CITED4)結合。在某些實施例中,與人類蛋白質具有小於75%序列一致性之合成鋅指DBD或鋅指DBD (例如EGR1或EGR3)與VP64或VPR TAD結合。
在某些實施例中,dCas蛋白質與如下文進一步描述之轉錄調節域,諸如TAD或TRD結合。在各種實施例中,dCas9可與來自病毒蛋白質之TAD (諸如VP64或VPR),或來自人類蛋白質之TAD (諸如CITED2或CITED4)結合。在例示性實施例中,dCas9與VP64或VPR TAD結合。
在某些實施例中,TALE蛋白質與如下文進一步描述之轉錄調節域,諸如TAD或TRD結合。在各種實施例中,TALE可與來自病毒蛋白質之TAD (諸如VP64或VPR),或來自人類蛋白質之TAD (諸如CITED2或CITED4)結合。在例示性實施例中,TALE與VP64或VPR TAD結合。
上調 SCN1A 之 eTF
在一個態樣中,本申請案提供能夠上調鈉電壓門控通道α次單位1 (SCN1A)基因之表現及增加其對應蛋白質產物Nav1.1之表現的eTF。SCN1A基因屬於編碼用於組裝鈉通道之次單位的基因家族。將帶正電鈉離子輸送至細胞中之此等通道在細胞產生及傳輸電信號之能力中起重要作用。SCN1A基因編碼稱作Nav1.1之鈉通道的一部分(α次單位)。此等通道主要發現於大腦中,其在大腦中控制鈉離子向細胞中之流動。Nav1.1通道參與將信號自一個神經細胞(或神經元)傳輸至另一個。已發現SCN1A基因中之若干突變引起遺傳性癲癇伴熱性癲癇附加症(GEFS+),其為具有改變嚴重度之一系列癲癇病症。此等病況包括簡單熱性(發熱相關)癲癇,其起始於嬰兒期且通常到5歲停止,及熱性癲癇附加症(FS+)。FS+包含熱性及其他類型之癲癇,包括超出兒童期繼續的與發熱無關之彼等(無發熱癲癇)。GEFS+範圍亦包括其他病況,諸如德拉韋症候群(亦稱為嬰兒期嚴重肌陣攣癲癇或SMEI),其引起持續較長時間且可能難以控制之更嚴重癲癇。此等反覆性癲癇(癲癇症)可隨時間推移惡化且通常伴有腦功能衰退。許多其他突變已與家族性偏癱性偏頭痛(在家族中流傳之一種偏頭痛形式)相關且至少一種突變已與某些抗癲癇藥物之有效性相關。因此,增加SCN1A表現之本文提供之eTF可用於治療多種與Nav1.1通道中之突變相關的疾病或病症。
在某些實施例中,上調SCN1A之本文揭示之eTF識別大小為至少9 bp、12 bp、15 bp、18 bp、21 bp、24 bp、27 bp、30 bp、33 bp或36 bp;大於9 bp、12 bp、15 bp、18 bp、21 bp、24 bp、27 bp或30 bp;或9-33 bp、9-30 bp、9-27 bp、9-24 bp、9-21 bp、9-18 bp、9-15 bp、9-12 bp、12-33 bp、12-30 bp、12-27 bp、12-24 bp、12-21 bp、12-18 bp、12-15 bp、15-33 bp、15-30 bp、15-27 bp、15-24 bp、15-21 bp、15-18 bp、18-33 bp、18-30 bp、18-27 bp、18-24 bp、18-21 bp、21-33 bp、21-30 bp、21-27 bp、21-24 bp、24-33 bp、24-30 bp、24-27 bp、27-33 bp、27-30 bp或30-33 bp之標靶結合位點。在例示性實施例中,上調SCN1A之本文揭示之eTF識別18-27 bp、18 bp或27 bp之標靶結合位點。
在某些實施例中,上調SCN1A之本文揭示之eTF識別位於染色體2上之標靶結合位點。在某些實施例中,上調SCN1A之本文揭示之eTF識別在染色體2上位於SCN1A之TSS上游或下游110 kb、100 kb、90 kb、80 kb、70 kb、60 kb、50 kb、40 kb、30 kb、20 kb、10 kb、5 kb、4 kb、3 kb、2 kb或1 kb內之標靶結合位點。在某些實施例中,上調SCN1A之本文揭示之eTF識別在染色體2上位於SCN1A之TSS上游110 kb內之標靶結合位點。在某些實施例中,上調SCN1A之本文揭示之eTF識別在染色體2上位於SCN1A之TSS下游110 kb內之標靶結合位點。在例示性實施例中,此類標靶結合位點為18-27 bp、18 bp或27 bp。
在某些實施例中,上調SCN1A之本文揭示之eTF識別在染色體2上位於位置166179652-165989571內、位置166128050-166127958內、位置166155414-166140590內、位置166179652-1661777272內或位置1659990246-165989592 (全部參考GRCh38.p12)內之標靶結合位點。在例示性實施例中,此類標靶結合位點為18-27 bp、18 bp或27 bp。
在某些實施例中,上調SCN1A之本文揭示之eTF識別標靶結合位點,其為(i) 18-27 bp、18 bp或27 bp,(ii)與染色體2上選自166178880、166178871、166177369、166177362、166177299、166177299、166155393、166155264、166149373、166149176、166149165、166149118、166148953、166148565、166142396、166142391、166142344、166142239、166141162、166140928、166140590、165990076、165989684、165989571、166155255、166155099、166148843、166148361、166142219、166141090、165990246、165990193、166149168、166127991、166128002、166128037或166128025 (全部參考GRCh38.p12)之位置重疊,及(iii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少1.2倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF (i)結合至包含SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267中之任一者或由其組成之標靶位點,及(ii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少1.2倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF識別標靶結合位點,其為(i)18-27 bp、18 bp或27 bp,(ii)與染色體2上選自166155255、166155099、166148843、166148361、166142219、166141090、165990246、165990193、166149168、166127991、166128002、166128037或166128025 (全部參考GRCh38.p12)之位置重疊,及(iii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少2倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF (i)結合至包含SEQ ID NO: 35-36、108-109、136、209-210、226、228、233、236或247-248中之任一者或由其組成之標靶位點,及(ii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少2倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF識別標靶結合位點,其為(i)18-27 bp、18 bp或27 bp,(ii)與染色體2上選自166149168、166127991、166128002、166128037或166128025 (全部參考GRCh38.p12)之位置重疊,及(iii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少5倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF (i)結合至包含SEQ ID NO: 35、36、108、109或136中之任一者或由其組成之標靶位點,及(ii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少5倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF識別標靶結合位點,其為(i)18-27 bp、18 bp或27 bp,(ii)與染色體2上選自166128002、166128037或166128025 (全部參考GRCh38.p12)之位置重疊,及(iii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少15倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF (i)結合至包含SEQ ID NO: 36、108或109中之任一者或由其組成之標靶位點,及(ii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少15倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF識別標靶結合位點,其為(i)18-27 bp、18 bp或27 bp,(ii)與染色體2上選自166128037或166128025 (全部參考GRCh38.p12)之位置重疊,及(iii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少20倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF (i)結合至包含SEQ ID NO: 36或109中之任一者或由其組成之標靶位點,及(ii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少20倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF識別標靶結合位點,其為(i)18-27 bp、18 bp或27 bp,(ii)與染色體2上位置166128025處之位置重疊,及(iii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少25倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF (i)結合至包含SEQ ID NO: 36或由其組成之標靶位點,及(ii)能夠在與本文揭示之eTF結合時產生SCN1A表現之至少25倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF識別標靶結合位點,其為(i) 18-27 bp、18 bp或27 bp,及(ii)結合至在具有SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267中之任一者之序列的基因組位置之至少1 kb、750 bp、500 bp、400 bp、300 bp、200 bp、100 bp或50 bp內之基因組區域。在某些實施例中,標靶結合位點能夠在與本文揭示之eTF結合時產生SCN1A表現之至少1.2倍、2倍、5倍、15倍、20倍或25倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF識別標靶結合位點,其為(i) 18-27 bp、18 bp或27 bp,及(ii)結合至與具有SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267中之任一者之序列的基因組位置至少部分重疊之基因組區域。在某些實施例中,標靶結合位點能夠在與本文揭示之eTF結合時產生SCN1A表現之至少1.2倍、2倍、5倍、15倍、20倍或25倍增加。
在某些實施例中,上調SCN1A之本文揭示之eTF識別具有以下序列中之任一者之標靶結合位點:SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267。在某些實施例中,標靶結合位點能夠在與本文揭示之eTF結合時產生SCN1A表現之至少1.2倍、2倍、5倍、15倍、20倍或25倍增加。
在某些實施例中,相比於對照(例如無eTF或eTF不識別標靶位點),上調SCN1A之本文揭示之eTF導致細胞中或活體內之SCN1A表現(SCN1A RNA及/或Nav1.1蛋白質)的至少1.5倍、2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、10倍、15倍、20倍、25倍、50倍、100倍或更大,或至少50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大上調。在各種實施例中,SCN1A表現之上調可使用PCR方法、西方墨點法或免疫分析來偵測。
在某些實施例中,上調SCN1A之本文揭示之eTF結合至標靶位點,其能夠相對於轉錄活化分析中之對照增加SCN1A表現至少1.2倍、1.3倍、1.4倍、1.5倍、1.6倍、1.7倍、1.8倍、1.9倍、2倍、3倍、4倍、5倍、8倍、10倍、12倍、15倍、18倍、20倍、25倍、30倍、40倍、50倍、75倍、100倍或更大,或至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。例示性SCN1A轉錄活化分析提供於本文實例3中。簡言之,HEK293經攜有eTF或對照eGFP報告子構築體之質體轉染。在轉染後48小時收集細胞,分離RNA,且反轉錄且藉由qPCR分析所得cDNA樣品(例如使用具有SEQ ID NO: 190及191之引物)以定量內源性SCN1A轉錄物之水準。GAPDH可用作參考基因以測定相對SCN1A表現量。
在某些實施例中,上調SCN1A之本文揭示之eTF具有極小脫靶效應,例如與非特異性結合相關之脫靶效應,諸如調節脫靶基因或除SCN1A以外的基因之表現。在一個實施例中,相比於對照,上調SCN1A之本文揭示之eTF特異性上調SCN1A,相比於對照,比針對一或多種脫靶基因由eTF產生之表現大至少5倍、10倍、15倍、20倍、25倍、30倍、40倍或50倍。在例示性實施例中,相比於對照,上調SCN1A之本文揭示之eTF自SCN1A基因特異性上調轉錄,比相對於對照由eTF產生之40個最近鄰基因(例如定位至染色體2上之SCN1A之編碼序列的40個最接近基因),例如PLA2R1、ITGB6、RBMS1、TANK、PSMD14、TBR1、SLC4A10、DPP4、FAP、IFIH1、GCA、FIGN、GRB14、COBLL1、SLC38A11、SCN3A、SCN2A、CSRNP3、GALNT3、TTC21B、SCN9A、SCN7A、B3GALT1、STK39、CERS6、NOSTRIN、SPC25、ABCB11、DHRS9、BBS5、KLHL41、FASTKD1、PPIG、CCDC173、PHOSPHO2、KLHL23、SSB、METTL5、UBR3及MYO3B (參見表33)之轉錄上調至少15倍。在各種實施例中,自SCN1A基因之轉錄上調可使用PCR方法偵測。
在某些實施例中,上調SCN1A之本文揭示之eTF能夠在德拉韋症候群之Scn1a
tm1kea 小鼠模型中降低高熱癲癇(HTS)分析之癲癇頻率。在某些實施例中,相比於對照(例如用包含編碼eGFP之序列的AAV載體處理之PBS或用該載體進行之PBS處理),本文揭示之eTF能夠在HTS分析中降低42.6℃處之癲癇頻率至少1.2倍、1.3倍、1.4倍、1.5倍、1.6倍、1.7倍、1.8倍、1.9倍、2.0倍或更大,或至少20%、30%、40%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、100%或更大。在某些實施例中,本文揭示之eTF能夠在HTS分析中降低42.6℃處之癲癇頻率,以使得該分析中運行之至少60%、62%、65%、70%、75%、76%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%小鼠在42.6℃下無癲癇。例示性HTS分析描述於本文實例11中。簡言之,由雄性Scn1a +/-小鼠與雌性C57BL/6J小鼠雜交產生之鼠幼仔可在P1處經由兩側ICV投配如本文所提供之編碼上調SCN1A之eTF的AAV9載體或編碼eGFP之對照載體。可向每隻小鼠投配約1.0E10-5.0E12 gc。HTS分析係在混合129Stac X C57BL/6背景下之P26-P28 SCN1A異型接合小鼠及SCN1A野生型小鼠中,藉由每2分鐘增加小鼠體溫(在受控條件下且在體溫監測下)約0.5℃直至開始第一次強直陣攣發作伴以姿勢喪失或直至達到43℃體溫。若在整個實驗過程中未偵測到癲癇與姿勢喪失,則將小鼠視為無癲癇。
在某些實施例中,上調SCN1A之本文揭示之eTF能夠增加針對SCN1A異型接合之小鼠,例如Scn1a
tm1kea 小鼠品系之存活率。在某些實施例中,相比於對照(例如用包含編碼eGFP之序列的AAV載體處理之PBS或用該載體進行之PBS處理),本文揭示之eTF能夠在P100處增加SCN1A異型接合小鼠之存活率至少1.2倍、1.3倍、1.4倍、1.5倍、1.6倍、1.7倍、1.8倍、1.9倍、2.0倍或更大,或至少20%、30%、40%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%、100%或更大。在某些實施例中,本文揭示之eTF能夠增加P100處SCN1A異型接合小鼠之存活率,以使得該分析中運行之至少65%、70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%小鼠在P100處仍存活。例示性存活率分析描述於本文實例12中。簡言之,由雄性Scn1a +/-小鼠與雌性C57BL/6J小鼠雜交產生之鼠幼仔可在P1處經由兩側ICV投配AAV9載體。可向每隻小鼠投配約1.0E10-5.0E12 gc。測定存活至P100之小鼠的數目。
在某些實施例中,上調SCN1A之本文揭示之eTF與一或多種人類蛋白質具有高百分比一致性(如下文進一步描述)。在某些實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。在某些實施例中,此類eTF可包含衍生自人類EGR1或EGR3之DBD及衍生自人類EGR1、EGR3、CITED2或CITED4之TAD。
在某些實施例中,上調SCN1A之本文揭示之eTF包含具有一或多個鋅指域之DNA結合域,該一或多個鋅指域包含有包含SEQ ID NO: 115-130中之任一者之識別螺旋。在某些實施例中,上調SCN1A之本文揭示之eTF包含具有至少一個、兩個、三個、四個、五個、六個、七個、八個、九個、十個、十一個或十二個鋅指域之DNA結合域,其中各鋅指域獨立地包含有包含SEQ ID NO: 115-130中之任一者之識別螺旋。在某些實施例中,上調SCN1A之本文揭示之eTF包含具有六個鋅指域之DNA結合域,其中各鋅指域獨立地包含有包含SEQ ID NO: 115-130中之任一者之識別螺旋。在某些實施例中,上調SCN1A之本文揭示之eTF包含具有九個鋅指域之DNA結合域,其中各鋅指域獨立地包含有包含SEQ ID NO: 115-130中之任一者之識別螺旋。在例示性實施例中,此類eTF包含具有SEQ ID NO: 421之DNA結合域,其中各X獨立地選自SEQ ID NO: 115-130中之任一者,且n為6或9。
在某些實施例中,上調SCN1A之本文揭示之eTF包含具有以下中之任一者之DNA結合域:(i)包含RSDNLVR x REDNLHT x RSDELVR x QSGNLTE x TSGHLVR x QNSTLTE (SEQ ID NO: 135)之序列,其中x可為1-50個胺基酸之連接子,(ii)與SEQ ID NO: 135具有至少80%、85%、90%、95%、96%、97%、98%或99%序列一致性之序列,或(ii) (i)或(ii)之功能片段。在某些實施例中,此類eTF進一步包含一或多個選自VP64、VPR、CITED2或CITED4之TAD。在一個實施例中,此類eTF包含與DBD之C端結合之VPR TAD域。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED4 TAD。在某些實施例中,此類eTF能夠結合至具有SEQ ID NO: 256之標靶位點且相比於對照上調SCN1A之表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調SCN1A之本文揭示之eTF包含具有以下中之任一者之DNA結合域:(i)包含RSDNLVR x HRTTLTN x REDNLHT x TSHSLTE x QSSSLVR x REDNLHT (SEQ ID NO: 371)之序列,其中x可為1-50個胺基酸之連接子,(ii)與SEQ ID NO: 371具有至少80%、85%、90%、95%、96%、97%、98%或99%序列一致性之序列,或(ii) (i)或(ii)之功能片段。在某些實施例中,此類eTF進一步包含一或多個選自VP64、VPR、CITED2或CITED4之TAD。在一個實施例中,此類eTF包含與DBD之C端結合之VPR TAD域。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED4 TAD。在某些實施例中,此類eTF能夠結合至具有SEQ ID NO: 264之標靶位點且相比於對照上調SCN1A之表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調SCN1A之本文揭示之eTF包含具有以下中之任一者之DNA結合域:(i)包含RRDELNV x RSDHLTN x RSDDLVR x RSDNLVR x HRTTLTN x REDNLHT x TSHSLTE x QSSSLVR x REDNLHT (SEQ ID NO: 372)之序列,(ii)與SEQ ID NO: 372具有至少80%、85%、90%、95%、96%、97%、98%或99%序列一致性之序列,或(ii) (i)或(ii)之功能片段。在某些實施例中,此類eTF進一步包含一或多個選自VP64、VPR、CITED2或CITED4之TAD。在一個實施例中,此類eTF包含與DBD之C端結合之VPR TAD域。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED4 TAD。在某些實施例中,此類eTF能夠結合至具有SEQ ID NO: 37之標靶位點且相比於對照上調SCN1A之表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調SCN1A之本文揭示之eTF包含具有以下中之任一者之DNA結合域:(i)包含DPGALVR x RSDNLVR x QSGDLRR x THLDLIR x TSGNLVR x RSDNLVR (SEQ ID NO: 376)之序列,(ii)與SEQ ID NO: 376具有至少89%、85%、90%、95%、96%、97%、98%或99%序列一致性之序列,或(ii) (i)或(ii)之功能片段。在某些實施例中,此類eTF進一步包含一或多個選自VP64、VPR、CITED2或CITED4之TAD。在一個實施例中,此類eTF包含與DBD之C端結合之VPR TAD域。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED4 TAD。在某些實施例中,此類eTF能夠結合至具有SEQ ID NO: 136之標靶位點且相比於對照上調SCN1A之表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 6-9、13-15、57-58、61-62、67-71、74-75、268-282、295-299、305-325或364-366中之任一者之序列;(ii)包含SEQ ID NO: 22-25、29-31、84-85、88、90-92、131-135、371-372、376、391-409或423-435中之任一者之序列;(iii)包含與(i)或(ii)之任何序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 268-282、305-312或365-366中之任一者之序列;(ii)包含SEQ ID NO: 131-135、371-372、376、391-409或423-426中之任一者之序列;(iii)包含與(i)或(ii)之任何序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 6-9、13-15、57-58、61-62、67-71、74-75、295-299、313-325或364中之任一者之序列;(ii)包含SEQ ID NO: 22-25、29-31、84-85、88、90-92或427-435中之任一者之序列;(iii)包含與(i)或(ii)之任何序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 305之序列;(ii)包含SEQ ID NO: 423之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 135且結合至具有SEQ ID NO: 256之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 306之序列;(ii)包含SEQ ID NO: 424之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 135且結合至具有SEQ ID NO: 256之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 308之序列;(ii)包含SEQ ID NO: 425之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 135且結合至具有SEQ ID NO: 256之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 313之序列;(ii)包含SEQ ID NO: 427之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 135且結合至具有SEQ ID NO: 256之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 316之序列;(ii)包含SEQ ID NO: 430之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 135且結合至具有SEQ ID NO: 256之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 317之序列;(ii)包含SEQ ID NO: 431之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 371且結合至具有SEQ ID NO: 264之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 315之序列;(ii)包含SEQ ID NO: 429之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 135且結合至具有SEQ ID NO: 256之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 319之序列;(ii)包含SEQ ID NO: 433之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 371且結合至具有SEQ ID NO: 264之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 318之序列;(ii)包含SEQ ID NO: 432之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 371且結合至具有SEQ ID NO: 264之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 314之序列;(ii)包含SEQ ID NO: 428之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 135且結合至具有SEQ ID NO: 256之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 440之序列;(ii)包含SEQ ID NO: 441之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 135且結合至具有SEQ ID NO: 256之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,上調SCN1A之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 325之序列;(ii)包含SEQ ID NO: 435之序列;(iii)包含與(i)或(ii)之序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF包含SEQ ID NO: 371且結合至具有SEQ ID NO: 264之標靶位點。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,上調SCN1A之本文揭示之eTF包含有包含gRNA/Cas複合物之DBD,其中gRNA包含有包含SEQ ID NO: 105-111、113、195-211、224-238或240-251中之任一者之靶向序列。gRNA之靶序列連接至具有以下序列之骨架序列的5'端:5'-GTTTTAGTACTCTGGAAACAGAATCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTCAACTTGTTGGCGAGA-3' (SEQ ID NO: 102)。在例示性實施例中,Cas蛋白為核酸酶去活化Cas9蛋白。在某些實施例中,此類eTF進一步包含一或多個與Cas蛋白結合之TAD,其中TAD選自VP64、VPR、CITED2或CITED4。在一個實施例中,此類eTF包含與Cas蛋白之C端結合的VPR TAD域。在某些實施例中,此類eTF包含與Cas蛋白之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與Cas蛋白之N端、C端或N端及C端結合之CITED4 TAD。在例示性實施例中,相比於對照,此類eTF能夠上調SCN1A表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大。
上調顆粒蛋白前體 ( GRN ) 之 eTF
在另一態樣中,本申請案提供能夠自顆粒蛋白前體(GRN)基因上調表現且增加GRN蛋白質之表現的eTF。顆粒蛋白前體(GRN或PGRN)亦稱為顆粒體蛋白前驅體,為具有生長因子樣特性的富含半胱胺酸之分泌醣蛋白。GRN位於染色體17q21.31上(NCBI參考序列:NC_000017.11)。顆粒體蛋白在血管生成、創傷修復、細胞增殖及發炎中起作用。顆粒蛋白前體基因突變及/或分泌顆粒蛋白前體缺乏與各種神經退化性疾病及代謝疾病相關,諸如額顳葉變性;額顳葉型變性或額顳葉型癡呆、與部分顆粒蛋白前體缺乏相關之早發型神經退化性疾病;進行性非流暢性失語症;詞義性癡呆;帕金森氏病;阿茲海默氏症;及神經元蠟樣質脂褐質沈積症伴以顆粒蛋白前體完全缺乏。顆粒蛋白前體之突變及/或缺乏亦與動脈粥樣硬化相關,動脈粥樣硬化為藉由發炎及動脈壁增厚(歸因於脂質積聚及細胞增殖)表徵之進行性疾病。因此,增加GRN表現之本文提供之eTF可用於治療多種與GRN突變相關之疾病或病症。
在某些實施例中,上調GRN之本文揭示之eTF識別大小為至少9 bp、12 bp、15 bp、18 bp、21 bp、24 bp、27 bp、30 bp、33 bp或36 bp;大於9 bp、12 bp、15 bp、18 bp、21 bp、24 bp、27 bp或30 bp;或9-33 bp、9-30 bp、9-27 bp、9-24 bp、9-21 bp、9-18 bp、9-15 bp、9-12 bp、12-33 bp、12-30 bp、12-27 bp、12-24 bp、12-21 bp、12-18 bp、12-15 bp、15-33 bp、15-30 bp、15-27 bp、15-24 bp、15-21 bp、15-18 bp、18-33 bp、18-30 bp、18-27 bp、18-24 bp、18-21 bp、21-33 bp、21-30 bp、21-27 bp、21-24 bp、24-33 bp、24-30 bp、24-27 bp、27-33 bp、27-30 bp或30-33 bp之標靶結合位點。在例示性實施例中,上調GRN之本文揭示之eTF識別18-27 bp、18 bp或27 bp之標靶結合位點。
在某些實施例中,上調GRN之本文揭示之eTF識別位於染色體17上之標靶結合位點。在某些實施例中,上調GRN之本文揭示之eTF識別在染色體17上位於GRN之TSS上游或下游110 kb、100 kb、90 kb、80 kb、70 kb、60 kb、50 kb、40 kb、30 kb、20 kb、10 kb、5 kb、4 kb、3 kb、2 kb或1 kb內之標靶結合位點。在例示性實施例中,此類標靶結合位點為18-27 bp、18 bp或27 bp。
在某些實施例中,上調GRN之本文揭示之eTF識別在染色體17上位於位置44、344、963-44、345、178 (參考GRCh38.p12)內之標靶結合位點。在例示性實施例中,此類標靶結合位點為18-27 bp、18 bp或27 bp。
在某些實施例中,上調GRN之本文揭示之eTF識別標靶結合位點,其為(i) 18-27 bp、18 bp或27 bp,及(ii)結合至在具有SEQ ID NO: 38、113或330-336中之任一者之序列之基因組位置的至少1 kb、750 bp、500 bp、400 bp、300 bp、200 bp、100 bp或50 bp內之基因組區域。在某些實施例中,標靶結合位點能夠在與本文揭示之eTF結合時產生GRN表現之至少1.2倍、2倍、5倍、15倍、20倍或25倍增加。
在某些實施例中,上調GRN之本文揭示之eTF識別標靶結合位點,其為(i) 18-27 bp、18 bp或27 bp,及(ii)結合至與具有SEQ ID NO: 38、113或330-336中之任一者之序列之基因組位置至少部分重疊的基因組區域。在某些實施例中,標靶結合位點能夠在與本文揭示之eTF結合時產生SCN1A表現之至少1.2倍、2倍、5倍、15倍、20倍或25倍增加。
在某些實施例中,上調GRN之本文揭示之eTF識別具有以下序列中之任一者之標靶結合位點:SEQ ID NO: 38、113、330-336。在某些實施例中,標靶結合位點能夠在與本文揭示之eTF結合時產生SCN1A表現之至少1.2倍、2倍、5倍、15倍、20倍或25倍增加。
在某些實施例中,相比於對照(例如無eTF或eTF不識別標靶位點),上調GRN之本文揭示之eTF導致細胞中或活體內之GRN表現(GRN RNA及/或蛋白質)的至少1.5倍、2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、10倍、15倍、20倍、25倍、50倍、100倍或更大,或20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大上調。在各種實施例中,GRN表現之上調可使用PCR方法、西方墨點法或免疫分析來偵測。
在某些實施例中,上調GRN之本文揭示之eTF具有極小脫靶效應,例如與非特異性結合相關之脫靶效應,諸如調節脫靶基因或除GRN以外的基因之表現。在一個實施例中,相比於對照,上調GRN之本文揭示之eTF特異性上調GRN,相比於對照,比針對一或多種脫靶基因由eTF產生之表現大至少5倍、10倍、15倍、20倍、25倍、30倍、40倍或50倍。在例示性實施例中,相比於對照,上調GRN之本文揭示之eTF自GRN基因特異性上調轉錄,比相對於對照由eTF產生之10、20、30、40或50個最近鄰基因(例如定位至染色體17上之GRN之編碼序列的10、20、30、40或50個最接近基因)之轉錄上調至少5倍、10倍、15倍、20倍或更大。在各種實施例中,自GRN基因之轉錄上調可使用PCR方法偵測。
在某些實施例中,上調GRN之本文揭示之eTF與一或多種人類蛋白質具有高百分比一致性(如下文進一步描述)。在某些實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。在某些實施例中,此類eTF可包含衍生自人類EGR1或EGR3之DBD及衍生自人類EGR1、EGR3、CITED2或CITED4之TAD。
在某些實施例中,上調GRN之本文揭示之eTF包含具有一或多個鋅指域之DNA結合域,該一或多個鋅指域包含有包含SEQ ID NO: 141-164中之任一者之識別螺旋。在某些實施例中,上調GRN之本文揭示之eTF包含具有至少一個、兩個、三個、四個、五個、六個、七個、八個、九個、十個、十一個或十二個鋅指域之DNA結合域,其中各鋅指域獨立地包含有包含SEQ ID NO: 141-164中之任一者之識別螺旋。在某些實施例中,上調GRN之本文揭示之eTF包含具有六個鋅指域之DNA結合域,其中各鋅指域獨立地包含有包含SEQ ID NO: 141-164中之任一者之識別螺旋。在某些實施例中,上調GRN之本文揭示之eTF包含具有九個鋅指域之DNA結合域,其中各鋅指域獨立地包含有包含SEQ ID NO: 141-164中之任一者之識別螺旋。在例示性實施例中,此類eTF包含具有SEQ ID NO: 421之DNA結合域,其中各X獨立地選自SEQ ID NO: 141-164中之任一者,且n為6或9。
在某些實施例中,上調GRN之本文揭示之eTF包含具有以下中之任一者之DNA結合域:(i)包含RNDTLTE x DPGALVR x TSGELVR x RSDNLVR x TSGELVR x TKNSLTE (SEQ ID NO: 171)之序列,(ii)與SEQ ID NO: 171具有至少89%、85%、90%、95%、96%、97%、98%或99%序列一致性之序列,或(ii) (i)或(ii)之功能片段。在某些實施例中,此類eTF進一步包含一或多個選自VP64、VPR、CITED2或CITED4之TAD。在一個實施例中,此類eTF包含與DBD之C端結合之VPR TAD域。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED4 TAD。在某些實施例中,此類eTF能夠結合至具有SEQ ID NO: 331之標靶位點且相比於對照上調GRN之表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調GRN之本文揭示之eTF包含具有以下中之任一者之DNA結合域:(i)包含RSDNLVR x DPGHLVR x RSDHLTT x RSDELVR x RSDKLVR x TTGNLTV (SEQ ID NO: 412)之序列,(ii)與SEQ ID NO: 412具有至少89%、85%、90%、95%、96%、97%、98%或99%序列一致性之序列,或(ii) (i)或(ii)之功能片段。在某些實施例中,此類eTF進一步包含一或多個選自VP64、VPR、CITED2或CITED4之TAD。在一個實施例中,此類eTF包含與DBD之C端結合之VPR TAD域。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED4 TAD。在某些實施例中,此類eTF能夠結合至具有SEQ ID NO: 332之標靶位點且相比於對照上調GRN之表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調GRN之本文揭示之eTF包含具有以下中之任一者之DNA結合域:(i)包含RSDHLTT x RSDELVR x RSDKLVR x TTGNLTV x QLAHLRA x TKNSLTE (SEQ ID NO: 413)之序列,(ii)與SEQ ID NO: 413具有至少89%、85%、90%、95%、96%、97%、98%或99%序列一致性之序列,或(ii) (i)或(ii)之功能片段。在某些實施例中,此類eTF進一步包含一或多個選自VP64、VPR、CITED2或CITED4之TAD。在一個實施例中,此類eTF包含與DBD之C端結合之VPR TAD域。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED4 TAD。在某些實施例中,此類eTF能夠結合至具有SEQ ID NO: 333之標靶位點且相比於對照上調GRN之表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調GRN之本文揭示之eTF包含具有以下中之任一者之DNA結合域:(i)包含SPADLTR x DSGNLRV x QLAHLRA x QRANLRA x REDNLHT x RSDNLVR (SEQ ID NO: 414)之序列,(ii)與SEQ ID NO: 414具有至少89%、85%、90%、95%、96%、97%、98%或99%序列一致性之序列,或(ii) (i)或(ii)之功能片段。在某些實施例中,此類eTF進一步包含一或多個選自VP64、VPR、CITED2或CITED4之TAD。在一個實施例中,此類eTF包含與DBD之C端結合之VPR TAD域。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED4 TAD。在某些實施例中,此類eTF能夠結合至具有SEQ ID NO: 38之標靶位點且相比於對照上調GRN之表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調GRN之本文揭示之eTF包含具有以下中之任一者之DNA結合域:(i)包含TSHSLTE x HKNALQN x ERSHLRE x SKKALTE x QRANLRA x RKDNLKN x QSSNLVR x QSSSLVR x QAGHLAS (SEQ ID NO: 415)之序列,(ii)與SEQ ID NO: 415具有至少89%、85%、90%、95%、96%、97%、98%或99%序列一致性之序列,或(ii) (i)或(ii)之功能片段。在某些實施例中,此類eTF進一步包含一或多個選自VP64、VPR、CITED2或CITED4之TAD。在一個實施例中,此類eTF包含與DBD之C端結合之VPR TAD域。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED4 TAD。在某些實施例中,此類eTF能夠結合至具有SEQ ID NO: 334之標靶位點且相比於對照上調GRN之表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調GRN之本文揭示之eTF包含具有以下中之任一者之DNA結合域:(i)包含QSGDLRR x SPADLTR x DSGNLRV x QLAHLRA x QRANLRA x REDNLHT x RSDNLVR (SEQ ID NO: 416)之序列,(ii)與SEQ ID NO: 416具有至少89%、85%、90%、95%、96%、97%、98%或99%序列一致性之序列,或(ii) (i)或(ii)之功能片段。在某些實施例中,此類eTF進一步包含一或多個選自VP64、VPR、CITED2或CITED4之TAD。在一個實施例中,此類eTF包含與DBD之C端結合之VPR TAD域。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與DBD之N端、C端或N端及C端結合之CITED4 TAD。在某些實施例中,此類eTF能夠結合至具有SEQ ID NO: 335之標靶位點且相比於對照上調GRN之表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調GRN之本文揭示之eTF包含以下中之任一者:(i)包含SEQ ID NO: 10、16、59-60、63-64、72-73、76-77或337-350中之任一者之序列;(ii)包含SEQ ID NO: 26、32、86-89、93、165-171、377-390或412-416中之任一者之序列;(iii)包含與(i)或(ii)之任何序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF能夠相比於對照上調GRN表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
在某些實施例中,上調GRN之本文揭示之eTF包含有包含gRNA/Cas複合物之DBD,其中gRNA包含有包含SEQ ID NO: 113之靶向序列。gRNA之靶序列連接至具有以下序列之骨架序列的5'端:5'-GTTTTAGTACTCTGGAAACAGAATCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTCAACTTGTTGGCGAGA-3' (SEQ ID NO: 102)。在例示性實施例中,Cas蛋白為核酸酶去活化Cas9蛋白。在某些實施例中,此類eTF進一步包含一或多個與Cas蛋白結合之TAD,其中TAD選自VP64、VPR、CITED2或CITED4。在一個實施例中,此類eTF包含與Cas蛋白之C端結合的VPR TAD域。在某些實施例中,此類eTF包含與Cas蛋白之N端、C端或N端及C端結合之CITED2 TAD。在某些實施例中,此類eTF包含與Cas蛋白之N端、C端或N端及C端結合之CITED4 TAD。在例示性實施例中,此類eTF能夠相比於對照上調GRN表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。
與人類蛋白質高度同源之 eTF
在另一態樣中,本申請案提供與一或多種人類蛋白質具有高序列一致性百分比之eTF,其可經設計以結合至基因組標靶位點且調節任何所關注之基因(包括例如SCN1A或GRN)之表現(上調或下調)。此類eTF當向個體投與時具有極小至無免疫原性或相比於與人類蛋白質序列具有較低百分比一致性之eTF具有降低的免疫原性。
在某些實施例中,本文提供之eTF與一或多種人類蛋白質具有至少75%、76%、77%、78%、79%、80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性。當本文提供之eTF包含衍生自相同蛋白質之DBD及TAD時,與人類蛋白質之百分比一致性可藉由計算eTF中匹配衍生其之人類蛋白質(例如EGR1或EGR3)之胺基酸殘基之總數目除以eTF中之胺基酸殘基之總數目來測定。當提供之eTF包含來自一種人類蛋白質之DBD及衍生自不同人類蛋白質之TAD時,與人類之百分比一致性可藉由分別計算各域與人類之百分比一致性且對兩者一起求和來測定,例如(i)計算DBD中匹配衍生其之人類蛋白質(例如EGR1或EGR3)之胺基酸殘基之總數目除以eTF中之胺基酸殘基之總數目;(ii)計算TAD中匹配衍生其之人類蛋白質(例如CITED2或CITED4)之胺基酸殘基之總數目除以eTF中之胺基酸殘基之總數目;及(iii)對(i)及(ii)之總數求和。在此類實施例中,域劃分如下:第一域自eTF之N端運行至第二域之編碼序列的起點,且第二域自第二域之編碼序列的起點運行至eTF之C端(例如對於具有組態NLS-DBD-連接子-NLS-TAD之eTF,第一域將為NLS-DBD-連接子且第二域將為NLS-TAD)。當本文提供之eTF包含來自一種人類蛋白質之DBD及衍生自一或多種不同人類蛋白質之兩個TAD時,與人類之百分比一致性可藉由分別計算各域與人類之百分比一致性且對所有三者一起求和來測定,例如(i)計算DBD中匹配衍生其之人類蛋白質(例如EGR1或EGR3)之胺基酸殘基之總數目除以eTF中之胺基酸殘基之總數目;(ii)計算第一TAD中匹配衍生其之人類蛋白質(例如CITED2或CITED4)之胺基酸殘基之總數目除以eTF中之胺基酸殘基之總數目;(iii)計算第二TAD中匹配衍生其之人類蛋白質(例如CITED2或CITED4)之胺基酸殘基之總數目除以eTF中之胺基酸殘基之總數目;及(iv)對(i)、(ii)及(iii)之總數求和。在此類實施例中,域劃分如下:第一域自eTF之N端運行至第二域之編碼序列的起點,第二域自第二域之編碼序列的起點運行至第三域之編碼序列的起點,且第三域自第三域之編碼序列的起點運行至eTF之C端(例如對於具有組態NLS-TAD1-連接子-NLS-DBD-連接子-NLS-TAD2之eTF,第一域將為NLS-TAD1-連接子,第二域將為NLS-DBD-連接子,且第三域將為NLS-TAD2)。如此部分中所述之與一或多種人類蛋白質之百分比一致性可使用百分比一致性輸出測定,該百分比一致性輸出使用購自NCBI之標準蛋白質BLAST工具(例如blastp程序組比對工具,使用具有預設參數之blastp (蛋白質->蛋白質)算法)(在全球資訊網上自NCBI網站blast.ncbi.nlm.nih.gov/可用)獲得。
在某些實施例中,本文提供之eTF具有歸因於與天然存在之人類蛋白質之高度序列一致性而在人類個體中引發極小、最小或不引發不良免疫反應之益處。在某些實施例中,相比於在包含與一或多種人類蛋白質之較低百分比一致性之eTF,例如包含與一或多種人類蛋白質之小於50%、55%、65%或70%序列一致性之eTF的情況下觀測之免疫原性,本文提供之eTF引發降低之免疫原性,例如免疫原性之至少0.5、1、1.5、2、2.5、3、3.5、4、4.5、5、10、15、20、25、30、35、40、45或50倍或更大倍數之降低。在一些情況下,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。具有低或極小免疫原性之基因療法具有若干優點,包括改良之患者耐受性、減少的獲得治療效應所需之劑量、延長的在一次投藥之後的治療效果、按需要投與多次或多劑量之能力、每次投與經較長時段之持續治療功效、增加之安全性及/或增加之基因療法有效性。
在某些實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF包含衍生自一或多種天然存在之人類蛋白質之DBD及TAD。在某些實施例中,此類eTF可包含衍生自任何包含DBD之天然存在之人類蛋白質的DBD。在例示性實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF包含衍生自天然存在之鋅指蛋白,諸如表7中所列之鋅指蛋白中之任一者的DBD。在某些實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF包含衍生自人類EGR蛋白質,諸如EGR1、EGR2、EGR3或EGR4之DBD。在例示性實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF包含衍生自人類EGR1或EGR3之DBD。在各種實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF包含衍生自人類鋅指蛋白之DBD,其中已在DBD之一或多個鋅指域中作出極小胺基酸變化(例如1、2、3、4、5、6、7或1-2、1-3、1-4、1-5、1-6、1-7、2-3、2-4、2-5、2-6、2-7、3-4、3-5、36或3-7個胺基酸變化)以改變DBD識別所關注之標靶結合位點的結合特異性。此類序列修飾較佳在DBD之鋅指域之識別螺旋中進行,而其餘的人類鋅指DBD或蛋白質(包括TAD)保持未經修飾,以保留與天然存在之人類蛋白質儘可能多的序列一致性。
在某些實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF包含一或多個衍生自人類蛋白質之轉錄調節域(例如TAD或TRD),其與衍生自人類蛋白質之DBD結合。在各種實施例中,轉錄調節域可衍生自任何具有能夠募集一或多個蛋白因子之域的天然存在之人類蛋白質,該一或多個蛋白因子可在eTF經由DBD結合至標靶位點時調節所關注之基因之轉錄(例如RNA聚合酶II、共活化子蛋白質或共抑制子蛋白質)或基因表現量。在例示性實施例中,TAD衍生自人類EGR蛋白質,諸如人類EGR1、EGR2、EGR3或EGR4,或人類列舉蛋白質,諸如人類CITED2或CITED4蛋白質。在例示性實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF包含來自人類EGR1或EGR3蛋白質之TAD。在另一例示性實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF包含來自人類CITED2或CITED4蛋白質之TAD。
在一個實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF可包含人類DBD (hDBD)及人類TAD (hTAD)(例如hTAD-hDBD或hDBD-hTAD),其中hDBD及hTAD可衍生自相同人類蛋白質或不同人類蛋白質。在另一實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF可包含一個hDBD及兩個hTAD,其中hDBD及hTAD衍生自相同人類蛋白質,hDBD衍生自第一人類蛋白質且兩個hTAD均衍生自第二人類蛋白質,hDBD及一個hTAD衍生自第一人類蛋白質且第二hTAD衍生自第二人類蛋白質,或hDBD衍生自第一人類蛋白質,一個hTAD衍生自第二人類蛋白質,且第二hTAD衍生自第三人類蛋白質(例如hTAD1-hDBD-hTAD1或hTAD1-hDBD-hTAD2)。
在例示性實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF包含以下組態中之任一者:(i)衍生自人類EGR1之hDBD及hTAD;(ii)衍生自人類EGR3之hDBD及hTAD;(iii)衍生自人類EGR1之hDBD及衍生自CITED2之hTAD (例如hEGR1 DBD-hCITED2 TAD或hCITED2 TAD-hEGR1 DBD);(iv)衍生自人類EGR1之hDBD及衍生自人類CITED4之hTAD (例如hEGR1 DBD-hCITED4 TAD或hCITED4 TAD-hEGR1 DBD);(v)衍生自人類EGR3之hDBD及衍生自CITED2之hTAD (例如hEGR3 DBD-hCITED2 TAD或hCITED2 TAD-hEGR3 DBD);(vi)衍生自人類EGR3之hDBD及衍生自人類CITED4之hTAD (例如hEGR3 DBD-hCITED4 TAD或hCITED4 TAD-hEGR3 DBD);(vii)衍生自人類EGR1之hDBD及衍生自CITED2之兩個hTAD (例如hCITED2 TAD-hEGR1 DBD-hCITED2 TAD);(viii)衍生自人類EGR1之hDBD及衍生自人類CITED4之兩個hTAD (例如hCITED4 TAD-hEGR1 DBD-hCITED4 TAD);(ix)衍生自人類EGR3之hDBD及衍生自人類CITED2之兩個hTAD (例如hCITED2 TAD-hEGR3 DBD-hCITED2 TAD);(x)衍生自人類EGR3之hDBD及衍生自人類CITED4之兩個hTAD (例如hCITED4 TAD-hEGR3 DBD-hCITED4 TAD);(xi)衍生自人類EGR1之hDBD、衍生自人類CITED2之第一hTAD、衍生自人類CITED4之第二hTAD (例如hCITED2 TAD-hEGR1 DBD-hCITED4 TAD或hCITED4 TAD-hEGR1 DBD-hCITED2 TAD);或(xii)衍生自人類EGR3之hDBD、衍生自人類CITED2之第一hTAD、衍生自人類CITED4之第二hTAD (例如hCITED2 TAD-hEGR3 DBD-hCITED4 TAD或hCITED4 TAD-hEGR3 DBD-hCITED2 TAD)。
在另一實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF可包含hDBD及hTRD (例如hTRD-hDBD或hDBD-hTRD),其中hDBD及hTRD可衍生自相同蛋白質或不同蛋白質。在另一實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF可包含一個hDBD及兩個hTRD,其中hDBD及hTRD衍生自相同人類蛋白質,hDBD衍生自第一人類蛋白質且兩個hTRD均衍生自第二人類蛋白質,hDBD及一個hTRD衍生自第一人類蛋白質且第二hTRD衍生自第二人類蛋白質,或hDBD衍生自第一人類蛋白質,一個hTRD衍生自第二人類蛋白質,且第二hTRD衍生自第三人類蛋白質(例如hTRD1-hDBD-hTRD1或hTRD1-hDBD-hTRD2)。
在某些實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF包含以下中之任一者:(i)包含SEQ ID NO: 6-10、13-16、57-64、67-77、295-299、313-325、345-350、364、436中之任一者之序列;(ii)包含SEQ ID NO: 22-26、29-32、84-93、385-390、406-409、427-435或437中之任一者之序列;(iii)包含與(i)或(ii)之任何序列之至少80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv) (i)、(ii)或(iii)之任何序列之功能片段或變異體。在例示性實施例中,此類eTF能夠相比於對照上調SCN1A或GRN表現至少2倍、5倍、10倍、15倍、20倍、25倍、30倍、40倍、50倍或更大,或相比於對照上調至少20%、30%、40%、50%、60%、70%、75%、80%、90%、100%、125%、150%、200%、250%、300%、400%或500%或更大。在例示性實施例中,此類eTF與一或多種人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%總體序列一致性。在某些實施例中,相比於與一或多種人類蛋白質具有較低總體序列一致性百分比之eTF,此類eTF展現降低之免疫原性。在各種實施例中,免疫原性之降低可使用elispot分析、免疫分析或電腦模擬方法量測。
在某些實施例中,與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF可另外包含除DBD及TAD域以外的一或多個胺基酸序列或域,諸如核定位信號或連接子等。另外,編碼與一或多種人類蛋白質具有高序列一致性百分比之本文提供之eTF的聚核苷酸可另外包含除eTF之編碼序列以外的一或多個核酸序列,諸如啟動子、增強子、polyA尾等。在此類實施例中,額外胺基酸序列及/或核酸序列中之一或多者較佳為人類序列、衍生自人類序列或與人類蛋白質具有至少75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性。
聚核苷酸
在另一態樣中,本申請案提供編碼本文揭示之eTF中之任一者的聚核苷酸。
在某些實施例中,本申請案提供包含以下中之任一者之聚核苷酸:(i)編碼包含SEQ ID NO: 6-10、13-16、57-64、67-77、268-282、305-325、337-350、364、295-299或365-366中之任一者之eTF的核酸序列,或其變異體或功能片段;(ii)編碼具有SEQ ID NO: 6-10、13-16、57-64、67-77、268-282、305-325、337-350、364、295-299或365-366中之任一者之eTF之功能片段的核酸;或(iii)編碼與具有SEQ ID NO: 6-10、13-16、57-64、67-77、112、268-282、305-325、337-350、364、295-299、365-366中之任一者之eTF具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之eTF的核酸,或其變異體或功能片段,其中eTF能夠上調SCN1A或GRN。
在某些實施例中,本申請案提供包含以下中之任一者之聚核苷酸:(i)編碼包含SEQ ID NO: 22-26、29-32、84-93、131-135、165-171、377-409或423-435中之任一者之DBD的核酸序列,或其變異體或功能片段;(ii)編碼具有SEQ ID NO: 22-26、29-32、84-93、131-135、165-171、377-409、423-435中之任一者之DBD之功能片段的核酸;或(iii)編碼與具有SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、377-409或432-435中之任一者之DBD具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之DBD的核酸,或其變異體或功能片段,其中eTF能夠結合至與SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、377-409、423-435中之任一者結合之標靶位點。
在某些實施例中,本申請案提供編碼上調內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)編碼包含SEQ ID NO: 6-9、13-15、57-58、61-62、67-71、74-75、268-282、295-299、305-325或364-366中之任一者之eTF的核酸序列;(ii)編碼具有SEQ ID NO: 6-9、13-15、57-58、61-62、67-71、74-75、268-282、295-299、305-325或364-366中之任一者之eTF之功能片段的核酸;或(iii)編碼與具有SEQ ID NO: 6-9、13-15、57-58、61-62、67-71、74-75、268-282、295-299、305-325或364-366中之任一者之eTF具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之eTF的核酸,其中eTF能夠上調SCN1A。
在某些實施例中,本申請案提供編碼DBD之聚核苷酸,該DBD結合至能夠在與本文揭示之eTF結合時上調內源性SCN1A之基因組標靶位點,其中聚核苷酸包含以下中之任一者:(i)編碼包含SEQ ID NO: 22-25、29-31、84-85、88、90-92、131-135、371-372、376、391-409或423-435中之任一者之DBD的核酸序列;(ii)編碼具有SEQ ID NO: 22-25、29-31、84-85、88、90-92、131-135、371-372、376、391-409或423-435中之任一者之DBD之功能片段的核酸;或(iii)編碼與具有SEQ ID NO: 22-25、29-31、84-85、88、90-92、131-135、371-372、376、391-409或423-435中之任一者之DBD具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之eTF的核酸,其中DBD能夠結合至與SEQ ID NO: 22-25、29-31、84-85、88、90-92、131-135、371-372、376、391-409或423-435中之任一者結合之標靶位點。
在某些實施例中,本申請案提供編碼DBD之聚核苷酸,該DBD結合至能夠在與本文揭示之eTF結合時上調內源性SCN1A之基因組標靶位點,其中聚核苷酸包含以下中之任一者:(i)編碼包含SEQ ID NO: 135、371、372或376中之任一者之DBD的核酸序列;(ii)編碼具有SEQ ID NO: 135、371、372或376中之任一者之DBD之功能片段的核酸;或(iii)編碼與具有SEQ ID NO: 135、371、372或376中之任一者之DBD具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之eTF的核酸,其中DBD能夠結合至與SEQ ID NO: 22-25、29-31、84-85、88、90-92、131-135、371-372、376或391-409中之任一者結合之標靶位點。
在某些實施例中,本申請案提供編碼上調內源性GRN之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:編碼包含SEQ ID NO: 10、16、59-60、63、64、72-73、76、77或337-350中之任一者之eTF的核酸序列;(ii)編碼具有SEQ ID NO: 10、16、59-60、63、64、72-73、76、77或337-350中之任一者之eTF之功能片段的核酸;或(iii)編碼與具有SEQ ID NO: 10、16、59-60、63、64、72-73、76、77或337-350中之任一者之eTF具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之eTF的核酸,其中eTF能夠上調GRN。
在某些實施例中,本申請案提供編碼DBD之聚核苷酸,該DBD結合至能夠在與本文揭示之eTF結合時上調內源性GRN之基因組標靶位點,其中聚核苷酸包含以下中之任一者:(i)編碼包含SEQ ID NO: 26、32、86-89、93、165-171或377-390中之任一者之DBD的核酸序列;(ii)編碼具有SEQ ID NO: 26、32、86-89、93、165-171或377-390中之任一者之DBD之功能片段的核酸;或(iii)編碼與具有SEQ ID NO: 26、32、86-89、93、165-171或377-390中之任一者之DBD具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之eTF的核酸,其中DBD能夠結合至與SEQ ID NO: 26、32、86-89、93、165-171或377-390中之任一者結合之標靶位點。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 353-363中之任一者之核酸序列;(ii)具有SEQ ID NO: 442-453中之任一者之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸,其中聚核苷酸編碼能夠上調SCN1A之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 353之核酸序列;(ii)具有SEQ ID NO: 442之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 305,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 354之核酸序列;(ii)具有SEQ ID NO: 443之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 306,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 355之核酸序列,(ii)具有SEQ ID NO: 444之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 308,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 356之核酸序列,(ii)具有SEQ ID NO: 445之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 313,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 357之核酸序列,(ii)具有SEQ ID NO: 451之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 314,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 358之核酸序列,(ii)具有SEQ ID NO: 448之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 315,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 359之核酸序列,(ii)具有SEQ ID NO: 446之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 316,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 360之核酸序列,(ii)具有SEQ ID NO: 447之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 317,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 361之核酸序列,(ii)具有SEQ ID NO: 450之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 318,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 362之核酸序列,(ii)具有SEQ ID NO: 449之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 319,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 452之核酸序列,(ii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iii)與(i)或(ii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 440,或其功能片段或變異體之eTF。
在某些實施例中,本申請案提供編碼能夠調節內源性SCN1A之eTF的聚核苷酸,其中聚核苷酸包含以下中之任一者:(i)具有SEQ ID NO: 363之核酸序列,(ii)具有SEQ ID NO: 453之核酸序列;(iii)具有(i)或(ii)之任何序列之功能片段的核酸;或(iv)與(i)、(ii)或(iii)之任何序列具有至少70%、75%、80%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或更大序列一致性之核酸。在例示性實施例中,此類聚核苷酸編碼能夠上調SCN1A的具有SEQ ID NO: 325,或其功能片段或變異體之eTF。
表現卡匣
在另一態樣中,本申請案提供表現卡匣,其包含編碼如本文所提供之eTF的聚核苷酸及一或多個調節元件。
在某些實施例中,編碼本文揭示之eTF之聚核苷酸為除編碼eTF之序列以外亦包含一或多個調節元件的表現卡匣部分。在例示性實施例中,編碼本文揭示之eTF之聚核苷酸為包含位於編碼eTF之序列上游以使得能夠驅動eTF於細胞中之表現之啟動子的表現卡匣部分。
在某些實施例中,本文揭示之表現卡匣包含編碼eTF之聚核苷酸及位於編碼eTF之序列上游以使得能夠驅動eTF於細胞中之表現的組成型啟動子。組成型啟動子之實例包括GAD2啟動子、人類突觸蛋白啟動子、CBA啟動子、CMV啟動子、minCMV啟動子、TATA盒、超核心啟動子或EF1α啟動子,或其組合。
在某些實施例中,本文揭示之表現卡匣包含編碼eTF之聚核苷酸及能夠驅動eTF於細胞中之表現的短啟動子。在某些實施例中,根據本文所述之核酸分子適用的短啟動子包含小於500 bp、450 bp、400 bp、350 bp、300 bp、250 bp、225 bp、200 bp、175 bp、150 bp、145 bp、140 bp、135 bp、130 bp、125 bp、120 bp、115 bp、110 bp、105 bp、100 bp、95 bp、90 bp、85 bp、80 bp或75 bp,或約80-300 bp、80-275 bp、80-250 bp、80-200 bp、80-150 bp、80-125 bp、80-120 bp、80-115 bp、80-110 bp、80-105 bp、80-100 bp、85-300 bp、85-275 bp、85-250 bp、85-200 bp、85-150 bp、85-125 bp、85-120 bp、85-115 bp、85-110 bp、85-105 bp、85-100 bp、90-300 bp、90-275 bp、90-250 bp、90-200 bp、90-150 bp、90-125 bp、90-120 bp、90-115 bp、90-110 bp、90-105 bp、90-100 bp、95-300 bp、95-275 bp、95-250 bp、95-200 bp、95-150 bp、95-125 bp、95-120 bp、95-115 bp、95-110 bp、95-105 bp、95-100 bp、100-300 bp、100-275 bp、100-250 bp、100-200 bp、100-150 bp、100-125 bp、100-120 bp、100-115 bp、100-110 bp或100-105 bp。在例示性實施例中,根據本文所述之表現卡匣適用的短啟動子包含約100-120 bp、約117 bp或約100 bp。
在某些實施例中,本文揭示之表現卡匣包含短啟動子,其包含或由以下中之任一者組成:(i) SEQ ID NO: 178;(ii)其變異體或功能片段;或(iii)可操作地連接於編碼本文揭示之eTF中之任一者之聚核苷酸的與(i)或(ii)中之任一者具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之核酸序列。短啟動子序列之其他實例可發現於PCT公開案第WO 2018/213786號中。
在某些實施例中,本文揭示之表現卡匣包含編碼eTF之聚核苷酸及位於編碼eTF之序列上游以使得能夠選擇性地驅動eTF於所關注之細胞中之表現的細胞類型選擇性啟動子。在某些實施例中,細胞類型選擇性啟動子可針對任何所關注之細胞類型,諸如心臟細胞、肝細胞、肌細胞、骨細胞、神經元或其亞群具選擇性(例如選擇性地驅動在其中之表現)。在例示性實施例中,本文揭示之表現卡匣包含編碼eTF之聚核苷酸及位於編碼eTF之序列上游以使得能夠選擇性地驅動eTF於PV細胞組織表現的PV選擇性調節元件(例如啟動子、增強子及/或啟動子及增強子)。PV選擇性調節元件係指特異性調節PV神經元中之基因表現的調節元件。在某些實施例中,相對於一或多種其他CNS細胞類型,PV選擇性調節元件增強PV神經元中之表現。在某些實施例中,PV選擇性調節元件抑制脫靶細胞類型中之轉錄及/或轉譯過程。
在某些實施例中,相比於脫靶細胞類型,本文提供之PV選擇性調節元件在PV細胞中導致選擇性基因表現。在一些情況下,脫靶細胞類型包括但不限於興奮性神經元、非PV CNS細胞類型及非神經元CNS細胞類型。在某些實施例中,PV選擇性調節元件在至少一種、兩種、三種、四種、五種或更多種非PV CNS細胞類型中導致PV神經元中之選擇性基因表現。在一些情況下,非PV CNS細胞為興奮性神經元、多巴胺激導性神經元、星形膠細胞、微神經膠細胞、運動神經元、血管細胞或非GABA能神經元(例如不表現GAD2、GAD1、NKX2.1、DLX1、DLX5、SST及VIP中之一或多者的細胞)、非PV神經元(例如不表現小白蛋白之GABA能神經元)或其他CNS細胞(例如從不表現PV、GAD2、GAD1、NKX2.1、DLX1、DLX5、SST及VIP中之任一者之CNS細胞類型)。在一些情況下,相比於非PVGABA能細胞,本文提供之PV選擇性調節元件導致PV神經元中增加之基因表現選擇性。在一些情況下,細胞類型係藉由具有不同細胞標記物、形態、表現型、基因型、功能及/或任何其他對細胞類型進行分類之方式來區分。
可以多種方法量測由PV選擇性調節元件驅動之表現的選擇性。在一個實施例中,可藉由比較自可操作地連接於PV選擇性調節元件之基因表現可偵測水準之轉錄物之PV細胞的數目與表現基因之細胞的總數目(例如表現基因之PV細胞與總細胞(PV+非PV細胞)之比)來量測PV細胞相對於非PV細胞中之基因表現的選擇性。舉例而言,可使用基於免疫組織化學之共定位分析,使用編碼可操作地連接於PV選擇性調節元件之螢光蛋白(例如eGFP)的基因量測基因表現及識別連接至第二螢光標記(例如紅色螢光蛋白)之PV細胞(例如與PV神經元特異性相互作用之抗PV抗體)之抗體來測定PV神經元之選擇性。PV細胞中之表現的選擇性可藉由表現PV及eGFP兩者之細胞(例如PV細胞)數目除以表現eGFP之細胞(例如PV細胞及非PV細胞)之總數目,且乘以100以轉化為百分比來計算。表現轉殖基因之PV細胞的百分比愈高,調節元件對於PV細胞愈具選擇性。在某些實施例中,本文提供之PV選擇性調節元件可對於PV細胞中之表現具高選擇性。舉例而言,本文提供之PV選擇性調節元件可對於PV神經元展現約50%、55%、60%、65%、70%、75%、80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或大於約99%之選擇性(例如PV神經元/總細胞×100)。
在一些情況下,本文提供之PV選擇性調節元件較短。在一些情況下,PV選擇性調節元件之尺寸與載體(例如病毒載體或rAAV)之選殖容量相容,使得轉殖基因及一或多個PV選擇性調節元件之組合尺寸不超過載體之選殖容量。在一些情況下,PV選擇性調節元件之長度為至多約2050 bp、2000 bp、1900 bp、1800 bp、1700 bp、1600 bp、1500 bp、1400 bp、1300 bp、1200 bp、1100 bp、1000 bp、900 bp、800 bp、700 bp、600 bp、500 bp、400 bp、300 bp、200 bp或100 bp。在一些情況下,PV選擇性調節元件在約500-600 bp、500-700 bp、500-800 bp、500-900 bp、500-1000 bp或500-1500 bp之間。
在某些實施例中,本文提供之PV選擇性調節元件包含或由以下中之任一者組成:(i) SEQ ID NO: 183-185及417;(ii)其變異體、功能片段或組合;或(iii)與(i)或(ii)中之任一者具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之核酸序列。在一些情況下,調節元件包含SEQ ID NO: 183-185及417中之任一者。PV選擇性調節元件之其他實例可發現於PCT公開案第WO 2018/187363號中。
在例示性實施例中,本申請案提供包含編碼在PV選擇性調節元件控制下之SCN1A eTF之核酸序列的表現卡匣。在某些實施例中,本申請案提供包含核酸序列之表現卡匣,該核酸序列編碼包含具有以下序列中之任一者之DBD的SCN1A eTF:在具有SEQ ID NO: 183-185或417中之任一者之PV選擇性調節元件控制下的SEQ ID NO: 135、371-372或376。在某些實施例中,本申請案提供包含核酸序列之表現卡匣,該核酸序列編碼包含以下序列中之任一者之SCN1A eTF:在具有SEQ ID NO: 183-185或417中之任一者之PV選擇性調節元件控制下的SEQ ID NO: 6-9、13-15、57-58、61-62、67-71、74-75、268-282、295-299、305-325或364-366。在某些實施例中,本申請案提供包含核酸序列之表現卡匣,該核酸序列包含以下序列中之任一者:在具有SEQ ID NO: 183-185或417中之任一者之PV選擇性調節元件控制下的SEQ ID NO: 353-363。在某些實施例中,本申請案提供包含核酸序列之表現卡匣,該核酸序列編碼包含具有以下序列中之任一者之DBD的SCN1A eTF:在具有SEQ ID NO: 183或185中之任一者之PV選擇性調節元件控制下的SEQ ID NO: 135、371、372或376。在某些實施例中,本申請案提供包含核酸序列之表現卡匣,該核酸序列編碼包含以下序列中之任一者之SCN1A eTF:在具有SEQ ID NO: 183或185中之任一者之PV選擇性調節元件控制下的SEQ ID NO: 6-9、13-15、57-58、61-62、67-71、74-75、268-282、295-299、305-325或364-366。在某些實施例中,本申請案提供包含核酸序列之表現卡匣,該核酸序列包含以下序列中之任一者:在具有SEQ ID NO: 183或185中之任一者之PV選擇性調節元件控制下的SEQ ID NO: 353-363。
在某些實施例中,本申請案提供包含在細胞類型選擇性調節元件控制下編碼GRN eTF之核酸序列的表現卡匣。在某些實施例中,細胞類型選擇性調節元件可相比於其他細胞類型(例如非CNS細胞)在選自由以下組成之群的細胞中以較高水準驅動上調GRN之eTF的表現:中樞神經系統細胞、額葉皮層細胞、神經膠細胞、微神經膠細胞、浦金埃氏細胞(Purkinje cell)、錐體細胞(例如貝茲細胞(Betz cells))、運動神經元、大腦皮質神經元及紋狀體細胞。
在某些實施例中,除啟動子以外,本文提供之表現卡匣亦可包含另外一個額外調節元件,諸如與轉錄起始或終止相關之序列、增強子序列及高效RNA處理信號。例示性調節元件包括例如內含子、增強子、UTR、穩定性元件、WPRE序列、Kozak共同序列、轉譯後反應元件、微RNA結合位點或聚腺苷酸化(polyA)序列,或其組合。調節元件可用以在基因表現之轉錄階段、轉錄後階段或轉譯階段調節基因表現。在RNA層級,調節可在轉譯(例如使mRNA穩定以用於轉譯之穩定性元件)、RNA裂解、RNA剪接及/或轉錄終止之層級進行。在各種實施例中,調節元件可將轉錄因子募集至編碼區,其增加所關注之細胞類型中之基因表現選擇性、增加RNA轉錄物之產生速率、增加所產生RNA之穩定性及/或增加自RNA轉錄物之蛋白質合成速率。
在某些實施例中,本文所述之表現卡匣進一步包含polyA序列。適合之polyA序列包括例如長度為約75 bp之人工polyA (PA75)(參見例如WO 2018/126116)、牛生長激素polyA、SV40早期polyA信號、SV40晚期polyA信號、兔β血球蛋白polyA、HSV胸苷激酶polyA、魚精蛋白基因polyA、腺病毒5 EIb polyA、生長激素polyA或PBGD polyA。在例示性實施例中,適用於本文提供之表現卡匣的polyA序列為hGH polyA (SEQ ID NO: 327)或合成polyA (SEQ ID NO: 326)。通常,polyA序列安置於本文所述之表現卡匣中編碼eTF之聚核苷酸下游。
在某些實施例中,本文提供之表現卡匣進一步包含一或多個編碼一或多個核定位信號(NLS)之核酸序列。可使用任何促進將蛋白質導入至與細胞核連接之NLS肽。NLS之實例包括例如SV40大型T-抗原NLS、核質蛋白NLS、EGL-13 NLS、c-Myc NLS及TUS-蛋白質NLS。參見例如C. Dingwall等人, J. Cell Biol. 107: 841-9 (1988);J.P. Makkerh等人, Curr Biol. 6: 1025-7 (1996);及M. Ray等人, Bioconjug. Chem. 26: 1004-7 (2015)。NLS可位於eTF蛋白質序列上之任何位置,但在較佳實施例中與eTF之N端或eTF之域結合。在例示性實施例中,本文提供之核酸卡匣編碼eTF,其中NLS融合至eTF之N端。在其他實施例中,本文提供之核酸卡匣編碼eTF,其中第一NLS融合至eTF之N端且第二NLS位於eTF之DBD與TAD域之間。
表現載體
在某些實施例中,本文所述之表現卡匣可併入至表現載體中。表現載體可用於經由轉染或轉導將表現卡匣遞送至靶細胞。載體可為整合或非整合載體,參考載體將表現卡匣或轉殖基因整合至宿主細胞之基因組中的能力。表現載體之實例包括但不限於(a)非病毒載體,諸如包括線性寡核苷酸及環形質體之核酸載體;人工染色體,諸如人類人工染色體(HAC)、酵母菌人工染色體(YAC)及細菌人工染色體(BAC或PAC));游離型載體;轉座子(例如PiggyBac);及(b)病毒載體,諸如反轉錄病毒載體、慢病毒載體、腺病毒載體及腺相關病毒載體。
表現載體可為線性寡核苷酸或環形質體且可經由各種轉染方法,包括物理及化學方法遞送至細胞。物理方法一般係指在促進遺傳物質之細胞內遞送中採用物理力來抵消細胞膜障壁之遞送方法。物理方法之實例包括使用針、彈道DNA、電穿孔、聲致穿孔、光致穿孔、磁轉染及水穿孔(hydroporation)。化學方法一般係指其中化學載劑將核酸分子遞送至細胞之方法且可包括無機顆粒、基於脂質之載體、基於聚合物之載體及基於肽之載體。
在一些實施例中,表現載體係使用陽離子脂質(例如陽離子脂質體)投與至靶細胞。已研究各種類型的脂質之基因遞送,諸如脂質奈米乳液(例如其為藉由乳化劑穩定化的一種不可混溶液體於另一種中之分散液)或固體脂質奈米粒子。
在一些實施例中,表現載體係使用基於肽之遞送媒劑投與至靶細胞。基於肽之遞送媒劑可具有保護待遞送之遺傳物質、靶向特定細胞受體、破壞內體膜及將遺傳物質遞送至細胞核中之優點。在一些實施例中,表現載體係使用基於聚合物之遞送媒劑投與至靶細胞。基於聚合物之遞送媒劑可包含天然蛋白質、肽及/或多醣或合成聚合物。在一個實施例中,基於聚合物之遞送媒劑包含聚乙烯亞胺(PEI)。PEI可將DNA縮合至帶正電粒子中,該等帶正電粒子結合至陰離子細胞表面殘基且經由內飲作用攜帶至細胞中。在其他實施例中,基於聚合物之遞送媒劑可包含聚-L-離胺酸(PLL)、聚(DL-乳酸)(PLA)、聚(DL-丙交酯-共-糖苷)(PLGA)、聚鳥胺酸、聚精胺酸、組蛋白、魚精蛋白、樹枝狀聚合物、聚葡萄胺糖、聚葡萄糖之合成胺基衍生物及/或陽離子丙烯酸聚合物。在某些實施例中,基於聚合物之遞送媒劑可包含聚合物之混合物,諸如PEG及PLL。
在某些實施例中,表現載體可為適合於基因療法之病毒載體。病毒基因療法載體或基因遞送載體之較佳特徵可包括可再現且穩定地傳播且純化至高效價;介導靶向遞送(例如將轉殖基因特異性遞送至所關注之組織或器官而無他處之廣泛載體播散);及在不誘導有害副作用的情況下介導基因遞送及轉殖基因表現之能力。
若干類型之病毒,例如稱為腺相關病毒之非致命性小病毒已出於基因療法之目的藉由利用病毒感染路徑工程化,但避免可導致複製及毒性之病毒基因的後續表現。可如下獲得此類病毒載體:藉由自病毒基因組刪除所有或一些編碼區,但使諸如將載體基因組包裝至病毒衣殼中或將載體核酸(例如DNA)整合至宿主染色體中之功能可能需要之彼等序列(例如末端重複序列)保留完整
在各種實施例中,適合之病毒載體包括反轉錄病毒(例如A型、B型、C型及D型病毒)、腺病毒、小病毒(例如腺相關病毒或AAV)、冠狀病毒、負股RNA病毒,諸如正黏液病毒(例如流感病毒)、棒狀病毒(例如狂犬病及水泡性口炎病毒)、副黏液病毒(例如麻疹及仙台病毒(Sendai))、正股RNA病毒,諸如小RNA病毒及α病毒,及雙股DNA病毒,包括腺病毒、疱疹病毒(例如1型及2型單純疱疹病毒、埃-巴二氏病毒(Epstein-Barr virus)、細胞巨大病毒)及痘病毒(例如痘瘡、鳥痘及金絲雀痘)。反轉錄病毒之實例包括禽類白血病肉瘤病毒、1型人類T-淋巴病毒(HTLV-1)、牛白血病病毒(BLV)、慢病毒及泡沫病毒屬。其他病毒包括例如諾沃克病毒(Norwalk virus)、披衣病毒、黃病毒、呼腸孤病毒、乳多泡病毒、嗜肝DNA病毒及肝炎病毒。病毒載體可根據其整合至宿主基因組中之能力分為兩組-整合及非整合。致癌反轉錄病毒及慢病毒可整合至宿主細胞染色體中,而腺病毒、腺相關病毒及疱疹病毒主要以染色體外游離基因體形式保持於細胞核中。
在某些實施例中,適合之病毒載體為反轉錄病毒載體。反轉錄病毒係指反轉錄病毒科之病毒。反轉錄病毒之實例包括致癌反轉錄病毒,諸如鼠類白血病病毒(MLV),及慢病毒,諸如人類免疫缺陷病毒1 (HIV-1)。反轉錄病毒基因組為單股(ss) RNA且包含可以順式或反式提供之各種基因。舉例而言,反轉錄病毒基因組可含有順式作用序列,諸如兩個長末端重複序列(LTR),具有用於基因表現、反轉錄及整合至宿主染色體中之元件。其他組分包括包裝信號(psi或ψ),用於將特定RNA包裝至新形成之病毒粒子中,及多嘌呤管道(PPT),在反轉錄期間起始正股DNA合成之位點。另外,反轉錄病毒基因組可包含gag、pol及env基因。gag基因編碼結構蛋白,pol基因編碼伴隨ssRNA且進行將病毒RNA反轉錄為DNA之酶,且env基因編碼病毒包膜。一般而言,gag、pol及env以反式提供用於病毒複製及包裝。
在某些實施例中,本文提供之反轉錄病毒載體可為慢病毒載體。識別慢病毒之至少五個血清組或血清型。不同血清型之病毒可不同地感染某些細胞類型及/或宿主。舉例而言,慢病毒包括靈長類反轉錄病毒及非靈長類反轉錄病毒。靈長類反轉錄病毒包括HIV及猿猴免疫缺陷病毒(SIV)。非靈長類反轉錄病毒包括貓免疫缺陷病毒(FIV)、牛免疫缺陷病毒(BIV)、山羊關節炎-腦炎病毒(CAEV)、馬傳染性貧血病毒(EIAV)及維思納病毒(visnavirus)。慢病毒或慢病毒載體可能能夠轉導靜止細胞。如同致癌反轉錄病毒載體,慢病毒載體之設計可基於順式作用及反式作用序列之分離。
在某些實施例中,本申請案提供已經設計以藉由最佳化治療性反轉錄病毒載體遞送之表現載體。反轉錄病毒載體可包含左側(5') LTR之慢病毒;幫助病毒之包裝及/或核輸入之序列;啟動子;視情況存在之一或多個額外調節元件(諸如增強子或polyA序列);視情況存在之慢病毒反向反應元件(RRE);包含可操作地連接於編碼eTF之序列之PV選擇性調節元件的構築體;視情況存在之絕緣子;及右側(3')反轉錄病毒LTR。
在例示性實施例中,本文提供之病毒載體為腺相關病毒(AAV)。AAV為感染人類及一些其他靈長類物種之小型、複製缺乏型、非包膜動物病毒。已知AAV不會引起人類疾病及誘導輕度免疫反應。AAV載體亦可在不整合至宿主細胞基因組中的情況下感染分裂及靜止細胞兩者。
AAV基因組由長度為約4.7 kb之直鏈單股DNA組成。基因組由藉由長度為約145 bp之反向末端重複(ITR)序列側接之兩個開放閱讀框架(ORF)組成。ITR由含有回文序列之5'端處之核苷酸序列(5' ITR)及位於3'端處之核苷酸序列(3' ITR)組成。ITR藉由在針對第二股合成起始DNA複製期間充當引物之互補鹼基配對摺疊形成T形髮夾結構而以順式起作用。兩個開放閱讀框架編碼參與病毒粒子之複製及包裝的rep及cap基因。在例示性實施例中,本文提供之AAV載體不含rep或cap基因。此類基因可以反式提供用於產生病毒粒子,如下文進一步描述。
在某些實施例中,AAV載體可包括填充片段核酸。在一些實施例中,填充片段核酸可編碼綠色螢光蛋白或抗生素抗性基因,諸如康黴素或安比西林(ampicillin)。在某些實施例中,填充片段核酸可位於ITR序列外部(例如相比於eTF轉基因序列及調節序列,其位於5'與3' ITR序列之間)。
存在AAV之各種血清型,包括AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、AAV12及AAV13。此等血清型之不同之處在於其向性,或其感染之細胞類型。AAV可包含來自多個血清型(例如假型)之基因組及衣殼。舉例而言,AAV可包含在來自血清型5或血清型9之衣殼中包裝之血清型2之基因組(例如ITR)。假型可提高轉導效率以及改變向性。
在一些情況下,可跨越血腦屏障或感染CNS之細胞的AAV血清型為較佳的。在一些情況下,AAV9或其變異體用於遞送本發明之表現卡匣,該表現卡匣包含可操作地連接於編碼上調SCN1A之eTF之轉殖基因的PV選擇性調節元件。
在例示性實施例中,本申請案提供已設計用於藉由AAV遞送之表現載體。AAV可為任何血清型,例如AAV1、AAV2、AAV3、AAV3b、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、AAV12、AAV-DJ,或嵌合、雜交或變異型AAV。AAV亦可為自補AAV (scAAV)。在某些實施例中,設計用於藉由AAV遞送之表現載體包含5' ITR及3' ITR。在某些實施例中,設計用於藉由AAV遞送之表現載體包含5' ITR、啟動子、編碼eTF之轉殖基因及3' ITR。在某些實施例中,設計用於藉由AAV遞送之表現載體包含5' ITR、增強子、啟動子、編碼eTF之轉殖基因、polyA序列及3' ITR。例示性AAV表現載體說明於
圖 36及
圖 37中。
宿主細胞
在另一態樣中,本發明係關於包含編碼本發明之eTF之表現卡匣或表現載體的宿主細胞。宿主細胞可為細菌細胞、酵母細胞、昆蟲細胞或哺乳動物細胞。在例示性實施例中,宿主細胞係指任何易受所關注之病毒感染,且能夠活體外培養之細胞株。
在某些實施例中,本文提供之宿主細胞可用於離體基因療法目的。在此類實施例中,細胞經包含編碼本發明之eTF之序列的核酸分子或表現載體轉染且隨後移植至患者或個體中。移植細胞可具有自體、同種異體或異種來源。對於臨床使用,細胞分離將一般在良好作業規範(GMP)條件下進行。在移植之前,通常檢查細胞品質及微生物或其他污染物之不存在且可進行預處理,諸如藉由輻射及/或免疫抑制治療。此外,宿主細胞可連同生長因子一起移植以刺激細胞增殖及/或分化。
在某些實施例中,宿主細胞可用於離體基因療法。較佳地,該等細胞為真核細胞,諸如哺乳動物細胞,此等包括但不限於人類、非人類靈長類動物,諸如猿;黑猩猩;猴及紅毛猩猩,家養動物,包括狗及貓,以及家畜,諸如馬、牛、豬、綿羊及山羊,或其他哺乳動物物種,包括但不限於小鼠、大鼠、天竺鼠、兔、倉鼠及其類似物。熟習此項技術者將根據待移植之患者或個體選擇更適當細胞。
在某些實施例中,本文提供之宿主細胞可為具有自體更新及多能性特性之細胞,諸如幹細胞或誘導多能幹細胞。幹細胞較佳為間充質幹細胞。間充質幹細胞(MSC)能夠分化為成骨細胞、軟骨細胞、脂肪細胞或肌細胞中之至少一者,且可自任何類型的組織分離。一般而言,MSC將自骨髓、脂肪組織、臍帶或外周血分離。獲得其之方法已為熟習此項技術者所熟知。誘導多能幹細胞(亦稱為iPS細胞或iPSC)為可直接自成人細胞產生之一種類型的多能幹細胞。Yamanaka等人藉由將Oct3/4、Sox2、Klf4及c-Myc基因轉移至小鼠及人類纖維母細胞中,且迫使細胞表現基因而誘導iPS細胞(WO 2007/069666)。Thomson等人隨後使用Nanog及Lin28替代Klf4及c-Myc來產生人類iPS細胞(WO 2008/118820)。
在例示性實施例中,本文提供之宿主細胞為包裝細胞。該等細胞可為黏附或懸浮細胞。包裝細胞及輔助載體或病毒或DNA構築體共同地以反式提供病毒載體之完全複製及包裝所需的所有缺失功能。
較佳地,該等包裝細胞為真核細胞,諸如哺乳動物細胞,包括猴、人類、狗及嚙齒動物細胞。人類細胞之實例為PER.C6細胞(WO01/38362)、MRC-5 (ATCC CCL-171)、WI-38 (ATCC CCL-75)、HEK-293細胞(ATCC CRL-1573)、HeLa細胞(ATCC CCL2)及胚胎恆河猴肺細胞(ATCC CL-160)。非人類靈長類細胞之實例為Vero細胞(ATCC CCL81)、COS-1細胞(ATCC CRL-1650)或COS-7細胞(ATCC CRL-1651)。犬細胞之實例為MDCK細胞(ATCC CCL-34)。嚙齒動物細胞之實例為倉鼠細胞,諸如BHK21-F、HKCC細胞或CHO細胞。
作為哺乳動物來源之替代方案,用於本發明之細胞株可衍生自禽類來源,諸如雞、鴨、鵝、鵪鶉或野雞。禽類細胞株之實例包括禽類胚胎幹細胞(WO01/85938及WO03/076601)、永生化鴨視網膜細胞(WO2005/042728),及禽類胚胎幹細胞源性細胞,包括雞細胞(WO2006/108846)或鴨細胞,諸如EB66細胞株(WO2008/129058及WO2008/142124)。
在另一實施例中,該宿主細胞為昆蟲細胞,諸如SF9細胞(ATCC CRL-1711)、Sf21細胞(IPLB-Sf21)、MG1細胞(BTI-TN-MG1)或High Five
TM細胞(BTI-TN-5B1-4)。
在某些實施例中,包含本發明之重組AAV載體/基因組(例如包含編碼eTF之序列)的本文提供之宿主細胞可進一步包含一或多個額外核酸構築體,諸如(i)編碼rep及cap基因,但不攜有ITR序列之核酸構築體(例如AAV輔助質體);及/或(ii)提供AAV複製所需之腺病毒功能之核酸構築體(例如質體)。在例示性實施例中,本文提供之宿主細胞包含:i)包含編碼本發明之eTF之序列的表現載體(亦即,重組AAV基因組);ii)編碼不攜有ITR序列之AAV rep及cap基因的核酸構築體;及iii)包含腺病毒輔助基因之核酸構築體(如下文進一步描述)。
在某些實施例中,rep、cap及腺病毒輔助基因可在單一質體上組合(Blouin V等人 J Gene Med. 2004; 6(增刊): S223-S228;Grimm D.等人 Hum. Gene Ther. 2003; 7: 839-850)。因此,在另一例示性實施例中,本文提供之宿主細胞包含:i)包含編碼本發明之eTF之序列的表現載體(亦即,重組AAV基因組);及ii)編碼不攜有ITR序列且進一步包含腺病毒輔助基因之AAV rep及cap基因的質體。
在另一實施例中,本文提供之宿主細胞包含:a)包含編碼本發明之eTF之序列的表現載體(亦即,重組AAV基因組);b)編碼不攜有ITR序列之AAV rep及cap基因的質體;及c)包含腺病毒輔助基因E2a、E4及VA RNA之質體;其中共轉染係在組成性表現且反補腺病毒E1基因之細胞,較佳哺乳動物細胞,如HEK-293細胞(ATCC CRL-1573)中進行。
在某些實施例中,適合於大規模產生AAV載體之宿主細胞為可經重組桿狀病毒之組合感染之昆蟲細胞(Urabe等人 Hum. Gene Ther. 2002; 13: 1935-1943)。舉例而言,SF9細胞可經分別表現待包裝之AAV rep、AAV cap及AAV載體之三種桿狀病毒載體共感染。重組桿狀病毒載體將提供病毒複製及/或包裝所需的病毒輔助基因功能。
構築及產生用於根據本發明之基因療法之病毒粒子的進一步指導可見於:Viral Vectors for Gene Therapy, Methods and Protocols. Series: Methods in Molecular Biology, 第737卷. Merten and Al-Rubeai (編); 2011 Humana Press (Springer); Gene Therapy. M. Giacca. 2010 Springer-Verlag;Heilbronn R.及Weger S. Viral Vectors for Gene Transfer: Current Status of Gene Therapeutics. Drug Delivery, Handbook of Experimental Pharmacology 197; M. Schafer-Korting (編). 2010 Springer-Verlag; 第143-170頁;Adeno-Associated Virus: Methods and Protocols. R. O. Snyder及P. Moulllier (編). 2011 Humana Press (Springer);Bunning H.等人 Recent developments in adeno-associated virus technology. J. Gene Med. 2008; 10:717-733;及Adenovirus: Methods and Protocols. M. Chillon and A. Bosch (編); 第三版. 2014 Humana Press (Springer)中。
病毒粒子及產生病毒粒子之方法
在某些實施例中,本申請案提供包含病毒載體之病毒粒子,該病毒載體包含編碼本發明之eTF之序列。術語「病毒粒子(viral particle)」及「病毒粒子(virion)」在本文可互換使用且涉及感染性且通常複製缺陷性的病毒粒子,其包含包裝於衣殼內之病毒基因組(例如病毒表現載體),且視具體情況,例如對於反轉錄病毒,包含衣殼周圍之脂質包膜。「衣殼」係指包裝病毒基因組之結構。衣殼由若干由蛋白質製成之寡聚結構次單位組成。舉例而言,AAV具有二十面體衣殼,其由三種衣殼蛋白(VP1、VP2及VP3)之相互作用形成。在一個實施例中,本文提供之病毒粒子為重組AAV病毒粒子或rAAV病毒粒子,其藉由在蛋白質外鞘中包裝包含可操作地連接於如本文所述之編碼eTF之序列之PV選擇性調節元件的AAV載體獲得。
在某些實施例中,本文提供之重組AAV病毒粒子可藉由殼體化衍生自病毒粒子中之特定AAV血清型之AAV基因組製備,該特定AAV血清型由對應於相同特定血清型之AAV之天然Cap蛋白質形成。在其他實施例中,本文提供之AAV病毒粒子包含病毒載體,該病毒載體包含包裝至來自不同血清型之蛋白質中之給定AAV血清型的ITR。參見例如Bunning H等人 J Gene Med 2008; 10: 717-733。舉例而言,具有來自給定AAV血清型之ITR的病毒載體可包裝至以下各者中:a)由衍生自相同或不同AAV血清型之衣殼蛋白(例如AAV2 ITR及AAV9衣殼蛋白;AAV2 ITR及AAV8衣殼蛋白;等)構成之病毒粒子;b)由來自不同AAV血清型之衣殼蛋白或突變體(例如AAV2 ITR與AAV1及AAV9衣殼蛋白)之混合物構成之嵌合體病毒粒子;c)由已藉由不同AAV血清型或變異體之間的域交換截短之衣殼蛋白構成之嵌合病毒粒子(例如具有AAV9域之AAV2 ITR與AAV8衣殼蛋白);或d)靶向病毒粒子,其經工程化以顯示選擇性結合域,使得能夠與靶細胞特異性受體進行嚴格相互作用(例如藉由插入肽配位體基因截短之AAV5 ITR與AAV9衣殼蛋白;或藉由將肽配位體偶合至衣殼表面非遺傳修飾之AAV9衣殼蛋白)。
技術人員應瞭解,本文提供之AAV病毒粒子可包含任何AAV血清型之衣殼蛋白。在一個實施例中,病毒粒子包含來自選自由AAV1、AAV2、AAV5、AAV8及AAV9組成之群的AAV血清型之衣殼蛋白,其更適合於遞送至CNS (M. Hocquemiller等人, Hum Gene Ther 27(7): 478-496 (2016))。在一特定實施例中,病毒粒子包含本發明之表現卡匣,其中表現卡匣之5' ITR及3' ITR序列為AAV2血清型且衣殼蛋白為AAV9血清型。
此項技術中已知多種用於產生rAAV病毒粒子之方法,包括轉染、穩定細胞株產生及感染性雜交病毒產生系統,其包括腺病毒-AAV雜合體、疱疹病毒-AAV雜合體(Conway, J E等人, (1997) J. Virology 71(11):8780-8789)及桿狀病毒-AAV雜合體。用於產生rAAV病毒粒子之rAAV產生培養物全部需要:1)適合之宿主細胞,包括例如人源性細胞株,諸如HeLa、A549或293細胞,或昆蟲源性細胞株,諸如SF-9,在桿狀病毒產生系統的情況下;2)適合之輔助病毒功能,其由野生型或突變型腺病毒(諸如溫度敏感性腺病毒)、疱疹病毒、桿狀病毒或提供輔助功能之質體構築體提供;3) AAV rep及cap基因及基因產物;4)由AAV ITR序列側接之轉殖基因(例如可操作地連接於編碼如本文所述之eTF之序列的啟動子);及5)支持rAAV產生之適合之培養基及培養基組分。
在各種實施例中,本文所述之宿主細胞包含以下三種組分:(1)rep基因及cap基因,(2)提供輔助功能之基因,及(3)轉殖基因(例如由ITR側接的可操作地連接於本文所述之編碼eTF之序列的啟動子)。AAV rep基因、AAV cap基因及提供輔助功能之基因可藉由將該等基因併入至諸如質體之載體中,及將該載體引入至宿主細胞中而引入至細胞中。rep、cap及輔助功能基因可併入至相同質體或不同質體中。在一較佳實施例中,AAV rep及cap基因併入至一種質體中且提供輔助功能之基因併入至另一質體中。形成用於病毒粒子產生之宿主細胞的各種質體(例如包含AAV rep及cap基因、輔助功能或轉殖基因)可藉由使用此項技術中熟知之任何適合方法引入至細胞中。轉染方法之實例包括但不限於與磷酸鈣、DEAE-右旋糖苷、凝聚胺共沈澱;電穿孔;顯微注射;脂質體介導融合;脂質體轉染;反轉錄病毒感染;及基因槍轉染。在某些實施例中,提供rep及cap基因、輔助功能及轉殖基因(例如由ITR側接的可操作地連接於編碼本文揭示之eTF之序列的啟動子)之質體可同時引入至細胞中。在另一實施例中,提供rep及cap基因及輔助功能之質體可在引入包含轉殖基因之質體之前或之後引入細胞中。在例示性實施例中,細胞同時經三種質體轉染(例如三重轉染方法):(1)包含轉殖基因(例如由ITR側接的可操作地連接於編碼本文揭示之eTF之序列的啟動子)之質體,(2)包含AAV rep及cap基因之質體,及(3)包含提供輔助功能之基因之質體。例示性宿主細胞可為293、A549或HeLa細胞。
在其他實施例中,(1)AAV rep及cap基因、(2)提供輔助功能之基因及(3)轉殖基因中之一或多者可藉由包裝細胞攜載,為游離地及/或整合至包裝細胞之基因組中。在一個實施例中,宿主細胞可為包裝細胞,其中AAV rep及cap基因及輔助功能在宿主細胞中穩定維持且宿主細胞經含有轉殖基因(例如由ITR側接的可操作地連接於編碼本文揭示之eTF之序列的啟動子)之質體瞬時轉染。在另一實施例中,宿主細胞為包裝細胞,其中AAV rep及cap基因在宿主細胞中穩定維持且宿主細胞經含有轉殖基因(例如由ITR側接的可操作地連接於編碼本文揭示之eTF之序列的啟動子)之質體及含有輔助功能之質體瞬時轉染。在另一實施例中,宿主細胞可為包裝細胞,其中輔助功能在宿主細胞中穩定維持且宿主細胞經含有轉殖基因(例如由ITR側接的可操作地連接於編碼本文揭示之eTF之序列的啟動子)之質體及含有rep及cap基因之質體瞬時轉染。在另一實施例中,宿主細胞可為經rep及cap基因、輔助功能及轉殖基因序列(例如由ITR側接的可操作地連接於編碼本文揭示之eTF之序列的啟動子)穩定轉染之生產細胞株。例示性包裝及生產細胞可衍生自293、A549或HeLa細胞。
在另一實施例中,生產細胞株為經提供Rep及Cap蛋白質之桿狀病毒表現載體感染之昆蟲細胞株(通常為Sf9細胞)。此系統不需要腺病毒輔助基因(Ayuso E等人, Curr. Gene Ther. 2010, 10:423-436)。
如本文所用,術語「cap蛋白質」係指具有天然AAV Cap蛋白質(例如VP1、VP2、VP3)之至少一種功能活性的多肽。cap蛋白質之功能活性之實例包括誘導衣殼形成、促進單股DNA積聚、促進AAV DNA包裝至衣殼中(亦即衣殼化)、結合至細胞受體及促進病毒粒子進入宿主細胞中之能力。原則上,任何Cap蛋白質可用於本發明之上下文中。
已報導Cap蛋白質對宿主向性、細胞、組織或器官特異性、受體使用、感染效率及AAV病毒之免疫原性具有影響。因此,用於rAAV之AAV cap可考慮例如個體之物種(例如人類或非人類)、個體之免疫狀態、個體對於長期或短期治療之適合性或特定治療應用(例如特定疾病或病症之治療或遞送至特定細胞、組織或器官)來選擇。在某些實施例中,cap蛋白質衍生自由AAV1、AAV2、AAV5、AAV8及AAV9血清型組成之群的AAV。在例示性實施例中,cap蛋白質衍生自AAV9。
在一些實施例中,用於本發明方法之AAV Cap可由上述AAV cap中之一者或其編碼核酸之突變誘發(亦即藉由插入、缺失或取代)產生。在一些實施例中,AAV cap與上述AAV cap中之一或多者具有至少70%、75%、80%、85%、90%、95%、98%或99%或更大相似性。
在一些實施例中,AAV cap為嵌合的,包含來自兩個、三個、四個或更多個上述AAV cap之域。在一些實施例中,AAV cap為源自兩種或三種不同AAV或重組AAV之VP1、VP2及VP3單體之嵌合體。在一些實施例中,rAAV組合物包含超過一個上述cap。
在一些實施例中,用於rAAV病毒粒子之AAV cap經工程化意含有異源序列或其他修飾。舉例而言,賦予選擇性靶向或免疫逃避之肽或蛋白質序列可工程化為cap蛋白質。或者或另外,cap可經化學修飾以使得rAAV之表面聚乙烯羥乙酸化(亦即,聚乙二醇化),其可促進免疫逃避。cap蛋白質亦可經突變誘發(例如以移除其天然受體結合,或遮蔽免疫原性抗原決定基)。
如本文所用,術語「rep蛋白質」係指具有天然AAV rep蛋白質(例如rep 40、52、68、78)之至少一種功能活性之多肽。rep蛋白質之功能活性之實例包括與蛋白質之生理功能相關之任何活性,包括經由識別促進DNA複製、DNA複製之AAV來源的結合及切割以及DNA解螺旋酶活性。額外功能包括自AAV (或其他異源)啟動子調節轉錄及將AAV DNA位點特異性整合至宿主染色體中。在一特定實施例中,AAV rep基因可來自血清型AAV1、AAV2、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10或AAVrh10;更佳來自選自由AAV1、AAV2、AAV5、AAV8及AAV9組成之群的AAV血清型。
在一些實施例中,用於本發明方法之AAV rep蛋白質可由上述AAV rep中之一者或其編碼核酸之突變誘發(亦即藉由插入、缺失或取代)產生。在一些實施例中,AAV rep與上述AAV rep中之一或多者具有至少70%、75%、80%、85%、90%、95%、98%或99%或更大相似性。
如本文所用,表述「輔助功能」或「輔助基因」係指AAV進行複製所依賴之病毒蛋白質。輔助功能包括AAV複製所需之彼等蛋白質,包括但不限於參與AAV基因轉錄活化、階段特異性AAV mRNA剪接、AAV DNA複製、cap表現產物合成及AAV衣殼裝配之彼等蛋白質。基於病毒之輔助功能可衍生自已知輔助病毒,諸如腺病毒、疱疹病毒(除1型單純疱疹病毒以外)及牛痘病毒中之任一者。輔助功能包括但不限於腺病毒E1、E2a、VA及E4或疱疹病毒UL5、ULB、UL52及UL29,及疱疹病毒聚合酶。在一較佳實施例中,AAV進行複製所依賴之蛋白質衍生自腺病毒。
在一些實施例中,用於本發明方法之AAV進行複製所依賴之病毒蛋白質可藉由上述病毒蛋白中之一者或其編碼核酸之突變誘發(亦即藉由插入、缺失或取代)產生。在一些實施例中,病毒蛋白質與上述病毒蛋白質中之一或多者具有至少70%、75%、80%、85%、90%、95%、98%或99%或更大相似性。
分析AAV進行複製所依賴之cap蛋白質、rep蛋白質及病毒蛋白質之功能的方法為此項技術中熟知的。
表現所關注之轉殖基因(例如可操作地連接於編碼eTF之序列的啟動子)之宿主細胞可在對於AAV病毒粒子之組裝而言足夠的條件下生長。在某些實施例中,宿主細胞生長適合之時段以促進AAV病毒粒子之組裝及病毒粒子釋放至培養基中。一般而言,細胞可生長約24小時、約36小時、約48小時、約72小時、約4天、約5天、約6天、約7天、約8天、約9天或至多約10天。在約10天(或更早,取決於培養條件及使用之特定宿主細胞)之後,產生水準一般顯著降低。一般而言,培養時間自病毒產生之時間點開始量測。舉例而言,在AAV的情況下,病毒產生一般在如本文所述之適當宿主細胞中提供輔助病毒功能後開始。一般而言,在輔助病毒感染之後(或在病毒產生開始之後)約48至約100、較佳約48至約96、較佳約72至約96、較佳約68至約72小時收穫細胞。
rAAV產生培養物可在適合於所用之特定宿主細胞的多種條件(跨越寬溫度範圍、持續不同時間長度及其類似者)下生長。rAAV產生培養物包括連接依賴性培養物,其可在適合之連接依賴性容器,諸如滾瓶、中空纖維過濾器、微載體及填充床或流體化床生物反應器中培養。rAAV載體產生培養物亦可包括懸浮適應宿主細胞,諸如HeLa、293及SF-9細胞,其可以多種方法培養,包括例如旋轉燒瓶、攪拌槽生物反應器,及拋棄式系統,諸如Wave袋系統。
此項技術中已知之適合培養基可用於產生rAAV病毒粒子。此等培養基包括但不限於由Hyclone Laboratories及JRH生產之培養基,包括改良伊格爾培養基(MEM)、杜爾貝科氏改良伊格爾培養基(DMEM),其各自以全文引用的方式併入本文中。在某些實施例中,rAAV產生培養基可補充有0.5%-20% (v/v或w/v)之含量的血清或血清源性重組蛋白。或者,rAAV載體可產生於無血清條件下,其亦可稱為無動物源性產物之培養基。
在培養宿主細胞以允許AAV病毒粒子產生之後,所得病毒粒子可接著收穫及純化。在某些實施例中,AAV病毒粒子可(1)藉由宿主細胞溶解獲自產生培養物之宿主細胞,及/或(2)在轉染後一段時間,較佳72小時之後獲自該等細胞之培養基。rAAV病毒粒子可自來自產生培養物之消耗培養基收穫,其限制條件為細胞在引起rAAV病毒粒子自完整細胞釋放至培養基中之條件下培養(參見例如美國專利第6,566,118號)。溶解細胞之適合方法亦為此項技術中已知的且包括例如多個冷凍/解凍循環、音波處理、微流體化及用化學品,諸如洗滌劑及/或蛋白酶處理。
在收穫之後,rAAV病毒粒子可經純化。如本文所用,術語「純化」包括製備不含亦可存在於rAAV病毒粒子天然存在或起初製備處之至少一些其他組分的rAAV病毒粒子。因此,舉例而言,純化rAAV病毒粒子可使用分離技術將其自源混合物,諸如培養溶解物或產生培養上清液富集來製備。富集可以多種方法量測,諸如藉由存在於溶液中之抗DNA酶粒子(DRPs)或基因組複本(gc)之比例,或藉由感染力,或其可相對於存在於源混合物,諸如污染物,包括產生培養物污染物或過程內污染物,包括輔助病毒、培養基組分及其類似物中之第二潛在干擾物質來量測。
在某些實施例中,rAAV產生培養物收穫物可經澄清以移除宿主細胞碎片。在一些實施例中,產生培養物收穫物可使用多種標準技術澄清,諸如離心或經由0.2 µm或更大孔徑之過濾器(例如乙酸纖維素過濾器或一系列深度過濾器)過濾。
在某些實施例中,rAAV產生培養物收穫物另外用Benzonase
TM處理以消化任何存在於產生培養物中之高分子量DNA。在一些實施例中,Benzonase
TM消化係在標準條件下進行,例如1-2.5個單元/毫升Benzonase
TM之最終濃度,在環境溫度至37℃範圍內之溫度下,持續30分鐘至幾個小時之時段。
在某些實施例中,rAAV病毒粒子可使用以下純化步驟中之一或多者來分離或純化:平衡離心;流通式陰離子交換過濾;用於濃縮rAAV粒子之切向流過濾(TFF);藉由磷灰石層析之rAAV捕獲;輔助病毒之熱不活化;藉由疏水相互作用層析之rAAV捕獲;藉由尺寸排阻層析(SEC)之緩衝液交換;奈米過濾;及藉由陰離子交換層析、陽離子交換層析或親和性層析之rAAV捕獲。此等步驟可單獨、以各種組合或一不同次序使用。純化rAAV粒子之方法見於例如Xiao等人, (1998) Journal of Virology 72:2224-2232;美國專利第6,989,264號及第8,137,948號;及WO 2010/148143中。
在某些實施例中,純化AAV病毒粒子可相對於PBS滲析、過濾且儲存於-80℃下。病毒基因組之效價可藉由使用線性化質體DNA作為標準曲線之定量PCR測定(參見例如Lock M等人, Hum. Gene Ther. 2010; 21:1273-1285)。
醫藥組合物
在某些實施例中,本申請案提供包含編碼eTF之序列及醫藥學上可接受之載劑的組合物。在其他實施例中,本申請案提供包含編碼eTF之序列及醫藥學上可接受之載劑的病毒粒子。在例示性實施例中,此類組合物適合於基因療法應用。醫藥組合物較佳在製造及儲存條件下為無菌且穩定的。無菌溶液可例如藉由經由無菌過濾膜過濾來實現。
醫藥組合物中之可接受載劑及賦形劑較佳在所用劑量及濃度下對受體無毒。可接受載劑及賦形劑可包括緩衝劑,諸如磷酸鹽、檸檬酸鹽、HEPES及TAE;抗氧化劑,諸如抗壞血酸及甲硫胺酸;防腐劑,諸如氯化六羥季銨、十八烷基二甲基苯甲基氯化銨、間苯二酚及苯紮氯銨;蛋白質,諸如人血清白蛋白、明膠、聚葡萄糖及免疫球蛋白;親水性聚合物,諸如聚乙烯吡咯啶酮;胺基酸,諸如甘胺酸、麩醯胺酸、組胺酸及離胺酸;及碳水化合物,諸如葡萄糖、甘露糖、蔗糖及山梨醇。本發明之醫藥組合物可以可注射調配物形式非經腸投與。注射用醫藥組合物可使用無菌溶液或任何醫藥學上可接受之液體作為媒劑來調配。醫藥學上可接受之媒劑包括但不限於無菌水及生理鹽水。
本發明之醫藥組合物可在微膠囊,諸如羥甲基纖維素或明膠-微膠囊及聚甲基丙烯酸甲酯微膠囊中製備。本發明之醫藥組合物亦可在其他藥物遞送系統,諸如脂質體、白蛋白微球體、微乳液、奈米粒子及奈米膠囊中製備。用於基因療法之醫藥組合物可在可接受之稀釋劑中,或可包含緩慢釋放基質,其中嵌入有基因遞送媒劑。
本文提供之醫藥組合物可調配用於非經腸投與、皮下投與、靜脈內投與、肌肉內投與、動脈內投與、腦實質內投與、鞘內投與、大池內投與、腦室內投與或腹膜內投與。醫藥組合物亦可調配用於,或經由經鼻、噴霧、經口、氣溶膠、經直腸或經陰道投藥來投與。在一個實施例中,本文提供之醫藥組合物係投與至CNS或腦脊髓液(CSF),亦即藉由腦實質內注射、鞘內注射、大池內注射或腦室內注射。組織標靶可為特異性的,例如CNS,或其可為若干組織,例如肌肉及CNS組織之組合。例示性組織或其他標靶可包括肝臟、骨胳肌、心肌、脂肪沈積物、腎、肺、血管內皮、上皮、造血細胞、CNS及/或CSF。在一較佳實施例中,包含上調SCN1A或GRN之ETF的本文提供之醫藥組合物投與至CNS或CSF注射液,亦即藉由腦實質內注射、鞘內注射、大池內注射或腦室內注射。此等方法中之一或多者可用於投與本發明之醫藥組合物。
在某些實施例中,本文提供之醫藥組合物包含「有效量」或「治療有效量」。如本文所用,此類量係指在達成所需治療結果,諸如增加SCN1A表現量及/或降低癲癇之頻率及/或持續時間或增加GRN表現量及/或治療與GRN相關之疾病或病症(諸如FTD)所必需之劑量及時段下有效的量。
本發明之醫藥組合物的劑量取決於包括投與途徑、待治療之疾病及個體之身體特徵(例如年齡、體重、一般健康)的因素。可調節劑量以提供最優治療反應。通常,劑量可為在不誘導顯著毒性的情況下有效治療疾病之量。在一個實施例中,本文提供之AAV載體可以5x10
11至1x10
14gc/kg (基因組複本/公斤患者體重(gc/kg))範圍內的量或劑量向患者投與以治療SCN1A缺乏症(包括例如德拉韋症候群)或治療GRN缺乏症(包括例如FTD)。在一更特定實施例中,AAV載體係以包含於約5×10
11gc/kg至約3×10
13gc/kg、或約1×10
12至約1×10
14gc/kg、或約1×10
12至約1×10
13gc/kg範圍內,或約5×10
11gc/kg、1×10
12gc/kg、1.5×10
12gc/kg、2.0×10
12gc/kg、2.5×10
12gc/kg、3×10
12gc/kg、3.5×10
12gc/kg、4×10
12gc/kg、4.5×10
12gc/kg、5×10
12gc/kg、5.5×10
12gc/kg、6×10
12gc/kg、6.5×10
12gc/kg、7×10
12gc/kg、7.5×10
12gc/kg、8×10
12gc/kg、8.5×10
12gc/kg、9×10
12gc/kg或9.5×10
12gc/kg的量投與。gc/kg可例如藉由qPCR或數位液滴PCR (ddPCR)測定(參見例如M. Lock等人, Hum Gene Ther Methods. 2014年4月;25(2): 115-25)。在另一實施例中,本文提供之AAV載體可以1×10
9至1×10
11iu/kg(載體之感染單位(iu)/個體或患者之體重(kg))範圍內的量或劑量向患者投與以治療SCN1A缺乏症(包括例如德拉韋症候群)。在某些實施例中,醫藥組合物可以所需單位劑量形成。此類單一劑量單位可含有約1×10
9gc至約1×10
15gc。
本發明之醫藥組合物可例如每天、每週、每月、每半年、每年或按醫療需要向有需要之個體投與一或多次(例如1-10次或更多次)。在例示性實施例中,單次投與為足夠的。在一個實施例中,包含編碼上調SCN1A或GRN之eTF之表現卡匣的醫藥組合物適用於人類個體且係藉由腦實質內注射、鞘內注射、大池內注射或腦室內注射來投與。在一個實施例中,醫藥組合物係藉由快速注射經由外周靜脈遞送。在其他實施例中,醫藥組合物係藉由經約10分鐘(±5分鐘)、經約20分鐘(±5分鐘)、經約30分鐘(±5分鐘)、經約60分鐘(±5分鐘)或經約90分鐘(±10分鐘)之輸注而經由外周靜脈遞送。
在另一態樣中,本申請案另外提供在一或多個容器中包含如本文所述之核酸分子、載體、宿主細胞、病毒粒子或醫藥組合物之套組。套組可包括描述如何向患者投與套組內所含之核酸分子、載體、宿主細胞或病毒粒子的說明書或包裝材料。套組之容器可為任何適合之材料,例如玻璃、塑膠、金屬等,且具有任何適合之尺寸、形狀或組態。在某些實施例中,套組可包括一或多個安瓿或注射器,其在適合之液體或溶液形式中含有核酸分子、載體、宿主細胞、病毒粒子或醫藥組合物。
治療方法
在各種實施例中,本申請案提供使用本文揭示之eTF之方法。在某些實施例中,本申請案提供投與包含編碼本文揭示之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子以調節所關注之基因於細胞中之表現的方法。在某些實施例中,eTF可上調所關注之基因的表現。在其他實施例中,eTF可下調所關注之基因的表現。在各種實施例中,eTF可用於在活體外、活體內或離體調節所關注之基因於細胞中之表現。
在某些實施例中,本申請案提供治療與所關注之基因相關之疾病或病症的方法,其藉由向有需要之個體投與包含編碼調節所關注之基因之表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子。在例示性實施例中,疾病或病症係與所關注之基因之單倍不足相關聯且表現卡匣、表現載體或病毒粒子包含編碼上調所關注之基因之表現之eTF的聚核苷酸。在某些實施例中,治療疾病或病症之方法包含投與表現卡匣、表現載體或病毒粒子,其包含編碼調節與此類疾病或病症相關之所關注之內源性基因之表現之eTF的聚核苷酸,使得此類基因之過度表現或低表現得以校正、引入至健康個體之水準內或引入至如由醫療照護標準所定義之正常範圍內。在某些實施例中,本文所揭示之方法用於治療與包含一或多個導致基因異常表現之突變之內源性基因相關的疾病或病症。在一些情況下,此類內源性基因為過大而無法作為基因療法中之轉殖基因遞送,或在作為轉殖基因遞送時低效地表現之基因。
在某些實施例中,本申請案提供改善與疾病或病症相關之症狀的方法,其藉由向有需要之個體投與包含編碼eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子,該eTF調節與此類疾病或病症相關之基因之表現。
在例示性實施例中,本申請案提供治療具有SCN1A之突變、Nav1.1之缺乏及/或降低之Nav1.1活性之疾病、病症或症狀的方法,其藉由向有需要之個體投與包含編碼eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子,該eTF上調SCN1A基因或其蛋白質產物Nav1.1之表現。電壓門控鈉離子通道對於在橫紋肌及神經元組織中產生及傳播動作電位重要。電壓門控鈉離子通道為由大型中心造孔糖基化α次單位及2個較小輔助β次單位組成之雜聚複合物。由SCN1A基因編碼之大型α次單位Nav1.1次單位與諸如德拉韋症候群之多種疾病或病症相關。Nav1.1表現於神經元中,且可與各種β次單位,包括由SCN1B基因表現之Navβ1一起組裝。
在某些實施例中,本申請案提供使用上調內源性SCN1A基因之表現的eTF治療與SCN1A之突變或降低之Nav1.1活性相關之疾病的方法。與SCN1A突變相關之疾病及病症包括但不限於:德拉韋症候群、大田原症候群(Ohtahara syndrome)、癲癇、早期嬰兒型癲癇性腦病6 (EIEE6)、家族性發熱性癲癇3A (FEB3A)、難治性兒童癲癇伴全身性強直陣攣發作(ICEGTC)、偏頭痛、家族性偏癱3 (FHM3)、潘尼歐托普拉症候群(Panayiotopoulos syndrome)、家族性心房顫動13 (ATFB13)、1型全身性癲癇伴熱性癲癇附加症(gefs+ 1型)、布魯加達症候群(Brugada syndrome)、非特異性心臟傳導缺陷、全身性癲癇伴熱性癲癇附加症、良性家族性嬰兒癲癇、早期嬰兒型癲癇癲癇性腦病11 (EIEE11)、良性家族性嬰兒癲癇症、神經退化、tau蛋白病及阿茲海默氏症。在一些情況下,神經病學病況為德拉韋症候群。SCN1A之突變或異常亦與癲癇病症、癲癇症、自閉症、3型家族性偏癱性偏頭痛(FHM3)、遺傳性癲癇伴熱性癲癇附加症(GEFS+)及某些抗癲癇藥物之有效性相關。舉例而言,SCN1A之ICS5N+5G>A突變與抗癲癇藥物苯妥英(phenytoin)及卡馬西平(carbamazepine)之最大安全量(劑量)相關。
在某些實施例中,本申請案提供一種治療患有德拉韋症候群或處於罹患症德拉韋候群之風險下之個體的方法,其藉由投與包含編碼上調SCN1A之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子。德拉韋症候群已藉由在兒童生命之第一年內的長期發熱性及非發熱性癲癇表徵。此疾病進展為其他癲癇類型,如肌陣攣及部分型癲癇、精神運動性遲緩及共濟失調。其藉由認知障礙、行為障礙及運動缺陷表徵。行為缺失通常包括機能亢進及衝動,且在更罕見情況下,自閉類行為。德拉韋症候群亦與包括嗜眠及失眠之睡眠障礙相關。在許多患者中,德拉韋症候群由導致產生非功能性蛋白質之基因突變引起。治療與遺傳成因相關之病症中存在許多挑戰。因此,大部分現有治療被吸引至癲癇及其他症狀之預防性醫學管理。
在70-90%患者中,德拉韋症候群由產生提前終止密碼子且因此產生非功能性蛋白質之SCN1A基因中之無義突變引起。通常,鈉通道孔隙之S5或S6區段中之錯義突變導致通道功能之損失及德拉韋症候群之產生。SCN1A突變之異型接合遺傳為產生缺陷性鈉通道所全部必需的;患有德拉韋症候群之患者仍將具有一個正常基因複本。因此,疾病表徵為單倍不足及增加SCN1A之起作用複本之表現可恢復Nav1.1之正常產生水準中之一者。
與德拉韋症候群相關之症狀包括癲癇、記憶缺陷、發育延緩、肌肉張力低下及/或認識問題。用本文所述之表現卡匣、表現載體或病毒粒子治療可導致一或多個症狀之改善,諸如癲癇數目、持續時間及/或強度之降低。向處於罹患德拉韋症候群風險下之個體投與如本文所述之基因療法可預防產生德拉韋之一或多個症狀或減緩其進展。
在某些實施例中,相比於未治療之對照或相比於治療之前的水準,用包含編碼如本文所述的上調SCN1A之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子治療降低癲癇(例如與德拉韋症候群相關之癲癇)持續時間及/或頻率至少1%、2%、3%、4%、5%、6%、7%、8%、9%、10%、11%、12%、13%、14%、15%、16%、17%、18%、19%、20%、21%、22%、23%、24%、25%、26%、27%、28%、29%、30%、31%、32%、33%、34%、35%、36%、37%、38%、39%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%、95%或更大。
在一些阿茲海默氏症患者中,產生澱粉樣β (Aβ)涉及許多可影響神經元之可激發性的肽及蛋白酶,引起癲癇及PV神經元中之Nav1.1鈉通道的下調。在另一實施例中,本申請案提供治療罹患阿茲海默氏症之個體的方法,其藉由投與包含編碼上調SCN1A之eTF之聚核苷酸的本文所述之表現卡匣、表現載體或病毒粒子。與阿茲海默氏症相關之症狀包括短期記憶缺失、認識困難、癲癇及語言、執行功能、感知(認知障礙症)及動作執行困難(失用症)。用包含編碼上調SCN1A之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子治療可導致一或多種阿茲海默氏症症狀之改善,諸如記憶缺失進展之減少,或一或多種症狀之預防。在一些情況下,治療可導致高γ功率大腦活動之校正。治療可導致相比於無治療,癲癇頻率及/或癲癇嚴重度,或高γ功率活動降低至少10%、20%、30%、40%、50%、60%、70%或更大。在一些情況下,治療可導致認知功能改善。相比於無治療,或在用如本文所揭示之編碼上調SCN1A之eTF之聚核苷酸治療之前,學習及/或記憶可改善至少10%、20%、30%、40%、50%、60%、70%、80%、90%、100%或大於100%。
在一些情況下,相比於未治療之對照或相比於治療之前的水準,用包含編碼上調SCN1A之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子治療降低高γ功率活性(例如與阿茲海默氏症相關之高γ功率活性)至少1%、2%、3%、4%、5%、6%、7%、8%、9%、10%、11%、12%、13%、14%、15%、16%、17%、18%、19%、20%、21%、22%、23%、24%、25%、26%、27%、28%、29%、30%、31%、32%、33%、34%、35%、36%、37%、38%、39%、40%、45%、50%、55%、60%、65%、70%、75%、80%、85%、90%或95%。
帕金森氏症係指發現於帕金森氏病(PD)中之病徵及症狀,包括緩慢(動作遲緩)、僵硬(stiffness/rigidity)、顫抖及不平衡(姿勢不穩)之集合。在一些情況下,相比於無治療,向處於患上或罹患帕金森氏病風險下之個體投與如本文所述之包含編碼上調SCN1A之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子可預防帕金森氏病之一或多種症狀之產生或減緩其進展至少10%、至少20%、至少30%、至少40%、至少50%、至少60%、至少70%、至少80%或至少90%。
在某些實施例中,本申請案提供可用於治療處於罹患疾病風險下之個體的方法。個體可已知易患疾病,例如神經疾病或與癲癇症、癲癇及/或腦病相關之疾病。個體可由於遺傳事件,或由於已知風險因素而易患疾病。舉例而言,個體可攜有與德拉韋症候群相關之SCN1A之突變。在一些情況下,個體可由於個體之年齡而易患諸如阿茲海默氏症之疾病。在一些情況下,個體可具有不足量的SCN1A蛋白質且治療與SCN1A相關之疾病涉及投與如本文所述之包含編碼上調內源性SCN1A之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子。
在某些實施例中,使用本文提供之包含編碼上調內源性SCN1A之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子進行治療可導致與德拉韋或其他SCN1A相關疾病或病症相關之症狀的減少或中止。舉例而言,治療可改善學習、記憶、認知功能及/或運動功能;降低癲癇之頻率及/或持續時間;及/或降低溫度敏感性(或增加觸發癲癇之溫度臨限值)。
在另一例示性實施例中,本申請案提供治療與GRN基因之突變或GRN蛋白質之缺乏或GRN蛋白質之活性降低相關之疾病或病症的方法,其藉由向有需要之個體投與包含編碼eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子,該eTF上調GRN基因或蛋白質產物之表現。
顆粒蛋白前體為具有生長因子樣特性之富含半胱胺酸之分泌醣蛋白且屬於顆粒體蛋白家族。顆粒體蛋白(例如顆粒體蛋白A至G及顆粒蛋白前體)在血管生成、傷口修復、細胞增殖及發炎中起作用。顆粒蛋白前體基因之突變,或分泌顆粒蛋白前體之缺乏與各種神經退化性疾病及代謝疾病相關。中樞神經系統(CNS)中之分泌顆粒體蛋白缺乏可導致神經退化,包括額顳葉變性(FTLD);額顳葉型變性或額顳葉型癡呆(FTD)、與部分顆粒蛋白前體缺乏相關之早發型神經退化性疾病;進行性非流暢性失語症(PNFA);詞義性癡呆;帕金森氏病;阿茲海默氏症;及神經元蠟樣質脂褐質沈積症(NCL)伴以顆粒蛋白前體完全缺乏。FTD係指一組複雜神經退化性疾病,其藉由導致行為及/或語音變化,諸如運動協調喪失、社交功能障礙、記憶喪失及肌震顫的進行性額顳葉退化表徵。
一般而言,在一個顆粒蛋白前體基因複本中具有一或多個病原突變之患者罹患FTD,其為FTLD之亞型。FTLD之臨床症狀包括前額葉及/或前顳葉萎縮、行為性額顳葉型癡呆(藉由社會及執行功能障礙表徵)、詞義性癡呆及進行性原發性非流暢失語症,伴以早期語言障礙。FTD為成年型行為障礙,接著為額葉癡呆、帕金森氏症及肌肉萎縮。
顆粒蛋白前體亦牽涉於代謝疾病中且識別為與飲食誘導肥胖及胰島素抗性有關的脂肪細胞激素(adipokine)。顆粒蛋白前體之突變或缺乏與動脈粥樣硬化相關,動脈粥樣硬化為藉由強力發炎性組分及動脈壁增厚(歸因於脂質積聚及細胞增殖)表徵之進行性疾病。
GRN之突變可包括無義突變、剪接位點突變;導致正常閱讀框架移位之插入及缺失;及各種點突變。無義、剪接位點及框移突變可導致歸因於轉錄物之mRNA無義介導之衰減或核降解的單倍不足。已在一些偶發性FTLD、阿茲海默氏症及肌肉萎縮性側索硬化(ALS)患者中觀測到錯義突變。與疾病或病症相關之GRN之各種突變為吾人所知且包括GRN編碼區中之突變,例如-8+5G>C;-8+3A>T;2T>C, 3G>A, 26CA(A9D);63_64insC;90_91insCTGC;102∆C;138+1G>A;154∆A;234_235∆AG;243∆C;361∆G;373C>T;380_381∆CT;384_387∆TAGT;388_391∆CAGT;463-1G>A;468_474∆CTGCTGT;675_676∆CA;708+1G>A;707+1G>C;709-2A>G;759_760∆TG;813_816∆CACT;835_835+1insCTGA;836-1G>C;909∆C;910_911insTG;911G>A;933+1G>A;942C>A;998∆G;1095_1096∆CT;1145∆C;1157G>A;1201C>T;1231_1232∆GT;1232_1233insGT;1252C>T;1395_1296insC;1402C>T;1414-15_1590∆;1477C>T;或其組合。參見Eriksen JL, Mackenzie IR. Progranulin: normal function and role in neurodegeneration.
J Neurochem. 2008年1月;104(2):287-97。當前,無法治癒此類GRN相關神經退化性疾病及代謝疾病。需要靶向GRN之治療選擇,例如增加活體內顆粒蛋白前體水準及/或功能之療法。
在某些實施例中,如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子可用於治療有需要之個體,其中個體具有以上列出之GRN突變中之任何一或多者。在一些情況下,有需要之個體包含GRN之單倍不足或GRN之缺乏。在一些情況下,有需要之個體患有FTD、阿茲海默氏症、帕金森氏病及/或動脈粥樣硬化或處於罹患其之風險下。
在某些實施例中,如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子向患有FTD、阿茲海默氏症、帕金森氏病及/或動脈粥樣硬化或處於罹患其之風險下之個體投與。在另一實例中,治療可向罹患FTD、阿茲海默氏症、帕金森氏病及/或動脈粥樣硬化之個體投與。用如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子治療可導致與FTD、阿茲海默氏症、帕金森氏病及/或動脈粥樣硬化相關之一或多種症狀的改善,諸如與歸因於FTD之行為及/或語音變化相關之一或多種症狀的減輕,或動脈粥樣硬化中之動脈壁厚度的減小。與GRN相關中樞神經系統病症相關之其他症狀包括例如路易體之存在、顆粒蛋白前體(GRN)單倍不足、社交缺陷、溶酶體異常、運動協調喪失、肌震顫。在某些實施例中,相比於野生型GRN,治療可導致GRN表現量或功能恢復至少5%、至少10%、至少20%、至少30%、至少40%、至少50%、至少60%或至少70%。在某些實施例中,相比於治療前,治療可導致認知功能改善,諸如語音及/或記憶改善至少10%、至少20%、至少30%、至少40%、至少50%、至少60%、至少70%、至少80%、至少90%、至少100%或大於100%。在某些實施例中,用如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子治療可延緩與FTD、阿茲海默氏症、帕金森氏病及/或動脈粥樣硬化相關之症狀或停止該等症狀之進展。在一些情況下,相比於無治療,用如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子治療可增加CNS、額葉皮層或紋狀體中之細胞修復或逆轉細胞損傷至少10%、至少20%、至少30%、至少40%、至少50%、至少60%、至少70%、至少80%、至少90%或至少100%。在一些情況下,治療GRN相關中樞神經系統病症包含降低肌震顫之頻率及/或嚴重度。
在某些實施例中,如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子可用於治療已診斷患有疾病,例如與GRN相關之神經疾病或神經退化性疾病或代謝疾病的個體。個體可為罹患FTD、阿茲海默氏症、帕金森氏病及/或動脈粥樣硬化之患者。在一些態樣中,個體為患有FTD之患者。個體可為罹患GRN相關疾病或病況,諸如癡呆或代謝疾病之患者。在一些情況下,基因測試可用於針對GRN基因之突變篩選患者。若患者包含GRN之病理性突變,則如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子可用於預防、減緩或治療神經退化或代謝疾病,例如FTD、阿茲海默氏症、帕金森氏病及/或動脈粥樣硬化之進展。
在某些實施例中,用如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子治療之個體為診斷患有GRN之突變或遺傳畸變之個體。此類突變可為同型接合或異型接合的,或GRN基因中一或多個影響活體內蛋白質表現、分泌、溶解度、活性及/或蛋白水解裂解之鹼基的異常插入、缺失或取代。
在某些實施例中,如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子可用於治療患有與GRN突變及/或缺乏相關之神經退化性疾病或代謝疾病或處於罹患其之風險下的個體,以提高活體內GRN表現及/或功能,以治療、預防疾病,例如FTLD、FTD、進行性非流暢性失語症、詞義性癡呆、帕金森氏病、阿茲海默氏症、NCL、糖尿病或動脈粥樣硬化,或減輕疾病之影響。在一些情況下,如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子用於治療、改善、減輕或管理此類疾病之症狀,例如言語障礙、社交缺乏、運動技能或運動協調受損、肌肉萎縮、肌震顫、神經元萎縮、記憶喪失、帕金森氏症及/或溶酶體異常。在一些情況下,此類組合物用於減輕發炎、減少細胞死亡、減輕神經元萎縮、減輕運動神經元萎縮及/或增加CNS中、或額葉皮層中或尤其紋狀體中之細胞修復。
在某些實施例中,如本文所述之包含編碼上調內源性GRN表現之eTF之聚核苷酸的表現卡匣、表現載體或病毒粒子可用於治療處於罹患神經退化性疾病或代謝疾病之風險下的個體。個體可經由各種篩檢或診斷方法,包括查看GRN之基因突變的方法或關於分泌GRN蛋白質水準之血液測試而已知易患疾病,例如神經疾病或代謝疾病。個體可由於遺傳事件,或由於已知風險因素而易患疾病。舉例而言,個體可攜有GRN之突變,其與FTD、阿茲海默氏症、帕金森氏病及/或動脈粥樣硬化相關。在一些情況下,個體可具有不足量的GRN蛋白質或其同功異型物。舉例而言,個體可已知具有不足量的GRN蛋白質。
術語「個體(subject)」及「個體(individual)」在本文中可互換使用以指脊椎動物,較佳為哺乳動物,更佳為人類。本文所描述之方法可適用於人類治療學、獸醫學應用及/或疾病或病況之動物模型臨床前研究。在各種實施例中,可根據本文所描述之方法治療之個體為哺乳動物,諸如小鼠、大鼠、倉鼠、天竺鼠、沙鼠、母牛、綿羊、豬、山羊、驢、馬、狗、貓、大羊駝、猴(例如獼猴,諸如恆河猴或食蟹獼猴),或人類。在例示性實施例中,個體為人類。
下表提供本文揭示之序列。
表 1 : SCN1A 及 GRN 之 基因組基因座及蛋白質序列
表 2 : 與人類 EGR1 / EGR3 具有高序列一致性之 eTF 之 序列。
表 3 : 表 2 中揭示之 eTF 之 DBD 序列
表 4 :藉由表 2 中揭示之 eTF 識別之標靶位點序列
表 5 :用於產生 eTF 之 不同類型的鋅指結構及蛋白質
表 6 : eTF 之 全長胺基酸序列之實例
表 7 : 表 6 中揭示之 eTF 之 DBD 序列
表 8 : 可融合至本文揭示之 eTF 之 任何 DBD 的例示性 TAD 之 胺基酸序列
表 9 : TAD 與 蛋白質平台之間的序列一致性百分比
表 10 : eTF 及其標靶位點序列之實例
表 11 : 用於靶向能夠上調內源性 SCN1A 基因之標靶位點的 dSaCas9 蛋白質序列及嚮導 RNA 之實例。
表 12 : 可在 eTF 中組合以調節 SCN1A 基因之鋅指之實例。
表 13 :用於調節 SCN1A 之 eTF 的 DBD 之實例
表 14 : 包含多個調節 SCN1A 之 鋅指之 DNA 結合域之實例
表 15 :用於調節 SCN1A 之 標靶位點序列之實例
表 16 : 可上調 SCN1A 表現之本文揭示之例示性 eTF 之 核酸序列
表 17 :上調 SCN1A 之 表現之 eTF 之實例
表 18 :上調 SCN1A 之 表現之 eTF 之 序列
表 19 : 本文揭示之 poly A 序列
表 20 :調節內源性 GRN 基因之表現之鋅指之實例
表 21 : 包含複數個 ZF 的 調節 GRN 之 表現 之 eTF 之 DBD 之實例
表 22 :調節 GRN 之 表現之標靶位點序列之實例
表 23 :調節 GRN 之 表現之 eTF 之實例
表 24 :本文揭示之調節元件 ( RE ) 之實例
表 25 : 本文揭示之其他序列
表 26 :藉由 gRNA 及 dCas 蛋白質靶向之 SCN1A 基因組區
表 27 :藉由鋅指 eTF 靶向之 SCN1A 基因組區之實例
表 28 :識別 SCN1A 標靶位點之胺基酸序列 eTF
表 29 : eTF 之 DBD 之 胺基酸序列
表 30 : 上調 GRN 之 表現之 GRN 標靶區域及 eTF
表 31 :上調 GRN 表現之 eTF 之 例示性 DBD
實例
所關注之內源性基因之染色體位置 | 蛋白質 SEQ ID NO. | 胺基酸序列 ( N 端 至 C 端 ) |
SCN1A 染色體2上之鹼基對165、989、160至166、149、216 (Homo sapiens Annotation Release 109, GRCh38.p12) | SEQ ID NO: 180 | MEQTVLVPPGPDSFNFFTRESLAAIERRIAEEKAKNPKPDKKDDDENGPKPNSDLEAGKNLPFIYGDIPPEMVSEPLEDLDPYYINKKTFIVLNKGKAIFRFSATSALYILTPFNPLRKIAIKILVHSLFSMLIMCTILTNCVFMTMSNPPDWTKNVEYTFTGIYTFESLIKIIARGFCLEDFTFLRDPWNWLDFTVITFAYVTEFVDLGNVSALRTFRVLRALKTISVIPGLKTIVGALIQSVKKLSDVMILTVFCLSVFALIGLQLFMGNLRNKCIQWPPTNASLEEHSIEKNITVNYNGTLINETVFEFDWKSYIQDSRYHYFLEGFLDALLCGNSSDAGQCPEGYMCVKAGRNPNYGYTSFDTFSWAFLSLFRLMTQDFWENLYQLTLRAAGKTYMIFFVLVIFLGSFYLINLILAVVAMAYEEQNQATLEEAEQKEAEFQQMIEQLKKQQEAAQQAATATASEHSREPSAAGRLSDSSSEASKLSSKSAKERRNRRKKRKQKEQSGGEEKDEDEFQKSESEDSIRRKGFRFSIEGNRLTYEKRYSSPHQSLLSIRGSLFSPRRNSRTSLFSFRGRAKDVGSENDFADDEHSTFEDNESRRDSLFVPRRHGERRNSNLSQTSRSSRMLAVFPANGKMHSTVDCNGVVSLVGGPSVPTSPVGQLLPEVIIDKPATDDNGTTTETEMRKRRSSSFHVSMDFLEDPSQRQRAMSIASILTNTVEELEESRQKCPPCWYKFSNIFLIWDCSPYWLKVKHVVNLVVMDPFVDLAITICIVLNTLFMAMEHYPMTDHFNNVLTVGNLVFTGIFTAEMFLKIIAMDPYYYFQEGWNIFDGFIVTLSLVELGLANVEGLSVLRSFRLLRVFKLAKSWPTLNMLIKIIGNSVGALGNLTLVLAIIVFIFAVVGMQLFGKSYKDCVCKIASDCQLPRWHMNDFFHSFLIVFRVLCGEWIETMWDCMEVAGQAMCLTVFMMVMVIGNLVVLNLFLALLLSSFSADNLAATDDDNEMNNLQIAVDRMHKGVAYVKRKIYEFIQQSFIRKQKILDEIKPLDDLNNKKDSCMSNHTAEIGKDLDYLKDVNGTTSGIGTGSSVEKYIIDESDYMSFINNPSLTVTVPIAVGESDFENLNTEDFSSESDLEESKEKLNESSSSSEGSTVDIGAPVEEQPVVEPEETLEPEACFTEGCVQRFKCCQINVEEGRGKQWWNLRRTCFRIVEHNWFETFIVFMILLSSGALAFEDIYIDQRKTIKTMLEYADKVFTYIFILEMLLKWVAYGYQTYFTNAWCWLDFLIVDVSLVSLTANALGYSELGAIKSLRTLRALRPLRALSRFEGMRVVVNALLGAIPSIMNVLLVCLIFWLIFSIMGVNLFAGKFYHCINTTTGDRFDIEDVNNHTDCLKLIERNETARWKNVKVNFDNVGFGYLSLLQVATFKGWMDIMYAAVDSRNVELQPKYEESLYMYLYFVIFIIFGSFFTLNLFIGVIIDNFNQQKKKFGGQDIFMTEEQKKYYNAMKKLGSKKPQKPIPRPGNKFQGMVFDFVTRQVFDISIMILICLNMVTMMVETDDQSEYVTTILSRINLVFIVLFTGECVLKLISLRHYYFTIGWNIFDFVVVILSIVGMFLAELIEKYFVSPTLFRVIRLARIGRILRLIKGAKGIRTLLFALMMSLPALFNIGLLLFLVMFIYAIFGMSNFAYVKREVGIDDMFNFETFGNSMICLFQITTSAGWDGLLAPILNSKPPDCDPNKVNPGSSVKGDCGNPSVGIFFFVSYIIISFLVVVNMYIAVILENFSVATEESAEPLSEDDFEMFYEVWEKFDPDATQFMEFEKLSQFAAALEPPLNLPQPNKLQLIAMDLPMVSGDRIHCLDILFAFTKRVLGESGEMDALRIQMEERFMASNPSKVSYQPITTTLKRKQEEVSAVIIQRAYRRHLLKRTVKQASFTYNKNKIKGGANLLIKEDMIIDRINENSITEKTDLTMSTAACPPSYDRVTKPIVEKHEQEGKDEKAKGK |
GRN 染色體17上之鹼基對44、345、086至44、353、106 (Homo sapiens Annotation Release 109, GRCh38.p12) | SEQ ID NO: 181 | MWTLVSWVALTAGLVAGTRCPDGQFCPVACCLDPGGASYSCCRPLLDKWPTTLSRHLGGPCQVDAHCSAGHSCIFTVSGTSSCCPFPEAVACGDGHHCCPRGFHCSADGRSCFQRSGNNSVGAIQCPDSQFECPDFSTCCVMVDGSWGCCPMPQASCCEDRVHCCPHGAFCDLVHTRCITPTGTHPLAKKLPAQRTNRAVALSSSVMCPDARSRCPDGSTCCELPSGKYGCCPMPNATCCSDHLHCCPQDTVCDLIQSKCLSKENATTDLLTKLPAHTVGDVKCDMEVSCPDGYTCCRLQSGAWGCCPFTQAVCCEDHIHCCPAGFTCDTQKGTCEQGPHQVPWMEKAPAHLSLPDPQALKRDVPCDNVSSCPSSDTCCQLTSGEWGCCPIPEAVCCSDHQHCCPQGYTCVAEGQCQRGSEIVAGLEKMPARRASLSHPRDIGCDQHTSCPVGQTCCPSLGGSWACCQLPHAVCCEDRQHCCPAGYTCNVKARSCEKEVVSAQPATFLARSPHVGVKDVECGEGHFCHDNQTCCRDNRQGWACCPYRQGVCCADRRHCCPAGFRCAARGTKCLRREAPRWDAPLRDPALRQLL |
胺基酸序列 ( N 端至 C 端 ) | |
與人類 EGR1 具有高序列一致性之 eTF 之 序列 | |
SEQ ID NO: 1 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDICGRKFARSDERKRHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 2 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHELEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSSRRTCRAHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTSKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 3 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 4 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 5 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHIRTHTGEKPFACDICGRKFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 6 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 7 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 8 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHIRTHTGEKPFACDICGRKFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 9 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSRSDHLTNHIRTHTGEKPFACDICGRKFARSDDLVRHTKIHLRQKDRPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 10 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 325 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHIRTHTGEKPFACDICGRKFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
與人類 EGR3 具有高序列一致性之 eTF 之 序列 | |
SEQ ID NO: 11 | MTGKLAEKLPVTMSSLLNQLPDNLYPEEIPSALNLFSGSSDSVVHYNQMATENVMDIGLTNEKPNPELSYSGSFQPAPGNKTVTYLGKFAFDSPSNWCQDNIISLMSAGILGVPPASGALSTQTSTASMVQPPQGDVEAMYPALPPYSNCGDLYSEPVSFHDPQGNPGLAYSPQDYQSAKPALDSNLFPMIPDYNLYHHPNDMGSIPEHKPFQGMDPIRVNPPPITPLETIKAFKDKQIHPGFGSLPQPPLTLKPIRPRKYPNRPSKTPLHERPHACPAEGCDRRFSQLAHLRAHLRIHTGHKPFQCRICMRSFSTSGNLVRHIRTHTGEKPFACEFCGRKFAHRTTLTNHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA |
SEQ ID NO: 12 | MTGKLAEKLPVTMSSLLNQLPDNLYPEEIPSALNLFSGSSDSVVHYNQMATENVMDIGLTNEKPNPELSYSGSFQPAPGNKTVTYLGKFAFDSPSNWCQDNIISLMSAGILGVPPASGALSTQTSTASMVQPPQGDVEAMYPALPPYSNCGDLYSEPVSFHDPQGNPGLAYSPQDYQSAKPALDSNLFPMIPDYNLYHHPNDMGSIPEHKPFQGMDPIRVNPPPITPLETIKAFKDKQIHPGFGSLPQPPLTLKPIRPRKYPNRPSKTPLHERPHACPAEGCDRRFSRRDELNVHLRIHTGHKPFQCRICMRSFSSRRTCRAHIRTHTGEKPFACEFCGRKFAQSSNLVRHAKIHLKQKEHACPAEGCDRRFSQLAHLRAHLRIHTGHKPFQCRICMRSFSTSGNLVRHIRTHTGEKPFACEFCGRKFAHRTTLTNHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA |
SEQ ID NO: 13 | MTGKLAEKLPVTMSSLLNQLPDNLYPEEIPSALNLFSGSSDSVVHYNQMATENVMDIGLTNEKPNPELSYSGSFQPAPGNKTVTYLGKFAFDSPSNWCQDNIISLMSAGILGVPPASGALSTQTSTASMVQPPQGDVEAMYPALPPYSNCGDLYSEPVSFHDPQGNPGLAYSPQDYQSAKPALDSNLFPMIPDYNLYHHPNDMGSIPEHKPFQGMDPIRVNPPPITPLETIKAFKDKQIHPGFGSLPQPPLTLKPIRPRKYPNRPSKTPLHERPHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDELVRHAKIHLKQKEHACPAEGCDRRFSQSGNLTEHLRIHTGHKPFQCRICMRSFSTSGHLVRHIRTHTGEKPFACEFCGRKFAQNSTLTEHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA |
SEQ ID NO: 14 | MTGKLAEKLPVTMSSLLNQLPDNLYPEEIPSALNLFSGSSDSVVHYNQMATENVMDIGLTNEKPNPELSYSGSFQPAPGNKTVTYLGKFAFDSPSNWCQDNIISLMSAGILGVPPASGALSTQTSTASMVQPPQGDVEAMYPALPPYSNCGDLYSEPVSFHDPQGNPGLAYSPQDYQSAKPALDSNLFPMIPDYNLYHHPNDMGSIPEHKPFQGMDPIRVNPPPITPLETIKAFKDKQIHPGFGSLPQPPLTLKPIRPRKYPNRPSKTPLHERPHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSHRTTLTNHIRTHTGEKPFACEFCGRKFAREDNLHTHAKIHLKQKEHACPAEGCDRRFSTSHSLTEHLRIHTGHKPFQCRICMRSFSQSSSLVRHIRTHTGEKPFACEFCGRKFAREDNLHTHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA |
SEQ ID NO: 15 | MTGKLAEKLPVTMSSLLNQLPDNLYPEEIPSALNLFSGSSDSVVHYNQMATENVMDIGLTNEKPNPELSYSGSFQPAPGNKTVTYLGKFAFDSPSNWCQDNIISLMSAGILGVPPASGALSTQTSTASMVQPPQGDVEAMYPALPPYSNCGDLYSEPVSFHDPQGNPGLAYSPQDYQSAKPALDSNLFPMIPDYNLYHHPNDMGSIPEHKPFQGMDPIRVNPPPITPLETIKAFKDKQIHPGFGSLPQPPLTLKPIRPRKYPNRPSKTPLHERPHACPAEGCDRRFSRRDELNVHLRIHTGHKPFQCRICMRSFSRSDHLTNHIRTHTGEKPFACEFCGRKFARSDDLVRHAKIHLKQKEHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSHRTTLTNHIRTHTGEKPFACEFCGRKFAREDNLHTHAKIHLKQKEHACPAEGCDRRFSTSHSLTEHLRIHTGHKPFQCRICMRSFSQSSSLVRHIRTHTGEKPFACEFCGRKFAREDNLHTHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA |
SEQ ID NO: 16 | MTGKLAEKLPVTMSSLLNQLPDNLYPEEIPSALNLFSGSSDSVVHYNQMATENVMDIGLTNEKPNPELSYSGSFQPAPGNKTVTYLGKFAFDSPSNWCQDNIISLMSAGILGVPPASGALSTQTSTASMVQPPQGDVEAMYPALPPYSNCGDLYSEPVSFHDPQGNPGLAYSPQDYQSAKPALDSNLFPMIPDYNLYHHPNDMGSIPEHKPFQGMDPIRVNPPPITPLETIKAFKDKQIHPGFGSLPQPPLTLKPIRPRKYPNRPSKTPLHERPHACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA |
eTF | DBD SEQ ID NO: | DBD 之 胺基酸序列 ( N 端至 C 端 ) |
與 EGR1 具有高序列一致性之 eTF 的 DBD 序列 | ||
SEQ ID NO: 1 | SEQ ID NO: 17 | RPYACPVESCDRRFSRSDELTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDICGRKFARSDERKRHTKIHLRQKD |
SEQ ID NO: 2 | SEQ ID NO: 18 | LEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSSRRTCRAHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTS |
SEQ ID NO: 3 | SEQ ID NO: 19 | RPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKD |
SEQ ID NO: 4 | SEQ ID NO: 20 | RPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKD |
SEQ ID NO: 5 | SEQ ID NO: 21 | RPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHIRTHTGEKPFACDICGRKFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKD |
SEQ ID NO: 6 | SEQ ID NO: 22 | RPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKD |
SEQ ID NO: 7 | SEQ ID NO: 23 | RPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKD |
SEQ ID NO: 8 | SEQ ID NO: 24 | RPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHIRTHTGEKPFACDICGRKFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKD |
SEQ ID NO: 9 | SEQ ID NO: 25 | RPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSRSDHLTNHIRTHTGEKPFACDICGRKFARSDDLVRHTKIHLRQKDRPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKD |
SEQ ID NO: 10 | SEQ ID NO: 26 | RPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKD |
SEQ ID NO: 325 | SEQ ID NO: 351 | RKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHIRTHTGEKPFACDICGRKFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVV |
與 EGR3 具有高序列一致性之 eTF 的 DBD 序列 | ||
SEQ ID NO: 11 | SEQ ID NO: 27 | PHACPAEGCDRRFSQLAHLRAHLRIHTGHKPFQCRICMRSFSTSGNLVRHIRTHTGEKPFACEFCGRKFAHRTTLTNHAKIHLKQKE |
SEQ ID NO: 12 | SEQ ID NO: 28 | HACPAEGCDRRFSRRDELNVHLRIHTGHKPFQCRICMRSFSSRRTCRAHIRTHTGEKPFACEFCGRKFAQSSNLVRHAKIHLKQKEHACPAEGCDRRFSQLAHLRAHLRIHTGHKPFQCRICMRSFSTSGNLVRHIRTHTGEKPFACEFCGRKFAHRTTLTNHAKIHLKQKE |
SEQ ID NO: 13 | SEQ ID NO: 29 | PHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDELVRHAKIHLKQKEHACPAEGCDRRFSQSGNLTEHLRIHTGHKPFQCRICMRSFSTSGHLVRHIRTHTGEKPFACEFCGRKFAQNSTLTEHAKIHLKQKE |
SEQ ID NO: 14 | SEQ ID NO: 30 | PHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSHRTTLTNHIRTHTGEKPFACEFCGRKFAREDNLHTHAKIHLKQKEHACPAEGCDRRFSTSHSLTEHLRIHTGHKPFQCRICMRSFSQSSSLVRHIRTHTGEKPFACEFCGRKFAREDNLHTHAKIHLKQKE |
SEQ ID NO: 15 | SEQ ID NO: 31 | PHACPAEGCDRRFSRRDELNVHLRIHTGHKPFQCRICMRSFSRSDHLTNHIRTHTGEKPFACEFCGRKFARSDDLVRHAKIHLKQKEHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSHRTTLTNHIRTHTGEKPFACEFCGRKFAREDNLHTHAKIHLKQKEHACPAEGCDRRFSTSHSLTEHLRIHTGHKPFQCRICMRSFSQSSSLVRHIRTHTGEKPFACEFCGRKFAREDNLHTHAKIHLKQKE |
SEQ ID NO: 16 | SEQ ID NO: 32 | PHACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKE |
eTF | 用於 eTF 之 蛋白質平台 | 標靶位點 SEQ IDNO: | 標靶結合位點序列 ( 5 ' 至 3 ' ) | 基因標靶 | 與蛋白質平台之 NCBI - BLAST 序列一致性 |
SEQ ID NO: 1 | WT EGR1 | N/A | N/A | N/A | 100% |
SEQ ID NO: 2 | EGR1 | SEQ ID NO: 33 | AGTGATAGAGAACGTATG | 報告子 | 87% |
SEQ ID NO: 3 | EGR1 | SEQ ID NO: 34 | AGTGATAGA | 報告子 | 97% |
SEQ ID NO: 4 | EGR1 | SEQ ID NO: 33 | AGTGATAGAGAACGTATG | 報告子 | 96% |
SEQ ID NO: 5 | EGR1 | SEQ ID NO: 33 | AGTGATAGAGAACGTATG | 報告子 | 94% |
SEQ ID NO: 6 | EGR1 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A | 97% |
SEQ ID NO: 7 | EGR1 | SEQ ID NO: 36 | TAGGTACCATAGAGTGAG | SCN1A | 96% |
SEQ ID NO: 8 | EGR1 | SEQ ID NO: 36 | TAGGTACCATAGAGTGAG | SCN1A | 94% |
SEQ ID NO: 9 | EGR1 | SEQ ID NO: 37 | TAGGTACCATAGAGTGAGGCGAGGATG | SCN1A | 97% |
SEQ ID NO: 10 | EGR1 | SEQ ID NO: 38 | GAGTAGAAAAGAAACACA | GRN | 95% |
SEQ ID NO: 11 | EGR3 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 | 94% |
SEQ ID NO: 12 | EGR3 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 | 96% |
SEQ ID NO: 13 | EGR3 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A | 97% |
SEQ ID NO: 14 | EGR3 | SEQ ID NO: 36 | TAGGTACCATAGAGTGAG | SCN1A | 96% |
SEQ ID NO: 15 | EGR3 | SEQ ID NO: 37 | TAGGTACCATAGAGTGAGGCGAGGATG | SCN1A | 97% |
SEQ ID NO: 16 | EGR3 | SEQ ID NO: 38 | GAGTAGAAAAGAAACACA | GRN | 95% |
ZF 類型名稱 | ZF 結構 ( 其中各 x 可獨立地為任何殘基 ) | 可充當本文揭示之 eTF 之 eTF 或 DNA 結合域之蛋白質平台的例示性蛋白質 | |
鋅指C2H2型(ZNF) | SEQ ID NO: 39 | C-x-C-x-H-x-H | KLF4, KLF5, EGR3, ZFP637, SLUG, ZNF750, ZNF281, ZBP89, GLIS1, GLIS3 |
環指蛋白(RNF) | SEQ ID NO: 40 | C-x-C-x-C-x-H-xxx-C-x-C-x-C-x-C | MDM2, BRCA1, ZNF179 |
PHD指蛋白(PHF) | SEQ ID NO: 41 | C-x-C-x-C-x-C-xxx-H-x-C-x-C-x-C | KDM2A, PHF1, ING1 |
LIM域含有 | SEQ ID NO: 42 | C-x-C-x-H-x-C-x-C-x-C-x-C-x-(C,H,D) | ZNF185, LIMK1, PXN |
核激素受體(NR) | SEQ ID NO: 43 | C-x-C-x-C-x-C-xxx-C-x-C-x-C-x-C | VDR, ESR1, NR4A1 |
鋅指CCCH型(ZC3H) | SEQ ID NO: 44 | C-x-C-x-C-x-H | RC3H1, HELZ, MBNL1, ZFP36, ZFP36L1 |
鋅指FYVE型(ZFYVE) | SEQ ID NO: 43 | C-x-C-x-C-x-C-xxx-C-x-C-x-C-x-C | EEA1, HGS, PIKFYVE |
鋅指CCHC型(ZCCHC) | SEQ ID NO: 45 | C-x-C-x-H-x-C | CNBP, SF1, LIN28A |
鋅指DHHC型(ZDHHC) | SEQ ID NO: 46 | C-x-C-x-H-x-C-xxx-C-x-C-x-H-x-C | ZDHHC2, ZDHHC8, ZDHHC9 |
鋅指MYND型(ZMYND) | SEQ ID NO: 47 | C-x-C-x-C-x-C-xxx-C-x-C-x-H-x-C | PDCD2, RUNX1T1, SMYD2, SMYD1 |
鋅指RANBP2型(ZRANB) | SEQ ID NO: 48 | C-x-C-x-C-x-C | YAF2, SHARPIN, EWSR1 |
鋅指ZZ型(ZZZ) | SEQ ID NO: 48 | C-x-C-x-C-x-C | HERC2, NBR1, CREBBP |
鋅指C2HC型(ZC2HC) | SEQ ID NO: 45 | C-x-C-x-H-x-C | IKBKG, L3MBTL1, ZNF746 |
GATA鋅指域含有(GATAD) | SEQ ID NO: 48 | C-x-C-x-C-x-C | GATA4, GATA6, MTA1 |
ZF類同源盒及假基因 | SEQ ID NO: 39 | C-x-C-x-H-x-H | ADNP, ZEB1, ZHX1 |
THAP域含有(THAP) | SEQ ID NO: 44 | C-x-C-x-C-x-H | THAP1, THAP4, THAP11 |
鋅指CXXC型(CXXC) | SEQ ID NO: 43 | C-x-C-x-C-x-C-xxx-C-x-C-x-C-x-C | CXXC1, CXXC5, MBD1, DNMT1 |
鋅指SWIM型(ZSWIM) | SEQ ID NO: 44 | C-x-C-x-C-x-H | MAP3K1, ZSWIM5, ZSWIM6 |
鋅指AN1型(ZFAND) | SEQ ID NO: 49 | C-x-C-x-C-x-C-xxx-C-x-H-x-H-x-C | ZFAND3, ZFAND6, IGHMBP2 |
鋅指3CxxC型(Z3CXXC) | SEQ ID NO: 45 | C-x-C-x-H-x-C | ZAR1, RTP1, RTP4 |
鋅指CW型(ZCW) | SEQ ID NO: 48 | C-x-C-x-C-x-C | MORC1, ZCWPW1, KDM1B |
鋅指GRF型(ZGRF) | SEQ ID NO: 48 | C-x-C-x-C-x-C | TTF2, NEIL3, TOP3A |
鋅指MIZ型(ZMIZ) | SEQ ID NO: 45 | C-x-C-x-H-x-C | PIAS1, PIAS3, PIAS4 |
鋅指BED型(ZBED) | SEQ ID NO: 39 | C-x-C-x-H-x-H | ZBED1, ZBED4, ZBED6 |
鋅指HIT型(ZNHIT) | SEQ ID NO: 47 | C-x-C-x-C-x-C-xxx-C-x-C-x-H-x-C | ZNHIT3, DDX59, INO80B |
鋅指MYM型(ZMYM) | SEQ ID NO: 48 | C-x-C-x-C-x-C | ZMYM2, ZMYM3, ZMYM4 |
鋅指matrin型(ZMAT) | SEQ ID NO: 39 | C-x-C-x-H-x-H | ZNF638, ZMAT1, ZMAT3, ZMAT5 |
鋅指C2H2C型 | SEQ ID NO: 39 | C-x-C-x-H-x-H | MYT1, MYT1L, ST18 |
鋅指DBF型(ZDBF) | SEQ ID NO: 39 | C-x-C-x-H-x-H | DBF4, DBF4B, ZDBF2 |
鋅指PARP型 | SEQ ID NO: 45 | C-x-C-x-H-x-C | LIG3, PARP1 |
胺基酸序列 ( N 端至 C 端 ) | |
SEQ ID NO: 50 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSSRRTCRAHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYA |
SEQ ID NO: 51 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSSRRTCRAHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 52 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSSRRTCRAHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEMSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGIRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC |
SEQ ID NO: 53 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSSRRTCRAHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 54 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSSRRTCRAHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 55 | MQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDKLEMSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGIRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC |
SEQ ID NO: 56 | MSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSCQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDK |
SEQ ID NO: 57 | MQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKLEMSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGIRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC |
SEQ ID NO: 58 | MSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSCQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDK |
SEQ ID NO: 59 | MQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDKLEMSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGXRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC (其中X可為I或V) |
SEQ ID NO: 60 | MSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSCQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDK |
SEQ ID NO: 61 | MQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 62 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 63 | MQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 64 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 65 | MQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 66 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 67 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 68 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDK |
SEQ ID NO: 69 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDK |
SEQ ID NO: 70 | MRPHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDELVRHAKIHLKQKEHACPAEGCDRRFSQSGNLTEHLRIHTGHKPFQCRICMRSFSTSGHLVRHIRTHTGEKPFACEFCGRKFAQNSTLTEHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCALEMSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGIRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC |
SEQ ID NO: 71 | MSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSCRPHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDELVRHAKIHLKQKEHACPAEGCDRRFSQSGNLTEHLRIHTGHKPFQCRICMRSFSTSGHLVRHIRTHTGEKPFACEFCGRKFAQNSTLTEHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA |
SEQ ID NO: 72 | MRPHACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCALEMSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGXRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC (其中X可為I或V) |
SEQ ID NO: 73 | MSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSCRPHACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA |
SEQ ID NO: 74 | MRPHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDELVRHAKIHLKQKEHACPAEGCDRRFSQSGNLTEHLRIHTGHKPFQCRICMRSFSTSGHLVRHIRTHTGEKPFACEFCGRKFAQNSTLTEHAKIHLKQKEKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 75 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGRPHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDELVRHAKIHLKQKEHACPAEGCDRRFSQSGNLTEHLRIHTGHKPFQCRICMRSFSTSGHLVRHIRTHTGEKPFACEFCGRKFAQNSTLTEHAKIHLKQKEKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 76 | MRPHACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKEKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 77 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGRPHACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKEKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 78 | MRPHACPAEGCDRRFSRRDELNVHLRIHTGHKPFQCRICMRSFSSRRTCRAHIRTHTGEKPFACEFCGRKFAQSSNLVRHAKIHLKQKEHACPAEGCDRRFSQLAHLRAHLRIHTGHKPFQCRICMRSFSTSGNLVRHIRTHTGEKPFACEFCGRKFAHRTTLTNHAKIHLKQKEKLEMSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGIRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC |
SEQ ID NO: 79 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGRPHACPAEGCDRRFSRRDELNVHLRIHTGHKPFQCRICMRSFSSRRTCRAHIRTHTGEKPFACEFCGRKFAQSSNLVRHAKIHLKQKEHACPAEGCDRRFSQLAHLRAHLRIHTGHKPFQCRICMRSFSTSGNLVRHIRTHTGEKPFACEFCGRKFAHRTTLTNHAKIHLKQKEKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 80 | MRPHACPAEGCDRRFSRRDELNVHLRIHTGHKPFQCRICMRSFSSRRTCRAHIRTHTGEKPFACEFCGRKFAQSSNLVRHAKIHLKQKEHACPAEGCDRRFSQLAHLRAHLRIHTGHKPFQCRICMRSFSTSGNLVRHIRTHTGEKPFACEFCGRKFAHRTTLTNHAKIHLKQKEKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 268 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSDPGHLVRHQRTHTGEKPYKCPECGKSFSTKNSLTEHQRTHTGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSERSHLREHQRTHTGEKPYKCPECGKSFSSKKHLAEHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGKKTSKRPAATKKAG |
SEQ ID NO: 269 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSSRRTCRAHQRTHTGEKPYKCPECGKSFSTTGALTEHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGKKTSKRPAATKKAG |
SEQ ID NO: 270 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRKDNLKNHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSRKDNLKNHQRTHTGKKTSKRPAATKKAG |
SEQ ID NO: 271 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 272 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 273 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGKKTSKRPAATKKAG |
SEQ ID NO: 274 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGKKTSKRPAATKKAG |
SEQ ID NO: 275 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSDCRDLARHQRTHTGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDPGNLVRHQRTHTGEKPYKCPECGKSFSQRAHLERHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTSKRPAATKKAG |
SEQ ID NO: 276 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDPGNLVRHQRTHTGEKPYKCPECGKSFSQRAHLERHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTSKRPAATKKAG |
SEQ ID NO: 277 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSTKNSLTEHQRTHTGEKPYKCPECGKSFSRADNLTEHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTKNSLTEHQRTHTGEKPYKCPECGKSFSQAGHLASHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGKKTSKRPAATKKAG |
SEQ ID NO: 278 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSDPGHLVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSRSDHLTNHQRTHTGKKTSKRPAATKKAG |
SEQ ID NO: 279 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 280 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 281 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSQAGHLASHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSGNLTEHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSQKSSLIAHQRTHTGEKPYKCPECGKSFSQAGHLASHQRTHTGKKTSKRPAATKKAG |
SEQ ID NO: 282 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSTTGNLTVHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSGNLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGKKTSKRPAATKKAG |
eTF SEQ ID NO: | DBD SEQ ID NO: | DBD 序列 | DBD 之 蛋白質平台 | DBD 與 蛋白質平台之間的 NCBI - BLAST 序列一致性 |
SEQ ID NO: 50 | SEQ ID NO: 81 | LEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSSRRTCRAHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTS | 合成 | 67% |
SEQ ID NO: 51 | SEQ ID NO: 81 | (與以上相同) | 合成 | 67% |
SEQ ID NO: 52 | SEQ ID NO: 81 | (與以上相同) | 合成 | 67% |
SEQ ID NO: 53 | SEQ ID NO: 81 | (與以上相同) | 合成 | 67% |
SEQ ID NO: 54 | SEQ ID NO: 81 | (與以上相同) | 合成 | 67% |
SEQ ID NO: 55 | SEQ ID NO: 82 | MQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDK | EGR1 | 86% |
SEQ ID NO: 56 | SEQ ID NO: 83 | QSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDK | EGR1 | 86% |
SEQ ID NO: 57 | SEQ ID NO: 84 | RPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKD | EGR1 | 93% |
SEQ ID NO: 58 | SEQ ID NO: 85 | QSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDK | EGR1 | 93% |
SEQ ID NO: 59 | SEQ ID NO: 86 | MQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDK | EGR1 | 84% |
SEQ ID NO: 60 | SEQ ID NO: 87 | RPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDK* | EGR1 | 84% |
SEQ ID NO: 61 | SEQ ID NO: 88 | RPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDK | EGR1 | 93% |
SEQ ID NO: 62 | SEQ ID NO: 88 | (與以上相同) | EGR1 | 93% |
SEQ ID NO: 63 | SEQ ID NO: 89 | RPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDK | EGR1 | 84% |
SEQ ID NO: 64 | SEQ ID NO: 89 | (與以上相同) | EGR1 | 84% |
SEQ ID NO: 65 | SEQ ID NO: 82 | (與以上相同) | EGR1 | 86% |
SEQ ID NO: 66 | SEQ ID NO: 82 | (與以上相同) | EGR1 | 86% |
SEQ ID NO: 67 | SEQ ID NO: 90 | QSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDK | EGR1 | 79% |
SEQ ID NO: 68 | SEQ ID NO: 90 | (與以上相同) | EGR1 | 79% |
SEQ ID NO: 69 | SEQ ID NO: 91 | QSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDK | EGR1 | 81% |
SEQ ID NO: 70 | SEQ ID NO: 92 | HACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDELVRHAKIHLKQKEHACPAEGCDRRFSQSGNLTEHLRIHTGHKPFQCRICMRSFSTSGHLVRHIRTHTGEKPFACEFCGRKFAQNSTLTEHAKIHLKQKE | EGR3 | 92% |
SEQ ID NO: 71 | SEQ ID NO: 92 | (與以上相同) | EGR3 | 92% |
SEQ ID NO: 72 | SEQ ID NO: 93 | HACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKE | EGR3 | 80% |
SEQ ID NO: 73 | SEQ ID NO: 93 | (與以上相同) | EGR3 | 80% |
SEQ ID NO: 74 | SEQ ID NO: 92 | (與以上相同) | EGR3 | 92% |
SEQ ID NO: 75 | SEQ ID NO: 92 | (與以上相同) | EGR3 | 92% |
SEQ ID NO: 76 | SEQ ID NO: 93 | (與以上相同) | EGR3 | 80% |
SEQ ID NO: 77 | SEQ ID NO: 93 | (與以上相同) | EGR3 | 80% |
SEQ ID NO: 78 | SEQ ID NO: 94 | HACPAEGCDRRFSRRDELNVHLRIHTGHKPFQCRICMRSFSSRRTCRAHIRTHTGEKPFACEFCGRKFAQSSNLVRHAKIHLKQKEHACPAEGCDRRFSQLAHLRAHLRIHTGHKPFQCRICMRSFSTSGNLVRHIRTHTGEKPFACEFCGRKFAHRTTLTNHAKIHLKQKE | EGR3 | 45% |
SEQ ID NO: 79 | SEQ ID NO: 94 | (與以上相同) | EGR3 | 45% |
SEQ ID NO: 80 | SEQ ID NO: 94 | (與以上相同) | EGR3 | 45% |
TAD SEQ ID NO. | TAD 序列 ( N 端至 C 端 ) | TAD 蛋白質平台 |
SEQ ID NO: 95 | DALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML | VP64 (病毒活化子域) |
SEQ ID NO: 114 | DALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF | VPR (病毒活化子域) |
SEQ ID NO: 96 | MSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC | CITED2 (人類蛋白質域) |
SEQ ID NO: 97 | MADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC | CITED4 (人類蛋白質域) |
SEQ ID NO: 98 | SGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC | CITED2 (人類蛋白質域) |
SEQ ID NO: 99 | MSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC | CITED2 (人類蛋白質域) |
SEQ ID NO: 100 | AADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC | CITED4 (人類蛋白質域) |
eTF SEQ ID NO: | DBD SEQ ID NO: | TAD SEQ ID NO: | TAD 之 蛋白質平台 | TAD 相對於 DBD 之 位置 | TAD 與蛋白質平台之 NCBI - BLAST 序列一致性 ( % ) |
SEQ ID NO: 50 | SEQ ID NO: 81 | N/A | N/A | N/A | N/A |
SEQ ID NO: 51 | SEQ ID NO: 81 | SEQ ID NO: 95 | VP64 | C端 | 0 |
SEQ ID NO: 52 | SEQ ID NO: 81 | SEQ ID NO: 96 | CITED2 | c端 | 100 |
SEQ ID NO: 53 | SEQ ID NO: 81 | SEQ ID NO: 97 | CITED4 | c端 | 100 |
SEQ ID NO: 54 | SEQ ID NO: 81 | SEQ ID NO: 97 | CITED4 | N/C端 | 100 |
SEQ ID NO: 55 | SEQ ID NO: 82 | SEQ ID NO: 96 | CITED2 | c端 | 100 |
SEQ ID NO: 56 | SEQ ID NO: 83 | SEQ ID NO: 98 | CITED2 | n端 | 100 |
SEQ ID NO: 57 | SEQ ID NO: 84 | SEQ ID NO: 96 | CITED2 | c端 | 100 |
SEQ ID NO: 58 | SEQ ID NO: 85 | SEQ ID NO: 99 | CITED2 | n端 | 100 |
SEQ ID NO: 59 | SEQ ID NO: 86 | SEQ ID NO: 96 | CITED2 | c端 | 100 |
SEQ ID NO: 60 | SEQ ID NO: 87 | SEQ ID NO: 99 | CITED2 | n端 | 100 |
SEQ ID NO: 61 | SEQ ID NO: 88 | SEQ ID NO: 97 | CITED4 | c端 | 100 |
SEQ ID NO: 62 | SEQ ID NO: 88 | SEQ ID NO: 97 | CITED4 | n/c端 | 100 |
SEQ ID NO: 63 | SEQ ID NO: 89 | SEQ ID NO: 97 | CITED4 | c端 | 100 |
SEQ ID NO: 64 | SEQ ID NO: 89 | SEQ ID NO: 97 | CITED4 | n/C端 | 100 |
SEQ ID NO: 65 | SEQ ID NO: 82 | SEQ ID NO: 97 | CITED4 | C端 | 100 |
SEQ ID NO: 66 | SEQ ID NO: 82 | SEQ ID NO: 97 | CITED4 | N/C端 | 100 |
SEQ ID NO: 67 | SEQ ID NO: 90 | SEQ ID NO: 100 | CITED4 | N/C端 | 100 |
SEQ ID NO: 68 | SEQ ID NO: 90 | SEQ ID NO: 100 | CITED4 | N端 | 100 |
SEQ ID NO: 69 | SEQ ID NO: 91 | SEQ ID NO: 100 | CITED4 | N端 | 100 |
SEQ ID NO: 70 | SEQ ID NO: 92 | SEQ ID NO: 96 | CITED2 | c端 | 100 |
SEQ ID NO: 71 | SEQ ID NO: 92 | SEQ ID NO: 99 | CITED2 | n端 | 100 |
SEQ ID NO: 72 | SEQ ID NO: 93 | SEQ ID NO: 6 | CITED2 | c端 | 100 |
SEQ ID NO: 73 | SEQ ID NO: 93 | SEQ ID NO: 99 | CITED2 | n端 | 100 |
SEQ ID NO: 74 | SEQ ID NO: 92 | SEQ ID NO: 97 | CITED4 | c端 | 100 |
SEQ ID NO: 75 | SEQ ID NO: 92 | SEQ ID NO: 97 | CITED4 | n/c端 | 100 |
SEQ ID NO: 76 | SEQ ID NO: 93 | SEQ ID NO: 97 | CITED4 | c端 | 100 |
SEQ ID NO: 77 | SEQ ID NO: 93 | SEQ ID NO: 97 | CITED4 | n/c端 | 100 |
SEQ ID NO: 78 | SEQ ID NO: 94 | SEQ ID NO: 96 | CITED2 | C端 | 100 |
SEQ ID NO: 79 | SEQ ID NO: 94 | SEQ ID NO: 97 | CITED4 | N/C端 | 100 |
SEQ ID NO: 80 | SEQ ID NO: 94 | SEQ ID NO: 97 | CITED4 | C端 | 100 |
eTF | 藉由 eTF 識別之標靶位點 | 標靶位點序列 ( 5 ' 至 3 ' ) | 基因標靶 |
SEQ ID NO: 50 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 51 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 52 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 53 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 54 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 55 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 56 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 57 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A |
SEQ ID NO: 58 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A |
SEQ ID NO: 59 | SEQ ID NO: 38 | GAGTAGAAAAGAAACACA | PGRN |
SEQ ID NO: 60 | SEQ ID NO: 38 | GAGTAGAAAAGAAACACA | PGRN |
SEQ ID NO: 61 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A |
SEQ ID NO: 62 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A |
SEQ ID NO: 63 | SEQ ID NO: 38 | GAGTAGAAAAGAAACACA | PGRN |
SEQ ID NO: 64 | SEQ ID NO: 38 | GAGTAGAAAAGAAACACA | PGRN |
SEQ ID NO: 65 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 66 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 67 | SEQ ID NO: 36 | TAGGTACCATAGAGTGAG | SCN1A |
SEQ ID NO: 68 | SEQ ID NO: 36 | TAGGTACCATAGAGTGAG | SCN1A |
SEQ ID NO: 69 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A |
SEQ ID NO: 70 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A |
SEQ ID NO: 71 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A |
SEQ ID NO: 72 | SEQ ID NO: 38 | GAGTAGAAAAGAAACACA | PGRN |
SEQ ID NO: 73 | SEQ ID NO: 38 | GAGTAGAAAAGAAACACA | PGRN |
SEQ ID NO: 74 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A |
SEQ ID NO: 75 | SEQ ID NO: 35 | CTAGGTCAAGTGTAGGAG | SCN1A |
SEQ ID NO: 76 | SEQ ID NO: 38 | GAGTAGAAAAGAAACACA | PGRN |
SEQ ID NO: 77 | SEQ ID NO: 38 | GAGTAGAAAAGAAACACA | PGRN |
SEQ ID NO: 78 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 79 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
SEQ ID NO: 80 | SEQ ID NO: 33 | AGT GAT AGA GAA CGT ATG | 報告子 |
dCas 骨架 | |
SEQ ID NO: 102 | GTTTTAGTACTCTGGAAACAGAATCTACTAAAACAAGGCAAAATGCCGTGTTTATCTCGTCAACTTGTTGGCGAGA |
dSaCas9 胺基酸序列 | |
SEQ ID NO: 103 | KRNYILGLAIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEEASKKGNRTPFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG |
SEQ ID NO: 104 (或具有NLS及HA標籤之SEQ ID NO: 103) | MAPKKKRKVGIHGVPAAKRNYILGLAIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEEASKKGNRTPFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKGKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SaCas9 嚮導 RNA ( gRNA ) 序列 | |
SEQ ID NO: 105 | TGACCTAGACAGCCTTACATA |
SEQ ID NO: 106 | TAAGGCTGTCTAGGTCAAGTG |
SEQ ID NO: 107 | AAGGCTGTCTAGGTCAAGTGT |
SEQ ID NO: 108 | GATGAAGCCGAGAGGATACTG |
SEQ ID NO: 109 | GCTGATTTGTATTAGGTACCA |
SpCas9 嚮導 RNA ( gRNA ) 序列 | |
SEQ ID NO: 110 | CTTCGTTATGTAAGGCTGTCT |
SEQ ID NO: 107 | AAGGCTGTCTAGGTCAAGTGT |
SEQ ID NO: 111 | CAAGTGTAGGAGACACACTGC |
序列 | 序列 | ||
SEQ ID NO: 115 | RSDNLVR | SEQ ID NO: 123 | QSGDLRR |
SEQ ID NO: 116 | REDNLHT | SEQ ID NO: 124 | TSHSLTE |
SEQ ID NO: 117 | RSDELVR | SEQ ID NO: 125 | THLDLIR |
SEQ ID NO: 118 | QSGNLTE | SEQ ID NO: 126 | QSSSLVR |
SEQ ID NO: 119 | TSGHLVR | SEQ ID NO: 127 | TSGNLVR |
SEQ ID NO: 120 | QNSTLTE | SEQ ID NO: 128 | RRDELNV |
SEQ ID NO: 121 | DPGALVR | SEQ ID NO: 129 | RSDDLVR |
SEQ ID NO: 122 | HRTTLTN | SEQ ID NO: 130 | RSDHLTN |
DBD 之 胺基酸序列 ( 包括連接子 ) | |
SEQ ID NO: 131 | LEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTS |
SEQ ID NO: 132 | LEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTS |
SEQ ID NO: 133 | LEPGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTS |
SEQ ID NO: 134 | LEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSRSDHLTNHQRTHTGEKPYKCPECGKSFSRSDDLVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTS |
SEQ ID NO: 135 | RSDNLVR x REDNLHT x RSDELVR x QSGNLTE x TSGHLVR x QNSTLTE (其中X指示包含1-50個胺基酸殘基之連接子) |
SEQ ID NO: 371 | RSDNLVR x HRTTLTN x REDNLHT x TSHSLTE x QSSSLVR x REDNLHT (其中X指示包含1-50個胺基酸殘基之連接子) |
SEQ ID NO: 372 | RRDELNV x RSDHLTN x RSDDLVR x RSDNLVR x HRTTLTN x REDNLHT x TSHSLTE x QSSSLVR x REDNLHT (其中X指示包含1-50個胺基酸殘基之連接子) |
SEQ ID NO: 376 | DPGALVR x RSDNLVR x QSGDLRR x THLDLIR x TSGNLVR x RSDNLVR (其中X指示包含1-50個胺基酸殘基之連接子) |
SEQ ID NO: 423 | LEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTS |
SEQ ID NO: 424 | LEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTS |
SEQ ID NO: 425 | LEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTS |
SEQ ID NO: 426 | LEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTS |
SEQ ID NO: 427 | RKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVV |
SEQ ID NO: 428 | RKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVV |
SEQ ID NO: 429 | RKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDK |
SEQ ID NO: 430 | RKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDK |
SEQ ID NO: 431 | RKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHIRTHTGEKPFACDICGRKFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVV |
SEQ ID NO: 432 | QSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDK |
SEQ ID NO: 433 | QSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIH |
SEQ ID NO: 434 | QSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDK |
SEQ ID NO: 435 | RKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHIRTHTGEKPFACDICGRKFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVV |
SEQ ID NO: 441 | RKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHIRTHTGEKPFACDICGRKFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVV |
SEQ ID NO: 406 | RKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVV |
SEQ ID NO: 407 | AAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 408 | RPYACPVESCDRRFSDPGALVRHIRIHTGQKPFQCRICMRNFSRSDNLVRHIRTHTGEKPFACDICGRKFAQSGDLRRHTKIHLRQKDRPYACPVESCDRRFSTHLDLIRHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDRPYACPVESCDRRFSQSGHLTEHIRIHTGQKPFQCRICMRNFSERSHLREHIRTHTGEKPFACDICGRKFAQAGHLASHTKIHLRQKD |
SEQ ID NO: 409 | RKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHIRTHTGEKPFACDICGRKFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVV |
SEQ ID NO: 391 | LEPGEKPYKCPECGKSFSDPGHLVRHQRTHTGEKPYKCPECGKSFSTKNSLTEHQRTHTGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSERSHLREHQRTHTGEKPYKCPECGKSFSSKKHLAEHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGKKTS |
SEQ ID NO: 392 | LEPGEKPYKCPECGKSFSSRRTCRAHQRTHTGEKPYKCPECGKSFSTTGALTEHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGKKTS |
SEQ ID NO: 393 | LEPGEKPYKCPECGKSFSRKDNLKNHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSRKDNLKNHQRTHTGKKTS |
SEQ ID NO: 394 | LEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTS |
SEQ ID NO: 395 | LEPGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTS |
SEQ ID NO: 396 | LEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGKKTS |
SEQ ID NO: 397 | LEPGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGKKTS |
SEQ ID NO: 398 | LEPGEKPYKCPECGKSFSDCRDLARHQRTHTGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDPGNLVRHQRTHTGEKPYKCPECGKSFSQRAHLERHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTS |
SEQ ID NO: 399 | LEPGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDPGNLVRHQRTHTGEKPYKCPECGKSFSQRAHLERHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTS |
SEQ ID NO: 400 | LEPGEKPYKCPECGKSFSTKNSLTEHQRTHTGEKPYKCPECGKSFSRADNLTEHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTKNSLTEHQRTHTGEKPYKCPECGKSFSQAGHLASHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGKKTS |
SEQ ID NO: 401 | LEPGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSDPGHLVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSRSDHLTNHQRTHTGKKTS |
SEQ ID NO: 402 | LEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTS |
SEQ ID NO: 403 | LEPGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTS |
SEQ ID NO: 404 | LEPGEKPYKCPECGKSFSQAGHLASHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSGNLTEHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSQKSSLIAHQRTHTGEKPYKCPECGKSFSQAGHLASHQRTHTGKKTS |
SEQ ID NO: 405 | LEPGEKPYKCPECGKSFSTTGNLTVHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSGNLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGKKTS |
DBD 中ZF 之 數目 | 包含以下ZF 之DBD (N 端 至C 端 ) : | ZF 序列: | DBD SEQ ID NO. |
6 | SEQ ID NO: 115 SEQ ID NO: 116 SQE ID NO: 117 SEQ ID NO: 118 SEQ ID NO: 119 SEQ ID NO: 120 | RSDNLVR; REDNLHT; RSDELVR; QSGNLTE; TSGHLVR; QNSTLTE | SEQ ID NO: 131 |
6 | SEQ ID NO: 115 SEQ ID NO: 122 SEQ ID NO: 116 SEQ ID NO: 124 SEQ ID NO: 126 SEQ ID NO: 116 | RSDNLVR; HRTTLTN; REDNLHT; TSHSLTE; QSSSLVR; REDNLHT | SEQ ID NO: 132 |
6 | SEQ ID NO: 121 SEQ ID NO: 115 SEQ ID NO: 123 SEQ ID NO: 125 SEQ ID NO: 127 SEQ ID NO: 115 | DPGALVR; RSDNLVR; QSGDLRR; THLDLIR; TSGNLVR; RSDNLVR | SEQ ID NO: 133 |
9 | SEQ ID NO: 128 SEQ ID NO: 130 SEQ ID NO: 129 SEQ ID NO: 115 SEQ ID NO: 122 SEQ ID NO: 116 SEQ ID NO: 124 SEQ ID NO: 126 SEQ ID NO: 116 | RRDELNV; RSDHLTN; RSDDLVR; RSDNLVR; HRTTLTN; REDNLHT; TSHSLTE; QSSSLVR; REDNLHT | SEQ ID NO: 134 |
靶序列SEQ ID NO. | 藉由ZF 或gRNA 識別 | 藉由eTF 識別之SCN1A 標靶位點序列 |
SEQ ID NO: 35 | ZF | CTAGGTCAAGTGTAGGAG |
SEQ ID NO: 36 | ZF | TAGGTACCATAGAGTGAG |
SEQ ID NO: 37 | ZF | TAGGTACCATAGAGTGAGGCGAGGATG |
SEQ ID NO: 136 | ZF | GAGGATACTGCAGAGGTC |
SEQ ID NO: 252 | ZF | CAAACTCCCAGCCTGCCTGGC |
SEQ ID NO: 253 | ZF | CCAGCACTGGTGCTTCGT |
SEQ ID NO: 254 | ZF | AAGGCTGTCTAGGTCAAG |
SEQ ID NO: 256 | ZF | CTAGGTCAAGTGTAGGAGACACAC |
SEQ ID NO: 257 | ZF | GGTCAAGTGTAGGAGACA |
SEQ ID NO: 258 | ZF | CAAGTGTAGGAGACACAC |
SEQ ID NO: 259 | ZF | AGTGTAGGAGACACACTGCTGGCC |
SEQ ID NO: 260 | ZF | AGTGTAGGAGACACACTG |
SEQ ID NO: 261 | ZF | ACTTGACCTAGACAGCCT |
SEQ ID NO: 262 | ZF | AGGAGACACACTGCTGGCCTG |
SEQ ID NO: 264 | ZF | TGAATAACTCATTAGTGA |
SEQ ID NO: 265 | ZF | AAAGTACATTAGGCTAAT |
SEQ ID NO: 105 | gRNA | TGACCTAGACAGCCTTACATA |
SEQ ID NO: 106 | gRNA | TAAGGCTGTCTAGGTCAAGTG |
SEQ ID NO: 108 | gRNA | GATGAAGCCGAGAGGATACTG |
SEQ ID NO: 109 | gRNA | GCTGATTTGTATTAGGTACCA |
SEQ ID NO: 110 | gRNA | CTTCGTTATGTAAGGCTGTCT |
SEQ ID NO: 107 | gRNA | AAGGCTGTCTAGGTCAAGTGT |
SEQ ID NO: 111 | gRNA | CAAGTGTAGGAGACACACTGC |
SEQ ID NO: 195 | gRNA | CACTCATTGAGGACAGAAGCA |
SEQ ID NO: 196 | gRNA | ACAAAGTGGAGAGACTACCCG |
SEQ ID NO: 197 | gRNA | GGTACGGGCAAAGATTTCTTG |
SEQ ID NO: 198 | gRNA | TTTGCCCGTACCAAAGTCTTG |
SEQ ID NO: 199 | gRNA | TCTTCAGCCACAAAAAAAAAA |
SEQ ID NO: 200 | gRNA | GTGTGCAACCCATGAGGTCGC |
SEQ ID NO: 201 | gRNA | ACACAATGAGCCACCTACAAG |
SEQ ID NO: 202 | gRNA | GTGGCTCATTGTGTGTGTGCC |
SEQ ID NO: 203 | gRNA | AGAAAGCTGATACAGATACAA |
SEQ ID NO: 205 | gRNA | AAACCAGCAACAAACAGTATA |
SEQ ID NO: 206 | gRNA | GAGAATCATCTAGGTCAGGAC |
SEQ ID NO: 207 | gRNA | TTCTCAGTTTTGAAATTAAAA |
SEQ ID NO: 208 | gRNA | CATATCCCTGCAGGTTCAGAA |
SEQ ID NO: 209 | gRNA | TGGATTCTCTTCTGAACCTGC |
SEQ ID NO: 210 | gRNA | AGAGAGAGAGAGAGAGAGAGA |
SEQ ID NO: 211 | gRNA | TGGTCTCATTCTTTTTGTGGG |
SEQ ID NO: 224 | gRNA | TGTTCCTCCAGATTAACACTT |
SEQ ID NO: 225 | gRNA | ATTACAGTTCTGTCAGCATGC |
SEQ ID NO: 226 | gRNA | ATCATCTGTAACCATCAAGGA |
SEQ ID NO: 227 | gRNA | TCCTGCCTACTTAGTTTCAAG |
SEQ ID NO: 228 | gRNA | TGCTGAGGCAGGACACAGTGT |
SEQ ID NO: 229 | gRNA | ACAAAGTAAGTGTCAGTGTGG |
SEQ ID NO: 230 | gRNA | CTGACACTTACTTTGTCTAAA |
SEQ ID NO: 231 | gRNA | ATAATAGTTGTGTCTTTATAA |
SEQ ID NO: 232 | gRNA | CGATATTTTCATGGATTCCTT |
SEQ ID NO: 233 | gRNA | AAAACTGGAACCGCATTCCCA |
SEQ ID NO: 234 | gRNA | TGTACAAGCAGGGCTGCAAAG |
SEQ ID NO: 235 | gRNA | AAAGGGGAATGGGAACACCCG |
SEQ ID NO: 236 | gRNA | ATGTTCAAGGTGCAGAAGGAA |
SEQ ID NO: 237 | gRNA | TTCAACAAGCTCCCAAGAAGT |
SEQ ID NO: 238 | gRNA | GTTAACAAATACACTAAACAC |
SEQ ID NO: 240 | gRNA | AAAACCGTCAACCCCATACAG |
SEQ ID NO: 241 | gRNA | AGGAATCACTTGTCAGACCTA |
SEQ ID NO: 242 | gRNA | GAGACTGTGCGTATAAAGGCA |
SEQ ID NO: 243 | gRNA | TACTGATACAGGAACTGTGCC |
SEQ ID NO: 244 | gRNA | CTTGTCATGAAACATGAGCTA |
SEQ ID NO: 245 | gRNA | TATCTGTATTCCTTTTATTTT |
SEQ ID NO: 246 | gRNA | ATAAATGGTAATTAAAATGTG |
SEQ ID NO: 247 | gRNA | TGTTTGCTCAAACGTGCACCA |
SEQ ID NO: 248 | gRNA | AAATATGTACCACAAGAAATG |
SEQ ID NO: 249 | gRNA | TATCTGGTTTCTCTCACTGCT |
SEQ ID NO: 250 | gRNA | AAATAAGACATGAAAACAAGA |
SEQ ID NO: 251 | gRNA | ATTGCAAAGCATAATTTGGAT |
eTF 蛋白質SEQ ID NO: | 核酸SEQ ID NO: | 核酸序列 |
SEQ ID NO: 305 | SEQ ID NO: 353 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCCTCGAACCAGGTGAAAAACCTTACAAATGTCCTGAATGTGGGAAATCATTCAGTCGCAGCGACAACCTGGTGAGACATCAACGCACCCATACAGGAGAAAAACCTTATAAATGTCCAGAATGTGGAAAGTCCTTCTCACGAGAGGATAACTTGCACACTCATCAACGAACACATACTGGTGAAAAACCATACAAGTGTCCCGAATGTGGTAAAAGTTTTAGCCGGAGCGATGAACTTGTCCGACACCAACGAACCCATACAGGCGAGAAGCCTTACAAATGTCCCGAGTGTGGCAAGAGCTTCTCACAATCAGGGAATCTGACTGAGCATCAACGAACTCATACCGGGGAAAAACCTTACAAGTGTCCAGAGTGTGGGAAGAGCTTTTCCACAAGTGGACATCTGGTACGCCACCAGAGGACACATACAGGGGAGAAGCCCTACAAATGCCCCGAATGCGGTAAAAGTTTCTCTCAGAATAGTACCCTGACCGAACACCAGCGAACACACACTGGGAAAAAAACGAGTAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGACGTACCAGATTACGCTCTCGAGGAGGCCAGCGGTTCCGGACGGGCTGACGCATTGGACGATTTTGATCTGGATATGCTGGGAAGTGACGCCCTCGATGATTTTGACCTTGACATGCTTGGTTCGGATGCCCTTGATGACTTTGACCTCGACATGCTCGGCAGTGACGCCCTTGATGATTTCGACCTGGACATGCTGATTAACTCTAGAAGTTCCGGATCTCCGAAAAAGAAACGCAAAGTTGGTAGCCAGTACCTGCCCGACACCGACGACCGGCACCGGATCGAGGAAAAGCGGAAGCGGACCTACGAGACATTCAAGAGCATCATGAAGAAGTCCCCCTTCAGCGGCCCCACCGACCCTAGACCTCCACCTAGAAGAATCGCCGTGCCCAGCAGATCCAGCGCCAGCGTGCCAAAACCTGCCCCCCAGCCTTACCCCTTCACCAGCAGCCTGAGCACCATCAACTACGACGAGTTCCCTACCATGGTGTTCCCCAGCGGCCAGATCTCTCAGGCCTCTGCTCTGGCTCCAGCCCCTCCTCAGGTGCTGCCTCAGGCTCCTGCTCCTGCACCAGCTCCAGCCATGGTGTCTGCACTGGCTCAGGCACCAGCACCCGTGCCTGTGCTGGCTCCTGGACCTCCACAGGCTGTGGCTCCACCAGCCCCTAAACCTACACAGGCCGGCGAGGGCACACTGTCTGAAGCTCTGCTGCAGCTGCAGTTCGACGACGAGGATCTGGGAGCCCTGCTGGGAAACAGCACCGATCCTGCCGTGTTCACCGACCTGGCCAGCGTGGACAACAGCGAGTTCCAGCAGCTGCTGAACCAGGGCATCCCTGTGGCCCCTCACACCACCGAGCCCATGCTGATGGAATACCCCGAGGCCATCACCCGGCTCGTGACAGGCGCTCAGAGGCCTCCTGATCCAGCTCCTGCCCCTCTGGGAGCACCAGGCCTGCCTAATGGACTGCTGTCTGGCGACGAGGACTTCAGCTCTATCGCCGATATGGATTTCTCAGCCTTGCTGGGCTCTGGCAGCGGCAGCCGGGATTCCAGGGAAGGGATGTTTTTGCCGAAGCCTGAGGCCGGCTCCGCTATTAGTGACGTGTTTGAGGGCCGCGAGGTGTGCCAGCCAAAACGAATCCGGCCATTTCATCCTCCAGGAAGTCCATGGGCCAACCGCCCACTCCCCGCCAGCCTCGCACCAACACCAACCGGTCCAGTACATGAGCCAGTCGGGTCACTGACCCCGGCACCAGTCCCTCAGCCACTGGATCCAGCGCCCGCAGTGACTCCCGAGGCCAGTCACCTGTTGGAGGATCCCGATGAAGAGACGAGCCAGGCTGTCAAAGCCCTTCGGGAGATGGCCGATACTGTGATTCCCCAGAAGGAAGAGGCTGCAATCTGTGGCCAAATGGACCTTTCCCATCCGCCCCCAAGGGGCCATCTGGATGAGCTGACAACCACACTTGAGTCCATGACCGAGGATCTGAACCTGGACTCACCCCTGACCCCGGAATTGAACGAGATTCTGGATACCTTCCTGAACGACGAGTGCCTCTTGCATGCCATGCATATCAGCACAGGACTGTCCATCTTCGACACATCTCTGTTTTAAACTAGTaataaaagatctttattttcattagatctgtgtgttggttttttgtgtg |
SEQ ID NO: 306 | SEQ ID NO: 354 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCCTCGAACCAGGTGAAAAACCTTACAAATGTCCTGAATGTGGGAAATCATTCAGTCGCAGCGACAACCTGGTGAGACATCAACGCACCCATACAGGAGAAAAACCTTATAAATGTCCAGAATGTGGAAAGTCCTTCTCACGAGAGGATAACTTGCACACTCATCAACGAACACATACTGGTGAAAAACCATACAAGTGTCCCGAATGTGGTAAAAGTTTTAGCCGGAGCGATGAACTTGTCCGACACCAACGAACCCATACAGGCGAGAAGCCTTACAAATGTCCCGAGTGTGGCAAGAGCTTCTCACAATCAGGGAATCTGACTGAGCATCAACGAACTCATACCGGGGAAAAACCTTACAAGTGTCCAGAGTGTGGGAAGAGCTTTTCCACAAGTGGACATCTGGTACGCCACCAGAGGACACATACAGGGGAGAAGCCCTACAAATGCCCCGAATGCGGTAAAAGTTTCTCTCAGAATAGTACCCTGACCGAACACCAGCGAACACACACTGGGAAAAAAACGAGTAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGACGTACCAGATTACGCTCTCGAGGACGCGCTGGACGATTTCGATCTCGACATGCTGGGTTCTGATGCCCTCGATGACTTTGACCTGGATATGTTGGGAAGCGACGCATTGGATGACTTTGATCTGGACATGCTCGGCTCCGATGCTCTGGACGATTTCGATCTCGATATGTTATAAACTAGTaaagagaccggttcactgtgacagtaaaagagaccggttcactgtgagaatgaaagagaccggttcactgtgatcggaaaagagaccggttcactgtgagcggccttgaaacccagcagacaatgtagctcagtagaaacccagcagacaatgtagctgaatggaaacccagcagacaatgtagcttcggagaaacccagcagacaatgtagctAAGCTTGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTT |
SEQ ID NO: 308 | SEQ ID NO: 355 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCCTCGAACCAGGTGAAAAACCTTACAAATGTCCTGAATGTGGGAAATCATTCAGTCGCAGCGACAACCTGGTGAGACATCAACGCACCCATACAGGAGAAAAACCTTATAAATGTCCAGAATGTGGAAAGTCCTTCTCACGAGAGGATAACTTGCACACTCATCAACGAACACATACTGGTGAAAAACCATACAAGTGTCCCGAATGTGGTAAAAGTTTTAGCCGGAGCGATGAACTTGTCCGACACCAACGAACCCATACAGGCGAGAAGCCTTACAAATGTCCCGAGTGTGGCAAGAGCTTCTCACAATCAGGGAATCTGACTGAGCATCAACGAACTCATACCGGGGAAAAACCTTACAAGTGTCCAGAGTGTGGGAAGAGCTTTTCCACAAGTGGACATCTGGTACGCCACCAGAGGACACATACAGGGGAGAAGCCCTACAAATGCCCCGAATGCGGTAAAAGTTTCTCTCAGAATAGTACCCTGACCGAACACCAGCGAACACACACTGGGAAAAAAACGAGTAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGACGTACCAGATTACGCTCTCGAGGACGCGCTGGACGATTTCGATCTCGACATGCTGGGTTCTGATGCCCTCGATGACTTTGACCTGGATATGTTGGGAAGCGACGCATTGGATGACTTTGATCTGGACATGCTCGGCTCCGATGCTCTGGACGATTTCGATCTCGATATGTTATAAACTAGTAAGCTTGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTT |
SEQ ID NO: 313 | SEQ ID NO: 356 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGccgcggccaaggccgagatgcagctgatgtccccgctgcagatctctgacccgttcggatcctttcctcactcgcccaccatggacaactaccctaagctggaggagatgatgctgctgagcaacggggctccccagttcctcggcgccgccggggccccagagggcagcggcagcaacagcagcagcagcagcagcgggggcggtggaggcggcgggggcggcagcaacagcagcagcagcagcagcaccttcaaccctcaggcggacacgggcgagcagccctacgagcacctgaccgcagagtcttttcctgacatctctctgaacaacgagaaggtgctggtggagaccagttaccccagccaaaccactcgactgccccccatcacctatactggccgcttttccctggagcctgcacccaacagtggcaacaccttgtggcccgagcccctcttcagcttggtcagtggcctagtgagcatgaccaacccaccggcctcctcgtcctcagcaccatctccagcggcctcctccgcctccgcctcccagagcccacccctgagctgcgcagtgccatccaacgacagcagtcccatttactcagcggcacccaccttccccacgccgaacactgacattttccctgagccacaaagccaggccttcccgggctcggcagggacagcgctccagtacccgcctcctgcctaccctgccgccaagggtggcttccaggttcccatgatccccgactacctgtttccacagcagcagggggatctgggcctgggcaccccagaccagaagcccttccagggcctggagagccgcacccagcagccttcgctaacccctctgtctactattaaggcctttgccactcagtcgggctcccaggacctgaaggccctcaataccagctaccagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCAGCGACAACCTGGTGAGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCGAGAGGATAACTTGCACACTcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCGGAGCGATGAACTTGTCCGAcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCAATCAGGGAATCTGACTGAGcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcACAAGTGGACATCTGGTACGCcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCAGAATAGTACCCTGACCGAAcataccaagatccacttgcggcagaaggacaagaaagcagacaaaagtgttgtgGCTAGCtcggccacctcctctctctcttcctacccgtccccggttgctacctcttacccgtccccggttactacctcttatccatccccggccaccacctcatacccatcccctgtgcccacctccttctcctctcccggctcctcgacctacccatcccctgtgcacagtggcttcccctccccgtcggtggccaccacgtactcctctgttccccctgctttcccggcccaggtcagcagcttcccttcctcagctgtcaccaactccttcagcgcctccacagggctttcggacatgacagcaaccttttctcccaggacaattgaaatttgctaaACTAGTaataaaagatctttattttcattagatctgtgtgttggttttttgtgtg |
SEQ ID NO: 314 | SEQ ID NO: 357 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGCCgccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgcggtggttctggtggtggttctggtcagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCAGCGACAACCTGGTGAGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCGAGAGGATAACTTGCACACTcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCGGAGCGATGAACTTGTCCGAcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCAATCAGGGAATCTGACTGAGcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcACAAGTGGACATCTGGTACGCcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCAGAATAGTACCCTGACCGAAcataccaagatccacttgcggcagaaggacaagCTCGAGatggccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgctaaACTAGTaataaaagatctttattttcattagatctgtgtgttggttttttgtgtg |
SEQ ID NO: 315 | SEQ ID NO: 358 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGccgcggccaaggccgagatgcagctgatgtccccgctgcagatctctgacccgttcggatcctttcctcactcgcccaccatggacaactaccctaagctggaggagatgatgctgctgagcaacggggctccccagttcctcggcgccgccggggccccagagggcagcggcagcaacagcagcagcagcagcagcgggggcggtggaggcggcgggggcggcagcaacagcagcagcagcagcagcaccttcaaccctcaggcggacacgggcgagcagccctacgagcacctgaccgcagagtcttttcctgacatctctctgaacaacgagaaggtgctggtggagaccagttaccccagccaaaccactcgactgccccccatcacctatactggccgcttttccctggagcctgcacccaacagtggcaacaccttgtggcccgagcccctcttcagcttggtcagtggcctagtgagcatgaccaacccaccggcctcctcgtcctcagcaccatctccagcggcctcctccgcctccgcctcccagagcccacccctgagctgcgcagtgccatccaacgacagcagtcccatttactcagcggcacccaccttccccacgccgaacactgacattttccctgagccacaaagccaggccttcccgggctcggcagggacagcgctccagtacccgcctcctgcctaccctgccgccaagggtggcttccaggttcccatgatccccgactacctgtttccacagcagcagggggatctgggcctgggcaccccagaccagaagcccttccagggcctggagagccgcacccagcagccttcgctaacccctctgtctactattaaggcctttgccactcagtcgggctcccaggacctgaaggccctcaataccagctaccagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCTCAGACAACCTCGTTCGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCACCGGACTACACTCACGAACcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGAGAAGACAATCTCCATACTCACATCCGGACACACACGGGAGAGAAGCCATTCGCATGtGATATATGTGGGAGAAAGTTCTCCACCAGCCATTCTCTCACTGAAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCAGTCTAGCTCACTGGTGAGGcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGGGAGGATAACCTGCATACGcataccaagatccacttgcggcagaaggacaagaaagcagacaaaagtgttgtgGCTAGCtcggccacctcctctctctcttcctacccgtccccggttgctacctcttacccgtccccggttactacctcttatccatccccggccaccacctcatacccatcccctgtgcccacctccttctcctctcccggctcctcgacctacccatcccctgtgcacagtggcttcccctccccgtcggtggccaccacgtactcctctgttccccctgctttcccggcccaggtcagcagcttcccttcctcagctgtcaccaactccttcagcgcctccacagggctttcggacatgacagcaaccttttctcccaggacaattgaaatttgctaaACTAGTaataaaagatctttattttcattagatctgtgtgttggttttttgtgtg |
SEQ ID NO: 316 | SEQ ID NO: 359 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGCCgccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgcggtggttctggtggtggttctggtcagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCAGCGACAACCTGGTGAGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCGAGAGGATAACTTGCACACTcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCGGAGCGATGAACTTGTCCGAcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCAATCAGGGAATCTGACTGAGcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcACAAGTGGACATCTGGTACGCcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCAGAATAGTACCCTGACCGAAcataccaagatccacttgcggcagaaggacaagtaaCTCGAGACTAGTaataaaagatctttattttcattagatctgtgtgttggttttttgtgtg |
SEQ ID NO: 317 | SEQ ID NO: 360 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGCCgccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgcggtggttctggtggtggttctggtcagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCTCAGACAACCTCGTTCGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCACCGGACTACACTCACGAACcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGAGAAGACAATCTCCATACTcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccACCAGCCATTCTCTCACTGAAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCAGTCTAGCTCACTGGTGAGGcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGGGAGGATAACCTGCATACGcataccaagatccacttgcggcagaaggacaagCTCGAGatggccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgctaaACTAGTaataaaagatctttattttcattagatctgtgtgttggttttttgtgtg |
SEQ ID NO: 318 | SEQ ID NO: 361 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGCCgccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgcggtggttctggtggtggttctggtcagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCTCAGACAACCTCGTTCGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCACCGGACTACACTCACGAACcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGAGAAGACAATCTCCATACTcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccACCAGCCATTCTCTCACTGAAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCAGTCTAGCTCACTGGTGAGGcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGGGAGGATAACCTGCATACGcataccaagatccacttgcggcagaaggacaagtaaCTCGAGACTAGTaataaaagatctttattttcattagatctgtgtgttggttttttgtgtg |
SEQ ID NO: 319 | SEQ ID NO: 362 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGccgcggccaaggccgagatgcagctgatgtccccgctgcagatctctgacccgttcggatcctttcctcactcgcccaccatggacaactaccctaagctggaggagatgatgctgctgagcaacggggctccccagttcctcggcgccgccggggccccagagggcagcggcagcaacagcagcagcagcagcagcgggggcggtggaggcggcgggggcggcagcaacagcagcagcagcagcagcaccttcaaccctcaggcggacacgggcgagcagccctacgagcacctgaccgcagagtcttttcctgacatctctctgaacaacgagaaggtgctggtggagaccagttaccccagccaaaccactcgactgccccccatcacctatactggccgcttttccctggagcctgcacccaacagtggcaacaccttgtggcccgagcccctcttcagcttggtcagtggcctagtgagcatgaccaacccaccggcctcctcgtcctcagcaccatctccagcggcctcctccgcctccgcctcccagagcccacccctgagctgcgcagtgccatccaacgacagcagtcccatttactcagcggcacccaccttccccacgccgaacactgacattttccctgagccacaaagccaggccttcccgggctcggcagggacagcgctccagtacccgcctcctgcctaccctgccgccaagggtggcttccaggttcccatgatccccgactacctgtttccacagcagcagggggatctgggcctgggcaccccagaccagaagcccttccagggcctggagagccgcacccagcagccttcgctaacccctctgtctactattaaggcctttgccactcagtcgggctcccaggacctgaaggccctcaataccagctaccagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCAGCGACAACCTGGTGAGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCGAGAGGATAACTTGCACACTcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCGGAGCGATGAACTTGTCCGAcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCAATCAGGGAATCTGACTGAGcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcACAAGTGGACATCTGGTACGCcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCAGAATAGTACCCTGACCGAAcataccaagatccacttgcggcagaaggacaagaaagcagacaaaagtgttgtgGCTAGCtcggccacctcctctctctcttcctacccgtccccggttgctacctcttacccgtccccggttactacctcttatccatccccggccaccacctcatacccatcccctgtgcccacctccttctcctctcccggctcctcgacctacccatcccctgtgcacagtggcttcccctccccgtcggtggccaccacgtactcctctgttccccctgctttcccggcccaggtcagcagcttcccttcctcagctgtcaccaactccttcagcgcctccacagggctttcggacatgacagcaaccttttctcccaggacaattgaaatttgctaaACTAGTAAGCTTGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTT |
SEQ ID NO: 325 | SEQ ID NO: 363 | ggaggaagccatcaactaaactacaatgactgtaagatacaaaattgggaatggtaacatattttgaagttctgttgacataaagaatcatgatattaatgcccatggaaatgaaagggcgatcaacactatggtttgaaaagggggaaattgtagagcacagatgtgttcgtgtggcagtgtgctgtctctagcaatactcagagaagagagagaacaatgaaattctgattggccccagtgtgagcccagatgaggttcagctgccaactttctctttcacatcttatgaaagtcatttaagcacaactaactttttttttttttttttttttttgagacagagtcttgctctgttgcccaggacagagtgcagtagtgactcaatctcggctcactgcagcctccacctcctaggctcaaacggtcctcctgcatcagcctcccaagtagctggaattacaggagtggcccaccatgcccagctaatttttgtatttttaatagatacgggggtttcaccatatcacccaggctggtctcgaactcctggcctcaagtgatccacctgcctcggcctcccaaagtgctgggattataggcgtcagccactatgcccaacccgaccaaccttttttaaaataaatatttaaaaaattggtatttcacatatatactagtatttacatttatccacacaaaacggacgggcctccgctgaaccagtgaggccccagacgtgcgcataaataacccctgcgtgctgcaccacctggggagagggggaggaccacggtaaatggagcgagcgcatagcaaaagggacgcggggtccttttctctgccggtggcactgggtagctgtggccaggtgtggtactttgatggggcccagggctggagctcaaggaagcgtcgcagggtcacagatctgggggaaccccggggaaaagcactgaggcaaaaccgccgctcgtctcctacaatatatgggagggggaggttgagtacgttctggattactcataagaccttttttttttccttccgggcgcaaaaccgtgagctggatttataatcgccctataaagctccagaggcggtcaggcacctgcagaggagccccgccgctccgccgactagctgcccccgcgagcaacggcctcgtgatttccccgccgatccggtccccgcctccccactctgcccccgcctaccccggagccgtgcagccgcctctccgaatctctctcttctcctggcgctcgcgtgcgagagggaactagcgagaacgaggaagcagctggaggtgacgccgggcagattacgcctgtcagggccgagccgagcggatcgctgggcgctgtgcagaggaaaggcgggagtgcccggctcgctgtcgcagagccgaggtgggtaagctagcgaccacctggacttcccagcgcccaaccgtggcttttcagccaggtcctctcctcccgcggcttctcaaccaaccccatcccagcgccggccacccaacctcccgaaatgagtgcttcctgccccagcagccgaaggcgctactaggaacggtaacctgttacttttccaggggccgtagtcgacccgctgcccgagttgctgtgcgactgcgcgcgcggggctagagtgcaaggtgactgtggttcttctctggccaagtccgagggagaacgtaaagatatgggcctttttccccctctcaccttgtctcaccaaagtccctagtccccggagcagttagcctctttctttccagggaattagccagacacaacaacgggaaccagacaccgaaccagacatgcccgccccgtgcgccctccccgctcgctgcctttcctccctcttgtctctccagagccggatcttcaaggggagcctccgtgcccccggctgctcagtccctccggtgtgcaggaccccggaagtcctccccgcacagctctcgcttctctttgcagcctgtttctgcgccggaccagtcgaggactctggacagtagaggccccgggacgaccgagctgGAATTCGCCACCATGGccgcggccaaggccgagatgcagctgatgtccccgctgcagatctctgacccgttcggatcctttcctcactcgcccaccatggacaactaccctaagctggaggagatgatgctgctgagcaacggggctccccagttcctcggcgccgccggggccccagagggcagcggcagcaacagcagcagcagcagcagcgggggcggtggaggcggcgggggcggcagcaacagcagcagcagcagcagcaccttcaaccctcaggcggacacgggcgagcagccctacgagcacctgaccgcagagtcttttcctgacatctctctgaacaacgagaaggtgctggtggagaccagttaccccagccaaaccactcgactgccccccatcacctatactggccgcttttccctggagcctgcacccaacagtggcaacaccttgtggcccgagcccctcttcagcttggtcagtggcctagtgagcatgaccaacccaccggcctcctcgtcctcagcaccatctccagcggcctcctccgcctccgcctcccagagcccacccctgagctgcgcagtgccatccaacgacagcagtcccatttactcagcggcacccaccttccccacgccgaacactgacattttccctgagccacaaagccaggccttcccgggctcggcagggacagcgctccagtacccgcctcctgcctaccctgccgccaagggtggcttccaggttcccatgatccccgactacctgtttccacagcagcagggggatctgggcctgggcaccccagaccagaagcccttccagggcctggagagccgcacccagcagccttcgctaacccctctgtctactattaaggcctttgccactcagtcgggctcccaggacctgaaggccctcaataccagctaccagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCAGCGACAACCTGGTGAGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCGAGAGGATAACTTGCACACTcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCGGAGCGATGAACTTGTCCGACACATCCGGACACACACGGGAGAGAAGCCATTCGCATGtGATATATGTGGGAGAAAGTTCTCCCAATCAGGGAATCTGACTGAGcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcACAAGTGGACATCTGGTACGCcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCAGAATAGTACCCTGACCGAAcataccaagatccacttgcggcagaaggacaagaaagcagacaaaagtgttgtgGCTAGCtcggccacctcctctctctcttcctacccgtccccggttgctacctcttacccgtccccggttactacctcttatccatccccggccaccacctcatacccatcccctgtgcccacctccttctcctctcccggctcctcgacctacccatcccctgtgcacagtggcttcccctccccgtcggtggccaccacgtactcctctgttccccctgctttcccggcccaggtcagcagcttcccttcctcagctgtcaccaactccttcagcgcctccacagggctttcggacatgacagcaaccttttctcccaggacaattgaaatttgctaaACTAGTAAGCTTGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTT |
SEQ ID NO: 442 | ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCCTCGAACCAGGTGAAAAACCTTACAAATGTCCTGAATGTGGGAAATCATTCAGTCGCAGCGACAACCTGGTGAGACATCAACGCACCCATACAGGAGAAAAACCTTATAAATGTCCAGAATGTGGAAAGTCCTTCTCACGAGAGGATAACTTGCACACTCATCAACGAACACATACTGGTGAAAAACCATACAAGTGTCCCGAATGTGGTAAAAGTTTTAGCCGGAGCGATGAACTTGTCCGACACCAACGAACCCATACAGGCGAGAAGCCTTACAAATGTCCCGAGTGTGGCAAGAGCTTCTCACAATCAGGGAATCTGACTGAGCATCAACGAACTCATACCGGGGAAAAACCTTACAAGTGTCCAGAGTGTGGGAAGAGCTTTTCCACAAGTGGACATCTGGTACGCCACCAGAGGACACATACAGGGGAGAAGCCCTACAAATGCCCCGAATGCGGTAAAAGTTTCTCTCAGAATAGTACCCTGACCGAACACCAGCGAACACACACTGGGAAAAAAACGAGTAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGACGTACCAGATTACGCTCTCGAGGAGGCCAGCGGTTCCGGACGGGCTGACGCATTGGACGATTTTGATCTGGATATGCTGGGAAGTGACGCCCTCGATGATTTTGACCTTGACATGCTTGGTTCGGATGCCCTTGATGACTTTGACCTCGACATGCTCGGCAGTGACGCCCTTGATGATTTCGACCTGGACATGCTGATTAACTCTAGAAGTTCCGGATCTCCGAAAAAGAAACGCAAAGTTGGTAGCCAGTACCTGCCCGACACCGACGACCGGCACCGGATCGAGGAAAAGCGGAAGCGGACCTACGAGACATTCAAGAGCATCATGAAGAAGTCCCCCTTCAGCGGCCCCACCGACCCTAGACCTCCACCTAGAAGAATCGCCGTGCCCAGCAGATCCAGCGCCAGCGTGCCAAAACCTGCCCCCCAGCCTTACCCCTTCACCAGCAGCCTGAGCACCATCAACTACGACGAGTTCCCTACCATGGTGTTCCCCAGCGGCCAGATCTCTCAGGCCTCTGCTCTGGCTCCAGCCCCTCCTCAGGTGCTGCCTCAGGCTCCTGCTCCTGCACCAGCTCCAGCCATGGTGTCTGCACTGGCTCAGGCACCAGCACCCGTGCCTGTGCTGGCTCCTGGACCTCCACAGGCTGTGGCTCCACCAGCCCCTAAACCTACACAGGCCGGCGAGGGCACACTGTCTGAAGCTCTGCTGCAGCTGCAGTTCGACGACGAGGATCTGGGAGCCCTGCTGGGAAACAGCACCGATCCTGCCGTGTTCACCGACCTGGCCAGCGTGGACAACAGCGAGTTCCAGCAGCTGCTGAACCAGGGCATCCCTGTGGCCCCTCACACCACCGAGCCCATGCTGATGGAATACCCCGAGGCCATCACCCGGCTCGTGACAGGCGCTCAGAGGCCTCCTGATCCAGCTCCTGCCCCTCTGGGAGCACCAGGCCTGCCTAATGGACTGCTGTCTGGCGACGAGGACTTCAGCTCTATCGCCGATATGGATTTCTCAGCCTTGCTGGGCTCTGGCAGCGGCAGCCGGGATTCCAGGGAAGGGATGTTTTTGCCGAAGCCTGAGGCCGGCTCCGCTATTAGTGACGTGTTTGAGGGCCGCGAGGTGTGCCAGCCAAAACGAATCCGGCCATTTCATCCTCCAGGAAGTCCATGGGCCAACCGCCCACTCCCCGCCAGCCTCGCACCAACACCAACCGGTCCAGTACATGAGCCAGTCGGGTCACTGACCCCGGCACCAGTCCCTCAGCCACTGGATCCAGCGCCCGCAGTGACTCCCGAGGCCAGTCACCTGTTGGAGGATCCCGATGAAGAGACGAGCCAGGCTGTCAAAGCCCTTCGGGAGATGGCCGATACTGTGATTCCCCAGAAGGAAGAGGCTGCAATCTGTGGCCAAATGGACCTTTCCCATCCGCCCCCAAGGGGCCATCTGGATGAGCTGACAACCACACTTGAGTCCATGACCGAGGATCTGAACCTGGACTCACCCCTGACCCCGGAATTGAACGAGATTCTGGATACCTTCCTGAACGACGAGTGCCTCTTGCATGCCATGCATATCAGCACAGGACTGTCCATCTTCGACACATCTCTGTTT | |
SEQ ID NO: 443 | ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCCTCGAACCAGGTGAAAAACCTTACAAATGTCCTGAATGTGGGAAATCATTCAGTCGCAGCGACAACCTGGTGAGACATCAACGCACCCATACAGGAGAAAAACCTTATAAATGTCCAGAATGTGGAAAGTCCTTCTCACGAGAGGATAACTTGCACACTCATCAACGAACACATACTGGTGAAAAACCATACAAGTGTCCCGAATGTGGTAAAAGTTTTAGCCGGAGCGATGAACTTGTCCGACACCAACGAACCCATACAGGCGAGAAGCCTTACAAATGTCCCGAGTGTGGCAAGAGCTTCTCACAATCAGGGAATCTGACTGAGCATCAACGAACTCATACCGGGGAAAAACCTTACAAGTGTCCAGAGTGTGGGAAGAGCTTTTCCACAAGTGGACATCTGGTACGCCACCAGAGGACACATACAGGGGAGAAGCCCTACAAATGCCCCGAATGCGGTAAAAGTTTCTCTCAGAATAGTACCCTGACCGAACACCAGCGAACACACACTGGGAAAAAAACGAGTAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGACGTACCAGATTACGCTCTCGAGGACGCGCTGGACGATTTCGATCTCGACATGCTGGGTTCTGATGCCCTCGATGACTTTGACCTGGATATGTTGGGAAGCGACGCATTGGATGACTTTGATCTGGACATGCTCGGCTCCGATGCTCTGGACGATTTCGATCTCGATATGTTA | |
SEQ ID NO: 444 | ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCCTCGAACCAGGTGAAAAACCTTACAAATGTCCTGAATGTGGGAAATCATTCAGTCGCAGCGACAACCTGGTGAGACATCAACGCACCCATACAGGAGAAAAACCTTATAAATGTCCAGAATGTGGAAAGTCCTTCTCACGAGAGGATAACTTGCACACTCATCAACGAACACATACTGGTGAAAAACCATACAAGTGTCCCGAATGTGGTAAAAGTTTTAGCCGGAGCGATGAACTTGTCCGACACCAACGAACCCATACAGGCGAGAAGCCTTACAAATGTCCCGAGTGTGGCAAGAGCTTCTCACAATCAGGGAATCTGACTGAGCATCAACGAACTCATACCGGGGAAAAACCTTACAAGTGTCCAGAGTGTGGGAAGAGCTTTTCCACAAGTGGACATCTGGTACGCCACCAGAGGACACATACAGGGGAGAAGCCCTACAAATGCCCCGAATGCGGTAAAAGTTTCTCTCAGAATAGTACCCTGACCGAACACCAGCGAACACACACTGGGAAAAAAACGAGTAAAAGGCCGGCGGCCACGAAAAAGGCCGGCCAGGCAAAAAAGAAAAAGGGATCCTACCCATACGACGTACCAGATTACGCTCTCGAGGACGCGCTGGACGATTTCGATCTCGACATGCTGGGTTCTGATGCCCTCGATGACTTTGACCTGGATATGTTGGGAAGCGACGCATTGGATGACTTTGATCTGGACATGCTCGGCTCCGATGCTCTGGACGATTTCGATCTCGATATGTTA | |
SEQ ID NO: 445 | ATGGccgcggccaaggccgagatgcagctgatgtccccgctgcagatctctgacccgttcggatcctttcctcactcgcccaccatggacaactaccctaagctggaggagatgatgctgctgagcaacggggctccccagttcctcggcgccgccggggccccagagggcagcggcagcaacagcagcagcagcagcagcgggggcggtggaggcggcgggggcggcagcaacagcagcagcagcagcagcaccttcaaccctcaggcggacacgggcgagcagccctacgagcacctgaccgcagagtcttttcctgacatctctctgaacaacgagaaggtgctggtggagaccagttaccccagccaaaccactcgactgccccccatcacctatactggccgcttttccctggagcctgcacccaacagtggcaacaccttgtggcccgagcccctcttcagcttggtcagtggcctagtgagcatgaccaacccaccggcctcctcgtcctcagcaccatctccagcggcctcctccgcctccgcctcccagagcccacccctgagctgcgcagtgccatccaacgacagcagtcccatttactcagcggcacccaccttccccacgccgaacactgacattttccctgagccacaaagccaggccttcccgggctcggcagggacagcgctccagtacccgcctcctgcctaccctgccgccaagggtggcttccaggttcccatgatccccgactacctgtttccacagcagcagggggatctgggcctgggcaccccagaccagaagcccttccagggcctggagagccgcacccagcagccttcgctaacccctctgtctactattaaggcctttgccactcagtcgggctcccaggacctgaaggccctcaataccagctaccagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCAGCGACAACCTGGTGAGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCGAGAGGATAACTTGCACACTcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCGGAGCGATGAACTTGTCCGAcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCAATCAGGGAATCTGACTGAGcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcACAAGTGGACATCTGGTACGCcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCAGAATAGTACCCTGACCGAAcataccaagatccacttgcggcagaaggacaagaaagcagacaaaagtgttgtgGCTAGCtcggccacctcctctctctcttcctacccgtccccggttgctacctcttacccgtccccggttactacctcttatccatccccggccaccacctcatacccatcccctgtgcccacctccttctcctctcccggctcctcgacctacccatcccctgtgcacagtggcttcccctccccgtcggtggccaccacgtactcctctgttccccctgctttcccggcccaggtcagcagcttcccttcctcagctgtcaccaactccttcagcgcctccacagggctttcggacatgacagcaaccttttctcccaggacaattgaaatttgc | |
SEQ ID NO: 446 | ATGGCCgccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgcggtggttctggtggtggttctggtcagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCAGCGACAACCTGGTGAGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCGAGAGGATAACTTGCACACTcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCGGAGCGATGAACTTGTCCGAcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCAATCAGGGAATCTGACTGAGcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcACAAGTGGACATCTGGTACGCcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCAGAATAGTACCCTGACCGAAcataccaagatccacttgcggcagaaggacaagCTCGAGatggccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgc | |
SEQ ID NO: 447 | ATGGccgcggccaaggccgagatgcagctgatgtccccgctgcagatctctgacccgttcggatcctttcctcactcgcccaccatggacaactaccctaagctggaggagatgatgctgctgagcaacggggctccccagttcctcggcgccgccggggccccagagggcagcggcagcaacagcagcagcagcagcagcgggggcggtggaggcggcgggggcggcagcaacagcagcagcagcagcagcaccttcaaccctcaggcggacacgggcgagcagccctacgagcacctgaccgcagagtcttttcctgacatctctctgaacaacgagaaggtgctggtggagaccagttaccccagccaaaccactcgactgccccccatcacctatactggccgcttttccctggagcctgcacccaacagtggcaacaccttgtggcccgagcccctcttcagcttggtcagtggcctagtgagcatgaccaacccaccggcctcctcgtcctcagcaccatctccagcggcctcctccgcctccgcctcccagagcccacccctgagctgcgcagtgccatccaacgacagcagtcccatttactcagcggcacccaccttccccacgccgaacactgacattttccctgagccacaaagccaggccttcccgggctcggcagggacagcgctccagtacccgcctcctgcctaccctgccgccaagggtggcttccaggttcccatgatccccgactacctgtttccacagcagcagggggatctgggcctgggcaccccagaccagaagcccttccagggcctggagagccgcacccagcagccttcgctaacccctctgtctactattaaggcctttgccactcagtcgggctcccaggacctgaaggccctcaataccagctaccagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCTCAGACAACCTCGTTCGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCACCGGACTACACTCACGAACcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGAGAAGACAATCTCCATACTCACATCCGGACACACACGGGAGAGAAGCCATTCGCATGtGATATATGTGGGAGAAAGTTCTCCACCAGCCATTCTCTCACTGAAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCAGTCTAGCTCACTGGTGAGGcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGGGAGGATAACCTGCATACGcataccaagatccacttgcggcagaaggacaagaaagcagacaaaagtgttgtgGCTAGCtcggccacctcctctctctcttcctacccgtccccggttgctacctcttacccgtccccggttactacctcttatccatccccggccaccacctcatacccatcccctgtgcccacctccttctcctctcccggctcctcgacctacccatcccctgtgcacagtggcttcccctccccgtcggtggccaccacgtactcctctgttccccctgctttcccggcccaggtcagcagcttcccttcctcagctgtcaccaactccttcagcgcctccacagggctttcggacatgacagcaaccttttctcccaggacaattgaaatttgc | |
SEQ ID NO: 448 | ATGGCCgccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgcggtggttctggtggtggttctggtcagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCAGCGACAACCTGGTGAGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCGAGAGGATAACTTGCACACTcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCGGAGCGATGAACTTGTCCGAcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCAATCAGGGAATCTGACTGAGcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcACAAGTGGACATCTGGTACGCcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCAGAATAGTACCCTGACCGAAcataccaagatccacttgcggcagaaggacaag | |
SEQ ID NO: 449 | ATGGCCgccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgcggtggttctggtggtggttctggtcagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCTCAGACAACCTCGTTCGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCACCGGACTACACTCACGAACcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGAGAAGACAATCTCCATACTcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccACCAGCCATTCTCTCACTGAAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCAGTCTAGCTCACTGGTGAGGcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGGGAGGATAACCTGCATACGcataccaagatccacttgcggcagaaggacaagCTCGAGatggccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgc | |
SEQ ID NO: 450 | ATGGCCgccgaccacctgatgctcgccgagggctaccgcctggtgcagaggccgccgtccgccgccgccgcccatggccctcatgcgctccggactctgccgccgtacgcgggcccgggcctggacagtgggctgaggccgcggggggctccgctggggccgccgccgccccgccaacccggggccctggcgtacggggccttcgggccgccgtcctccttccagccctttccggccgtgcctccgccggccgcgggcatcgcgcacctgcagcctgtggcgacgccgtaccccggccgcgcggccgcgccccccaacgctccgggaggccccccgggcccgcagccggccccaagcgccgcagccccgccgccgcccgcgcacgccctgggcggcatggacgccgaactcatcgacgaggaggcgctgacgtcgctggagctggagctggggctgcaccgcgtgcgcgagctgcccgagctgttcctgggccagagcgagttcgactgcttctcggacttggggtccgcgccgcccgccggctccgtgagctgcggtggttctggtggtggttctggtcagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCTCAGACAACCTCGTTCGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCACCGGACTACACTCACGAACcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGAGAAGACAATCTCCATACTcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccACCAGCCATTCTCTCACTGAAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCAGTCTAGCTCACTGGTGAGGcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGGGAGGATAACCTGCATACGcataccaagatccacttgcggcagaaggacaag | |
SEQ ID NO: 451 | ATGGccgcggccaaggccgagatgcagctgatgtccccgctgcagatctctgacccgttcggatcctttcctcactcgcccaccatggacaactaccctaagctggaggagatgatgctgctgagcaacggggctccccagttcctcggcgccgccggggccccagagggcagcggcagcaacagcagcagcagcagcagcgggggcggtggaggcggcgggggcggcagcaacagcagcagcagcagcagcaccttcaaccctcaggcggacacgggcgagcagccctacgagcacctgaccgcagagtcttttcctgacatctctctgaacaacgagaaggtgctggtggagaccagttaccccagccaaaccactcgactgccccccatcacctatactggccgcttttccctggagcctgcacccaacagtggcaacaccttgtggcccgagcccctcttcagcttggtcagtggcctagtgagcatgaccaacccaccggcctcctcgtcctcagcaccatctccagcggcctcctccgcctccgcctcccagagcccacccctgagctgcgcagtgccatccaacgacagcagtcccatttactcagcggcacccaccttccccacgccgaacactgacattttccctgagccacaaagccaggccttcccgggctcggcagggacagcgctccagtacccgcctcctgcctaccctgccgccaagggtggcttccaggttcccatgatccccgactacctgtttccacagcagcagggggatctgggcctgggcaccccagaccagaagcccttccagggcctggagagccgcacccagcagccttcgctaacccctctgtctactattaaggcctttgccactcagtcgggctcccaggacctgaaggccctcaataccagctaccagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCAGCGACAACCTGGTGAGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCGAGAGGATAACTTGCACACTcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCGGAGCGATGAACTTGTCCGAcataccaagatccacttgcggcagaaggaccgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCAATCAGGGAATCTGACTGAGcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcACAAGTGGACATCTGGTACGCcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCAGAATAGTACCCTGACCGAAcataccaagatccacttgcggcagaaggacaagaaagcagacaaaagtgttgtgGCTAGCtcggccacctcctctctctcttcctacccgtccccggttgctacctcttacccgtccccggttactacctcttatccatccccggccaccacctcatacccatcccctgtgcccacctccttctcctctcccggctcctcgacctacccatcccctgtgcacagtggcttcccctccccgtcggtggccaccacgtactcctctgttccccctgctttcccggcccaggtcagcagcttcccttcctcagctgtcaccaactccttcagcgcctccacagggctttcggacatgacagcaaccttttctcccaggacaattgaaatttgc | |
SEQ ID NO: 452 | ATGGccgcggccaaggccgagatgcagctgatgtccccgctgcagatctctgacccgttcggatcctttcctcactcgcccaccatggacaactaccctaagctggaggagatgatgctgctgagcaacggggctccccagttcctcggcgccgccggggccccagagggcagcggcagcaacagcagcagcagcagcagcgggggcggtggaggcggcgggggcggcagcaacagcagcagcagcagcagcaccttcaaccctcaggcggacacgggcgagcagccctacgagcacctgaccgcagagtcttttcctgacatctctctgaacaacgagaaggtgctggtggagaccagttaccccagccaaaccactcgactgccccccatcacctatactggccgcttttccctggagcctgcacccaacagtggcaacaccttgtggcccgagcccctcttcagcttggtcagtggcctagtgagcatgaccaacccaccggcctcctcgtcctcagcaccatctccagcggcctcctccgcctccgcctcccagagcccacccctgagctgcgcagtgccatccaacgacagcagtcccatttactcagcggcacccaccttccccacgccgaacactgacattttccctgagccacaaagccaggccttcccgggctcggcagggacagcgctccagtacccgcctcctgcctaccctgccgccaagggtggcttccaggttcccatgatccccgactacctgtttccacagcagcagggggatctgggcctgggcaccccagaccagaagcccttccagggcctggagagccgcacccagcagccttcgctaacccctctgtctactattaaggcctttgccactcagtcgggctcccaggacctgaaggccctcaataccagctaccagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCAGCGACAACCTGGTGAGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCGAGAGGATAACTTGCACACTcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCGGAGCGATGAACTTGTCCGACACATCCGGACACACACGGGAGAGAAGCCATTCGCATGtGATATATGTGGGAGAAAGTTCTCCCAATCAGGGAATCTGACTGAGcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcACAAGTGGACATCTGGTACGCcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccCAGAATAGTACCCTGACCGAAcataccaagatccacttgcggcagaaggacaagaaagcagacaaaagtgttgtgGCTAGCtcggccacctcctctctctcttcctacccgtccccggttgctacctcttacccgtccccggttactacctcttatccatccccggccaccacctcatacccatcccctgtgcccacctccttctcctctcccggctcctcgacctacccatcccctgtgcacagtggcttcccctccccgtcggtggccaccacgtactcctctgttccccctgctttcccggcccaggtcagcagcttcccttcctcagctgtcaccaactccttcagcgcctccacagggctttcggacatgacagcaaccttttctcccaggacaattgaaatttgc | |
SEQ ID NO: 453 | ATGGccgcggccaaggccgagatgcagctgatgtccccgctgcagatctctgacccgttcggatcctttcctcactcgcccaccatggacaactaccctaagctggaggagatgatgctgctgagcaacggggctccccagttcctcggcgccgccggggccccagagggcagcggcagcaacagcagcagcagcagcagcgggggcggtggaggcggcgggggcggcagcaacagcagcagcagcagcagcaccttcaaccctcaggcggacacgggcgagcagccctacgagcacctgaccgcagagtcttttcctgacatctctctgaacaacgagaaggtgctggtggagaccagttaccccagccaaaccactcgactgccccccatcacctatactggccgcttttccctggagcctgcacccaacagtggcaacaccttgtggcccgagcccctcttcagcttggtcagtggcctagtgagcatgaccaacccaccggcctcctcgtcctcagcaccatctccagcggcctcctccgcctccgcctcccagagcccacccctgagctgcgcagtgccatccaacgacagcagtcccatttactcagcggcacccaccttccccacgccgaacactgacattttccctgagccacaaagccaggccttcccgggctcggcagggacagcgctccagtacccgcctcctgcctaccctgccgccaagggtggcttccaggttcccatgatccccgactacctgtttccacagcagcagggggatctgggcctgggcaccccagaccagaagcccttccagggcctggagagccgcacccagcagccttcgctaacccctctgtctactattaaggcctttgccactcagtcgggctcccaggacctgaaggccctcaataccagctaccagtcccagctcatcaaacccagccgcatgcgcaagtaccccaaccggcccagcaagacgcccccccacgaacgcccttacgcttgcccagtggagtcctgtgatcgccgcttctccCGCTCAGACAACCTCGTTCGAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCACCGGACTACACTCACGAACcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGAGAAGACAATCTCCATACTCACATCCGGACACACACGGGAGAGAAGCCATTCGCATGtGATATATGTGGGAGAAAGTTCTCCACCAGCCATTCTCTCACTGAAcacatccgcatccacacaggccagaagcccttccagtgccgcatctgcatgAGAaacttcagcCAGTCTAGCTCACTGGTGAGGcacatccgcacccacacaggcgaaaagcccttcgcctgcgacatctgtggaagaaagtttgccAGGGAGGATAACCTGCATACGcataccaagatccacttgcggcagaaggacaagaaagcagacaaaagtgttgtgGCTAGCtcggccacctcctctctctcttcctacccgtccccggttgctacctcttacccgtccccggttactacctcttatccatccccggccaccacctcatacccatcccctgtgcccacctccttctcctctcccggctcctcgacctacccatcccctgtgcacagtggcttcccctccccgtcggtggccaccacgtactcctctgttccccctgctttcccggcccaggtcagcagcttcccttcctcagctgtcaccaactccttcagcgcctccacagggctttcggacatgacagcaaccttttctcccaggacaattgaaatttgc |
表現卡匣 | 標靶位點SEQ ID NO : | DBD SEQ ID NO: | TAD SEQ ID NO: |
對照 | N/A | 無 | 無 |
A | SEQ ID NO: 35 | SEQ ID NO: 131 | SEQ ID NO: 95 |
B | SEQ ID NO: 35 | SEQ ID NO: 131 | SEQ ID NO: 114 |
C | SEQ ID NO: 36 | SEQ ID NO: 132 | SEQ ID NO: 95 |
D | SEQ ID NO: 36 | SEQ ID NO: 132 | SEQ ID NO: 114 |
E | SEQ ID NO: 37 | SEQ ID NO: 133 | SEQ ID NO: 95 |
F | SEQ ID NO: 136 | SEQ ID NO: 134 | SEQ ID NO: 114 |
G | SEQ ID NO: 107 | SEQ ID NO: 103 | SEQ ID NO: 95 |
H | SEQ ID NO: 108 | SEQ ID NO: 103 | SEQ ID NO: 114 |
eTF SEQ ID NO: | eTF 蛋白質序列 |
SEQ ID NO: 305 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF |
SEQ ID NO: 306 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 307 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 308 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 309 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF |
SEQ ID NO: 310 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 311 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSRSDHLTNHQRTHTGEKPYKCPECGKSFSRSDDLVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF |
SEQ ID NO: 312 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRRDELNVHQRTHTGEKPYKCPECGKSFSRSDHLTNHQRTHTGEKPYKCPECGKSFSRSDDLVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 313 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 314 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 315 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDK |
SEQ ID NO: 316 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 317 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHIRTHTGEKPFACDICGRKFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 318 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDK |
SEQ ID NO: 319 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
SEQ ID NO: 320 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSRSDHLTNHIRTHTGEKPFACDICGRKFARSDDLVRHTKIHLRQKDRPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 321 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSRSDHLTNHIRTHTGEKPFACDICGRKFARSDDLVRHTKIHLRQKDRPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 322 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSRSDHLTNHIRTHTGEKPFACDICGRKFARSDDLVRHTKIHLRQKDRPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 323 | MTGKLAEKLPVTMSSLLNQLPDNLYPEEIPSALNLFSGSSDSVVHYNQMATENVMDIGLTNEKPNPELSYSGSFQPAPGNKTVTYLGKFAFDSPSNWCQDNIISLMSAGILGVPPASGALSTQTSTASMVQPPQGDVEAMYPALPPYSNCGDLYSEPVSFHDPQGNPGLAYSPQDYQSAKPALDSNLFPMIPDYNLYHHPNDMGSIPEHKPFQGMDPIRVNPPPITPLETIKAFKDKQIHPGFGSLPQPPLTLKPIRPRKYPNRPSKTPLHERPHACPAEGCDRRFSRSDNLVRHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDELVRHAKIHLKQKEHACPAEGCDRRFSQSGNLTEHLRIHTGHKPFQCRICMRSFSTSGHLVRHIRTHTGEKPFACEFCGRKFAQNSTLTEHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA |
SEQ ID NO: 324 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDK |
SEQ ID NO: 325 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHIRTHTGEKPFACDICGRKFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 365 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 366 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF |
SEQ ID NO: 364 | MYPYDVPDYAGYPYDVPDYAGSYPYDVPDYAGSGSGSAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSHRTTLTNHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDRPYACPVESCDRRFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLVRHIRTHTGEKPFACDICGRKFAREDNLHTHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 295 | MYPYDVPDYAGYPYDVPDYAGSYPYDVPDYAGSGSGSAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHTKIHLRQKDRPYACPVESCDRRFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 296 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSDPGALVRHIRIHTGQKPFQCRICMRNFSRSDNLVRHIRTHTGEKPFACDICGRKFAQSGDLRRHTKIHLRQKDRPYACPVESCDRRFSTHLDLIRHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDRPYACPVESCDRRFSQSGHLTEHIRIHTGQKPFQCRICMRNFSERSHLREHIRTHTGEKPFACDICGRKFAQAGHLASHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 297 | MRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLTRHIRIHTGQKPFQCRICMRNFSHSTTLTNHIRTHTGEKPFACDICGRKFARSDNRKTHIRTHTGEKPFACDICGRKFSTSHSLTEHIRIHTGQKPFQCRICMRNFSQSSSLTRHIRTHTGEKPFACDICGRKFARSDNRKTHTKIHLRQKDKKADKSVVAS |
SEQ ID NO: 298 | MRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLTRHIRIHTGQKPFQCRICMRNFSRSDNLTTHIRTHTGEKPFACDICGRKFARSDERKRHIRTHTGEKPFACDICGRKFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLTRHIRTHTGEKPFACDICGRKFAQSSTRKEHTKIHLRQKDKKADKSVVAS |
SEQ ID NO: 299 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHIRTHTGEKPFACDICGRKFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
SEQ ID NO: 440 | MAAAKAEMQLMSPLQISDPFGSFPHSPTMDNYPKLEEMMLLSNGAPQFLGAAGAPEGSGSNSSSSSSGGGGGGGGGSNSSSSSSTFNPQADTGEQPYEHLTAESFPDISLNNEKVLVETSYPSQTTRLPPITYTGRFSLEPAPNSGNTLWPEPLFSLVSGLVSMTNPPASSSSAPSPAASSASASQSPPLSCAVPSNDSSPIYSAAPTFPTPNTDIFPEPQSQAFPGSAGTALQYPPPAYPAAKGGFQVPMIPDYLFPQQQGDLGLGTPDQKPFQGLESRTQQPSLTPLSTIKAFATQSGSQDLKALNTSYQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRSDNLVRHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDELVRHIRTHTGEKPFACDICGRKFSQSGNLTEHIRIHTGQKPFQCRICMRNFSTSGHLVRHIRTHTGEKPFACDICGRKFAQNSTLTEHTKIHLRQKDKKADKSVVASSATSSLSSYPSPVATSYPSPVTTSYPSPATTSYPSPVPTSFSSPGSSTYPSPVHSGFPSPSVATTYSSVPPAFPAQVSSFPSSAVTNSFSASTGLSDMTATFSPRTIEIC |
PolyA 序列 | |
SEQ ID NO: 326 spA (合成poly A) | AATAAAAGATCTTTATTTTCATTAGATCTGTGTGTTGGTTTTTTGTGTGCGGACCGCACGTG |
SEQ ID NO: 327 hGH (人類生長激素poly A) | GGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTT |
胺基酸序列 | 胺基酸序列 | ||
SEQ ID NO: 141 | RNDTLTE | SEQ ID NO: 153 | RSDKLVR |
SEQ ID NO: 142 | RSDNLVR | SEQ ID NO: 154 | QLAHLRA |
SEQ ID NO: 143 | RSDHLTT | SEQ ID NO: 155 | ERSHLRE |
SEQ ID NO: 144 | SPADLTR | SEQ ID NO: 156 | TTGNLTV |
SEQ ID NO: 145 | TSHSLTE | SEQ ID NO: 157 | QRANLRA |
SEQ ID NO: 146 | QSGDLRR | SEQ ID NO: 158 | SKKALTE |
SEQ ID NO: 147 | DPGALVR | SEQ ID NO: 159 | REDNLHT |
SEQ ID NO: 148 | DPGHLVR | SEQ ID NO: 160 | TKNSLTE |
SEQ ID NO: 149 | RSDELVR | SEQ ID NO: 161 | RKDNLKN |
SEQ ID NO: 150 | DSGNLRV | SEQ ID NO: 162 | QSSNLVR |
SEQ ID NO: 151 | HKNALQN | SEQ ID NO: 163 | QSSSLVR |
SEQ ID NO: 152 | TSGELVR | SEQ ID NO: 164 | QAGHLAS |
胺基酸序列 | |
SEQ ID NO: 165 | LEPGEKPYKCPECGKSFSRNDTLTEHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSTKNSLTEHQRTHTGKKTS |
SEQ ID NO: 166 | LEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSDPGHLVRHQRTHTGEKPYKCPECGKSFSRSDHLTTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSRSDKLVRHQRTHTGEKPYKCPECGKSFSTTGNLTVHQRTHTGKKTS |
SEQ ID NO: 167 | LEPGEKPYKCPECGKSFSRSDHLTTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSRSDKLVRHQRTHTGEKPYKCPECGKSFSTTGNLTVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSTKNSLTEHQRTHTGKKTS |
SEQ ID NO: 168 | LEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDSGNLRVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTS |
SEQ ID NO: 169 | LEPGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSHKNALQNHQRTHTGEKPYKCPECGKSFSERSHLREHQRTHTGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSRKDNLKNHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSQAGHLASHQRTHTGKKTS |
SEQ ID NO: 170 | LEPGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDSGNLRVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTS |
SEQ ID NO: 171 | RNDTLTE xDPGALVR xTSGELVR xRSDNLVR xTSGELVR xTKNSLTE (其中X指示包含1-50個胺基酸殘基之連接子) |
SEQ ID NO: 412 | RSDNLVR x DPGHLVR x RSDHLTT x RSDELVR x RSDKLVR x TTGNLTV (其中X指示包含1-50個胺基酸殘基之連接子) |
SEQ ID NO: 413 | RSDHLTT x RSDELVR x RSDKLVR x TTGNLTV x QLAHLRA x TKNSLTE (其中X指示包含1-50個胺基酸殘基之連接子) |
SEQ ID NO:414 | SPADLTR x DSGNLRV x QLAHLRA x QRANLRA x REDNLHT x RSDNLVR (其中X指示包含1-50個胺基酸殘基之連接子) |
SEQ ID NO: 415 | TSHSLTE x HKNALQN x ERSHLRE x SKKALTE x QRANLRA x RKDNLKN x QSSNLVR x QSSSLVR x QAGHLAS (其中X指示包含1-50個胺基酸殘基之連接子) |
SEQ ID NO: 416 | QSGDLRR x SPADLTR x DSGNLRV x QLAHLRA x QRANLRA x REDNLHT x RSDNLVR (其中X指示包含1-50個胺基酸殘基之連接子) |
標靶位點SEQ ID NO: | 識別標靶位點之ZF 或gRNA | 標靶位點序列 | chr17 起始座標 |
SEQ ID NO: 38 | ZF | GAGTAGAAAAGAAACACA | 44345153 |
SEQ ID NO: 330 | ZF | CGCACTGTCAATGCCCCA | 44344963 |
SEQ ID NO: 331 | ZF | CCTGCTGAGGCTGTCCCG | 44345058 |
SEQ ID NO: 332 | ZF | AATGGGGTGTGGGGCGAG | 44345111 |
SEQ ID NO: 333 | ZF | CCTAGAAATGGGGTGTGG | 44345105 |
SEQ ID NO: 334 | ZF | TGAGTAGAAAAGAAACACAGCATTCCA | 44345152 |
SEQ ID NO: 335 | ZF | GAGTAGAAAAGAAACACAGCA | 44345153 |
SEQ ID NO: 336 | ZF | AGTAGAAAAGAAACACAGCAT | 44345154 |
SEQ ID NO: 113 | gRNA | CATGATCCCTAGAAATGGGGT | 44345098 |
表現卡匣 | 標靶位點SEQ ID NO: | DBD SEQ ID NO: | TAD SEQ ID NO: | 調節元件SEQ ID NO : |
對照 | N/A | 無 | 無 | SEQ ID NO: 178 |
A | SEQ ID NO: 331 | SEQ ID NO: 165 | SEQ ID NO: 95 | SEQ ID NO: 178 |
B | SEQ ID NO: 331 | SEQ ID NO: 165 | SEQ ID NO: 114 | SEQ ID NO: 178 |
C | SEQ ID NO: 332 | SEQ ID NO: 166 | SEQ ID NO: 95 | SEQ ID NO: 178 |
D | SEQ ID NO: 333 | SEQ ID NO: 167 | SEQ ID NO: 95 | SEQ ID NO: 178 |
E | SEQ ID NO: 333 | SEQ ID NO: 167 | SEQ ID NO: 114 | SEQ ID NO: 178 |
F | SEQ ID NO: 38 | SEQ ID NO: 168 | SEQ ID NO: 95 | SEQ ID NO: 178 |
G | SEQ ID NO: 38 | SEQ ID NO: 168 | SEQ ID NO: 114 | SEQ ID NO: 178 |
H | SEQ ID NO: 334 | SEQ ID NO: 169 | SEQ ID NO: 114 | SEQ ID NO: 178 |
I | SEQ ID NO: 335 | SEQ ID NO: 170 | SEQ ID NO: 114 | SEQ ID NO: 179 |
J (K+eGFP) | SEQ ID NO: 38 | SEQ ID NO: 168 | SEQ ID NO: 95 | SEQ ID NO: 179 |
K | SEQ ID NO: 38 | SEQ ID NO: 168 | SEQ ID NO: 95 | SEQ ID NO: 179 |
L | SEQ ID NO: 38 | SEQ ID NO: 168 | SEQ ID NO: 114 | SEQ ID NO: 179 |
M | SEQ ID NO: 113 | SEQ ID NO: 112 | SEQ ID NO: 95 | SEQ ID NO: 178 |
RE 之類型 | 序列 | |
SEQ ID NO: 178 | 內含子 | GTGTGTATGCTCAGGGGCTGGGAAAGGAGGGGAGGGAGCTCCGGCTCAG |
SEQ ID NO: 179 | CBA啟動子 | CGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGGTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCCCCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGTGCGGCGGCAGCCAATCAGAGCGGCGCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCCCTATAAAAAGCGAAGCGCGCGGCGGGCGGGAGTCGCTGCGTTGCCTTCGCCCCGTGCCCCGCTCCGCGCCGCCTCGCGCCGCCCGCCCCGGCTCTGACTGACCGCGTTACTCCCACAGGTGAGCGGGCGGGACGGCCCTTCTCCTCCGGGCTGTAATTAGCGCTTGGTTTAATGACGGCTCGTTTCTTTTCTGTGGCTGCGTGAAAGCCTTAAAGGGCTCCGGGAGGGCCCTTTGTGCGGGGGGGAGCGGCTCGGGGGGTGCGTGCGTGTGTGTGTGCGTGGGGAGCGCCGCGTGCGGCCCGCGCTGCCCGGCGGCTGTGAGCGCTGCGGGCGCGGCGCGGGGCTTTGTGCGCTCCGCGTGTGCGCGAGGGGAGCGCGGCCGGGGGCGGTGCCCCGCGGTGCGGGGGGGCTGCGAGGGGAACAAAGGCTGCGTGCGGGGTGTGTGCGTGGGGGGGTGAGCAGGGGGTGTGGGCGCGGCGGTCGGGCTGTAACCCCCCCCTGCACCCCCCTCCCCGAGTTGCTGAGCACGGCCCGGCTTCGGGTGCGGGGCTCCGTGCGGGGCGTGGCGCGGGGCTCGCCGTGCCGGGCGGGGGGTGGCGGCAGGTGGGGGTGCCGGGCGGGGCGGGGCCGCCTCGGGCCGGGGAGGGCTCGGGGGAGGGGCGCGGCGGCCCCGGAGCGCCGGCGGCTGTCGAGGCGCGGCGAGCCGCAGCCATTGCCTTTTATGGTAATCGTGCGAGAGGGCGCAGGGACTTCCTTTGTCCCAAATCTGGCGGAGCCGAAATCTGGGAGGCGCCGCCGCACCCCCTCTAGCGGGCGCGGGCGAAGCGGTGCGGCGCCGGCAGGAAGGAAATGGGCGGGGAGGGCCTTCGTGCGTCGCCGCGCCGCCGTCCCCTTCTCCATCTCCAGCCTCGGGGCTGCCGCAGGGGGACGGCTGCCTTCGGGGGGGACGGGGCAGGGCGGGGTTCGGCTTCTGGCGTGTGACCGGCGGCTCTAGAGCCTCTGCTAACCATGTTCATGCCTTCTTCTTTTTCCTACAGCTCCTGGGCAACGTGCTGGTTGTTGTGCTGTCTCATCATTTTGGCAAAGAATT |
SEQ ID NO: 182 | 內含子 | GTAAGGTAAGAATTGAATTTCTCAGTTGAAGGATGCTTACACTCTTGTCCATCTAG |
SEQ ID NO: 183 | 小白蛋白(PV)選擇性 | GGAGGAAGCCATCAACTAAACTACAATGACTGTAAGATACAAAATTGGGAATGGTAACATATTTTGAAGTTCTGTTGACATAAAGAATCATGATATTAATGCCCATGGAAATGAAAGGGCGATCAACACTATGGTTTGAAAAGGGGGAAATTGTAGAGCACAGATGTGTTCGTGTGGCAGTGTGCTGTCTCTAGCAATACTCAGAGAAGAGAGAGAACAATGAAATTCTGATTGGCCCCAGTGTGAGCCCAGATGAGGTTCAGCTGCCAACTTTCTCTTTCACATCTTATGAAAGTCATTTAAGCACAACTAACTTTTTTTTTTTTTTTTTTTTTTTGAGACAGAGTCTTGCTCTGTTGCCCAGGACAGAGTGCAGTAGTGACTCAATCTCGGCTCACTGCAGCCTCCACCTCCTAGGCTCAAACGGTCCTCCTGCATCAGCCTCCCAAGTAGCTGGAATTACAGGAGTGGCCCACCATGCCCAGCTAATTTTTGTATTTTTAATAGATACGGGGGTTTCACCATATCACCCAGGCTGGTCTCGAACTCCTGGCCTCAAGTGATCCACCTGCCTCGGCCTCCCAAAGTGCTGGGATTATAGGCGTCAGCCACTATGCCCAACCCGACCAACCTTTTTTAAAATAAATATTTAAAAAATTGGTATTTCACATATATACTAGTATTTACATTTATCCACACAAAACGGACGGGCCTCCGCTGAACCAGTGAGGCCCCAGACGTGCGCATAAATAACCCCTGCGTGCTGCACCACCTGGGGAGAGGGGGAGGACCACGGTAAATGGAGCGAGCGCATAGCAAAAGGGACGCGGGGTCCTTTTCTCTGCCGGTGGCACTGGGTAGCTGTGGCCAGGTGTGGTACTTTGATGGGGCCCAGGGCTGGAGCTCAAGGAAGCGTCGCAGGGTCACAGATCTGGGGGAACCCCGGGGAAAAGCACTGAGGCAAAACCGCCGCTCGTCTCCTACAATATATGGGAGGGGGAGGTTGAGTACGTTCTGGATTACTCATAAGACCTTTTTTTTTTCCTTCCGGGCGCAAAACCGTGAGCTGGATTTATAATCGCCCTATAAAGCTCCAGAGGCGGTCAGGCACCTGCAGAGGAGCCCCGCCGCTCCGCCGACTAGCTGCCCCCGCGAGCAACGGCCTCGTGATTTCCCCGCCGATCCGGTCCCCGCCTCCCCACTCTGCCCCCGCCTACCCCGGAGCCGTGCAGCCGCCTCTCCGAATCTCTCTCTTCTCCTGGCGCTCGCGTGCGAGAGGGAACTAGCGAGAACGAGGAAGCAGCTGGAGGTGACGCCGGGCAGATTACGCCTGTCAGGGCCGAGCCGAGCGGATCGCTGGGCGCTGTGCAGAGGAAAGGCGGGAGTGCCCGGCTCGCTGTCGCAGAGCCGAGGTGGGTAAGCTAGCGACCACCTGGACTTCCCAGCGCCCAACCGTGGCTTTTCAGCCAGGTCCTCTCCTCCCGCGGCTTCTCAACCAACCCCATCCCAGCGCCGGCCACCCAACCTCCCGAAATGAGTGCTTCCTGCCCCAGCAGCCGAAGGCGCTACTAGGAACGGTAACCTGTTACTTTTCCAGGGGCCGTAGTCGACCCGCTGCCCGAGTTGCTGTGCGACTGCGCGCGCGGGGCTAGAGTGCAAGGTGACTGTGGTTCTTCTCTGGCCAAGTCCGAGGGAGAACGTAAAGATATGGGCCTTTTTCCCCCTCTCACCTTGTCTCACCAAAGTCCCTAGTCCCCGGAGCAGTTAGCCTCTTTCTTTCCAGGGAATTAGCCAGACACAACAACGGGAACCAGACACCGAACCAGACATGCCCGCCCCGTGCGCCCTCCCCGCTCGCTGCCTTTCCTCCCTCTTGTCTCTCCAGAGCCGGATCTTCAAGGGGAGCCTCCGTGCCCCCGGCTGCTCAGTCCCTCCGGTGTGCAGGACCCCGGAAGTCCTCCCCGCACAGCTCTCGCTTCTCTTTGCAGCCTGTTTCTGCGCCGGACCAGTCGAGGACTCTGGACAGTAGAGGCCCCGGGACGACCGAGCTG |
SEQ ID NO: 184 | 小白蛋白(PV)選擇性 | TCAACAGGGGGACACTTGGGAAAGAAGGATGGGGACAGAGCCGAGAGGACTGTTACACATTAGAGAAACATCAGTGACTGTGCCAGCTTTGGGGTAGACTGCACAAAAGCCCTGAGGCAGCACAGGCAGGATCCAGTCTGCTGGTCCCAGGAAGCTAACCGTCTCAGACAGAGCACAAAGCACCGAGACATGTGCCACAAGGCTTGTGTAGAGAGGTCAGAGGACAGCGTACAGGTCCCAGAGATCAAACTCAACCTCACCAGGCTTGGCAGCAAGCCTTTACCAACCCACCCCCACCCCACCCACCCTGCACGCGCCCCTCTCCCCTCCCCATGGTCTCCCATGGCTATCTCACTTGGCCCTAAAATGTTTAAGGATGACACTGGCTGCTGAGTGGAAATGAGACAGCAGAAGTCAACAGTAGATTTTAGGAAAGCCAGAGAAAAAGGCTTGTGCTGTTTTTAGAAAGCCAAGGGACAAGCTAAGATAGGGCCCAAGTAATGCTAGTATTTACATTTATCCACACAAAACGGACGGGCCTCCGCTGAACCAGTGAGGCCCCAGACGTGCGCATAAATAACCCCTGCGTGCTGCACCACCTGGGGAGAGGGGGAGGACCACGGTAAATGGAGCGAGCGCATAGCAAAAGGGACGCGGGGTCCTTTTCTCTGCCGGTGGCACTGGGTAGCTGTGGCCAGGTGTGGTACTTTGATGGGGCCCAGGGCTGGAGCTCAAGGAAGCGTCGCAGGGTCACAGATCTGGGGGAACCCCGGGGAAAAGCACTGAGGCAAAACCGCCGCTCGTCTCCTACAATATATGGGAGGGGGAGGTTGAGTACGTTCTGGATTACTCATAAGACCTTTTTTTTTTCCTTCCGGGCGCAAAACCGTGAGCTGGATTTATAATCGCCCTATAAAGCTCCAGAGGCGGTCAGGCACCTGCAGAGGAGCCCCGCCGCTCCGCCGACTAGCTGCCCCCGCGAGCAACGGCCTCGTGATTTCCCCGCCGATCCGGTCCCCGCCTCCCCACTCTGCCCCCGCCTACCCCGGAGCCGTGCAGCCGCCTCTCCGAATCTCTCTCTTCTCCTGGCGCTCGCGTGCGAGAGGGAACTAGCGAGAACGAGGAAGCAGCTGGAGGTGACGCCGGGCAGATTACGCCTGTCAGGGCCGAGCCGAGCGGATCGCTGGGCGCTGTGCAGAGGAAAGGCGGGAGTGCCCGGCTCGCTGTCGCAGAGCCGAGGTGGGTAAGCTAGCGACCACCTGGACTTCCCAGCGCCCAACCGTGGCTTTTCAGCCAGGTCCTCTCCTCCCGCGGCTTCTCAACCAACCCCATCCCAGCGCCGGCCACCCAACCTCCCGAAATGAGTGCTTCCTGCCCCAGCAGCCGAAGGCGCTACTAGGAACGGTAACCTGTTACTTTTCCAGGGGCCGTAGTCGACCCGCTGCCCGAGTTGCTGTGCGACTGCGCGCGCGGGGCTAGAGTGCAAGGTGACTGTGGTTCTTCTCTGGCCAAGTCCGAGGGAGAACGTAAAGATATGGGCCTTTTTCCCCCTCTCACCTTGTCTCACCAAAGTCCCTAGTCCCCGGAGCAGTTAGCCTCTTTCTTTCCAGGGAATTAGCCAGACACAACAACGGGAACCAGACACCGAACCAGACATGCCCGCCCCGTGCGCCCTCCCCGCTCGCTGCCTTTCCTCCCTCTTGTCTCTCCAGAGCCGGATCTTCAAGGGGAGCCTCCGTGCCCCCGGCTGCTCAGTCCCTCCGGTGTGCAGGACCCCGGAAGTCCTCCCCGCACAGCTCTCGCTTCTCTTTGCAGCCTGTTTCTGCGCCGGACCAGTCGAGGACTCTGGACAGTAGAGGCCCCGGGACGACCGAGCTG |
SEQ ID NO: 185 | 小白蛋白(PV)選擇性 | GGAGGAAGCCATCAACTAAACTACAATGACTGTAAGATACAAAATTGGGAATGGTAACATATTTTGAAGTTCTGTTGACATAAAGAATCATGATATTAATGCCCATGGAAATGAAAGGGCGATCAACACTATGGTTTGAAAAGGGGGAAATTGTAGAGCACAGATGTGTTCGTGTGGCAGTGTGCTGTCTCTAGCAATACTCAGAGAAGAGAGAGAACAATGAAATTCTGATTGGCCCCAGTGTGAGCCCAGATGAGGTTCAGCTGCCAACTTTCTCTTTCACATCTTATGAAAGTCATTTAAGCACAACTAACTTTTTTTTTTTTTTTTTTTTTTTGAGACAGAGTCTTGCTCTGTTGCCCAGGACAGAGTGCAGTAGTGACTCAATCTCGGCTCACTGCAGCCTCCACCTCCTAGGCTCAAACGGTCCTCCTGCATCAGCCTCCCAAGTAGCTGGAATTACAGGAGTGGCCCACCATGCCCAGCTAATTTTTGTATTTTTAATAGATACGGGGGTTTCACCATATCACCCAGGCTGGTCTCGAACTCCTGGCCTCAAGTGATCCACCTGCCTCGGCCTCCCAAAGTGCTGGGATTATAGGCGTCAGCCACTATGCCCAACCCGACCAACCTTTTTTAAAATAAATATTTAAAAAATTGGTATTTCACATATATACTAGT |
SEQ ID NO: 417 | GCCCTCTAGGCCACCTGACCAGGTCCCCTCAGTCCCCCCCTTCCCACACTCCCACACTCAGCCCCCCTCCCCCCCCCCCGACCCCTGCAGGATTATCCTGTCTGTGTTCCTGACTCAGCCTGGGAGCCACCTGGGCAGCAGGGGCCAAGGGTGTCCTAGAAGGGACCTGGAGTCCACGCTGGGCCAAGCCTGCCCTTTCTCCCTCTGTCTTCCGTCCCTGCTTGCGGTTCTGCTGAATGTGGTTATTTCTCTGGCTCCTTTTACAGAGAATGCTGCTGCTAATTTTATGTGGAGCTCTGAGGCAGTGTAATTGGAAGCCAGACACCCTGTCAGCAGTGGGCTCCCGTCCTGAGCTGCCATGCTTCCTGCTCTCCTCCCGTCCCGGCTCCTCATTTCATGCAGCCACCTGTCCCAGGGAGAGAGGAGTCACCCAGGCCCCTCAGTCCGCCCCTTAAATAAGAAAGCCTCCGTTGCTCGGCACACATACCAAGCAGCCGCTGGTGCAATCT |
序列 | |
SEQ ID NO: 112 (用於調節GRN之dSaCas9序列) | KRNYILGLAIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRRHRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHNVNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKEAKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHCTYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTLKQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIYQSSEDIQEELTNLNSELTQEEIEQISNLKGYTGTHNLSLKAINLILDELWHTNDNQIAIFNRLKLVPKKVDLSQQKEIPTTLVDDFILSPVVKRSFIQSIKVINAIIKKYGLPNDIIIELAREKNSKDAQKMINEMQKRNRQTNERIEEIIRTTGKENAKYLIEKIKLHDMQEGKCLYSLEAIPLEDLLNNPFNYEVDHIIPRSVSFDNSFNNKVLVKQEEASKKGNRTPFQYLSSSDSKISYETFKKHILNLAKGKGRISKTKKEYLLEERDINRFSVQKDFINRNLVDTRYATRGLMNLLRSYFRVNNLDVKVKSINGGFTSFLRRKWKFKKERNKGYKHHAEDALIIANADFIFKEWKKLDKAKKVMENQMFEEKQAESMPEIETEQEYKEIFITPHQIKHIKDFKDYKYSHRVDKKPNRELINDTLYSTRKDDKGNTLIVNNLNGLYDKDNDKLKKLINKSPEKLLMYHHDPQTYQKLKLIMEQYGDEKNPLYKYYEETGNYLTKYSKKDNGPVIKKIKYYGNKLNAHLDITDDYPNSRNKVVKLSLKPYRFDVYLDNGVYKFVTVKNLDVIKKENYYEVNSKCYEEAKKLKKISNQAEFIASFYNNDLIKINGELYRVIGVNNDLLNRIEVNMIDITYREYLENMNDKRPPRIIKTIASKTQSIKKYSTDILGNLYEVKSKKHPQIIKKG |
SEQ ID NO: 186 EF1a啟動子 | GAGTAATTCATACAAAAGGACTCGCCCCTGCCTTGGGGAATCCCAGGGACCGTCGTTAAACTCCCACTAACGTAGAACCCAGAGATCGCTGCGTTCCCGCCCCCTCACCCGCCCGCTCTCGTCATCACTGAGGTGGAGAAGAGCATGCGTGAGGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACATCGCCCACAGTCCCCGAGAAGTTGGGGGGAGGGGTCGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGCGGGGTAAACTGGGAAAGTGATGTCGTGTACTGGCTCCGCCTTTTTCCCGAGGGTGGGGGAGAACCGTATATAAGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGGTAAGTGCCGTGTGTGGTTCCCGCGGGCCTGGCCTCTTTACGGGTTATGGCCCTTGCGTGCCTTGAATTACTTCCACGCCCCTGGCTGCAGTACGTGATTCTTGATCCCGAGCTTCGGGTTGGAAGTGGGTGGGAGAGTTCGAGGCCTTGCGCTTAAGGAGCCCCTTCGCCTCGTGCTTGAGTTGAGGCCTGGCTTGGGCGCTGGGGCCGCCGCGTGCGAATCTGGTGGCACCTTCGCGCCTGTCTCGCTGCTTTCGATAAGTCTCTAGCCATTTAAAATTTTTGATGACCTGCTGCGACGCTTTTTTTCTGGCAAGATAGTCTTGTAAATGCGGGCCAAGATCTGCACACTGGTATTTCGGTTTTTGGGGCCGCGGGCGGCGACGGGGCCCGTGCGTCCCAGCGCACATGTTCGGCGAGGCGGGGCCTGCGAGCGCGGCCACCGAGAATCGGACGGGGGTAGTCTCAAGCTGGCCGGCCTGCTCTGGTGCCTGGCCTCGCGCCGCCGTGTATCGCCCCGCCCTGGGCGGCAAGGCTGGCCCGGTCGGCACCAGTTGCGTGAGCGGAAAGATGGCCGCTTCCCGGCCCTGCTGCAGGGAGCTCAAAATGGAGGACGCGGCGCTCGGGAGAGCGGGCGGGTGAGTCACCCACACAAAGGAAAAGGGCCTTTCCGTCCTCAGCCGTCGCTTCATGTGACTCCACGGAGTACCGGGCGCCGTCCAGGCACCTCGATTAGTTCTCGAGCTTTTGGAGTACGTCGTCTTTAGGTTGGGGGGAGGGGTTTTATGCGATGGAGTTTCCCCACACTGAGTGGGTGGAGACTGAAGTTAGGCCAGCTTGGCACTTGATGTAATTCTCCTTGGAATTTGCCCTTTTTGAGTTTGGATCTTGGTTCATTCTCAAGCCTCAGACAGTGGTTCAAAGTTTTTTTCTTCCATTTCAGGTGTCGTGA |
SEQ ID NO: 187 | GAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTATCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGGTAGGCGTGTACGGTGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCCGAATTCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTCCGGACTCAGATCTCGAGAGGAGGAGGAGGAGACAGACAGCAGGATGCCCCACCTCGACAGCCCCGGCAGCTCCCAGCCGAGACGCTCCTTCCTCTCAAGGGTGATCAGGGCAGCTCTACCGTTGCAGCTGCTTCTGCTGCTGCTGCTGCTCCTGGCCTGCCTGCTACCTGCCTCTGAAGATGACTACAGCTGCACCCAGGCCAACAACTTTGCCCGATCCTTCTACCCCATGCTGCGGTACACCAACGGGCCACCTCCCACCTAGACTAGTaataaaagatctttattttcattagatctgtgtgttggttttttgtgtg |
SEQ ID NO: 188 | GAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGTTTATCCCTATCAGTGATAGAGAACGTATGTCGAGTTTACTCCCTATCAGTGATAGAGAACGTATGTCGAGGTAGGCGTGTACGGTGGGAGGCCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCC |
SEQ ID NO: 418 | GCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTCCGGACTCAGATCTCGAGAGGAGGAGGAGGAGACAGACAGCAGGATGCCCCACCTCGACAGCCCCGGCAGCTCCCAGCCGAGACGCTCCTTCCTCTCAAGGGTGATCAGGGCAGCTCTACCGTTGCAGCTGCTTCTGCTGCTGCTGCTGCTCCTGGCCTGCCTGCTACCTGCCTCTGAAGATGACTACAGCTGCACCCAGGCCAACAACTTTGCCCGATCCTTCTACCCCATGCTGCGGTACACCAACGGGCCACCTCCCACCTAG |
SEQ ID NO: 365 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML |
SEQ ID NO: 366 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF |
SEQ ID NO: 367 對照 載體EGFP-KASH | GCGGCCGCACGCGTGGCGCGCCGTTTAAACTTAATTAAGCTAGCCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGggtcgaggtgagccccacgttctgcttcactctccccatctcccccccctccccacccccaattttgtatttatttattttttaattattttgtgcagcgatgggggcggggggggggggggcgcgcgccaggcggggcggggcggggcgaggggcggggcggggcgaggcggagaggtgcggcggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgaggcggcggcggcggcggccctataaaaagcgaagcgcgcggcgggcgggagtcgctgcgttgccttcgccccgtgccccgctccgcgccgcctcgcgccgcccgccccggctctgactgaccgcgttactcccacaggtgagcgggcgggacggcccttctcctccgggctgtaattagcgcttggtttaatgacggctcgtttcttttctgtggctgcgtgaaagccttaaagggctccgggagggccctttgtgcgggggggagcggctcggggggtgcgtgcgtgtgtgtgtgcgtggggagcgccgcgtgcggcccgcgctgcccggcggctgtgagcgctgcgggcgcggcgcggggctttgtgcgctccgcgtgtgcgcgaggggagcgcggccgggggcggtgccccgcggtgcgggggggctgcgaggggaacaaaggctgcgtgcggggtgtgtgcgtgggggggtgagcagggggtgtgggcgcggcggtcgggctgtaacccccccctgcacccccctccccgagttgctgagcacggcccggcttcgggtgcggggctccgtgcggggcgtggcgcggggctcgccgtgccgggcggggggtggcggcaggtgggggtgccgggcggggcggggccgcctcgggccggggagggctcgggggaggggcgcggcggccccggagcgccggcggctgtcgaggcgcggcgagccgcagccattgccttttatggtaatcgtgcgagagggcgcagggacttcctttgtcccaaatctggcggagccgaaatctgggaggcgccgccgcaccccctctagcgggcgcgggcgaagcggtgcggcgccggcaggaaggaaatgggcggggagggccttcgtgcgtcgccgcgccgccgtccccttctccatctccagcctcggggctgccgcagggggacggctgccttcgggggggacggggcagggcggggttcggcttctggcgtgtgaccggcggctctagagcctctgctaaccatgttcatgccttcttctttttcctacagctcctgggcaacgtgctggttgttgtgctgtctcatcattttggcaaagaattGGTACCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTCCGGACTCAGATCTCGAGAGGAGGAGGAGGAGACAGACAGCAGGATGCCCCACCTCGACAGCCCCGGCAGCTCCCAGCCGAGACGCTCCTTCCTCTCAAGGGTGATCAGGGCAGCTCTACCGTTGCAGCTGCTTCTGCTGCTGCTGCTGCTCCTGGCCTGCCTGCTACCTGCCTCTGAAGATGACTACAGCTGCACCCAGGCCAACAACTTTGCCCGATCCTTCTACCCCATGCTGCGGTACACCAACGGGCCACCTCCCACCTAGAGCGCTaatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaatcatcgtcctttccttggctgctcgcctatgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccgcAGATCTACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACGTGCGGACCGAGCGGCCGC |
SEQ ID NO: 368 由CBA啟動子驅動之EGFP-KASH | GCGGCCGCACGCGTGGCGCGCCGTTTAAACTTAATTAAGCTAGCCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGggtcgaggtgagccccacgttctgcttcactctccccatctcccccccctccccacccccaattttgtatttatttattttttaattattttgtgcagcgatgggggcggggggggggggggcgcgcgccaggcggggcggggcggggcgaggggcggggcggggcgaggcggagaggtgcggcggcagccaatcagagcggcgcgctccgaaagtttccttttatggcgaggcggcggcggcggcggccctataaaaagcgaagcgcgcggcgggcgggagtcgctgcgttgccttcgccccgtgccccgctccgcgccgcctcgcgccgcccgccccggctctgactgaccgcgttactcccacaggtgagcgggcgggacggcccttctcctccgggctgtaattagcgcttggtttaatgacggctcgtttcttttctgtggctgcgtgaaagccttaaagggctccgggagggccctttgtgcgggggggagcggctcggggggtgcgtgcgtgtgtgtgtgcgtggggagcgccgcgtgcggcccgcgctgcccggcggctgtgagcgctgcgggcgcggcgcggggctttgtgcgctccgcgtgtgcgcgaggggagcgcggccgggggcggtgccccgcggtgcgggggggctgcgaggggaacaaaggctgcgtgcggggtgtgtgcgtgggggggtgagcagggggtgtgggcgcggcggtcgggctgtaacccccccctgcacccccctccccgagttgctgagcacggcccggcttcgggtgcggggctccgtgcggggcgtggcgcggggctcgccgtgccgggcggggggtggcggcaggtgggggtgccgggcggggcggggccgcctcgggccggggagggctcgggggaggggcgcggcggccccggagcgccggcggctgtcgaggcgcggcgagccgcagccattgccttttatggtaatcgtgcgagagggcgcagggacttcctttgtcccaaatctggcggagccgaaatctgggaggcgccgccgcaccccctctagcgggcgcgggcgaagcggtgcggcgccggcaggaaggaaatgggcggggagggccttcgtgcgtcgccgcgccgccgtccccttctccatctccagcctcggggctgccgcagggggacggctgccttcgggggggacggggcagggcggggttcggcttctggcgtgtgaccggcggctctagagcctctgctaaccatgttcatgccttcttctttttcctacagctcctgggcaacgtgctggttgttgtgctgtctcatcattttggcaaagaattGGTACCGCCACCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTCCGGACTCAGATCTCGAGAGGAGGAGGAGGAGACAGACAGCAGGATGCCCCACCTCGACAGCCCCGGCAGCTCCCAGCCGAGACGCTCCTTCCTCTCAAGGGTGATCAGGGCAGCTCTACCGTTGCAGCTGCTTCTGCTGCTGCTGCTGCTCCTGGCCTGCCTGCTACCTGCCTCTGAAGATGACTACAGCTGCACCCAGGCCAACAACTTTGCCCGATCCTTCTACCCCATGCTGCGGTACACCAACGGGCCACCTCCCACCTAGAGCGCTaatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaatcatcgtcctttccttggctgctcgcctatgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcctccccgcAGATCTACGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGTGGTATGGAGCAAGGGGCAAGTTGGGAAGACAACCTGTAGGGCCTGCGGGGTCTATTGGGAACCAAGCTGGAGTGCAGTGGCACAATCTTGGCTCACTGCAATCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCGAGTTGTTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTTGGTAGAGACGGGGTTTCACCATATTGGCCAGGCTGGTCTCCAACTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAACCACTGCTCCCTTCCCTGTCCTTCTGATTTTGTAGGTAACCACGTGCGGACCGAGCGGCCGC |
SEQ ID NO: 422 WT EGR3 | MTGKLAEKLPVTMSSLLNQLPDNLYPEEIPSALNLFSGSSDSVVHYNQMATENVMDIGLTNEKPNPELSYSGSFQPAPGNKTVTYLGKFAFDSPSNWCQDNIISLMSAGILGVPPASGALSTQTSTASMVQPPQGDVEAMYPALPPYSNCGDLYSEPVSFHDPQGNPGLAYSPQDYQSAKPALDSNLFPMIPDYNLYHHPNDMGSIPEHKPFQGMDPIRVNPPPITPLETIKAFKDKQIHPGFGSLPQPPLTLKPIRPRKYPNRPSKTPLHERPHACPAEGCDRRFSRSDELTRHLRIHTGHKPFQCRICMRSFSRSDHLTTHIRTHTGEKPFACEFCGRKFARSDERKRHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA |
人類Chr 2 起始位置 - 靶序列位於之位置 | gRNA 之SEQ ID NO | 嚮導 RNA 序列 ( 對應於藉由gRNA 識別之基因組序列 ) |
166178880 | 197 | ggtacgggcaaagatttcttg |
166178871 | 198 | tttgcccgtaccaaagtcttg |
166177369 | 201 | ACACAATGAGCCACCTACAAG |
166177362 | 202 | GTGGCTCATTGTGTGTGTGCC |
166177299 | 203 | AGAAAGCTGATACAGATACAA |
166155393 | 207 | TTCTCAGTTTTGAAATTAAAA |
166155264 | 208 | CATATCCCTGCAGGTTCAGAA |
166155255 | 209 | TGGATTCTCTTCTGAACCTGC |
166155099 | 210 | agagagagagagagagagaga |
166149373 | 211 | TGGTCTCATTCTTTTTGTGGG |
166149176 | 107 | aaggctgtctaggtcaagtgt |
166149118 | 224 | tgttcctccagattaacactt |
166148953 | 225 | ATTACAGTTCTGTCAGCATGC |
166148843 | 226 | ATCATCTGTAACCATCAAGGA |
166148565 | 227 | TCCTGCCTACTTAGTTTCAAG |
166148361 | 228 | TGCTGAGGCAGGACACAGTGT |
166142396 | 229 | ACAAAGTAAGTGTCAGTGTGG |
166142391 | 230 | CTGACACTTACTTTGTCTAAA |
166142344 | 231 | ATAATAGTTGTGTCTTTATAA |
166142239 | 232 | CGATATTTTCATGGATTCCTT |
166142219 | 233 | AAAACTGGAACCGCATTCCCA |
166141162 | 234 | TGTACAAGCAGGGCTGCAAAG |
166141145 | 235 | AAAGGGGAATGGGAACACCCG |
166141090 | 236 | ATGTTCAAGGTGCAGAAGGAA |
166140928 | 237 | ttcaacaagctcccaagaagt |
166140590 | 238 | GTTAACAAATACACTAAACAC |
166128037 | 109 | gctgatttgtattaggtacca |
166128002 | 108 | gatgaagccgagaggatactg |
165990246 | 247 | TGTTTGCTCAAACGTGCACCA |
165990193 | 248 | AAATATGTACCACAAGAAATG |
165990076 | 249 | TATCTGGTTTCTCTCACTGCT |
165989684 | 250 | AAATAAGACATGAAAACAAGA |
165989571 | 251 | ATTGCAAAGCATAATTTGGAT |
人類Chr 2 起始位置 - 靶序列位於之位置 | 標靶位點之SEQ ID NO | 藉由DNA結合蛋白識別之標靶位點序列 | eTF之SEQ ID NO |
166149168 | 35 | ctaggtcaagtgtaggag | 271 |
166149165 | 257 | GGTCAAGTGTAGGAGACA | 273 |
166128025 | 36 | taggtaccatagagtgag | 279 |
166127991 | 136 | gaggatactgcagaggtc | 280 |
eTF SEQ ID NO: | eTF 序列 | 識別之標靶位點 |
SEQ ID NO: 272 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML | SEQ ID NO: 257 |
SEQ ID NO: 280 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML | SEQ ID NO: 136 |
eTF SEQ ID NO: | DBD SEQ ID NO: | DBD 序列 |
SEQ ID NO: 270 | SEQ ID NO: 393 | LEPGEKPYKCPECGKSFSRKDNLKNHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSRKDNLKNHQRTHTGKKTS |
SEQ ID NO: 272 | SEQ ID NO: 395 | LEPGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDELVRHQRTHTGEKPYKCPECGKSFSQSGNLTEHQRTHTGEKPYKCPECGKSFSTSGHLVRHQRTHTGEKPYKCPECGKSFSQNSTLTEHQRTHTGKKTS |
SEQ ID NO: 278 | SEQ ID NO: 401 | LEPGEKPYKCPECGKSFSRNDALTEHQRTHTGEKPYKCPECGKSFSDPGHLVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSRSDHLTNHQRTHTGKKTS |
SEQ ID NO: 280 | SEQ ID NO: 403 | LEPGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSQSGDLRRHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSTSGNLVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTS |
SEQ ID NO: 281 | SEQ ID NO: 404 | LEPGEKPYKCPECGKSFSQAGHLASHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSGNLTEHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSQKSSLIAHQRTHTGEKPYKCPECGKSFSQAGHLASHQRTHTGKKTS |
SEQ ID NO: 282 | SEQ ID NO: 405 | LEPGEKPYKCPECGKSFSTTGNLTVHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSTSGNLTEHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGKKTS |
eTF SEQ ID NO: | eTF 序列 | 標靶位點SEQ ID NO: |
SEQ ID NO: 337 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSDCRDLARHQRTHTGEKPYKCPECGKSFSTTGNLTVHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSHTGHLLEHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML | SEQ ID NO: 330 |
SEQ ID NO: 338 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSRNDTLTEHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSTKNSLTEHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML | SEQ ID NO: 331 |
SEQ ID NO: 339 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSTSGNLTEHQRTHTGEKPYKCPECGKSFSRADNLTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF | SEQ ID No: 336 |
SEQ ID NO: 340 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDSGNLRVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML | SEQ ID NO: 38 |
SEQ ID NO: 341 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDSGNLRVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF | SEQ ID NO: 38 |
SEQ ID NO: 342 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDSGNLRVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF | SEQ ID NO: 38 |
SEQ ID NO: 343 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDSGNLRVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDML | SEQ ID NO: 38 |
SEQ ID NO: 344 | MAPKKKRKVGIHGVPAALEPGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSHKNALQNHQRTHTGEKPYKCPECGKSFSERSHLREHQRTHTGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSRKDNLKNHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSQAGHLASHQRTHTGKKTSKRPAATKKAGQAKKKKGSYPYDVPDYALEEASGSGRADALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLGSDALDDFDLDMLINSRSSGSPKKKRKVGSQYLPDTDDRHRIEEKRKRTYETFKSIMKKSPFSGPTDPRPPPRRIAVPSRSSASVPKPAPQPYPFTSSLSTINYDEFPTMVFPSGQISQASALAPAPPQVLPQAPAPAPAPAMVSALAQAPAPVPVLAPGPPQAVAPPAPKPTQAGEGTLSEALLQLQFDDEDLGALLGNSTDPAVFTDLASVDNSEFQQLLNQGIPVAPHTTEPMLMEYPEAITRLVTGAQRPPDPAPAPLGAPGLPNGLLSGDEDFSSIADMDFSALLGSGSGSRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF | SEQ ID NO: 335 |
SEQ ID NO: 345 | MQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDKLEMSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGIRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC | SEQ ID NO: 38 |
SEQ ID NO: 60 | MSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSCQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSRRDELNVHIRIHTGQKPFQCRICMRNFSSRRTCRAHIRTHTGEKPFACDICGRKFAQSSNLVRHTKIHLRQKDRPYACPVESCDRRFSQLAHLRAHIRIHTGQKPFQCRICMRNFSTSGNLVRHIRTHTGEKPFACDICGRKFAHRTTLTNHTKIHLRQKDK | SEQ ID NO: 38 |
SEQ ID NO: 346 | MSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSCQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDK | SEQ ID NO: 38 |
SEQ ID NO: 63 | MQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC | SEQ ID NO: 38 |
SEQ ID NO: 64 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGQSQLIKPSRMRKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC | SEQ ID NO: 38 |
SEQ ID NO: 347 | MRPHACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCALEMSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGIRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSC | SEQ ID NO: 38 |
SEQ ID NO: 348 | MSGLEMADHMMAMNHGRFPDGTNGLHHHPAHRMGMGQFPSPHHHQQQQPQHAFNALMGEHIHYGAGNMNATSGVRHAMGPGTVNGGHPPSALAPAARFNNSQFMGPPVASQGGSLPASMQLQKLNNQYFNHHPYPHNHYMPDLHPAAGHQMNGTNQHFRDCNPKHSGGSSTPGGSGGSSTPGGSGSSSGGGAGSSNSGGGSGSGNMPASVAHVPAAMLPPNVIDTDFIDEEVLMSLVIEMGLDRIKELPELWLGQNEFDFMTDFVCKQQPSRVSCRPHACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKEKKAEKGGAPSASSAPPVSLAPVVTTCA | SEQ ID NO: 38 |
SEQ ID NO: 349 | MRPHACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKEKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC | SEQ ID NO: 38 |
SEQ ID NO: 350 | MAADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSCGGSGGGSGRPHACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKEKLEMADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC | SEQ ID NO: 38 |
eTF SEQ ID NO: | DBD SEQ ID NO: | DBD 序列 |
SEQ ID NO: 337 | SEQ ID NO: 377 | LEPGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSDCRDLARHQRTHTGEKPYKCPECGKSFSTTGNLTVHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSTHLDLIRHQRTHTGEKPYKCPECGKSFSHTGHLLEHQRTHTGKKTS |
SEQ ID NO: 338 | SEQ ID NO: 378 | LEPGEKPYKCPECGKSFSRNDTLTEHQRTHTGEKPYKCPECGKSFSDPGALVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGEKPYKCPECGKSFSTSGELVRHQRTHTGEKPYKCPECGKSFSTKNSLTEHQRTHTGKKTSKRPAATKKAGQAKKKK |
SEQ ID NO: 339 | SEQ ID NO: 379 | LEPGEKPYKCPECGKSFSTSGNLTEHQRTHTGEKPYKCPECGKSFSRADNLTEHQRTHTGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSHRTTLTNHQRTHTGKKTS |
SEQ ID NO: 340 | SEQ ID NO: 380 | LEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDSGNLRVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTS |
SEQ ID NO: 341 | SEQ ID NO: 381 | LEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDSGNLRVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTS |
SEQ ID NO: 342 | SEQ ID NO: 382 | LEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDSGNLRVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTS |
SEQ ID NO: 343 | SEQ ID NO: 383 | LEPGEKPYKCPECGKSFSSPADLTRHQRTHTGEKPYKCPECGKSFSDSGNLRVHQRTHTGEKPYKCPECGKSFSQLAHLRAHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSREDNLHTHQRTHTGEKPYKCPECGKSFSRSDNLVRHQRTHTGKKTS |
SEQ ID NO: 344 | SEQ ID NO: 384 | LEPGEKPYKCPECGKSFSTSHSLTEHQRTHTGEKPYKCPECGKSFSHKNALQNHQRTHTGEKPYKCPECGKSFSERSHLREHQRTHTGEKPYKCPECGKSFSSKKALTEHQRTHTGEKPYKCPECGKSFSQRANLRAHQRTHTGEKPYKCPECGKSFSRKDNLKNHQRTHTGEKPYKCPECGKSFSQSSNLVRHQRTHTGEKPYKCPECGKSFSQSSSLVRHQRTHTGEKPYKCPECGKSFSQAGHLASHQRTHTGKKTS |
SEQ ID NO: 345 | SEQ ID NO: 385 | RKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKD |
SEQ ID NO: 346 | SEQ ID NO: 386 | RKYPNRPSKTPPHERPYACPVESCDRRFSSPADLTRHIRIHTGQKPFQCRICMRNFSDSGNLRVHIRTHTGEKPFACDICGRKFAQLAHLRAHTKIHLRQKDRPYACPVESCDRRFSQRANLRAHIRIHTGQKPFQCRICMRNFSREDNLHTHIRTHTGEKPFACDICGRKFARSDNLVRHTKIHLRQKDK |
SEQ ID NO: 347 | SEQ ID NO: 387 | HACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKE |
SEQ ID NO: 348 | SEQ ID NO: 388 | HACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKE |
SEQ ID NO: 349 | SEQ ID NO: 389 | HACPAEGCDRRFSSPADLTRHLRIHTGHKPFQCRICMRSFSDSGNLRVHIRTHTGEKPFACEFCGRKFAQLAHLRAHAKIHLKQKEHACPAEGCDRRFSQRANLRAHLRIHTGHKPFQCRICMRSFSREDNLHTHIRTHTGEKPFACEFCGRKFARSDNLVRHAKIHLKQKE |
SEQ ID NO: 350 | SEQ ID NO: 390 | MADHLMLAEGYRLVQRPPSAAAAHGPHALRTLPPYAGPGLDSGLRPRGAPLGPPPPRQPGALAYGAFGPPSSFQPFPAVPPPAAGIAHLQPVATPYPGRAAAPPNAPGGPPGPQPAPSAAAPPPPAHALGGMDAELIDEEALTSLELELGLHRVRELPELFLGQSEFDCFSDLGSAPPAGSVSC |
包括以下實例以進一步描述本發明之一些態樣,且不應用於限制本發明之範疇。
實例 1 增加 HEK293T 細胞中之基因表現
HEK293T細胞在若干不同調節元件中之一者控制下經含有螢光素酶基因之質體DNA轉染,亦即無啟動子對照;SCP;CMV;可操作地連接於minCMV之SEQ ID NO: 178;可操作地連接於minCMV之SEQ ID NO: 182;及CAG。來自各構築體之標準化螢光素酶值說明於
圖 1中。來自各構築體之尺寸標準化活性值說明於
圖 2中。具有連接至SEQ ID NO: 178或182之調節元件之minCMV啟動子的構築體比單獨的minCMV及單獨的SCP驅動更高量之螢光素酶表現。
此實驗指示及SEQ ID NO: 178及182為在細胞中驅動高基因表現之RE。此類RE可添加至包含SCN1A之非天然存在之轉錄活化子的本文揭示之表現卡匣以提高轉錄活化子於細胞中之表現,其導致增加的內源性SCN1A基因之表現。在一些情況下,一或多個選自SEQ ID NO: 178及/或182之RE可操作地連接於轉錄活化子以提高細胞中之SCN1A表現。此類調節元件可在表現卡匣中之轉錄活化子的上游及/或下游添加至表現卡匣。
實例 2 針對小白蛋白神經元之選擇性
針對小白蛋白細胞(一種類型的GABA能神經元)之選擇性係使用螢光成像測定。含有可操作地連接於對照啟動子(EF1α)或PV選擇性RE之eGFP的AAV載體及含有CRE依賴性tdTomato之AAV載體共注射至GAD2-IRES-CRE小鼠(Jackson Labs)中。
以0.3 µL/min之速率向小鼠之背側及腹側海馬區兩側地輸注1.5 µL LAAV載體(5
12至1
13gc/ml),在注射之後具有4分鐘休息時段。小鼠使用異氟醚(2%,800 mL/min O
2)麻醉以進行注射。布比卡因/腎上腺素用於局部鎮痛且卡洛芬用於圍手術期/手術後鎮痛。將動物置於立體定位架(Kopf instruments, USA)中,使用以下座標:對於背側海馬區(AP -2.0 mm,橫向±1.5,DV -1.4 mm距硬腦膜)及腹側海馬區(AP -3.1 mm,橫向±2.8,DV -3.8 mm距硬腦膜)。漢密爾頓注射器(Hamilton syringe)(型號80308;10 µL注射器,具有對應30 ga鈍尖針)與立體定向微操作器一起使用,以指示及鑽取鑽孔。鑽孔機僅用於穿透骨骼。在鑽孔之後,輸注套管降低至大腦中以到達所需位置之深度。具有micro4控制器之超微型泵III (World Precision Instruments)之注射設定為:注射量:1.5 µL;注射速率:0.3 μL/min。針緩慢降低(經大致1分鐘)至低於輸注座標DV -0.1 mm (對於背側海馬區為-1.5 mm且對於腹側海馬區為-3.9 mm,且接著分別升高至DV -1.4或-3.8)。在輸注之前,使針平衡1分鐘。一旦完成遞送,針保持4分鐘且接著經大致1分鐘抽出。一旦完全所有四次輸注,皮膚切口用縫合線封閉。治療之小鼠在研究之剩餘部分內每天進行健康檢查且每週稱重一次以監測體重。
對於組織收集,小鼠經由過劑量異氟醚安樂死且灌注4%三聚甲醛(PFA)。提取出一片含有海馬區之腦組織且置於4℃下之4% PFA中至少12小時。腦組織接著在4℃下於30%蔗糖(於磷酸鹽緩衝鹽水中)中脫水直至組織下沉到管底部。腦組織包埋於Tissue-Tek OCT中以在低溫恆溫器中切片。使用標準免疫組織化學程序,用抗RFP多株兔抗體(Rockland Antibodies and Assay)及抗eGFP多株雞抗體(Aves Labs)對切片之腦組織的eGFP及tdTomato染色。
圖 3說明來自用含有eGFP及PV選擇性元件(SEQ ID NO: 183或SEQ ID NO: 184)或組成型EF1α對照啟動子(SEQ ID NO: 186)之AAV載體,連同含有tdTomato螢光報告子(其表現取決於Cre重組酶活性)之第二AAV載體處理之小鼠的代表性影像。GAD2選擇性地表現於GABA能神經元(包括PV神經元)中,因此,tdTomato表現識別GABA能神經元(
圖 3,下部列)。
圖 4說明各啟動子或調節元件在PV細胞中之表現的效率。由EF1α (組成型啟動子)驅動之eGFP表現顯示約40%之表現效率。相比之下,由SEQ ID NO: 183 (其包含具有序列SEQ ID NO: 185之啟動子)或SEQ ID NO: 184驅動之eGFP表現顯示約90%之表現效率,顯示比EF1α啟動子高得多的表現效率。
圖 5說明不同調節序列之表現的特異性,相比於針對小白蛋白(PV)細胞顯示小於10%特異性之EF1α啟動子,SEQ ID NO: 183及184均在PV細胞以約75%特異性驅動eGFP之表現。
此等實驗確認SEQ ID NO: 183及184調節元件針對GABA能/PV神經元之選擇性且說明可用於量測針對GABA能/PV細胞之選擇性的分析。SEQ ID NO: 183-184調節元件中之一或多者可包括於本文所述之表現卡匣中以相比於非GABA能細胞提高轉錄活化子於GABA能/PV細胞中之選擇性表現,以使脫靶效應降至最低,如使用上文所述之分析所測定。在一些情況下,針對PV細胞具選擇性之一或多個RE用於表現卡匣中以相比於非PV細胞提高轉錄活化子於PV細胞中之選擇性表現(使用與上文所述類似的分析)。
實例 3 使用 SCN1A 特異性轉錄活化子鑑別能夠上調 SCN1A 之 標靶區域
為了鑑別能夠上調內源性SCN1A表現之基因組的區域,設計靶向如以上
表 26 - 29中所闡述之基因組之各種區域的各種工程化轉錄因子(鋅指核酸酶或gRNA/daCas9構築體)。對於gRNA/daCas9構築體,gRNA與標靶區域具有相同序列,因為gRNA經設計以靶向互補基因組股。dCas9蛋白質之序列為SEQ ID NO: 104,其亦為具有NLS及HA標籤之SEQ ID NO: 103。
HEK293細胞係根據標準方法培養,且在6孔盤之每個孔經3 μg攜有工程化轉錄因子或對照構築體之質體轉染(FugeneHD, Promega)。細胞經表現上文
表 26 - 29中顯示之構築體的質體轉染。在轉染後48 h,收集細胞且分離RNA (Qiagen RNeasy Mini套組),且用DNA酶處理。RNA (3 μg)使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析:(在98℃下30 s,40×[在98℃下10 s,在66℃下15 s,在72℃下15 s])。針對SCN1A之引物(5'-TGTCTCGGCATTGAGAACATTC-3' (SEQ ID NO: 190);5'-ATTGGTGGGAGGCCATTGTAT-3' (SEQ ID NO: 191))用於定量內源性SCN1A轉錄物之含量,且相對SCN1A表現量係藉由以GAPDH作為參考基因(5'-ACCACAGTCCATGCCATCAC'-3' (SEQ ID NO: 192);5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO: 193))之δ-δ Ct方法測定。資料呈現為相對於對照條件之倍數變化。
結果在
圖 6及下
表 32中展示為SCN1A轉錄相對於對照條件(例如EGFP-KASH報告子構築體)之倍數變化。
表 32 :不同基因組標靶位點及對應 eTF 對 轉錄具有的影響
實例 4 SCN1A 自表現卡匣之相對表現
標靶位點SEQ ID NO: | 藉由eTF 識別之靶序列 | 平均值 | T 測試 |
197 | ggtacgggcaaagatttcttg | 1.36801947 | 0.48762102 |
198 | tttgcccgtaccaaagtcttg | 1.26748653 | 0.71262289 |
201 | ACACAATGAGCCACCTACAAG | 1.31187425 | 0.42605224 |
202 | GTGGCTCATTGTGTGTGTGCC | 1.25217773 | 0.26572657 |
203 | AGAAAGCTGATACAGATACAA | 1.7542842 | 0.34519408 |
203 | AGAAAGCTGATACAGATACAA | 1.45636874 | 0.44464045 |
207 | TTCTCAGTTTTGAAATTAAAA | 1.64498972 | 0.21705582 |
208 | CATATCCCTGCAGGTTCAGAA | 1.75688991 | 0.28984533 |
209 | TGGATTCTCTTCTGAACCTGC | 2.27026665 | 0.43195546 |
210 | agagagagagagagagagaga | 2.05701745 | 0.42409102 |
211 | TGGTCTCATTCTTTTTGTGGG | 1.71471378 | 0.32104302 |
107 | aaggctgtctaggtcaagtgt | 1.36378425 | 0.18753821 |
35 | ctaggtcaagtgtaggag | 5.12090848 | 0.0096628 |
257 | GGTCAAGTGTAGGAGACA | 1.52068773 | 0.62403349 |
224 | tgttcctccagattaacactt | 1.63040825 | 0.46710683 |
225 | ATTACAGTTCTGTCAGCATGC | 1.34500323 | 0.32186367 |
226 | ATCATCTGTAACCATCAAGGA | 2.58328006 | 0.0748197 |
227 | TCCTGCCTACTTAGTTTCAAG | 1.97097781 | 0.25980859 |
228 | TGCTGAGGCAGGACACAGTGT | 2.4290169 | 0.30364553 |
229 | ACAAAGTAAGTGTCAGTGTGG | 1.30739959 | 0.72725347 |
230 | CTGACACTTACTTTGTCTAAA | 1.95513108 | 0.02069095 |
231 | ATAATAGTTGTGTCTTTATAA | 1.55783618 | 0.29846459 |
232 | CGATATTTTCATGGATTCCTT | 1.7735976 | 0.21954265 |
233 | AAAACTGGAACCGCATTCCCA | 2.08698135 | 0.0454403 |
234 | TGTACAAGCAGGGCTGCAAAG | 1.4663605 | 0.02946062 |
235 | AAAGGGGAATGGGAACACCCG | 1.16749665 | 0.65768346 |
236 | ATGTTCAAGGTGCAGAAGGAA | 2.04547409 | 0.09880194 |
237 | ttcaacaagctcccaagaagt | 1.46929899 | 0.24465271 |
238 | GTTAACAAATACACTAAACAC | 1.37399196 | 0.33638238 |
109 | gctgatttgtattaggtacca | 22.4892633 | 0.09291316 |
36 | taggtaccatagagtgag | 25.4730028 | 0.14942042 |
108 | gatgaagccgagaggatactg | 18.7579211 | 0.13148732 |
136 | gaggatactgcagaggtc | 8.6766618 | 0.16432794 |
247 | TGTTTGCTCAAACGTGCACCA | 2.13402102 | 0.25583999 |
248 | AAATATGTACCACAAGAAATG | 2.29522738 | 0.41829497 |
249 | TATCTGGTTTCTCTCACTGCT | 1.44542116 | 0.0947106 |
250 | AAATAAGACATGAAAACAAGA | 1.27016182 | 0.32368695 |
251 | ATTGCAAAGCATAATTTGGAT | 1.42246971 | 0.18117243 |
此實例描述SCN1A自各種包含增加SCN1A基因表現之非天然存在之轉錄調節子之表現卡匣的相對表現。SCN1A基因屬於為製造鈉離子通道提供指示之基因家族。此等通道將帶正電鈉原子(鈉離子)輸送至細胞中,在細胞產生及傳輸電信號之能力中起重要作用。為了測試表現卡匣,HEK293細胞係根據標準方法培養,且在6孔盤之每個孔經3 µg質體來轉染(PEI)。在轉染後48 h,收集細胞且分離RNA (Qiagen RNeasy Mini套組),且用DNA酶處理。RNA (3 μg)使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析:(在98℃下30 s,40×[在98℃下10 s,在66℃下15 s,在72℃下15 s])。
構築各種表現卡匣,包括包含eGFP報告子轉殖基因且不具有轉錄活化子之對照表現卡匣;及如上
表 17中所述之表現卡匣A-H。對於表現卡匣A-F,各包含非天然存在之DNA結合域,該結合域包含六至九個根據SEQ ID NO: 103、131-134之鋅指,連接至具有序列SEQ ID NO: 95之VP64轉錄活化域或具有序列SEQ ID NO: 114之VPR轉錄活化域。此類非天然存在之轉錄活化子經工程化以結合具有SEQ ID NO: 35-37、107-108或136中之任一者之序列的標靶位點,或包含SEQ ID NO: 35-37、107-108或136中之任一者的基因組區域。表現卡匣G及H各包含具有序列SEQ ID NO: 103之dSaCas9 DNA結合域,其連接至具有序列SEQ ID NO: 95之VP64轉錄活化域。各G及H表現卡匣亦包含用於靶向非天然存在之轉錄活化子之gRNA,其中各gRNA包含選自SEQ ID NO: 107-108之序列。各表現卡匣亦包含具有序列SEQ ID NO: 178之RE。
針對SCN1A之引物(5'-TGTCTCGGCATTGAGAACATTC-3' (SEQ ID NO: 190);5'-ATTGGTGGGAGGCCATTGTAT-3' (SEQ ID NO: 191))用於定量內源性SCN1A轉錄物之含量,且相對SCN1A表現量係藉由以GAPDH作為參考基因(5'-ACCACAGTCCATGCCATCAC'3' (SEQ ID NO: 192);5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO: 193))之δ-δ Ct方法測定。
圖 7說明SCN1A針對經不同表現卡匣轉染之細胞的相對表現,呈現為相對於對照eGFP構築體之倍數變化(Log
10)。非天然存在之轉錄活化劑自表現卡匣A-H之表現導致HEK293細胞中之SCN1A基因表現相對於對照表現卡匣的增加。
圖 8說明用於在HEK293細胞中相比於其他基因增加SCN1A基因之表現的包含非天然存在之轉錄活化子之表現卡匣A。另外,針對TTC21B (5'-GGTCACGTACAGCTTCGCAT-3' (SEQ ID NO: 283);5'-CTGGTTTCTGGCTCGTGGAG-3' (SEQ ID NO: 284))、SCN9A (5'-AAGCCCCAAAGCCAAGCAG-3' (SEQ ID NO: 285);5'-AGGTGTGGCATTGAAACGG-3' (SEQ ID NO: 286))、GRN (5'-ATGGTCAGTTCTGCCCTGTG-3' (SEQ ID NO: 287);5'-CGGTAAAGATGCAGGAGTGGC-3' (SEQ ID NO: 288))、UTRN (5'-TGACAATGGGCAGAACGAAT-3' (SEQ ID NO: 289);5'-TGCAGCACTCTGTTGACGTT (SEQ ID NO: 290))及TTN (5'-TGTTGCCACTGGTGCTAAAG-3' (SEQ ID NO: 291);5'-ACAGCAGTCTTCTCCGCTTC-3' (SEQ ID NO: 292))之引物用於定量內源性TTC21B、SCN9A、GRN、UTRN及TTN轉錄物之含量,且此等基因之相對表現量係藉由使用具有序列SEQ ID NO: 192-193之引物,以GAPDH作為參考基因之δ-δ Ct方法測定。
圖 8說明呈現為相對於對照條件之倍數變化的內源性SCN1A、TTC21B、SCN9A、GRN、UTRN及TTN轉錄物之相對表現。如上文所述之表現卡匣A能夠相比於測試之其他基因特異性增加SCN1A基因或Nav1.1蛋白質之表現。此指示藉由表現卡匣A之轉錄活化子識別之標靶位點對SCN1A基因具有特異性,因此導致HEK293細胞中之SCN1A基因表現的增加。
實例 5 SCN1A 活化
HEK293細胞係根據標準方法培養,且經3 μg之各測試活化子,或EGFP對照轉染(FuGene HD, Promega)。在轉染後48 h,收集細胞且分離RNA (Qiagen RNeasy Mini套組),且用DNA酶處理。RNA (3 μg)使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析:(在98℃下30 s,40×[在98℃下10 s,在68℃下15 s,在72℃下15 s])。針對人類SCN1A之引物(5'-TGTCTCGGCATTGAGAACATTC-3' (SEQ ID NO: 190);5'-ATTGGTGGGAGGCCATTGTAT-3' (SEQ ID NO: 191))用於定量報告子驅動之EGFP轉錄物之含量,且相對EGFP表現量係藉由以GAPDH作為參考基因(5'-ACCACAGTCCATGCCATCAC-3' (SEQ ID NO: 192);5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO: 193))之δ-δ Ct方法測定。資料呈現為相對於對照條件之倍數變化。參見
圖 12B及
圖 13B。SEQ ID NO: 6、7及9為衍生自人類EGR1蛋白質之eTF且經工程化以結合至內源性SCN1A基因附近或該基因處之標靶位點,其中標靶位點為SEQ ID NO: 35-37。相比於報告子EGFP對照,包含SEQ ID NO: 6、7或9中之任一者之eTF分別產生至少2倍、7倍或20倍之相對SCN1A表現。
實例 6 使用 SCN1A 特異性轉錄因子上調 HEK293 細胞中之 內源性 SCN1A
HEK293細胞係根據標準方法培養,且在6孔盤之每個孔經3 μg攜有工程化轉錄因子或EGFP對照構築體之質體轉染(FugeneHD, Promega)。細胞經含有下
表 33中顯示之構築體的質體轉染。在轉染後48 h,收集細胞且分離RNA (Qiagen RNeasy Mini套組),且用DNA酶處理。RNA (3 μg)使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析:(在98℃下30 s,40×[在98℃下10 s,在66℃下15 s,在72℃下15 s])。針對SCN1A之引物(5'-TGTCTCGGCATTGAGAACATTC-3' (SEQ ID NO: 190); 5'-ATTGGTGGGAGGCCATTGTAT-3' (SEQ ID NO: 191))用於定量內源性SCN1A轉錄物之含量,且相對SCN1A表現量係藉由以GAPDH作為參考基因(5'-ACCACAGTCCATGCCATCAC'3' (SEQ ID NO: 192);5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO: 193))之δ-δ Ct方法測定。資料呈現為相對於對照條件之倍數變化(參見
圖 15)。對照構築體由在具有根據SEQ ID NO: 178之序列之啟動子控制下表現的EGFP組成。遞送工程化轉錄因子在內源性SCN1A轉錄物中誘導相對於EGFP條件的改變程度之上調。
表 33 . 實例 6 及圖 15 中所用之構築體。
表 34 :實例 6 及 圖 15 中所用之構築體。
實例 7 使用 SCN1A 特異性轉錄因子上調 GABA 神經元 中之 內源性 SCN1A
eTF SEQ ID NO: | |
表17中之表現卡匣D | SEQ ID NO: 15 |
表17中之表現卡匣B | SEQ ID NO: 364 |
表17中之表現卡匣C | SEQ ID NO: 9 |
表17中之表現卡匣E | SEQ ID NO: 8 |
SEQ ID NO: 67 | SEQ ID NO: 7 |
SEQ ID NO: 68 | SEQ ID NO: 295 |
SEQ ID NO: 88 | SEQ ID NO: 14 |
SEQ ID NO: 69 | SEQ ID NO: 296 |
SEQ ID NO: 87 | SEQ ID NO: 297 |
SEQ ID NO: 83 | SEQ ID NO: 13 |
SEQ ID NO: 84 | SEQ ID NO: 298 |
SEQ ID NO: 75 | SEQ ID NO: 299 |
SEQ ID NO: 74 | |
SEQ ID NO: 70 | |
SEQ ID NO: 71 |
eTF SEQ ID NO: | DBD SEQ ID NO: |
SEQ ID NO: 364 | SEQ ID NO: 406 |
SEQ ID NO: 295 | SEQ ID NO: 407 |
SEQ ID NO: 296 | SEQ ID NO: 408 |
SEQ ID NO: 299 | SEQ ID NO: 409 |
iCell GABA神經元(Cellular Dynamics)平鋪於6孔盤中(約1E6個細胞/孔)且根據製造商推薦之方案維持。在平鋪之後72 h,將在普遍存在的啟動子(CBA啟動子)控制下表現EGFP或活化子(
圖 16A中之SEQ ID NO: 366或
圖 16B中之SEQ ID NO: 13或SEQ ID NO: 15)之重組AAV (血清型AAV-DJ)以每孔大致2E11個基因組複本添加至培養基。在感染之後一週(
圖 16A)或兩週(
圖 16B),RNA自培養細胞分離(Qiagen RNeasy Mini套組),且用DNA酶處理。回收之RNA使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析:(在98℃下30 s,40×[在98℃下10 s,在66℃下15 s,在72℃下15 s])。針對SCN1A之引物(5'-TGTCTCGGCATTGAGAACATTC-3' (SEQ ID NO: 190); 5'-ATTGGTGGGAGGCCATTGTAT-3' (SEQ ID NO: 191))用於定量內源性SCN1A轉錄物之含量,且相對SCN1A表現量係藉由以GAPDH作為參考基因(5'-ACCACAGTCCATGCCATCAC'3' (SEQ ID NO: 192);5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO: 193))之δ-δ Ct方法測定。資料呈現為相對於對照條件之倍數變化(參見
圖 16A及
圖 16B)。AAV驅動之工程化轉錄因子表現在培養之iPS源性GABA神經元中產生內源性SCN1A轉錄物之顯著上調。
實例 8 使用 SCN1A 特異性轉錄因子特異性上調 GABA 神經元 中之 內源性 SCN1A
iCell GABA神經元(Cellular Dynamics)平鋪於6孔盤中(約1E6個細胞/孔)且根據製造商推薦之方案維持。在平鋪之後72 h,將在CBA啟動子控制下表現EGFP或活化子(SEQ ID NO: 366,其包含由CBA啟動子驅動而融合至VPR TAD之鋅指DBD)之重組AAV (血清型AAV-DJ)以每孔大致2E11個基因組複本添加至培養基。
在感染之後一週,RNA自培養細胞分離(Qiagen RNeasy Mini套組),且用DNA酶處理。RNAseq文庫係使用TruSeq Stranded mRNA文庫套組(Illumina)由回收之RNA製備,且在Illumina NextSeq上定序(2×75循環配對末端定序)。定序讀段與人類基因組比對(RNASTAR)且用DESeq2進行差異表現分析。資料呈現為相對於對照(AAVDJ-CBA-EGFP)樣品之倍數變化(參見
圖 17)。
表 35及
圖 17中展示之結果說明呈現為相對於對照條件之倍數變化的內源性SCN1A及40個最近鄰基因轉錄物之相對表現。如上文所述之SEQ ID NO: 366能夠相比於檢查之其他基因特異性增加SCN1A基因或Nav1.1蛋白質之表現。此指示藉由SEQ ID NO: 366之轉錄活化子識別之標靶位點對SCN1A基因具有特異性,因此導致GABA神經元中之SCN1A基因表現的增加。
表 35 .對用SCN1A特異性轉錄因子(SEQ ID NO: 366)處理之GABA神經元中之內源性SCN1A及40個最近鄰基因之轉錄的影響。
實例 9 SCN1A 在 活體內自表現卡匣之表現
基因名稱 | Chr 2 起點 | Chr 2 終點 | Chr 股 | 相對於對照之倍數變化 |
PLA2R1 | 160788518 | 160919121 | - | 0.16367458 |
ITGB6 | 160956176 | 161128399 | - | 0.20679884 |
RBMS1 | 161128661 | 161350305 | - | 1.63514667 |
TANK | 161993418 | 162092732 | + | 0.90946407 |
PSMD14 | 162164548 | 162268228 | + | 0.92699237 |
TBR1 | 162272604 | 162282381 | + | 0.53199642 |
SLC4A10 | 162280842 | 162841792 | + | 1.89407328 |
DPP4 | 162848750 | 162931052 | - | 2.82345284 |
FAP | 163027193 | 163101661 | - | 2.26977379 |
IFIH1 | 163123588 | 163175213 | - | 1.46146481 |
GCA | 163175349 | 163228105 | + | 2.58702426 |
FIGN | 164449905 | 164592522 | - | 0.46785861 |
GRB14 | 165349321 | 165478358 | - | 0.5631965 |
COBLL1 | 165510133 | 165700189 | - | 0.43199257 |
SLC38A11 | 165752695 | 165812035 | - | 4.06730119 |
SCN3A | 165944031 | 166060577 | - | 1.0807866 |
SCN2A | 166095911 | 166248818 | + | 1.24475196 |
CSRNP3 | 166326156 | 166545917 | + | 0.82971233 |
GALNT3 | 166604100 | 166651192 | - | 0.33804418 |
TTC21B | 166713984 | 166810353 | - | 1.58661143 |
SCN1A | 166845669 | 166984523 | - | 62.9552975 |
SCN9A | 167051694 | 167232503 | - | 1.71659087 |
SCN7A | 167260082 | 167350757 | - | 0.29331967 |
B3GALT1 | 168675181 | 168730551 | + | 0.64436013 |
STK39 | 168810529 | 169104651 | - | 1.19821739 |
CERS6 | 169312371 | 169631644 | + | 0.86828378 |
NOSTRIN | 169643048 | 169722024 | + | 1.82142718 |
SPC25 | 169690641 | 169769881 | - | 0.86880697 |
ABCB11 | 169779447 | 169887832 | - | 3.1441368 |
DHRS9 | 169921298 | 169952677 | + | 1.10381777 |
BBS5 | 170335687 | 170382432 | + | 0.65476347 |
KLHL41 | 170366211 | 170382772 | + | 0.87373377 |
FASTKD1 | 170386258 | 170430385 | - | 1.02786927 |
PPIG | 170440849 | 170497916 | + | 1.09866236 |
CCDC173 | 170501934 | 170550943 | - | 0.67290779 |
PHOSPHO2 | 170550974 | 170558218 | + | 0.91339152 |
KLHL23 | 170550997 | 170633499 | + | 0.73926347 |
SSB | 170648442 | 170668574 | + | 1.00631994 |
METTL5 | 170666590 | 170681441 | - | 1.21271497 |
UBR3 | 170683967 | 170940641 | + | 1.21350908 |
MYO3B | 171034654 | 171511681 | + | 0.52839217 |
為了測試SCN1A之轉錄活化子在活體內之表現,重組AAV9載體係由Vector Biolabs (Malvern, PA)產生。向雄性C57BL/6小鼠(N=5/組,7-8週齡)之背側海馬區(AP -2.0 mm,橫向±1.5,DV -1.4 mm距硬腦膜)及腹側海馬區(AP -3.1 mm,橫向±2.8,DV -3.8 mm距硬腦膜)中兩側地輸注1.5 μl純化之AAV載體,總共為4個注射部位。AAV以0.3 μl/min之速率遞送,在各注射之後具有4 min休息時段。在治療後四週,使小鼠安樂死且解剖海馬組織。對於各組,在大部分動物(N=4)中收集來自左側及右側海馬區組織之組織,彙集進行均質化,一隻動物除外,在該動物中僅收集左側海馬區且均質化。RNA自勻漿分離(Qiagen RNeasy Mini套組),且用DNA酶處理。RNA (3 μg)使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析小鼠SCN1A之表現:在98℃下30 s,40×[在98℃下10 s,在64℃下15 s,在72℃下15 s]。使用與如上文實例1中所述相同之GAPDH引物,針對小鼠SCN1A之引物(5'-CAAAAAAGCCACAAAAGCCT-3' (SEQ ID NO: 374);5'-TTAGCTCCGCAAGAAACATC-3' (SEQ ID NO: 375))用於定量內源性SCN1A轉錄物之含量,且活體內相對SCN1A表現量係藉由以GAPDH作為參考基因之δ-δ Ct方法測定。
圖 18A及
圖1
8B說明各注射AAV9構築體之五隻動物的平均結果。eGFP對照構築體包含eGFP報告子轉殖基因。表現卡匣A (參見
表 17)包含識別包含SEQ ID NO: 35之靶序列的轉錄活化子,如上
表 17中所述。
圖 18A說明活體內SCN1A之相對表現。
圖 18B說明作為平均eGFP表現之百分比的活體內SCN1A表現之變化。此等結果指示表現卡匣A之SCN1A轉錄活化子導致活體內SCN1A表現之大致20%-30%上調。
此類表現卡匣可適用於人體內以治療德拉韋症候群、癲癇症、癲癇、阿茲海默氏症、帕金森氏病及/或任何其他與SCN1A之缺乏及/或活性受損相關之疾病或病況。
實例 10 藉由 qPCR 測定的內源性 SCN1A 轉錄物使用 SCN1A 特異性轉錄因子在 WT 小鼠海馬區中之上調
重組AAV9載體係由Vector Biolabs (Malvern, PA)產生。向雄性C57BL/6小鼠(N=5/組,7-8週齡)之背側海馬區(AP -2.0 mm,橫向±1.5,DV -1.4 mm距硬腦膜)及腹側海馬區(AP -3.1 mm,橫向±2.8,DV -3.8 mm距硬腦膜)中兩側地輸注1.5 μl純化之AAV載體,總共為4個注射部位。使用含有各種SCN1A特異性轉錄因子之AAV載體:
表 17中之表現卡匣A (
圖 19A)、表現卡匣B (
圖 19B)以及SEQ ID NO: 366及SEQ ID NO: 365(
圖 19C)且相比於對照載體(由相同啟動子驅動之EGFP-KASH)(
圖 19A - C)及由CBA啟動子驅動之EGFP-KASH (
圖 19C)。
AAV以0.3 μl/min之速率遞送,在各注射之後具有4 min休息時段。在治療後四週,使小鼠安樂死且解剖海馬組織。對於各組,在大部分動物(N=4)中收集來自左側及右側海馬區組織之組織,彙集進行均質化,一隻動物除外,在該動物中僅收集左側海馬區且均質化。RNA自勻漿分離(Qiagen RNeasy Mini套組),且用DNA酶處理。RNA (3 μg)使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR分析小鼠SCN1A (mNav1.1正向引物:5'-CAAAAAAGCCACAAAAGCCT-3' (SEQ ID NO: 293)及mNav1.1反向引物:5'-TTAGCTCCGCAAGAAACATC-3' (SEQ ID NO: 294)):(在98℃下30 s,40×[在98℃下10 s,在64℃下15 s,在72℃下15 s])。
直接注射攜有工程化轉錄因子構築體中之每一者之AAV導致小鼠海馬區組織中之內源性SCN1A轉錄物的上調。
實例 11 德拉韋症候群小鼠模型中之高熱癲癇 ( HTS ) 分析
在Scn1a
tm1Kea小鼠品系中測試使用表現卡匣治療德拉韋症候群及/或其症狀。此小鼠品系為針對德拉韋症候群之已確立小鼠模型。Scn1a
tm1Kea 小鼠品系不需要CRE重組酶。Scn1a
tm1Kea 小鼠(購自Jackson Laboratory;描述於Hawkins等人, Scientific Reports, 第7: 15327卷 (2017)中)包含SCN1A之第一編碼外顯子的缺失。針對SCN1A基因敲除對偶基因為同型接合之小鼠係藉由震顫、共濟失調、癲癇表徵,且在產後第16天死亡。C57BL/6背景之異型接合小鼠患上自發性癲癇且大部分在數週內死亡。此類小鼠品系可用於研究癲癇症及德拉韋症候群之安全性及治療功效。關於額外資訊,參見Miller等人, Genes Brain Behav. 2014年2月;13(2):163-72。
為了測試轉錄活化子在Scn1a
tm1Kea小鼠品系中之功效,由雄性Scn1a +/-與雌性C57BL/6J育種雜交產生之鼠幼仔在P1處經由兩側ICV投配AAV載體。向小鼠投配下
表 36中概述之構築體。小鼠用障壁保持不受干擾直至在P18處斷奶且接著再次保持不受干擾直至P26-P28,此時起始HTS分析。投藥P1小鼠之分離幼仔在P18處斷奶且每天觀測死亡率。在混合129Stac X C57BL/6背景下在P26-P28 HET及WT Scn1a小鼠中進行高熱癲癇誘導。在分析之前,小鼠插入有潤滑之直腸溫度探針(Ret-4)且連接至與加熱燈(HL-1)串聯連接之溫度控制模組(TCAT 2DF, Physitemp)。接著將小鼠置於大玻璃燒杯中且使其短暫地與環境平衡。在此之後,體溫每2分鐘增加約0.5℃直至開始第一次強直陣攣發作伴以姿勢喪失或直至達到43℃。若小鼠經歷癲癇伴以姿勢喪失,則實驗結束且記錄小鼠之內部體溫。若在整個實驗過程中未偵測到癲癇伴以姿勢喪失,則將小鼠視為無癲癇且分析得出結論。組織樣品在P1處獲自小鼠且在實驗過程期間使用即時PCR進行小鼠之基因分型。基因分型在分析完成之後為非盲的且小鼠作為HET或WT之狀態與獲得之資料相關。資料標繪於Kaplan-Meier存活率曲線中且藉由Mantel-Cox測試來測定顯著性。結果展示於
表 36及
表 37及
圖 20A - E中。
表 36 .實例11中所用之條件的概述。
表 37 . 高熱癲癇分析之結果的概述。
實例 12 德拉韋症候群小鼠模型中之存活率分析
eTF 之SEQ ID NO | 劑量 (gc / 小鼠 ) | 調節元件 | 藉由eTF 識別之標靶位點 | eTF 之DBD +TAD 結構 | PolyA |
SEQ ID NO: 305 | 5.8E+10 | SEQ ID NO: 185 | SEQ ID NO: 35 | ZF DBD + VPR | sPA |
SEQ ID NO: 306 | 6.0E+10 | SEQ ID NO: 185 | SEQ ID NO: 35 | ZF DBD + VP64 | hGH |
SEQ ID NO: 307 | 1.4/1.7E+11 | SEQ ID NO: 417 | SEQ ID NO: 35 | ZF DBD + VP64 | sPA |
SEQ ID NO: 308 | 3.1E+11 | SEQ ID NO: 185 | SEQ ID NO: 35 | ZF DBD + VP64 | hGH |
SEQ ID NO: 309 | 4.3E+11 | SEQ ID NO: 183 | SEQ ID NO: 36 | ZF DBD + VPR | sPA |
eTF 之SEQ ID NO | # 對照動物 (PBS 治療 ) | # 治療動物 | 在42 .6 ℃下無癲癇 % | P 值 |
EGFP報告子 | 16 | N/A | 44% | |
SEQ ID NO: 305 | 16 | 14 | 93 | P<0.001 |
SEQ ID NO: 306 | 16 | 18 | 95 | P<0.0001 |
SEQ ID NO: 307 | 16 | 15 | 87 | P<0.01 |
SEQ ID NO: 308 | 16 | 21 | 76 | P<0.05 |
SEQ ID NO: 309 | 16 | 24 | 62.5 | P<0.05 |
為了測試轉錄活化子在Scn1a
tm1Kea小鼠品系中之功效,由雄性Scn1a +/-與雌性C57BL/6J育種雜交產生之鼠幼仔在P1處經由兩側ICV投配AAV載體。小鼠用障壁保持不受干擾直至斷奶。在P18處斷奶之後,每天進行Scn1a +/-小鼠之健康狀況觀測。對發現由於任何原因在其飼養籠中死亡之小鼠記錄日期。資料標繪於Kaplan-Meier存活率曲線中且藉由Mantel-Cox測試來測定顯著性。
結果展示於
表 38及
圖 21A - E中。
表 38 :存活率分析之條件及結果的概述。
實例 13 非人類靈長類動物在用編碼 SCN1A 特異性轉錄因子之 AAV 治療後之 SCN1A 轉錄水準
SEQ ID | 劑量 (gc / 小鼠 ) | # 對照動物 (PBS 治療 ) | # 治療動物 | 在P100 處 ( * 在P83 處 ) 之存活率 % | P 值 |
PBS | N/A | 53 | N/A | 49% | |
SEQ ID NO: 305 | 5.8E+10 | 53 | 29 | 76% | P<0.05 |
SEQ ID NO: 306 | 6.0E+10 | 53 | 34 | 97% | P<0.0001 |
SEQ ID NO: 307 | 1.7E+11 | 53 | 37 | 92% | P<0.0001 |
SEQ ID NO: 309 | 4.3E+11 | 53 | 12 | 100% | P<0.001 |
研究使用2歲與3歲之間的雄性食蟹獼猴(長尾獼猴)。動物在研究登記之前藉由基於細胞之中和抗體分析針對AAV9之交叉反應性抗體進行預篩選。表現SCN1A特異性轉錄因子之AAV9 (SEQ ID NO: 305)或對照稀釋於PBS中且以每隻動物1.2E12 gc腦實質內注射。針對注射在各腦半球中鑑別三個不同立體定位座標,每隻動物六個注射位點。每個位點注射10 μl體積。右腦半球中之注射與左腦半球中之注射對稱。兩隻未治療之動物用作對照。
為了評估Scn1A mRNA表現,進行反轉錄繼之以qPCR方法。在給藥後28天屍檢時,來自對照及治療動物之腦部之不同區域(額葉皮層、頂葉皮層、顳葉皮層、枕葉皮層、海馬區、髓質、小腦;各200 mg)的組織切片收集於RNAlater中且接著冷凍。簡言之,30 mg組織經解剖,提取RNA(用Qiagen Rneasy Lipid tissue mini套組,目錄號1023539),藉由反轉錄轉化為cDNA (使用Applied Biosystems高容量cDNA反轉錄套組,目錄號4368814)且使用引物/探針組對於Scn1A及管家基因GAPDH進行qPCR (Applied Biosystems, 目錄號Rh02621745-gI FAM)。
用於SCN1A之引物/探針組在下文給出。
表 39 :用於實例 13 的 引物序列
用於SCN1A之引物/探針組在下文給出。各測試樣品中之Scn1A之基因表現係藉由使用比較Ct(∆Ct)法之相對定量(RQ)測定。此方法量測靶基因與管家基因之間的Ct差異(∆Ct),接著比較處理樣品與對照樣品之∆Ct值。
基因 | SEQ ID NO | 序列(5'-3') | 附注 |
Scn1A | SEQ ID NO: 328 | CCATGGAACTGGCTCGATTTCAC | F-引物 |
SEQ ID NO: 439 | ATTGGTGGGAGGCCACTGTAT | R-引物 | |
SEQ ID NO: 329 | AGGCCTGAAAACCATTGTGGGAGCCCT | 探針(FAM) |
∆Ct = 靶基因之Ct平均值-管家基因之Ct平均值
∆∆Ct = 處理樣品之∆Ct-對照樣品之∆Ct
相對表現(處理樣品) = 2
- ∆∆ Ct
資料報導為來自腦部之不同組織切片中之標靶mRNA的標準化表現(參見
圖 22)。如
圖 22中所說明,靠近腦實質內注射位點之腦部位點顯示最高SCN1A轉錄物表現量。
實例 14 治療不同小鼠品系中之德拉韋症候群
使用本文所述之表現卡匣治療德拉韋症候群及/或其症狀可在各種小鼠品系,諸如B6(Cg)-
Scn1a
tm1 . 1Dsf /J、Scn1a
tm1Kea及Scn1a-R1470X小鼠品系中進行測試。此等小鼠品系為針對德拉韋症候群之已確立小鼠模型。Scn1a
tm1Kea 及Scn1a-R1470X小鼠品系不需要CRE重組酶。
B6(Cg)-
Scn1a
tm1 . 1Dsf /J可經由Jackson Laboratories獲自德拉韋症候群歐洲聯盟(Dravet Syndrome European Federation)以研究本文中所描述之SCN1A轉錄活化子組合物在治療德拉韋症候群中之安全性及功效。此等小鼠在SCN1A之外顯子24 (位置1783處之A至V)中含有德拉韋症候群相關突變。小鼠亦含有具有野生型序列的兩側放有loxP序列(floxed)之外顯子24。當未操縱時,此小鼠品系表現SCN1A之WT對偶基因的兩個複本。然而,在遞送AAV表現Cre重組酶或此品系與表現Cre之小鼠品系雜交後,任何表現Cre之細胞將切換為表現突變型對偶基因之一個複本。在表現突變型SCN1A次單位後,小鼠在4週內患上自發性癲癇。對於B6(Cg)-
Scn1a
tm1 . 1Dsf /J小鼠實驗,可使用B6(Cg)-
Scn1a
tm1 . 1Dsf /J小鼠及對照C57Bl6小鼠。
Scn1a
tm1Kea小鼠(購自Jackson Laboratory;描述於Hawkins等人, Scientific Reports, 第7: 15327卷 (2017)中)包含SCN1A之第一編碼外顯子的缺失。針對SCN1A基因敲除對偶基因為同型接合之小鼠係藉由震顫、共濟失調、癲癇表徵,且在產後第16天死亡。C57BL/6背景之異型接合小鼠患上自發性癲癇且在數週內死亡。此類小鼠品系可用於研究癲癇症及德拉韋症候群之安全性及治療功效。關於額外資訊,參見Miller等人, Genes Brain Behav. 2014年2月;13(2):163-72。
Scn1a-R1470X小鼠為在SCN1A基因之外顯子21中攜有提前終止密碼子R1407X之基因敲入小鼠。相同突變已鑑別為三個不相關SMEI患者中之致病突變。Scn1a
RX / RX幼鼠藉由產後12天處之反覆性自發性癲癇,包括產後12-16天處之強直陣攣發作及陣攣發作,以及節律性急動及不隨意肌收縮表徵。關於額外資訊,參見Ogiwara等人, Journal of Neuroscience, 2007年5月30日, 27 (22) 5903-5914。
為了測試本文中所描述之組合物,包括AAV基因療法及使用此類基因療法之治療,包含上調活體內SCN1A表現之eTF,上文所述之小鼠品系中之每一者之德拉韋小鼠及對照小鼠(例如具有野生型SCN1A之小鼠或該品系之未治療德拉韋小鼠)用表現EGFP或另一報導基因之AAV,或包含結合至靠近內源性SCN1A之標靶結合序列之eTF的表現卡匣(例如本文揭示之表現卡匣中之任一者)注射(例如藉由腹膜內注射投與)。一些AAV可進一步包含一或多個細胞類型選擇性調節元件。
在AAV注射之後,隨時間推移監測小鼠存活率。每天監測所有小鼠之一般健康(例如體重、水合、理毛及活動性)且記錄死亡。
可緊接在AAV注射之後進行遙測植入(F20-EET,Data Sciences International)。可在手術之後10天開始連續記錄及監測腦皮層電圖資料,持續至少14天。可在AAV治療之後持續至少14天記錄所有癲癇事件,用日期、開始時間、停止時間、持續時間及嚴重度評分來註釋。相比於EGFP對照或未治療之對照,在用包含SCN1A轉錄活化子之AAV治療後的癲癇之頻率及/或持續時間之降低指示SCN1A轉錄活化子在減輕德拉韋症候群之症狀及/或嚴重度中之功效。
在用AAV治療小鼠之後,可使用各種PCR及/或定序方法來監測SCN1A隨時間推移之表現量以顯示藉由SCN1A轉錄活化子之AAV治療可導致內源性SCN1A表現之增加。北方墨點分析及原位雜交亦可用於分析活體內SCN1A表現。亦可在治療後監測Nav1.1蛋白質之水準以顯示SCN1A表現之增加與Nav1.1蛋白質之增加相關。Nav1.1蛋白質可使用各種方法來分析,包括但不限於西方墨點分析、免疫組織化學、免疫螢光組織化學及/或ELISA分析。功能性電壓門控鈉離子通道之形成亦可使用電流鉗分析來分析。
可評估高熱誘發性癲癇以比較野生型小鼠及/或未治療德拉韋小鼠與用包含本文所述之表現卡匣之AAV基因療法治療的德拉韋小鼠。在此類實驗中,核心體溫係用RET-3直腸溫度探針(Physitemp Instruments, Inc., New Jersey, USA)監測且藉由連接至用Partlow 1160 +控制器(West Control Solutions, Brighton, UK)重組態之嚙齒動物溫度調節器(TCAT-2DF, Physitemp)的熱燈控制。體溫每兩分鐘升高0.5℃直至開始第一次陣攣性驚厥。預期相比於未治療之德拉韋小鼠,用包含SCN1A轉錄活化子之AAV治療的德拉韋小鼠在開始第一次陣攣性驚厥之前具有更高臨限值溫度。
亦可向小鼠投與不同劑量的包含表現卡匣之AAV以測定各基因療法治療之安全性及功效概況。此等臨床前研究亦可告知用於治療德拉韋症候群之基因療法的最佳劑量。
實例 15 治療小鼠之阿茲海默氏症
雌性APP/PS1及野生型(WT)小鼠(其在PsychoGenics育種且為阿茲海默氏症之已確立小鼠模型)可用於研究本文中所描述之SCN1A轉錄活化子組合物在治療阿茲海默氏症中之安全性及功效。針對均處於Thy1啟動子控制下的攜有瑞典突變(670 G-T及671 A-C)之澱粉樣β前驅蛋白(APP)及含有L166P突變之早老素1 (PSEN1),APP/PS1小鼠含有人類轉殖基因。此等小鼠出現阿茲海默氏症之症狀,包括澱粉樣蛋白斑及記憶缺陷。此等小鼠之另外描述可見於Radde等人, 2006 (Radde, Rebecca等人 「Aβ42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology」. EMBO reports 7.9 (2006): 940-946)中。
APP/PS1小鼠及非轉殖基因對照用表現EGFP之對照AAV載體或包含SCN1A轉錄活化子之治療AAV載體(例如本文揭示之表現卡匣中之任一者)注射。一些AAV可進一步包含GABA能選擇性及/或PV選擇性調節元件。
在AAV注射之後,隨時間推移監測小鼠存活率。每天監測所有小鼠之一般健康(例如體重、水合、理毛及活動性)且記錄死亡。在注射AAV之後,小鼠亦植入有EET傳輸器。可在手術後持續至少4週經24小時記錄及監測大腦活動。可自動分析腦皮層電圖資料,且可跨越不同組比較不同頻帶(50-100 Hz)中之功率位準:WT小鼠、未治療之APP/PS1小鼠及AAV治療之APP/PS1小鼠,其各用如上文所述之AAV基因療法治療。增加之高γ功率活動與阿茲海默氏症患者及癲癇症患者之癲癇相關。因此,預期未治療之APP/PS1小鼠比對照小鼠顯示更高水準之高γ功率活動,同時預期此增加在治療小鼠中不存在或減少,指示用包含SCN1A之轉錄活化子之AAV基因療法的有效治療。
在用AAV治療小鼠之後,可使用各種PCR及/或定序方法來監測SCN1A隨時間推移之表現量以顯示藉由SCN1A轉錄活化子之AAV治療可導致內源性SCN1A表現之增加。北方墨點分析及原位雜交亦可用於分析活體內SCN1A表現。亦可在治療後監測Nav1.1蛋白質之水準以顯示SCN1A表現之增加與Nav1.1蛋白質之增加相關。Nav1.1蛋白質可使用各種方法來分析,包括但不限於西方墨點分析、免疫組織化學、免疫螢光組織化學及/或ELISA分析。功能性電壓門控鈉離子通道之形成亦可使用電流鉗分析來分析。
亦可向小鼠投與不同劑量的包含表現卡匣之AAV以測定各基因療法治療之安全性及功效概況。此等臨床前研究亦可告知用於治療阿茲海默氏症之基因療法的最佳劑量。
實例 16 使用 GRN 特異性轉錄活化子鑑別能夠上調 GRN 之 標靶區域
為了鑑別能夠上調內源性GRN表現之基因組的區域,設計靶向如下
表 40中所闡述之基因組之各種區域的各種工程化轉錄因子(鋅指核酸酶或gRNA/daCas9構築體)。對於gRNA/daCas9構築體,gRNA與標靶區域具有相同序列,因為gRNA經設計以靶向互補基因組股。HEK293細胞係根據標準方法培養,且在6孔盤之每個孔經3 μg攜有工程化轉錄因子或對照構築體之質體轉染(FugeneHD, Promega)。細胞經表現下
表 40及
表 41中顯示之構築體的質體轉染。在轉染後48 h,收集細胞且分離RNA (Qiagen RNeasy Mini套組),且用DNA酶處理。RNA (3 μg)使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析:(在98℃下30 s,40×[在98℃下10 s,在66℃下15 s,在72℃下15 s])。針對SCN1A之引物(5'-TGTCTCGGCATTGAGAACATTC-3' (SEQ ID NO: 190);5'-ATTGGTGGGAGGCCATTGTAT-3' (SEQ ID NO: 191))用於定量內源性SCN1A轉錄物之含量,且相對SCN1A表現量係藉由以GAPDH作為參考基因(5'-ACCACAGTCCATGCCATCAC'3' (SEQ ID NO: 192);5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO: 193))之δ-δ Ct方法測定。資料呈現為相對於對照條件之倍數變化。
結果在
圖 23及下
表 40中顯示為相對於對照條件(例如EGFP-KASH對照)之GRN轉錄的倍數變化。
表 40 : GRN 標靶區域及對使用指定轉錄因子上調內源性 GRN 之影響 。
表 41 : GRN DBD
實例 17 GRN 自表現卡匣之相對表現
eTF SEQ ID NO: | eTF 序列 | 標靶位點SEQ ID NO: |
SEQ ID NO: 337 | (見上文) | SEQ ID NO: 330 |
A | (參見表23) | SEQ ID NO: 331 |
C | (參見表23) | SEQ ID NO: 332 |
M | (參見表23) | SEQ ID NO:113 |
D | (參見表23) | SEQ ID NO: 333 |
E | (參見表23) | EQ ID NO: 333 |
F | (參見表23) | SEQ ID NO: 38 |
J | (參見表23) | SEQ ID NO: 38 |
G | (參見表23) | SEQ ID NO: 38 |
B | (參見表23) | SEQ ID NO: 331 |
SEQ ID NO: 338 | (見上文) | SEQ ID NO: 331 |
H | (參見表23) | SEQ ID NO: 334 |
I | (參見表23) | SEQ ID NO: 335 |
SEQ ID NO: 339 | (見上文) | SEQ ID No: 336 |
SEQ ID NO: 340 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 341 | (見上文) | SEQ ID NO: 38 |
K | (參見表23) | SEQ ID NO: 38 |
L | (參見表23) | SEQ ID NO: 38 |
SEQ ID NO: 342 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 343 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 344 | (見上文) | SEQ ID NO: 335 |
SEQ ID NO: 10 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 16 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 46 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 345 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 60 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 346 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 63 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 64 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 347 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 348 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 349 | (見上文) | SEQ ID NO: 38 |
SEQ ID NO: 350 | (見上文) | SEQ ID NO: 38 |
eTF SEQ ID NO: | DBD SEQ ID NO: |
SEQ ID NO: 337 | SEQ ID NO: 377 |
SEQ ID NO: 338 | SEQ ID NO: 378 |
SEQ ID NO: 339 | SEQ ID NO: 379 |
SEQ ID NO: 340 | SEQ ID NO: 380 |
SEQ ID NO: 341 | SEQ ID NO: 381 |
SEQ ID NO: 342 | SEQ ID NO: 382 |
SEQ ID NO: 343 | SEQ ID NO: 383 |
SEQ ID NO: 344 | SEQ ID NO: 384 |
SEQ ID NO: 345 | SEQ ID NO: 385 |
SEQ ID NO: 346 | SEQ ID NO: 386 |
SEQ ID NO: 347 | SEQ ID NO: 387 |
SEQ ID NO: 348 | SEQ ID NO: 388 |
SEQ ID NO: 349 | SEQ ID NO: 389 |
SEQ ID NO: 350 | SEQ ID NO: 390 |
此實例描述GRN自表現卡匣之相對表現,該表現卡匣包含增加GRN基因於HEK293細胞中之表現(如藉由GRN RNA所量測)的非天然存在之轉錄活化子。構築表現卡匣A、B、C、D、E、F、J、K、L、G、H、I及M,其各自包含非天然存在之轉錄調節子,該轉錄調節子包含連接至VPR或VP64轉錄活化域(例如SEQ ID NO: 95或SEQ ID NO: 114)的選自SEQ ID NO: 165-170及SEQ ID NO: 112之DNA結合域,如上
表 23中所述。各表現卡匣亦包含具有序列SEQ ID NO: 178或179之調節元件。表現卡匣J與表現卡匣K類似,除了J另外包含eGFP報告子。
為了測試GRN轉錄活化子,HEK293細胞係根據標準方法培養,且在6孔盤之每個孔經3 µg質體來轉染(PEI)。在轉染後48 h,收集細胞且分離RNA (Qiagen RNeasy Mini套組),且用DNA酶處理。RNA (3 μg)使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析:(在98℃下30 s,40×[在98℃下10 s,在66℃下15 s,在72℃下15 s])。針對GRN之引物(5'- ATGGTCAGTTCTGCCCTGTG-3' (SEQ ID NO: 287);5'-CGGTAAAGATGCAGGAGTGGC-3' (SEQ ID NO: 288))用於定量內源性GRN轉錄物之含量,且相對GRN表現量係藉由以GAPDH作為參考基因(5'-ACCACAGTCCATGCCATCAC-3' (SEQ ID NO: 192);5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO: 193))之δ-δ Ct方法測定。
對照係指包含SEQ ID NO: XX且不具有轉錄活化子之表現卡匣。
圖 24A說明GRN於經各表現卡匣轉染之HEK293細胞中之相對表現,呈現為相對於對照條件之倍數變化。此實驗顯示如本文所述之轉錄活化子導致自內源性GRN基因轉錄之RNA的上調。所有測試之轉錄活化子表現卡匣導致HEK293細胞中之GRN表現的增加。
亦進行ELISA實驗以評估包含GRN之各種轉錄活化子的表現卡匣增加細胞中之分泌顆粒蛋白前體(hPGRN)蛋白質的能力。293T細胞經
表 23中所述之某些表現卡匣轉染,且培養基在轉染之後48小時收集。在短暫旋轉以移除細胞碎片之後,使用來自R&D Systems之人類顆粒蛋白前體ELISA套組根據製造商之說明書對培養基進行ELISA分析。基於套組手冊中所述之標準曲線分析來計算顆粒蛋白前體之濃度。
圖 24B說明針對關於上清液中之人類顆粒蛋白前體(hPGRN)(ng/mL)測試之各表現卡匣獲得之三個獨立ELISA結果的平均值。所有測試之轉錄活化子表現卡匣導致相對於對照表現卡匣的細胞中之分泌hPRGN的增加。
實例 18 增加 HEK293T 細胞中之基因表現
HEK293T細胞在若干不同調節元件中之一者控制下經含有螢光素酶基因之質體DNA轉染,亦即無啟動子對照、SCP、CMV、可操作地連接於minCMV之SEQ ID NO: 178及CAG。來自各構築體之標準化螢光素酶值說明於
圖 25中。可操作地連接於minCMV啟動子之調節元件SEQ ID NO: XX比單獨的minCMV及單獨的SCP驅動更高量的螢光素酶表現。
此實驗指示SEQ ID NO: 178為在細胞中驅動高基因表現之RE。此類RE可添加至包含GRN之非天然存在之轉錄活化子的本文揭示之表現卡匣以提高轉錄活化子於細胞中之表現,其導致增加的內源性GRN基因之表現。在一些情況下,一或多個具有序列SEQ ID NO: 178之RE可操作地連接於轉錄活化子以增加細胞中之GRN表現。此類調節元件可在表現卡匣中之轉錄活化子的上游及/或下游添加至表現卡匣。
實例 19 使用顆粒蛋白前體特異性轉錄因子上調 HEK293 細胞中之 顆粒蛋白前體轉錄物及蛋白質水準
HEK293細胞係根據標準方法培養,且經6孔盤之每孔3 μg質體轉染(FugeneHD, Promega)。細胞經含有下
表 42中顯示之構築體的質體轉染。在轉染後48 h,自細胞分離RNA用於qPCR分析且自感染孔收集培養基以藉由ELISA分析來定量分泌PGRN水準。 對於qPCR分析,收集細胞且分離RNA (Qiagen RNeasy Mini套組),且用DNA酶處理。RNA (3 μg)使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析:(在98℃下30 s,40×[在98℃下10 s,在66℃下15 s,在72℃下15 s])。針對PGRN之引物(5'-ATGGTCAGTTCTGCCCTGTG-3' (SEQ ID NO: 287);5'-CGGTAAAGATGCAGGAGTGGC-3' (SEQ ID NO: 288))用於定量內源性PGRN轉錄物之含量,且相對PGRN表現量係藉由以GAPDH作為參考基因(5'-ACCACAGTCCATGCCATCAC'-3' (SEQ ID NO: 192);5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO: 193)之δ-δ Ct方法測定。資料呈現為相對於對照條件之倍數變化(參見
圖 26)。遞送工程化轉錄因子在內源性GRN轉錄物中誘導相對於EGFP對照條件的改變程度之上調。
對於ELISA分析,在病毒感染之後的指定日期收集細胞培養基,且使用人類PGRN ELISA套組(R&D systems, DPGRN0)進行ELISA分析。根據製造商之說明書進行ELISA程序。資料呈現為相對於對照條件之倍數變化(參見
圖 27)。此等資料確認藉由工程化轉錄因子上調GRN導致增加的PGRN蛋白質分泌。
表 42 .用於實例19之GRN構築體。
實例 20 使用顆粒蛋白前體特異性轉錄因子上調 GABA 神經元中之顆粒蛋白前體轉錄物及蛋白質水準
eTF之SEQ ID NO |
SEQ ID NO: 10 |
SEQ ID NO: 16 |
SEQ ID NO: 59 |
SEQ ID NO: 341 |
SEQ ID NO: 63 |
SEQ ID NO: 60 |
SEQ ID NO: 64 |
SEQ ID NO: 335 |
SEQ ID NO: 336 |
iCell GABA神經元(Cellular Dynamics)平鋪於6孔盤中(約1E6個細胞/孔)且根據製造商推薦之方案維持。在平鋪之後72 h,將在CBA啟動子控制下表現EGFP或活化子(SEQ ID NO: 342)之重組AAV (血清型AAV-DJ)以每孔大致2E11個基因組複本添加至培養基。在感染後一週,自細胞分離RNA用於qPCR分析且自感染孔收集培養基以藉由ELISA分析來定量分泌PGRN水準。
對於qPCR分析,自培養細胞分離RNA (Qiagen RNeasy Mini套組),且用DNA酶處理。回收之RNA使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析:(在98℃下30 s,40×[在98℃下10 s,在66℃下15 s,在72℃下15 s])。針對PGRN之引物(5'-ATGGTCAGTTCTGCCCTGTG-3' (SEQ ID NO: 287);5'-CGGTAAAGATGCAGGAGTGGC-3' (SEQ ID NO: 288))用於定量內源性PGRN轉錄物之含量,且相對PGRN表現量係藉由以GAPDH作為參考基因(5'-ACCACAGTCCATGCCATCAC'-3' (SEQ ID NO: 192);5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO: 193))之δ-δ Ct方法測定。資料呈現為相對於對照條件之倍數變化(參見
圖 28)。遞送SEQ ID NO: 342在內源性GRN轉錄物中產生相對於EGFP對照條件的穩定上調。
對於ELISA分析,在病毒感染之後的指定日期以每孔0.5E11個基因組複本(低劑量條件)或每孔2E11個基因組複本(高劑量條件)收集細胞培養基,且使用人類PGRN ELISA套組(R&D systems, DPGRN0)進行ELISA分析。根據製造商之說明書進行ELISA程序。資料呈現為(參見
圖 29)。此等資料確認藉由SEQ ID NO: 342上調GRN導致培養神經元中增加之PGRN蛋白質分泌。
實例 21 增加活體內血漿 GRN 蛋白質
為了測試GRN之轉錄活化子的活體內表現,將包含如上
表 23中所述之表現卡匣J或G之AAV9注射至小鼠中。純化AAV9病毒在VectorBioLabs產生,且在注射之前復原為200 μl總體積(用PBS)。6至9週齡C57BL6雄性動物在適應時段之後用於尾部靜脈注射。經由尾部靜脈出血進行生活中採血(in-life blood collection),且使用K2EDTA方法產生血漿樣品。根據製造商手冊用小鼠PGRN ELISA套組(Thermo Fisher Scientific)進行ELISA分析。
圖 30說明在注射之後一週,用不同AAV9構築體或對照治療之小鼠的關於血漿GRN之ELISA結果(以µg/mL計)。相比於PBS緩衝液對照,所有用包含GRN轉錄活化子之AAV9治療之小鼠顯示血漿GRN蛋白質水準之顯著增加。測試不同劑量之AAV9-J及AAV9-G:每隻小鼠1E11個基因組複本(GC)及5E11 GC。對於AAV9-G,增加每隻小鼠注射之基因組複本導致血漿GRN蛋白質相比於每隻小鼠1E11 GC之較低劑量的至少兩倍增加。
實例 22 在神經膠細胞中驅動高 GRN 表現
可使用螢光成像測定針對神經膠細胞,或尤其針對微神經膠細胞之選擇性。含有eGFP報導基因之AAV載體可操作地連接於對照啟動子(EF1α)或神經膠或微神經膠細胞選擇性RE。此類AAV載體與CRE依賴性tdTomato載體共注射至CRE小鼠中,其中Cre表現於神經膠細胞或尤其微神經膠細胞中。
以0.3 µL/min之速率向小鼠之額葉皮層或紋狀體中兩側地輸注1.5 µL AAV載體(5
12至1
13gc/ml),在注射後具有4 min休息時段。治療後,每日監測小鼠之健康及體重。對於組織收集,小鼠經由過劑量異氟醚安樂死且灌注4%三聚甲醛(PFA)。為了分析報導基因於神經膠細胞或微神經膠細胞中之選擇性表現,自額葉皮層或紋狀體獲得一片腦組織,切片,且使用標準免疫組織化學程序,用抗RFP多株兔抗體(Rockland Antibodies and Assay)及抗eGFP多株雞抗體(Aves Labs)染色以用於eGFP及tdTomato。使用螢光顯微法,相比於對照的eGFP報導基因之螢光與tdTomato螢光之間的強覆蓋指示神經膠細胞或微神經膠細胞中之選擇性表現。
此方法可用於鑑別靶向額葉皮層或其他CNS細胞,諸如浦金埃氏細胞、錐體細胞(例如貝茲細胞)、運動神經元及大腦皮質神經元中之高基因表現(受GRN缺乏影響)的調節元件。
一旦鑑別對神經膠細胞、微神經膠細胞或受GRN缺乏不利影響的CNS中之任何其他細胞類型具選擇性之調節元件,此類調節元件能夠可操作地連接於靶向本文所述之表現卡匣中之GRN基因的轉錄活化子以選擇性地增加靶細胞或組織類型之活體內GRN表現。舉例而言,對神經膠細胞或微神經膠細胞具選擇性之RE可以可操作方式連接於本文所述之表現卡匣的任何轉錄活化子以選擇性地增加活體內GRN。
實例 23 增加活體內血漿 GRN 蛋白質
為了測試GRN轉錄活化子的活體內表現,包含本文所述之表現卡匣中之任一者的AAV9。純化AAV9病毒可在VectorBioLabs產生且在注射之前復原為200 μl總體積(用PBS)。6至9週齡C57BL6雄性動物可在適應時段之後用於尾部靜脈注射。可經由尾部靜脈出血進行生活中採血,且可使用K2EDTA方法產生血漿樣品。可根據製造商手冊用小鼠GRN ELISA套組(Thermo Fisher Scientific)進行ELISA分析。相比於PBS緩衝液對照,預期所有用包含GRN轉錄活化子之AAV9治療之小鼠顯示血漿GRN蛋白質水準之顯著增加。可測試不同劑量之AAV9-eTF,諸如每隻小鼠1E11個基因組複本(GC)及5E11 GC。
實例 24 治療小鼠之 FTD 症狀
呈現FTD症狀,亦即GRN之單倍不足的異型接合GRN基因剔除小鼠為驗證本文所述之組合物及方法提供活體內動物模型。本文所述之AAV表現卡匣注射至小鼠中以藉由增加活體內GRN表現量來解救GRN單倍不足。一旦表現卡匣經由注射/輸注遞送至小鼠中,GRN單倍不足之解救可使用各種方法隨時間推移監測,諸如量測血液樣品中之分泌GRN的水準、使用PCR方法量測GRN之轉錄及/或量測治療小鼠相比於對照及/或未治療組之行為變化(例如運動協調、學習、與其他小鼠之社會化及其他認知功能)。
類似方法可用於阿茲海默氏症、帕金森氏病及動脈粥樣硬化之小鼠模型(例如在使用本文所述之表現卡匣治療後量測小鼠之動脈壁增厚的減輕)。
實例 25 報導系統篩選
HEK293細胞係根據標準方法培養,且經1.5 μg由處於四環素反應元件(TRE)緊密啟動子控制下之EGFP組成的報告子質體、及1.5 μg各測試活化子或空載體對照(pUC57)共轉染(FuGene HD, Promega)。在轉染後48 h,細胞使用落射螢光顯微鏡成像以用於GFP表現。收集細胞且分離RNA (Qiagen RNeasy Mini套組),且用DNA酶處理。RNA (3 μg)使用OligoDT引物(Superscript IV, Invitrogen)反轉錄。cDNA樣品係藉由使用Phusion聚合酶(New England Biolabs)及SYBR Green I之qPCR來分析:(在98℃下30 s,40×[在98℃下10 s,在65℃下15 s,在72℃下15 s])。針對EGFP之引物(5'- GCTACCCCGACCACATGAAG-3' (SEQ ID NO: 369);5'-TCTTGTAGTTGCCGTCGTCC-3' (SEQ ID NO: 370))用於定量報告子驅動之EGFP轉錄物之含量,且相對EGFP表現量係藉由以GAPDH作為參考基因(5'-ACCACAGTCCATGCCATCAC-3' (SEQ ID NO: 192);5'-TCCACCACCCTGTTGCTGTA-3' (SEQ ID NO: 193))之δ-δ Ct方法測定。
資料呈現為相對於對照條件之倍數變化。參見
圖 31A及
圖 31B,其說明SEQ ID NO: 2-4之eTF導致相比於空載體對照增加之EGFP表現。包含病毒VP64 TAD之SEQ ID NO: 51之eTF導致最高相對EGFP表現量。如
圖 32中所說明,包含SEQ ID NO: 12之eTF導致相比於對照SEQ ID NO: 187之至少5倍相對EGFP表現。
圖 33說明SEQ ID NO: 51-53之eTF導致相比於單獨的報告子或對照蛋白質(SEQ ID NO: 50)(無TAD)之超過10倍相對EGFP表現。
本發明之各種實施例係參考以下編號項來定義: 1. 一種核酸卡匣,其編碼包含三個或超過三個DNA結合域之非天然存在之DNA結合蛋白,其中非天然存在之DNA結合蛋白以至少1.5、2、3、4、5、6、7、8、9、10、20、25、50或100倍之因數增加或抑制內源性基因之表現,其中非天然存在之DNA結合蛋白與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%全局序列一致性。
2. 一種編碼非天然存在之DNA結合蛋白之核酸卡匣,該DNA結合蛋白包含複數個共同地結合至人類基因組中之至少21個鹼基之結合域且與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%全局序列一致性。
3. 如第1或2項之核酸卡匣,其中DNA結合蛋白結合至人類對應物不結合之標靶位點。
4. 如第1至3項中任一項之核酸卡匣,其中人類對應物為EGR1或EGR3。
5. 如第1至4項中任一項之核酸卡匣,其中結合域為鋅指。
6. 如第1至5項中任一項之核酸卡匣,其中結合域包含人類對應物之結合域的複製或三倍化複製。
7. 如第1至5項中任一項之核酸卡匣,其中結合域包含人類對應物之DNA結合域或鋅指之2、3、4、5、6、7、8或9個複本。
8. 如第1至7項中任一項之核酸卡匣,其中非天然存在之DNA結合蛋白包含至少6、7、8、9、10、11或12個鋅指。
9. 如第1至8項中任一項之核酸卡匣,其中內源性基因為SCN1A或GRN。
10. 如第1至9項中任一項之核酸卡匣,其中DNA結合蛋白識別基因組位置處之結合位點,使得位點處之結合允許DNA結合蛋白調節內源性基因之表現。
11. 如第1至10項中任一項之核酸卡匣,其中DNA結合蛋白識別位於內源性SCN1A或GRN基因座附近或該基因座處之結合位點。
12. 如第1至11項中任一項之核酸卡匣,其中DNA結合蛋白識別具有以下序列之結合位點:(i) SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336;(ii)其變異體;(iii)與(i)或(ii)中之任一者具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv)在其5 bp、10 bp、50 bp、100 bp、200 bp或500 bp內之基因組區域。
13. 如第1至11項中任一項之核酸卡匣,其中DNA結合蛋白識別具有以下序列之結合位點:(i) SEQ ID NO: 36或38;(ii)其變異體;(iii)與(i)或(ii)中之任一者具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列;或(iv)在其5 bp、10 bp、50 bp、100 bp、200 bp或500 bp內之基因組區域。
14. 如第1至12項中任一項之核酸卡匣,其中DNA結合蛋白具有以下序列:(i) SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列。
15. 如第1至11及13項中任一項之核酸卡匣,其中DNA結合蛋白具有以下序列:(i) SEQ ID NO: 6-10、13-16、57-61、63、64、67-73、74-77、268-282、295-299、337-350或365-366;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列。
16. 如第1至15項中任一項之核酸卡匣,其中DNA結合蛋白包含衍生自EGR1或EGR3之轉錄效應子域。
17. 如第1至15項中任一項之核酸卡匣,其中DNA結合蛋白包含衍生自CITED2或CITED4之轉錄效應子域。
18. 如第16至17項中任一項之核酸卡匣,其中效應子域安置於DNA結合蛋白之DNA結合域的C端。
19. 如第16至17項中任一項之核酸卡匣,其中效應子域安置於DNA結合蛋白之DNA結合域的N端。
20. 如第1至19項中任一項之核酸卡匣,其中DNA結合域共同地包含以下序列:(i) SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列。
21. 如第1至20項中任一項之核酸卡匣,其中DNA結合蛋白包含具有以下序列之效應子域:(i) SEQ ID NO: 95-100或114;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性之序列。
22. 如第1至21項中任一項之核酸卡匣,其中DNA結合域包含域中之鋅指之識別螺旋之位置-1、2、3或6處之至少一個胺基酸取代。
23. 如第1至22項中任一項之核酸卡匣,其中DNA結合蛋白識別18 nt或更長、21 nt或更長或24 nt或更長之標靶結合位點。
24. 如第1至23項中任一項之核酸卡匣,其中序列一致性係使用BLAST或ClustalW來量測。
25. 如第1至24項中任一項之核酸卡匣,其中DNA結合蛋白在病毒載體中。
26. 如第25項之核酸卡匣,其中病毒載體為AAV。
27. 如第26項之核酸卡匣,其中AAV為AAV9。
28. 如第1至27項中任一項之核酸卡匣,其中非天然存在之DNA結合蛋白與其人類對應物具有類似免疫原性,如藉由elispot分析所量測(例如其中類似係指在由天然存在之人類蛋白質產生之免疫反應之1%、2%、3%、4%、5%、6%、7%、8%、9%或10%內的免疫原性水準)。
29. 一種包含核酸卡匣之AAV載體,該核酸卡匣編碼非天然存在之DNA結合蛋白,該結合蛋白與人類蛋白質具有>90%序列一致性,或與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%全局序列一致性,且包含DNA結合域,其包含複數個共同地結合>9、>10、>11、>12、>13、>14、>15、>16、>17、>18、>19、>20、>21、>22、>23、>24、>25、>26、>27、>28、>29或>30個鹼基之結合基元。
30. 如第29項之AAV載體,其中非天然存在之DNA結合蛋白結合至人類蛋白質不結合之人類基因組中之標靶位點。
31. 如第29至30項中任一項之AAV載體,其中人類蛋白質為EGR1或EGR3。
32. 如第29至31項中任一項之AAV載體,其中DNA結合域包含至少6、7、8、9、10、11或12個鋅指。
33. 如第29至32項中任一項之AAV載體,其中DNA結合域包含人類蛋白質之DNA結合域的複製、三倍化複製或四倍化複製。
34. 如第29至33項中任一項之AAV載體,其中非天然存在之DNA結合蛋白識別SCN1A或GRN之基因組基因座(例如如表1中所述之基因組基因座附近或該基因座處,或內源性SCN1A或GRN之起始密碼子上游之標靶結合位點。
35. 如第29至34項中任一項之AAV載體,其中非天然存在之DNA結合蛋白調節內源性SCN1A或GRN之表現(例如增加其表現)。
36. 如第29至35項中任一項之AAV載體,其中非天然存在之DNA結合蛋白識別包含以下序列之結合位點:(i) SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336;(ii)其變異體;(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列;或(iv)在其5 bp、10 bp、50 bp、100 bp、200 bp或500 bp內之基因組區域。
37. 如第29至36項中任一項之AAV載體,其中非天然存在之DNA結合蛋白包含以下序列:(i) SEQ ID NO: 6-9、13-15、44-45、48-49、54-55、58-62、67-77、103、112、114、268-282、305-325、337-350、364、295-299、365-366;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
38. 如以上項中任一項之AAV載體,其中非天然存在之DNA結合蛋白包含以下序列:(i) SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
39. 如第29至38項中任一項之AAV載體,其中非天然存在之DNA結合蛋白包含EGR1或EGR3之轉錄效應子域。
40. 如第29至39項中任一項之AAV載體,其中非天然存在之DNA結合蛋白包含CITED2或CITED4之轉錄效應子域。
41. 如第39至40項中任一項之AAV載體,其中效應子域安置於DNA結合蛋白之DNA結合域的C端。
42. 如第39至41項中任一項之AAV載體,其中效應子域安置於DNA結合蛋白之DNA結合域的N端。
43. 如第29至42項中任一項之AAV載體,其中DNA結合域包含以下序列:(i) SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
44. 如第29至43項中任一項之AAV載體,其中DNA結合蛋白包含具有以下序列之效應子域:(i) SEQ ID NO: 95-100或114,(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
45. 如第29至44項中任一項之AAV載體,其中DNA結合域包含域中之鋅指之識別螺旋之位置-1、2、3或6處之至少一個胺基酸取代。
46. 如第29至45項中任一項之AAV載體,其中DNA結合蛋白識別18 nt或更長、21 nt或更長或24 nt或更長之標靶結合位點。
47. 如第29至46項中任一項之AAV載體,其中非天然存在之DNA結合蛋白與人類蛋白質具有類似免疫原性,如藉由elispot分析所量測(例如其中類似係指在由天然存在之人類蛋白質產生之免疫反應之1%、2%、3%、4%、5%、6%、7%、8%、9%或10%內的免疫原性水準)。
48. 如第29至47項中任一項之AAV載體,其中序列一致性係使用BLAST或ClustalW來量測。
49. 如第29至48項中任一項之AAV載體,其中AAV為AAV9。
50. 一種編碼非天然存在之DNA結合蛋白之載體,該DNA結合蛋白與人類蛋白質具有90%或更大序列一致性,或與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%全局序列一致性,其中DNA結合蛋白能夠調節內源性人類基因之表現。
51. 如第50項之載體,其中非天然存在之DNA結合蛋白包含識別長度為至少9 bp之標靶結合位點的DNA結合域。
52. 如第50至51項中任一項之載體,其中非天然存在之DNA結合蛋白包含識別長度為至少12 bp、15 bp、18 bp、21 bp或24 bp之標靶結合位點的DNA結合域。
53. 如第50至52項中任一項之載體,其中DNA結合蛋白結合至未藉由人類EGR1或EGR3識別之人類基因組中之標靶位點。
54. 如第50至53項中任一項之載體,其中內源性人類基因為SCN1A或GRN。
55. 如第50至54項中任一項之載體,其中DNA結合蛋白識別SCN1A或GRN之基因組基因座(例如如表1中所述之基因組基因座)附近或該基因座處,或內源性SCN1A或GRN之起始密碼子上游之標靶結合位點。
56. 如第50至55項中任一項之載體,其中DNA結合蛋白包含至少6、7、8、9、10、11或12個鋅指。
57. 如第50至56項中任一項之載體,其中DNA結合蛋白包含EGR1或EGR3之DNA結合域或一或多個鋅指之複製、三倍化複製或四倍化複製。
58. 如第50至57項中任一項之載體,其中DNA結合蛋白識別包含以下序列之結合位點:(i) SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336;(ii)其變異體;(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列;或(iv)在其5 bp、10 bp、50 bp、100 bp、200 bp或500 bp內之基因組區域。
59. 如第50至58項中任一項之載體,其中DNA結合蛋白包含以下序列:(i) SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
60. 如以上項中任一項之載體,其中DNA結合蛋白包含以下序列:(i) SEQ ID NO: 6-9、13-15、44-45、48-49、54-55、58-62、67-77、103、112、114、268-282、305-325、337-350、364、295-299或365-366;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
61. 如第50至60項中任一項之載體,其中序列一致性係指DNA結合蛋白之DNA結合域之局部序列一致性及EGR1或EGR3之局部序列一致性。
62. 如第61項之載體,其中DNA結合蛋白包含衍生自CITED2或CITED4之轉錄效應子域。
63. 如第50至62項中任一項之載體,其中序列一致性係指DNA結合蛋白相比於人類EGR1或EGR3之全局序列一致性。
64. 如第63項之載體,其中DNA結合蛋白包含衍生自EGR1或EGR3之轉錄效應子域。
65. 如第62或64項之載體,其中效應子域安置於DNA結合蛋白之DNA結合域的C端。
66. 如第62或64項之載體,其中效應子域安置於DNA結合蛋白之DNA結合域的N端。
67. 如第50至66項中任一項之載體,其中DNA結合蛋白包含具有以下序列之DNA結合域:(i) SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
68. 如第50至67項中任一項之載體,其中效應子域具有以下序列:(i) SEQ ID NO: 95-100或114;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
69. 如第50至68項中任一項之載體,其中鋅指包含鋅指之識別螺旋之位置-1、2、3或6處之至少一個胺基酸取代。
70. 如第50至69項中任一項之載體,其中DNA結合蛋白與人類EGR1或ERG3具有類似免疫原性,如藉由elispot分析所量測(例如其中類似係指在由天然存在之人類蛋白質產生之免疫反應之1%、2%、3%、4%、5%、6%、7%、8%、9%或10%內的水準)。
71. 如第50至70項中任一項之載體,其中序列一致性係使用BLAST或ClustalW來量測。
72. 如第70至72項中任一項之載體,其中載體為病毒載體。
73. 如第72項之載體,其中病毒載體為AAV。
74. 如第73項之載體,其中AAV為AAV9。
75. 一種編碼非天然存在之DNA結合蛋白之核酸卡匣,該DNA結合蛋白與天然存在之人類蛋白質具有90%或更大序列一致性,或與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%全局序列一致性,其中DNA結合蛋白能夠調節SCN1A之表現。
76. 如第75項之核酸卡匣,其中非天然存在之DNA結合蛋白選擇性地結合至具有SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336中之任一者之區域,或在其5 bp、10 bp、50 bp、100 bp、200 bp或500 bp內之區域。
77. 如第75至76項中任一項之核酸卡匣,其中非天然存在之DNA結合蛋白能夠相比於對照以至少1.5、2、3、4、5、6、7、8、9、10、15、20、50或100倍之因數增加SCN1A之表現。
78. 如第75至77項中任一項之核酸卡匣,其中非天然存在之DNA結合蛋白包含具有以下序列之DNA結合域:(i) SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
79. 如第75至78項中任一項之核酸卡匣,其中卡匣為病毒載體。
80. 如第75至79項中任一項之核酸卡匣,其中卡匣為AAV載體,諸如AAV9。
81. 一種編碼非天然DNA結合蛋白之核酸卡匣,該DNA結合蛋白與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%全局序列一致性,其中DNA結合蛋白能夠調節GRN之表現。
82. 如第81項之核酸卡匣,其中非天然存在之DNA結合蛋白選擇性地結合至具有SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336之區域,或在其5 bp、10 bp、50 bp、100 bp、200 bp或500 bp內之區域。
83. 如第81之82項中任一項之核酸卡匣,其中非天然存在之DNA結合蛋白能夠相比於對照以至少1.5、2、3、4、5、6、7、8、9、10、15、20、25、50或100倍之因數增加GRN之表現。
84. 如第81至83項中任一項之核酸卡匣,其中非天然存在之DNA結合蛋白包含具有以下序列之DNA結合域:(i) SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
85. 如第81至84項中任一項之核酸卡匣,其中DNA結合蛋白包含以下序列:(i) SEQ ID NO: 6-9、13-15、44-45、48-49、54-55、58-62、67-77、103、112、114、268-282、305-325、337-350、364、295-299、365-366;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
86. 如第81至85項中任一項之核酸卡匣,其中卡匣為病毒載體。
87. 如第81至86項中任一項之核酸卡匣,其中卡匣為AAV載體。
88. 一種編碼調節SCN1A之蛋白質的載體,其中蛋白質具有SEQ ID NO: 6-9、13、15、57、58、61-62、67-71、74-75、268-282、295-299、305-325或364-366之胺基酸序列。
89. 一種編碼調節SCN1A之蛋白質的載體,其中蛋白質包含具有SEQ ID NO: 22-25、29-31、84-85、88、90-92、131-135、371-372、376或391-409之序列的DNA結合域。
90. 如第88至89項中任一項之載體,其中蛋白質識別包含SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267之序列的標靶結合序列。
91. 一種編碼調節GRN之蛋白質的載體,其中蛋白質具有SEQ ID NO: 10、16、59-60、63-64、72-73、76-77、112或337-350之胺基酸序列。
92. 一種編碼調節GRN之蛋白質的載體,其中蛋白質包含具有SEQ ID NO: 26、32、86-89、93、165-171、112或377-390之序列的DNA結合域。
93. 如第91至92項中任一項之載體,其中蛋白質識別包含SEQ ID NO: 38、113或330-336之序列的標靶結合序列。
94. 如第91至93項中任一項之載體,其中DNA結合域融合至CITED2或CITED4之轉錄活化域。
95. 一種治療疾病或病況之方法,其包含使細胞或個體與包含第1至94項中任一項之組合物接觸。
96. 如第95項之方法,其中個體為動物、哺乳動物或人類。
97. 一種治療疾病或病況之方法,其包含投與包含核酸卡匣之基因療法,該核酸卡匣編碼包含DNA結合域之非天然存在之DNA結合蛋白,其中非天然存在之DNA結合蛋白以至少5倍之因數調節內源性基因之表現,且其中非天然存在之DNA結合蛋白與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有全局序列一致性。
98. 如第97項之方法,其中非天然存在之DNA結合蛋白在表現於細胞中或活體內時引發減小或極小的免疫反應。
99. 如第98項之方法,其中非天然存在之DNA結合蛋白引發與天然存在之人類蛋白質類似的免疫反應,其中類似係指在由天然存在之人類蛋白質(例如EGR1或EGR3)產生之免疫反應之1%、2%、3%、4%、5%、6%、7%、8%、9%或10%內的水準。
100. 如第92至99中任一項之方法,其中免疫反應係使用elispot分析來量測。
101. 如第97至100項中任一項之方法,其中疾病或病況為德拉韋症候群。
102. 如第97至100項中任一項之方法,其中疾病或病況為額顳葉型癡呆或癡呆。
103. 如第97至100項中任一項之方法,其中疾病或病況選自由以下組成之群:德拉韋症候群、帕金森氏病、阿茲海默氏症、GABA能機能減退、神經元機能亢進、癲癇症及癲癇。
104. 如第97至100項中任一項之方法,其中疾病或病況選自由以下組成之群:神經退化、神經發炎、額顳葉變性、額顳葉型癡呆、癡呆、帕金森氏病、阿茲海默氏症及動脈粥樣硬化。
105. 如第97至104項中任一項之方法,其中DNA結合蛋白具有SEQ ID NO: 6-9、13-15、44-45、48-49、54-55、58-62、67-77、103、112、114、268-282、305-325、337-350、364、295-299、365-366之胺基酸序列。
106. 如第97至105項中任一項之方法,其中DNA結合蛋白具有SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416之胺基酸序列。
107. 如以上項中任一項之方法,其中DNA結合蛋白包含具有SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416之序列的DNA結合域。
108. 如第97至107項中任一項之方法,其中DNA結合蛋白識別包含SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336之序列的標靶結合序列。
109. 如以上項中任一項之方法,其中內源性基因為SCN1A或GRN。
110. 如以上項中任一項之方法,其中基因療法為AAV。
111. 一種調節內源性基因之表現之方法,該方法包含投與編碼非天然存在之DNA結合蛋白之核酸卡匣,該DNA結合蛋白包含複數個共同地結合人類基因組中具有至少21個鹼基之目標結合位點的DNA結合域,且與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有全局序列一致性。
112. 如第111項之方法,其中天然存在之蛋白質為人類EGR1或EGR3。
113. 如第111至112項中任一項之方法,其中DNA結合蛋白包含CITED2或CITED4之域。
114. 一種治療疾病或病況之方法,該方法包含投與包含非天然存在之DNA結合蛋白之AAV載體,該DNA結合蛋白與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有全局序列一致性,且包含至少6、7、8、9、10、11或12個鋅指或DNA結合域。
115. 如第114項之方法,其中人類蛋白質為EGR1或EGR3。
116. 如第114至115項中任一項之方法,其中疾病或病況為CNS疾病或病況。
117. 如第116項之方法,其中疾病或病況為德拉韋症候群。
118. 如第116項之方法,其中疾病或病況為癡呆或額顳葉型癡呆。
119. 如第114至115項中任一項之方法,其中針對全局序列一致性,序列一致性係使用尼德曼-翁施算法來量測。
120. 如以上項中任一項之方法,其中針對局部序列一致性,序列一致性係使用史密斯-沃特曼算法來量測。
121. 一種治療德拉韋症候群之方法,其包含投與編碼非天然存在之DNA結合蛋白之載體,該DNA結合蛋白與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有全局序列一致性,其中DNA結合蛋白能夠活化或增加內源性SCN1A之表現。
122. 如第121項之方法,其中非天然存在之DNA結合蛋白選擇性地結合至具有SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336中之任一者之區域,或在其5 bp、10 bp、50 bp、100 bp、200 bp或500 bp內之區域。
123. 如第121至122項中任一項之方法,其中非天然存在之DNA結合蛋白能夠相比於對照以至少1.5、2、3、4、5、6、7、8、9、10、15、20、25、50或100倍之因數增加SCN1A之表現。
124. 如第121至123項中任一項之方法,其中非天然存在之DNA結合蛋白包含具有以下序列之DNA結合域:(i) SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
125. 如第121至124項中任一項之方法,其中載體為病毒載體。
126. 如第125項之方法,其中載體為AAV載體。
127. 一種治療額顳葉型癡呆或癡呆之方法,其包含投與編碼非天然存在之DNA結合蛋白之載體,該DNA結合蛋白與天然存在之人類蛋白質之對應域具有至少80%、81%、82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、94%、95%、96%、97%、98%或99%局部序列一致性(例如在兩個蛋白質之間的DNA結合域或轉錄效應子域內),或與天然存在之人類蛋白質(例如EGR1或EGR3)具有至少全局序列一致性,其中DNA結合蛋白能夠活化或增加內源性GRN或其同功異型物之表現。
128. 如第127項之方法,其中非天然存在之DNA結合蛋白選擇性地結合至具有SEQ ID NO: 38、113或330-336之區域,或在其5 bp、10 bp、50 bp、100 bp、200 bp或500 bp內之區域。
129. 如第127至128項中任一項之方法,其中非天然存在之DNA結合蛋白能夠相比於對照以至少1.5、2、3、4、5、6、7、8、9、10、15、20、25、50或100倍之因數增加GRN之表現。
130. 如第127至129項中任一項之方法,其中非天然存在之DNA結合蛋白包含具有以下序列之DNA結合域:(i) SEQ ID NO: 26、32、86-89、93、165-171、165-171或377-390;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
131. 如第127至130項中任一項之方法,其中DNA結合蛋白包含以下序列:(i) SEQ ID NO: 10、16、59-60、63-64、72-73、76、77、112或337-350;(ii)其變異體或功能片段;或(iii)與(i)或(ii)中之任一者具有至少90%序列一致性(或至少91%、92%、93%、94%、95%、96%、97%、98%或99%序列一致性)之序列。
132. 如第127至131項中任一項之方法,其中載體為病毒載體。
133. 如第133項之方法,其中載體為AAV載體。
本文提供包含非天然存在之轉錄調節子之表現卡匣,諸如增加SCN1A基因之表現之表現卡匣,及使用其治療與SCN1A基因相關之病況的方法。本文亦提供調節神經蛋白質,諸如SCN1A之表現的非天然存在之DNA結合蛋白。
本發明之各種實施例係參考以下編號項來定義: 1. 一種表現卡匣,其包含增加SCN1A基因之表現的非天然存在之轉錄調節子。
2. 如第1項之表現卡匣,其中非天然存在之轉錄調節子結合選自由以下組成之群的基因組區域:SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267,或在其至少200 bp內之區域。
3. 如第1至2項之表現卡匣,其中非天然存在之轉錄調節子結合選自由以下組成之群的基因組區域:SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267,或在其至少100 bp內之區域。
4. 如第1至2項之表現卡匣,其中非天然存在之轉錄調節子結合選自由以下組成之群的基因組區域:SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267,或在其至少50 bp內之區域。
5. 如第1至2項之表現卡匣,其中非天然存在之轉錄調節子結合選自由以下組成之群的基因組區域:SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267,或在其至少10 bp內之區域。
6. 如第1至2項之表現卡匣,其中非天然存在之轉錄調節子結合對應於hg19之區域的基因組區域,其匹配選自由以下組成之群的序列:SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267。
7. 如以上項中任一項之表現卡匣,其中表現卡匣為病毒載體之一部分。
8. 如第6項之表現卡匣,其中病毒載體為AAV病毒。
9. 如第7項之表現卡匣,其中AAV病毒為AAV9病毒或scAAV9病毒。
10. 如以上項中任一項之表現卡匣,其中轉錄調節子包含DNA結合域及轉錄活化域。
11. 如以上項中任一項之表現卡匣,其中轉錄活化域包含選自由以下組成之清單之至少一種蛋白質的一部分:VPR、VP64、VP16、VP128及p300。
12. 如以上項中任一項之表現卡匣,其中轉錄活化域包含95-100或114,或與其具有至少80%序列相似性之域。
13. 如以上項中任一項之表現卡匣,其中DNA結合域為鋅指域。
14. 如以上項中任一項之表現卡匣,其中DNA結合域為Cas蛋白。
15. 如以上項中任一項之表現卡匣,其中表現卡匣進一步包含gRNA。
16. 如以上項中任一項之表現卡匣,其中gRNA包含選自由以下組成之群的序列:SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336,或與其具有至少80%序列相似性之序列。
17. 如第16項之表現卡匣,其中gRNA包含選自由以下組成之群的序列:SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336,或與其具有至少90%序列相似性、與其具有至少95%序列相似性或與其具有至少99%序列相似性之序列。
18. 如以上項中任一項之表現卡匣,其中Cas蛋白為核酸酶不活化Cas蛋白。
19. 如第18項之表現卡匣,其中核酸酶不活化Cas蛋白為核酸酶不活化Cas9。
20. 如第19項之表現卡匣,其中核酸酶不活化Cas蛋白為核酸酶不活化Cas3。
21. 如請求項中任一項之表現卡匣,其中DNA結合域為TAL效應DNA結合域。
22. 如以上項中任一項之表現卡匣,其中表現卡匣進一步包含調節元件,其在GABA能神經元中以比在其他細胞類型中更高之水準驅動非天然存在之轉錄調節子之表現。
23. 如以上項中任一項之表現卡匣,其中表現卡匣進一步包含調節元件,其小於100 bp且驅動非天然存在之轉錄調節子之高表現。
24. 如以上項中任一項之表現卡匣,其中表現卡匣進一步包含至少一個選自由以下組成之群的調節元件:SEQ ID NO: 178-179、182-185或417,或與其具有至少80%、至少90%、至少95%或至少99%序列一致性之序列。
25. 如以上項中任一項之表現卡匣,其中非天然存在之轉錄調節子選自由以下組成之群:SEQ ID NO: 6-9、13-15、44-45、48-49、54-55、58-62、67-77、103、112、114、268-282、305-325、337-350、364、295-299、365-366,或與其具有至少80%、至少90%、至少95%或至少99%序列一致性。
26. 如以上項中任一項之表現卡匣,其中非天然存在之轉錄調節子選自由以下組成之群:SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416。
27. 一種非天然存在之DNA結合蛋白,其結合至少一個選自由以下組成之群的基因組位置:SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336,或在其200 bp內、100 bp內或50 bp內之基因組位置。
28. 如任何以上項之非天然存在之DNA結合蛋白,其中非天然存在之DNA結合蛋白結合至少一個選自由以下組成之群的基因組位置:SEQ ID NO: 35-38、105-111、113、136、195-211、224-238、240-267或330-336。
29. 如任何以上項之非天然存在之DNA結合蛋白,其進一步包含轉錄調節域。
30. 如第29項之非天然存在之DNA結合蛋白,其中轉錄調節域為轉錄活化域。
31. 如第29至30項之非天然存在之DNA結合蛋白,其中轉錄活化域為轉錄因子之轉錄活化域。
32. 如以上項之非天然存在之DNA結合蛋白,其中轉錄活化域包含鋅指轉錄因子之轉錄活化域。
33. 如任何以上項之非天然存在之DNA結合蛋白,其中轉錄活化域包含選自由以下組成之清單之至少一種蛋白質的一部分:VPR、VP64、VP16及VP128,或與其同源之蛋白質。
34. 如任何以上項之非天然存在之DNA結合蛋白,其中轉錄活化域包含SEQ ID NO: 95-100或114中之任一者,或與其具有至少80%序列相似性之域。
35. 如任何以上項之非天然存在之DNA結合蛋白,其中轉錄活化域包含SEQ ID NO: 95-100或114中之任一者,或與其具有至少90%、至少95%或至少99%序列相似性之域。
36. 如任何以上項之非天然存在之DNA結合蛋白,其中轉錄調節域包含轉錄共活化蛋白質,或轉錄共活化域之域。
37. 如第36項之非天然存在之DNA結合蛋白,其中轉錄共活化域包含p300之全部或一部分。
38. 如任何以上項之非天然存在之DNA結合蛋白,其中DNA結合蛋白包含鋅指域。
39. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含四個鋅指。
40. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含五個鋅指。
41. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含六個鋅指。
42. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含七個鋅指。
43. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含八個鋅指。
44. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含九個鋅指。
45. 如任何以上項之非天然存在之DNA結合蛋白,其中DNA結合蛋白包含Cas蛋白。
46. 如第45項之非天然存在之DNA結合蛋白,其中Cas蛋白為核酸酶不活化Cas蛋白。
47. 如第46項之非天然存在之DNA結合蛋白,其中核酸酶不活化Cas蛋白為核酸酶不活化Cas9。
48. 如第46項之非天然存在之DNA結合蛋白,其中核酸酶不活化Cas蛋白為核酸酶不活化Cas3。
49. 如任何以上項之非天然存在之DNA結合蛋白,其中DNA結合蛋白包含TAL效應DNA結合域。
50. 如任何以上項之非天然存在之DNA結合蛋白,其中非天然存在之DNA結合蛋白選自由以下組成之群:SEQ ID NO: 22-26、29-32、84-93、112、131-135、165-171、371-372、376-409或412-416,或與其具有至少90%、至少95%或至少99%序列一致性。
51. 如任何以上項之非天然存在之DNA結合蛋白,其中非天然存在之DNA結合蛋白在轉染至細胞中時調節SCN1A之表現。
52. 一種調節SCN1A於細胞中之表現的方法,其藉由投與非天然存在之轉錄調節子,該轉錄調節子結合至少一個選自由以下組成之群的基因組位置:SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267,或在其200 bp內、100 bp內或20 bp內之基因組位置。
53. 如第52項之方法,其中非天然存在之轉錄調節子結合至少一個選自由以下組成之群的基因組位置:SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267。
54. 如第52至53項之方法,其中非天然存在之轉錄調節子結合選自由以下組成之群的序列:SEQ ID NO: 35-37、101、105-111、136、195-211、224-238或240-267。
55. 一種調節SCN1A於細胞中之表現的方法,其藉由投與編碼非天然存在之轉錄調節子之表現卡匣。
56. 如第55項之方法,其中表現卡匣為病毒載體的一部分。
57. 如第56項之方法,其中病毒載體為AAV病毒。
58. 如第57項之方法,其中AAV病毒為AAV9病毒或scAAV9病毒。
59. 如任何以上項之方法,其中細胞為小白蛋白(PV)細胞。
60. 如以上項中任一項之方法,其中細胞在生物體內。
61. 如第60項之方法,其中生物體為哺乳動物。
62. 如第60項之方法,其中生物體為人類。
63. 如第60項之方法,其中調節SCN1A之表現治療疾病或病症。
64. 如第60項之方法,其中病症為中樞神經系統病症。
65. 如第60項之方法,其中病症為帕金森氏病。
66. 如第60項之方法,其中病症為德拉韋症候群。
67. 如第60項之方法,其中病症為阿茲海默氏症。
68. 如第60項之方法,其中中樞神經系統病症之症狀為GABA能機能減退。
69. 如任何以上項之方法,其中治療中樞神經系統病症包含增強PV細胞功能。
70. 如任何以上項之方法,其中中樞神經系統病症之症狀為神經元機能亢進。
71. 如任何以上項之方法,其中治療中樞神經系統病症包含降低神經元機能亢進。
72. 如任何以上項之方法,其中中樞神經系統病症之症狀為癲癇。
73. 如任何以上項之方法,其中治療中樞神經系統病症包含降低癲癇之頻率。
74. 如任何以上項之方法,其中治療中樞神經系統病症包含降低癲癇之嚴重度。
75. 如任何以上項之方法,其中轉錄調節子包含DNA結合域及轉錄活化域。
76. 如任何以上項之方法,其中轉錄活化域包含轉錄因子之轉錄活化域。
77. 如任何以上項之方法,其中轉錄活化域包含鋅指轉錄因子之轉錄活化域。
78. 如任何以上項之方法,其中轉錄活化域包含選自由以下組成之清單之至少一種蛋白質的一部分:VPR、VP64、VP16及VP128。
79. 如任何以上項之方法,其中轉錄活化域包含95-100或114,或與其具有至少80%序列相似性之域。
80. 如任何以上項之方法,其中轉錄活化域包含轉錄共活化蛋白質,或轉錄共活化域之域。
81. 如任何以上項之方法,其中轉錄活化域包含p300。
82. 如任何以上項之方法,其中DNA結合域為鋅指域。
83. 如任何以上項之方法,其中DNA結合域為Cas蛋白。
84. 如任何以上項之方法,其中表現卡匣進一步包含gRNA。
85. 如任何以上項之方法,其中gRNA包含選自由以下組成之群的序列:SEQ ID NO: 105-111或113,或與其具有至少80%序列一致性之序列。
86. 如任何以上項之方法,其中Cas蛋白為核酸酶不活化Cas蛋白。
87. 如任何以上項之方法,其中核酸酶不活化Cas蛋白為核酸酶不活化Cas9。
88. 如任何以上項之方法,其中核酸酶不活化Cas蛋白為核酸酶不活化Cas3。
89. 如任何以上項之方法,其中DNA結合域為TAL效應DNA結合域。
90. 如任何以上項之方法,其中表現卡匣進一步包含對小白蛋白細胞具有特異性之調節元件。
91. 如任何以上項之方法,其中表現卡匣進一步包含小於100 bp且驅動高表現之調節元件。
92. 如任何以上項之方法,其中表現卡匣進一步包含至少一個選自由以下組成之群的調節元件:SEQ ID NO: 178-179、182-185或417,或與其具有至少80%序列一致性之序列。
93. 如任何以上項之方法,其中調節SCN1A之表現包含增加SCN1A基因或Nav1.1蛋白質之表現。
94. 如任何以上項之方法,其中增加SCN1A基因或Nav1.1蛋白質之表現特異性發生於小白蛋白細胞中。
95. 如任何以上項之方法,其中增加SCN1A基因或Nav1.1蛋白質之表現特異性發生於小白蛋白神經元中。
96. 如以上項中任一項之方法,其中非天然存在之轉錄調節子選自由SEQ ID NO: 95-100或114組成之群,或與其具有至少80%、至少90%、至少95%或至少99%序列一致性。
本文提供包含增加顆粒蛋白前體(GRN)或其功能片段或變異體之表現之非天然存在之轉錄調節子的表現卡匣,及使用此類組合物治療與GRN基因相關之病況或疾病的方法。本文亦提供調節GRN於細胞中之表現的非天然存在之DNA結合蛋白。
本發明之各種實施例係參考以下編號項來定義: 1. 一種表現卡匣,其包含增加GRN基因之表現的非天然存在之轉錄調節子。
2. 如第1項之表現卡匣,其中非天然存在之轉錄調節子結合選自由以下組成之群的基因組區域:SEQ ID NO: 38、113或330-336,或在其至少200 bp內、至少100 bp內、至少50 bp內或至少10 bp內之區域。
3. 如任何以上項之表現卡匣,其中非天然存在之轉錄調節子結合對應於hg19之區域的基因組區域,其匹配選自由以下組成之群的序列:SEQ ID NO: 38、113或330-336。
4. 如任何以上項之表現卡匣,其中表現卡匣為病毒載體之一部分。
5. 如第4項之表現卡匣,其中病毒載體為AAV病毒。
6. 如第5項之表現卡匣,其中AAV病毒為AAV9病毒或scAAV9病毒。
7. 如任何以上項之表現卡匣,其中轉錄調節子包含DNA結合域及轉錄活化域。
8. 如任何以上項之表現卡匣,其中轉錄活化域包含選自由以下組成之清單之至少一種蛋白質的一部分:VPR、VP64、VP16、VP128、p65及p300。
9. 如任何以上項之表現卡匣,其中轉錄活化域包含SEQ ID NO: 95-100或114,或與其具有至少80%序列相似性之域。
10. 如任何以上項之表現卡匣,其中DNA結合域為鋅指域。
11. 如任何以上項之表現卡匣,其中DNA結合域為Cas蛋白。
12. 如任何以上項之表現卡匣,其中表現卡匣進一步包含gRNA。
13. 如任何以上項之表現卡匣,其中gRNA包含選自由以下組成之群的序列:SEQ ID NO: 113,或與其具有至少80%、至少90%、至少95%或至少99%序列相似性之序列。
14. 如任何以上項之表現卡匣,其中Cas蛋白為核酸酶不活化Cas蛋白(dCas)。
15. 如任何以上項之表現卡匣,其中核酸酶不活化Cas蛋白為核酸酶不活化Cas9 (dCas9)或dSaCas9。
16. 如任何以上項之表現卡匣,其中DNA結合域為TAL效應DNA結合域。
17. 如任何以上項之表現卡匣,其中表現卡匣進一步包含調節元件,其在選自由以下組成之群的細胞中以比在其他細胞類型中更高之水準驅動非天然存在之轉錄調節子之表現:中樞神經系統細胞、額葉皮層細胞、神經膠細胞、微神經膠細胞及紋狀體細胞。
18. 如任何以上項之表現卡匣,其中表現卡匣進一步包含調節元件,其小於100 bp或小於50 bp且驅動非天然存在之轉錄調節子之高表現。
19. 如任何以上項之表現卡匣,其中表現卡匣進一步包含根據SEQ ID NO: 178-179、182-185或417之序列,或與其具有至少80%、至少90%、至少95%或至少99%序列一致性之序列。
20. 如任何以上項之表現卡匣,其中非天然存在之轉錄調節子選自由以下組成之群:SEQ ID NO: 10、16、59-60、63-64、72-73、76-77、112或337-335,或與其具有至少80%、至少90%、至少95%或至少99%序列一致性。
21. 一種非天然存在之DNA結合蛋白,其結合至少一個選自由以下組成之群的基因組位置:SEQ ID NO: 38、113或330-336,或在其200 bp內、100 bp內、或50 bp內、或10 bp內之基因組位置。
22. 如任何以上項之非天然存在之DNA結合蛋白,其中非天然存在之DNA結合蛋白結合至少一個選自由以下組成之群的基因組位置:SEQ ID NO: 38、113或330-336。
23. 如任何以上項之非天然存在之DNA結合蛋白,其進一步包含轉錄調節域。
24. 如任何以上項之非天然存在之DNA結合蛋白,其中轉錄調節域為轉錄活化域。
25. 如任何以上項之非天然存在之DNA結合蛋白,其中轉錄活化域為轉錄因子之轉錄活化域。
26. 如任何以上項之非天然存在之DNA結合蛋白,其中轉錄活化域包含鋅指轉錄因子之轉錄活化域。
27. 如任何以上項之非天然存在之DNA結合蛋白,其中轉錄活化域包含至少一種選自由以下組成之清單之蛋白質的一部分:VPR、VP64、VP16及VP128,或與其同源之蛋白質。
28. 如任何以上項之非天然存在之DNA結合蛋白,其中轉錄活化域包含SEQ ID NO: 95-100或114,或與其具有至少80%、至少90%、至少95%或至少99%序列相似性之域。
29. 如任何以上項之非天然存在之DNA結合蛋白,其中轉錄調節域包含轉錄共活化蛋白質,或轉錄共活化域之域。
30. 如第29項之非天然存在之DNA結合蛋白,其中轉錄共活化域包含p300之全部或一部分。
31. 如任何以上項之非天然存在之DNA結合蛋白,其中DNA結合蛋白包含鋅指域。
32. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含四個鋅指。
33. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含五個鋅指。
34. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含六個鋅指。
35. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含七個鋅指。
36. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含八個鋅指。
37. 如任何以上項之非天然存在之DNA結合蛋白,其中鋅指域包含九個鋅指。
38. 如任何以上項之非天然存在之DNA結合蛋白,其中DNA結合蛋白包含Cas蛋白。
39. 如任何以上項之非天然存在之DNA結合蛋白,其中Cas蛋白為核酸酶不活化Cas蛋白。
40. 如任何以上項之非天然存在之DNA結合蛋白,其中核酸酶不活化Cas蛋白為核酸酶不活化Cas9。
41. 如任何以上項之非天然存在之DNA結合蛋白,其中DNA結合蛋白包含TAL效應DNA結合域。
42. 如任何以上項之非天然存在之DNA結合蛋白,其中非天然存在之DNA結合蛋白選自包含SEQ ID NO: 26、32、86-89、93、165-171、112或377-390之群,或與其具有至少90%、至少95%或至少99%序列一致性。
43. 如任何以上項之非天然存在之DNA結合蛋白,其中非天然存在之DNA結合蛋白在轉染至細胞中時調節GRN之表現。
44. 一種調節GRN於細胞中之表現的方法,其藉由投與非天然存在之轉錄調節子,該轉錄調節子結合至少一個選自由以下組成之群的基因組位置:SEQ ID NO: 38、113或330-336,或在其200 bp內、100 bp內或20 bp內之基因組位置。
45. 如第44項之方法,其中非天然存在之轉錄調節子結合由以下組成之序列:SEQ ID NO: 38、113或330-336。
46. 一種調節GRN於細胞中之表現的方法,其藉由投與編碼非天然存在之轉錄調節子之表現卡匣。
47. 如第46項之方法,其中表現卡匣為病毒載體的一部分。
48. 如第47項之方法,其中病毒載體為AAV病毒。
49. 如第48項之方法,其中AAV病毒為AAV9病毒或scAAV9病毒。
50. 如任何以上項之方法,其中細胞選自由以下組成之群:中樞神經系統細胞、額葉皮層細胞、神經膠細胞、微神經膠細胞及紋狀體細胞。
51. 如以上項中任一項之方法,其中細胞在生物體內。
52. 如第51項之方法,其中生物體為哺乳動物。
53. 如第52項之方法,其中生物體為人類。
54. 如任何以上項之方法,其中調節GRN之表現治療疾病或病症。
55. 如任何以上項之方法,其中病症為中樞神經系統病症。
56. 如任何以上項之方法,其中病症為額顳葉型變性(FTD)。
57. 如任何以上項之方法,其中病症為帕金森氏病。
58. 如任何以上項之方法,其中病症為阿茲海默氏症。
59. 如任何以上項之方法,其中病症為動脈粥樣硬化。
60. 如任何以上項之方法,其中中樞神經系統病症之症狀為路易體之存在。
61. 如任何以上項之方法,其中中樞神經系統病症之症狀為顆粒蛋白前體(GRN)單倍不足。
62. 如任何以上項之方法,其中中樞神經系統病症之症狀為社交缺陷。
63. 如任何以上項之方法,其中中樞神經系統病症之症狀為溶酶體異常。
64. 如任何以上項之方法,其中中樞神經系統病症之症狀為記憶喪失。
65. 如任何以上項之方法,其中中樞神經系統病症之症狀為運動協調喪失。
66. 如任何以上項之方法,其中中樞神經系統病症之症狀為肌震顫。
67. 如任何以上項之方法,其中治療中樞神經系統病症包含降低肌震顫之頻率。
68. 如任何以上項之方法,其中治療中樞神經系統病症包含降低肌震顫之嚴重度。
69. 如任何以上項之方法,其中轉錄調節子包含DNA結合域及轉錄活化域。
70. 如任何以上項之方法,其中轉錄活化域包含轉錄因子之轉錄活化域。
71. 如任何以上項之方法,其中轉錄活化域包含鋅指轉錄因子之轉錄活化域。
72. 如任何以上項之方法,其中轉錄活化域包含選自由以下組成之清單之至少一種蛋白質的一部分:VPR、VP64、VP16及VP128。
73. 如任何以上項之方法,其中轉錄活化域包含SEQ ID NO: 95-100或114,或與其具有至少80%序列相似性之域。
74. 如任何以上項之方法,其中轉錄活化域包含轉錄共活化蛋白質,或轉錄共活化域之域。
75. 如任何以上項之方法,其中轉錄活化域包含p300。
76. 如任何以上項之方法,其中DNA結合域為鋅指域。
77. 如任何以上項之方法,其中DNA結合域為Cas蛋白。
78. 如任何以上項之方法,其中表現卡匣進一步包含gRNA。
79. 如任何以上項之方法,其中gRNA包含選自由以下組成之群的序列:SEQ ID NO: 113,或與其具有至少80%序列一致性之序列。
80. 如任何以上項之方法,其中Cas蛋白為核酸酶不活化Cas蛋白。
81. 如任何以上項之方法,其中核酸酶不活化Cas蛋白為核酸酶不活化Cas9。
82. 如任何以上項之方法,其中DNA結合域為TAL效應DNA結合域。
83. 如任何以上項之方法,其中表現卡匣進一步包含非細胞特異性調節元件。
84. 如任何以上項之方法,其中表現卡匣進一步包含小於100 bp且驅動高表現之調節元件。
85. 如任何以上項之方法,其中表現卡匣進一步包含調節元件,其包含根據SEQ ID NO: 178-179、182-185或417之序列,或與其具有至少80%序列一致性之序列。
86. 如任何以上項之方法,其中調節GRN之表現包含增加GRN基因或顆粒蛋白前體蛋白質之表現。
87. 如任何以上項之方法,其中增加GRN基因或顆粒蛋白前體蛋白質之表現發生於複數個細胞類型中。
88. 如任何以上項之方法,其中相比於其他細胞類型,增加GRN基因或顆粒蛋白前體蛋白質之表現特異性發生於選自由以下組成之群的細胞中:中樞神經系統細胞、額葉皮層細胞、神經膠細胞、微神經膠細胞及紋狀體細胞。
89. 如任何以上項之方法,其中非天然存在之轉錄調節子選自由以下組成之群:SEQ ID NO: 10、16、59-60、72-72、76-77、112或337-350,或與其具有至少80%、至少90%、至少95%或至少99%序列一致性。
本發明之新穎特徵在隨附申請專利範圍中細緻闡述。將參考闡述利用本發明原理之說明性案例及隨附圖式的以下詳細描述來獲得對本發明之特徵及優點的更佳理解,在隨附圖式中:
圖 1說明關於標準化螢光素酶活性量測之不同調節元件對螢光素酶於293T細胞中之表現之效應。舉例而言,與最小CMV (minCMV)啟動子組合以相比於由單獨的minCMV啟動子驅動之表現高約1.4倍,及相比於由SCP啟動子驅動之表現高約60倍之水準驅動螢光素酶表現。在相同實驗中,連接至minCMV啟動子之SEQ ID NO: 178以相比於單獨的minCMV啟動子高約3.5倍,及相比於SCP啟動子高約140倍之水準驅動螢光素酶表現。
圖 2說明各調節元件之尺寸標準化活性(藉由如
圖 1中所示之標準化螢光素酶活性除以鹼基對中之調節元件的長度來計算)。
圖 3說明在GABA能選擇性調節元件(RE),諸如對小白蛋白(PV)細胞具選擇性之RE控制下的eGFP之選擇性表現。含有eGFP (在EF1α啟動子或GABA能/PV選擇性RE,諸如包括SEQ ID NO: 185之SEQ ID NO: 183或SEQ ID NO: 184控制下)的AAVDJ載體注射至在GABA能/PV細胞中表現tdTomato (紅色螢光蛋白(RFP))之小鼠中。頂部列影像顯示自含有EF1α啟動子(SEQ ID NO: 186)、GABA能/PV選擇性RE SEQ ID NO: 183或SEQ ID NO: 184之構築體表現之eGFP的圖案。下部列影像顯示GABA能/PV神經元,其為GAD2陽性的。表現eGFP及tdTomato兩者之細胞可藉由用下部影像覆蓋頂部列影像,或藉由鑑別來自頂部列及下部列影像中之相同位置的螢光來鑑定。表現eGFP及tdTomato之細胞之實例由箭頭指示。
圖 4說明
圖 3中之藉由GABA能/PV神經元之eGFP表現的效率定量(如例如量測為亦表現eGFP之tdTomato表現細胞的百分比)。
圖 5說明
圖 3中之藉由GABA能/PV神經元之eGFP表現的特異性定量(如例如量測為亦表現tdTomato (或RFP+)之eGFP表現細胞的百分比)。
圖 6說明使用結合至染色體2上之不同區(參看GRCh38.p12)的工程化轉錄因子上調內源性SCN1A。資料呈現為相對於對照(EGFP-KASH)條件之SCN1A表現的倍數變化。
圖 7說明呈現為相對於eGFP對照之倍數變化的SCN1A之相對表現(Log
10)。
圖 8說明呈現為相對於對照之倍數變化的內源性SCN1A、TTC21B、SCN9A、SNCA、GRN、UTRN及TTN轉錄物之相對表現。
圖 9A說明本文揭示之eTF之一個實施例,其中天然存在之人類轉錄因子(TF)之DNA結合域(DBD)已經修飾、再程式化或工程化以識別所關注之基因標靶處或附近之標靶結合位點。上圖說明與標靶位點不具有結合親和力之天然存在之轉錄因子(由黑色條表示),該標靶位點與所關注之內源性基因或基因標靶相關。下圖說明eTF,其中DBD包含多個已經修飾、工程化或再程式化以結合至所關注之基因之標靶位點的鋅指(由圓柱表示),例如藉由複製或三倍化複製天然存在之DBD之鋅指及/或在鋅指中進行胺基酸取代。
圖 9B說明
本文揭示之eTF之另一實施例,或雜交eTF,包含衍生自天然存在之人類TF之DBD,該DBD融合至人類輔調節因子蛋白質或轉錄輔因子之轉活化域(TAD),例如Cbp/p300相互作用轉活化蛋白質(諸如CITED2或CITED4)之TAD。上圖說明衍生自人類蛋白質且經工程化以特異性地結合於基因組中之所需標靶位點(黑色條)的DBD。下圖說明融合至TAD,例如CITED2之TAD以形成雜交eTF的DBD。此類雜交eTF藉由結合至基因組中之標靶位點序列及經由eTF中之TAD調節(例如活化)基因標靶之轉錄來驅動靶基因之表現。
圖 10說明各種轉錄調節蛋白質與天然存在之人類蛋白質之間的百分比保守(或序列一致性)及其在鹼基對中之尺寸(bp)。在各種實施例中,本發明之eTF可由1,000-1,800 bp之核酸序列編碼且包含與天然存在之人類蛋白質之>90%全局序列一致性(亦即,經eTF之全長胺基酸序列的序列一致性),其可在例如經由基因療法遞送至細胞中或活體內時降低免疫反應或免疫原性。相比之下,基於dCas9之轉錄因子(包含去活化Cas9 (dCas9)域)與內源性人類蛋白質不具有全局序列一致性且尺寸較大。以習知方式構築之鋅指蛋白(ZFP)或電腦模擬設計之包含鋅指之人工或合成DNA結合蛋白可尺寸較小,但與內源性人類蛋白質具有較低序列一致性(約55%)。
圖 11說明調節內源性基因之各種方法。在頂圖中,轉錄調節蛋白包含DBD,其包含多個合成鋅指(ZF),諸如電腦模擬設計之ZF,融合至VP64之轉錄活化域(TAD)。在第二圖中,野生型TF為天然存在的,但不結合至所關注之基因之標靶位點。在第三圖中,eTF包含天然存在之TF,其DBD已經修飾或再程式化以結合至所關注之基因處或附近之18 nt標靶位點,例如其中野生型TF之DBD經合成鋅指置換。在第四圖中,eTF衍生自野生型TF,其中DBD經工程化以識別所關注之基因處或附近之9 nt標靶結合位點。在底圖中,eTF衍生自野生型TF,其中野生型TF之DBD已經複製及再程式化(例如經由ZF中之胺基酸取代)以形成識別所關注之基因處或附近之18 nt標靶結合的6-鋅指DBD。可使用報導活化分析來分析eTF之此等各種實施例,其中基因標靶為報導基因(例如EGFP)。頂圖、第三圖、第四圖及第五圖中之eTF導致報導基因之表現。
圖 12A說明
SCN1A活化分析之示意圖,其中SCN1A於HEK293細胞中之表現指示結合至SCN1A特異性標靶結合位點及藉由eTF活化SCN1A基因表現。上圖說明經工程化以識別EGFP報導基因之TRE結合位點的eTF,其未能結合至SCN1A標靶結合位點且因此未能表現SCN1A。下圖說明衍生自天然存在之人類蛋白質之eTF,其包含與人類蛋白質之至少98%序列一致性及經工程化以結合至18 nt SCN1A標靶結合位點之DBD,導致SCN1A基因活化且因此導致SCN1A表現。
圖 12B說明用
圖 12A中所說明之例示性eTF進行SCN1A活化分析之結果的定量。與EGR1具有高全局或總體序列一致性且其中其DBD經工程化以識別內源性SCN1A基因附近或該基因處之特異性結合位點的包含六個鋅指之eTF (SEQ ID NO: 6)相比於SEQ ID NO: 4 (其DBD經工程化以識別TRE結合位點,而非SCN1A標靶結合位點)導致經轉染HEK293細胞中之2.5倍SCN1A表現。
圖 13A說明藉由各衍生自天然存在之人類蛋白質之兩種例示性eTF之SCN1A活化的示意圖。上圖說明eTF,其中天然存在之人類蛋白質(例如EGR1或EGR3)之DBD經複製以形成具有6個鋅指之DBD且經修飾或再程式化以結合至內源性SCN1A基因附近或該基因處之標靶結合位點。下圖說明eTF,其中天然存在之人類蛋白質之DBD經三倍化複製以形成具有9個鋅指之DBD且經修飾或再程式化以結合至內源性SCN1A基因附近或該基因處之標靶結合位點。
圖 13B說明藉由
圖 13A中所說明之eTF中之每一者活化之相對SCN1A表現的定量。在經轉染HEK293細胞中,包含與EGR1之高序列一致性及衍生自EGR1且經工程化以識別SCN1A標靶結合位點之6-鋅指DBD的eTF (SEQ ID NO: 7)導致相對於空載體對照之約7倍SCN1A表現。包含與EGR1之高序列一致性及衍生自EGR1且經工程化以識別SCN1A標靶結合位點之9-鋅指DBD的eTF (SEQ ID NO: 9)導致相對於對照之約20倍SCN1A表現。
圖 14說明雜交eTF之各種實施例,該等雜交eTF包含與天然存在之人類蛋白質具有高序列一致性之人類DBD,其融合至另一蛋白質之TAD,諸如另一人類蛋白質(諸如CITED2)之病毒活化域或TAD。在各種實施例中,eTF之DBD與天然存在之人類蛋白質之DBD之間的局部序列一致性為至少85%。此類DBD可融合至各種活化域,例如病毒活化域,諸如VP64,其與人類蛋白質具有0%序列一致性;或CITED2活化域。相比於天然存在之人類蛋白質,用人類CITED序列置換VP64域增加第三列中之雜交eTF的總體序列一致性。
圖 15說明使用
SCN1A特異性轉錄活化子之HERK293細胞中之相對內源性SCN1A表現(參見實例6中之
表 33 - 34)。資料呈現為相對於對照條件之倍數變化,且以Log
10標度顯示。
圖 16A說明使用SCN1A特異性轉錄活化子(SEQ ID NO: 366)之GABA神經元中之相對內源性SCN1A表現。資料呈現為相對於對照條件(CBA-EGFP)之倍數變化。
圖 16B說明使用
SCN1A特異性轉錄活化子(SEQ ID NO: 13或SEQ ID NO: 15)之GABA神經元中之相對內源性SCN1A表現。資料呈現為以Log
10計之相對於對照條件(CBA-EGFP)之倍數變化。
圖 17說明由SCN1A特異性轉錄因子SEQ ID NO: 366)驅動之內源性SCN1A及40個最近鄰基因之相對表現。資料呈現為以Log
10計之相對於對照條件(CBA-EGFP-KASH)之倍數變化。
圖 18A及
圖 18B說明相比於表現eGFP之對照表現卡匣,SCN1A特異性轉錄活化子在活體內之表現。
圖 18A說明注射對照eGFP表現卡匣或表現卡匣A之小鼠中之相對SCN1A基因表現,表現卡匣A包含結合至標靶位點,導致自內源性SCN1A基因之表現上調的轉錄活化子。
圖 18B說明就百分比平均eGFP而言之SCN1A表現的變化。此等實驗指示表現卡匣A之轉錄活化子導致SCN1A表現之約20-30%上調。
圖 19A、
圖 19B及
圖 19C說明使用若干SCN1A特異性轉錄因子上調野生型小鼠之海馬區中之內源性SCN1A。
圖 19A:表現卡匣A;
圖 19B:表現卡匣B;及
圖 19C:SEQ ID NO: 365或366。將SCN1A轉錄因子相比於對照載體(EGFP-KASH)及CBA-EGFP-KASH。資料呈現為相對於EGFP-KASH條件之倍數變化。
圖 20A、
圖 20B、
圖 20C、
圖 20D及
圖 20E說明相比於對照,對使用各種SCN1A特異性轉錄因子之德拉韋症候群小鼠模型之高熱癲癇的影響。向P1 Scn1a +/-小鼠輸注AAV9-EGFP或表現SCN1A特異性轉錄因子(SEQ ID NO: 305-309)之AAV9載體。在P26-P28處,輸注小鼠通過高熱誘發性癲癇分析且記錄其經歷強直陣攣發作之內部溫度。
圖 21A、
圖 21B 、 圖 21C、
圖 21D及
圖 21E說明德拉韋症候群小鼠模型在各種條件下之存活率。
圖 21A說明存活率分析中之野生型與Scn1a +/-小鼠之間的比較。向P1 Scn1a +/- (N=53)及Scn1a +/+ (N=54)小鼠輸注PBS。每天在飼養籠中觀測小鼠且在任何死亡之情況下,記錄日期。Scn1a +/-與Scn1a +/+動物之間存在存活率之顯著差異(P<0.0001)。
圖 21B - E說明相比於對照,對用各種SCN1A特異性轉錄因子治療之小鼠之德拉韋症候群小鼠模型中之存活率的影響。向P1 Scn1a +/-小鼠輸注PBS或表現SCN1A特異性轉錄因子(SEQ ID NO: 305-307,或309)之AAV9載體。每天在飼養籠中觀測小鼠且在任何死亡之情況下,記錄日期。
圖 22說明在腦實質內遞送編碼SCN1A特異性轉錄因子(SEQ ID NO: 305)之AAV9載體之後,不同腦組織中之相對Scn1A mRNA表現,該載體以每隻動物1.2×10
12gc向兩隻食蟹獼猴投與,相對於兩隻未治療之對照動物標準化。在注射之後28天殺死所有動物且藉由Taqman PCR定量組織樣品中之Scn1A mRNA。資料報導為來自腦部之不同組織切片中之標靶mRNA的標準化表現。亦由不同Scn1a基因衍生之引物/探針組記錄類似結果。
圖 23說明使用結合至各種基因組區域之工程化轉錄因子上調內源性GRN。
圖 24A及
圖 24B說明藉由各自包含GRN之轉錄活化子之各種表現卡匣的活體外實驗。
圖 24A說明呈現為相對於對照之倍數變化的顆粒蛋白前體之相對表現。
圖 24B說明藉由顆粒蛋白前體之各種轉錄活化子之ELISA實驗,關於上清液中之hPGRN (ng/mL)來表示。
圖 25說明各種調節元件(RE)對在293T細胞中表現螢光素酶之標準化螢光素酶活性。舉例而言,可操作地連接於minCMV啟動子之調節元件SEQ ID NO: 178以相比於單獨的minCMV啟動子高約3.5倍,及相比於SCP啟動子高約140倍之水準驅動螢光素酶表現。
圖 26說明PGRN轉錄物之水準,其如在經表現EGFP或GRN特異性活化子(SEQ ID NO: 10、16、59、60、63、64、72、73、77、L或342)之質體轉染之HEK293細胞中藉由qPCR所量測。資料呈現為相對於對照條件之倍數變化。
圖 27說明如藉由ELISA所量測之分泌自HEK293細胞之PGRN蛋白質的水準,該等細胞經表現EGFP或GRN特異性活化子(SEQ ID NO: 10或16)之質體轉染。資料呈現為相對於對照條件之倍數變化。
圖 28說明如藉由qPCR所量測的GABA神經元中之PGRN轉錄物的水準,該等神經元經表現處於CBA啟動子控制下的EGFP或GRN特異性活化子(SEQ ID NO: 342)之AAV載體(血清型AAV-DJ)轉染。資料呈現為相對於對照條件之倍數變化。
圖 29說明如藉由ELISA所量測的分泌自GABA神經元之PGRN蛋白質的水準,該等神經元經表現處於CBA啟動子控制下的EGFP或GRN特異性活化子(SEQ ID NO: 342)之AAV載體(血清型AAV-DJ)以低劑量(0.5E11個基因組複本/孔)及高劑量(2E11個基因組複本/孔)感染。資料呈現為相對於對照條件之倍數變化。
圖 30說明用相比於PBS對照不同劑量的包含表現卡匣J或G (各自包含GRN之轉錄活化子)之AAV9治療之小鼠的血漿PGRN蛋白質水準(以µg/mL量測)。
圖 31A說明藉由各種eTF之報告子(EGFP)活化分析之結果的定量,表示為相比於空載體對照之相對EGFP表現。包含強力病毒活化域之人工轉錄因子(SEQ ID NO: 51)導致70倍相對EGFP表現。未經修飾之人類轉錄因子EGR1 (SEQ ID NO: 1)不相對於對照(空載體)活化報導基因。包含六個工程化鋅指的衍生自EGR1之eTF (SEQ ID NO: 2)導致10倍EGFP表現。包含三個鋅指,在其鋅指中具有至少一或多個胺基酸變化的衍生自EGR1之eTF (SEQ ID NO: 3)導致3倍相對EGFP表現。在EGR1指(SEQ ID NO: 4)中複製鋅指導致15倍相對EGFP表現。
圖 31B說明在
圖 31A中定量之報告子(EGFP)活化分析的螢光顯微照片。表現EGFP之細胞呈現為淺灰色。
圖 32說明衍生自EGR3且經工程化以識別標靶結合位點之eTF的各種實施例,該標靶結合位點導致EGFP報導基因之表現。衍生自EGR3蛋白質且經工程化以在報導分析中識別TRE結合位點的包含六個鋅指之eTF (SEQ ID NO: 12)導致與包含衍生自VP64之TAD的衍生自EGR1之eTF (SEQ ID NO: 51)類似的EGFP表現。相比於包含經修飾人類DBD而無活化域之對照(由SEQ ID NO: 187編碼),兩種eTF均導致高EGFP表現。
圖 33A說明經工程化以在EGFP報告子活化分析中識別TRE結合序列之各種eTF的示意圖。第一圖說明經工程化以識別TRE結合位點但不具有活化域(SEQ ID NO: 50)之經修飾人類DBD,其不導致EGFP表現之任何活化。在第二圖中,經修飾人類DBD融合至強力病毒活化域VP64 (SEQ ID NO: 95),導致EGFP表現之活化。在第三及第四圖中,經修飾人類DBD融合至人類活化域CITED2 (SEQ ID NO: 96)或CITED4 (SEQ ID NO: 97),其均活化EGFP表現。
圖 33B說明
圖 33A中所述之各eTF之相對EGFP表現的定量。SEQ ID NO: 50導致與單獨報告子之對照類似的EGFP表現量。相比於單獨報告子之對照,具有序列SEQ ID NO: 51-53之eTF各分別地導致約40、15及10倍相對EGFP表現。
圖 33C說明
圖 33A中所說明及
圖 33B中所定量之EGFP報告子活化分析中之各eTF的螢光顯微照片。
圖 34說明具有大範圍之轉錄活性(或相對報告子表現)及改變程度的與天然存在之人類蛋白質之序列一致性(或保守)之eTF之各種實施例的概述。
圖 35A說明用於測試本文揭示之eTF之免疫原性之Elispot分析的示意圖。Elispot分析用於測試來自正常健康供體之T細胞是否可識別及回應於預測具有免疫原性之肽。T細胞將與抗原呈遞細胞(例如樹突狀細胞或DC)及待測試之肽的集合在elispot孔中混合。若T細胞將肽識別為外來的,則T細胞變得活化、增殖且分泌細胞介素(諸如干擾素-γ)。在用顯色試劑處理之後,可計數干擾素-γ (IFNγ)陽性點。相比於對照(例如單獨的已知非免疫原性肽或緩衝液)之較高點數與較高免疫原性相關。
圖 35B說明顯示相比於對照(左側圓)增加之免疫原性(右側圓)之elispot結果的特寫實例。IFN-γ陽性點顯示為黑點。
圖 36說明包含有包含非天然存在之轉錄調節子之表現卡匣的載體,其包含可操作地連接於VP64之活化域的轉錄因子之DNA結合域,用於增加SCN1A基因之表現。
圖 37說明包含表現卡匣之AAV載體,該表現卡匣包含非天然存在之轉錄調節子,諸如可操作地連接於VP64之轉錄活化域的核酸酶不活化dSaCa9域。此類表現卡匣亦包含藉由dSaCas9轉殖基因表現之嚮導RNA。說明之其他元件包括核定位信號(NLS)、啟動子、AAV ITR、polyA信號及選擇標記物。
<![CDATA[<110> 美商編碼製藥公司(ENCODED THERAPEUTICS, INC.)]]> <![CDATA[<120> 工程化DNA結合蛋白]]> <![CDATA[<130> 46482-711.851]]> <![CDATA[<140> ]]> <![CDATA[<141> ]]> <![CDATA[<150> US62/664,817]]> <![CDATA[<151> 2018-04-30]]> <![CDATA[<150>]]> US62/664,814 <![CDATA[<151> 2018-04-30]]> <![CDATA[<150> US62/646,198]]> <![CDATA[<151> 2018-03-21]]> <![CDATA[<150> US62/641,806]]> <![CDATA[<151> 2018-03-12]]> <![CDATA[<150> US62/618,966]]> <![CDATA[<151> 2018-01-18]]> <![CDATA[<150> US62/610,014]]> <![CDATA[<151> 2017-12-22]]> <![CDATA[<150> US62/593,824]]> <![CDATA[<151> 2017-12-01]]> <![CDATA[<150> PCT/US18/63498]]> <![CDATA[<151> 2018-11-30]]> <![CDATA[<160> 453 ]]> <![CDATA[<170> PatentIn version 3.5]]> <![CDATA[<210> 1]]> <![CDATA[<211> 543]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 1]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 340 345 350 Asp Glu Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu Thr 370 375 380 Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Arg Lys Arg His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala 420 425 430 Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr 435 440 445 Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr 450 455 460 Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser 465 470 475 480 Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala 485 490 495 Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser 500 505 510 Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu 515 520 525 Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys 530 535 540 <![CDATA[<210> 2]]> <![CDATA[<211> 631]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 2]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Leu 325 330 335 Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe 340 345 350 Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr Gly Glu 355 360 365 Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser Arg Arg 370 375 380 Thr Cys Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys 385 390 395 400 Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu Val Arg 405 410 415 His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys 420 425 430 Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg Ala His Gln Arg Thr 435 440 445 His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe 450 455 460 Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr Gly Glu 465 470 475 480 Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Arg Thr 485 490 495 Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr Ser Lys 500 505 510 Lys Ala Asp Lys Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser 515 520 525 Ser Tyr Pro Ser Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr 530 535 540 Ser Tyr Pro Ser Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr 545 550 555 560 Ser Phe Ser Ser Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser 565 570 575 Gly Phe Pro Ser Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro 580 585 590 Ala Phe Pro Ala Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn 595 600 605 Ser Phe Ser Ala Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser 610 615 620 Pro Arg Thr Ile Glu Ile Cys 625 630 <![CDATA[<210> 3]]> <![CDATA[<211> 543]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 3]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Gln Leu 340 345 350 Ala His Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly Asn Leu Val 370 375 380 Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr Asn His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala 420 425 430 Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr 435 440 445 Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr 450 455 460 Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser 465 470 475 480 Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala 485 490 495 Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser 500 505 510 Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu 515 520 525 Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys 530 535 540 <![CDATA[<210> 4]]> <![CDATA[<211> 631]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 4]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg 340 345 350 Asp Glu Leu Asn Val His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Ser Arg Arg Thr Cys Arg 370 375 380 Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Gln Leu Ala His Leu Arg Ala His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser Thr Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His Arg 485 490 495 Thr Thr Leu Thr Asn His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 500 505 510 Lys Ala Asp Lys Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser 515 520 525 Ser Tyr Pro Ser Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr 530 535 540 Ser Tyr Pro Ser Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr 545 550 555 560 Ser Phe Ser Ser Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser 565 570 575 Gly Phe Pro Ser Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro 580 585 590 Ala Phe Pro Ala Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn 595 600 605 Ser Phe Ser Ala Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser 610 615 620 Pro Arg Thr Ile Glu Ile Cys 625 630 <![CDATA[<210> 5]]> <![CDATA[<211> 627]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 5]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg 340 345 350 Asp Glu Leu Asn Val His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Ser Arg Arg Thr Cys Arg 370 375 380 Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His Ile Arg 405 410 415 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 420 425 430 Phe Ser Gln Leu Ala His Leu Arg Ala His Ile Arg Ile His Thr Gly 435 440 445 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser 450 455 460 Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 465 470 475 480 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr 485 490 495 Asn His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys 500 505 510 Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser 515 520 525 Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser 530 535 540 Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser 545 550 555 560 Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser 565 570 575 Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala 580 585 590 Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala 595 600 605 Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile 610 615 620 Glu Ile Cys 625 <![CDATA[<210> 6]]> <![CDATA[<211> 631]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 6]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His 370 375 380 Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn 485 490 495 Ser Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 500 505 510 Lys Ala Asp Lys Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser 515 520 525 Ser Tyr Pro Ser Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr 530 535 540 Ser Tyr Pro Ser Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr 545 550 555 560 Ser Phe Ser Ser Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser 565 570 575 Gly Phe Pro Ser Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro 580 585 590 Ala Phe Pro Ala Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn 595 600 605 Ser Phe Ser Ala Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser 610 615 620 Pro Arg Thr Ile Glu Ile Cys 625 630 <![CDATA[<210> 7]]> <![CDATA[<211> 631]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 7]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr Leu Thr 370 375 380 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Thr Ser His Ser Leu Thr Glu His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser Gln Ser Ser Ser Leu Val Arg His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu 485 490 495 Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 500 505 510 Lys Ala Asp Lys Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser 515 520 525 Ser Tyr Pro Ser Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr 530 535 540 Ser Tyr Pro Ser Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr 545 550 555 560 Ser Phe Ser Ser Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser 565 570 575 Gly Phe Pro Ser Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro 580 585 590 Ala Phe Pro Ala Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn 595 600 605 Ser Phe Ser Ala Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser 610 615 620 Pro Arg Thr Ile Glu Ile Cys 625 630 <![CDATA[<210> 8]]> <![CDATA[<211> 627]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 8]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr Leu Thr 370 375 380 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Ile Arg 405 410 415 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 420 425 430 Phe Ser Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly 435 440 445 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser 450 455 460 Ser Ser Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 465 470 475 480 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His 485 490 495 Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys 500 505 510 Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser 515 520 525 Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser 530 535 540 Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser 545 550 555 560 Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser 565 570 575 Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala 580 585 590 Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala 595 600 605 Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile 610 615 620 Glu Ile Cys 625 <![CDATA[<210> 9]]> <![CDATA[<211> 719]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 9]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg 340 345 350 Asp Glu Leu Asn Val His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu Thr 370 375 380 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Ser Asp Asp Leu Val Arg His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu 485 490 495 Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Arg 500 505 510 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Thr Ser 515 520 525 His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 530 535 540 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser Leu Val 545 550 555 560 Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 565 570 575 Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr Lys 580 585 590 Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala 595 600 605 Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr 610 615 620 Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr 625 630 635 640 Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser 645 650 655 Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala 660 665 670 Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser 675 680 685 Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu 690 695 700 Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys 705 710 715 <![CDATA[<210> 10]]> <![CDATA[<211> 631]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述]]>:合成多肽 <![CDATA[<400> 10]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Ser Pro 340 345 350 Ala Asp Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Asp Ser Gly Asn Leu Arg 370 375 380 Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser 485 490 495 Asp Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 500 505 510 Lys Ala Asp Lys Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser 515 520 525 Ser Tyr Pro Ser Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr 530 535 540 Ser Tyr Pro Ser Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr 545 550 555 560 Ser Phe Ser Ser Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser 565 570 575 Gly Phe Pro Ser Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro 580 585 590 Ala Phe Pro Ala Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn 595 600 605 Ser Phe Ser Ala Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser 610 615 620 Pro Arg Thr Ile Glu Ile Cys 625 630 <![CDATA[<210> 11]]> <![CDATA[<211> 387]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 11]]> Met Thr Gly Lys Leu Ala Glu Lys Leu Pro Val Thr Met Ser Ser Leu 1 5 10 15 Leu Asn Gln Leu Pro Asp Asn Leu Tyr Pro Glu Glu Ile Pro Ser Ala 20 25 30 Leu Asn Leu Phe Ser Gly Ser Ser Asp Ser Val Val His Tyr Asn Gln 35 40 45 Met Ala Thr Glu Asn Val Met Asp Ile Gly Leu Thr Asn Glu Lys Pro 50 55 60 Asn Pro Glu Leu Ser Tyr Ser Gly Ser Phe Gln Pro Ala Pro Gly Asn 65 70 75 80 Lys Thr Val Thr Tyr Leu Gly Lys Phe Ala Phe Asp Ser Pro Ser Asn 85 90 95 Trp Cys Gln Asp Asn Ile Ile Ser Leu Met Ser Ala Gly Ile Leu Gly 100 105 110 Val Pro Pro Ala Ser Gly Ala Leu Ser Thr Gln Thr Ser Thr Ala Ser 115 120 125 Met Val Gln Pro Pro Gln Gly Asp Val Glu Ala Met Tyr Pro Ala Leu 130 135 140 Pro Pro Tyr Ser Asn Cys Gly Asp Leu Tyr Ser Glu Pro Val Ser Phe 145 150 155 160 His Asp Pro Gln Gly Asn Pro Gly Leu Ala Tyr Ser Pro Gln Asp Tyr 165 170 175 Gln Ser Ala Lys Pro Ala Leu Asp Ser Asn Leu Phe Pro Met Ile Pro 180 185 190 Asp Tyr Asn Leu Tyr His His Pro Asn Asp Met Gly Ser Ile Pro Glu 195 200 205 His Lys Pro Phe Gln Gly Met Asp Pro Ile Arg Val Asn Pro Pro Pro 210 215 220 Ile Thr Pro Leu Glu Thr Ile Lys Ala Phe Lys Asp Lys Gln Ile His 225 230 235 240 Pro Gly Phe Gly Ser Leu Pro Gln Pro Pro Leu Thr Leu Lys Pro Ile 245 250 255 Arg Pro Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Leu His Glu 260 265 270 Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Gln 275 280 285 Leu Ala His Leu Arg Ala His Leu Arg Ile His Thr Gly His Lys Pro 290 295 300 Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Thr Ser Gly Asn Leu 305 310 315 320 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu 325 330 335 Phe Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr Asn His Ala 340 345 350 Lys Ile His Leu Lys Gln Lys Glu Lys Lys Ala Glu Lys Gly Gly Ala 355 360 365 Pro Ser Ala Ser Ser Ala Pro Pro Val Ser Leu Ala Pro Val Val Thr 370 375 380 Thr Cys Ala 385 <![CDATA[<210> 12]]> <![CDATA[<211> 473]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 12]]> Met Thr Gly Lys Leu Ala Glu Lys Leu Pro Val Thr Met Ser Ser Leu 1 5 10 15 Leu Asn Gln Leu Pro Asp Asn Leu Tyr Pro Glu Glu Ile Pro Ser Ala 20 25 30 Leu Asn Leu Phe Ser Gly Ser Ser Asp Ser Val Val His Tyr Asn Gln 35 40 45 Met Ala Thr Glu Asn Val Met Asp Ile Gly Leu Thr Asn Glu Lys Pro 50 55 60 Asn Pro Glu Leu Ser Tyr Ser Gly Ser Phe Gln Pro Ala Pro Gly Asn 65 70 75 80 Lys Thr Val Thr Tyr Leu Gly Lys Phe Ala Phe Asp Ser Pro Ser Asn 85 90 95 Trp Cys Gln Asp Asn Ile Ile Ser Leu Met Ser Ala Gly Ile Leu Gly 100 105 110 Val Pro Pro Ala Ser Gly Ala Leu Ser Thr Gln Thr Ser Thr Ala Ser 115 120 125 Met Val Gln Pro Pro Gln Gly Asp Val Glu Ala Met Tyr Pro Ala Leu 130 135 140 Pro Pro Tyr Ser Asn Cys Gly Asp Leu Tyr Ser Glu Pro Val Ser Phe 145 150 155 160 His Asp Pro Gln Gly Asn Pro Gly Leu Ala Tyr Ser Pro Gln Asp Tyr 165 170 175 Gln Ser Ala Lys Pro Ala Leu Asp Ser Asn Leu Phe Pro Met Ile Pro 180 185 190 Asp Tyr Asn Leu Tyr His His Pro Asn Asp Met Gly Ser Ile Pro Glu 195 200 205 His Lys Pro Phe Gln Gly Met Asp Pro Ile Arg Val Asn Pro Pro Pro 210 215 220 Ile Thr Pro Leu Glu Thr Ile Lys Ala Phe Lys Asp Lys Gln Ile His 225 230 235 240 Pro Gly Phe Gly Ser Leu Pro Gln Pro Pro Leu Thr Leu Lys Pro Ile 245 250 255 Arg Pro Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Leu His Glu 260 265 270 Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg 275 280 285 Arg Asp Glu Leu Asn Val His Leu Arg Ile His Thr Gly His Lys Pro 290 295 300 Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Ser Arg Arg Thr Cys 305 310 315 320 Arg Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu 325 330 335 Phe Cys Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His Ala 340 345 350 Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys 355 360 365 Asp Arg Arg Phe Ser Gln Leu Ala His Leu Arg Ala His Leu Arg Ile 370 375 380 His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe 385 390 395 400 Ser Thr Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly Glu 405 410 415 Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala His Arg Thr 420 425 430 Thr Leu Thr Asn His Ala Lys Ile His Leu Lys Gln Lys Glu Lys Lys 435 440 445 Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro Pro Val Ser 450 455 460 Leu Ala Pro Val Val Thr Thr Cys Ala 465 470 <![CDATA[<210> 13]]> <![CDATA[<211> 473]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 13]]> Met Thr Gly Lys Leu Ala Glu Lys Leu Pro Val Thr Met Ser Ser Leu 1 5 10 15 Leu Asn Gln Leu Pro Asp Asn Leu Tyr Pro Glu Glu Ile Pro Ser Ala 20 25 30 Leu Asn Leu Phe Ser Gly Ser Ser Asp Ser Val Val His Tyr Asn Gln 35 40 45 Met Ala Thr Glu Asn Val Met Asp Ile Gly Leu Thr Asn Glu Lys Pro 50 55 60 Asn Pro Glu Leu Ser Tyr Ser Gly Ser Phe Gln Pro Ala Pro Gly Asn 65 70 75 80 Lys Thr Val Thr Tyr Leu Gly Lys Phe Ala Phe Asp Ser Pro Ser Asn 85 90 95 Trp Cys Gln Asp Asn Ile Ile Ser Leu Met Ser Ala Gly Ile Leu Gly 100 105 110 Val Pro Pro Ala Ser Gly Ala Leu Ser Thr Gln Thr Ser Thr Ala Ser 115 120 125 Met Val Gln Pro Pro Gln Gly Asp Val Glu Ala Met Tyr Pro Ala Leu 130 135 140 Pro Pro Tyr Ser Asn Cys Gly Asp Leu Tyr Ser Glu Pro Val Ser Phe 145 150 155 160 His Asp Pro Gln Gly Asn Pro Gly Leu Ala Tyr Ser Pro Gln Asp Tyr 165 170 175 Gln Ser Ala Lys Pro Ala Leu Asp Ser Asn Leu Phe Pro Met Ile Pro 180 185 190 Asp Tyr Asn Leu Tyr His His Pro Asn Asp Met Gly Ser Ile Pro Glu 195 200 205 His Lys Pro Phe Gln Gly Met Asp Pro Ile Arg Val Asn Pro Pro Pro 210 215 220 Ile Thr Pro Leu Glu Thr Ile Lys Ala Phe Lys Asp Lys Gln Ile His 225 230 235 240 Pro Gly Phe Gly Ser Leu Pro Gln Pro Pro Leu Thr Leu Lys Pro Ile 245 250 255 Arg Pro Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Leu His Glu 260 265 270 Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg 275 280 285 Ser Asp Asn Leu Val Arg His Leu Arg Ile His Thr Gly His Lys Pro 290 295 300 Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Glu Asp Asn Leu 305 310 315 320 His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu 325 330 335 Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Ala 340 345 350 Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys 355 360 365 Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Leu Arg Ile 370 375 380 His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe 385 390 395 400 Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu 405 410 415 Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Gln Asn Ser 420 425 430 Thr Leu Thr Glu His Ala Lys Ile His Leu Lys Gln Lys Glu Lys Lys 435 440 445 Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro Pro Val Ser 450 455 460 Leu Ala Pro Val Val Thr Thr Cys Ala 465 470 <![CDATA[<210> 14]]> <![CDATA[<211> 473]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 14]]> Met Thr Gly Lys Leu Ala Glu Lys Leu Pro Val Thr Met Ser Ser Leu 1 5 10 15 Leu Asn Gln Leu Pro Asp Asn Leu Tyr Pro Glu Glu Ile Pro Ser Ala 20 25 30 Leu Asn Leu Phe Ser Gly Ser Ser Asp Ser Val Val His Tyr Asn Gln 35 40 45 Met Ala Thr Glu Asn Val Met Asp Ile Gly Leu Thr Asn Glu Lys Pro 50 55 60 Asn Pro Glu Leu Ser Tyr Ser Gly Ser Phe Gln Pro Ala Pro Gly Asn 65 70 75 80 Lys Thr Val Thr Tyr Leu Gly Lys Phe Ala Phe Asp Ser Pro Ser Asn 85 90 95 Trp Cys Gln Asp Asn Ile Ile Ser Leu Met Ser Ala Gly Ile Leu Gly 100 105 110 Val Pro Pro Ala Ser Gly Ala Leu Ser Thr Gln Thr Ser Thr Ala Ser 115 120 125 Met Val Gln Pro Pro Gln Gly Asp Val Glu Ala Met Tyr Pro Ala Leu 130 135 140 Pro Pro Tyr Ser Asn Cys Gly Asp Leu Tyr Ser Glu Pro Val Ser Phe 145 150 155 160 His Asp Pro Gln Gly Asn Pro Gly Leu Ala Tyr Ser Pro Gln Asp Tyr 165 170 175 Gln Ser Ala Lys Pro Ala Leu Asp Ser Asn Leu Phe Pro Met Ile Pro 180 185 190 Asp Tyr Asn Leu Tyr His His Pro Asn Asp Met Gly Ser Ile Pro Glu 195 200 205 His Lys Pro Phe Gln Gly Met Asp Pro Ile Arg Val Asn Pro Pro Pro 210 215 220 Ile Thr Pro Leu Glu Thr Ile Lys Ala Phe Lys Asp Lys Gln Ile His 225 230 235 240 Pro Gly Phe Gly Ser Leu Pro Gln Pro Pro Leu Thr Leu Lys Pro Ile 245 250 255 Arg Pro Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Leu His Glu 260 265 270 Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg 275 280 285 Ser Asp Asn Leu Val Arg His Leu Arg Ile His Thr Gly His Lys Pro 290 295 300 Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser His Arg Thr Thr Leu 305 310 315 320 Thr Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu 325 330 335 Phe Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Ala 340 345 350 Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys 355 360 365 Asp Arg Arg Phe Ser Thr Ser His Ser Leu Thr Glu His Leu Arg Ile 370 375 380 His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe 385 390 395 400 Ser Gln Ser Ser Ser Leu Val Arg His Ile Arg Thr His Thr Gly Glu 405 410 415 Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Glu Asp 420 425 430 Asn Leu His Thr His Ala Lys Ile His Leu Lys Gln Lys Glu Lys Lys 435 440 445 Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro Pro Val Ser 450 455 460 Leu Ala Pro Val Val Thr Thr Cys Ala 465 470 <![CDATA[<210> 15]]> <![CDATA[<211> 559]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 15]]> Met Thr Gly Lys Leu Ala Glu Lys Leu Pro Val Thr Met Ser Ser Leu 1 5 10 15 Leu Asn Gln Leu Pro Asp Asn Leu Tyr Pro Glu Glu Ile Pro Ser Ala 20 25 30 Leu Asn Leu Phe Ser Gly Ser Ser Asp Ser Val Val His Tyr Asn Gln 35 40 45 Met Ala Thr Glu Asn Val Met Asp Ile Gly Leu Thr Asn Glu Lys Pro 50 55 60 Asn Pro Glu Leu Ser Tyr Ser Gly Ser Phe Gln Pro Ala Pro Gly Asn 65 70 75 80 Lys Thr Val Thr Tyr Leu Gly Lys Phe Ala Phe Asp Ser Pro Ser Asn 85 90 95 Trp Cys Gln Asp Asn Ile Ile Ser Leu Met Ser Ala Gly Ile Leu Gly 100 105 110 Val Pro Pro Ala Ser Gly Ala Leu Ser Thr Gln Thr Ser Thr Ala Ser 115 120 125 Met Val Gln Pro Pro Gln Gly Asp Val Glu Ala Met Tyr Pro Ala Leu 130 135 140 Pro Pro Tyr Ser Asn Cys Gly Asp Leu Tyr Ser Glu Pro Val Ser Phe 145 150 155 160 His Asp Pro Gln Gly Asn Pro Gly Leu Ala Tyr Ser Pro Gln Asp Tyr 165 170 175 Gln Ser Ala Lys Pro Ala Leu Asp Ser Asn Leu Phe Pro Met Ile Pro 180 185 190 Asp Tyr Asn Leu Tyr His His Pro Asn Asp Met Gly Ser Ile Pro Glu 195 200 205 His Lys Pro Phe Gln Gly Met Asp Pro Ile Arg Val Asn Pro Pro Pro 210 215 220 Ile Thr Pro Leu Glu Thr Ile Lys Ala Phe Lys Asp Lys Gln Ile His 225 230 235 240 Pro Gly Phe Gly Ser Leu Pro Gln Pro Pro Leu Thr Leu Lys Pro Ile 245 250 255 Arg Pro Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Leu His Glu 260 265 270 Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg 275 280 285 Arg Asp Glu Leu Asn Val His Leu Arg Ile His Thr Gly His Lys Pro 290 295 300 Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Ser Asp His Leu 305 310 315 320 Thr Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu 325 330 335 Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Asp Leu Val Arg His Ala 340 345 350 Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys 355 360 365 Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Leu Arg Ile 370 375 380 His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe 385 390 395 400 Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr Gly Glu 405 410 415 Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Glu Asp 420 425 430 Asn Leu His Thr His Ala Lys Ile His Leu Lys Gln Lys Glu His Ala 435 440 445 Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Thr Ser His Ser Leu 450 455 460 Thr Glu His Leu Arg Ile His Thr Gly His Lys Pro Phe Gln Cys Arg 465 470 475 480 Ile Cys Met Arg Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Ile 485 490 495 Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg 500 505 510 Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Ala Lys Ile His Leu 515 520 525 Lys Gln Lys Glu Lys Lys Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser 530 535 540 Ser Ala Pro Pro Val Ser Leu Ala Pro Val Val Thr Thr Cys Ala 545 550 555 <![CDATA[<210> 16]]> <![CDATA[<211> 473]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 16]]> Met Thr Gly Lys Leu Ala Glu Lys Leu Pro Val Thr Met Ser Ser Leu 1 5 10 15 Leu Asn Gln Leu Pro Asp Asn Leu Tyr Pro Glu Glu Ile Pro Ser Ala 20 25 30 Leu Asn Leu Phe Ser Gly Ser Ser Asp Ser Val Val His Tyr Asn Gln 35 40 45 Met Ala Thr Glu Asn Val Met Asp Ile Gly Leu Thr Asn Glu Lys Pro 50 55 60 Asn Pro Glu Leu Ser Tyr Ser Gly Ser Phe Gln Pro Ala Pro Gly Asn 65 70 75 80 Lys Thr Val Thr Tyr Leu Gly Lys Phe Ala Phe Asp Ser Pro Ser Asn 85 90 95 Trp Cys Gln Asp Asn Ile Ile Ser Leu Met Ser Ala Gly Ile Leu Gly 100 105 110 Val Pro Pro Ala Ser Gly Ala Leu Ser Thr Gln Thr Ser Thr Ala Ser 115 120 125 Met Val Gln Pro Pro Gln Gly Asp Val Glu Ala Met Tyr Pro Ala Leu 130 135 140 Pro Pro Tyr Ser Asn Cys Gly Asp Leu Tyr Ser Glu Pro Val Ser Phe 145 150 155 160 His Asp Pro Gln Gly Asn Pro Gly Leu Ala Tyr Ser Pro Gln Asp Tyr 165 170 175 Gln Ser Ala Lys Pro Ala Leu Asp Ser Asn Leu Phe Pro Met Ile Pro 180 185 190 Asp Tyr Asn Leu Tyr His His Pro Asn Asp Met Gly Ser Ile Pro Glu 195 200 205 His Lys Pro Phe Gln Gly Met Asp Pro Ile Arg Val Asn Pro Pro Pro 210 215 220 Ile Thr Pro Leu Glu Thr Ile Lys Ala Phe Lys Asp Lys Gln Ile His 225 230 235 240 Pro Gly Phe Gly Ser Leu Pro Gln Pro Pro Leu Thr Leu Lys Pro Ile 245 250 255 Arg Pro Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Leu His Glu 260 265 270 Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Ser 275 280 285 Pro Ala Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys Pro 290 295 300 Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn Leu 305 310 315 320 Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu 325 330 335 Phe Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Ala 340 345 350 Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys 355 360 365 Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg Ile 370 375 380 His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe 385 390 395 400 Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu 405 410 415 Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp 420 425 430 Asn Leu Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu Lys Lys 435 440 445 Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro Pro Val Ser 450 455 460 Leu Ala Pro Val Val Thr Thr Cys Ala 465 470 <![CDATA[<210> 17]]> <![CDATA[<211> 88]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> ]]>17 Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg 1 5 10 15 Ser Asp Glu Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu 35 40 45 Thr Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Arg Lys Arg His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp 85 <![CDATA[<210> 18]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 18]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser Arg 35 40 45 Arg Thr Cys Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg Ala His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Arg 145 150 155 160 Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 19]]> <![CDATA[<211> 88]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 19]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Gln 1 5 10 15 Leu Ala His Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly Asn Leu 35 40 45 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr Asn His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp 85 <![CDATA[<210> 20]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 20]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg 1 5 10 15 Arg Asp Glu Leu Asn Val His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Ser Arg Arg Thr Cys 35 40 45 Arg Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu 85 90 95 Ser Cys Asp Arg Arg Phe Ser Gln Leu Ala His Leu Arg Ala His Ile 100 105 110 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 115 120 125 Asn Phe Ser Thr Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr 130 135 140 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His 145 150 155 160 Arg Thr Thr Leu Thr Asn His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 175 <![CDATA[<210> 21]]> <![CDATA[<211> 172]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 21]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg 1 5 10 15 Arg Asp Glu Leu Asn Val His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Ser Arg Arg Thr Cys 35 40 45 Arg Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His Ile 65 70 75 80 Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg 85 90 95 Lys Phe Ser Gln Leu Ala His Leu Arg Ala His Ile Arg Ile His Thr 100 105 110 Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr 115 120 125 Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro 130 135 140 Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu 145 150 155 160 Thr Asn His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 <![CDATA[<210> 22]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 22]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg 1 5 10 15 Ser Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu 35 40 45 His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu 85 90 95 Ser Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile 100 105 110 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 115 120 125 Asn Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr 130 135 140 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln 145 150 155 160 Asn Ser Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 175 <![CDATA[<210> 23]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 23]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg 1 5 10 15 Ser Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr Leu 35 40 45 Thr Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu 85 90 95 Ser Cys Asp Arg Arg Phe Ser Thr Ser His Ser Leu Thr Glu His Ile 100 105 110 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 115 120 125 Asn Phe Ser Gln Ser Ser Ser Leu Val Arg His Ile Arg Thr His Thr 130 135 140 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 145 150 155 160 Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 175 <![CDATA[<210> 24]]> <![CDATA[<211> 172]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 24]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg 1 5 10 15 Ser Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr Leu 35 40 45 Thr Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Ile 65 70 75 80 Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg 85 90 95 Lys Phe Ser Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr 100 105 110 Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln 115 120 125 Ser Ser Ser Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro 130 135 140 Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu 145 150 155 160 His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 <![CDATA[<210>]]> 25 <![CDATA[<211> 264]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 25]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg 1 5 10 15 Arg Asp Glu Leu Asn Val His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu 35 40 45 Thr Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Asp Leu Val Arg His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu 85 90 95 Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile 100 105 110 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 115 120 125 Asn Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr 130 135 140 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 145 150 155 160 Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 175 Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Thr 180 185 190 Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro 195 200 205 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser Leu 210 215 220 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 225 230 235 240 Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr 245 250 255 Lys Ile His Leu Arg Gln Lys Asp 260 <![CDATA[<210> 26]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 26]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Ser 1 5 10 15 Pro Ala Asp Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Asp Ser Gly Asn Leu 35 40 45 Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu 85 90 95 Ser Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Ile 100 105 110 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 115 120 125 Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr 130 135 140 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 145 150 155 160 Ser Asp Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 175 <![CDATA[<210> 27]]> <![CDATA[<211> 87]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 27]]> Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Gln Leu 1 5 10 15 Ala His Leu Arg Ala His Leu Arg Ile His Thr Gly His Lys Pro Phe 20 25 30 Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Thr Ser Gly Asn Leu Val 35 40 45 Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe 50 55 60 Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr Asn His Ala Lys 65 70 75 80 Ile His Leu Lys Gln Lys Glu 85 <![CDATA[<210> 28]]> <![CDATA[<211> 172]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 28]]> His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg Arg Asp 1 5 10 15 Glu Leu Asn Val His Leu Arg Ile His Thr Gly His Lys Pro Phe Gln 20 25 30 Cys Arg Ile Cys Met Arg Ser Phe Ser Ser Arg Arg Thr Cys Arg Ala 35 40 45 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys 50 55 60 Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His Ala Lys Ile 65 70 75 80 His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp Arg 85 90 95 Arg Phe Ser Gln Leu Ala His Leu Arg Ala His Leu Arg Ile His Thr 100 105 110 Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Thr 115 120 125 Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro 130 135 140 Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu 145 150 155 160 Thr Asn His Ala Lys Ile His Leu Lys Gln Lys Glu 165 170 <![CDATA[<210> 29]]> <![CDATA[<211> 173]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 29]]> Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg Ser 1 5 10 15 Asp Asn Leu Val Arg His Leu Arg Ile His Thr Gly His Lys Pro Phe 20 25 30 Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Glu Asp Asn Leu His 35 40 45 Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe 50 55 60 Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Ala Lys 65 70 75 80 Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp 85 90 95 Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Leu Arg Ile His 100 105 110 Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser 115 120 125 Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys 130 135 140 Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr 145 150 155 160 Leu Thr Glu His Ala Lys Ile His Leu Lys Gln Lys Glu 165 170 <![CDATA[<210> 30]]> <![CDATA[<211> 173]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 30]]> Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg Ser 1 5 10 15 Asp Asn Leu Val Arg His Leu Arg Ile His Thr Gly His Lys Pro Phe 20 25 30 Gln Cys Arg Ile Cys Met Arg Ser Phe Ser His Arg Thr Thr Leu Thr 35 40 45 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe 50 55 60 Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Ala Lys 65 70 75 80 Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp 85 90 95 Arg Arg Phe Ser Thr Ser His Ser Leu Thr Glu His Leu Arg Ile His 100 105 110 Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser 115 120 125 Gln Ser Ser Ser Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys 130 135 140 Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn 145 150 155 160 Leu His Thr His Ala Lys Ile His Leu Lys Gln Lys Glu 165 170 <![CDATA[<210> 31]]> <![CDATA[<211> 259]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 31]]> Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg Arg 1 5 10 15 Asp Glu Leu Asn Val His Leu Arg Ile His Thr Gly His Lys Pro Phe 20 25 30 Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Ser Asp His Leu Thr 35 40 45 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe 50 55 60 Cys Gly Arg Lys Phe Ala Arg Ser Asp Asp Leu Val Arg His Ala Lys 65 70 75 80 Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp 85 90 95 Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Leu Arg Ile His 100 105 110 Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser 115 120 125 His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr Gly Glu Lys 130 135 140 Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn 145 150 155 160 Leu His Thr His Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys 165 170 175 Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Thr Ser His Ser Leu Thr 180 185 190 Glu His Leu Arg Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile 195 200 205 Cys Met Arg Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Ile Arg 210 215 220 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys 225 230 235 240 Phe Ala Arg Glu Asp Asn Leu His Thr His Ala Lys Ile His Leu Lys 245 250 255 Gln Lys Glu <![CDATA[<210> 32]]> <![CDATA[<211> 173]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 32]]> Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Ser Pro 1 5 10 15 Ala Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys Pro Phe 20 25 30 Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn Leu Arg 35 40 45 Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe 50 55 60 Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Ala Lys 65 70 75 80 Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp 85 90 95 Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg Ile His 100 105 110 Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser 115 120 125 Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys 130 135 140 Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn 145 150 155 160 Leu Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu 165 170 <![CDATA[<210> 33]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 33]]> agtgatagag aacgtatg 18 <![CDATA[<210> 34]]> <![CDATA[<211> 9]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 34]]> agtgataga 9 <![CDATA[<210> 35]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 35]]> ctaggtcaag tgtaggag 18 <![CDATA[<210> ]]>36 <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 36]]> taggtaccat agagtgag 18 <![CDATA[<210> 37]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 37]]> taggtaccat agagtgaggc gaggatg 27 <![CDATA[<210> 38]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 38]]> gagtagaaaa gaaacaca 18 <![CDATA[<210> 39]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<400> 39]]> Cys Xaa Cys Xaa His Xaa His 1 5 <![CDATA[<210> 40]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(10)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (12)..(12)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (16)..(16)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<400> 40]]> Cys Xaa Cys Xaa Cys Xaa His Xaa Xaa Xaa Cys Xaa Cys Xaa Cys Xaa 1 5 10 15 Cys <![CDATA[<210> 41]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(10)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (12)..(12)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (16)..(16)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<400> 41]]> Cys Xaa Cys Xaa Cys Xaa Cys Xaa Xaa Xaa His Xaa Cys Xaa Cys Xaa 1 5 10 15 Cys <![CDATA[<210> 42]]> <![CDATA[<211> 15]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..]]>(4) <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(8)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (10)..(10)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (12)..(12)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (15)..(15)]]> <![CDATA[<223> Cys, His, 或 Asp]]> <![CDATA[<400> 42]]> Cys Xaa Cys Xaa His Xaa Cys Xaa Cys Xaa Cys Xaa Cys Xaa Xaa 1 5 10 15 <![CDATA[<210> 43]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(10)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (12)..(12)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (16)..(16)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<400> 43]]> Cys Xaa Cys Xaa Cys Xaa Cys Xaa Xaa Xaa Cys Xaa Cys Xaa Cys Xaa 1 5 10 15 Cys <![CDATA[<210> 44]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<400> 44]]> Cys Xaa Cys Xaa Cys Xaa His 1 5 <![CDATA[<210> 45]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<400> 45]]> Cys Xaa Cys Xaa His Xaa Cys 1 5 <![CDATA[<210> 46]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(10)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (12)..(12)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (16)..(16)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<400> 46]]> Cys Xaa Cys Xaa His Xaa Cys Xaa Xaa Xaa Cys Xaa Cys Xaa His Xaa 1 5 10 15 Cys <![CDATA[<210> 47]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD]]>_RES <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(10)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (12)..(12)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (16)..(16)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<400> 47]]> Cys Xaa Cys Xaa Cys Xaa Cys Xaa Xaa Xaa Cys Xaa Cys Xaa His Xaa 1 5 10 15 Cys <![CDATA[<210> 48]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<400> 48]]> Cys Xaa Cys Xaa Cys Xaa Cys 1 5 <![CDATA[<210> 49]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (2)..(2)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> ]]>MOD_RES <![CDATA[<222> (4)..(4)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (6)..(6)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(10)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (12)..(12)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (14)..(14)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (16)..(16)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<400> 49]]> Cys Xaa Cys Xaa Cys Xaa Cys Xaa Xaa Xaa Cys Xaa His Xaa His Xaa 1 5 10 15 Cys <![CDATA[<210> 50]]> <![CDATA[<211> 220]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 50]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser 50 55 60 Arg Arg Thr Cys Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg Ala His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 165 170 175 Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala 210 215 220 <![CDATA[<210> 51]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 51]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser 50 55 60 Arg Arg Thr Cys Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg Ala His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 165 170 175 Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 52]]> <![CDATA[<211> 497]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 52]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser 50 55 60 Arg Arg Thr Cys Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg Ala His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 165 170 175 Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Met Ser 210 215 220 Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly Arg Phe 225 230 235 240 Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg Met Gly 245 250 255 Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln Pro Gln 260 265 270 His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly Ala Gly 275 280 285 Asn Met Asn Ala Thr Ser Gly Ile Arg His Ala Met Gly Pro Gly Thr 290 295 300 Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala Arg Phe 305 310 315 320 Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly Gly Ser 325 330 335 Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr Phe Asn 340 345 350 His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His Pro Ala 355 360 365 Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp Cys Asn 370 375 380 Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly Gly Ser 385 390 395 400 Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala Gly Ser 405 410 415 Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala Ser Val 420 425 430 Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp Thr Asp 435 440 445 Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met Gly Leu 450 455 460 Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn Glu Phe 465 470 475 480 Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg Val Ser 485 490 495 Cys <![CDATA[<210> 53]]> <![CDATA[<211> 406]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 53]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser 50 55 60 Arg Arg Thr Cys Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg Ala His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 165 170 175 Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Met Ala 210 215 220 Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro 225 230 235 240 Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro 245 250 255 Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro 260 265 270 Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala 275 280 285 Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro 290 295 300 Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly 305 310 315 320 Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln 325 330 335 Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly 340 345 350 Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu 355 360 365 Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu 370 375 380 Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro 385 390 395 400 Ala Gly Ser Val Ser Cys 405 <![CDATA[<210> 54]]> <![CDATA[<211> 597]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 54]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala Ala 195 200 205 Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 210 215 220 Phe Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr Gly 225 230 235 240 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser Arg 245 250 255 Arg Thr Cys Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 260 265 270 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu Val 275 280 285 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 290 295 300 Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg Ala His Gln Arg 305 310 315 320 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 325 330 335 Phe Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr Gly 340 345 350 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Arg 355 360 365 Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 370 375 380 Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys 385 390 395 400 Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Met Ala Asp 405 410 415 His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro Ser 420 425 430 Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro Tyr 435 440 445 Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro Leu 450 455 460 Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala Phe 465 470 475 480 Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro Ala 485 490 495 Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly Arg 500 505 510 Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln Pro 515 520 525 Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly Gly 530 535 540 Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu Leu 545 550 555 560 Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu Gly 565 570 575 Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro Ala 580 585 590 Gly Ser Val Ser Cys 595 <![CDATA[<210> 55]]> <![CDATA[<211> 479]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 55]]> Met Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 1 5 10 15 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 20 25 30 Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg Asp Glu Leu Asn Val His 35 40 45 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 50 55 60 Arg Asn Phe Ser Ser Arg Arg Thr Cys Arg Ala His Ile Arg Thr His 65 70 75 80 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 85 90 95 Gln Ser Ser Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys 100 105 110 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 115 120 125 Gln Leu Ala His Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys 130 135 140 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly Asn 145 150 155 160 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 165 170 175 Asp Ile Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr Asn His 180 185 190 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ser Gly Leu 195 200 205 Glu Met Ala Asp His Met Met Ala Met Asn His Gly Arg Phe Pro Asp 210 215 220 Gly Thr Asn Gly Leu His His His Pro Ala His Arg Met Gly Met Gly 225 230 235 240 Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln Pro Gln His Ala 245 250 255 Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly Ala Gly Asn Met 260 265 270 Asn Ala Thr Ser Gly Ile Arg His Ala Met Gly Pro Gly Thr Val Asn 275 280 285 Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala Arg Phe Asn Asn 290 295 300 Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly Gly Ser Leu Pro 305 310 315 320 Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr Phe Asn His His 325 330 335 Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His Pro Ala Ala Gly 340 345 350 His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp Cys Asn Pro Lys 355 360 365 His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly Gly Ser Ser Thr 370 375 380 Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala Gly Ser Ser Asn 385 390 395 400 Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala Ser Val Ala His 405 410 415 Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp Thr Asp Phe Ile 420 425 430 Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met Gly Leu Asp Arg 435 440 445 Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn Glu Phe Asp Phe 450 455 460 Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg Val Ser Cys 465 470 475 <![CDATA[<210> 56]]> <![CDATA[<211> 476]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 56]]> Met Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly 1 5 10 15 Arg Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg 20 25 30 Met Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln 35 40 45 Pro Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly 50 55 60 Ala Gly Asn Met Asn Ala Thr Ser Gly Val Arg His Ala Met Gly Pro 65 70 75 80 Gly Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala 85 90 95 Arg Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly 100 105 110 Gly Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr 115 120 125 Phe Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His 130 135 140 Pro Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp 145 150 155 160 Cys Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly 165 170 175 Gly Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala 180 185 190 Gly Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala 195 200 205 Ser Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp 210 215 220 Thr Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met 225 230 235 240 Gly Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn 245 250 255 Glu Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg 260 265 270 Val Ser Cys Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr 275 280 285 Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys 290 295 300 Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg Asp Glu Leu Asn 305 310 315 320 Val His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile 325 330 335 Cys Met Arg Asn Phe Ser Ser Arg Arg Thr Cys Arg Ala His Ile Arg 340 345 350 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 355 360 365 Phe Ala Gln Ser Ser Asn Leu Val Arg His Thr Lys Ile His Leu Arg 370 375 380 Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg 385 390 395 400 Phe Ser Gln Leu Ala His Leu Arg Ala His Ile Arg Ile His Thr Gly 405 410 415 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser 420 425 430 Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 435 440 445 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr 450 455 460 Asn His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 465 470 475 <![CDATA[<210> 57]]> <![CDATA[<211> 479]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 57]]> Met Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 1 5 10 15 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 20 25 30 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His 35 40 45 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 50 55 60 Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His 65 70 75 80 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 85 90 95 Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys 100 105 110 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 115 120 125 Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys 130 135 140 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly His 145 150 155 160 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 165 170 175 Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr Glu His 180 185 190 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ser Gly Leu 195 200 205 Glu Met Ala Asp His Met Met Ala Met Asn His Gly Arg Phe Pro Asp 210 215 220 Gly Thr Asn Gly Leu His His His Pro Ala His Arg Met Gly Met Gly 225 230 235 240 Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln Pro Gln His Ala 245 250 255 Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly Ala Gly Asn Met 260 265 270 Asn Ala Thr Ser Gly Ile Arg His Ala Met Gly Pro Gly Thr Val Asn 275 280 285 Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala Arg Phe Asn Asn 290 295 300 Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly Gly Ser Leu Pro 305 310 315 320 Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr Phe Asn His His 325 330 335 Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His Pro Ala Ala Gly 340 345 350 His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp Cys Asn Pro Lys 355 360 365 His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly Gly Ser Ser Thr 370 375 380 Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala Gly Ser Ser Asn 385 390 395 400 Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala Ser Val Ala His 405 410 415 Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp Thr Asp Phe Ile 420 425 430 Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met Gly Leu Asp Arg 435 440 445 Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn Glu Phe Asp Phe 450 455 460 Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg Val Ser Cys 465 470 475 <![CDATA[<210> 58]]> <![CDATA[<211> 476]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 58]]> Met Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly 1 5 10 15 Arg Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg 20 25 30 Met Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln 35 40 45 Pro Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly 50 55 60 Ala Gly Asn Met Asn Ala Thr Ser Gly Val Arg His Ala Met Gly Pro 65 70 75 80 Gly Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala 85 90 95 Arg Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly 100 105 110 Gly Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr 115 120 125 Phe Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His 130 135 140 Pro Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp 145 150 155 160 Cys Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly 165 170 175 Gly Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala 180 185 190 Gly Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala 195 200 205 Ser Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp 210 215 220 Thr Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met 225 230 235 240 Gly Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn 245 250 255 Glu Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg 260 265 270 Val Ser Cys Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr 275 280 285 Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys 290 295 300 Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val 305 310 315 320 Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile 325 330 335 Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg 340 345 350 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 355 360 365 Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile His Leu Arg 370 375 380 Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg 385 390 395 400 Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly 405 410 415 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser 420 425 430 Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 435 440 445 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr 450 455 460 Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 465 470 475 <![CDATA[<210> 59]]> <![CDATA[<211> 479]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (278)..(278)]]> <![CDATA[<223> Ile 或 Val]]> <![CDATA[<400> 59]]> Met Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 1 5 10 15 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 20 25 30 Glu Ser Cys Asp Arg Arg Phe Ser Ser Pro Ala Asp Leu Thr Arg His 35 40 45 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 50 55 60 Arg Asn Phe Ser Asp Ser Gly Asn Leu Arg Val His Ile Arg Thr His 65 70 75 80 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 85 90 95 Gln Leu Ala His Leu Arg Ala His Thr Lys Ile His Leu Arg Gln Lys 100 105 110 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 115 120 125 Gln Arg Ala Asn Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys 130 135 140 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn 145 150 155 160 Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 165 170 175 Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Leu Val Arg His 180 185 190 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ser Gly Leu 195 200 205 Glu Met Ala Asp His Met Met Ala Met Asn His Gly Arg Phe Pro Asp 210 215 220 Gly Thr Asn Gly Leu His His His Pro Ala His Arg Met Gly Met Gly 225 230 235 240 Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln Pro Gln His Ala 245 250 255 Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly Ala Gly Asn Met 260 265 270 Asn Ala Thr Ser Gly Xaa Arg His Ala Met Gly Pro Gly Thr Val Asn 275 280 285 Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala Arg Phe Asn Asn 290 295 300 Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly Gly Ser Leu Pro 305 310 315 320 Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr Phe Asn His His 325 330 335 Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His Pro Ala Ala Gly 340 345 350 His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp Cys Asn Pro Lys 355 360 365 His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly Gly Ser Ser Thr 370 375 380 Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala Gly Ser Ser Asn 385 390 395 400 Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala Ser Val Ala His 405 410 415 Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp Thr Asp Phe Ile 420 425 430 Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met Gly Leu Asp Arg 435 440 445 Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn Glu Phe Asp Phe 450 455 460 Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg Val Ser Cys 465 470 475 <![CDATA[<210> 60]]> <![CDATA[<211> 476]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 60]]> Met Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly 1 5 10 15 Arg Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg 20 25 30 Met Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln 35 40 45 Pro Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly 50 55 60 Ala Gly Asn Met Asn Ala Thr Ser Gly Val Arg His Ala Met Gly Pro 65 70 75 80 Gly Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala 85 90 95 Arg Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly 100 105 110 Gly Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr 115 120 125 Phe Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His 130 135 140 Pro Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp 145 150 155 160 Cys Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly 165 170 175 Gly Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala 180 185 190 Gly Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala 195 200 205 Ser Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp 210 215 220 Thr Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met 225 230 235 240 Gly Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn 245 250 255 Glu Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg 260 265 270 Val Ser Cys Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr 275 280 285 Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys 290 295 300 Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg Asp Glu Leu Asn 305 310 315 320 Val His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile 325 330 335 Cys Met Arg Asn Phe Ser Ser Arg Arg Thr Cys Arg Ala His Ile Arg 340 345 350 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 355 360 365 Phe Ala Gln Ser Ser Asn Leu Val Arg His Thr Lys Ile His Leu Arg 370 375 380 Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg 385 390 395 400 Phe Ser Gln Leu Ala His Leu Arg Ala His Ile Arg Ile His Thr Gly 405 410 415 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser 420 425 430 Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 435 440 445 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr 450 455 460 Asn His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 465 470 475 <![CDATA[<210> 61]]> <![CDATA[<211> 388]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 61]]> Met Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 1 5 10 15 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 20 25 30 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His 35 40 45 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 50 55 60 Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His 65 70 75 80 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 85 90 95 Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys 100 105 110 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 115 120 125 Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys 130 135 140 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly His 145 150 155 160 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 165 170 175 Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr Glu His 180 185 190 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ala Asp His 195 200 205 Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro Ser Ala 210 215 220 Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro Tyr Ala 225 230 235 240 Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro Leu Gly 245 250 255 Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala Phe Gly 260 265 270 Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro Ala Ala 275 280 285 Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly Arg Ala 290 295 300 Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln Pro Ala 305 310 315 320 Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly Gly Met 325 330 335 Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu Leu Glu 340 345 350 Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu Gly Gln 355 360 365 Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro Ala Gly 370 375 380 Ser Val Ser Cys 385 <![CDATA[<210> 62]]> <![CDATA[<211> 580]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 62]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 195 200 205 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 210 215 220 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His 225 230 235 240 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 245 250 255 Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His 260 265 270 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 275 280 285 Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys 290 295 300 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 305 310 315 320 Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys 325 330 335 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly His 340 345 350 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 355 360 365 Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr Glu His 370 375 380 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ala Asp His 385 390 395 400 Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro Ser Ala 405 410 415 Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro Tyr Ala 420 425 430 Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro Leu Gly 435 440 445 Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala Phe Gly 450 455 460 Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro Ala Ala 465 470 475 480 Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly Arg Ala 485 490 495 Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln Pro Ala 500 505 510 Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly Gly Met 515 520 525 Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu Leu Glu 530 535 540 Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu Gly Gln 545 550 555 560 Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro Ala Gly 565 570 575 Ser Val Ser Cys 580 <![CDATA[<210> 63]]> <![CDATA[<211> 388]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 63]]> Met Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 1 5 10 15 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 20 25 30 Glu Ser Cys Asp Arg Arg Phe Ser Ser Pro Ala Asp Leu Thr Arg His 35 40 45 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 50 55 60 Arg Asn Phe Ser Asp Ser Gly Asn Leu Arg Val His Ile Arg Thr His 65 70 75 80 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 85 90 95 Gln Leu Ala His Leu Arg Ala His Thr Lys Ile His Leu Arg Gln Lys 100 105 110 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 115 120 125 Gln Arg Ala Asn Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys 130 135 140 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn 145 150 155 160 Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 165 170 175 Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Leu Val Arg His 180 185 190 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ala Asp His 195 200 205 Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro Ser Ala 210 215 220 Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro Tyr Ala 225 230 235 240 Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro Leu Gly 245 250 255 Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala Phe Gly 260 265 270 Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro Ala Ala 275 280 285 Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly Arg Ala 290 295 300 Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln Pro Ala 305 310 315 320 Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly Gly Met 325 330 335 Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu Leu Glu 340 345 350 Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu Gly Gln 355 360 365 Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro Ala Gly 370 375 380 Ser Val Ser Cys 385 <![CDATA[<210> 64]]> <![CDATA[<211> 580]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 64]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 195 200 205 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 210 215 220 Glu Ser Cys Asp Arg Arg Phe Ser Ser Pro Ala Asp Leu Thr Arg His 225 230 235 240 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 245 250 255 Arg Asn Phe Ser Asp Ser Gly Asn Leu Arg Val His Ile Arg Thr His 260 265 270 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 275 280 285 Gln Leu Ala His Leu Arg Ala His Thr Lys Ile His Leu Arg Gln Lys 290 295 300 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 305 310 315 320 Gln Arg Ala Asn Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys 325 330 335 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn 340 345 350 Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 355 360 365 Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Leu Val Arg His 370 375 380 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ala Asp His 385 390 395 400 Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro Ser Ala 405 410 415 Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro Tyr Ala 420 425 430 Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro Leu Gly 435 440 445 Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala Phe Gly 450 455 460 Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro Ala Ala 465 470 475 480 Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly Arg Ala 485 490 495 Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln Pro Ala 500 505 510 Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly Gly Met 515 520 525 Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu Leu Glu 530 535 540 Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu Gly Gln 545 550 555 560 Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro Ala Gly 565 570 575 Ser Val Ser Cys 580 <![CDATA[<210> 65]]> <![CDATA[<211> 388]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 65]]> Met Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 1 5 10 15 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 20 25 30 Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg Asp Glu Leu Asn Val His 35 40 45 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 50 55 60 Arg Asn Phe Ser Ser Arg Arg Thr Cys Arg Ala His Ile Arg Thr His 65 70 75 80 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 85 90 95 Gln Ser Ser Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys 100 105 110 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 115 120 125 Gln Leu Ala His Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys 130 135 140 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly Asn 145 150 155 160 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 165 170 175 Asp Ile Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr Asn His 180 185 190 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ala Asp His 195 200 205 Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro Ser Ala 210 215 220 Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro Tyr Ala 225 230 235 240 Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro Leu Gly 245 250 255 Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala Phe Gly 260 265 270 Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro Ala Ala 275 280 285 Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly Arg Ala 290 295 300 Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln Pro Ala 305 310 315 320 Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly Gly Met 325 330 335 Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu Leu Glu 340 345 350 Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu Gly Gln 355 360 365 Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro Ala Gly 370 375 380 Ser Val Ser Cys 385 <![CDATA[<210> 66]]> <![CDATA[<211> 580]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 66]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 195 200 205 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 210 215 220 Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg Asp Glu Leu Asn Val His 225 230 235 240 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 245 250 255 Arg Asn Phe Ser Ser Arg Arg Thr Cys Arg Ala His Ile Arg Thr His 260 265 270 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 275 280 285 Gln Ser Ser Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys 290 295 300 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 305 310 315 320 Gln Leu Ala His Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys 325 330 335 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly Asn 340 345 350 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 355 360 365 Asp Ile Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr Asn His 370 375 380 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ala Asp His 385 390 395 400 Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro Ser Ala 405 410 415 Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro Tyr Ala 420 425 430 Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro Leu Gly 435 440 445 Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala Phe Gly 450 455 460 Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro Ala Ala 465 470 475 480 Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly Arg Ala 485 490 495 Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln Pro Ala 500 505 510 Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly Gly Met 515 520 525 Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu Leu Glu 530 535 540 Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu Gly Gln 545 550 555 560 Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro Ala Gly 565 570 575 Ser Val Ser Cys 580 <![CDATA[<210> 67]]> <![CDATA[<211> 580]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 67]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 195 200 205 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 210 215 220 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His 225 230 235 240 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 245 250 255 Arg Asn Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His 260 265 270 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 275 280 285 Arg Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys 290 295 300 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 305 310 315 320 Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys 325 330 335 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser 340 345 350 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 355 360 365 Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His 370 375 380 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ala Asp His 385 390 395 400 Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro Ser Ala 405 410 415 Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro Tyr Ala 420 425 430 Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro Leu Gly 435 440 445 Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala Phe Gly 450 455 460 Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro Ala Ala 465 470 475 480 Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly Arg Ala 485 490 495 Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln Pro Ala 500 505 510 Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly Gly Met 515 520 525 Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu Leu Glu 530 535 540 Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu Gly Gln 545 550 555 560 Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro Ala Gly 565 570 575 Ser Val Ser Cys 580 <![CDATA[<210> 68]]> <![CDATA[<211> 394]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 68]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 195 200 205 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 210 215 220 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His 225 230 235 240 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 245 250 255 Arg Asn Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His 260 265 270 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 275 280 285 Arg Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys 290 295 300 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 305 310 315 320 Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys 325 330 335 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser 340 345 350 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 355 360 365 Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His 370 375 380 Thr Lys Ile His Leu Arg Gln Lys Asp Lys 385 390 <![CDATA[<210> 69]]> <![CDATA[<211> 394]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 69]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 195 200 205 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 210 215 220 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His 225 230 235 240 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 245 250 255 Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His 260 265 270 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 275 280 285 Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys 290 295 300 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 305 310 315 320 Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys 325 330 335 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly His 340 345 350 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 355 360 365 Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr Glu His 370 375 380 Thr Lys Ile His Leu Arg Gln Lys Asp Lys 385 390 <![CDATA[<210> 70]]> <![CDATA[<211> 479]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 70]]> Met Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 1 5 10 15 Arg Ser Asp Asn Leu Val Arg His Leu Arg Ile His Thr Gly His Lys 20 25 30 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Glu Asp Asn 35 40 45 Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 50 55 60 Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His 65 70 75 80 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 85 90 95 Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Leu Arg 100 105 110 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 115 120 125 Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Gln Asn 145 150 155 160 Ser Thr Leu Thr Glu His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 165 170 175 Lys Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro Pro Val 180 185 190 Ser Leu Ala Pro Val Val Thr Thr Cys Ala Leu Glu Met Ser Gly Leu 195 200 205 Glu Met Ala Asp His Met Met Ala Met Asn His Gly Arg Phe Pro Asp 210 215 220 Gly Thr Asn Gly Leu His His His Pro Ala His Arg Met Gly Met Gly 225 230 235 240 Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln Pro Gln His Ala 245 250 255 Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly Ala Gly Asn Met 260 265 270 Asn Ala Thr Ser Gly Ile Arg His Ala Met Gly Pro Gly Thr Val Asn 275 280 285 Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala Arg Phe Asn Asn 290 295 300 Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly Gly Ser Leu Pro 305 310 315 320 Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr Phe Asn His His 325 330 335 Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His Pro Ala Ala Gly 340 345 350 His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp Cys Asn Pro Lys 355 360 365 His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly Gly Ser Ser Thr 370 375 380 Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala Gly Ser Ser Asn 385 390 395 400 Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala Ser Val Ala His 405 410 415 Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp Thr Asp Phe Ile 420 425 430 Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met Gly Leu Asp Arg 435 440 445 Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn Glu Phe Asp Phe 450 455 460 Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg Val Ser Cys 465 470 475 <![CDATA[<210> 71]]> <![CDATA[<211> 476]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 71]]> Met Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly 1 5 10 15 Arg Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg 20 25 30 Met Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln 35 40 45 Pro Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly 50 55 60 Ala Gly Asn Met Asn Ala Thr Ser Gly Val Arg His Ala Met Gly Pro 65 70 75 80 Gly Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala 85 90 95 Arg Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly 100 105 110 Gly Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr 115 120 125 Phe Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His 130 135 140 Pro Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp 145 150 155 160 Cys Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly 165 170 175 Gly Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala 180 185 190 Gly Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala 195 200 205 Ser Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp 210 215 220 Thr Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met 225 230 235 240 Gly Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn 245 250 255 Glu Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg 260 265 270 Val Ser Cys Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg 275 280 285 Phe Ser Arg Ser Asp Asn Leu Val Arg His Leu Arg Ile His Thr Gly 290 295 300 His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Glu 305 310 315 320 Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 325 330 335 Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val 340 345 350 Arg His Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala 355 360 365 Glu Gly Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His 370 375 380 Leu Arg Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met 385 390 395 400 Arg Ser Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His 405 410 415 Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala 420 425 430 Gln Asn Ser Thr Leu Thr Glu His Ala Lys Ile His Leu Lys Gln Lys 435 440 445 Glu Lys Lys Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro 450 455 460 Pro Val Ser Leu Ala Pro Val Val Thr Thr Cys Ala 465 470 475 <![CDATA[<210> 72]]> <![CDATA[<211> 479]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (278)..(278)]]> <![CDATA[<223> Ile 或 Val]]> <![CDATA[<400> 72]]> Met Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 1 5 10 15 Ser Pro Ala Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys 20 25 30 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn 35 40 45 Leu Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 50 55 60 Glu Phe Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His 65 70 75 80 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 85 90 95 Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg 100 105 110 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 115 120 125 Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 165 170 175 Lys Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro Pro Val 180 185 190 Ser Leu Ala Pro Val Val Thr Thr Cys Ala Leu Glu Met Ser Gly Leu 195 200 205 Glu Met Ala Asp His Met Met Ala Met Asn His Gly Arg Phe Pro Asp 210 215 220 Gly Thr Asn Gly Leu His His His Pro Ala His Arg Met Gly Met Gly 225 230 235 240 Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln Pro Gln His Ala 245 250 255 Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly Ala Gly Asn Met 260 265 270 Asn Ala Thr Ser Gly Xaa Arg His Ala Met Gly Pro Gly Thr Val Asn 275 280 285 Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala Arg Phe Asn Asn 290 295 300 Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly Gly Ser Leu Pro 305 310 315 320 Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr Phe Asn His His 325 330 335 Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His Pro Ala Ala Gly 340 345 350 His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp Cys Asn Pro Lys 355 360 365 His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly Gly Ser Ser Thr 370 375 380 Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala Gly Ser Ser Asn 385 390 395 400 Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala Ser Val Ala His 405 410 415 Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp Thr Asp Phe Ile 420 425 430 Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met Gly Leu Asp Arg 435 440 445 Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn Glu Phe Asp Phe 450 455 460 Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg Val Ser Cys 465 470 475 <![CDATA[<210> 73]]> <![CDATA[<211> 476]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 73]]> Met Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly 1 5 10 15 Arg Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg 20 25 30 Met Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln 35 40 45 Pro Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly 50 55 60 Ala Gly Asn Met Asn Ala Thr Ser Gly Val Arg His Ala Met Gly Pro 65 70 75 80 Gly Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala 85 90 95 Arg Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly 100 105 110 Gly Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr 115 120 125 Phe Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His 130 135 140 Pro Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp 145 150 155 160 Cys Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly 165 170 175 Gly Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala 180 185 190 Gly Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala 195 200 205 Ser Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp 210 215 220 Thr Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met 225 230 235 240 Gly Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn 245 250 255 Glu Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg 260 265 270 Val Ser Cys Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg 275 280 285 Phe Ser Ser Pro Ala Asp Leu Thr Arg His Leu Arg Ile His Thr Gly 290 295 300 His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser 305 310 315 320 Gly Asn Leu Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 325 330 335 Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg 340 345 350 Ala His Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala 355 360 365 Glu Gly Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His 370 375 380 Leu Arg Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met 385 390 395 400 Arg Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His 405 410 415 Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala 420 425 430 Arg Ser Asp Asn Leu Val Arg His Ala Lys Ile His Leu Lys Gln Lys 435 440 445 Glu Lys Lys Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro 450 455 460 Pro Val Ser Leu Ala Pro Val Val Thr Thr Cys Ala 465 470 475 <![CDATA[<210>]]> 74 <![CDATA[<211> 362]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 74]]> Met Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 1 5 10 15 Arg Ser Asp Asn Leu Val Arg His Leu Arg Ile His Thr Gly His Lys 20 25 30 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Glu Asp Asn 35 40 45 Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 50 55 60 Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His 65 70 75 80 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 85 90 95 Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Leu Arg 100 105 110 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 115 120 125 Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Gln Asn 145 150 155 160 Ser Thr Leu Thr Glu His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 165 170 175 Leu Glu Met Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val 180 185 190 Gln Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg 195 200 205 Thr Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro 210 215 220 Arg Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu 225 230 235 240 Ala Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala 245 250 255 Val Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr 260 265 270 Pro Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro 275 280 285 Pro Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala 290 295 300 His Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu 305 310 315 320 Thr Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro 325 330 335 Glu Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly 340 345 350 Ser Ala Pro Pro Ala Gly Ser Val Ser Cys 355 360 <![CDATA[<210> 75]]> <![CDATA[<211> 554]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 75]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 195 200 205 Arg Ser Asp Asn Leu Val Arg His Leu Arg Ile His Thr Gly His Lys 210 215 220 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Glu Asp Asn 225 230 235 240 Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 245 250 255 Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His 260 265 270 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 275 280 285 Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Leu Arg 290 295 300 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 305 310 315 320 Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly 325 330 335 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Gln Asn 340 345 350 Ser Thr Leu Thr Glu His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 355 360 365 Leu Glu Met Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val 370 375 380 Gln Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg 385 390 395 400 Thr Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro 405 410 415 Arg Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu 420 425 430 Ala Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala 435 440 445 Val Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr 450 455 460 Pro Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro 465 470 475 480 Pro Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala 485 490 495 His Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu 500 505 510 Thr Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro 515 520 525 Glu Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly 530 535 540 Ser Ala Pro Pro Ala Gly Ser Val Ser Cys 545 550 <![CDATA[<210> 76]]> <![CDATA[<211> 362]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 7]]>6 Met Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 1 5 10 15 Ser Pro Ala Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys 20 25 30 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn 35 40 45 Leu Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 50 55 60 Glu Phe Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His 65 70 75 80 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 85 90 95 Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg 100 105 110 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 115 120 125 Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 165 170 175 Leu Glu Met Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val 180 185 190 Gln Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg 195 200 205 Thr Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro 210 215 220 Arg Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu 225 230 235 240 Ala Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala 245 250 255 Val Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr 260 265 270 Pro Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro 275 280 285 Pro Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala 290 295 300 His Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu 305 310 315 320 Thr Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro 325 330 335 Glu Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly 340 345 350 Ser Ala Pro Pro Ala Gly Ser Val Ser Cys 355 360 <![CDATA[<210> 77]]> <![CDATA[<211> 554]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 77]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 195 200 205 Ser Pro Ala Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys 210 215 220 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn 225 230 235 240 Leu Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 245 250 255 Glu Phe Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His 260 265 270 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 275 280 285 Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg 290 295 300 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 305 310 315 320 Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly 325 330 335 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 355 360 365 Leu Glu Met Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val 370 375 380 Gln Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg 385 390 395 400 Thr Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro 405 410 415 Arg Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu 420 425 430 Ala Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala 435 440 445 Val Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr 450 455 460 Pro Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro 465 470 475 480 Pro Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala 485 490 495 His Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu 500 505 510 Thr Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro 515 520 525 Glu Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly 530 535 540 Ser Ala Pro Pro Ala Gly Ser Val Ser Cys 545 550 <![CDATA[<210> 78]]> <![CDATA[<211> 453]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 78]]> Met Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 1 5 10 15 Arg Arg Asp Glu Leu Asn Val His Leu Arg Ile His Thr Gly His Lys 20 25 30 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Ser Arg Arg Thr 35 40 45 Cys Arg Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 50 55 60 Glu Phe Cys Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His 65 70 75 80 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 85 90 95 Cys Asp Arg Arg Phe Ser Gln Leu Ala His Leu Arg Ala His Leu Arg 100 105 110 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 115 120 125 Phe Ser Thr Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala His Arg 145 150 155 160 Thr Thr Leu Thr Asn His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 165 170 175 Leu Glu Met Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn 180 185 190 His Gly Arg Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala 195 200 205 His Arg Met Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln 210 215 220 Gln Gln Pro Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His 225 230 235 240 Tyr Gly Ala Gly Asn Met Asn Ala Thr Ser Gly Ile Arg His Ala Met 245 250 255 Gly Pro Gly Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro 260 265 270 Ala Ala Arg Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser 275 280 285 Gln Gly Gly Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn 290 295 300 Gln Tyr Phe Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp 305 310 315 320 Leu His Pro Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe 325 330 335 Arg Asp Cys Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly 340 345 350 Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly 355 360 365 Gly Ala Gly Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met 370 375 380 Pro Ala Ser Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val 385 390 395 400 Ile Asp Thr Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile 405 410 415 Glu Met Gly Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly 420 425 430 Gln Asn Glu Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro 435 440 445 Ser Arg Val Ser Cys 450 <![CDATA[<210> 79]]> <![CDATA[<211> 554]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 79]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 195 200 205 Arg Arg Asp Glu Leu Asn Val His Leu Arg Ile His Thr Gly His Lys 210 215 220 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Ser Arg Arg Thr 225 230 235 240 Cys Arg Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 245 250 255 Glu Phe Cys Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His 260 265 270 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 275 280 285 Cys Asp Arg Arg Phe Ser Gln Leu Ala His Leu Arg Ala His Leu Arg 290 295 300 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 305 310 315 320 Phe Ser Thr Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly 325 330 335 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala His Arg 340 345 350 Thr Thr Leu Thr Asn His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 355 360 365 Leu Glu Met Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val 370 375 380 Gln Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg 385 390 395 400 Thr Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro 405 410 415 Arg Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu 420 425 430 Ala Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala 435 440 445 Val Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr 450 455 460 Pro Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro 465 470 475 480 Pro Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala 485 490 495 His Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu 500 505 510 Thr Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro 515 520 525 Glu Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly 530 535 540 Ser Ala Pro Pro Ala Gly Ser Val Ser Cys 545 550 <![CDATA[<210> 80]]> <![CDATA[<211> 362]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 80]]> Met Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 1 5 10 15 Arg Arg Asp Glu Leu Asn Val His Leu Arg Ile His Thr Gly His Lys 20 25 30 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Ser Arg Arg Thr 35 40 45 Cys Arg Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 50 55 60 Glu Phe Cys Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His 65 70 75 80 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 85 90 95 Cys Asp Arg Arg Phe Ser Gln Leu Ala His Leu Arg Ala His Leu Arg 100 105 110 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 115 120 125 Phe Ser Thr Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala His Arg 145 150 155 160 Thr Thr Leu Thr Asn His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 165 170 175 Leu Glu Met Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val 180 185 190 Gln Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg 195 200 205 Thr Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro 210 215 220 Arg Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu 225 230 235 240 Ala Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala 245 250 255 Val Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr 260 265 270 Pro Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro 275 280 285 Pro Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala 290 295 300 His Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu 305 310 315 320 Thr Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro 325 330 335 Glu Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly 340 345 350 Ser Ala Pro Pro Ala Gly Ser Val Ser Cys 355 360 <![CDATA[<210> 81]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 81]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser Arg 35 40 45 Arg Thr Cys Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg Ala His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Arg 145 150 155 160 Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 82]]> <![CDATA[<211> 202]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 82]]> Met Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 1 5 10 15 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 20 25 30 Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg Asp Glu Leu Asn Val His 35 40 45 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 50 55 60 Arg Asn Phe Ser Ser Arg Arg Thr Cys Arg Ala His Ile Arg Thr His 65 70 75 80 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 85 90 95 Gln Ser Ser Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys 100 105 110 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 115 120 125 Gln Leu Ala His Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys 130 135 140 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly Asn 145 150 155 160 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 165 170 175 Asp Ile Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr Asn His 180 185 190 Thr Lys Ile His Leu Arg Gln Lys Asp Lys 195 200 <![CDATA[<210> 83]]> <![CDATA[<211> 201]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 83]]> Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn Arg 1 5 10 15 Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val Glu 20 25 30 Ser Cys Asp Arg Arg Phe Ser Arg Arg Asp Glu Leu Asn Val His Ile 35 40 45 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 50 55 60 Asn Phe Ser Ser Arg Arg Thr Cys Arg Ala His Ile Arg Thr His Thr 65 70 75 80 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln 85 90 95 Ser Ser Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys Asp 100 105 110 Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Gln 115 120 125 Leu Ala His Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys Pro 130 135 140 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly Asn Leu 145 150 155 160 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 165 170 175 Ile Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu Thr Asn His Thr 180 185 190 Lys Ile His Leu Arg Gln Lys Asp Lys 195 200 <![CDATA[<210> 84]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 84]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg 1 5 10 15 Ser Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu 35 40 45 His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu 85 90 95 Ser Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile 100 105 110 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 115 120 125 Asn Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr 130 135 140 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln 145 150 155 160 Asn Ser Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 175 <![CDATA[<210> 85]]> <![CDATA[<211> 201]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 85]]> Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn Arg 1 5 10 15 Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val Glu 20 25 30 Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile 35 40 45 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 50 55 60 Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr 65 70 75 80 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 85 90 95 Ser Asp Glu Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys Asp 100 105 110 Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Gln 115 120 125 Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro 130 135 140 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly His Leu 145 150 155 160 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 165 170 175 Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr Glu His Thr 180 185 190 Lys Ile His Leu Arg Gln Lys Asp Lys 195 200 <![CDATA[<210> 86]]> <![CDATA[<211> 202]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 86]]> Met Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 1 5 10 15 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 20 25 30 Glu Ser Cys Asp Arg Arg Phe Ser Ser Pro Ala Asp Leu Thr Arg His 35 40 45 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 50 55 60 Arg Asn Phe Ser Asp Ser Gly Asn Leu Arg Val His Ile Arg Thr His 65 70 75 80 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 85 90 95 Gln Leu Ala His Leu Arg Ala His Thr Lys Ile His Leu Arg Gln Lys 100 105 110 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 115 120 125 Gln Arg Ala Asn Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys 130 135 140 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn 145 150 155 160 Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 165 170 175 Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Leu Val Arg His 180 185 190 Thr Lys Ile His Leu Arg Gln Lys Asp Lys 195 200 <![CDATA[<210> 87]]> <![CDATA[<211> 177]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 87]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg 1 5 10 15 Arg Asp Glu Leu Asn Val His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Ser Arg Arg Thr Cys 35 40 45 Arg Ala His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu 85 90 95 Ser Cys Asp Arg Arg Phe Ser Gln Leu Ala His Leu Arg Ala His Ile 100 105 110 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 115 120 125 Asn Phe Ser Thr Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr 130 135 140 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala His 145 150 155 160 Arg Thr Thr Leu Thr Asn His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 175 Lys <![CDATA[<210> 88]]> <![CDATA[<211> 177]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 88]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg 1 5 10 15 Ser Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu 35 40 45 His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu 85 90 95 Ser Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile 100 105 110 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 115 120 125 Asn Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr 130 135 140 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln 145 150 155 160 Asn Ser Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 175 Lys <![CDATA[<210> 89]]> <![CDATA[<211> 177]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 89]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Ser 1 5 10 15 Pro Ala Asp Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Asp Ser Gly Asn Leu 35 40 45 Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu 85 90 95 Ser Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Ile 100 105 110 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 115 120 125 Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr 130 135 140 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 145 150 155 160 Ser Asp Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 175 Lys <![CDATA[<210> 90]]> <![CDATA[<211> 201]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 90]]> Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn Arg 1 5 10 15 Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val Glu 20 25 30 Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile 35 40 45 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 50 55 60 Asn Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr 65 70 75 80 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 85 90 95 Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp 100 105 110 Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Thr 115 120 125 Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro 130 135 140 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser Leu 145 150 155 160 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 165 170 175 Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr 180 185 190 Lys Ile His Leu Arg Gln Lys Asp Lys 195 200 <![CDATA[<210> 91]]> <![CDATA[<211> 201]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 91]]> Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn Arg 1 5 10 15 Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val Glu 20 25 30 Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile 35 40 45 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 50 55 60 Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr 65 70 75 80 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 85 90 95 Ser Asp Glu Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys Asp 100 105 110 Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Gln 115 120 125 Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro 130 135 140 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly His Leu 145 150 155 160 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 165 170 175 Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr Glu His Thr 180 185 190 Lys Ile His Leu Arg Gln Lys Asp Lys 195 200 <![CDATA[<210> 92]]> <![CDATA[<211> 172]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 92]]> His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg Ser Asp 1 5 10 15 Asn Leu Val Arg His Leu Arg Ile His Thr Gly His Lys Pro Phe Gln 20 25 30 Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Glu Asp Asn Leu His Thr 35 40 45 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys 50 55 60 Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Ala Lys Ile 65 70 75 80 His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp Arg 85 90 95 Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Leu Arg Ile His Thr 100 105 110 Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Thr 115 120 125 Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro 130 135 140 Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu 145 150 155 160 Thr Glu His Ala Lys Ile His Leu Lys Gln Lys Glu 165 170 <![CDATA[<210> 93]]> <![CDATA[<211> 172]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 93]]> His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Ser Pro Ala 1 5 10 15 Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys Pro Phe Gln 20 25 30 Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn Leu Arg Val 35 40 45 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys 50 55 60 Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Ala Lys Ile 65 70 75 80 His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp Arg 85 90 95 Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg Ile His Thr 100 105 110 Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg 115 120 125 Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro 130 135 140 Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Leu 145 150 155 160 Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu 165 170 <![CDATA[<210> 94]]> <![CDATA[<211> 172]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 94]]> His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg Arg Asp 1 5 10 15 Glu Leu Asn Val His Leu Arg Ile His Thr Gly His Lys Pro Phe Gln 20 25 30 Cys Arg Ile Cys Met Arg Ser Phe Ser Ser Arg Arg Thr Cys Arg Ala 35 40 45 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys 50 55 60 Gly Arg Lys Phe Ala Gln Ser Ser Asn Leu Val Arg His Ala Lys Ile 65 70 75 80 His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp Arg 85 90 95 Arg Phe Ser Gln Leu Ala His Leu Arg Ala His Leu Arg Ile His Thr 100 105 110 Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Thr 115 120 125 Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro 130 135 140 Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala His Arg Thr Thr Leu 145 150 155 160 Thr Asn His Ala Lys Ile His Leu Lys Gln Lys Glu 165 170 <![CDATA[<210> 95]]> <![CDATA[<211> 50]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 95]]> Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu 1 5 10 15 Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe 20 25 30 Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp 35 40 45 Met Leu 50 <![CDATA[<210> 96]]> <![CDATA[<211> 275]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 96]]> Met Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly 1 5 10 15 Arg Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg 20 25 30 Met Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln 35 40 45 Pro Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly 50 55 60 Ala Gly Asn Met Asn Ala Thr Ser Gly Val Arg His Ala Met Gly Pro 65 70 75 80 Gly Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala 85 90 95 Arg Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly 100 105 110 Gly Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr 115 120 125 Phe Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His 130 135 140 Pro Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp 145 150 155 160 Cys Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly 165 170 175 Gly Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala 180 185 190 Gly Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala 195 200 205 Ser Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp 210 215 220 Thr Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met 225 230 235 240 Gly Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn 245 250 255 Glu Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg 260 265 270 Val Ser Cys 275 <![CDATA[<210> 97]]> <![CDATA[<211> 184]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 97]]> Met Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg 1 5 10 15 Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu 20 25 30 Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly 35 40 45 Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr 50 55 60 Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro 65 70 75 80 Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr 85 90 95 Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly 100 105 110 Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala 115 120 125 Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser 130 135 140 Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu 145 150 155 160 Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala 165 170 175 Pro Pro Ala Gly Ser Val Ser Cys 180 <![CDATA[<210> 98]]> <![CDATA[<211> 274]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 98]]> Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly Arg 1 5 10 15 Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg Met 20 25 30 Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln Pro 35 40 45 Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly Ala 50 55 60 Gly Asn Met Asn Ala Thr Ser Gly Val Arg His Ala Met Gly Pro Gly 65 70 75 80 Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala Arg 85 90 95 Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly Gly 100 105 110 Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr Phe 115 120 125 Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His Pro 130 135 140 Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp Cys 145 150 155 160 Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly Gly 165 170 175 Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala Gly 180 185 190 Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala Ser 195 200 205 Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp Thr 210 215 220 Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met Gly 225 230 235 240 Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn Glu 245 250 255 Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg Val 260 265 270 Ser Cys <![CDATA[<210> 99]]> <![CDATA[<211> 275]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 99]]> Met Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly 1 5 10 15 Arg Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg 20 25 30 Met Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln 35 40 45 Pro Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly 50 55 60 Ala Gly Asn Met Asn Ala Thr Ser Gly Val Arg His Ala Met Gly Pro 65 70 75 80 Gly Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala 85 90 95 Arg Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly 100 105 110 Gly Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr 115 120 125 Phe Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His 130 135 140 Pro Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp 145 150 155 160 Cys Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly 165 170 175 Gly Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala 180 185 190 Gly Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala 195 200 205 Ser Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp 210 215 220 Thr Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met 225 230 235 240 Gly Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn 245 250 255 Glu Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg 260 265 270 Val Ser Cys 275 <![CDATA[<210> 100]]> <![CDATA[<211> 184]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 100]]> Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg 1 5 10 15 Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu 20 25 30 Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly 35 40 45 Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr 50 55 60 Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro 65 70 75 80 Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr 85 90 95 Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly 100 105 110 Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala 115 120 125 Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser 130 135 140 Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu 145 150 155 160 Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala 165 170 175 Pro Pro Ala Gly Ser Val Ser Cys 180 <![CDATA[<210> 101]]> <![CDATA[<400> 101]]> 000 <![CDATA[<210> 102]]> <![CDATA[<211> 76]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成寡核苷酸]]> <![CDATA[<400> 102]]> gttttagtac tctggaaaca gaatctacta aaacaaggca aaatgccgtg tttatctcgt 60 caacttgttg gcgaga 76 <![CDATA[<210> 103]]> <![CDATA[<211> 1052]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 103]]> Lys Arg Asn Tyr Ile Leu Gly Leu Ala Ile Gly Ile Thr Ser Val Gly 1 5 10 15 Tyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly Val 20 25 30 Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg Ser 35 40 45 Lys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile Gln 50 55 60 Arg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His Ser 65 70 75 80 Glu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu Ser 85 90 95 Gln Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu Ala 100 105 110 Lys Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr Gly 115 120 125 Asn Glu Leu Ser Thr Lys Glu Gln Ile Ser Arg Asn Ser Lys Ala Leu 130 135 140 Glu Glu Lys Tyr Val Ala Glu Leu Gln Leu Glu Arg Leu Lys Lys Asp 145 150 155 160 Gly Glu Val Arg Gly Ser Ile Asn Arg Phe Lys Thr Ser Asp Tyr Val 165 170 175 Lys Glu Ala Lys Gln Leu Leu Lys Val Gln Lys Ala Tyr His Gln Leu 180 185 190 Asp Gln Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg Arg 195 200 205 Thr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp Lys Asp 210 215 220 Ile Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe Pro 225 230 235 240 Glu Glu Leu Arg Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr Asn 245 250 255 Ala Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn Glu 260 265 270 Lys Leu Glu Tyr Tyr Glu Lys Phe Gln Ile Ile Glu Asn Val Phe Lys 275 280 285 Gln Lys Lys Lys Pro Thr Leu Lys Gln Ile Ala Lys Glu Ile Leu Val 290 295 300 Asn Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys Pro 305 310 315 320 Glu Phe Thr Asn Leu Lys Val Tyr His Asp Ile Lys Asp Ile Thr Ala 325 330 335 Arg Lys Glu Ile Ile Glu Asn Ala Glu Leu Leu Asp Gln Ile Ala Lys 340 345 350 Ile Leu Thr Ile Tyr Gln Ser Ser Glu Asp Ile Gln Glu Glu Leu Thr 355 360 365 Asn Leu Asn Ser Glu Leu Thr Gln Glu Glu Ile Glu Gln Ile Ser Asn 370 375 380 Leu Lys Gly Tyr Thr Gly Thr His Asn Leu Ser Leu Lys Ala Ile Asn 385 390 395 400 Leu Ile Leu Asp Glu Leu Trp His Thr Asn Asp Asn Gln Ile Ala Ile 405 410 415 Phe Asn Arg Leu Lys Leu Val Pro Lys Lys Val Asp Leu Ser Gln Gln 420 425 430 Lys Glu Ile Pro Thr Thr Leu Val Asp Asp Phe Ile Leu Ser Pro Val 435 440 445 Val Lys Arg Ser Phe Ile Gln Ser Ile Lys Val Ile Asn Ala Ile Ile 450 455 460 Lys Lys Tyr Gly Leu Pro Asn Asp Ile Ile Ile Glu Leu Ala Arg Glu 465 470 475 480 Lys Asn Ser Lys Asp Ala Gln Lys Met Ile Asn Glu Met Gln Lys Arg 485 490 495 Asn Arg Gln Thr Asn Glu Arg Ile Glu Glu Ile Ile Arg Thr Thr Gly 500 505 510 Lys Glu Asn Ala Lys Tyr Leu Ile Glu Lys Ile Lys Leu His Asp Met 515 520 525 Gln Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu Glu Asp 530 535 540 Leu Leu Asn Asn Pro Phe Asn Tyr Glu Val Asp His Ile Ile Pro Arg 545 550 555 560 Ser Val Ser Phe Asp Asn Ser Phe Asn Asn Lys Val Leu Val Lys Gln 565 570 575 Glu Glu Ala Ser Lys Lys Gly Asn Arg Thr Pro Phe Gln Tyr Leu Ser 580 585 590 Ser Ser Asp Ser Lys Ile Ser Tyr Glu Thr Phe Lys Lys His Ile Leu 595 600 605 Asn Leu Ala Lys Gly Lys Gly Arg Ile Ser Lys Thr Lys Lys Glu Tyr 610 615 620 Leu Leu Glu Glu Arg Asp Ile Asn Arg Phe Ser Val Gln Lys Asp Phe 625 630 635 640 Ile Asn Arg Asn Leu Val Asp Thr Arg Tyr Ala Thr Arg Gly Leu Met 645 650 655 Asn Leu Leu Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys Val 660 665 670 Lys Ser Ile Asn Gly Gly Phe Thr Ser Phe Leu Arg Arg Lys Trp Lys 675 680 685 Phe Lys Lys Glu Arg Asn Lys Gly Tyr Lys His His Ala Glu Asp Ala 690 695 700 Leu Ile Ile Ala Asn Ala Asp Phe Ile Phe Lys Glu Trp Lys Lys Leu 705 710 715 720 Asp Lys Ala Lys Lys Val Met Glu Asn Gln Met Phe Glu Glu Lys Gln 725 730 735 Ala Glu Ser Met Pro Glu Ile Glu Thr Glu Gln Glu Tyr Lys Glu Ile 740 745 750 Phe Ile Thr Pro His Gln Ile Lys His Ile Lys Asp Phe Lys Asp Tyr 755 760 765 Lys Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Glu Leu Ile Asn 770 775 780 Asp Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr Leu Ile 785 790 795 800 Val Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu Lys 805 810 815 Lys Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His Asp 820 825 830 Pro Gln Thr Tyr Gln Lys Leu Lys Leu Ile Met Glu Gln Tyr Gly Asp 835 840 845 Glu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr Leu 850 855 860 Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile Lys 865 870 875 880 Tyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp Tyr 885 890 895 Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr Arg 900 905 910 Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val Lys 915 920 925 Asn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser Lys 930 935 940 Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala Glu 945 950 955 960 Phe Ile Ala Ser Phe Tyr Asn Asn Asp Leu Ile Lys Ile Asn Gly Glu 965 970 975 Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile Glu 980 985 990 Val Asn Met Ile Asp Ile Thr Tyr Arg Glu Tyr Leu Glu Asn Met Asn 995 1000 1005 Asp Lys Arg Pro Pro Arg Ile Ile Lys Thr Ile Ala Ser Lys Thr 1010 1015 1020 Gln Ser Ile Lys Lys Tyr Ser Thr Asp Ile Leu Gly Asn Leu Tyr 1025 1030 1035 Glu Val Lys Ser Lys Lys His Pro Gln Ile Ile Lys Lys Gly 1040 1045 1050 <![CDATA[<210> 104]]> <![CDATA[<211> 1148]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 104]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Lys Arg Asn Tyr Ile Leu Gly Leu Ala Ile Gly Ile Thr Ser Val 20 25 30 Gly Tyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly 35 40 45 Val Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg 50 55 60 Ser Lys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile 65 70 75 80 Gln Arg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His 85 90 95 Ser Glu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu 100 105 110 Ser Gln Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu 115 120 125 Ala Lys Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr 130 135 140 Gly Asn Glu Leu Ser Thr Lys Glu Gln Ile Ser Arg Asn Ser Lys Ala 145 150 155 160 Leu Glu Glu Lys Tyr Val Ala Glu Leu Gln Leu Glu Arg Leu Lys Lys 165 170 175 Asp Gly Glu Val Arg Gly Ser Ile Asn Arg Phe Lys Thr Ser Asp Tyr 180 185 190 Val Lys Glu Ala Lys Gln Leu Leu Lys Val Gln Lys Ala Tyr His Gln 195 200 205 Leu Asp Gln Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg 210 215 220 Arg Thr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp Lys 225 230 235 240 Asp Ile Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe 245 250 255 Pro Glu Glu Leu Arg Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr 260 265 270 Asn Ala Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn 275 280 285 Glu Lys Leu Glu Tyr Tyr Glu Lys Phe Gln Ile Ile Glu Asn Val Phe 290 295 300 Lys Gln Lys Lys Lys Pro Thr Leu Lys Gln Ile Ala Lys Glu Ile Leu 305 310 315 320 Val Asn Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys 325 330 335 Pro Glu Phe Thr Asn Leu Lys Val Tyr His Asp Ile Lys Asp Ile Thr 340 345 350 Ala Arg Lys Glu Ile Ile Glu Asn Ala Glu Leu Leu Asp Gln Ile Ala 355 360 365 Lys Ile Leu Thr Ile Tyr Gln Ser Ser Glu Asp Ile Gln Glu Glu Leu 370 375 380 Thr Asn Leu Asn Ser Glu Leu Thr Gln Glu Glu Ile Glu Gln Ile Ser 385 390 395 400 Asn Leu Lys Gly Tyr Thr Gly Thr His Asn Leu Ser Leu Lys Ala Ile 405 410 415 Asn Leu Ile Leu Asp Glu Leu Trp His Thr Asn Asp Asn Gln Ile Ala 420 425 430 Ile Phe Asn Arg Leu Lys Leu Val Pro Lys Lys Val Asp Leu Ser Gln 435 440 445 Gln Lys Glu Ile Pro Thr Thr Leu Val Asp Asp Phe Ile Leu Ser Pro 450 455 460 Val Val Lys Arg Ser Phe Ile Gln Ser Ile Lys Val Ile Asn Ala Ile 465 470 475 480 Ile Lys Lys Tyr Gly Leu Pro Asn Asp Ile Ile Ile Glu Leu Ala Arg 485 490 495 Glu Lys Asn Ser Lys Asp Ala Gln Lys Met Ile Asn Glu Met Gln Lys 500 505 510 Arg Asn Arg Gln Thr Asn Glu Arg Ile Glu Glu Ile Ile Arg Thr Thr 515 520 525 Gly Lys Glu Asn Ala Lys Tyr Leu Ile Glu Lys Ile Lys Leu His Asp 530 535 540 Met Gln Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu Glu 545 550 555 560 Asp Leu Leu Asn Asn Pro Phe Asn Tyr Glu Val Asp His Ile Ile Pro 565 570 575 Arg Ser Val Ser Phe Asp Asn Ser Phe Asn Asn Lys Val Leu Val Lys 580 585 590 Gln Glu Glu Ala Ser Lys Lys Gly Asn Arg Thr Pro Phe Gln Tyr Leu 595 600 605 Ser Ser Ser Asp Ser Lys Ile Ser Tyr Glu Thr Phe Lys Lys His Ile 610 615 620 Leu Asn Leu Ala Lys Gly Lys Gly Arg Ile Ser Lys Thr Lys Lys Glu 625 630 635 640 Tyr Leu Leu Glu Glu Arg Asp Ile Asn Arg Phe Ser Val Gln Lys Asp 645 650 655 Phe Ile Asn Arg Asn Leu Val Asp Thr Arg Tyr Ala Thr Arg Gly Leu 660 665 670 Met Asn Leu Leu Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys 675 680 685 Val Lys Ser Ile Asn Gly Gly Phe Thr Ser Phe Leu Arg Arg Lys Trp 690 695 700 Lys Phe Lys Lys Glu Arg Asn Lys Gly Tyr Lys His His Ala Glu Asp 705 710 715 720 Ala Leu Ile Ile Ala Asn Ala Asp Phe Ile Phe Lys Glu Trp Lys Lys 725 730 735 Leu Asp Lys Ala Lys Lys Val Met Glu Asn Gln Met Phe Glu Glu Lys 740 745 750 Gln Ala Glu Ser Met Pro Glu Ile Glu Thr Glu Gln Glu Tyr Lys Glu 755 760 765 Ile Phe Ile Thr Pro His Gln Ile Lys His Ile Lys Asp Phe Lys Asp 770 775 780 Tyr Lys Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Glu Leu Ile 785 790 795 800 Asn Asp Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr Leu 805 810 815 Ile Val Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu 820 825 830 Lys Lys Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His 835 840 845 Asp Pro Gln Thr Tyr Gln Lys Leu Lys Leu Ile Met Glu Gln Tyr Gly 850 855 860 Asp Glu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr 865 870 875 880 Leu Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile 885 890 895 Lys Tyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp 900 905 910 Tyr Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr 915 920 925 Arg Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val 930 935 940 Lys Asn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser 945 950 955 960 Lys Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala 965 970 975 Glu Phe Ile Ala Ser Phe Tyr Asn Asn Asp Leu Ile Lys Ile Asn Gly 980 985 990 Glu Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile 995 1000 1005 Glu Val Asn Met Ile Asp Ile Thr Tyr Arg Glu Tyr Leu Glu Asn 1010 1015 1020 Met Asn Asp Lys Arg Pro Pro Arg Ile Ile Lys Thr Ile Ala Ser 1025 1030 1035 Lys Thr Gln Ser Ile Lys Lys Tyr Ser Thr Asp Ile Leu Gly Asn 1040 1045 1050 Leu Tyr Glu Val Lys Ser Lys Lys His Pro Gln Ile Ile Lys Lys 1055 1060 1065 Gly Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys 1070 1075 1080 Lys Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu 1085 1090 1095 Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala 1100 1105 1110 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp 1115 1120 1125 Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe 1130 1135 1140 Asp Leu Asp Met Leu 1145 <![CDATA[<210> 105]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成寡核苷酸]]> <![CDATA[<400> 105]]> tgacctagac agccttacat a 21 <![CDATA[<210> 106]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 106]]> taaggctgtc taggtcaagt g 21 <![CDATA[<210> 107]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 107]]> aaggctgtct aggtcaagtg t 21 <![CDATA[<210> 108]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 108]]> gatgaagccg agaggatact g 21 <![CDATA[<210> 109]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 109]]> gctgatttgt attaggtacc a 21 <![CDATA[<210> 110]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成寡核苷酸]]> <![CDATA[<400> 110]]> cttcgttatg taaggctgtc t 21 <![CDATA[<210> 111]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成寡核苷酸]]> <![CDATA[<400> 111]]> caagtgtagg agacacactg c 21 <![CDATA[<210> 112]]> <![CDATA[<211> 1052]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 112]]> Lys Arg Asn Tyr Ile Leu Gly Leu Ala Ile Gly Ile Thr Ser Val Gly 1 5 10 15 Tyr Gly Ile Ile Asp Tyr Glu Thr Arg Asp Val Ile Asp Ala Gly Val 20 25 30 Arg Leu Phe Lys Glu Ala Asn Val Glu Asn Asn Glu Gly Arg Arg Ser 35 40 45 Lys Arg Gly Ala Arg Arg Leu Lys Arg Arg Arg Arg His Arg Ile Gln 50 55 60 Arg Val Lys Lys Leu Leu Phe Asp Tyr Asn Leu Leu Thr Asp His Ser 65 70 75 80 Glu Leu Ser Gly Ile Asn Pro Tyr Glu Ala Arg Val Lys Gly Leu Ser 85 90 95 Gln Lys Leu Ser Glu Glu Glu Phe Ser Ala Ala Leu Leu His Leu Ala 100 105 110 Lys Arg Arg Gly Val His Asn Val Asn Glu Val Glu Glu Asp Thr Gly 115 120 125 Asn Glu Leu Ser Thr Lys Glu Gln Ile Ser Arg Asn Ser Lys Ala Leu 130 135 140 Glu Glu Lys Tyr Val Ala Glu Leu Gln Leu Glu Arg Leu Lys Lys Asp 145 150 155 160 Gly Glu Val Arg Gly Ser Ile Asn Arg Phe Lys Thr Ser Asp Tyr Val 165 170 175 Lys Glu Ala Lys Gln Leu Leu Lys Val Gln Lys Ala Tyr His Gln Leu 180 185 190 Asp Gln Ser Phe Ile Asp Thr Tyr Ile Asp Leu Leu Glu Thr Arg Arg 195 200 205 Thr Tyr Tyr Glu Gly Pro Gly Glu Gly Ser Pro Phe Gly Trp Lys Asp 210 215 220 Ile Lys Glu Trp Tyr Glu Met Leu Met Gly His Cys Thr Tyr Phe Pro 225 230 235 240 Glu Glu Leu Arg Ser Val Lys Tyr Ala Tyr Asn Ala Asp Leu Tyr Asn 245 250 255 Ala Leu Asn Asp Leu Asn Asn Leu Val Ile Thr Arg Asp Glu Asn Glu 260 265 270 Lys Leu Glu Tyr Tyr Glu Lys Phe Gln Ile Ile Glu Asn Val Phe Lys 275 280 285 Gln Lys Lys Lys Pro Thr Leu Lys Gln Ile Ala Lys Glu Ile Leu Val 290 295 300 Asn Glu Glu Asp Ile Lys Gly Tyr Arg Val Thr Ser Thr Gly Lys Pro 305 310 315 320 Glu Phe Thr Asn Leu Lys Val Tyr His Asp Ile Lys Asp Ile Thr Ala 325 330 335 Arg Lys Glu Ile Ile Glu Asn Ala Glu Leu Leu Asp Gln Ile Ala Lys 340 345 350 Ile Leu Thr Ile Tyr Gln Ser Ser Glu Asp Ile Gln Glu Glu Leu Thr 355 360 365 Asn Leu Asn Ser Glu Leu Thr Gln Glu Glu Ile Glu Gln Ile Ser Asn 370 375 380 Leu Lys Gly Tyr Thr Gly Thr His Asn Leu Ser Leu Lys Ala Ile Asn 385 390 395 400 Leu Ile Leu Asp Glu Leu Trp His Thr Asn Asp Asn Gln Ile Ala Ile 405 410 415 Phe Asn Arg Leu Lys Leu Val Pro Lys Lys Val Asp Leu Ser Gln Gln 420 425 430 Lys Glu Ile Pro Thr Thr Leu Val Asp Asp Phe Ile Leu Ser Pro Val 435 440 445 Val Lys Arg Ser Phe Ile Gln Ser Ile Lys Val Ile Asn Ala Ile Ile 450 455 460 Lys Lys Tyr Gly Leu Pro Asn Asp Ile Ile Ile Glu Leu Ala Arg Glu 465 470 475 480 Lys Asn Ser Lys Asp Ala Gln Lys Met Ile Asn Glu Met Gln Lys Arg 485 490 495 Asn Arg Gln Thr Asn Glu Arg Ile Glu Glu Ile Ile Arg Thr Thr Gly 500 505 510 Lys Glu Asn Ala Lys Tyr Leu Ile Glu Lys Ile Lys Leu His Asp Met 515 520 525 Gln Glu Gly Lys Cys Leu Tyr Ser Leu Glu Ala Ile Pro Leu Glu Asp 530 535 540 Leu Leu Asn Asn Pro Phe Asn Tyr Glu Val Asp His Ile Ile Pro Arg 545 550 555 560 Ser Val Ser Phe Asp Asn Ser Phe Asn Asn Lys Val Leu Val Lys Gln 565 570 575 Glu Glu Ala Ser Lys Lys Gly Asn Arg Thr Pro Phe Gln Tyr Leu Ser 580 585 590 Ser Ser Asp Ser Lys Ile Ser Tyr Glu Thr Phe Lys Lys His Ile Leu 595 600 605 Asn Leu Ala Lys Gly Lys Gly Arg Ile Ser Lys Thr Lys Lys Glu Tyr 610 615 620 Leu Leu Glu Glu Arg Asp Ile Asn Arg Phe Ser Val Gln Lys Asp Phe 625 630 635 640 Ile Asn Arg Asn Leu Val Asp Thr Arg Tyr Ala Thr Arg Gly Leu Met 645 650 655 Asn Leu Leu Arg Ser Tyr Phe Arg Val Asn Asn Leu Asp Val Lys Val 660 665 670 Lys Ser Ile Asn Gly Gly Phe Thr Ser Phe Leu Arg Arg Lys Trp Lys 675 680 685 Phe Lys Lys Glu Arg Asn Lys Gly Tyr Lys His His Ala Glu Asp Ala 690 695 700 Leu Ile Ile Ala Asn Ala Asp Phe Ile Phe Lys Glu Trp Lys Lys Leu 705 710 715 720 Asp Lys Ala Lys Lys Val Met Glu Asn Gln Met Phe Glu Glu Lys Gln 725 730 735 Ala Glu Ser Met Pro Glu Ile Glu Thr Glu Gln Glu Tyr Lys Glu Ile 740 745 750 Phe Ile Thr Pro His Gln Ile Lys His Ile Lys Asp Phe Lys Asp Tyr 755 760 765 Lys Tyr Ser His Arg Val Asp Lys Lys Pro Asn Arg Glu Leu Ile Asn 770 775 780 Asp Thr Leu Tyr Ser Thr Arg Lys Asp Asp Lys Gly Asn Thr Leu Ile 785 790 795 800 Val Asn Asn Leu Asn Gly Leu Tyr Asp Lys Asp Asn Asp Lys Leu Lys 805 810 815 Lys Leu Ile Asn Lys Ser Pro Glu Lys Leu Leu Met Tyr His His Asp 820 825 830 Pro Gln Thr Tyr Gln Lys Leu Lys Leu Ile Met Glu Gln Tyr Gly Asp 835 840 845 Glu Lys Asn Pro Leu Tyr Lys Tyr Tyr Glu Glu Thr Gly Asn Tyr Leu 850 855 860 Thr Lys Tyr Ser Lys Lys Asp Asn Gly Pro Val Ile Lys Lys Ile Lys 865 870 875 880 Tyr Tyr Gly Asn Lys Leu Asn Ala His Leu Asp Ile Thr Asp Asp Tyr 885 890 895 Pro Asn Ser Arg Asn Lys Val Val Lys Leu Ser Leu Lys Pro Tyr Arg 900 905 910 Phe Asp Val Tyr Leu Asp Asn Gly Val Tyr Lys Phe Val Thr Val Lys 915 920 925 Asn Leu Asp Val Ile Lys Lys Glu Asn Tyr Tyr Glu Val Asn Ser Lys 930 935 940 Cys Tyr Glu Glu Ala Lys Lys Leu Lys Lys Ile Ser Asn Gln Ala Glu 945 950 955 960 Phe Ile Ala Ser Phe Tyr Asn Asn Asp Leu Ile Lys Ile Asn Gly Glu 965 970 975 Leu Tyr Arg Val Ile Gly Val Asn Asn Asp Leu Leu Asn Arg Ile Glu 980 985 990 Val Asn Met Ile Asp Ile Thr Tyr Arg Glu Tyr Leu Glu Asn Met Asn 995 1000 1005 Asp Lys Arg Pro Pro Arg Ile Ile Lys Thr Ile Ala Ser Lys Thr 1010 1015 1020 Gln Ser Ile Lys Lys Tyr Ser Thr Asp Ile Leu Gly Asn Leu Tyr 1025 1030 1035 Glu Val Lys Ser Lys Lys His Pro Gln Ile Ile Lys Lys Gly 1040 1045 1050 <![CDATA[<210> 113]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 113]]> catgatccct agaaatgggg t 21 <![CDATA[<210> 114]]> <![CDATA[<211> 523]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 114]]> Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu 1 5 10 15 Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe 20 25 30 Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp 35 40 45 Met Leu Ile Asn Ser Arg Ser Ser Gly Ser Pro Lys Lys Lys Arg Lys 50 55 60 Val Gly Ser Gln Tyr Leu Pro Asp Thr Asp Asp Arg His Arg Ile Glu 65 70 75 80 Glu Lys Arg Lys Arg Thr Tyr Glu Thr Phe Lys Ser Ile Met Lys Lys 85 90 95 Ser Pro Phe Ser Gly Pro Thr Asp Pro Arg Pro Pro Pro Arg Arg Ile 100 105 110 Ala Val Pro Ser Arg Ser Ser Ala Ser Val Pro Lys Pro Ala Pro Gln 115 120 125 Pro Tyr Pro Phe Thr Ser Ser Leu Ser Thr Ile Asn Tyr Asp Glu Phe 130 135 140 Pro Thr Met Val Phe Pro Ser Gly Gln Ile Ser Gln Ala Ser Ala Leu 145 150 155 160 Ala Pro Ala Pro Pro Gln Val Leu Pro Gln Ala Pro Ala Pro Ala Pro 165 170 175 Ala Pro Ala Met Val Ser Ala Leu Ala Gln Ala Pro Ala Pro Val Pro 180 185 190 Val Leu Ala Pro Gly Pro Pro Gln Ala Val Ala Pro Pro Ala Pro Lys 195 200 205 Pro Thr Gln Ala Gly Glu Gly Thr Leu Ser Glu Ala Leu Leu Gln Leu 210 215 220 Gln Phe Asp Asp Glu Asp Leu Gly Ala Leu Leu Gly Asn Ser Thr Asp 225 230 235 240 Pro Ala Val Phe Thr Asp Leu Ala Ser Val Asp Asn Ser Glu Phe Gln 245 250 255 Gln Leu Leu Asn Gln Gly Ile Pro Val Ala Pro His Thr Thr Glu Pro 260 265 270 Met Leu Met Glu Tyr Pro Glu Ala Ile Thr Arg Leu Val Thr Gly Ala 275 280 285 Gln Arg Pro Pro Asp Pro Ala Pro Ala Pro Leu Gly Ala Pro Gly Leu 290 295 300 Pro Asn Gly Leu Leu Ser Gly Asp Glu Asp Phe Ser Ser Ile Ala Asp 305 310 315 320 Met Asp Phe Ser Ala Leu Leu Gly Ser Gly Ser Gly Ser Arg Asp Ser 325 330 335 Arg Glu Gly Met Phe Leu Pro Lys Pro Glu Ala Gly Ser Ala Ile Ser 340 345 350 Asp Val Phe Glu Gly Arg Glu Val Cys Gln Pro Lys Arg Ile Arg Pro 355 360 365 Phe His Pro Pro Gly Ser Pro Trp Ala Asn Arg Pro Leu Pro Ala Ser 370 375 380 Leu Ala Pro Thr Pro Thr Gly Pro Val His Glu Pro Val Gly Ser Leu 385 390 395 400 Thr Pro Ala Pro Val Pro Gln Pro Leu Asp Pro Ala Pro Ala Val Thr 405 410 415 Pro Glu Ala Ser His Leu Leu Glu Asp Pro Asp Glu Glu Thr Ser Gln 420 425 430 Ala Val Lys Ala Leu Arg Glu Met Ala Asp Thr Val Ile Pro Gln Lys 435 440 445 Glu Glu Ala Ala Ile Cys Gly Gln Met Asp Leu Ser His Pro Pro Pro 450 455 460 Arg Gly His Leu Asp Glu Leu Thr Thr Thr Leu Glu Ser Met Thr Glu 465 470 475 480 Asp Leu Asn Leu Asp Ser Pro Leu Thr Pro Glu Leu Asn Glu Ile Leu 485 490 495 Asp Thr Phe Leu Asn Asp Glu Cys Leu Leu His Ala Met His Ile Ser 500 505 510 Thr Gly Leu Ser Ile Phe Asp Thr Ser Leu Phe 515 520 <![CDATA[<210> 115]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 115]]> Arg Ser Asp Asn Leu Val Arg 1 5 <![CDATA[<210> 116]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 116]]> Arg Glu Asp Asn Leu His Thr 1 5 <![CDATA[<210> 117]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 117]]> Arg Ser Asp Glu Leu Val Arg 1 5 <![CDATA[<210> 118]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 118]]> Gln Ser Gly Asn Leu Thr Glu 1 5 <![CDATA[<210> 119]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> ]]>人工序列 <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 119]]> Thr Ser Gly His Leu Val Arg 1 5 <![CDATA[<210> 120]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 120]]> Gln Asn Ser Thr Leu Thr Glu 1 5 <![CDATA[<210> 121]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 121]]> Asp Pro Gly Ala Leu Val Arg 1 5 <![CDATA[<210> 122]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 122]]> His Arg Thr Thr Leu Thr Asn 1 5 <![CDATA[<210> 123]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 123]]> Gln Ser Gly Asp Leu Arg Arg 1 5 <![CDATA[<210> 124]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 124]]> Thr Ser His Ser Leu Thr Glu 1 5 <![CDATA[<210> 125]]> <![CDATA[<211]]>> 7]]> <br/><![CDATA[<212> PRT]]> <br/><![CDATA[<213> 人工序列]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<223> 人工序列之描述:合成肽]]> <br/> <br/><![CDATA[<400> 125]]> <br/><![CDATA[Thr His Leu Asp Leu Ile Arg 1 5 <![CDATA[<210> 126]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 126]]> Gln Ser Ser Ser Leu Val Arg 1 5 <![CDATA[<210> 127]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 127]]> Thr Ser Gly Asn Leu Val Arg 1 5 <![CDATA[<210> 128]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 128]]> Arg Arg Asp Glu Leu Asn Val 1 5 <![CDATA[<210> 129]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 129]]> Arg Ser Asp Asp Leu Val Arg 1 5 <![CDATA[<210> 130]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 130]]> Arg Ser Asp His Leu Thr Asn 1 5 <![CDATA[<210> 131]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 131]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 35 40 45 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly His Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Asn 145 150 155 160 Ser Thr Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 132]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 132]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Arg 35 40 45 Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu His 65 70 75 80 Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 145 150 155 160 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 133]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 133]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Asp Pro Gly Ala Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 35 40 45 Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Gly Asp Leu Arg 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Thr His Leu Asp Leu Ile Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 134]]> <![CDATA[<211> 260]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 134]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 35 40 45 Asp His Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asp Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser His Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 145 150 155 160 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 165 170 175 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu Thr 180 185 190 Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 195 200 205 Cys Gly Lys Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg 210 215 220 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 225 230 235 240 Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly 245 250 255 Lys Lys Thr Ser 260 <![CDATA[<210> 135]]> <![CDATA[<211> 292]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<400> 135]]> Arg Ser Asp Asn Leu Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Glu Asp Asn Leu His Thr 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Arg Ser Asp Glu Leu Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Ser Gly Asn Leu 165 170 175 Thr Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Thr Ser Gly His Leu Val Arg Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Asn Ser 275 280 285 Thr Leu Thr Glu 290 <![CDATA[<210> 136]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 136]]> gaggatactg cagaggtc 18 <![CDATA[<210> 137]]> <![CDATA[<400> 137]]> 000 <![CDATA[<210> 138]]> <![CDATA[<400> 138]]> 000 <![CDATA[<210> 139]]> <![CDATA[<400> 139]]> 000 <![CDATA[<210> 140]]> <![CDATA[<400> 140]]> 000 <![CDATA[<210> 141]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 141]]> Arg Asn Asp Thr Leu Thr Glu 1 5 <![CDATA[<210> 142]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 142]]> Arg Ser Asp Asn Leu Val Arg 1 5 <![CDATA[<210>]]> 143 <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 143]]> Arg Ser Asp His Leu Thr Thr 1 5 <![CDATA[<210> 144]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 144]]> Ser Pro Ala Asp Leu Thr Arg 1 5 <![CDATA[<210> 145]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 145]]> Thr Ser His Ser Leu Thr Glu 1 5 <![CDATA[<210> 146]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 146]]> Gln Ser Gly Asp Leu Arg Arg 1 5 <![CDATA[<210> 147]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 147]]> Asp Pro Gly Ala Leu Val Arg 1 5 <![CDATA[<210> 148]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 148]]> Asp Pro Gly His Leu Val Arg 1 5 <![CDATA[<210> 149]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 149]]> Arg Ser Asp Glu Leu Val Arg 1 5 <![CDATA[<210> 150]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 150]]> Asp Ser Gly Asn Leu Arg Val 1 5 <![CDATA[<210> 151]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 151]]> His Lys Asn Ala Leu Gln Asn 1 5 <![CDATA[<210> 152]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 152]]> Thr Ser Gly Glu Leu Val Arg 1 5 <![CDATA[<210> 153]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 153]]> Arg Ser Asp Lys Leu Val Arg 1 5 <![CDATA[<210> 154]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 154]]> Gln Leu Ala His Leu Arg Ala 1 5 <![CDATA[<210> 155]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 155]]> Glu Arg Ser His Leu Arg Glu 1 5 <![CDATA[<21]]>0> 156]]> <br/><![CDATA[<211> 7]]> <br/><![CDATA[<212> PRT]]> <br/><![CDATA[<213> 人工序列]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<223> 人工序列之描述:合成肽]]> <br/> <br/><![CDATA[<400> 156]]> <br/><![CDATA[Thr Thr Gly Asn Leu Thr Val 1 5 <![CDATA[<210> 157]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 157]]> Gln Arg Ala Asn Leu Arg Ala 1 5 <![CDATA[<210> 158]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 158]]> Ser Lys Lys Ala Leu Thr Glu 1 5 <![CDATA[<210> 159]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 159]]> Arg Glu Asp Asn Leu His Thr 1 5 <![CDATA[<210> 160]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 160]]> Thr Lys Asn Ser Leu Thr Glu 1 5 <![CDATA[<210> 161]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 161]]> Arg Lys Asp Asn Leu Lys Asn 1 5 <![CDATA[<210> 162]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 162]]> Gln Ser Ser Asn Leu Val Arg 1 5 <![CDATA[<210> 163]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 163]]> Gln Ser Ser Ser Leu Val Arg 1 5 <![CDATA[<210> 164]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 164]]> Gln Ala Gly His Leu Ala Ser 1 5 <![CDATA[<210> 165]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 165]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Asn Asp Thr Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Pro 35 40 45 Gly Ala Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser Gly Glu Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly Glu Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Lys 145 150 155 160 Asn Ser Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 166]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 166]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Pro 35 40 45 Gly His Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp His Leu Thr 65 70 75 80 Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu Val Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Arg Ser Asp Lys Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Thr 145 150 155 160 Gly Asn Leu Thr Val His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 167]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 167]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Ser Asp His Leu Thr Thr His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 35 40 45 Asp Glu Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Lys Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Thr Thr Gly Asn Leu Thr Val His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Leu Ala His Leu Arg Ala His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Lys 145 150 155 160 Asn Ser Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 168]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 168]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Ser 35 40 45 Gly Asn Leu Arg Val His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg 65 70 75 80 Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 169]]> <![CDATA[<211> 260]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 169]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Thr Ser His Ser Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Lys 35 40 45 Asn Ala Leu Gln Asn His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Glu Arg Ser His Leu Arg 65 70 75 80 Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Ser Lys Lys Ala Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Lys 145 150 155 160 Asp Asn Leu Lys Asn His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 165 170 175 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu Val 180 185 190 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 195 200 205 Cys Gly Lys Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg 210 215 220 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 225 230 235 240 Phe Ser Gln Ala Gly His Leu Ala Ser His Gln Arg Thr His Thr Gly 245 250 255 Lys Lys Thr Ser 260 <![CDATA[<210> 170]]> <![CDATA[<211> 204]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> ]]>170 Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Gln Ser Gly Asp Leu Arg Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser Pro 35 40 45 Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Ser Gly Asn Leu Arg 65 70 75 80 Val His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg Ala His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 145 150 155 160 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 165 170 175 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu Val 180 185 190 Arg His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 195 200 <![CDATA[<210> 171]]> <![CDATA[<211> 292]]> <![CDATA[<212> PRT]]> <![CDATA[<213> ]]>人工序列 <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222]]>> (65)..(114)]]> <br/><![CDATA[<223> 此區可包含1-50個殘基]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<221> MOD_RES]]> <br/><![CDATA[<222> (122)..(171)]]> <br/><![CDATA[<223> 任何胺基酸]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<221> MISC_FEATURE ]]> <br/><![CDATA[<222]]><![CDATA[> (122)..(171)]]> <br/><![CDATA[<223> 此區可包含1-50個殘基]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<221> MOD_RES]]> <br/><![CDATA[<222> (179)..(228)]]> <br/><![CDATA[<223> 任何胺基酸]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<221> MISC_FEATURE ]]> <br/><![CDATA[<222> (179)..(228)]]> <br/><![CDATA[<223> 此區可包含1-50個殘基]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<221> MOD_RES]]> <br/><![CDATA[<222> (236)..(285)]]> <br/><![CDATA[<223> 任何胺基酸]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<221> MISC_FEATURE ]]> <br/><![CDATA[<222> (236)..(285)]]> <br/><![CDATA[<223> 此區可包含1-50個殘基]]> <br/> <br/><![CDATA[<400> 171]]> <br/><![CDATA[Arg Asn Asp Thr Leu Thr Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Pro Gly Ala Leu Val Arg 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Thr Ser Gly Glu Leu Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Asp Asn Leu 165 170 175 Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Thr Ser Gly Glu Leu Val Arg Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Lys Asn 275 280 285 Ser Leu Thr Glu 290 <![CDATA[<210> 172]]> <![CDATA[<400> 172]]> 000 <![CDATA[<210> 173]]> <![CDATA[<400> 173]]> 000 <![CDATA[<210> 174]]> <![CDATA[<400> 174]]> 000 <![CDATA[<210> 175]]> <![CDATA[<400> 175]]> 000 <![CDATA[<210> 176]]> <![CDATA[<400> 176]]> 000 <![CDATA[<210> 177]]> <![CDATA[<400> 177]]> 000 <![CDATA[<210> 178]]> <![CDATA[<211> 49]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成寡核苷酸]]> <![CDATA[<400> 178]]> gtgtgtatgc tcaggggctg ggaaaggagg ggagggagct ccggctcag 49 <![CDATA[<210> 179]]> <![CDATA[<211> 1644]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 179]]> cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt 60 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca 120 atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc 180 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta 240 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac 300 catgggtcga ggtgagcccc acgttctgct tcactctccc catctccccc ccctccccac 360 ccccaatttt gtatttattt attttttaat tattttgtgc agcgatgggg gcgggggggg 420 ggggggcgcg cgccaggcgg ggcggggcgg ggcgaggggc ggggcggggc gaggcggaga 480 ggtgcggcgg cagccaatca gagcggcgcg ctccgaaagt ttccttttat ggcgaggcgg 540 cggcggcggc ggccctataa aaagcgaagc gcgcggcggg cgggagtcgc tgcgttgcct 600 tcgccccgtg ccccgctccg cgccgcctcg cgccgcccgc cccggctctg actgaccgcg 660 ttactcccac aggtgagcgg gcgggacggc ccttctcctc cgggctgtaa ttagcgcttg 720 gtttaatgac ggctcgtttc ttttctgtgg ctgcgtgaaa gccttaaagg gctccgggag 780 ggccctttgt gcggggggga gcggctcggg gggtgcgtgc gtgtgtgtgt gcgtggggag 840 cgccgcgtgc ggcccgcgct gcccggcggc tgtgagcgct gcgggcgcgg cgcggggctt 900 tgtgcgctcc gcgtgtgcgc gaggggagcg cggccggggg cggtgccccg cggtgcgggg 960 gggctgcgag gggaacaaag gctgcgtgcg gggtgtgtgc gtgggggggt gagcaggggg 1020 tgtgggcgcg gcggtcgggc tgtaaccccc ccctgcaccc ccctccccga gttgctgagc 1080 acggcccggc ttcgggtgcg gggctccgtg cggggcgtgg cgcggggctc gccgtgccgg 1140 gcggggggtg gcggcaggtg ggggtgccgg gcggggcggg gccgcctcgg gccggggagg 1200 gctcggggga ggggcgcggc ggccccggag cgccggcggc tgtcgaggcg cggcgagccg 1260 cagccattgc cttttatggt aatcgtgcga gagggcgcag ggacttcctt tgtcccaaat 1320 ctggcggagc cgaaatctgg gaggcgccgc cgcaccccct ctagcgggcg cgggcgaagc 1380 ggtgcggcgc cggcaggaag gaaatgggcg gggagggcct tcgtgcgtcg ccgcgccgcc 1440 gtccccttct ccatctccag cctcggggct gccgcagggg gacggctgcc ttcggggggg 1500 acggggcagg gcggggttcg gcttctggcg tgtgaccggc ggctctagag cctctgctaa 1560 ccatgttcat gccttcttct ttttcctaca gctcctgggc aacgtgctgg ttgttgtgct 1620 gtctcatcat tttggcaaag aatt 1644 <![CDATA[<210> 180]]> <![CDATA[<211> 2009]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 180]]> Met Glu Gln Thr Val Leu Val Pro Pro Gly Pro Asp Ser Phe Asn Phe 1 5 10 15 Phe Thr Arg Glu Ser Leu Ala Ala Ile Glu Arg Arg Ile Ala Glu Glu 20 25 30 Lys Ala Lys Asn Pro Lys Pro Asp Lys Lys Asp Asp Asp Glu Asn Gly 35 40 45 Pro Lys Pro Asn Ser Asp Leu Glu Ala Gly Lys Asn Leu Pro Phe Ile 50 55 60 Tyr Gly Asp Ile Pro Pro Glu Met Val Ser Glu Pro Leu Glu Asp Leu 65 70 75 80 Asp Pro Tyr Tyr Ile Asn Lys Lys Thr Phe Ile Val Leu Asn Lys Gly 85 90 95 Lys Ala Ile Phe Arg Phe Ser Ala Thr Ser Ala Leu Tyr Ile Leu Thr 100 105 110 Pro Phe Asn Pro Leu Arg Lys Ile Ala Ile Lys Ile Leu Val His Ser 115 120 125 Leu Phe Ser Met Leu Ile Met Cys Thr Ile Leu Thr Asn Cys Val Phe 130 135 140 Met Thr Met Ser Asn Pro Pro Asp Trp Thr Lys Asn Val Glu Tyr Thr 145 150 155 160 Phe Thr Gly Ile Tyr Thr Phe Glu Ser Leu Ile Lys Ile Ile Ala Arg 165 170 175 Gly Phe Cys Leu Glu Asp Phe Thr Phe Leu Arg Asp Pro Trp Asn Trp 180 185 190 Leu Asp Phe Thr Val Ile Thr Phe Ala Tyr Val Thr Glu Phe Val Asp 195 200 205 Leu Gly Asn Val Ser Ala Leu Arg Thr Phe Arg Val Leu Arg Ala Leu 210 215 220 Lys Thr Ile Ser Val Ile Pro Gly Leu Lys Thr Ile Val Gly Ala Leu 225 230 235 240 Ile Gln Ser Val Lys Lys Leu Ser Asp Val Met Ile Leu Thr Val Phe 245 250 255 Cys Leu Ser Val Phe Ala Leu Ile Gly Leu Gln Leu Phe Met Gly Asn 260 265 270 Leu Arg Asn Lys Cys Ile Gln Trp Pro Pro Thr Asn Ala Ser Leu Glu 275 280 285 Glu His Ser Ile Glu Lys Asn Ile Thr Val Asn Tyr Asn Gly Thr Leu 290 295 300 Ile Asn Glu Thr Val Phe Glu Phe Asp Trp Lys Ser Tyr Ile Gln Asp 305 310 315 320 Ser Arg Tyr His Tyr Phe Leu Glu Gly Phe Leu Asp Ala Leu Leu Cys 325 330 335 Gly Asn Ser Ser Asp Ala Gly Gln Cys Pro Glu Gly Tyr Met Cys Val 340 345 350 Lys Ala Gly Arg Asn Pro Asn Tyr Gly Tyr Thr Ser Phe Asp Thr Phe 355 360 365 Ser Trp Ala Phe Leu Ser Leu Phe Arg Leu Met Thr Gln Asp Phe Trp 370 375 380 Glu Asn Leu Tyr Gln Leu Thr Leu Arg Ala Ala Gly Lys Thr Tyr Met 385 390 395 400 Ile Phe Phe Val Leu Val Ile Phe Leu Gly Ser Phe Tyr Leu Ile Asn 405 410 415 Leu Ile Leu Ala Val Val Ala Met Ala Tyr Glu Glu Gln Asn Gln Ala 420 425 430 Thr Leu Glu Glu Ala Glu Gln Lys Glu Ala Glu Phe Gln Gln Met Ile 435 440 445 Glu Gln Leu Lys Lys Gln Gln Glu Ala Ala Gln Gln Ala Ala Thr Ala 450 455 460 Thr Ala Ser Glu His Ser Arg Glu Pro Ser Ala Ala Gly Arg Leu Ser 465 470 475 480 Asp Ser Ser Ser Glu Ala Ser Lys Leu Ser Ser Lys Ser Ala Lys Glu 485 490 495 Arg Arg Asn Arg Arg Lys Lys Arg Lys Gln Lys Glu Gln Ser Gly Gly 500 505 510 Glu Glu Lys Asp Glu Asp Glu Phe Gln Lys Ser Glu Ser Glu Asp Ser 515 520 525 Ile Arg Arg Lys Gly Phe Arg Phe Ser Ile Glu Gly Asn Arg Leu Thr 530 535 540 Tyr Glu Lys Arg Tyr Ser Ser Pro His Gln Ser Leu Leu Ser Ile Arg 545 550 555 560 Gly Ser Leu Phe Ser Pro Arg Arg Asn Ser Arg Thr Ser Leu Phe Ser 565 570 575 Phe Arg Gly Arg Ala Lys Asp Val Gly Ser Glu Asn Asp Phe Ala Asp 580 585 590 Asp Glu His Ser Thr Phe Glu Asp Asn Glu Ser Arg Arg Asp Ser Leu 595 600 605 Phe Val Pro Arg Arg His Gly Glu Arg Arg Asn Ser Asn Leu Ser Gln 610 615 620 Thr Ser Arg Ser Ser Arg Met Leu Ala Val Phe Pro Ala Asn Gly Lys 625 630 635 640 Met His Ser Thr Val Asp Cys Asn Gly Val Val Ser Leu Val Gly Gly 645 650 655 Pro Ser Val Pro Thr Ser Pro Val Gly Gln Leu Leu Pro Glu Val Ile 660 665 670 Ile Asp Lys Pro Ala Thr Asp Asp Asn Gly Thr Thr Thr Glu Thr Glu 675 680 685 Met Arg Lys Arg Arg Ser Ser Ser Phe His Val Ser Met Asp Phe Leu 690 695 700 Glu Asp Pro Ser Gln Arg Gln Arg Ala Met Ser Ile Ala Ser Ile Leu 705 710 715 720 Thr Asn Thr Val Glu Glu Leu Glu Glu Ser Arg Gln Lys Cys Pro Pro 725 730 735 Cys Trp Tyr Lys Phe Ser Asn Ile Phe Leu Ile Trp Asp Cys Ser Pro 740 745 750 Tyr Trp Leu Lys Val Lys His Val Val Asn Leu Val Val Met Asp Pro 755 760 765 Phe Val Asp Leu Ala Ile Thr Ile Cys Ile Val Leu Asn Thr Leu Phe 770 775 780 Met Ala Met Glu His Tyr Pro Met Thr Asp His Phe Asn Asn Val Leu 785 790 795 800 Thr Val Gly Asn Leu Val Phe Thr Gly Ile Phe Thr Ala Glu Met Phe 805 810 815 Leu Lys Ile Ile Ala Met Asp Pro Tyr Tyr Tyr Phe Gln Glu Gly Trp 820 825 830 Asn Ile Phe Asp Gly Phe Ile Val Thr Leu Ser Leu Val Glu Leu Gly 835 840 845 Leu Ala Asn Val Glu Gly Leu Ser Val Leu Arg Ser Phe Arg Leu Leu 850 855 860 Arg Val Phe Lys Leu Ala Lys Ser Trp Pro Thr Leu Asn Met Leu Ile 865 870 875 880 Lys Ile Ile Gly Asn Ser Val Gly Ala Leu Gly Asn Leu Thr Leu Val 885 890 895 Leu Ala Ile Ile Val Phe Ile Phe Ala Val Val Gly Met Gln Leu Phe 900 905 910 Gly Lys Ser Tyr Lys Asp Cys Val Cys Lys Ile Ala Ser Asp Cys Gln 915 920 925 Leu Pro Arg Trp His Met Asn Asp Phe Phe His Ser Phe Leu Ile Val 930 935 940 Phe Arg Val Leu Cys Gly Glu Trp Ile Glu Thr Met Trp Asp Cys Met 945 950 955 960 Glu Val Ala Gly Gln Ala Met Cys Leu Thr Val Phe Met Met Val Met 965 970 975 Val Ile Gly Asn Leu Val Val Leu Asn Leu Phe Leu Ala Leu Leu Leu 980 985 990 Ser Ser Phe Ser Ala Asp Asn Leu Ala Ala Thr Asp Asp Asp Asn Glu 995 1000 1005 Met Asn Asn Leu Gln Ile Ala Val Asp Arg Met His Lys Gly Val 1010 1015 1020 Ala Tyr Val Lys Arg Lys Ile Tyr Glu Phe Ile Gln Gln Ser Phe 1025 1030 1035 Ile Arg Lys Gln Lys Ile Leu Asp Glu Ile Lys Pro Leu Asp Asp 1040 1045 1050 Leu Asn Asn Lys Lys Asp Ser Cys Met Ser Asn His Thr Ala Glu 1055 1060 1065 Ile Gly Lys Asp Leu Asp Tyr Leu Lys Asp Val Asn Gly Thr Thr 1070 1075 1080 Ser Gly Ile Gly Thr Gly Ser Ser Val Glu Lys Tyr Ile Ile Asp 1085 1090 1095 Glu Ser Asp Tyr Met Ser Phe Ile Asn Asn Pro Ser Leu Thr Val 1100 1105 1110 Thr Val Pro Ile Ala Val Gly Glu Ser Asp Phe Glu Asn Leu Asn 1115 1120 1125 Thr Glu Asp Phe Ser Ser Glu Ser Asp Leu Glu Glu Ser Lys Glu 1130 1135 1140 Lys Leu Asn Glu Ser Ser Ser Ser Ser Glu Gly Ser Thr Val Asp 1145 1150 1155 Ile Gly Ala Pro Val Glu Glu Gln Pro Val Val Glu Pro Glu Glu 1160 1165 1170 Thr Leu Glu Pro Glu Ala Cys Phe Thr Glu Gly Cys Val Gln Arg 1175 1180 1185 Phe Lys Cys Cys Gln Ile Asn Val Glu Glu Gly Arg Gly Lys Gln 1190 1195 1200 Trp Trp Asn Leu Arg Arg Thr Cys Phe Arg Ile Val Glu His Asn 1205 1210 1215 Trp Phe Glu Thr Phe Ile Val Phe Met Ile Leu Leu Ser Ser Gly 1220 1225 1230 Ala Leu Ala Phe Glu Asp Ile Tyr Ile Asp Gln Arg Lys Thr Ile 1235 1240 1245 Lys Thr Met Leu Glu Tyr Ala Asp Lys Val Phe Thr Tyr Ile Phe 1250 1255 1260 Ile Leu Glu Met Leu Leu Lys Trp Val Ala Tyr Gly Tyr Gln Thr 1265 1270 1275 Tyr Phe Thr Asn Ala Trp Cys Trp Leu Asp Phe Leu Ile Val Asp 1280 1285 1290 Val Ser Leu Val Ser Leu Thr Ala Asn Ala Leu Gly Tyr Ser Glu 1295 1300 1305 Leu Gly Ala Ile Lys Ser Leu Arg Thr Leu Arg Ala Leu Arg Pro 1310 1315 1320 Leu Arg Ala Leu Ser Arg Phe Glu Gly Met Arg Val Val Val Asn 1325 1330 1335 Ala Leu Leu Gly Ala Ile Pro Ser Ile Met Asn Val Leu Leu Val 1340 1345 1350 Cys Leu Ile Phe Trp Leu Ile Phe Ser Ile Met Gly Val Asn Leu 1355 1360 1365 Phe Ala Gly Lys Phe Tyr His Cys Ile Asn Thr Thr Thr Gly Asp 1370 1375 1380 Arg Phe Asp Ile Glu Asp Val Asn Asn His Thr Asp Cys Leu Lys 1385 1390 1395 Leu Ile Glu Arg Asn Glu Thr Ala Arg Trp Lys Asn Val Lys Val 1400 1405 1410 Asn Phe Asp Asn Val Gly Phe Gly Tyr Leu Ser Leu Leu Gln Val 1415 1420 1425 Ala Thr Phe Lys Gly Trp Met Asp Ile Met Tyr Ala Ala Val Asp 1430 1435 1440 Ser Arg Asn Val Glu Leu Gln Pro Lys Tyr Glu Glu Ser Leu Tyr 1445 1450 1455 Met Tyr Leu Tyr Phe Val Ile Phe Ile Ile Phe Gly Ser Phe Phe 1460 1465 1470 Thr Leu Asn Leu Phe Ile Gly Val Ile Ile Asp Asn Phe Asn Gln 1475 1480 1485 Gln Lys Lys Lys Phe Gly Gly Gln Asp Ile Phe Met Thr Glu Glu 1490 1495 1500 Gln Lys Lys Tyr Tyr Asn Ala Met Lys Lys Leu Gly Ser Lys Lys 1505 1510 1515 Pro Gln Lys Pro Ile Pro Arg Pro Gly Asn Lys Phe Gln Gly Met 1520 1525 1530 Val Phe Asp Phe Val Thr Arg Gln Val Phe Asp Ile Ser Ile Met 1535 1540 1545 Ile Leu Ile Cys Leu Asn Met Val Thr Met Met Val Glu Thr Asp 1550 1555 1560 Asp Gln Ser Glu Tyr Val Thr Thr Ile Leu Ser Arg Ile Asn Leu 1565 1570 1575 Val Phe Ile Val Leu Phe Thr Gly Glu Cys Val Leu Lys Leu Ile 1580 1585 1590 Ser Leu Arg His Tyr Tyr Phe Thr Ile Gly Trp Asn Ile Phe Asp 1595 1600 1605 Phe Val Val Val Ile Leu Ser Ile Val Gly Met Phe Leu Ala Glu 1610 1615 1620 Leu Ile Glu Lys Tyr Phe Val Ser Pro Thr Leu Phe Arg Val Ile 1625 1630 1635 Arg Leu Ala Arg Ile Gly Arg Ile Leu Arg Leu Ile Lys Gly Ala 1640 1645 1650 Lys Gly Ile Arg Thr Leu Leu Phe Ala Leu Met Met Ser Leu Pro 1655 1660 1665 Ala Leu Phe Asn Ile Gly Leu Leu Leu Phe Leu Val Met Phe Ile 1670 1675 1680 Tyr Ala Ile Phe Gly Met Ser Asn Phe Ala Tyr Val Lys Arg Glu 1685 1690 1695 Val Gly Ile Asp Asp Met Phe Asn Phe Glu Thr Phe Gly Asn Ser 1700 1705 1710 Met Ile Cys Leu Phe Gln Ile Thr Thr Ser Ala Gly Trp Asp Gly 1715 1720 1725 Leu Leu Ala Pro Ile Leu Asn Ser Lys Pro Pro Asp Cys Asp Pro 1730 1735 1740 Asn Lys Val Asn Pro Gly Ser Ser Val Lys Gly Asp Cys Gly Asn 1745 1750 1755 Pro Ser Val Gly Ile Phe Phe Phe Val Ser Tyr Ile Ile Ile Ser 1760 1765 1770 Phe Leu Val Val Val Asn Met Tyr Ile Ala Val Ile Leu Glu Asn 1775 1780 1785 Phe Ser Val Ala Thr Glu Glu Ser Ala Glu Pro Leu Ser Glu Asp 1790 1795 1800 Asp Phe Glu Met Phe Tyr Glu Val Trp Glu Lys Phe Asp Pro Asp 1805 1810 1815 Ala Thr Gln Phe Met Glu Phe Glu Lys Leu Ser Gln Phe Ala Ala 1820 1825 1830 Ala Leu Glu Pro Pro Leu Asn Leu Pro Gln Pro Asn Lys Leu Gln 1835 1840 1845 Leu Ile Ala Met Asp Leu Pro Met Val Ser Gly Asp Arg Ile His 1850 1855 1860 Cys Leu Asp Ile Leu Phe Ala Phe Thr Lys Arg Val Leu Gly Glu 1865 1870 1875 Ser Gly Glu Met Asp Ala Leu Arg Ile Gln Met Glu Glu Arg Phe 1880 1885 1890 Met Ala Ser Asn Pro Ser Lys Val Ser Tyr Gln Pro Ile Thr Thr 1895 1900 1905 Thr Leu Lys Arg Lys Gln Glu Glu Val Ser Ala Val Ile Ile Gln 1910 1915 1920 Arg Ala Tyr Arg Arg His Leu Leu Lys Arg Thr Val Lys Gln Ala 1925 1930 1935 Ser Phe Thr Tyr Asn Lys Asn Lys Ile Lys Gly Gly Ala Asn Leu 1940 1945 1950 Leu Ile Lys Glu Asp Met Ile Ile Asp Arg Ile Asn Glu Asn Ser 1955 1960 1965 Ile Thr Glu Lys Thr Asp Leu Thr Met Ser Thr Ala Ala Cys Pro 1970 1975 1980 Pro Ser Tyr Asp Arg Val Thr Lys Pro Ile Val Glu Lys His Glu 1985 1990 1995 Gln Glu Gly Lys Asp Glu Lys Ala Lys Gly Lys 2000 2005 <![CDATA[<210> 181]]> <![CDATA[<211> 593]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 181]]> Met Trp Thr Leu Val Ser Trp Val Ala Leu Thr Ala Gly Leu Val Ala 1 5 10 15 Gly Thr Arg Cys Pro Asp Gly Gln Phe Cys Pro Val Ala Cys Cys Leu 20 25 30 Asp Pro Gly Gly Ala Ser Tyr Ser Cys Cys Arg Pro Leu Leu Asp Lys 35 40 45 Trp Pro Thr Thr Leu Ser Arg His Leu Gly Gly Pro Cys Gln Val Asp 50 55 60 Ala His Cys Ser Ala Gly His Ser Cys Ile Phe Thr Val Ser Gly Thr 65 70 75 80 Ser Ser Cys Cys Pro Phe Pro Glu Ala Val Ala Cys Gly Asp Gly His 85 90 95 His Cys Cys Pro Arg Gly Phe His Cys Ser Ala Asp Gly Arg Ser Cys 100 105 110 Phe Gln Arg Ser Gly Asn Asn Ser Val Gly Ala Ile Gln Cys Pro Asp 115 120 125 Ser Gln Phe Glu Cys Pro Asp Phe Ser Thr Cys Cys Val Met Val Asp 130 135 140 Gly Ser Trp Gly Cys Cys Pro Met Pro Gln Ala Ser Cys Cys Glu Asp 145 150 155 160 Arg Val His Cys Cys Pro His Gly Ala Phe Cys Asp Leu Val His Thr 165 170 175 Arg Cys Ile Thr Pro Thr Gly Thr His Pro Leu Ala Lys Lys Leu Pro 180 185 190 Ala Gln Arg Thr Asn Arg Ala Val Ala Leu Ser Ser Ser Val Met Cys 195 200 205 Pro Asp Ala Arg Ser Arg Cys Pro Asp Gly Ser Thr Cys Cys Glu Leu 210 215 220 Pro Ser Gly Lys Tyr Gly Cys Cys Pro Met Pro Asn Ala Thr Cys Cys 225 230 235 240 Ser Asp His Leu His Cys Cys Pro Gln Asp Thr Val Cys Asp Leu Ile 245 250 255 Gln Ser Lys Cys Leu Ser Lys Glu Asn Ala Thr Thr Asp Leu Leu Thr 260 265 270 Lys Leu Pro Ala His Thr Val Gly Asp Val Lys Cys Asp Met Glu Val 275 280 285 Ser Cys Pro Asp Gly Tyr Thr Cys Cys Arg Leu Gln Ser Gly Ala Trp 290 295 300 Gly Cys Cys Pro Phe Thr Gln Ala Val Cys Cys Glu Asp His Ile His 305 310 315 320 Cys Cys Pro Ala Gly Phe Thr Cys Asp Thr Gln Lys Gly Thr Cys Glu 325 330 335 Gln Gly Pro His Gln Val Pro Trp Met Glu Lys Ala Pro Ala His Leu 340 345 350 Ser Leu Pro Asp Pro Gln Ala Leu Lys Arg Asp Val Pro Cys Asp Asn 355 360 365 Val Ser Ser Cys Pro Ser Ser Asp Thr Cys Cys Gln Leu Thr Ser Gly 370 375 380 Glu Trp Gly Cys Cys Pro Ile Pro Glu Ala Val Cys Cys Ser Asp His 385 390 395 400 Gln His Cys Cys Pro Gln Gly Tyr Thr Cys Val Ala Glu Gly Gln Cys 405 410 415 Gln Arg Gly Ser Glu Ile Val Ala Gly Leu Glu Lys Met Pro Ala Arg 420 425 430 Arg Ala Ser Leu Ser His Pro Arg Asp Ile Gly Cys Asp Gln His Thr 435 440 445 Ser Cys Pro Val Gly Gln Thr Cys Cys Pro Ser Leu Gly Gly Ser Trp 450 455 460 Ala Cys Cys Gln Leu Pro His Ala Val Cys Cys Glu Asp Arg Gln His 465 470 475 480 Cys Cys Pro Ala Gly Tyr Thr Cys Asn Val Lys Ala Arg Ser Cys Glu 485 490 495 Lys Glu Val Val Ser Ala Gln Pro Ala Thr Phe Leu Ala Arg Ser Pro 500 505 510 His Val Gly Val Lys Asp Val Glu Cys Gly Glu Gly His Phe Cys His 515 520 525 Asp Asn Gln Thr Cys Cys Arg Asp Asn Arg Gln Gly Trp Ala Cys Cys 530 535 540 Pro Tyr Arg Gln Gly Val Cys Cys Ala Asp Arg Arg His Cys Cys Pro 545 550 555 560 Ala Gly Phe Arg Cys Ala Ala Arg Gly Thr Lys Cys Leu Arg Arg Glu 565 570 575 Ala Pro Arg Trp Asp Ala Pro Leu Arg Asp Pro Ala Leu Arg Gln Leu 580 585 590 Leu <![CDATA[<210> 182]]> <![CDATA[<211> 56]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成寡核苷酸]]> <![CDATA[<400> 182]]> gtaaggtaag aattgaattt ctcagttgaa ggatgcttac actcttgtcc atctag 56 <![CDATA[<210> 183]]> <![CDATA[<211> 2051]]> <![CDATA[<212> DNA]]> <![CDATA[<213]]>> 人工序列]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <br/> <br/><![CDATA[<400> 183]]> <br/><![CDATA[ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct g 2051 <![CDATA[<210> 184]]> <![CDATA[<211> 1878]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 184]]> tcaacagggg gacacttggg aaagaaggat ggggacagag ccgagaggac tgttacacat 60 tagagaaaca tcagtgactg tgccagcttt ggggtagact gcacaaaagc cctgaggcag 120 cacaggcagg atccagtctg ctggtcccag gaagctaacc gtctcagaca gagcacaaag 180 caccgagaca tgtgccacaa ggcttgtgta gagaggtcag aggacagcgt acaggtccca 240 gagatcaaac tcaacctcac caggcttggc agcaagcctt taccaaccca cccccacccc 300 acccaccctg cacgcgcccc tctcccctcc ccatggtctc ccatggctat ctcacttggc 360 cctaaaatgt ttaaggatga cactggctgc tgagtggaaa tgagacagca gaagtcaaca 420 gtagatttta ggaaagccag agaaaaaggc ttgtgctgtt tttagaaagc caagggacaa 480 gctaagatag ggcccaagta atgctagtat ttacatttat ccacacaaaa cggacgggcc 540 tccgctgaac cagtgaggcc ccagacgtgc gcataaataa cccctgcgtg ctgcaccacc 600 tggggagagg gggaggacca cggtaaatgg agcgagcgca tagcaaaagg gacgcggggt 660 ccttttctct gccggtggca ctgggtagct gtggccaggt gtggtacttt gatggggccc 720 agggctggag ctcaaggaag cgtcgcaggg tcacagatct gggggaaccc cggggaaaag 780 cactgaggca aaaccgccgc tcgtctccta caatatatgg gagggggagg ttgagtacgt 840 tctggattac tcataagacc tttttttttt ccttccgggc gcaaaaccgt gagctggatt 900 tataatcgcc ctataaagct ccagaggcgg tcaggcacct gcagaggagc cccgccgctc 960 cgccgactag ctgcccccgc gagcaacggc ctcgtgattt ccccgccgat ccggtccccg 1020 cctccccact ctgcccccgc ctaccccgga gccgtgcagc cgcctctccg aatctctctc 1080 ttctcctggc gctcgcgtgc gagagggaac tagcgagaac gaggaagcag ctggaggtga 1140 cgccgggcag attacgcctg tcagggccga gccgagcgga tcgctgggcg ctgtgcagag 1200 gaaaggcggg agtgcccggc tcgctgtcgc agagccgagg tgggtaagct agcgaccacc 1260 tggacttccc agcgcccaac cgtggctttt cagccaggtc ctctcctccc gcggcttctc 1320 aaccaacccc atcccagcgc cggccaccca acctcccgaa atgagtgctt cctgccccag 1380 cagccgaagg cgctactagg aacggtaacc tgttactttt ccaggggccg tagtcgaccc 1440 gctgcccgag ttgctgtgcg actgcgcgcg cggggctaga gtgcaaggtg actgtggttc 1500 ttctctggcc aagtccgagg gagaacgtaa agatatgggc ctttttcccc ctctcacctt 1560 gtctcaccaa agtccctagt ccccggagca gttagcctct ttctttccag ggaattagcc 1620 agacacaaca acgggaacca gacaccgaac cagacatgcc cgccccgtgc gccctccccg 1680 ctcgctgcct ttcctccctc ttgtctctcc agagccggat cttcaagggg agcctccgtg 1740 cccccggctg ctcagtccct ccggtgtgca ggaccccgga agtcctcccc gcacagctct 1800 cgcttctctt tgcagcctgt ttctgcgccg gaccagtcga ggactctgga cagtagaggc 1860 cccgggacga ccgagctg 1878 <![CDATA[<210> 185]]> <![CDATA[<211> 681]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 185]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag t 681 <![CDATA[<210> 186]]> <![CDATA[<211> 1335]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 186]]> gagtaattca tacaaaagga ctcgcccctg ccttggggaa tcccagggac cgtcgttaaa 60 ctcccactaa cgtagaaccc agagatcgct gcgttcccgc cccctcaccc gcccgctctc 120 gtcatcactg aggtggagaa gagcatgcgt gaggctccgg tgcccgtcag tgggcagagc 180 gcacatcgcc cacagtcccc gagaagttgg ggggaggggt cggcaattga accggtgcct 240 agagaaggtg gcgcggggta aactgggaaa gtgatgtcgt gtactggctc cgcctttttc 300 ccgagggtgg gggagaaccg tatataagtg cagtagtcgc cgtgaacgtt ctttttcgca 360 acgggtttgc cgccagaaca caggtaagtg ccgtgtgtgg ttcccgcggg cctggcctct 420 ttacgggtta tggcccttgc gtgccttgaa ttacttccac gcccctggct gcagtacgtg 480 attcttgatc ccgagcttcg ggttggaagt gggtgggaga gttcgaggcc ttgcgcttaa 540 ggagcccctt cgcctcgtgc ttgagttgag gcctggcttg ggcgctgggg ccgccgcgtg 600 cgaatctggt ggcaccttcg cgcctgtctc gctgctttcg ataagtctct agccatttaa 660 aatttttgat gacctgctgc gacgcttttt ttctggcaag atagtcttgt aaatgcgggc 720 caagatctgc acactggtat ttcggttttt ggggccgcgg gcggcgacgg ggcccgtgcg 780 tcccagcgca catgttcggc gaggcggggc ctgcgagcgc ggccaccgag aatcggacgg 840 gggtagtctc aagctggccg gcctgctctg gtgcctggcc tcgcgccgcc gtgtatcgcc 900 ccgccctggg cggcaaggct ggcccggtcg gcaccagttg cgtgagcgga aagatggccg 960 cttcccggcc ctgctgcagg gagctcaaaa tggaggacgc ggcgctcggg agagcgggcg 1020 ggtgagtcac ccacacaaag gaaaagggcc tttccgtcct cagccgtcgc ttcatgtgac 1080 tccacggagt accgggcgcc gtccaggcac ctcgattagt tctcgagctt ttggagtacg 1140 tcgtctttag gttgggggga ggggttttat gcgatggagt ttccccacac tgagtgggtg 1200 gagactgaag ttaggccagc ttggcacttg atgtaattct ccttggaatt tgcccttttt 1260 gagtttggat cttggttcat tctcaagcct cagacagtgg ttcaaagttt ttttcttcca 1320 tttcaggtgt cgtga 1335 <![CDATA[<210> 187]]> <![CDATA[<211> 1366]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 187]]> gagtttactc cctatcagtg atagagaacg tatgtcgagt ttactcccta tcagtgatag 60 agaacgatgt cgagtttact ccctatcagt gatagagaac gtatgtcgag tttactccct 120 atcagtgata gagaacgtat gtcgagttta ctccctatca gtgatagaga acgtatgtcg 180 agtttatccc tatcagtgat agagaacgta tgtcgagttt actccctatc agtgatagag 240 aacgtatgtc gaggtaggcg tgtacggtgg gaggcctata taagcagagc tcgtttagtg 300 aaccgtcaga tcgccgaatt cgccaccatg gtgagcaagg gcgaggagct gttcaccggg 360 gtggtgccca tcctggtcga gctggacggc gacgtaaacg gccacaagtt cagcgtgtcc 420 ggcgagggcg agggcgatgc cacctacggc aagctgaccc tgaagttcat ctgcaccacc 480 ggcaagctgc ccgtgccctg gcccaccctc gtgaccaccc tgacctacgg cgtgcagtgc 540 ttcagccgct accccgacca catgaagcag cacgacttct tcaagtccgc catgcccgaa 600 ggctacgtcc aggagcgcac catcttcttc aaggacgacg gcaactacaa gacccgcgcc 660 gaggtgaagt tcgagggcga caccctggtg aaccgcatcg agctgaaggg catcgacttc 720 aaggaggacg gcaacatcct ggggcacaag ctggagtaca actacaacag ccacaacgtc 780 tatatcatgg ccgacaagca gaagaacggc atcaaggtga acttcaagat ccgccacaac 840 atcgaggacg gcagcgtgca gctcgccgac cactaccagc agaacacccc catcggcgac 900 ggccccgtgc tgctgcccga caaccactac ctgagcaccc agtccgccct gagcaaagac 960 cccaacgaga agcgcgatca catggtcctg ctggagttcg tgaccgccgc cgggatcact 1020 ctcggcatgg acgagctgta caagtccgga ctcagatctc gagaggagga ggaggagaca 1080 gacagcagga tgccccacct cgacagcccc ggcagctccc agccgagacg ctccttcctc 1140 tcaagggtga tcagggcagc tctaccgttg cagctgcttc tgctgctgct gctgctcctg 1200 gcctgcctgc tacctgcctc tgaagatgac tacagctgca cccaggccaa caactttgcc 1260 cgatccttct accccatgct gcggtacacc aacgggccac ctcccaccta gactagtaat 1320 aaaagatctt tattttcatt agatctgtgt gttggttttt tgtgtg 1366 <![CDATA[<210> 188]]> <![CDATA[<211> 315]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 188]]> gagtttactc cctatcagtg atagagaacg tatgtcgagt ttactcccta tcagtgatag 60 agaacgatgt cgagtttact ccctatcagt gatagagaac gtatgtcgag tttactccct 120 atcagtgata gagaacgtat gtcgagttta ctccctatca gtgatagaga acgtatgtcg 180 agtttatccc tatcagtgat agagaacgta tgtcgagttt actccctatc agtgatagag 240 aacgtatgtc gaggtaggcg tgtacggtgg gaggcctata taagcagagc tcgtttagtg 300 aaccgtcaga tcgcc 315 <![CDATA[<210> 189]]> <![CDATA[<400> 189]]> 000 <![CDATA[<210> 190]]> <![CDATA[<211> 22]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 190]]> tgtctcggca ttgagaacat tc 22 <![CDATA[<210> 191]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 191]]> attggtggga ggccattgta t 21 <![CDATA[<210> 192]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 192]]> accacagtcc atgccatcac 20 <![CDATA[<210> 193]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 193]]> tccaccaccc tgttgctgta 20 <![CDATA[<210> 194]]> <![CDATA[<400> 194]]> 000 <![CDATA[<210> 195]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 195]]> cactcattga ggacagaagc a 21 <![CDATA[<210> 196]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 196]]> acaaagtgga gagactaccc g 21 <![CDATA[<210> 197]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 197]]> ggtacgggca aagatttctt g 21 <![CDATA[<210> 198]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 198]]> tttgcccgta ccaaagtctt g 21 <![CDATA[<210> 199]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 199]]> tcttcagcca caaaaaaaaa a 21 <![CDATA[<210> 200]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 200]]> gtgtgcaacc catgaggtcg c 21 <![CDATA[<210> 201]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 201]]> acacaatgag ccacctacaa g 21 <![CDATA[<210> 202]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 202]]> gtggctcatt gtgtgtgtgc c 21 <![CDATA[<210> 203]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 203]]> agaaagctga tacagataca a 21 <![CDATA[<210> 204]]> <![CDATA[<400> 204]]> 000 <![CDATA[<210> 205]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 205]]> aaaccagcaa caaacagtat a 21 <![CDATA[<210> 206]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 206]]> gagaatcatc taggtcagga c 21 <![CDATA[<210> 207]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 207]]> ttctcagttt tgaaattaaa a 21 <![CDATA[<210> 208]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 208]]> catatccctg caggttcaga a 21 <![CDATA[<210> 209]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 209]]> tggattctct tctgaacctg c 21 <![CDATA[<210> 210]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 210]]> agagagagag agagagagag a 21 <![CDATA[<210> 211]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 211]]> tggtctcatt ctttttgtgg g 21 <![CDATA[<210> 212]]> <![CDATA[<400> 212]]> 000 <![CDATA[<210> 213]]> <![CDATA[<400> 213]]> 000 <![CDATA[<210> 214]]> <![CDATA[<400> 214]]> 000 <![CDATA[<210> 215]]> <![CDATA[<400> 215]]> 000 <![CDATA[<210> 216]]> <![CDATA[<400> 216]]> 000 <![CDATA[<210> 217]]> <![CDATA[<400> 217]]> 000 <![CDATA[<210> 218]]> <![CDATA[<400> 218]]> 000 <![CDATA[<210> 219]]> <![CDATA[<400> 219]]> 000 <![CDATA[<210> 220]]> <![CDATA[<400> 220]]> 000 <![CDATA[<210> 221]]> <![CDATA[<400> 221]]> 000 <![CDATA[<210> 222]]> <![CDATA[<400> 222]]> 000 <![CDATA[<210> 2]]>23 <![CDATA[<400> 223]]> 000 <![CDATA[<210> 224]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 224]]> tgttcctcca gattaacact t 21 <![CDATA[<210> 225]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 225]]> attacagttc tgtcagcatg c 21 <![CDATA[<210> 226]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 226]]> atcatctgta accatcaagg a 21 <![CDATA[<210> 227]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 227]]> tcctgcctac ttagtttcaa g 21 <![CDATA[<210> 228]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 228]]> tgctgaggca ggacacagtg t 21 <![CDATA[<210> 229]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 229]]> acaaagtaag tgtcagtgtg g 21 <![CDATA[<210> 230]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 230]]> ctgacactta ctttgtctaa a 21 <![CDATA[<210> 231]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 231]]> ataatagttg tgtctttata a 21 <![CDATA[<210> 232]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 232]]> cgatattttc atggattcct t 21 <![CDATA[<210> 233]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 233]]> aaaactggaa ccgcattccc a 21 <![CDATA[<210> 234]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 234]]> tgtacaagca gggctgcaaa g 21 <![CDATA[<210> 235]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 235]]> aaaggggaat gggaacaccc g 21 <![CDATA[<210> 236]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 236]]> atgttcaagg tgcagaagga a 21 <![CDATA[<210> 237]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 237]]> ttcaacaagc tcccaagaag t 21 <![CDATA[<210> 238]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 238]]> gttaacaaat acactaaaca c 21 <![CDATA[<210> 239]]> <![CDATA[<400> 239]]> 000 <![CDATA[<210> 240]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 240]]> aaaaccgtca accccataca g 21 <![CDATA[<210> 241]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 241]]> aggaatcact tgtcagacct a 21 <![CDATA[<210> 242]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 242]]> gagactgtgc gtataaaggc a 21 <![CDATA[<210> 243]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 243]]> tactgataca ggaactgtgc c 21 <![CDATA[<210> 244]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 244]]> cttgtcatga aacatgagct a 21 <![CDATA[<210> 245]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 245]]> tatctgtatt ccttttattt t 21 <![CDATA[<210> 246]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 246]]> ataaatggta attaaaatgt g 21 <![CDATA[<210> 247]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 247]]> tgtttgctca aacgtgcacc a 21 <![CDATA[<210> 248]]> <![CDATA[<211> 21]]> <![CDATA[<212> D]]>NA <![CDATA[<213> 智人]]> <![CDATA[<400> 248]]> aaatatgtac cacaagaaat g 21 <![CDATA[<210> 249]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 249]]> tatctggttt ctctcactgc t 21 <![CDATA[<210> 250]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 250]]> aaataagaca tgaaaacaag a 21 <![CDATA[<210> 251]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 251]]> attgcaaagc ataatttgga t 21 <![CDATA[<210> 252]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 252]]> caaactccca gcctgcctgg c 21 <![CDATA[<210> 253]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 253]]> ccagcactgg tgcttcgt 18 <![CDATA[<210> 254]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 254]]> aaggctgtct aggtcaag 18 <![CDATA[<210> 255]]> <![CDATA[<400> 255]]> 000 <![CDATA[<210> 256]]> <![CDATA[<211> 24]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 256]]> ctaggtcaag tgtaggagac acac 24 <![CDATA[<210> 257]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 257]]> ggtcaagtgt aggagaca 18 <![CDATA[<210> 258]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 258]]> caagtgtagg agacacac 18 <![CDATA[<210> 259]]> <![CDATA[<211> 24]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 259]]> agtgtaggag acacactgct ggcc 24 <![CDATA[<210> 260]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 260]]> agtgtaggag acacactg 18 <![CDATA[<210> 261]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 261]]> acttgaccta gacagcct 18 <![CDATA[<210> 262]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 262]]> aggagacaca ctgctggcct g 21 <![CDATA[<210> 263]]> <![CDATA[<400> 263]]> 000 <![CDATA[<210> 264]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 264]]> tgaataactc attagtga 18 <![CDATA[<210> 265]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 265]]> aaagtacatt aggctaat 18 <![CDATA[<210> 266]]> <![CDATA[<400> 266]]> 000 <![CDATA[<210> 267]]> <![CDATA[<400> 267]]> 000 <![CDATA[<210> 268]]> <![CDATA[<211> 231]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 268]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Asp Pro Gly His Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr 50 55 60 Lys Asn Ser Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Asn Asp Ala Leu 85 90 95 Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Glu Arg Ser His Leu Arg Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Ser Lys Lys His Leu Ala Glu His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr 165 170 175 His Leu Asp Leu Ile Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 180 185 190 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu 195 200 205 Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser Lys Arg Pro 210 215 220 Ala Ala Thr Lys Lys Ala Gly 225 230 <![CDATA[<210> 269]]> <![CDATA[<211> 203]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 269]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Ser Arg Arg Thr Cys Arg Ala His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr 50 55 60 Thr Gly Ala Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Arg Asn Asp Ala Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Ser Gly Asp Leu Arg Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr 165 170 175 Ser His Ser Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly 195 200 <![CDATA[<210> 270]]> <![CDATA[<211> 203]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 270]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Lys Asp Asn Leu Lys Asn His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp 50 55 60 Pro Gly Ala Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu 85 90 95 His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Asp Pro Gly Ala Leu Val Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly Glu Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Lys Asp Asn Leu Lys Asn His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly 195 200 <![CDATA[<210> 271]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 271]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly His Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Asn Ser Thr Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 272]]> <![CDATA[<211> 328]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 272]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Ser Lys Lys Ala Leu Thr Glu His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser 50 55 60 Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Arg Ser Asp Glu Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Ser Gly Asn Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro 180 185 190 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser Gly His Leu 195 200 205 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 210 215 220 Glu Cys Gly Lys Ser Phe Ser Gln Asn Ser Thr Leu Thr Glu His Gln 225 230 235 240 Arg Thr His Thr Gly Lys Lys Thr Ser Lys Arg Pro Ala Ala Thr Lys 245 250 255 Lys Ala Gly Gln Ala Lys Lys Lys Lys Gly Ser Tyr Pro Tyr Asp Val 260 265 270 Pro Asp Tyr Ala Leu Glu Asp Ala Leu Asp Asp Phe Asp Leu Asp Met 275 280 285 Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser 290 295 300 Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu 305 310 315 320 Asp Asp Phe Asp Leu Asp Met Leu 325 <![CDATA[<210> 273]]> <![CDATA[<211> 203]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序]]>列 <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 273]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu 85 90 95 His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu Val Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr 165 170 175 Ser Gly His Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly 195 200 <![CDATA[<210> 274]]> <![CDATA[<211> 203]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 274]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Ser Lys Lys Ala Leu Thr Glu His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser 50 55 60 Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Arg Ser Asp Glu Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Ser Gly Asn Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly 195 200 <![CDATA[<210> 275]]> <![CDATA[<211> 259]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 275]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Asp Cys Arg Asp Leu Ala Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Asn Asp Ala Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Asn Asp Ala Leu 85 90 95 Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Asp Pro Gly Asn Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Arg Ala His Leu Glu Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 180 185 190 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Ser Leu 195 200 205 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 210 215 220 Glu Cys Gly Lys Ser Phe Ser His Arg Thr Thr Leu Thr Asn His Gln 225 230 235 240 Arg Thr His Thr Gly Lys Lys Thr Ser Lys Arg Pro Ala Ala Thr Lys 245 250 255 Lys Ala Gly <![CDATA[<210> 276]]> <![CDATA[<211> 203]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 276]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Asn Asp Ala Leu Thr Glu His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser 50 55 60 Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Pro Gly Asn Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Arg Ala His Leu Glu Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 165 170 175 Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly 195 200 <![CDATA[<210> 277]]> <![CDATA[<211> 203]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 277]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Thr Lys Asn Ser Leu Thr Glu His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Ala Asp Asn Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu 85 90 95 Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Thr Lys Asn Ser Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Ala Gly His Leu Ala Ser His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr 165 170 175 His Leu Asp Leu Ile Arg His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly 195 200 <![CDATA[<210> 278]]> <![CDATA[<211> 231]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 278]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Asn Asp Ala Leu Thr Glu His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp 50 55 60 Pro Gly His Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser Gly Glu Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Thr His Leu Asp Leu Ile Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Ser Lys Lys Ala Leu Thr Glu His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Leu Ala His Leu Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro 180 185 190 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp His Leu 195 200 205 Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr Ser Lys Arg Pro 210 215 220 Ala Ala Thr Lys Lys Ala Gly 225 230 <![CDATA[<210> 279]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 279]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 50 55 60 Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu 85 90 95 His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 280]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 280]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Asp Pro Gly Ala Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Gly Asp Leu 85 90 95 Arg Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Thr His Leu Asp Leu Ile Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 281]]> <![CDATA[<211> 203]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 281]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Gln Ala Gly His Leu Ala Ser His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser Gly Asn Leu 85 90 95 Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Thr His Leu Asp Leu Ile Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Lys Ser Ser Leu Ile Ala His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Ala Gly His Leu Ala Ser His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly 195 200 <![CDATA[<210> 282]]> <![CDATA[<211> 203]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 282]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Thr Thr Gly Asn Leu Thr Val His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr 50 55 60 Ser Gly Glu Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu 85 90 95 His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Thr Ser Gly Asn Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Arg Ala Asn Leu Arg Ala His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly 195 200 <![CDATA[<210> 283]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 283]]> ggtcacgtac agcttcgcat 20 <![CDATA[<210> 284]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 284]]> ctggtttctg gctcgtggag 20 <![CDATA[<210> 285]]> <![CDATA[<211> 19]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 285]]> aagccccaaa gccaagcag 19 <![CDATA[<210> 286]]> <![CDATA[<211> 19]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 286]]> aggtgtggca ttgaaacgg 19 <![CDATA[<210> 287]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 287]]> atggtcagtt ctgccctgtg 20 <![CDATA[<210> 288]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 288]]> cggtaaagat gcaggagtgg c 21 <![CDATA[<210> 289]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 289]]> tgacaatggg cagaacgaat 20 <![CDATA[<210> 290]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 290]]> tgcagcactc tgttgacgtt 20 <![CDATA[<210> 291]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 291]]> tgttgccact ggtgctaaag 20 <![CDATA[<210> 292]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 292]]> acagcagtct tctccgcttc 20 <![CDATA[<210> 293]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 293]]> caaaaaagcc acaaaagcct 20 <![CDATA[<210> 294]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 294]]> ttagctccgc aagaaacatc 20 <![CDATA[<210> 295]]> <![CDATA[<211> 667]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 2]]>95 Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Gly Tyr Pro Tyr Asp Val 1 5 10 15 Pro Asp Tyr Ala Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Gly 20 25 30 Ser Gly Ser Gly Ser Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser 35 40 45 Pro Leu Gln Ile Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr 50 55 60 Met Asp Asn Tyr Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly 65 70 75 80 Ala Pro Gln Phe Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser 85 90 95 Asn Ser Ser Ser Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly 100 105 110 Ser Asn Ser Ser Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr 115 120 125 Gly Glu Gln Pro Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile 130 135 140 Ser Leu Asn Asn Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln 145 150 155 160 Thr Thr Arg Leu Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu 165 170 175 Pro Ala Pro Asn Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser 180 185 190 Leu Val Ser Gly Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser 195 200 205 Ser Ala Pro Ser Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro 210 215 220 Pro Leu Ser Cys Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser 225 230 235 240 Ala Ala Pro Thr Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro 245 250 255 Gln Ser Gln Ala Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro 260 265 270 Pro Pro Ala Tyr Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile 275 280 285 Pro Asp Tyr Leu Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr 290 295 300 Pro Asp Gln Lys Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro 305 310 315 320 Ser Leu Thr Pro Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly 325 330 335 Ser Gln Asp Leu Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile 340 345 350 Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro 355 360 365 Pro His Glu Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg 370 375 380 Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly 385 390 395 400 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu 405 410 415 Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 420 425 430 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val 435 440 445 Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys 450 455 460 Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr 465 470 475 480 Glu His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile 485 490 495 Cys Met Arg Asn Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg 500 505 510 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 515 520 525 Phe Ala Gln Asn Ser Thr Leu Thr Glu His Thr Lys Ile His Leu Arg 530 535 540 Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala Ser Ser Ala Thr 545 550 555 560 Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr Ser Tyr Pro Ser 565 570 575 Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr Ser Tyr Pro Ser 580 585 590 Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser Thr Tyr Pro Ser 595 600 605 Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala Thr Thr Tyr Ser 610 615 620 Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser Phe Pro Ser Ser 625 630 635 640 Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu Ser Asp Met Thr 645 650 655 Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys 660 665 <![CDATA[<210> 296]]> <![CDATA[<211> 719]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 296]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Asp Pro 340 345 350 Gly Ala Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp Asn Leu Val 370 375 380 Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Gln Ser Gly Asp Leu Arg Arg His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Thr His Leu Asp Leu Ile Arg His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser Thr Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser 485 490 495 Asp Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Arg 500 505 510 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Gln Ser 515 520 525 Gly His Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 530 535 540 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Glu Arg Ser His Leu Arg 545 550 555 560 Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 565 570 575 Cys Gly Arg Lys Phe Ala Gln Ala Gly His Leu Ala Ser His Thr Lys 580 585 590 Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala 595 600 605 Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr 610 615 620 Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr 625 630 635 640 Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser 645 650 655 Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala 660 665 670 Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser 675 680 685 Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu 690 695 700 Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys 705 710 715 <![CDATA[<210> 297]]> <![CDATA[<211> 197]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 297]]> Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 1 5 10 15 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 20 25 30 Asp Asn Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 35 40 45 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser His Ser Thr Thr Leu Thr 50 55 60 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 65 70 75 80 Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Arg Lys Thr His Ile Arg 85 90 95 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 100 105 110 Phe Ser Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly 115 120 125 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser 130 135 140 Ser Ser Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 145 150 155 160 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Arg Lys 165 170 175 Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys 180 185 190 Ser Val Val Ala Ser 195 <![CDATA[<210> 298]]> <![CDATA[<211> 197]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 298]]> Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 1 5 10 15 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 20 25 30 Asp Asn Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 35 40 45 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp Asn Leu Thr 50 55 60 Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 65 70 75 80 Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Arg Lys Arg His Ile Arg 85 90 95 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 100 105 110 Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly 115 120 125 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser 130 135 140 Gly His Leu Thr Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 145 150 155 160 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Ser Ser Thr Arg Lys 165 170 175 Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys 180 185 190 Ser Val Val Ala Ser 195 <![CDATA[<210> 299]]> <![CDATA[<211> 627]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 299]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His 370 375 380 Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Ile Arg 405 410 415 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 420 425 430 Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly 435 440 445 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser 450 455 460 Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 465 470 475 480 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr 485 490 495 Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys 500 505 510 Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser 515 520 525 Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser 530 535 540 Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser 545 550 555 560 Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser 565 570 575 Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala 580 585 590 Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala 595 600 605 Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile 610 615 620 Glu Ile Cys 625 <![CDATA[<210> 300]]> <![CDATA[<400> 300]]> 000 <![CDATA[<210> 301]]> <![CDATA[<400> 301]]> 000 <![CDATA[<210> 302]]> <![CDATA[<400> 302]]> 000 <![CDATA[<210> 303]]> <![CDATA[<400> 303]]> 000 <![CDATA[<210> 304]]> <![CDATA[<400> 304]]> 000 <![CDATA[<210> 305]]> <![CDATA[<211> 753]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 305]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly His Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Asn Ser Thr Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Glu Ala 210 215 220 Ser Gly Ser Gly Arg Ala Asp Ala Leu Asp Asp Phe Asp Leu Asp Met 225 230 235 240 Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser 245 250 255 Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu 260 265 270 Asp Asp Phe Asp Leu Asp Met Leu Ile Asn Ser Arg Ser Ser Gly Ser 275 280 285 Pro Lys Lys Lys Arg Lys Val Gly Ser Gln Tyr Leu Pro Asp Thr Asp 290 295 300 Asp Arg His Arg Ile Glu Glu Lys Arg Lys Arg Thr Tyr Glu Thr Phe 305 310 315 320 Lys Ser Ile Met Lys Lys Ser Pro Phe Ser Gly Pro Thr Asp Pro Arg 325 330 335 Pro Pro Pro Arg Arg Ile Ala Val Pro Ser Arg Ser Ser Ala Ser Val 340 345 350 Pro Lys Pro Ala Pro Gln Pro Tyr Pro Phe Thr Ser Ser Leu Ser Thr 355 360 365 Ile Asn Tyr Asp Glu Phe Pro Thr Met Val Phe Pro Ser Gly Gln Ile 370 375 380 Ser Gln Ala Ser Ala Leu Ala Pro Ala Pro Pro Gln Val Leu Pro Gln 385 390 395 400 Ala Pro Ala Pro Ala Pro Ala Pro Ala Met Val Ser Ala Leu Ala Gln 405 410 415 Ala Pro Ala Pro Val Pro Val Leu Ala Pro Gly Pro Pro Gln Ala Val 420 425 430 Ala Pro Pro Ala Pro Lys Pro Thr Gln Ala Gly Glu Gly Thr Leu Ser 435 440 445 Glu Ala Leu Leu Gln Leu Gln Phe Asp Asp Glu Asp Leu Gly Ala Leu 450 455 460 Leu Gly Asn Ser Thr Asp Pro Ala Val Phe Thr Asp Leu Ala Ser Val 465 470 475 480 Asp Asn Ser Glu Phe Gln Gln Leu Leu Asn Gln Gly Ile Pro Val Ala 485 490 495 Pro His Thr Thr Glu Pro Met Leu Met Glu Tyr Pro Glu Ala Ile Thr 500 505 510 Arg Leu Val Thr Gly Ala Gln Arg Pro Pro Asp Pro Ala Pro Ala Pro 515 520 525 Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu Ser Gly Asp Glu Asp 530 535 540 Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala Leu Leu Gly Ser Gly 545 550 555 560 Ser Gly Ser Arg Asp Ser Arg Glu Gly Met Phe Leu Pro Lys Pro Glu 565 570 575 Ala Gly Ser Ala Ile Ser Asp Val Phe Glu Gly Arg Glu Val Cys Gln 580 585 590 Pro Lys Arg Ile Arg Pro Phe His Pro Pro Gly Ser Pro Trp Ala Asn 595 600 605 Arg Pro Leu Pro Ala Ser Leu Ala Pro Thr Pro Thr Gly Pro Val His 610 615 620 Glu Pro Val Gly Ser Leu Thr Pro Ala Pro Val Pro Gln Pro Leu Asp 625 630 635 640 Pro Ala Pro Ala Val Thr Pro Glu Ala Ser His Leu Leu Glu Asp Pro 645 650 655 Asp Glu Glu Thr Ser Gln Ala Val Lys Ala Leu Arg Glu Met Ala Asp 660 665 670 Thr Val Ile Pro Gln Lys Glu Glu Ala Ala Ile Cys Gly Gln Met Asp 675 680 685 Leu Ser His Pro Pro Pro Arg Gly His Leu Asp Glu Leu Thr Thr Thr 690 695 700 Leu Glu Ser Met Thr Glu Asp Leu Asn Leu Asp Ser Pro Leu Thr Pro 705 710 715 720 Glu Leu Asn Glu Ile Leu Asp Thr Phe Leu Asn Asp Glu Cys Leu Leu 725 730 735 His Ala Met His Ile Ser Thr Gly Leu Ser Ile Phe Asp Thr Ser Leu 740 745 750 Phe <![CDATA[<210> 306]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 306]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly His Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Asn Ser Thr Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 307]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 307]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly His Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Asn Ser Thr Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 308]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 308]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly His Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Asn Ser Thr Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 309]]> <![CDATA[<211> 753]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 309]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 50 55 60 Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu 85 90 95 His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Glu Ala 210 215 220 Ser Gly Ser Gly Arg Ala Asp Ala Leu Asp Asp Phe Asp Leu Asp Met 225 230 235 240 Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser 245 250 255 Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu 260 265 270 Asp Asp Phe Asp Leu Asp Met Leu Ile Asn Ser Arg Ser Ser Gly Ser 275 280 285 Pro Lys Lys Lys Arg Lys Val Gly Ser Gln Tyr Leu Pro Asp Thr Asp 290 295 300 Asp Arg His Arg Ile Glu Glu Lys Arg Lys Arg Thr Tyr Glu Thr Phe 305 310 315 320 Lys Ser Ile Met Lys Lys Ser Pro Phe Ser Gly Pro Thr Asp Pro Arg 325 330 335 Pro Pro Pro Arg Arg Ile Ala Val Pro Ser Arg Ser Ser Ala Ser Val 340 345 350 Pro Lys Pro Ala Pro Gln Pro Tyr Pro Phe Thr Ser Ser Leu Ser Thr 355 360 365 Ile Asn Tyr Asp Glu Phe Pro Thr Met Val Phe Pro Ser Gly Gln Ile 370 375 380 Ser Gln Ala Ser Ala Leu Ala Pro Ala Pro Pro Gln Val Leu Pro Gln 385 390 395 400 Ala Pro Ala Pro Ala Pro Ala Pro Ala Met Val Ser Ala Leu Ala Gln 405 410 415 Ala Pro Ala Pro Val Pro Val Leu Ala Pro Gly Pro Pro Gln Ala Val 420 425 430 Ala Pro Pro Ala Pro Lys Pro Thr Gln Ala Gly Glu Gly Thr Leu Ser 435 440 445 Glu Ala Leu Leu Gln Leu Gln Phe Asp Asp Glu Asp Leu Gly Ala Leu 450 455 460 Leu Gly Asn Ser Thr Asp Pro Ala Val Phe Thr Asp Leu Ala Ser Val 465 470 475 480 Asp Asn Ser Glu Phe Gln Gln Leu Leu Asn Gln Gly Ile Pro Val Ala 485 490 495 Pro His Thr Thr Glu Pro Met Leu Met Glu Tyr Pro Glu Ala Ile Thr 500 505 510 Arg Leu Val Thr Gly Ala Gln Arg Pro Pro Asp Pro Ala Pro Ala Pro 515 520 525 Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu Ser Gly Asp Glu Asp 530 535 540 Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala Leu Leu Gly Ser Gly 545 550 555 560 Ser Gly Ser Arg Asp Ser Arg Glu Gly Met Phe Leu Pro Lys Pro Glu 565 570 575 Ala Gly Ser Ala Ile Ser Asp Val Phe Glu Gly Arg Glu Val Cys Gln 580 585 590 Pro Lys Arg Ile Arg Pro Phe His Pro Pro Gly Ser Pro Trp Ala Asn 595 600 605 Arg Pro Leu Pro Ala Ser Leu Ala Pro Thr Pro Thr Gly Pro Val His 610 615 620 Glu Pro Val Gly Ser Leu Thr Pro Ala Pro Val Pro Gln Pro Leu Asp 625 630 635 640 Pro Ala Pro Ala Val Thr Pro Glu Ala Ser His Leu Leu Glu Asp Pro 645 650 655 Asp Glu Glu Thr Ser Gln Ala Val Lys Ala Leu Arg Glu Met Ala Asp 660 665 670 Thr Val Ile Pro Gln Lys Glu Glu Ala Ala Ile Cys Gly Gln Met Asp 675 680 685 Leu Ser His Pro Pro Pro Arg Gly His Leu Asp Glu Leu Thr Thr Thr 690 695 700 Leu Glu Ser Met Thr Glu Asp Leu Asn Leu Asp Ser Pro Leu Thr Pro 705 710 715 720 Glu Leu Asn Glu Ile Leu Asp Thr Phe Leu Asn Asp Glu Cys Leu Leu 725 730 735 His Ala Met His Ile Ser Thr Gly Leu Ser Ile Phe Asp Thr Ser Leu 740 745 750 Phe <![CDATA[<210> 310]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 310]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 50 55 60 Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu 85 90 95 His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 311]]> <![CDATA[<211> 837]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 311]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Ser Asp His Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asp Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser His Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro 180 185 190 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu 195 200 205 Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 210 215 220 Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln 225 230 235 240 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 245 250 255 Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr 260 265 270 Gly Lys Lys Thr Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln 275 280 285 Ala Lys Lys Lys Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala 290 295 300 Leu Glu Glu Ala Ser Gly Ser Gly Arg Ala Asp Ala Leu Asp Asp Phe 305 310 315 320 Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp 325 330 335 Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly 340 345 350 Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Ile Asn Ser Arg 355 360 365 Ser Ser Gly Ser Pro Lys Lys Lys Arg Lys Val Gly Ser Gln Tyr Leu 370 375 380 Pro Asp Thr Asp Asp Arg His Arg Ile Glu Glu Lys Arg Lys Arg Thr 385 390 395 400 Tyr Glu Thr Phe Lys Ser Ile Met Lys Lys Ser Pro Phe Ser Gly Pro 405 410 415 Thr Asp Pro Arg Pro Pro Pro Arg Arg Ile Ala Val Pro Ser Arg Ser 420 425 430 Ser Ala Ser Val Pro Lys Pro Ala Pro Gln Pro Tyr Pro Phe Thr Ser 435 440 445 Ser Leu Ser Thr Ile Asn Tyr Asp Glu Phe Pro Thr Met Val Phe Pro 450 455 460 Ser Gly Gln Ile Ser Gln Ala Ser Ala Leu Ala Pro Ala Pro Pro Gln 465 470 475 480 Val Leu Pro Gln Ala Pro Ala Pro Ala Pro Ala Pro Ala Met Val Ser 485 490 495 Ala Leu Ala Gln Ala Pro Ala Pro Val Pro Val Leu Ala Pro Gly Pro 500 505 510 Pro Gln Ala Val Ala Pro Pro Ala Pro Lys Pro Thr Gln Ala Gly Glu 515 520 525 Gly Thr Leu Ser Glu Ala Leu Leu Gln Leu Gln Phe Asp Asp Glu Asp 530 535 540 Leu Gly Ala Leu Leu Gly Asn Ser Thr Asp Pro Ala Val Phe Thr Asp 545 550 555 560 Leu Ala Ser Val Asp Asn Ser Glu Phe Gln Gln Leu Leu Asn Gln Gly 565 570 575 Ile Pro Val Ala Pro His Thr Thr Glu Pro Met Leu Met Glu Tyr Pro 580 585 590 Glu Ala Ile Thr Arg Leu Val Thr Gly Ala Gln Arg Pro Pro Asp Pro 595 600 605 Ala Pro Ala Pro Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu Ser 610 615 620 Gly Asp Glu Asp Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala Leu 625 630 635 640 Leu Gly Ser Gly Ser Gly Ser Arg Asp Ser Arg Glu Gly Met Phe Leu 645 650 655 Pro Lys Pro Glu Ala Gly Ser Ala Ile Ser Asp Val Phe Glu Gly Arg 660 665 670 Glu Val Cys Gln Pro Lys Arg Ile Arg Pro Phe His Pro Pro Gly Ser 675 680 685 Pro Trp Ala Asn Arg Pro Leu Pro Ala Ser Leu Ala Pro Thr Pro Thr 690 695 700 Gly Pro Val His Glu Pro Val Gly Ser Leu Thr Pro Ala Pro Val Pro 705 710 715 720 Gln Pro Leu Asp Pro Ala Pro Ala Val Thr Pro Glu Ala Ser His Leu 725 730 735 Leu Glu Asp Pro Asp Glu Glu Thr Ser Gln Ala Val Lys Ala Leu Arg 740 745 750 Glu Met Ala Asp Thr Val Ile Pro Gln Lys Glu Glu Ala Ala Ile Cys 755 760 765 Gly Gln Met Asp Leu Ser His Pro Pro Pro Arg Gly His Leu Asp Glu 770 775 780 Leu Thr Thr Thr Leu Glu Ser Met Thr Glu Asp Leu Asn Leu Asp Ser 785 790 795 800 Pro Leu Thr Pro Glu Leu Asn Glu Ile Leu Asp Thr Phe Leu Asn Asp 805 810 815 Glu Cys Leu Leu His Ala Met His Ile Ser Thr Gly Leu Ser Ile Phe 820 825 830 Asp Thr Ser Leu Phe 835 <![CDATA[<210> 312]]> <![CDATA[<211> 356]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 312]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Arg Asp Glu Leu Asn Val His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Ser Asp His Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asp Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser His Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro 180 185 190 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu 195 200 205 Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 210 215 220 Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln 225 230 235 240 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 245 250 255 Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr 260 265 270 Gly Lys Lys Thr Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln 275 280 285 Ala Lys Lys Lys Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala 290 295 300 Leu Glu Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp 305 310 315 320 Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp 325 330 335 Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp 340 345 350 Leu Asp Met Leu 355 <![CDATA[<210> 313]]> <![CDATA[<211> 631]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 313]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His 370 375 380 Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn 485 490 495 Ser Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 500 505 510 Lys Ala Asp Lys Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser 515 520 525 Ser Tyr Pro Ser Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr 530 535 540 Ser Tyr Pro Ser Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr 545 550 555 560 Ser Phe Ser Ser Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser 565 570 575 Gly Phe Pro Ser Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro 580 585 590 Ala Phe Pro Ala Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn 595 600 605 Ser Phe Ser Ala Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser 610 615 620 Pro Arg Thr Ile Glu Ile Cys 625 630 <![CDATA[<210> 314]]> <![CDATA[<211> 631]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 314]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His 370 375 380 Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn 485 490 495 Ser Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 500 505 510 Lys Ala Asp Lys Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser 515 520 525 Ser Tyr Pro Ser Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr 530 535 540 Ser Tyr Pro Ser Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr 545 550 555 560 Ser Phe Ser Ser Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser 565 570 575 Gly Phe Pro Ser Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro 580 585 590 Ala Phe Pro Ala Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn 595 600 605 Ser Phe Ser Ala Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser 610 615 620 Pro Arg Thr Ile Glu Ile Cys 625 630 <![CDATA[<210> 3]]>15 <![CDATA[<211> 394]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 315]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 195 200 205 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 210 215 220 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His 225 230 235 240 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 245 250 255 Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His 260 265 270 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 275 280 285 Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys 290 295 300 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 305 310 315 320 Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys 325 330 335 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly His 340 345 350 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 355 360 365 Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr Glu His 370 375 380 Thr Lys Ile His Leu Arg Gln Lys Asp Lys 385 390 <![CDATA[<210> 316]]> <![CDATA[<211> 580]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 316]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 195 200 205 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 210 215 220 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His 225 230 235 240 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 245 250 255 Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His 260 265 270 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 275 280 285 Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys 290 295 300 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 305 310 315 320 Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys 325 330 335 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly His 340 345 350 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 355 360 365 Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr Glu His 370 375 380 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ala Asp His 385 390 395 400 Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro Ser Ala 405 410 415 Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro Tyr Ala 420 425 430 Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro Leu Gly 435 440 445 Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala Phe Gly 450 455 460 Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro Ala Ala 465 470 475 480 Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly Arg Ala 485 490 495 Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln Pro Ala 500 505 510 Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly Gly Met 515 520 525 Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu Leu Glu 530 535 540 Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu Gly Gln 545 550 555 560 Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro Ala Gly 565 570 575 Ser Val Ser Cys 580 <![CDATA[<210> 317]]> <![CDATA[<211> 627]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 317]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr Leu Thr 370 375 380 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Ile Arg 405 410 415 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 420 425 430 Phe Ser Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly 435 440 445 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser 450 455 460 Ser Ser Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 465 470 475 480 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His 485 490 495 Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys 500 505 510 Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser 515 520 525 Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser 530 535 540 Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser 545 550 555 560 Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser 565 570 575 Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala 580 585 590 Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala 595 600 605 Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile 610 615 620 Glu Ile Cys 625 <![CDATA[<210> 318]]> <![CDATA[<211> 394]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 318]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 195 200 205 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 210 215 220 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His 225 230 235 240 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 245 250 255 Arg Asn Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His 260 265 270 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 275 280 285 Arg Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys 290 295 300 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 305 310 315 320 Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys 325 330 335 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser 340 345 350 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 355 360 365 Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His 370 375 380 Thr Lys Ile His Leu Arg Gln Lys Asp Lys 385 390 <![CDATA[<210> 319]]> <![CDATA[<211> 580]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 319]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 195 200 205 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 210 215 220 Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His 225 230 235 240 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 245 250 255 Arg Asn Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His 260 265 270 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 275 280 285 Arg Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys 290 295 300 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 305 310 315 320 Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys 325 330 335 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser 340 345 350 Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 355 360 365 Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His 370 375 380 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ala Asp His 385 390 395 400 Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg Pro Pro Ser Ala 405 410 415 Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu Pro Pro Tyr Ala 420 425 430 Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly Ala Pro Leu Gly 435 440 445 Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr Gly Ala Phe Gly 450 455 460 Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro Pro Pro Ala Ala 465 470 475 480 Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr Pro Gly Arg Ala 485 490 495 Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly Pro Gln Pro Ala 500 505 510 Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala Leu Gly Gly Met 515 520 525 Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser Leu Glu Leu Glu 530 535 540 Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu Phe Leu Gly Gln 545 550 555 560 Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala Pro Pro Ala Gly 565 570 575 Ser Val Ser Cys 580 <![CDATA[<210> 320]]> <![CDATA[<211> 719]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 320]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg 340 345 350 Asp Glu Leu Asn Val His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu Thr 370 375 380 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Ser Asp Asp Leu Val Arg His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu 485 490 495 Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Arg 500 505 510 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Thr Ser 515 520 525 His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 530 535 540 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser Leu Val 545 550 555 560 Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 565 570 575 Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr Lys 580 585 590 Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala 595 600 605 Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr 610 615 620 Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr 625 630 635 640 Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser 645 650 655 Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala 660 665 670 Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser 675 680 685 Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu 690 695 700 Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys 705 710 715 <![CDATA[<210> 321]]> <![CDATA[<211> 719]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 321]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg 340 345 350 Asp Glu Leu Asn Val His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu Thr 370 375 380 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Ser Asp Asp Leu Val Arg His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu 485 490 495 Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Arg 500 505 510 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Thr Ser 515 520 525 His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 530 535 540 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser Leu Val 545 550 555 560 Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 565 570 575 Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr Lys 580 585 590 Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala 595 600 605 Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr 610 615 620 Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr 625 630 635 640 Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser 645 650 655 Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala 660 665 670 Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser 675 680 685 Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu 690 695 700 Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys 705 710 715 <![CDATA[<210> 322]]> <![CDATA[<211> 719]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 322]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Arg 340 345 350 Asp Glu Leu Asn Val His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp His Leu Thr 370 375 380 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Ser Asp Asp Leu Val Arg His Thr Lys 405 410 415 Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser 420 425 430 Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile Arg 435 440 445 Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn 450 455 460 Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr Gly 465 470 475 480 Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu 485 490 495 Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Arg 500 505 510 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Thr Ser 515 520 525 His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 530 535 540 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser Leu Val 545 550 555 560 Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 565 570 575 Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr Lys 580 585 590 Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala 595 600 605 Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr 610 615 620 Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr 625 630 635 640 Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser 645 650 655 Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala 660 665 670 Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser 675 680 685 Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu 690 695 700 Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys 705 710 715 <![CDATA[<210> 323]]> <![CDATA[<211> 473]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 323]]> Met Thr Gly Lys Leu Ala Glu Lys Leu Pro Val Thr Met Ser Ser Leu 1 5 10 15 Leu Asn Gln Leu Pro Asp Asn Leu Tyr Pro Glu Glu Ile Pro Ser Ala 20 25 30 Leu Asn Leu Phe Ser Gly Ser Ser Asp Ser Val Val His Tyr Asn Gln 35 40 45 Met Ala Thr Glu Asn Val Met Asp Ile Gly Leu Thr Asn Glu Lys Pro 50 55 60 Asn Pro Glu Leu Ser Tyr Ser Gly Ser Phe Gln Pro Ala Pro Gly Asn 65 70 75 80 Lys Thr Val Thr Tyr Leu Gly Lys Phe Ala Phe Asp Ser Pro Ser Asn 85 90 95 Trp Cys Gln Asp Asn Ile Ile Ser Leu Met Ser Ala Gly Ile Leu Gly 100 105 110 Val Pro Pro Ala Ser Gly Ala Leu Ser Thr Gln Thr Ser Thr Ala Ser 115 120 125 Met Val Gln Pro Pro Gln Gly Asp Val Glu Ala Met Tyr Pro Ala Leu 130 135 140 Pro Pro Tyr Ser Asn Cys Gly Asp Leu Tyr Ser Glu Pro Val Ser Phe 145 150 155 160 His Asp Pro Gln Gly Asn Pro Gly Leu Ala Tyr Ser Pro Gln Asp Tyr 165 170 175 Gln Ser Ala Lys Pro Ala Leu Asp Ser Asn Leu Phe Pro Met Ile Pro 180 185 190 Asp Tyr Asn Leu Tyr His His Pro Asn Asp Met Gly Ser Ile Pro Glu 195 200 205 His Lys Pro Phe Gln Gly Met Asp Pro Ile Arg Val Asn Pro Pro Pro 210 215 220 Ile Thr Pro Leu Glu Thr Ile Lys Ala Phe Lys Asp Lys Gln Ile His 225 230 235 240 Pro Gly Phe Gly Ser Leu Pro Gln Pro Pro Leu Thr Leu Lys Pro Ile 245 250 255 Arg Pro Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Leu His Glu 260 265 270 Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg 275 280 285 Ser Asp Asn Leu Val Arg His Leu Arg Ile His Thr Gly His Lys Pro 290 295 300 Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Glu Asp Asn Leu 305 310 315 320 His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu 325 330 335 Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Ala 340 345 350 Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys 355 360 365 Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Leu Arg Ile 370 375 380 His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe 385 390 395 400 Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu 405 410 415 Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Gln Asn Ser 420 425 430 Thr Leu Thr Glu His Ala Lys Ile His Leu Lys Gln Lys Glu Lys Lys 435 440 445 Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro Pro Val Ser 450 455 460 Leu Ala Pro Val Val Thr Thr Cys Ala 465 470 <![CDATA[<210> 324]]> <![CDATA[<211> 386]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 324]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gln Ser Gln Leu Ile Lys Pro 180 185 190 Ser Arg Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His 195 200 205 Glu Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 210 215 220 Arg Ser Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys 225 230 235 240 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr 245 250 255 Leu Thr Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 260 265 270 Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His 275 280 285 Thr Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val 290 295 300 Glu Ser Cys Asp Arg Arg Phe Ser Thr Ser His Ser Leu Thr Glu His 305 310 315 320 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 325 330 335 Arg Asn Phe Ser Gln Ser Ser Ser Leu Val Arg His Ile Arg Thr His 340 345 350 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 355 360 365 Arg Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys 370 375 380 Asp Lys 385 <![CDATA[<210> 325]]> <![CDATA[<211> 627]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 325]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr Leu Thr 370 375 380 Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Ile Arg 405 410 415 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 420 425 430 Phe Ser Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly 435 440 445 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser 450 455 460 Ser Ser Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 465 470 475 480 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His 485 490 495 Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys 500 505 510 Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser 515 520 525 Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser 530 535 540 Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser 545 550 555 560 Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser 565 570 575 Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala 580 585 590 Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala 595 600 605 Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile 610 615 620 Glu Ile Cys 625 <![CDATA[<210> 326]]> <![CDATA[<211> 62]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成寡核苷酸]]> <![CDATA[<400> 326]]> aataaaagat ctttattttc attagatctg tgtgttggtt ttttgtgtgc ggaccgcacg 60 tg 62 <![CDATA[<210> 327]]> <![CDATA[<211> 477]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 327]]> gggtggcatc cctgtgaccc ctccccagtg cctctcctgg ccctggaagt tgccactcca 60 gtgcccacca gccttgtcct aataaaatta agttgcatca ttttgtctga ctaggtgtcc 120 ttctataata ttatggggtg gaggggggtg gtatggagca aggggcaagt tgggaagaca 180 acctgtaggg cctgcggggt ctattgggaa ccaagctgga gtgcagtggc acaatcttgg 240 ctcactgcaa tctccgcctc ctgggttcaa gcgattctcc tgcctcagcc tcccgagttg 300 ttgggattcc aggcatgcat gaccaggctc agctaatttt tgtttttttg gtagagacgg 360 ggtttcacca tattggccag gctggtctcc aactcctaat ctcaggtgat ctacccacct 420 tggcctccca aattgctggg attacaggcg tgaaccactg ctcccttccc tgtcctt 477 <![CDATA[<210> 328]]> <![CDATA[<211> 23]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 328]]> ccatggaact ggctcgattt cac 23 <![CDATA[<210> 329]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成探針]]> <![CDATA[<400> 329]]> aggcctgaaa accattgtgg gagccct 27 <![CDATA[<210> 330]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 330]]> cgcactgtca atgcccca 18 <![CDATA[<210> 331]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 331]]> cctgctgagg ctgtcccg 18 <![CDATA[<210> 332]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 332]]> aatggggtgt ggggcgag 18 <![CDATA[<210> 333]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 333]]> cctagaaatg gggtgtgg 18 <![CDATA[<210> 334]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 334]]> tgagtagaaa agaaacacag cattcca 27 <![CDATA[<210> 335]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 335]]> gagtagaaaa gaaacacagc a 21 <![CDATA[<210> 336]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 智人]]> <![CDATA[<400> 336]]> agtagaaaag aaacacagca t 21 <![CDATA[<210> 337]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 337]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Thr Ser His Ser Leu Thr Glu His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp 50 55 60 Cys Arg Asp Leu Ala Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Thr Gly Asn Leu 85 90 95 Thr Val His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Asp Pro Gly Ala Leu Val Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr His Leu Asp Leu Ile Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 165 170 175 Thr Gly His Leu Leu Glu His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 338]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 338]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Asn Asp Thr Leu Thr Glu His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp 50 55 60 Pro Gly Ala Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser Gly Glu Leu 85 90 95 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Thr Ser Gly Glu Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr 165 170 175 Lys Asn Ser Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 339]]> <![CDATA[<211> 781]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 339]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Thr Ser Gly Asn Leu Thr Glu His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 50 55 60 Ala Asp Asn Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser Pro Ala Asp Leu 85 90 95 Thr Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu Val Arg His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln 165 170 175 Leu Ala His Leu Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro 180 185 190 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Arg Thr Thr Leu 195 200 205 Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr Ser Lys Arg Pro 210 215 220 Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys Gly Ser Tyr 225 230 235 240 Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Glu Ala Ser Gly Ser Gly 245 250 255 Arg Ala Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp 260 265 270 Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp 275 280 285 Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp 290 295 300 Leu Asp Met Leu Ile Asn Ser Arg Ser Ser Gly Ser Pro Lys Lys Lys 305 310 315 320 Arg Lys Val Gly Ser Gln Tyr Leu Pro Asp Thr Asp Asp Arg His Arg 325 330 335 Ile Glu Glu Lys Arg Lys Arg Thr Tyr Glu Thr Phe Lys Ser Ile Met 340 345 350 Lys Lys Ser Pro Phe Ser Gly Pro Thr Asp Pro Arg Pro Pro Pro Arg 355 360 365 Arg Ile Ala Val Pro Ser Arg Ser Ser Ala Ser Val Pro Lys Pro Ala 370 375 380 Pro Gln Pro Tyr Pro Phe Thr Ser Ser Leu Ser Thr Ile Asn Tyr Asp 385 390 395 400 Glu Phe Pro Thr Met Val Phe Pro Ser Gly Gln Ile Ser Gln Ala Ser 405 410 415 Ala Leu Ala Pro Ala Pro Pro Gln Val Leu Pro Gln Ala Pro Ala Pro 420 425 430 Ala Pro Ala Pro Ala Met Val Ser Ala Leu Ala Gln Ala Pro Ala Pro 435 440 445 Val Pro Val Leu Ala Pro Gly Pro Pro Gln Ala Val Ala Pro Pro Ala 450 455 460 Pro Lys Pro Thr Gln Ala Gly Glu Gly Thr Leu Ser Glu Ala Leu Leu 465 470 475 480 Gln Leu Gln Phe Asp Asp Glu Asp Leu Gly Ala Leu Leu Gly Asn Ser 485 490 495 Thr Asp Pro Ala Val Phe Thr Asp Leu Ala Ser Val Asp Asn Ser Glu 500 505 510 Phe Gln Gln Leu Leu Asn Gln Gly Ile Pro Val Ala Pro His Thr Thr 515 520 525 Glu Pro Met Leu Met Glu Tyr Pro Glu Ala Ile Thr Arg Leu Val Thr 530 535 540 Gly Ala Gln Arg Pro Pro Asp Pro Ala Pro Ala Pro Leu Gly Ala Pro 545 550 555 560 Gly Leu Pro Asn Gly Leu Leu Ser Gly Asp Glu Asp Phe Ser Ser Ile 565 570 575 Ala Asp Met Asp Phe Ser Ala Leu Leu Gly Ser Gly Ser Gly Ser Arg 580 585 590 Asp Ser Arg Glu Gly Met Phe Leu Pro Lys Pro Glu Ala Gly Ser Ala 595 600 605 Ile Ser Asp Val Phe Glu Gly Arg Glu Val Cys Gln Pro Lys Arg Ile 610 615 620 Arg Pro Phe His Pro Pro Gly Ser Pro Trp Ala Asn Arg Pro Leu Pro 625 630 635 640 Ala Ser Leu Ala Pro Thr Pro Thr Gly Pro Val His Glu Pro Val Gly 645 650 655 Ser Leu Thr Pro Ala Pro Val Pro Gln Pro Leu Asp Pro Ala Pro Ala 660 665 670 Val Thr Pro Glu Ala Ser His Leu Leu Glu Asp Pro Asp Glu Glu Thr 675 680 685 Ser Gln Ala Val Lys Ala Leu Arg Glu Met Ala Asp Thr Val Ile Pro 690 695 700 Gln Lys Glu Glu Ala Ala Ile Cys Gly Gln Met Asp Leu Ser His Pro 705 710 715 720 Pro Pro Arg Gly His Leu Asp Glu Leu Thr Thr Thr Leu Glu Ser Met 725 730 735 Thr Glu Asp Leu Asn Leu Asp Ser Pro Leu Thr Pro Glu Leu Asn Glu 740 745 750 Ile Leu Asp Thr Phe Leu Asn Asp Glu Cys Leu Leu His Ala Met His 755 760 765 Ile Ser Thr Gly Leu Ser Ile Phe Asp Thr Ser Leu Phe 770 775 780 <![CDATA[<210> 340]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 340]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp 50 55 60 Ser Gly Asn Leu Arg Val His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu 85 90 95 Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 341]]> <![CDATA[<211> 753]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 341]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp 50 55 60 Ser Gly Asn Leu Arg Val His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu 85 90 95 Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Glu Ala 210 215 220 Ser Gly Ser Gly Arg Ala Asp Ala Leu Asp Asp Phe Asp Leu Asp Met 225 230 235 240 Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser 245 250 255 Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu 260 265 270 Asp Asp Phe Asp Leu Asp Met Leu Ile Asn Ser Arg Ser Ser Gly Ser 275 280 285 Pro Lys Lys Lys Arg Lys Val Gly Ser Gln Tyr Leu Pro Asp Thr Asp 290 295 300 Asp Arg His Arg Ile Glu Glu Lys Arg Lys Arg Thr Tyr Glu Thr Phe 305 310 315 320 Lys Ser Ile Met Lys Lys Ser Pro Phe Ser Gly Pro Thr Asp Pro Arg 325 330 335 Pro Pro Pro Arg Arg Ile Ala Val Pro Ser Arg Ser Ser Ala Ser Val 340 345 350 Pro Lys Pro Ala Pro Gln Pro Tyr Pro Phe Thr Ser Ser Leu Ser Thr 355 360 365 Ile Asn Tyr Asp Glu Phe Pro Thr Met Val Phe Pro Ser Gly Gln Ile 370 375 380 Ser Gln Ala Ser Ala Leu Ala Pro Ala Pro Pro Gln Val Leu Pro Gln 385 390 395 400 Ala Pro Ala Pro Ala Pro Ala Pro Ala Met Val Ser Ala Leu Ala Gln 405 410 415 Ala Pro Ala Pro Val Pro Val Leu Ala Pro Gly Pro Pro Gln Ala Val 420 425 430 Ala Pro Pro Ala Pro Lys Pro Thr Gln Ala Gly Glu Gly Thr Leu Ser 435 440 445 Glu Ala Leu Leu Gln Leu Gln Phe Asp Asp Glu Asp Leu Gly Ala Leu 450 455 460 Leu Gly Asn Ser Thr Asp Pro Ala Val Phe Thr Asp Leu Ala Ser Val 465 470 475 480 Asp Asn Ser Glu Phe Gln Gln Leu Leu Asn Gln Gly Ile Pro Val Ala 485 490 495 Pro His Thr Thr Glu Pro Met Leu Met Glu Tyr Pro Glu Ala Ile Thr 500 505 510 Arg Leu Val Thr Gly Ala Gln Arg Pro Pro Asp Pro Ala Pro Ala Pro 515 520 525 Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu Ser Gly Asp Glu Asp 530 535 540 Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala Leu Leu Gly Ser Gly 545 550 555 560 Ser Gly Ser Arg Asp Ser Arg Glu Gly Met Phe Leu Pro Lys Pro Glu 565 570 575 Ala Gly Ser Ala Ile Ser Asp Val Phe Glu Gly Arg Glu Val Cys Gln 580 585 590 Pro Lys Arg Ile Arg Pro Phe His Pro Pro Gly Ser Pro Trp Ala Asn 595 600 605 Arg Pro Leu Pro Ala Ser Leu Ala Pro Thr Pro Thr Gly Pro Val His 610 615 620 Glu Pro Val Gly Ser Leu Thr Pro Ala Pro Val Pro Gln Pro Leu Asp 625 630 635 640 Pro Ala Pro Ala Val Thr Pro Glu Ala Ser His Leu Leu Glu Asp Pro 645 650 655 Asp Glu Glu Thr Ser Gln Ala Val Lys Ala Leu Arg Glu Met Ala Asp 660 665 670 Thr Val Ile Pro Gln Lys Glu Glu Ala Ala Ile Cys Gly Gln Met Asp 675 680 685 Leu Ser His Pro Pro Pro Arg Gly His Leu Asp Glu Leu Thr Thr Thr 690 695 700 Leu Glu Ser Met Thr Glu Asp Leu Asn Leu Asp Ser Pro Leu Thr Pro 705 710 715 720 Glu Leu Asn Glu Ile Leu Asp Thr Phe Leu Asn Asp Glu Cys Leu Leu 725 730 735 His Ala Met His Ile Ser Thr Gly Leu Ser Ile Phe Asp Thr Ser Leu 740 745 750 Phe <![CDATA[<210> 342]]> <![CDATA[<211> 753]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 342]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp 50 55 60 Ser Gly Asn Leu Arg Val His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu 85 90 95 Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Glu Ala 210 215 220 Ser Gly Ser Gly Arg Ala Asp Ala Leu Asp Asp Phe Asp Leu Asp Met 225 230 235 240 Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser 245 250 255 Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu 260 265 270 Asp Asp Phe Asp Leu Asp Met Leu Ile Asn Ser Arg Ser Ser Gly Ser 275 280 285 Pro Lys Lys Lys Arg Lys Val Gly Ser Gln Tyr Leu Pro Asp Thr Asp 290 295 300 Asp Arg His Arg Ile Glu Glu Lys Arg Lys Arg Thr Tyr Glu Thr Phe 305 310 315 320 Lys Ser Ile Met Lys Lys Ser Pro Phe Ser Gly Pro Thr Asp Pro Arg 325 330 335 Pro Pro Pro Arg Arg Ile Ala Val Pro Ser Arg Ser Ser Ala Ser Val 340 345 350 Pro Lys Pro Ala Pro Gln Pro Tyr Pro Phe Thr Ser Ser Leu Ser Thr 355 360 365 Ile Asn Tyr Asp Glu Phe Pro Thr Met Val Phe Pro Ser Gly Gln Ile 370 375 380 Ser Gln Ala Ser Ala Leu Ala Pro Ala Pro Pro Gln Val Leu Pro Gln 385 390 395 400 Ala Pro Ala Pro Ala Pro Ala Pro Ala Met Val Ser Ala Leu Ala Gln 405 410 415 Ala Pro Ala Pro Val Pro Val Leu Ala Pro Gly Pro Pro Gln Ala Val 420 425 430 Ala Pro Pro Ala Pro Lys Pro Thr Gln Ala Gly Glu Gly Thr Leu Ser 435 440 445 Glu Ala Leu Leu Gln Leu Gln Phe Asp Asp Glu Asp Leu Gly Ala Leu 450 455 460 Leu Gly Asn Ser Thr Asp Pro Ala Val Phe Thr Asp Leu Ala Ser Val 465 470 475 480 Asp Asn Ser Glu Phe Gln Gln Leu Leu Asn Gln Gly Ile Pro Val Ala 485 490 495 Pro His Thr Thr Glu Pro Met Leu Met Glu Tyr Pro Glu Ala Ile Thr 500 505 510 Arg Leu Val Thr Gly Ala Gln Arg Pro Pro Asp Pro Ala Pro Ala Pro 515 520 525 Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu Ser Gly Asp Glu Asp 530 535 540 Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala Leu Leu Gly Ser Gly 545 550 555 560 Ser Gly Ser Arg Asp Ser Arg Glu Gly Met Phe Leu Pro Lys Pro Glu 565 570 575 Ala Gly Ser Ala Ile Ser Asp Val Phe Glu Gly Arg Glu Val Cys Gln 580 585 590 Pro Lys Arg Ile Arg Pro Phe His Pro Pro Gly Ser Pro Trp Ala Asn 595 600 605 Arg Pro Leu Pro Ala Ser Leu Ala Pro Thr Pro Thr Gly Pro Val His 610 615 620 Glu Pro Val Gly Ser Leu Thr Pro Ala Pro Val Pro Gln Pro Leu Asp 625 630 635 640 Pro Ala Pro Ala Val Thr Pro Glu Ala Ser His Leu Leu Glu Asp Pro 645 650 655 Asp Glu Glu Thr Ser Gln Ala Val Lys Ala Leu Arg Glu Met Ala Asp 660 665 670 Thr Val Ile Pro Gln Lys Glu Glu Ala Ala Ile Cys Gly Gln Met Asp 675 680 685 Leu Ser His Pro Pro Pro Arg Gly His Leu Asp Glu Leu Thr Thr Thr 690 695 700 Leu Glu Ser Met Thr Glu Asp Leu Asn Leu Asp Ser Pro Leu Thr Pro 705 710 715 720 Glu Leu Asn Glu Ile Leu Asp Thr Phe Leu Asn Asp Glu Cys Leu Leu 725 730 735 His Ala Met His Ile Ser Thr Gly Leu Ser Ile Phe Asp Thr Ser Leu 740 745 750 Phe <![CDATA[<210> 343]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 343]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp 50 55 60 Ser Gly Asn Leu Arg Val His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu 85 90 95 Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 344]]> <![CDATA[<211> 837]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 344]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Thr Ser His Ser Leu Thr Glu His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 50 55 60 Lys Asn Ala Leu Gln Asn His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Glu Arg Ser His Leu 85 90 95 Arg Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Ser Lys Lys Ala Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Lys Asp Asn Leu Lys Asn His Gln Arg Thr His Thr Gly Glu Lys Pro 180 185 190 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu 195 200 205 Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 210 215 220 Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln 225 230 235 240 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 245 250 255 Ser Phe Ser Gln Ala Gly His Leu Ala Ser His Gln Arg Thr His Thr 260 265 270 Gly Lys Lys Thr Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln 275 280 285 Ala Lys Lys Lys Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala 290 295 300 Leu Glu Glu Ala Ser Gly Ser Gly Arg Ala Asp Ala Leu Asp Asp Phe 305 310 315 320 Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp 325 330 335 Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly 340 345 350 Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Ile Asn Ser Arg 355 360 365 Ser Ser Gly Ser Pro Lys Lys Lys Arg Lys Val Gly Ser Gln Tyr Leu 370 375 380 Pro Asp Thr Asp Asp Arg His Arg Ile Glu Glu Lys Arg Lys Arg Thr 385 390 395 400 Tyr Glu Thr Phe Lys Ser Ile Met Lys Lys Ser Pro Phe Ser Gly Pro 405 410 415 Thr Asp Pro Arg Pro Pro Pro Arg Arg Ile Ala Val Pro Ser Arg Ser 420 425 430 Ser Ala Ser Val Pro Lys Pro Ala Pro Gln Pro Tyr Pro Phe Thr Ser 435 440 445 Ser Leu Ser Thr Ile Asn Tyr Asp Glu Phe Pro Thr Met Val Phe Pro 450 455 460 Ser Gly Gln Ile Ser Gln Ala Ser Ala Leu Ala Pro Ala Pro Pro Gln 465 470 475 480 Val Leu Pro Gln Ala Pro Ala Pro Ala Pro Ala Pro Ala Met Val Ser 485 490 495 Ala Leu Ala Gln Ala Pro Ala Pro Val Pro Val Leu Ala Pro Gly Pro 500 505 510 Pro Gln Ala Val Ala Pro Pro Ala Pro Lys Pro Thr Gln Ala Gly Glu 515 520 525 Gly Thr Leu Ser Glu Ala Leu Leu Gln Leu Gln Phe Asp Asp Glu Asp 530 535 540 Leu Gly Ala Leu Leu Gly Asn Ser Thr Asp Pro Ala Val Phe Thr Asp 545 550 555 560 Leu Ala Ser Val Asp Asn Ser Glu Phe Gln Gln Leu Leu Asn Gln Gly 565 570 575 Ile Pro Val Ala Pro His Thr Thr Glu Pro Met Leu Met Glu Tyr Pro 580 585 590 Glu Ala Ile Thr Arg Leu Val Thr Gly Ala Gln Arg Pro Pro Asp Pro 595 600 605 Ala Pro Ala Pro Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu Ser 610 615 620 Gly Asp Glu Asp Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala Leu 625 630 635 640 Leu Gly Ser Gly Ser Gly Ser Arg Asp Ser Arg Glu Gly Met Phe Leu 645 650 655 Pro Lys Pro Glu Ala Gly Ser Ala Ile Ser Asp Val Phe Glu Gly Arg 660 665 670 Glu Val Cys Gln Pro Lys Arg Ile Arg Pro Phe His Pro Pro Gly Ser 675 680 685 Pro Trp Ala Asn Arg Pro Leu Pro Ala Ser Leu Ala Pro Thr Pro Thr 690 695 700 Gly Pro Val His Glu Pro Val Gly Ser Leu Thr Pro Ala Pro Val Pro 705 710 715 720 Gln Pro Leu Asp Pro Ala Pro Ala Val Thr Pro Glu Ala Ser His Leu 725 730 735 Leu Glu Asp Pro Asp Glu Glu Thr Ser Gln Ala Val Lys Ala Leu Arg 740 745 750 Glu Met Ala Asp Thr Val Ile Pro Gln Lys Glu Glu Ala Ala Ile Cys 755 760 765 Gly Gln Met Asp Leu Ser His Pro Pro Pro Arg Gly His Leu Asp Glu 770 775 780 Leu Thr Thr Thr Leu Glu Ser Met Thr Glu Asp Leu Asn Leu Asp Ser 785 790 795 800 Pro Leu Thr Pro Glu Leu Asn Glu Ile Leu Asp Thr Phe Leu Asn Asp 805 810 815 Glu Cys Leu Leu His Ala Met His Ile Ser Thr Gly Leu Ser Ile Phe 820 825 830 Asp Thr Ser Leu Phe 835 <![CDATA[<210> 345]]> <![CDATA[<211> 479]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 345]]> Met Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn 1 5 10 15 Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val 20 25 30 Glu Ser Cys Asp Arg Arg Phe Ser Ser Pro Ala Asp Leu Thr Arg His 35 40 45 Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met 50 55 60 Arg Asn Phe Ser Asp Ser Gly Asn Leu Arg Val His Ile Arg Thr His 65 70 75 80 Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala 85 90 95 Gln Leu Ala His Leu Arg Ala His Thr Lys Ile His Leu Arg Gln Lys 100 105 110 Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser 115 120 125 Gln Arg Ala Asn Leu Arg Ala His Ile Arg Ile His Thr Gly Gln Lys 130 135 140 Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn 145 150 155 160 Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 165 170 175 Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Leu Val Arg His 180 185 190 Thr Lys Ile His Leu Arg Gln Lys Asp Lys Leu Glu Met Ser Gly Leu 195 200 205 Glu Met Ala Asp His Met Met Ala Met Asn His Gly Arg Phe Pro Asp 210 215 220 Gly Thr Asn Gly Leu His His His Pro Ala His Arg Met Gly Met Gly 225 230 235 240 Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln Pro Gln His Ala 245 250 255 Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly Ala Gly Asn Met 260 265 270 Asn Ala Thr Ser Gly Ile Arg His Ala Met Gly Pro Gly Thr Val Asn 275 280 285 Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala Arg Phe Asn Asn 290 295 300 Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly Gly Ser Leu Pro 305 310 315 320 Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr Phe Asn His His 325 330 335 Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His Pro Ala Ala Gly 340 345 350 His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp Cys Asn Pro Lys 355 360 365 His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly Gly Ser Ser Thr 370 375 380 Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala Gly Ser Ser Asn 385 390 395 400 Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala Ser Val Ala His 405 410 415 Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp Thr Asp Phe Ile 420 425 430 Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met Gly Leu Asp Arg 435 440 445 Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn Glu Phe Asp Phe 450 455 460 Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg Val Ser Cys 465 470 475 <![CDATA[<210> 346]]> <![CDATA[<211> 476]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 346]]> Met Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly 1 5 10 15 Arg Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg 20 25 30 Met Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln 35 40 45 Pro Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly 50 55 60 Ala Gly Asn Met Asn Ala Thr Ser Gly Val Arg His Ala Met Gly Pro 65 70 75 80 Gly Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala 85 90 95 Arg Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly 100 105 110 Gly Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr 115 120 125 Phe Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His 130 135 140 Pro Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp 145 150 155 160 Cys Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly 165 170 175 Gly Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala 180 185 190 Gly Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala 195 200 205 Ser Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp 210 215 220 Thr Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met 225 230 235 240 Gly Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn 245 250 255 Glu Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg 260 265 270 Val Ser Cys Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr 275 280 285 Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys 290 295 300 Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Ser Pro Ala Asp Leu Thr 305 310 315 320 Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile 325 330 335 Cys Met Arg Asn Phe Ser Asp Ser Gly Asn Leu Arg Val His Ile Arg 340 345 350 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 355 360 365 Phe Ala Gln Leu Ala His Leu Arg Ala His Thr Lys Ile His Leu Arg 370 375 380 Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg 385 390 395 400 Phe Ser Gln Arg Ala Asn Leu Arg Ala His Ile Arg Ile His Thr Gly 405 410 415 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu 420 425 430 Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 435 440 445 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Leu Val 450 455 460 Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 465 470 475 <![CDATA[<210> 347]]> <![CDATA[<211> 479]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 347]]> Met Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 1 5 10 15 Ser Pro Ala Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys 20 25 30 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn 35 40 45 Leu Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 50 55 60 Glu Phe Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His 65 70 75 80 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 85 90 95 Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg 100 105 110 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 115 120 125 Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 165 170 175 Lys Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro Pro Val 180 185 190 Ser Leu Ala Pro Val Val Thr Thr Cys Ala Leu Glu Met Ser Gly Leu 195 200 205 Glu Met Ala Asp His Met Met Ala Met Asn His Gly Arg Phe Pro Asp 210 215 220 Gly Thr Asn Gly Leu His His His Pro Ala His Arg Met Gly Met Gly 225 230 235 240 Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln Pro Gln His Ala 245 250 255 Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly Ala Gly Asn Met 260 265 270 Asn Ala Thr Ser Gly Ile Arg His Ala Met Gly Pro Gly Thr Val Asn 275 280 285 Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala Arg Phe Asn Asn 290 295 300 Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly Gly Ser Leu Pro 305 310 315 320 Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr Phe Asn His His 325 330 335 Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His Pro Ala Ala Gly 340 345 350 His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp Cys Asn Pro Lys 355 360 365 His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly Gly Ser Ser Thr 370 375 380 Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala Gly Ser Ser Asn 385 390 395 400 Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala Ser Val Ala His 405 410 415 Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp Thr Asp Phe Ile 420 425 430 Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met Gly Leu Asp Arg 435 440 445 Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn Glu Phe Asp Phe 450 455 460 Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg Val Ser Cys 465 470 475 <![CDATA[<210> 348]]> <![CDATA[<211> 476]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:]]>合成多肽 <![CDATA[<400> 348]]> Met Ser Gly Leu Glu Met Ala Asp His Met Met Ala Met Asn His Gly 1 5 10 15 Arg Phe Pro Asp Gly Thr Asn Gly Leu His His His Pro Ala His Arg 20 25 30 Met Gly Met Gly Gln Phe Pro Ser Pro His His His Gln Gln Gln Gln 35 40 45 Pro Gln His Ala Phe Asn Ala Leu Met Gly Glu His Ile His Tyr Gly 50 55 60 Ala Gly Asn Met Asn Ala Thr Ser Gly Val Arg His Ala Met Gly Pro 65 70 75 80 Gly Thr Val Asn Gly Gly His Pro Pro Ser Ala Leu Ala Pro Ala Ala 85 90 95 Arg Phe Asn Asn Ser Gln Phe Met Gly Pro Pro Val Ala Ser Gln Gly 100 105 110 Gly Ser Leu Pro Ala Ser Met Gln Leu Gln Lys Leu Asn Asn Gln Tyr 115 120 125 Phe Asn His His Pro Tyr Pro His Asn His Tyr Met Pro Asp Leu His 130 135 140 Pro Ala Ala Gly His Gln Met Asn Gly Thr Asn Gln His Phe Arg Asp 145 150 155 160 Cys Asn Pro Lys His Ser Gly Gly Ser Ser Thr Pro Gly Gly Ser Gly 165 170 175 Gly Ser Ser Thr Pro Gly Gly Ser Gly Ser Ser Ser Gly Gly Gly Ala 180 185 190 Gly Ser Ser Asn Ser Gly Gly Gly Ser Gly Ser Gly Asn Met Pro Ala 195 200 205 Ser Val Ala His Val Pro Ala Ala Met Leu Pro Pro Asn Val Ile Asp 210 215 220 Thr Asp Phe Ile Asp Glu Glu Val Leu Met Ser Leu Val Ile Glu Met 225 230 235 240 Gly Leu Asp Arg Ile Lys Glu Leu Pro Glu Leu Trp Leu Gly Gln Asn 245 250 255 Glu Phe Asp Phe Met Thr Asp Phe Val Cys Lys Gln Gln Pro Ser Arg 260 265 270 Val Ser Cys Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg 275 280 285 Phe Ser Ser Pro Ala Asp Leu Thr Arg His Leu Arg Ile His Thr Gly 290 295 300 His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser 305 310 315 320 Gly Asn Leu Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 325 330 335 Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg 340 345 350 Ala His Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala 355 360 365 Glu Gly Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His 370 375 380 Leu Arg Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met 385 390 395 400 Arg Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His 405 410 415 Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala 420 425 430 Arg Ser Asp Asn Leu Val Arg His Ala Lys Ile His Leu Lys Gln Lys 435 440 445 Glu Lys Lys Ala Glu Lys Gly Gly Ala Pro Ser Ala Ser Ser Ala Pro 450 455 460 Pro Val Ser Leu Ala Pro Val Val Thr Thr Cys Ala 465 470 475 <![CDATA[<210>]]> 349 <![CDATA[<211> 362]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 349]]> Met Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 1 5 10 15 Ser Pro Ala Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys 20 25 30 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn 35 40 45 Leu Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 50 55 60 Glu Phe Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His 65 70 75 80 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 85 90 95 Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg 100 105 110 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 115 120 125 Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 165 170 175 Leu Glu Met Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val 180 185 190 Gln Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg 195 200 205 Thr Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro 210 215 220 Arg Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu 225 230 235 240 Ala Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala 245 250 255 Val Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr 260 265 270 Pro Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro 275 280 285 Pro Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala 290 295 300 His Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu 305 310 315 320 Thr Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro 325 330 335 Glu Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly 340 345 350 Ser Ala Pro Pro Ala Gly Ser Val Ser Cys 355 360 <![CDATA[<210> 350]]> <![CDATA[<211> 554]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 350]]> Met Ala Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln 1 5 10 15 Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr 20 25 30 Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg 35 40 45 Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala 50 55 60 Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val 65 70 75 80 Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro 85 90 95 Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro 100 105 110 Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His 115 120 125 Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr 130 135 140 Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu 145 150 155 160 Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser 165 170 175 Ala Pro Pro Ala Gly Ser Val Ser Cys Gly Gly Ser Gly Gly Gly Ser 180 185 190 Gly Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser 195 200 205 Ser Pro Ala Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys 210 215 220 Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn 225 230 235 240 Leu Arg Val His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys 245 250 255 Glu Phe Cys Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His 260 265 270 Ala Lys Ile His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly 275 280 285 Cys Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg 290 295 300 Ile His Thr Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser 305 310 315 320 Phe Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly 325 330 335 Glu Lys Pro Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu Lys 355 360 365 Leu Glu Met Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val 370 375 380 Gln Arg Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg 385 390 395 400 Thr Leu Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro 405 410 415 Arg Gly Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu 420 425 430 Ala Tyr Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala 435 440 445 Val Pro Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr 450 455 460 Pro Tyr Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro 465 470 475 480 Pro Gly Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala 485 490 495 His Ala Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu 500 505 510 Thr Ser Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro 515 520 525 Glu Leu Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly 530 535 540 Ser Ala Pro Pro Ala Gly Ser Val Ser Cys 545 550 <![CDATA[<210> 351]]> <![CDATA[<211> 194]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 351]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 20 25 30 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr Leu Thr Asn 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Ile Arg Thr 85 90 95 His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe 100 105 110 Ser Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln 115 120 125 Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser 130 135 140 Ser Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala 145 150 155 160 Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr 165 170 175 His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser 180 185 190 Val Val <![CDATA[<210> 352]]> <![CDATA[<400> 352]]> 000 <![CDATA[<210> 353]]> <![CDATA[<211> 4380]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 353]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccc caaagaagaa gcggaaggtc ggtatccacg 2100 gagtcccagc agccctcgaa ccaggtgaaa aaccttacaa atgtcctgaa tgtgggaaat 2160 cattcagtcg cagcgacaac ctggtgagac atcaacgcac ccatacagga gaaaaacctt 2220 ataaatgtcc agaatgtgga aagtccttct cacgagagga taacttgcac actcatcaac 2280 gaacacatac tggtgaaaaa ccatacaagt gtcccgaatg tggtaaaagt tttagccgga 2340 gcgatgaact tgtccgacac caacgaaccc atacaggcga gaagccttac aaatgtcccg 2400 agtgtggcaa gagcttctca caatcaggga atctgactga gcatcaacga actcataccg 2460 gggaaaaacc ttacaagtgt ccagagtgtg ggaagagctt ttccacaagt ggacatctgg 2520 tacgccacca gaggacacat acaggggaga agccctacaa atgccccgaa tgcggtaaaa 2580 gtttctctca gaatagtacc ctgaccgaac accagcgaac acacactggg aaaaaaacga 2640 gtaaaaggcc ggcggccacg aaaaaggccg gccaggcaaa aaagaaaaag ggatcctacc 2700 catacgacgt accagattac gctctcgagg aggccagcgg ttccggacgg gctgacgcat 2760 tggacgattt tgatctggat atgctgggaa gtgacgccct cgatgatttt gaccttgaca 2820 tgcttggttc ggatgccctt gatgactttg acctcgacat gctcggcagt gacgcccttg 2880 atgatttcga cctggacatg ctgattaact ctagaagttc cggatctccg aaaaagaaac 2940 gcaaagttgg tagccagtac ctgcccgaca ccgacgaccg gcaccggatc gaggaaaagc 3000 ggaagcggac ctacgagaca ttcaagagca tcatgaagaa gtcccccttc agcggcccca 3060 ccgaccctag acctccacct agaagaatcg ccgtgcccag cagatccagc gccagcgtgc 3120 caaaacctgc cccccagcct taccccttca ccagcagcct gagcaccatc aactacgacg 3180 agttccctac catggtgttc cccagcggcc agatctctca ggcctctgct ctggctccag 3240 cccctcctca ggtgctgcct caggctcctg ctcctgcacc agctccagcc atggtgtctg 3300 cactggctca ggcaccagca cccgtgcctg tgctggctcc tggacctcca caggctgtgg 3360 ctccaccagc ccctaaacct acacaggccg gcgagggcac actgtctgaa gctctgctgc 3420 agctgcagtt cgacgacgag gatctgggag ccctgctggg aaacagcacc gatcctgccg 3480 tgttcaccga cctggccagc gtggacaaca gcgagttcca gcagctgctg aaccagggca 3540 tccctgtggc ccctcacacc accgagccca tgctgatgga ataccccgag gccatcaccc 3600 ggctcgtgac aggcgctcag aggcctcctg atccagctcc tgcccctctg ggagcaccag 3660 gcctgcctaa tggactgctg tctggcgacg aggacttcag ctctatcgcc gatatggatt 3720 tctcagcctt gctgggctct ggcagcggca gccgggattc cagggaaggg atgtttttgc 3780 cgaagcctga ggccggctcc gctattagtg acgtgtttga gggccgcgag gtgtgccagc 3840 caaaacgaat ccggccattt catcctccag gaagtccatg ggccaaccgc ccactccccg 3900 ccagcctcgc accaacacca accggtccag tacatgagcc agtcgggtca ctgaccccgg 3960 caccagtccc tcagccactg gatccagcgc ccgcagtgac tcccgaggcc agtcacctgt 4020 tggaggatcc cgatgaagag acgagccagg ctgtcaaagc ccttcgggag atggccgata 4080 ctgtgattcc ccagaaggaa gaggctgcaa tctgtggcca aatggacctt tcccatccgc 4140 ccccaagggg ccatctggat gagctgacaa ccacacttga gtccatgacc gaggatctga 4200 acctggactc acccctgacc ccggaattga acgagattct ggataccttc ctgaacgacg 4260 agtgcctctt gcatgccatg catatcagca caggactgtc catcttcgac acatctctgt 4320 tttaaactag taataaaaga tctttatttt cattagatct gtgtgttggt tttttgtgtg 4380 <![CDATA[<210> 354]]> <![CDATA[<211> 3585]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 354]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccc caaagaagaa gcggaaggtc ggtatccacg 2100 gagtcccagc agccctcgaa ccaggtgaaa aaccttacaa atgtcctgaa tgtgggaaat 2160 cattcagtcg cagcgacaac ctggtgagac atcaacgcac ccatacagga gaaaaacctt 2220 ataaatgtcc agaatgtgga aagtccttct cacgagagga taacttgcac actcatcaac 2280 gaacacatac tggtgaaaaa ccatacaagt gtcccgaatg tggtaaaagt tttagccgga 2340 gcgatgaact tgtccgacac caacgaaccc atacaggcga gaagccttac aaatgtcccg 2400 agtgtggcaa gagcttctca caatcaggga atctgactga gcatcaacga actcataccg 2460 gggaaaaacc ttacaagtgt ccagagtgtg ggaagagctt ttccacaagt ggacatctgg 2520 tacgccacca gaggacacat acaggggaga agccctacaa atgccccgaa tgcggtaaaa 2580 gtttctctca gaatagtacc ctgaccgaac accagcgaac acacactggg aaaaaaacga 2640 gtaaaaggcc ggcggccacg aaaaaggccg gccaggcaaa aaagaaaaag ggatcctacc 2700 catacgacgt accagattac gctctcgagg acgcgctgga cgatttcgat ctcgacatgc 2760 tgggttctga tgccctcgat gactttgacc tggatatgtt gggaagcgac gcattggatg 2820 actttgatct ggacatgctc ggctccgatg ctctggacga tttcgatctc gatatgttat 2880 aaactagtaa agagaccggt tcactgtgac agtaaaagag accggttcac tgtgagaatg 2940 aaagagaccg gttcactgtg atcggaaaag agaccggttc actgtgagcg gccttgaaac 3000 ccagcagaca atgtagctca gtagaaaccc agcagacaat gtagctgaat ggaaacccag 3060 cagacaatgt agcttcggag aaacccagca gacaatgtag ctaagcttgg gtggcatccc 3120 tgtgacccct ccccagtgcc tctcctggcc ctggaagttg ccactccagt gcccaccagc 3180 cttgtcctaa taaaattaag ttgcatcatt ttgtctgact aggtgtcctt ctataatatt 3240 atggggtgga ggggggtggt atggagcaag gggcaagttg ggaagacaac ctgtagggcc 3300 tgcggggtct attgggaacc aagctggagt gcagtggcac aatcttggct cactgcaatc 3360 tccgcctcct gggttcaagc gattctcctg cctcagcctc ccgagttgtt gggattccag 3420 gcatgcatga ccaggctcag ctaatttttg tttttttggt agagacgggg tttcaccata 3480 ttggccaggc tggtctccaa ctcctaatct caggtgatct acccaccttg gcctcccaaa 3540 ttgctgggat tacaggcgtg aaccactgct cccttccctg tcctt 3585 <![CDATA[<210> 355]]> <![CDATA[<211> 3371]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 355]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccc caaagaagaa gcggaaggtc ggtatccacg 2100 gagtcccagc agccctcgaa ccaggtgaaa aaccttacaa atgtcctgaa tgtgggaaat 2160 cattcagtcg cagcgacaac ctggtgagac atcaacgcac ccatacagga gaaaaacctt 2220 ataaatgtcc agaatgtgga aagtccttct cacgagagga taacttgcac actcatcaac 2280 gaacacatac tggtgaaaaa ccatacaagt gtcccgaatg tggtaaaagt tttagccgga 2340 gcgatgaact tgtccgacac caacgaaccc atacaggcga gaagccttac aaatgtcccg 2400 agtgtggcaa gagcttctca caatcaggga atctgactga gcatcaacga actcataccg 2460 gggaaaaacc ttacaagtgt ccagagtgtg ggaagagctt ttccacaagt ggacatctgg 2520 tacgccacca gaggacacat acaggggaga agccctacaa atgccccgaa tgcggtaaaa 2580 gtttctctca gaatagtacc ctgaccgaac accagcgaac acacactggg aaaaaaacga 2640 gtaaaaggcc ggcggccacg aaaaaggccg gccaggcaaa aaagaaaaag ggatcctacc 2700 catacgacgt accagattac gctctcgagg acgcgctgga cgatttcgat ctcgacatgc 2760 tgggttctga tgccctcgat gactttgacc tggatatgtt gggaagcgac gcattggatg 2820 actttgatct ggacatgctc ggctccgatg ctctggacga tttcgatctc gatatgttat 2880 aaactagtaa gcttgggtgg catccctgtg acccctcccc agtgcctctc ctggccctgg 2940 aagttgccac tccagtgccc accagccttg tcctaataaa attaagttgc atcattttgt 3000 ctgactaggt gtccttctat aatattatgg ggtggagggg ggtggtatgg agcaaggggc 3060 aagttgggaa gacaacctgt agggcctgcg gggtctattg ggaaccaagc tggagtgcag 3120 tggcacaatc ttggctcact gcaatctccg cctcctgggt tcaagcgatt ctcctgcctc 3180 agcctcccga gttgttggga ttccaggcat gcatgaccag gctcagctaa tttttgtttt 3240 tttggtagag acggggtttc accatattgg ccaggctggt ctccaactcc taatctcagg 3300 tgatctaccc accttggcct cccaaattgc tgggattaca ggcgtgaacc actgctccct 3360 tccctgtcct t 3371 <![CDATA[<210> 356]]> <![CDATA[<211> 4014]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 356]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccg cggccaaggc cgagatgcag ctgatgtccc 2100 cgctgcagat ctctgacccg ttcggatcct ttcctcactc gcccaccatg gacaactacc 2160 ctaagctgga ggagatgatg ctgctgagca acggggctcc ccagttcctc ggcgccgccg 2220 gggccccaga gggcagcggc agcaacagca gcagcagcag cagcgggggc ggtggaggcg 2280 gcgggggcgg cagcaacagc agcagcagca gcagcacctt caaccctcag gcggacacgg 2340 gcgagcagcc ctacgagcac ctgaccgcag agtcttttcc tgacatctct ctgaacaacg 2400 agaaggtgct ggtggagacc agttacccca gccaaaccac tcgactgccc cccatcacct 2460 atactggccg cttttccctg gagcctgcac ccaacagtgg caacaccttg tggcccgagc 2520 ccctcttcag cttggtcagt ggcctagtga gcatgaccaa cccaccggcc tcctcgtcct 2580 cagcaccatc tccagcggcc tcctccgcct ccgcctccca gagcccaccc ctgagctgcg 2640 cagtgccatc caacgacagc agtcccattt actcagcggc acccaccttc cccacgccga 2700 acactgacat tttccctgag ccacaaagcc aggccttccc gggctcggca gggacagcgc 2760 tccagtaccc gcctcctgcc taccctgccg ccaagggtgg cttccaggtt cccatgatcc 2820 ccgactacct gtttccacag cagcaggggg atctgggcct gggcacccca gaccagaagc 2880 ccttccaggg cctggagagc cgcacccagc agccttcgct aacccctctg tctactatta 2940 aggcctttgc cactcagtcg ggctcccagg acctgaaggc cctcaatacc agctaccagt 3000 cccagctcat caaacccagc cgcatgcgca agtaccccaa ccggcccagc aagacgcccc 3060 cccacgaacg cccttacgct tgcccagtgg agtcctgtga tcgccgcttc tcccgcagcg 3120 acaacctggt gagacacatc cgcatccaca caggccagaa gcccttccag tgccgcatct 3180 gcatgagaaa cttcagccga gaggataact tgcacactca catccgcacc cacacaggcg 3240 aaaagccctt cgcctgcgac atctgtggaa gaaagtttgc ccggagcgat gaacttgtcc 3300 gacataccaa gatccacttg cggcagaagg accgccctta cgcttgccca gtggagtcct 3360 gtgatcgccg cttctcccaa tcagggaatc tgactgagca catccgcatc cacacaggcc 3420 agaagccctt ccagtgccgc atctgcatga gaaacttcag cacaagtgga catctggtac 3480 gccacatccg cacccacaca ggcgaaaagc ccttcgcctg cgacatctgt ggaagaaagt 3540 ttgcccagaa tagtaccctg accgaacata ccaagatcca cttgcggcag aaggacaaga 3600 aagcagacaa aagtgttgtg gctagctcgg ccacctcctc tctctcttcc tacccgtccc 3660 cggttgctac ctcttacccg tccccggtta ctacctctta tccatccccg gccaccacct 3720 catacccatc ccctgtgccc acctccttct cctctcccgg ctcctcgacc tacccatccc 3780 ctgtgcacag tggcttcccc tccccgtcgg tggccaccac gtactcctct gttccccctg 3840 ctttcccggc ccaggtcagc agcttccctt cctcagctgt caccaactcc ttcagcgcct 3900 ccacagggct ttcggacatg acagcaacct tttctcccag gacaattgaa atttgctaaa 3960 ctagtaataa aagatcttta ttttcattag atctgtgtgt tggttttttg tgtg 4014 <![CDATA[<210> 357]]> <![CDATA[<211> 3861]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 357]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccg ccgaccacct gatgctcgcc gagggctacc 2100 gcctggtgca gaggccgccg tccgccgccg ccgcccatgg ccctcatgcg ctccggactc 2160 tgccgccgta cgcgggcccg ggcctggaca gtgggctgag gccgcggggg gctccgctgg 2220 ggccgccgcc gccccgccaa cccggggccc tggcgtacgg ggccttcggg ccgccgtcct 2280 ccttccagcc ctttccggcc gtgcctccgc cggccgcggg catcgcgcac ctgcagcctg 2340 tggcgacgcc gtaccccggc cgcgcggccg cgccccccaa cgctccggga ggccccccgg 2400 gcccgcagcc ggccccaagc gccgcagccc cgccgccgcc cgcgcacgcc ctgggcggca 2460 tggacgccga actcatcgac gaggaggcgc tgacgtcgct ggagctggag ctggggctgc 2520 accgcgtgcg cgagctgccc gagctgttcc tgggccagag cgagttcgac tgcttctcgg 2580 acttggggtc cgcgccgccc gccggctccg tgagctgcgg tggttctggt ggtggttctg 2640 gtcagtccca gctcatcaaa cccagccgca tgcgcaagta ccccaaccgg cccagcaaga 2700 cgccccccca cgaacgccct tacgcttgcc cagtggagtc ctgtgatcgc cgcttctccc 2760 gcagcgacaa cctggtgaga cacatccgca tccacacagg ccagaagccc ttccagtgcc 2820 gcatctgcat gagaaacttc agccgagagg ataacttgca cactcacatc cgcacccaca 2880 caggcgaaaa gcccttcgcc tgcgacatct gtggaagaaa gtttgcccgg agcgatgaac 2940 ttgtccgaca taccaagatc cacttgcggc agaaggaccg cccttacgct tgcccagtgg 3000 agtcctgtga tcgccgcttc tcccaatcag ggaatctgac tgagcacatc cgcatccaca 3060 caggccagaa gcccttccag tgccgcatct gcatgagaaa cttcagcaca agtggacatc 3120 tggtacgcca catccgcacc cacacaggcg aaaagccctt cgcctgcgac atctgtggaa 3180 gaaagtttgc ccagaatagt accctgaccg aacataccaa gatccacttg cggcagaagg 3240 acaagctcga gatggccgac cacctgatgc tcgccgaggg ctaccgcctg gtgcagaggc 3300 cgccgtccgc cgccgccgcc catggccctc atgcgctccg gactctgccg ccgtacgcgg 3360 gcccgggcct ggacagtggg ctgaggccgc ggggggctcc gctggggccg ccgccgcccc 3420 gccaacccgg ggccctggcg tacggggcct tcgggccgcc gtcctccttc cagccctttc 3480 cggccgtgcc tccgccggcc gcgggcatcg cgcacctgca gcctgtggcg acgccgtacc 3540 ccggccgcgc ggccgcgccc cccaacgctc cgggaggccc cccgggcccg cagccggccc 3600 caagcgccgc agccccgccg ccgcccgcgc acgccctggg cggcatggac gccgaactca 3660 tcgacgagga ggcgctgacg tcgctggagc tggagctggg gctgcaccgc gtgcgcgagc 3720 tgcccgagct gttcctgggc cagagcgagt tcgactgctt ctcggacttg gggtccgcgc 3780 cgcccgccgg ctccgtgagc tgctaaacta gtaataaaag atctttattt tcattagatc 3840 tgtgtgttgg ttttttgtgt g 3861 <![CDATA[<210> 358]]> <![CDATA[<211> 4002]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 358]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccg cggccaaggc cgagatgcag ctgatgtccc 2100 cgctgcagat ctctgacccg ttcggatcct ttcctcactc gcccaccatg gacaactacc 2160 ctaagctgga ggagatgatg ctgctgagca acggggctcc ccagttcctc ggcgccgccg 2220 gggccccaga gggcagcggc agcaacagca gcagcagcag cagcgggggc ggtggaggcg 2280 gcgggggcgg cagcaacagc agcagcagca gcagcacctt caaccctcag gcggacacgg 2340 gcgagcagcc ctacgagcac ctgaccgcag agtcttttcc tgacatctct ctgaacaacg 2400 agaaggtgct ggtggagacc agttacccca gccaaaccac tcgactgccc cccatcacct 2460 atactggccg cttttccctg gagcctgcac ccaacagtgg caacaccttg tggcccgagc 2520 ccctcttcag cttggtcagt ggcctagtga gcatgaccaa cccaccggcc tcctcgtcct 2580 cagcaccatc tccagcggcc tcctccgcct ccgcctccca gagcccaccc ctgagctgcg 2640 cagtgccatc caacgacagc agtcccattt actcagcggc acccaccttc cccacgccga 2700 acactgacat tttccctgag ccacaaagcc aggccttccc gggctcggca gggacagcgc 2760 tccagtaccc gcctcctgcc taccctgccg ccaagggtgg cttccaggtt cccatgatcc 2820 ccgactacct gtttccacag cagcaggggg atctgggcct gggcacccca gaccagaagc 2880 ccttccaggg cctggagagc cgcacccagc agccttcgct aacccctctg tctactatta 2940 aggcctttgc cactcagtcg ggctcccagg acctgaaggc cctcaatacc agctaccagt 3000 cccagctcat caaacccagc cgcatgcgca agtaccccaa ccggcccagc aagacgcccc 3060 cccacgaacg cccttacgct tgcccagtgg agtcctgtga tcgccgcttc tcccgctcag 3120 acaacctcgt tcgacacatc cgcatccaca caggccagaa gcccttccag tgccgcatct 3180 gcatgagaaa cttcagccac cggactacac tcacgaacca catccgcacc cacacaggcg 3240 aaaagccctt cgcctgcgac atctgtggaa gaaagtttgc cagagaagac aatctccata 3300 ctcacatccg gacacacacg ggagagaagc cattcgcatg tgatatatgt gggagaaagt 3360 tctccaccag ccattctctc actgaacaca tccgcatcca cacaggccag aagcccttcc 3420 agtgccgcat ctgcatgaga aacttcagcc agtctagctc actggtgagg cacatccgca 3480 cccacacagg cgaaaagccc ttcgcctgcg acatctgtgg aagaaagttt gccagggagg 3540 ataacctgca tacgcatacc aagatccact tgcggcagaa ggacaagaaa gcagacaaaa 3600 gtgttgtggc tagctcggcc acctcctctc tctcttccta cccgtccccg gttgctacct 3660 cttacccgtc cccggttact acctcttatc catccccggc caccacctca tacccatccc 3720 ctgtgcccac ctccttctcc tctcccggct cctcgaccta cccatcccct gtgcacagtg 3780 gcttcccctc cccgtcggtg gccaccacgt actcctctgt tccccctgct ttcccggccc 3840 aggtcagcag cttcccttcc tcagctgtca ccaactcctt cagcgcctcc acagggcttt 3900 cggacatgac agcaaccttt tctcccagga caattgaaat ttgctaaact agtaataaaa 3960 gatctttatt ttcattagat ctgtgtgttg gttttttgtg tg 4002 <![CDATA[<210> 359]]> <![CDATA[<211> 3309]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 359]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccg ccgaccacct gatgctcgcc gagggctacc 2100 gcctggtgca gaggccgccg tccgccgccg ccgcccatgg ccctcatgcg ctccggactc 2160 tgccgccgta cgcgggcccg ggcctggaca gtgggctgag gccgcggggg gctccgctgg 2220 ggccgccgcc gccccgccaa cccggggccc tggcgtacgg ggccttcggg ccgccgtcct 2280 ccttccagcc ctttccggcc gtgcctccgc cggccgcggg catcgcgcac ctgcagcctg 2340 tggcgacgcc gtaccccggc cgcgcggccg cgccccccaa cgctccggga ggccccccgg 2400 gcccgcagcc ggccccaagc gccgcagccc cgccgccgcc cgcgcacgcc ctgggcggca 2460 tggacgccga actcatcgac gaggaggcgc tgacgtcgct ggagctggag ctggggctgc 2520 accgcgtgcg cgagctgccc gagctgttcc tgggccagag cgagttcgac tgcttctcgg 2580 acttggggtc cgcgccgccc gccggctccg tgagctgcgg tggttctggt ggtggttctg 2640 gtcagtccca gctcatcaaa cccagccgca tgcgcaagta ccccaaccgg cccagcaaga 2700 cgccccccca cgaacgccct tacgcttgcc cagtggagtc ctgtgatcgc cgcttctccc 2760 gcagcgacaa cctggtgaga cacatccgca tccacacagg ccagaagccc ttccagtgcc 2820 gcatctgcat gagaaacttc agccgagagg ataacttgca cactcacatc cgcacccaca 2880 caggcgaaaa gcccttcgcc tgcgacatct gtggaagaaa gtttgcccgg agcgatgaac 2940 ttgtccgaca taccaagatc cacttgcggc agaaggaccg cccttacgct tgcccagtgg 3000 agtcctgtga tcgccgcttc tcccaatcag ggaatctgac tgagcacatc cgcatccaca 3060 caggccagaa gcccttccag tgccgcatct gcatgagaaa cttcagcaca agtggacatc 3120 tggtacgcca catccgcacc cacacaggcg aaaagccctt cgcctgcgac atctgtggaa 3180 gaaagtttgc ccagaatagt accctgaccg aacataccaa gatccacttg cggcagaagg 3240 acaagtaact cgagactagt aataaaagat ctttattttc attagatctg tgtgttggtt 3300 ttttgtgtg 3309 <![CDATA[<210> 360]]> <![CDATA[<211> 3861]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 360]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccg ccgaccacct gatgctcgcc gagggctacc 2100 gcctggtgca gaggccgccg tccgccgccg ccgcccatgg ccctcatgcg ctccggactc 2160 tgccgccgta cgcgggcccg ggcctggaca gtgggctgag gccgcggggg gctccgctgg 2220 ggccgccgcc gccccgccaa cccggggccc tggcgtacgg ggccttcggg ccgccgtcct 2280 ccttccagcc ctttccggcc gtgcctccgc cggccgcggg catcgcgcac ctgcagcctg 2340 tggcgacgcc gtaccccggc cgcgcggccg cgccccccaa cgctccggga ggccccccgg 2400 gcccgcagcc ggccccaagc gccgcagccc cgccgccgcc cgcgcacgcc ctgggcggca 2460 tggacgccga actcatcgac gaggaggcgc tgacgtcgct ggagctggag ctggggctgc 2520 accgcgtgcg cgagctgccc gagctgttcc tgggccagag cgagttcgac tgcttctcgg 2580 acttggggtc cgcgccgccc gccggctccg tgagctgcgg tggttctggt ggtggttctg 2640 gtcagtccca gctcatcaaa cccagccgca tgcgcaagta ccccaaccgg cccagcaaga 2700 cgccccccca cgaacgccct tacgcttgcc cagtggagtc ctgtgatcgc cgcttctccc 2760 gctcagacaa cctcgttcga cacatccgca tccacacagg ccagaagccc ttccagtgcc 2820 gcatctgcat gagaaacttc agccaccgga ctacactcac gaaccacatc cgcacccaca 2880 caggcgaaaa gcccttcgcc tgcgacatct gtggaagaaa gtttgccaga gaagacaatc 2940 tccatactca taccaagatc cacttgcggc agaaggaccg cccttacgct tgcccagtgg 3000 agtcctgtga tcgccgcttc tccaccagcc attctctcac tgaacacatc cgcatccaca 3060 caggccagaa gcccttccag tgccgcatct gcatgagaaa cttcagccag tctagctcac 3120 tggtgaggca catccgcacc cacacaggcg aaaagccctt cgcctgcgac atctgtggaa 3180 gaaagtttgc cagggaggat aacctgcata cgcataccaa gatccacttg cggcagaagg 3240 acaagctcga gatggccgac cacctgatgc tcgccgaggg ctaccgcctg gtgcagaggc 3300 cgccgtccgc cgccgccgcc catggccctc atgcgctccg gactctgccg ccgtacgcgg 3360 gcccgggcct ggacagtggg ctgaggccgc ggggggctcc gctggggccg ccgccgcccc 3420 gccaacccgg ggccctggcg tacggggcct tcgggccgcc gtcctccttc cagccctttc 3480 cggccgtgcc tccgccggcc gcgggcatcg cgcacctgca gcctgtggcg acgccgtacc 3540 ccggccgcgc ggccgcgccc cccaacgctc cgggaggccc cccgggcccg cagccggccc 3600 caagcgccgc agccccgccg ccgcccgcgc acgccctggg cggcatggac gccgaactca 3660 tcgacgagga ggcgctgacg tcgctggagc tggagctggg gctgcaccgc gtgcgcgagc 3720 tgcccgagct gttcctgggc cagagcgagt tcgactgctt ctcggacttg gggtccgcgc 3780 cgcccgccgg ctccgtgagc tgctaaacta gtaataaaag atctttattt tcattagatc 3840 tgtgtgttgg ttttttgtgt g 3861 <![CDATA[<210> 361]]> <![CDATA[<211> 3309]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 361]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccg ccgaccacct gatgctcgcc gagggctacc 2100 gcctggtgca gaggccgccg tccgccgccg ccgcccatgg ccctcatgcg ctccggactc 2160 tgccgccgta cgcgggcccg ggcctggaca gtgggctgag gccgcggggg gctccgctgg 2220 ggccgccgcc gccccgccaa cccggggccc tggcgtacgg ggccttcggg ccgccgtcct 2280 ccttccagcc ctttccggcc gtgcctccgc cggccgcggg catcgcgcac ctgcagcctg 2340 tggcgacgcc gtaccccggc cgcgcggccg cgccccccaa cgctccggga ggccccccgg 2400 gcccgcagcc ggccccaagc gccgcagccc cgccgccgcc cgcgcacgcc ctgggcggca 2460 tggacgccga actcatcgac gaggaggcgc tgacgtcgct ggagctggag ctggggctgc 2520 accgcgtgcg cgagctgccc gagctgttcc tgggccagag cgagttcgac tgcttctcgg 2580 acttggggtc cgcgccgccc gccggctccg tgagctgcgg tggttctggt ggtggttctg 2640 gtcagtccca gctcatcaaa cccagccgca tgcgcaagta ccccaaccgg cccagcaaga 2700 cgccccccca cgaacgccct tacgcttgcc cagtggagtc ctgtgatcgc cgcttctccc 2760 gctcagacaa cctcgttcga cacatccgca tccacacagg ccagaagccc ttccagtgcc 2820 gcatctgcat gagaaacttc agccaccgga ctacactcac gaaccacatc cgcacccaca 2880 caggcgaaaa gcccttcgcc tgcgacatct gtggaagaaa gtttgccaga gaagacaatc 2940 tccatactca taccaagatc cacttgcggc agaaggaccg cccttacgct tgcccagtgg 3000 agtcctgtga tcgccgcttc tccaccagcc attctctcac tgaacacatc cgcatccaca 3060 caggccagaa gcccttccag tgccgcatct gcatgagaaa cttcagccag tctagctcac 3120 tggtgaggca catccgcacc cacacaggcg aaaagccctt cgcctgcgac atctgtggaa 3180 gaaagtttgc cagggaggat aacctgcata cgcataccaa gatccacttg cggcagaagg 3240 acaagtaact cgagactagt aataaaagat ctttattttc attagatctg tgtgttggtt 3300 ttttgtgtg 3309 <![CDATA[<210> 362]]> <![CDATA[<211> 4448]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 362]]> ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccg cggccaaggc cgagatgcag ctgatgtccc 2100 cgctgcagat ctctgacccg ttcggatcct ttcctcactc gcccaccatg gacaactacc 2160 ctaagctgga ggagatgatg ctgctgagca acggggctcc ccagttcctc ggcgccgccg 2220 gggccccaga gggcagcggc agcaacagca gcagcagcag cagcgggggc ggtggaggcg 2280 gcgggggcgg cagcaacagc agcagcagca gcagcacctt caaccctcag gcggacacgg 2340 gcgagcagcc ctacgagcac ctgaccgcag agtcttttcc tgacatctct ctgaacaacg 2400 agaaggtgct ggtggagacc agttacccca gccaaaccac tcgactgccc cccatcacct 2460 atactggccg cttttccctg gagcctgcac ccaacagtgg caacaccttg tggcccgagc 2520 ccctcttcag cttggtcagt ggcctagtga gcatgaccaa cccaccggcc tcctcgtcct 2580 cagcaccatc tccagcggcc tcctccgcct ccgcctccca gagcccaccc ctgagctgcg 2640 cagtgccatc caacgacagc agtcccattt actcagcggc acccaccttc cccacgccga 2700 acactgacat tttccctgag ccacaaagcc aggccttccc gggctcggca gggacagcgc 2760 tccagtaccc gcctcctgcc taccctgccg ccaagggtgg cttccaggtt cccatgatcc 2820 ccgactacct gtttccacag cagcaggggg atctgggcct gggcacccca gaccagaagc 2880 ccttccaggg cctggagagc cgcacccagc agccttcgct aacccctctg tctactatta 2940 aggcctttgc cactcagtcg ggctcccagg acctgaaggc cctcaatacc agctaccagt 3000 cccagctcat caaacccagc cgcatgcgca agtaccccaa ccggcccagc aagacgcccc 3060 cccacgaacg cccttacgct tgcccagtgg agtcctgtga tcgccgcttc tcccgcagcg 3120 acaacctggt gagacacatc cgcatccaca caggccagaa gcccttccag tgccgcatct 3180 gcatgagaaa cttcagccga gaggataact tgcacactca catccgcacc cacacaggcg 3240 aaaagccctt cgcctgcgac atctgtggaa gaaagtttgc ccggagcgat gaacttgtcc 3300 gacataccaa gatccacttg cggcagaagg accgccctta cgcttgccca gtggagtcct 3360 gtgatcgccg cttctcccaa tcagggaatc tgactgagca catccgcatc cacacaggcc 3420 agaagccctt ccagtgccgc atctgcatga gaaacttcag cacaagtgga catctggtac 3480 gccacatccg cacccacaca ggcgaaaagc ccttcgcctg cgacatctgt ggaagaaagt 3540 ttgcccagaa tagtaccctg accgaacata ccaagatcca cttgcggcag aaggacaaga 3600 aagcagacaa aagtgttgtg gctagctcgg ccacctcctc tctctcttcc tacccgtccc 3660 cggttgctac ctcttacccg tccccggtta ctacctctta tccatccccg gccaccacct 3720 catacccatc ccctgtgccc acctccttct cctctcccgg ctcctcgacc tacccatccc 3780 ctgtgcacag tggcttcccc tccccgtcgg tggccaccac gtactcctct gttccccctg 3840 ctttcccggc ccaggtcagc agcttccctt cctcagctgt caccaactcc ttcagcgcct 3900 ccacagggct ttcggacatg acagcaacct tttctcccag gacaattgaa atttgctaaa 3960 ctagtaagct tgggtggcat ccctgtgacc cctccccagt gcctctcctg gccctggaag 4020 ttgccactcc agtgcccacc agccttgtcc taataaaatt aagttgcatc attttgtctg 4080 actaggtgtc cttctataat attatggggt ggaggggggt ggtatggagc aaggggcaag 4140 ttgggaagac aacctgtagg gcctgcgggg tctattggga accaagctgg agtgcagtgg 4200 cacaatcttg gctcactgca atctccgcct cctgggttca agcgattctc ctgcctcagc 4260 ctcccgagtt gttgggattc caggcatgca tgaccaggct cagctaattt ttgttttttt 4320 ggtagagacg gggtttcacc atattggcca ggctggtctc caactcctaa tctcaggtga 4380 tctacccacc ttggcctccc aaattgctgg gattacaggc gtgaaccact gctcccttcc 4440 ctgtcctt 4448 <![CDATA[<210> 363]]> <![CDATA[<211> 4436]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<40]]>0> 363]]> <br/><![CDATA[ggaggaagcc atcaactaaa ctacaatgac tgtaagatac aaaattggga atggtaacat 60 attttgaagt tctgttgaca taaagaatca tgatattaat gcccatggaa atgaaagggc 120 gatcaacact atggtttgaa aagggggaaa ttgtagagca cagatgtgtt cgtgtggcag 180 tgtgctgtct ctagcaatac tcagagaaga gagagaacaa tgaaattctg attggcccca 240 gtgtgagccc agatgaggtt cagctgccaa ctttctcttt cacatcttat gaaagtcatt 300 taagcacaac taactttttt tttttttttt tttttttgag acagagtctt gctctgttgc 360 ccaggacaga gtgcagtagt gactcaatct cggctcactg cagcctccac ctcctaggct 420 caaacggtcc tcctgcatca gcctcccaag tagctggaat tacaggagtg gcccaccatg 480 cccagctaat ttttgtattt ttaatagata cgggggtttc accatatcac ccaggctggt 540 ctcgaactcc tggcctcaag tgatccacct gcctcggcct cccaaagtgc tgggattata 600 ggcgtcagcc actatgccca acccgaccaa ccttttttaa aataaatatt taaaaaattg 660 gtatttcaca tatatactag tatttacatt tatccacaca aaacggacgg gcctccgctg 720 aaccagtgag gccccagacg tgcgcataaa taacccctgc gtgctgcacc acctggggag 780 agggggagga ccacggtaaa tggagcgagc gcatagcaaa agggacgcgg ggtccttttc 840 tctgccggtg gcactgggta gctgtggcca ggtgtggtac tttgatgggg cccagggctg 900 gagctcaagg aagcgtcgca gggtcacaga tctgggggaa ccccggggaa aagcactgag 960 gcaaaaccgc cgctcgtctc ctacaatata tgggaggggg aggttgagta cgttctggat 1020 tactcataag accttttttt tttccttccg ggcgcaaaac cgtgagctgg atttataatc 1080 gccctataaa gctccagagg cggtcaggca cctgcagagg agccccgccg ctccgccgac 1140 tagctgcccc cgcgagcaac ggcctcgtga tttccccgcc gatccggtcc ccgcctcccc 1200 actctgcccc cgcctacccc ggagccgtgc agccgcctct ccgaatctct ctcttctcct 1260 ggcgctcgcg tgcgagaggg aactagcgag aacgaggaag cagctggagg tgacgccggg 1320 cagattacgc ctgtcagggc cgagccgagc ggatcgctgg gcgctgtgca gaggaaaggc 1380 gggagtgccc ggctcgctgt cgcagagccg aggtgggtaa gctagcgacc acctggactt 1440 cccagcgccc aaccgtggct tttcagccag gtcctctcct cccgcggctt ctcaaccaac 1500 cccatcccag cgccggccac ccaacctccc gaaatgagtg cttcctgccc cagcagccga 1560 aggcgctact aggaacggta acctgttact tttccagggg ccgtagtcga cccgctgccc 1620 gagttgctgt gcgactgcgc gcgcggggct agagtgcaag gtgactgtgg ttcttctctg 1680 gccaagtccg agggagaacg taaagatatg ggcctttttc cccctctcac cttgtctcac 1740 caaagtccct agtccccgga gcagttagcc tctttctttc cagggaatta gccagacaca 1800 acaacgggaa ccagacaccg aaccagacat gcccgccccg tgcgccctcc ccgctcgctg 1860 cctttcctcc ctcttgtctc tccagagccg gatcttcaag gggagcctcc gtgcccccgg 1920 ctgctcagtc cctccggtgt gcaggacccc ggaagtcctc cccgcacagc tctcgcttct 1980 ctttgcagcc tgtttctgcg ccggaccagt cgaggactct ggacagtaga ggccccggga 2040 cgaccgagct ggaattcgcc accatggccg cggccaaggc cgagatgcag ctgatgtccc 2100 cgctgcagat ctctgacccg ttcggatcct ttcctcactc gcccaccatg gacaactacc 2160 ctaagctgga ggagatgatg ctgctgagca acggggctcc ccagttcctc ggcgccgccg 2220 gggccccaga gggcagcggc agcaacagca gcagcagcag cagcgggggc ggtggaggcg 2280 gcgggggcgg cagcaacagc agcagcagca gcagcacctt caaccctcag gcggacacgg 2340 gcgagcagcc ctacgagcac ctgaccgcag agtcttttcc tgacatctct ctgaacaacg 2400 agaaggtgct ggtggagacc agttacccca gccaaaccac tcgactgccc cccatcacct 2460 atactggccg cttttccctg gagcctgcac ccaacagtgg caacaccttg tggcccgagc 2520 ccctcttcag cttggtcagt ggcctagtga gcatgaccaa cccaccggcc tcctcgtcct 2580 cagcaccatc tccagcggcc tcctccgcct ccgcctccca gagcccaccc ctgagctgcg 2640 cagtgccatc caacgacagc agtcccattt actcagcggc acccaccttc cccacgccga 2700 acactgacat tttccctgag ccacaaagcc aggccttccc gggctcggca gggacagcgc 2760 tccagtaccc gcctcctgcc taccctgccg ccaagggtgg cttccaggtt cccatgatcc 2820 ccgactacct gtttccacag cagcaggggg atctgggcct gggcacccca gaccagaagc 2880 ccttccaggg cctggagagc cgcacccagc agccttcgct aacccctctg tctactatta 2940 aggcctttgc cactcagtcg ggctcccagg acctgaaggc cctcaatacc agctaccagt 3000 cccagctcat caaacccagc cgcatgcgca agtaccccaa ccggcccagc aagacgcccc 3060 cccacgaacg cccttacgct tgcccagtgg agtcctgtga tcgccgcttc tcccgcagcg 3120 acaacctggt gagacacatc cgcatccaca caggccagaa gcccttccag tgccgcatct 3180 gcatgagaaa cttcagccga gaggataact tgcacactca catccgcacc cacacaggcg 3240 aaaagccctt cgcctgcgac atctgtggaa gaaagtttgc ccggagcgat gaacttgtcc 3300 gacacatccg gacacacacg ggagagaagc cattcgcatg tgatatatgt gggagaaagt 3360 tctcccaatc agggaatctg actgagcaca tccgcatcca cacaggccag aagcccttcc 3420 agtgccgcat ctgcatgaga aacttcagca caagtggaca tctggtacgc cacatccgca 3480 cccacacagg cgaaaagccc ttcgcctgcg acatctgtgg aagaaagttt gcccagaata 3540 gtaccctgac cgaacatacc aagatccact tgcggcagaa ggacaagaaa gcagacaaaa 3600 gtgttgtggc tagctcggcc acctcctctc tctcttccta cccgtccccg gttgctacct 3660 cttacccgtc cccggttact acctcttatc catccccggc caccacctca tacccatccc 3720 ctgtgcccac ctccttctcc tctcccggct cctcgaccta cccatcccct gtgcacagtg 3780 gcttcccctc cccgtcggtg gccaccacgt actcctctgt tccccctgct ttcccggccc 3840 aggtcagcag cttcccttcc tcagctgtca ccaactcctt cagcgcctcc acagggcttt 3900 cggacatgac agcaaccttt tctcccagga caattgaaat ttgctaaact agtaagcttg 3960 ggtggcatcc ctgtgacccc tccccagtgc ctctcctggc cctggaagtt gccactccag 4020 tgcccaccag ccttgtccta ataaaattaa gttgcatcat tttgtctgac taggtgtcct 4080 tctataatat tatggggtgg aggggggtgg tatggagcaa ggggcaagtt gggaagacaa 4140 cctgtagggc ctgcggggtc tattgggaac caagctggag tgcagtggca caatcttggc 4200 tcactgcaat ctccgcctcc tgggttcaag cgattctcct gcctcagcct cccgagttgt 4260 tgggattcca ggcatgcatg accaggctca gctaattttt gtttttttgg tagagacggg 4320 gtttcaccat attggccagg ctggtctcca actcctaatc tcaggtgatc tacccacctt 4380 ggcctcccaa attgctggga ttacaggcgt gaaccactgc tcccttccct gtcctt 4436 <![CDATA[<210> 364]]> <![CDATA[<211> 667]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 364]]> Met Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Gly Tyr Pro Tyr Asp Val 1 5 10 15 Pro Asp Tyr Ala Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Gly 20 25 30 Ser Gly Ser Gly Ser Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser 35 40 45 Pro Leu Gln Ile Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr 50 55 60 Met Asp Asn Tyr Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly 65 70 75 80 Ala Pro Gln Phe Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser 85 90 95 Asn Ser Ser Ser Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly 100 105 110 Ser Asn Ser Ser Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr 115 120 125 Gly Glu Gln Pro Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile 130 135 140 Ser Leu Asn Asn Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln 145 150 155 160 Thr Thr Arg Leu Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu 165 170 175 Pro Ala Pro Asn Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser 180 185 190 Leu Val Ser Gly Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser 195 200 205 Ser Ala Pro Ser Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro 210 215 220 Pro Leu Ser Cys Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser 225 230 235 240 Ala Ala Pro Thr Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro 245 250 255 Gln Ser Gln Ala Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro 260 265 270 Pro Pro Ala Tyr Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile 275 280 285 Pro Asp Tyr Leu Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr 290 295 300 Pro Asp Gln Lys Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro 305 310 315 320 Ser Leu Thr Pro Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly 325 330 335 Ser Gln Asp Leu Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile 340 345 350 Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro 355 360 365 Pro His Glu Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg 370 375 380 Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly 385 390 395 400 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg 405 410 415 Thr Thr Leu Thr Asn His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 420 425 430 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His 435 440 445 Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys 450 455 460 Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Thr Ser His Ser Leu Thr 465 470 475 480 Glu His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile 485 490 495 Cys Met Arg Asn Phe Ser Gln Ser Ser Ser Leu Val Arg His Ile Arg 500 505 510 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 515 520 525 Phe Ala Arg Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg 530 535 540 Gln Lys Asp Lys Lys Ala Asp Lys Ser Val Val Ala Ser Ser Ala Thr 545 550 555 560 Ser Ser Leu Ser Ser Tyr Pro Ser Pro Val Ala Thr Ser Tyr Pro Ser 565 570 575 Pro Val Thr Thr Ser Tyr Pro Ser Pro Ala Thr Thr Ser Tyr Pro Ser 580 585 590 Pro Val Pro Thr Ser Phe Ser Ser Pro Gly Ser Ser Thr Tyr Pro Ser 595 600 605 Pro Val His Ser Gly Phe Pro Ser Pro Ser Val Ala Thr Thr Tyr Ser 610 615 620 Ser Val Pro Pro Ala Phe Pro Ala Gln Val Ser Ser Phe Pro Ser Ser 625 630 635 640 Ala Val Thr Asn Ser Phe Ser Ala Ser Thr Gly Leu Ser Asp Met Thr 645 650 655 Ala Thr Phe Ser Pro Arg Thr Ile Glu Ile Cys 660 665 <![CDATA[<210> 365]]> <![CDATA[<211> 272]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 365]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 50 55 60 Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu 85 90 95 His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Asp Ala 210 215 220 Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp 225 230 235 240 Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu 245 250 255 Asp Met Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu 260 265 270 <![CDATA[<210> 366]]> <![CDATA[<211> 753]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 366]]> Met Ala Pro Lys Lys Lys Arg Lys Val Gly Ile His Gly Val Pro Ala 1 5 10 15 Ala Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 20 25 30 Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr 35 40 45 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His 50 55 60 Arg Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro 65 70 75 80 Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu 85 90 95 His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro 100 105 110 Glu Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu Thr Glu His Gln 115 120 125 Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys 130 135 140 Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr 145 150 155 160 Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg 165 170 175 Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Lys Lys Thr 180 185 190 Ser Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys 195 200 205 Lys Gly Ser Tyr Pro Tyr Asp Val Pro Asp Tyr Ala Leu Glu Glu Ala 210 215 220 Ser Gly Ser Gly Arg Ala Asp Ala Leu Asp Asp Phe Asp Leu Asp Met 225 230 235 240 Leu Gly Ser Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser 245 250 255 Asp Ala Leu Asp Asp Phe Asp Leu Asp Met Leu Gly Ser Asp Ala Leu 260 265 270 Asp Asp Phe Asp Leu Asp Met Leu Ile Asn Ser Arg Ser Ser Gly Ser 275 280 285 Pro Lys Lys Lys Arg Lys Val Gly Ser Gln Tyr Leu Pro Asp Thr Asp 290 295 300 Asp Arg His Arg Ile Glu Glu Lys Arg Lys Arg Thr Tyr Glu Thr Phe 305 310 315 320 Lys Ser Ile Met Lys Lys Ser Pro Phe Ser Gly Pro Thr Asp Pro Arg 325 330 335 Pro Pro Pro Arg Arg Ile Ala Val Pro Ser Arg Ser Ser Ala Ser Val 340 345 350 Pro Lys Pro Ala Pro Gln Pro Tyr Pro Phe Thr Ser Ser Leu Ser Thr 355 360 365 Ile Asn Tyr Asp Glu Phe Pro Thr Met Val Phe Pro Ser Gly Gln Ile 370 375 380 Ser Gln Ala Ser Ala Leu Ala Pro Ala Pro Pro Gln Val Leu Pro Gln 385 390 395 400 Ala Pro Ala Pro Ala Pro Ala Pro Ala Met Val Ser Ala Leu Ala Gln 405 410 415 Ala Pro Ala Pro Val Pro Val Leu Ala Pro Gly Pro Pro Gln Ala Val 420 425 430 Ala Pro Pro Ala Pro Lys Pro Thr Gln Ala Gly Glu Gly Thr Leu Ser 435 440 445 Glu Ala Leu Leu Gln Leu Gln Phe Asp Asp Glu Asp Leu Gly Ala Leu 450 455 460 Leu Gly Asn Ser Thr Asp Pro Ala Val Phe Thr Asp Leu Ala Ser Val 465 470 475 480 Asp Asn Ser Glu Phe Gln Gln Leu Leu Asn Gln Gly Ile Pro Val Ala 485 490 495 Pro His Thr Thr Glu Pro Met Leu Met Glu Tyr Pro Glu Ala Ile Thr 500 505 510 Arg Leu Val Thr Gly Ala Gln Arg Pro Pro Asp Pro Ala Pro Ala Pro 515 520 525 Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu Ser Gly Asp Glu Asp 530 535 540 Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala Leu Leu Gly Ser Gly 545 550 555 560 Ser Gly Ser Arg Asp Ser Arg Glu Gly Met Phe Leu Pro Lys Pro Glu 565 570 575 Ala Gly Ser Ala Ile Ser Asp Val Phe Glu Gly Arg Glu Val Cys Gln 580 585 590 Pro Lys Arg Ile Arg Pro Phe His Pro Pro Gly Ser Pro Trp Ala Asn 595 600 605 Arg Pro Leu Pro Ala Ser Leu Ala Pro Thr Pro Thr Gly Pro Val His 610 615 620 Glu Pro Val Gly Ser Leu Thr Pro Ala Pro Val Pro Gln Pro Leu Asp 625 630 635 640 Pro Ala Pro Ala Val Thr Pro Glu Ala Ser His Leu Leu Glu Asp Pro 645 650 655 Asp Glu Glu Thr Ser Gln Ala Val Lys Ala Leu Arg Glu Met Ala Asp 660 665 670 Thr Val Ile Pro Gln Lys Glu Glu Ala Ala Ile Cys Gly Gln Met Asp 675 680 685 Leu Ser His Pro Pro Pro Arg Gly His Leu Asp Glu Leu Thr Thr Thr 690 695 700 Leu Glu Ser Met Thr Glu Asp Leu Asn Leu Asp Ser Pro Leu Thr Pro 705 710 715 720 Glu Leu Asn Glu Ile Leu Asp Thr Phe Leu Asn Asp Glu Cys Leu Leu 725 730 735 His Ala Met His Ile Ser Thr Gly Leu Ser Ile Phe Asp Thr Ser Leu 740 745 750 Phe <![CDATA[<210> 367]]> <![CDATA[<211> 3803]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 367]]> gcggccgcac gcgtggcgcg ccgtttaaac ttaattaagc tagccgttac ataacttacg 60 gtaaatggcc cgcctggctg accgcccaac gacccccgcc cattgacgtc aataatgacg 120 tatgttccca tagtaacgcc aatagggact ttccattgac gtcaatgggt ggagtattta 180 cggtaaactg cccacttggc agtacatcaa gtgtatcata tgccaagtac gccccctatt 240 gacgtcaatg acggtaaatg gcccgcctgg cattatgccc agtacatgac cttatgggac 300 tttcctactt ggcagtacat ctacgtatta gtcatcgcta ttaccatggg tcgaggtgag 360 ccccacgttc tgcttcactc tccccatctc ccccccctcc ccacccccaa ttttgtattt 420 atttattttt taattatttt gtgcagcgat gggggcgggg gggggggggg cgcgcgccag 480 gcggggcggg gcggggcgag gggcggggcg gggcgaggcg gagaggtgcg gcggcagcca 540 atcagagcgg cgcgctccga aagtttcctt ttatggcgag gcggcggcgg cggcggccct 600 ataaaaagcg aagcgcgcgg cgggcgggag tcgctgcgtt gccttcgccc cgtgccccgc 660 tccgcgccgc ctcgcgccgc ccgccccggc tctgactgac cgcgttactc ccacaggtga 720 gcgggcggga cggcccttct cctccgggct gtaattagcg cttggtttaa tgacggctcg 780 tttcttttct gtggctgcgt gaaagcctta aagggctccg ggagggccct ttgtgcgggg 840 gggagcggct cggggggtgc gtgcgtgtgt gtgtgcgtgg ggagcgccgc gtgcggcccg 900 cgctgcccgg cggctgtgag cgctgcgggc gcggcgcggg gctttgtgcg ctccgcgtgt 960 gcgcgagggg agcgcggccg ggggcggtgc cccgcggtgc gggggggctg cgaggggaac 1020 aaaggctgcg tgcggggtgt gtgcgtgggg gggtgagcag ggggtgtggg cgcggcggtc 1080 gggctgtaac ccccccctgc acccccctcc ccgagttgct gagcacggcc cggcttcggg 1140 tgcggggctc cgtgcggggc gtggcgcggg gctcgccgtg ccgggcgggg ggtggcggca 1200 ggtgggggtg ccgggcgggg cggggccgcc tcgggccggg gagggctcgg gggaggggcg 1260 cggcggcccc ggagcgccgg cggctgtcga ggcgcggcga gccgcagcca ttgcctttta 1320 tggtaatcgt gcgagagggc gcagggactt cctttgtccc aaatctggcg gagccgaaat 1380 ctgggaggcg ccgccgcacc ccctctagcg ggcgcgggcg aagcggtgcg gcgccggcag 1440 gaaggaaatg ggcggggagg gccttcgtgc gtcgccgcgc cgccgtcccc ttctccatct 1500 ccagcctcgg ggctgccgca gggggacggc tgccttcggg ggggacgggg cagggcgggg 1560 ttcggcttct ggcgtgtgac cggcggctct agagcctctg ctaaccatgt tcatgccttc 1620 ttctttttcc tacagctcct gggcaacgtg ctggttgttg tgctgtctca tcattttggc 1680 aaagaattgg taccgccacc atggtgagca agggcgagga gctgttcacc ggggtggtgc 1740 ccatcctggt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg 1800 gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc accggcaagc 1860 tgcccgtgcc ctggcccacc ctcgtgacca ccctgaccta cggcgtgcag tgcttcagcc 1920 gctaccccga ccacatgaag cagcacgact tcttcaagtc cgccatgccc gaaggctacg 1980 tccaggagcg caccatcttc ttcaaggacg acggcaacta caagacccgc gccgaggtga 2040 agttcgaggg cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg 2100 acggcaacat cctggggcac aagctggagt acaactacaa cagccacaac gtctatatca 2160 tggccgacaa gcagaagaac ggcatcaagg tgaacttcaa gatccgccac aacatcgagg 2220 acggcagcgt gcagctcgcc gaccactacc agcagaacac ccccatcggc gacggccccg 2280 tgctgctgcc cgacaaccac tacctgagca cccagtccgc cctgagcaaa gaccccaacg 2340 agaagcgcga tcacatggtc ctgctggagt tcgtgaccgc cgccgggatc actctcggca 2400 tggacgagct gtacaagtcc ggactcagat ctcgagagga ggaggaggag acagacagca 2460 ggatgcccca cctcgacagc cccggcagct cccagccgag acgctccttc ctctcaaggg 2520 tgatcagggc agctctaccg ttgcagctgc ttctgctgct gctgctgctc ctggcctgcc 2580 tgctacctgc ctctgaagat gactacagct gcacccaggc caacaacttt gcccgatcct 2640 tctaccccat gctgcggtac accaacgggc cacctcccac ctagagcgct aatcaacctc 2700 tggattacaa aatttgtgaa agattgactg gtattcttaa ctatgttgct ccttttacgc 2760 tatgtggata cgctgcttta atgcctttgt atcatgctat tgcttcccgt atggctttca 2820 ttttctcctc cttgtataaa tcctggttgc tgtctcttta tgaggagttg tggcccgttg 2880 tcaggcaacg tggcgtggtg tgcactgtgt ttgctgacgc aacccccact ggttggggca 2940 ttgccaccac ctgtcagctc ctttccggga ctttcgcttt ccccctccct attgccacgg 3000 cggaactcat cgccgcctgc cttgcccgct gctggacagg ggctcggctg ttgggcactg 3060 acaattccgt ggtgttgtcg gggaaatcat cgtcctttcc ttggctgctc gcctatgttg 3120 ccacctggat tctgcgcggg acgtccttct gctacgtccc ttcggccctc aatccagcgg 3180 accttccttc ccgcggcctg ctgccggctc tgcggcctct tccgcgtctt cgccttcgcc 3240 ctcagacgag tcggatctcc ctttgggccg cctccccgca gatctacggg tggcatccct 3300 gtgacccctc cccagtgcct ctcctggccc tggaagttgc cactccagtg cccaccagcc 3360 ttgtcctaat aaaattaagt tgcatcattt tgtctgacta ggtgtccttc tataatatta 3420 tggggtggag gggggtggta tggagcaagg ggcaagttgg gaagacaacc tgtagggcct 3480 gcggggtcta ttgggaacca agctggagtg cagtggcaca atcttggctc actgcaatct 3540 ccgcctcctg ggttcaagcg attctcctgc ctcagcctcc cgagttgttg ggattccagg 3600 catgcatgac caggctcagc taatttttgt ttttttggta gagacggggt ttcaccatat 3660 tggccaggct ggtctccaac tcctaatctc aggtgatcta cccaccttgg cctcccaaat 3720 tgctgggatt acaggcgtga accactgctc ccttccctgt ccttctgatt ttgtaggtaa 3780 ccacgtgcgg accgagcggc cgc 3803 <![CDATA[<210> 368]]> <![CDATA[<211> 3803]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 368]]> gcggccgcac gcgtggcgcg ccgtttaaac ttaattaagc tagccgttac ataacttacg 60 gtaaatggcc cgcctggctg accgcccaac gacccccgcc cattgacgtc aataatgacg 120 tatgttccca tagtaacgcc aatagggact ttccattgac gtcaatgggt ggagtattta 180 cggtaaactg cccacttggc agtacatcaa gtgtatcata tgccaagtac gccccctatt 240 gacgtcaatg acggtaaatg gcccgcctgg cattatgccc agtacatgac cttatgggac 300 tttcctactt ggcagtacat ctacgtatta gtcatcgcta ttaccatggg tcgaggtgag 360 ccccacgttc tgcttcactc tccccatctc ccccccctcc ccacccccaa ttttgtattt 420 atttattttt taattatttt gtgcagcgat gggggcgggg gggggggggg cgcgcgccag 480 gcggggcggg gcggggcgag gggcggggcg gggcgaggcg gagaggtgcg gcggcagcca 540 atcagagcgg cgcgctccga aagtttcctt ttatggcgag gcggcggcgg cggcggccct 600 ataaaaagcg aagcgcgcgg cgggcgggag tcgctgcgtt gccttcgccc cgtgccccgc 660 tccgcgccgc ctcgcgccgc ccgccccggc tctgactgac cgcgttactc ccacaggtga 720 gcgggcggga cggcccttct cctccgggct gtaattagcg cttggtttaa tgacggctcg 780 tttcttttct gtggctgcgt gaaagcctta aagggctccg ggagggccct ttgtgcgggg 840 gggagcggct cggggggtgc gtgcgtgtgt gtgtgcgtgg ggagcgccgc gtgcggcccg 900 cgctgcccgg cggctgtgag cgctgcgggc gcggcgcggg gctttgtgcg ctccgcgtgt 960 gcgcgagggg agcgcggccg ggggcggtgc cccgcggtgc gggggggctg cgaggggaac 1020 aaaggctgcg tgcggggtgt gtgcgtgggg gggtgagcag ggggtgtggg cgcggcggtc 1080 gggctgtaac ccccccctgc acccccctcc ccgagttgct gagcacggcc cggcttcggg 1140 tgcggggctc cgtgcggggc gtggcgcggg gctcgccgtg ccgggcgggg ggtggcggca 1200 ggtgggggtg ccgggcgggg cggggccgcc tcgggccggg gagggctcgg gggaggggcg 1260 cggcggcccc ggagcgccgg cggctgtcga ggcgcggcga gccgcagcca ttgcctttta 1320 tggtaatcgt gcgagagggc gcagggactt cctttgtccc aaatctggcg gagccgaaat 1380 ctgggaggcg ccgccgcacc ccctctagcg ggcgcgggcg aagcggtgcg gcgccggcag 1440 gaaggaaatg ggcggggagg gccttcgtgc gtcgccgcgc cgccgtcccc ttctccatct 1500 ccagcctcgg ggctgccgca gggggacggc tgccttcggg ggggacgggg cagggcgggg 1560 ttcggcttct ggcgtgtgac cggcggctct agagcctctg ctaaccatgt tcatgccttc 1620 ttctttttcc tacagctcct gggcaacgtg ctggttgttg tgctgtctca tcattttggc 1680 aaagaattgg taccgccacc atggtgagca agggcgagga gctgttcacc ggggtggtgc 1740 ccatcctggt cgagctggac ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg 1800 gcgagggcga tgccacctac ggcaagctga ccctgaagtt catctgcacc accggcaagc 1860 tgcccgtgcc ctggcccacc ctcgtgacca ccctgaccta cggcgtgcag tgcttcagcc 1920 gctaccccga ccacatgaag cagcacgact tcttcaagtc cgccatgccc gaaggctacg 1980 tccaggagcg caccatcttc ttcaaggacg acggcaacta caagacccgc gccgaggtga 2040 agttcgaggg cgacaccctg gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg 2100 acggcaacat cctggggcac aagctggagt acaactacaa cagccacaac gtctatatca 2160 tggccgacaa gcagaagaac ggcatcaagg tgaacttcaa gatccgccac aacatcgagg 2220 acggcagcgt gcagctcgcc gaccactacc agcagaacac ccccatcggc gacggccccg 2280 tgctgctgcc cgacaaccac tacctgagca cccagtccgc cctgagcaaa gaccccaacg 2340 agaagcgcga tcacatggtc ctgctggagt tcgtgaccgc cgccgggatc actctcggca 2400 tggacgagct gtacaagtcc ggactcagat ctcgagagga ggaggaggag acagacagca 2460 ggatgcccca cctcgacagc cccggcagct cccagccgag acgctccttc ctctcaaggg 2520 tgatcagggc agctctaccg ttgcagctgc ttctgctgct gctgctgctc ctggcctgcc 2580 tgctacctgc ctctgaagat gactacagct gcacccaggc caacaacttt gcccgatcct 2640 tctaccccat gctgcggtac accaacgggc cacctcccac ctagagcgct aatcaacctc 2700 tggattacaa aatttgtgaa agattgactg gtattcttaa ctatgttgct ccttttacgc 2760 tatgtggata cgctgcttta atgcctttgt atcatgctat tgcttcccgt atggctttca 2820 ttttctcctc cttgtataaa tcctggttgc tgtctcttta tgaggagttg tggcccgttg 2880 tcaggcaacg tggcgtggtg tgcactgtgt ttgctgacgc aacccccact ggttggggca 2940 ttgccaccac ctgtcagctc ctttccggga ctttcgcttt ccccctccct attgccacgg 3000 cggaactcat cgccgcctgc cttgcccgct gctggacagg ggctcggctg ttgggcactg 3060 acaattccgt ggtgttgtcg gggaaatcat cgtcctttcc ttggctgctc gcctatgttg 3120 ccacctggat tctgcgcggg acgtccttct gctacgtccc ttcggccctc aatccagcgg 3180 accttccttc ccgcggcctg ctgccggctc tgcggcctct tccgcgtctt cgccttcgcc 3240 ctcagacgag tcggatctcc ctttgggccg cctccccgca gatctacggg tggcatccct 3300 gtgacccctc cccagtgcct ctcctggccc tggaagttgc cactccagtg cccaccagcc 3360 ttgtcctaat aaaattaagt tgcatcattt tgtctgacta ggtgtccttc tataatatta 3420 tggggtggag gggggtggta tggagcaagg ggcaagttgg gaagacaacc tgtagggcct 3480 gcggggtcta ttgggaacca agctggagtg cagtggcaca atcttggctc actgcaatct 3540 ccgcctcctg ggttcaagcg attctcctgc ctcagcctcc cgagttgttg ggattccagg 3600 catgcatgac caggctcagc taatttttgt ttttttggta gagacggggt ttcaccatat 3660 tggccaggct ggtctccaac tcctaatctc aggtgatcta cccaccttgg cctcccaaat 3720 tgctgggatt acaggcgtga accactgctc ccttccctgt ccttctgatt ttgtaggtaa 3780 ccacgtgcgg accgagcggc cgc 3803 <![CDATA[<210> 369]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 369]]> gctaccccga ccacatgaag 20 <![CDATA[<210> 370]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 370]]> tcttgtagtt gccgtcgtcc 20 <![CDATA[<210> 371]]> <![CDATA[<211> 292]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<400> 371]]> Arg Ser Asp Asn Leu Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa His Arg Thr Thr Leu Thr Asn 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Arg Glu Asp Asn Leu His Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Ser His Ser Leu 165 170 175 Thr Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Gln Ser Ser Ser Leu Val Arg Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Glu Asp 275 280 285 Asn Leu His Thr 290 <![CDATA[<210> 372]]> <![CDATA[<211> 463]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (293)..(342)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (293)..(342)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (350)..(399)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (350)..(399)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (407)..(456)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> ]]>MISC_FEATURE <![CDATA[<222> (407)..(456)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<400> 372]]> Arg Arg Asp Glu Leu Asn Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Asp His Leu Thr Asn 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Arg Ser Asp Asp Leu Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Asp Asn Leu 165 170 175 Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa His Arg Thr Thr Leu Thr Asn Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Glu Asp 275 280 285 Asn Leu His Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 290 295 300 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 305 310 315 320 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 325 330 335 Xaa Xaa Xaa Xaa Xaa Xaa Thr Ser His Ser Leu Thr Glu Xaa Xaa Xaa 340 345 350 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 355 360 365 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 370 375 380 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln 385 390 395 400 Ser Ser Ser Leu Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 405 410 415 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 420 425 430 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 435 440 445 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Glu Asp Asn Leu His Thr 450 455 460 <![CDATA[<210> 373]]> <![CDATA[<211> 9]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成寡核苷酸]]> <![CDATA[<400> 373]]> gcgkgggcg 9 <![CDATA[<210> 374]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 374]]> caaaaaagcc acaaaagcct 20 <![CDATA[<210> 375]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 375]]> ttagctccgc aagaaacatc 20 <![CDATA[<210> 376]]> <![CDATA[<211> 292]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<400> 376]]> Asp Pro Gly Ala Leu Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Asp Asn Leu Val Arg 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Gln Ser Gly Asp Leu Arg Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr His Leu Asp Leu 165 170 175 Ile Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Thr Ser Gly Asn Leu Val Arg Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Asp 275 280 285 Asn Leu Val Arg 290 <![CDATA[<210> 377]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 377]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Thr Ser His Ser Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Cys 35 40 45 Arg Asp Leu Ala Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Thr Gly Asn Leu Thr 65 70 75 80 Val His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Asp Pro Gly Ala Leu Val Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr His Leu Asp Leu Ile Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Thr 145 150 155 160 Gly His Leu Leu Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 378]]> <![CDATA[<211> 192]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 378]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Asn Asp Thr Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Pro 35 40 45 Gly Ala Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser Gly Glu Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly Glu Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Lys 145 150 155 160 Asn Ser Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys 180 185 190 <![CDATA[<210> 379]]> <![CDATA[<211> 204]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 379]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Thr Ser Gly Asn Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ala 35 40 45 Asp Asn Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser Pro Ala Asp Leu Thr 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu Val Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu 145 150 155 160 Ala His Leu Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 165 170 175 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Arg Thr Thr Leu Thr 180 185 190 Asn His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 195 200 <![CDATA[<210> 380]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 380]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Ser 35 40 45 Gly Asn Leu Arg Val His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg 65 70 75 80 Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 381]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 381]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Ser 35 40 45 Gly Asn Leu Arg Val His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg 65 70 75 80 Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 382]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 382]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Ser 35 40 45 Gly Asn Leu Arg Val His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg 65 70 75 80 Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 383]]> <![CDATA[<211> 176]]> <![CDATA[<212]]>> PRT]]> <br/><![CDATA[<213> 人工序列]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<223> 人工序列之描述:合成多肽]]> <br/> <br/><![CDATA[<400> 383]]> <br/><![CDATA[Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Ser 35 40 45 Gly Asn Leu Arg Val His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg 65 70 75 80 Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 384]]> <![CDATA[<211> 260]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 384]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Thr Ser His Ser Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Lys 35 40 45 Asn Ala Leu Gln Asn His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Glu Arg Ser His Leu Arg 65 70 75 80 Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Ser Lys Lys Ala Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Arg Ala Asn Leu Arg Ala His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Lys 145 150 155 160 Asp Asn Leu Lys Asn His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 165 170 175 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Asn Leu Val 180 185 190 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 195 200 205 Cys Gly Lys Ser Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg 210 215 220 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 225 230 235 240 Phe Ser Gln Ala Gly His Leu Ala Ser His Gln Arg Thr His Thr Gly 245 250 255 Lys Lys Thr Ser 260 <![CDATA[<210> 385]]> <![CDATA[<211> 190]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> ]]>人工序列之描述:合成多肽 <![CDATA[<400> 385]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Ser Pro Ala 20 25 30 Asp Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser Asp Ser Gly Asn Leu Arg Val 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Thr Lys Ile 85 90 95 His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys 100 105 110 Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Ile Arg Ile 115 120 125 His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe 130 135 140 Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu 145 150 155 160 Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp 165 170 175 Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys Asp 180 185 190 <![CDATA[<210> 386]]> <![CDATA[<211> 191]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 386]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Ser Pro Ala 20 25 30 Asp Leu Thr Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser Asp Ser Gly Asn Leu Arg Val 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Thr Lys Ile 85 90 95 His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys 100 105 110 Asp Arg Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Ile Arg Ile 115 120 125 His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe 130 135 140 Ser Arg Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu 145 150 155 160 Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Ser Asp 165 170 175 Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 180 185 190 <![CDATA[<210> 38]]>7 <![CDATA[<211> 172]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 387]]> His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Ser Pro Ala 1 5 10 15 Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys Pro Phe Gln 20 25 30 Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn Leu Arg Val 35 40 45 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys 50 55 60 Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Ala Lys Ile 65 70 75 80 His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp Arg 85 90 95 Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg Ile His Thr 100 105 110 Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg 115 120 125 Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro 130 135 140 Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Leu 145 150 155 160 Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu 165 170 <![CDATA[<210> 388]]> <![CDATA[<211> 172]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 388]]> His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Ser Pro Ala 1 5 10 15 Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys Pro Phe Gln 20 25 30 Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn Leu Arg Val 35 40 45 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys 50 55 60 Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Ala Lys Ile 65 70 75 80 His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp Arg 85 90 95 Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg Ile His Thr 100 105 110 Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg 115 120 125 Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro 130 135 140 Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Leu 145 150 155 160 Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu 165 170 <![CDATA[<210> 389]]> <![CDATA[<211> 172]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 389]]> His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Ser Pro Ala 1 5 10 15 Asp Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys Pro Phe Gln 20 25 30 Cys Arg Ile Cys Met Arg Ser Phe Ser Asp Ser Gly Asn Leu Arg Val 35 40 45 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu Phe Cys 50 55 60 Gly Arg Lys Phe Ala Gln Leu Ala His Leu Arg Ala His Ala Lys Ile 65 70 75 80 His Leu Lys Gln Lys Glu His Ala Cys Pro Ala Glu Gly Cys Asp Arg 85 90 95 Arg Phe Ser Gln Arg Ala Asn Leu Arg Ala His Leu Arg Ile His Thr 100 105 110 Gly His Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg 115 120 125 Glu Asp Asn Leu His Thr His Ile Arg Thr His Thr Gly Glu Lys Pro 130 135 140 Phe Ala Cys Glu Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Asn Leu 145 150 155 160 Val Arg His Ala Lys Ile His Leu Lys Gln Lys Glu 165 170 <![CDATA[<210> 390]]> <![CDATA[<211> 184]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 390]]> Met Ala Asp His Leu Met Leu Ala Glu Gly Tyr Arg Leu Val Gln Arg 1 5 10 15 Pro Pro Ser Ala Ala Ala Ala His Gly Pro His Ala Leu Arg Thr Leu 20 25 30 Pro Pro Tyr Ala Gly Pro Gly Leu Asp Ser Gly Leu Arg Pro Arg Gly 35 40 45 Ala Pro Leu Gly Pro Pro Pro Pro Arg Gln Pro Gly Ala Leu Ala Tyr 50 55 60 Gly Ala Phe Gly Pro Pro Ser Ser Phe Gln Pro Phe Pro Ala Val Pro 65 70 75 80 Pro Pro Ala Ala Gly Ile Ala His Leu Gln Pro Val Ala Thr Pro Tyr 85 90 95 Pro Gly Arg Ala Ala Ala Pro Pro Asn Ala Pro Gly Gly Pro Pro Gly 100 105 110 Pro Gln Pro Ala Pro Ser Ala Ala Ala Pro Pro Pro Pro Ala His Ala 115 120 125 Leu Gly Gly Met Asp Ala Glu Leu Ile Asp Glu Glu Ala Leu Thr Ser 130 135 140 Leu Glu Leu Glu Leu Gly Leu His Arg Val Arg Glu Leu Pro Glu Leu 145 150 155 160 Phe Leu Gly Gln Ser Glu Phe Asp Cys Phe Ser Asp Leu Gly Ser Ala 165 170 175 Pro Pro Ala Gly Ser Val Ser Cys 180 <![CDATA[<210> 391]]> <![CDATA[<211> 204]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 391]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Asp Pro Gly His Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Lys 35 40 45 Asn Ser Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Asn Asp Ala Leu Thr 65 70 75 80 Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Glu Arg Ser His Leu Arg Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Ser Lys Lys His Leu Ala Glu His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr His 145 150 155 160 Leu Asp Leu Ile Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 165 170 175 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr 180 185 190 Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 195 200 <![CDATA[<210> 392]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 392]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Ser Arg Arg Thr Cys Arg Ala His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Thr 35 40 45 Gly Ala Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Arg Asn Asp Ala Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Ser Gly Asp Leu Arg Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser 145 150 155 160 His Ser Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 393]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工]]>序列 <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 393]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Lys Asp Asn Leu Lys Asn His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Pro 35 40 45 Gly Ala Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu His 65 70 75 80 Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Asp Pro Gly Ala Leu Val Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly Glu Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Lys 145 150 155 160 Asp Asn Leu Lys Asn His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 394]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 394]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 35 40 45 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly His Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Asn 145 150 155 160 Ser Thr Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 395]]> <![CDATA[<211> 232]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 395]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Ser Lys Lys Ala Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser Pro 35 40 45 Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Arg Ser Asp Glu Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser 145 150 155 160 Gly Asn Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 165 170 175 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser Gly His Leu Val 180 185 190 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 195 200 205 Cys Gly Lys Ser Phe Ser Gln Asn Ser Thr Leu Thr Glu His Gln Arg 210 215 220 Thr His Thr Gly Lys Lys Thr Ser 225 230 <![CDATA[<210> 396]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 396]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 35 40 45 Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu His 65 70 75 80 Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu Val Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser 145 150 155 160 Gly His Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 397]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 397]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Ser Lys Lys Ala Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser Pro 35 40 45 Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Asn Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu His Thr His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Arg Ser Asp Glu Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser 145 150 155 160 Gly Asn Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 398]]> <![CDATA[<211> 232]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 398]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Asp Cys Arg Asp Leu Ala Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Asn 35 40 45 Asp Ala Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Asn Asp Ala Leu Thr 65 70 75 80 Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Ser Pro Ala Asp Leu Thr Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Asp Pro Gly Asn Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Arg 145 150 155 160 Ala His Leu Glu Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 165 170 175 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Ser Ser Leu Val 180 185 190 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 195 200 205 Cys Gly Lys Ser Phe Ser His Arg Thr Thr Leu Thr Asn His Gln Arg 210 215 220 Thr His Thr Gly Lys Lys Thr Ser 225 230 <![CDATA[<210> 399]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 399]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Asn Asp Ala Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Ser Pro 35 40 45 Ala Asp Leu Thr Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Pro Gly Asn Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Arg Ala His Leu Glu Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Arg 145 150 155 160 Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 400]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 400]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Thr Lys Asn Ser Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ala 35 40 45 Asp Asn Leu Thr Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu Ala His Leu Arg 65 70 75 80 Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Thr Lys Asn Ser Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Ala Gly His Leu Ala Ser His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr His 145 150 155 160 Leu Asp Leu Ile Arg His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 401]]> <![CDATA[<211> 204]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 401]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Asn Asp Ala Leu Thr Glu His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Asp Pro 35 40 45 Gly His Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser Gly Glu Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Thr His Leu Asp Leu Ile Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Ser Lys Lys Ala Leu Thr Glu His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Leu 145 150 155 160 Ala His Leu Arg Ala His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 165 170 175 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp His Leu Thr 180 185 190 Asn His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 195 200 <![CDATA[<210> 402]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 402]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Arg 35 40 45 Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu His 65 70 75 80 Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 145 150 155 160 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 403]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 403]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Asp Pro Gly Ala Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 35 40 45 Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ser Gly Asp Leu Arg 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Thr His Leu Asp Leu Ile Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly Asn Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser 145 150 155 160 Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 404]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 404]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Gln Ala Gly His Leu Ala Ser His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 35 40 45 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser Gly Asn Leu Thr 65 70 75 80 Glu His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Thr His Leu Asp Leu Ile Arg His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Lys Ser Ser Leu Ile Ala His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Ala 145 150 155 160 Gly His Leu Ala Ser His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 405]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 405]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Thr Thr Gly Asn Leu Thr Val His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Thr Ser 35 40 45 Gly Glu Leu Val Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu His 65 70 75 80 Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Thr Ser Gly Asn Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Arg 145 150 155 160 Ala Asn Leu Arg Ala His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 406]]> <![CDATA[<211> 198]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 406]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 20 25 30 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr Leu Thr Asn 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr Lys Ile 85 90 95 His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys 100 105 110 Asp Arg Arg Phe Ser Thr Ser His Ser Leu Thr Glu His Ile Arg Ile 115 120 125 His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe 130 135 140 Ser Gln Ser Ser Ser Leu Val Arg His Ile Arg Thr His Thr Gly Glu 145 150 155 160 Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp 165 170 175 Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys 180 185 190 Ala Asp Lys Ser Val Val 195 <![CDATA[<210> 407]]> <![CDATA[<211> 630]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 407]]> Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile Ser 1 5 10 15 Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr Pro 20 25 30 Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe Leu 35 40 45 Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser Ser 50 55 60 Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser Ser 65 70 75 80 Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro Tyr 85 90 95 Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn Glu 100 105 110 Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu Pro 115 120 125 Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn Ser 130 135 140 Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly Leu 145 150 155 160 Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser Pro 165 170 175 Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys Ala 180 185 190 Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr Phe 195 200 205 Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala Phe 210 215 220 Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr Pro 225 230 235 240 Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu Phe 245 250 255 Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys Pro 260 265 270 Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro Leu 275 280 285 Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu Lys 290 295 300 Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg Met 305 310 315 320 Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 325 330 335 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 340 345 350 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 355 360 365 Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr 370 375 380 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 385 390 395 400 Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile 405 410 415 His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys 420 425 430 Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile 435 440 445 His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe 450 455 460 Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu 465 470 475 480 Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser 485 490 495 Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys 500 505 510 Ala Asp Lys Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser Ser 515 520 525 Tyr Pro Ser Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr Ser 530 535 540 Tyr Pro Ser Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr Ser 545 550 555 560 Phe Ser Ser Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser Gly 565 570 575 Phe Pro Ser Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro Ala 580 585 590 Phe Pro Ala Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn Ser 595 600 605 Phe Ser Ala Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser Pro 610 615 620 Arg Thr Ile Glu Ile Cys 625 630 <![CDATA[<210> 408]]> <![CDATA[<211> 264]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 408]]> Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Asp 1 5 10 15 Pro Gly Ala Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro 20 25 30 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Ser Asp Asn Leu 35 40 45 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 50 55 60 Ile Cys Gly Arg Lys Phe Ala Gln Ser Gly Asp Leu Arg Arg His Thr 65 70 75 80 Lys Ile His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu 85 90 95 Ser Cys Asp Arg Arg Phe Ser Thr His Leu Asp Leu Ile Arg His Ile 100 105 110 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 115 120 125 Asn Phe Ser Thr Ser Gly Asn Leu Val Arg His Ile Arg Thr His Thr 130 135 140 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 145 150 155 160 Ser Asp Asn Leu Val Arg His Thr Lys Ile His Leu Arg Gln Lys Asp 165 170 175 Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Gln 180 185 190 Ser Gly His Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro 195 200 205 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Glu Arg Ser His Leu 210 215 220 Arg Glu His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 225 230 235 240 Ile Cys Gly Arg Lys Phe Ala Gln Ala Gly His Leu Ala Ser His Thr 245 250 255 Lys Ile His Leu Arg Gln Lys Asp 260 <![CDATA[<210> 409]]> <![CDATA[<211> 194]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 409]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 20 25 30 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Ile Arg Thr 85 90 95 His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe 100 105 110 Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly Gln 115 120 125 Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly 130 135 140 His Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala 145 150 155 160 Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr Glu 165 170 175 His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser 180 185 190 Val Val <![CDATA[<210> 410]]> <![CDATA[<211> 8]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 410]]> Gly Gly Ser Gly Gly Gly Ser Gly 1 5 <![CDATA[<210> 411]]> <![CDATA[<400> 411]]> 000 <![CDATA[<210> 412]]> <![CDATA[<211> 292]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221]]>> MISC_F]]><![CDATA[EATURE <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<400> 412]]> Arg Ser Asp Asn Leu Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Pro Gly His Leu Val Arg 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Arg Ser Asp His Leu Thr Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Asp Glu Leu 165 170 175 Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Arg Ser Asp Lys Leu Val Arg Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Thr Gly 275 280 285 Asn Leu Thr Val 290 <![CDATA[<210> 413]]> <![CDATA[<211> 292]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<400> 413]]> Arg Ser Asp His Leu Thr Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Asp Glu Leu Val Arg 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Arg Ser Asp Lys Leu Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Thr Gly Asn Leu 165 170 175 Thr Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Gln Leu Ala His Leu Arg Ala Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Thr Lys Asn 275 280 285 Ser Leu Thr Glu 290 <![CDATA[<210> 414]]> <![CDATA[<211> 292]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<400> 414]]> Ser Pro Ala Asp Leu Thr Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Ser Gly Asn Leu Arg Val 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Gln Leu Ala His Leu Arg Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Arg Ala Asn Leu 165 170 175 Arg Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Arg Glu Asp Asn Leu His Thr Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Asp 275 280 285 Asn Leu Val Arg 290 <![CDATA[<210> 415]]> <![CDATA[<211> 463]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (179)..(228]]>) <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (293)..(342)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (293)..(342)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (350)..(399)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (350)..(399)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (407)..(456)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (407)..(456)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<400> 415]]> Thr Ser His Ser Leu Thr Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa His Lys Asn Ala Leu Gln Asn 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Glu Arg Ser His Leu Arg Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Lys Lys Ala Leu 165 170 175 Thr Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Gln Arg Ala Asn Leu Arg Ala Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Lys Asp 275 280 285 Asn Leu Lys Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 290 295 300 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 305 310 315 320 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 325 330 335 Xaa Xaa Xaa Xaa Xaa Xaa Gln Ser Ser Asn Leu Val Arg Xaa Xaa Xaa 340 345 350 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 355 360 365 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 370 375 380 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln 385 390 395 400 Ser Ser Ser Leu Val Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 405 410 415 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 420 425 430 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 435 440 445 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Ala Gly His Leu Ala Ser 450 455 460 <![CDATA[<210> 416]]> <![CDATA[<211> 349]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(57)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (65)..(114)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (122)..(171)]]> <![CDATA[<223> 此區可]]>包含1-50個殘基 <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (179)..(228)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (236)..(285)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (293)..(342)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (293)..(342)]]> <![CDATA[<223> 此區可包含1-50個殘基]]> <![CDATA[<400> 416]]> Gln Ser Gly Asp Leu Arg Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 40 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ser Pro Ala Asp Leu Thr Arg 50 55 60 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 65 70 75 80 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 85 90 95 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 105 110 Xaa Xaa Asp Ser Gly Asn Leu Arg Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 120 125 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 135 140 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 150 155 160 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Leu Ala His Leu 165 170 175 Arg Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 185 190 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 200 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 215 220 Xaa Xaa Xaa Xaa Gln Arg Ala Asn Leu Arg Ala Xaa Xaa Xaa Xaa Xaa 225 230 235 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 250 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 265 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Glu Asp 275 280 285 Asn Leu His Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 290 295 300 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 305 310 315 320 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 325 330 335 Xaa Xaa Xaa Xaa Xaa Xaa Arg Ser Asp Asn Leu Val Arg 340 345 <![CDATA[<210> 417]]> <![CDATA[<211> 509]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 417]]> gccctctagg ccacctgacc aggtcccctc agtccccccc ttcccacact cccacactca 60 gcccccctcc cccccccccg acccctgcag gattatcctg tctgtgttcc tgactcagcc 120 tgggagccac ctgggcagca ggggccaagg gtgtcctaga agggacctgg agtccacgct 180 gggccaagcc tgccctttct ccctctgtct tccgtccctg cttgcggttc tgctgaatgt 240 ggttatttct ctggctcctt ttacagagaa tgctgctgct aattttatgt ggagctctga 300 ggcagtgtaa ttggaagcca gacaccctgt cagcagtggg ctcccgtcct gagctgccat 360 gcttcctgct ctcctcccgt cccggctcct catttcatgc agccacctgt cccagggaga 420 gaggagtcac ccaggcccct cagtccgccc cttaaataag aaagcctccg ttgctcggca 480 cacataccaa gcagccgctg gtgcaatct 509 <![CDATA[<210> 418]]> <![CDATA[<211> 990]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 418]]> gccaccatgg tgagcaaggg cgaggagctg ttcaccgggg tggtgcccat cctggtcgag 60 ctggacggcg acgtaaacgg ccacaagttc agcgtgtccg gcgagggcga gggcgatgcc 120 acctacggca agctgaccct gaagttcatc tgcaccaccg gcaagctgcc cgtgccctgg 180 cccaccctcg tgaccaccct gacctacggc gtgcagtgct tcagccgcta ccccgaccac 240 atgaagcagc acgacttctt caagtccgcc atgcccgaag gctacgtcca ggagcgcacc 300 atcttcttca aggacgacgg caactacaag acccgcgccg aggtgaagtt cgagggcgac 360 accctggtga accgcatcga gctgaagggc atcgacttca aggaggacgg caacatcctg 420 gggcacaagc tggagtacaa ctacaacagc cacaacgtct atatcatggc cgacaagcag 480 aagaacggca tcaaggtgaa cttcaagatc cgccacaaca tcgaggacgg cagcgtgcag 540 ctcgccgacc actaccagca gaacaccccc atcggcgacg gccccgtgct gctgcccgac 600 aaccactacc tgagcaccca gtccgccctg agcaaagacc ccaacgagaa gcgcgatcac 660 atggtcctgc tggagttcgt gaccgccgcc gggatcactc tcggcatgga cgagctgtac 720 aagtccggac tcagatctcg agaggaggag gaggagacag acagcaggat gccccacctc 780 gacagccccg gcagctccca gccgagacgc tccttcctct caagggtgat cagggcagct 840 ctaccgttgc agctgcttct gctgctgctg ctgctcctgg cctgcctgct acctgcctct 900 gaagatgact acagctgcac ccaggccaac aactttgccc gatccttcta ccccatgctg 960 cggtacacca acgggccacc tcccacctag 990 <![CDATA[<210> 419]]> <![CDATA[<400> 419]]> 000 <![CDATA[<210> 420]]> <![CDATA[<400> 420]]> 000 <![CDATA[<210> 421]]> <![CDATA[<211> 360]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (19)..(19)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (41)..(41)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (63)..(63)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (85)..(85)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (107)..(107)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (129)..(129)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (151)..(151)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (173)..(173)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (195)..(195)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (217)..(217)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (239)..(239)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (261)..(261)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (283)..(283)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (305)..(305)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (327)..(327)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220>]]> <![CDATA[<221> MISC_FEATURE ]]> <![CDATA[<222> (8)..(337)]]> <![CDATA[<223> 此區可包含1-15個 "Tyr Lys Cys Pro Glu Cys Gly ]]> Lys Ser Phe Ser Xaa His Gln Arg Thr His Thr Gly Glu Lys Pro" 重複單元 <![CDATA[<220>]]> <![CDATA[<221> MOD_RES]]> <![CDATA[<222> (349)..(349)]]> <![CDATA[<223> 任何胺基酸]]> <![CDATA[<220> ]]> <![CDATA[<223> 參見如關於取代及較佳實施例之詳細描述歸檔之說明書]]> <![CDATA[<400> 421]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Xaa His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys 20 25 30 Pro Glu Cys Gly Lys Ser Phe Ser Xaa His Gln Arg Thr His Thr Gly 35 40 45 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Xaa His 50 55 60 Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly 65 70 75 80 Lys Ser Phe Ser Xaa His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 85 90 95 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Xaa His Gln Arg Thr His 100 105 110 Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser 115 120 125 Xaa His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 130 135 140 Cys Gly Lys Ser Phe Ser Xaa His Gln Arg Thr His Thr Gly Glu Lys 145 150 155 160 Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Xaa His Gln Arg 165 170 175 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 180 185 190 Phe Ser Xaa His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys 195 200 205 Pro Glu Cys Gly Lys Ser Phe Ser Xaa His Gln Arg Thr His Thr Gly 210 215 220 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Xaa His 225 230 235 240 Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly 245 250 255 Lys Ser Phe Ser Xaa His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 260 265 270 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Xaa His Gln Arg Thr His 275 280 285 Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser 290 295 300 Xaa His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 305 310 315 320 Cys Gly Lys Ser Phe Ser Xaa His Gln Arg Thr His Thr Gly Glu Lys 325 330 335 Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Xaa His Gln Arg 340 345 350 Thr His Thr Gly Lys Lys Thr Ser 355 360 <![CDATA[<210> 422]]> <![CDATA[<211> 387]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 422]]> Met Thr Gly Lys Leu Ala Glu Lys Leu Pro Val Thr Met Ser Ser Leu 1 5 10 15 Leu Asn Gln Leu Pro Asp Asn Leu Tyr Pro Glu Glu Ile Pro Ser Ala 20 25 30 Leu Asn Leu Phe Ser Gly Ser Ser Asp Ser Val Val His Tyr Asn Gln 35 40 45 Met Ala Thr Glu Asn Val Met Asp Ile Gly Leu Thr Asn Glu Lys Pro 50 55 60 Asn Pro Glu Leu Ser Tyr Ser Gly Ser Phe Gln Pro Ala Pro Gly Asn 65 70 75 80 Lys Thr Val Thr Tyr Leu Gly Lys Phe Ala Phe Asp Ser Pro Ser Asn 85 90 95 Trp Cys Gln Asp Asn Ile Ile Ser Leu Met Ser Ala Gly Ile Leu Gly 100 105 110 Val Pro Pro Ala Ser Gly Ala Leu Ser Thr Gln Thr Ser Thr Ala Ser 115 120 125 Met Val Gln Pro Pro Gln Gly Asp Val Glu Ala Met Tyr Pro Ala Leu 130 135 140 Pro Pro Tyr Ser Asn Cys Gly Asp Leu Tyr Ser Glu Pro Val Ser Phe 145 150 155 160 His Asp Pro Gln Gly Asn Pro Gly Leu Ala Tyr Ser Pro Gln Asp Tyr 165 170 175 Gln Ser Ala Lys Pro Ala Leu Asp Ser Asn Leu Phe Pro Met Ile Pro 180 185 190 Asp Tyr Asn Leu Tyr His His Pro Asn Asp Met Gly Ser Ile Pro Glu 195 200 205 His Lys Pro Phe Gln Gly Met Asp Pro Ile Arg Val Asn Pro Pro Pro 210 215 220 Ile Thr Pro Leu Glu Thr Ile Lys Ala Phe Lys Asp Lys Gln Ile His 225 230 235 240 Pro Gly Phe Gly Ser Leu Pro Gln Pro Pro Leu Thr Leu Lys Pro Ile 245 250 255 Arg Pro Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Leu His Glu 260 265 270 Arg Pro His Ala Cys Pro Ala Glu Gly Cys Asp Arg Arg Phe Ser Arg 275 280 285 Ser Asp Glu Leu Thr Arg His Leu Arg Ile His Thr Gly His Lys Pro 290 295 300 Phe Gln Cys Arg Ile Cys Met Arg Ser Phe Ser Arg Ser Asp His Leu 305 310 315 320 Thr Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Glu 325 330 335 Phe Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Arg Lys Arg His Ala 340 345 350 Lys Ile His Leu Lys Gln Lys Glu Lys Lys Ala Glu Lys Gly Gly Ala 355 360 365 Pro Ser Ala Ser Ser Ala Pro Pro Val Ser Leu Ala Pro Val Val Thr 370 375 380 Thr Cys Ala 385 <![CDATA[<210> 423]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 423]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 35 40 45 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly His Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Asn 145 150 155 160 Ser Thr Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 424]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成]]>多肽 <![CDATA[<400> 424]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 35 40 45 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly His Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Asn 145 150 155 160 Ser Thr Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 425]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 425]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 35 40 45 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Ser Asp Glu Leu Val 65 70 75 80 Arg His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Gln Ser Gly Asn Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Thr Ser Gly His Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Gln Asn 145 150 155 160 Ser Thr Leu Thr Glu His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 426]]> <![CDATA[<211> 176]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 426]]> Leu Glu Pro Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 1 5 10 15 Phe Ser Arg Ser Asp Asn Leu Val Arg His Gln Arg Thr His Thr Gly 20 25 30 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser His Arg 35 40 45 Thr Thr Leu Thr Asn His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr 50 55 60 Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu Asp Asn Leu His 65 70 75 80 Thr His Gln Arg Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu 85 90 95 Cys Gly Lys Ser Phe Ser Thr Ser His Ser Leu Thr Glu His Gln Arg 100 105 110 Thr His Thr Gly Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser 115 120 125 Phe Ser Gln Ser Ser Ser Leu Val Arg His Gln Arg Thr His Thr Gly 130 135 140 Glu Lys Pro Tyr Lys Cys Pro Glu Cys Gly Lys Ser Phe Ser Arg Glu 145 150 155 160 Asp Asn Leu His Thr His Gln Arg Thr His Thr Gly Lys Lys Thr Ser 165 170 175 <![CDATA[<210> 427]]> <![CDATA[<211> 198]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 427]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 20 25 30 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile 85 90 95 His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys 100 105 110 Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile 115 120 125 His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe 130 135 140 Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu 145 150 155 160 Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser 165 170 175 Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys 180 185 190 Ala Asp Lys Ser Val Val 195 <![CDATA[<210> 428]]> <![CDATA[<211> 198]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 428]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 20 25 30 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile 85 90 95 His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys 100 105 110 Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile 115 120 125 His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe 130 135 140 Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu 145 150 155 160 Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser 165 170 175 Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys 180 185 190 Ala Asp Lys Ser Val Val 195 <![CDATA[<210> 429]]> <![CDATA[<211> 191]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 429]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 20 25 30 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile 85 90 95 His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys 100 105 110 Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile 115 120 125 His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe 130 135 140 Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu 145 150 155 160 Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser 165 170 175 Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 180 185 190 <![CDATA[<210> 430]]> <![CDATA[<211> 191]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 430]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 20 25 30 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Thr Lys Ile 85 90 95 His Leu Arg Gln Lys Asp Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys 100 105 110 Asp Arg Arg Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile 115 120 125 His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe 130 135 140 Ser Thr Ser Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu 145 150 155 160 Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser 165 170 175 Thr Leu Thr Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys 180 185 190 <![CDATA[<210> 431]]> <![CDATA[<211> 194]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 431]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 20 25 30 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr Leu Thr Asn 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Ile Arg Thr 85 90 95 His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe 100 105 110 Ser Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln 115 120 125 Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser 130 135 140 Ser Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala 145 150 155 160 Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr 165 170 175 His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser 180 185 190 Val Val <![CDATA[<210> 432]]> <![CDATA[<211> 201]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 432]]> Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn Arg 1 5 10 15 Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val Glu 20 25 30 Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile 35 40 45 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 50 55 60 Asn Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr 65 70 75 80 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 85 90 95 Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp 100 105 110 Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Thr 115 120 125 Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro 130 135 140 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser Leu 145 150 155 160 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 165 170 175 Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr 180 185 190 Lys Ile His Leu Arg Gln Lys Asp Lys 195 200 <![CDATA[<210> 433]]> <![CDATA[<211> 195]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 433]]> Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn Arg 1 5 10 15 Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val Glu 20 25 30 Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile 35 40 45 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 50 55 60 Asn Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr 65 70 75 80 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 85 90 95 Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp 100 105 110 Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Thr 115 120 125 Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro 130 135 140 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser Leu 145 150 155 160 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 165 170 175 Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr 180 185 190 Lys Ile His 195 <![CDATA[<210> 434]]> <![CDATA[<211> 201]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 434]]> Gln Ser Gln Leu Ile Lys Pro Ser Arg Met Arg Lys Tyr Pro Asn Arg 1 5 10 15 Pro Ser Lys Thr Pro Pro His Glu Arg Pro Tyr Ala Cys Pro Val Glu 20 25 30 Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp Asn Leu Val Arg His Ile 35 40 45 Arg Ile His Thr Gly Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg 50 55 60 Asn Phe Ser His Arg Thr Thr Leu Thr Asn His Ile Arg Thr His Thr 65 70 75 80 Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg 85 90 95 Glu Asp Asn Leu His Thr His Thr Lys Ile His Leu Arg Gln Lys Asp 100 105 110 Arg Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Thr 115 120 125 Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln Lys Pro 130 135 140 Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser Ser Leu 145 150 155 160 Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp 165 170 175 Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Thr 180 185 190 Lys Ile His Leu Arg Gln Lys Asp Lys 195 200 <![CDATA[<210> 435]]> <![CDATA[<211> 194]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 435]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 20 25 30 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser His Arg Thr Thr Leu Thr Asn 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr His Ile Arg Thr 85 90 95 His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe 100 105 110 Ser Thr Ser His Ser Leu Thr Glu His Ile Arg Ile His Thr Gly Gln 115 120 125 Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Gln Ser Ser 130 135 140 Ser Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala 145 150 155 160 Cys Asp Ile Cys Gly Arg Lys Phe Ala Arg Glu Asp Asn Leu His Thr 165 170 175 His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser 180 185 190 Val Val <![CDATA[<210> ]]>436 <![CDATA[<211> 4]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 436]]> Gly Gly Gly Ser 1 <![CDATA[<210> 437]]> <![CDATA[<211> 5]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 437]]> Gly Gly Gly Gly Ser 1 5 <![CDATA[<210> 438]]> <![CDATA[<211> 4]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成肽]]> <![CDATA[<400> 438]]> Gly Gly Ser Gly 1 <![CDATA[<210> 439]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成引物]]> <![CDATA[<400> 439]]> attggtggga ggccactgta t 21 <![CDATA[<210> 440]]> <![CDATA[<211> 627]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 440]]> Met Ala Ala Ala Lys Ala Glu Met Gln Leu Met Ser Pro Leu Gln Ile 1 5 10 15 Ser Asp Pro Phe Gly Ser Phe Pro His Ser Pro Thr Met Asp Asn Tyr 20 25 30 Pro Lys Leu Glu Glu Met Met Leu Leu Ser Asn Gly Ala Pro Gln Phe 35 40 45 Leu Gly Ala Ala Gly Ala Pro Glu Gly Ser Gly Ser Asn Ser Ser Ser 50 55 60 Ser Ser Ser Gly Gly Gly Gly Gly Gly Gly Gly Gly Ser Asn Ser Ser 65 70 75 80 Ser Ser Ser Ser Thr Phe Asn Pro Gln Ala Asp Thr Gly Glu Gln Pro 85 90 95 Tyr Glu His Leu Thr Ala Glu Ser Phe Pro Asp Ile Ser Leu Asn Asn 100 105 110 Glu Lys Val Leu Val Glu Thr Ser Tyr Pro Ser Gln Thr Thr Arg Leu 115 120 125 Pro Pro Ile Thr Tyr Thr Gly Arg Phe Ser Leu Glu Pro Ala Pro Asn 130 135 140 Ser Gly Asn Thr Leu Trp Pro Glu Pro Leu Phe Ser Leu Val Ser Gly 145 150 155 160 Leu Val Ser Met Thr Asn Pro Pro Ala Ser Ser Ser Ser Ala Pro Ser 165 170 175 Pro Ala Ala Ser Ser Ala Ser Ala Ser Gln Ser Pro Pro Leu Ser Cys 180 185 190 Ala Val Pro Ser Asn Asp Ser Ser Pro Ile Tyr Ser Ala Ala Pro Thr 195 200 205 Phe Pro Thr Pro Asn Thr Asp Ile Phe Pro Glu Pro Gln Ser Gln Ala 210 215 220 Phe Pro Gly Ser Ala Gly Thr Ala Leu Gln Tyr Pro Pro Pro Ala Tyr 225 230 235 240 Pro Ala Ala Lys Gly Gly Phe Gln Val Pro Met Ile Pro Asp Tyr Leu 245 250 255 Phe Pro Gln Gln Gln Gly Asp Leu Gly Leu Gly Thr Pro Asp Gln Lys 260 265 270 Pro Phe Gln Gly Leu Glu Ser Arg Thr Gln Gln Pro Ser Leu Thr Pro 275 280 285 Leu Ser Thr Ile Lys Ala Phe Ala Thr Gln Ser Gly Ser Gln Asp Leu 290 295 300 Lys Ala Leu Asn Thr Ser Tyr Gln Ser Gln Leu Ile Lys Pro Ser Arg 305 310 315 320 Met Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg 325 330 335 Pro Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser 340 345 350 Asp Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe 355 360 365 Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His 370 375 380 Thr His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile 385 390 395 400 Cys Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Ile Arg 405 410 415 Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys 420 425 430 Phe Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly 435 440 445 Gln Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser 450 455 460 Gly His Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe 465 470 475 480 Ala Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr 485 490 495 Glu His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys 500 505 510 Ser Val Val Ala Ser Ser Ala Thr Ser Ser Leu Ser Ser Tyr Pro Ser 515 520 525 Pro Val Ala Thr Ser Tyr Pro Ser Pro Val Thr Thr Ser Tyr Pro Ser 530 535 540 Pro Ala Thr Thr Ser Tyr Pro Ser Pro Val Pro Thr Ser Phe Ser Ser 545 550 555 560 Pro Gly Ser Ser Thr Tyr Pro Ser Pro Val His Ser Gly Phe Pro Ser 565 570 575 Pro Ser Val Ala Thr Thr Tyr Ser Ser Val Pro Pro Ala Phe Pro Ala 580 585 590 Gln Val Ser Ser Phe Pro Ser Ser Ala Val Thr Asn Ser Phe Ser Ala 595 600 605 Ser Thr Gly Leu Ser Asp Met Thr Ala Thr Phe Ser Pro Arg Thr Ile 610 615 620 Glu Ile Cys 625 <![CDATA[<210> 441]]> <![CDATA[<211> 194]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多肽]]> <![CDATA[<400> 441]]> Arg Lys Tyr Pro Asn Arg Pro Ser Lys Thr Pro Pro His Glu Arg Pro 1 5 10 15 Tyr Ala Cys Pro Val Glu Ser Cys Asp Arg Arg Phe Ser Arg Ser Asp 20 25 30 Asn Leu Val Arg His Ile Arg Ile His Thr Gly Gln Lys Pro Phe Gln 35 40 45 Cys Arg Ile Cys Met Arg Asn Phe Ser Arg Glu Asp Asn Leu His Thr 50 55 60 His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys 65 70 75 80 Gly Arg Lys Phe Ala Arg Ser Asp Glu Leu Val Arg His Ile Arg Thr 85 90 95 His Thr Gly Glu Lys Pro Phe Ala Cys Asp Ile Cys Gly Arg Lys Phe 100 105 110 Ser Gln Ser Gly Asn Leu Thr Glu His Ile Arg Ile His Thr Gly Gln 115 120 125 Lys Pro Phe Gln Cys Arg Ile Cys Met Arg Asn Phe Ser Thr Ser Gly 130 135 140 His Leu Val Arg His Ile Arg Thr His Thr Gly Glu Lys Pro Phe Ala 145 150 155 160 Cys Asp Ile Cys Gly Arg Lys Phe Ala Gln Asn Ser Thr Leu Thr Glu 165 170 175 His Thr Lys Ile His Leu Arg Gln Lys Asp Lys Lys Ala Asp Lys Ser 180 185 190 Val Val <![CDATA[<210> 442]]> <![CDATA[<211> 2259]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 442]]> atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cctcgaacca 60 ggtgaaaaac cttacaaatg tcctgaatgt gggaaatcat tcagtcgcag cgacaacctg 120 gtgagacatc aacgcaccca tacaggagaa aaaccttata aatgtccaga atgtggaaag 180 tccttctcac gagaggataa cttgcacact catcaacgaa cacatactgg tgaaaaacca 240 tacaagtgtc ccgaatgtgg taaaagtttt agccggagcg atgaacttgt ccgacaccaa 300 cgaacccata caggcgagaa gccttacaaa tgtcccgagt gtggcaagag cttctcacaa 360 tcagggaatc tgactgagca tcaacgaact cataccgggg aaaaacctta caagtgtcca 420 gagtgtggga agagcttttc cacaagtgga catctggtac gccaccagag gacacataca 480 ggggagaagc cctacaaatg ccccgaatgc ggtaaaagtt tctctcagaa tagtaccctg 540 accgaacacc agcgaacaca cactgggaaa aaaacgagta aaaggccggc ggccacgaaa 600 aaggccggcc aggcaaaaaa gaaaaaggga tcctacccat acgacgtacc agattacgct 660 ctcgaggagg ccagcggttc cggacgggct gacgcattgg acgattttga tctggatatg 720 ctgggaagtg acgccctcga tgattttgac cttgacatgc ttggttcgga tgcccttgat 780 gactttgacc tcgacatgct cggcagtgac gcccttgatg atttcgacct ggacatgctg 840 attaactcta gaagttccgg atctccgaaa aagaaacgca aagttggtag ccagtacctg 900 cccgacaccg acgaccggca ccggatcgag gaaaagcgga agcggaccta cgagacattc 960 aagagcatca tgaagaagtc ccccttcagc ggccccaccg accctagacc tccacctaga 1020 agaatcgccg tgcccagcag atccagcgcc agcgtgccaa aacctgcccc ccagccttac 1080 cccttcacca gcagcctgag caccatcaac tacgacgagt tccctaccat ggtgttcccc 1140 agcggccaga tctctcaggc ctctgctctg gctccagccc ctcctcaggt gctgcctcag 1200 gctcctgctc ctgcaccagc tccagccatg gtgtctgcac tggctcaggc accagcaccc 1260 gtgcctgtgc tggctcctgg acctccacag gctgtggctc caccagcccc taaacctaca 1320 caggccggcg agggcacact gtctgaagct ctgctgcagc tgcagttcga cgacgaggat 1380 ctgggagccc tgctgggaaa cagcaccgat cctgccgtgt tcaccgacct ggccagcgtg 1440 gacaacagcg agttccagca gctgctgaac cagggcatcc ctgtggcccc tcacaccacc 1500 gagcccatgc tgatggaata ccccgaggcc atcacccggc tcgtgacagg cgctcagagg 1560 cctcctgatc cagctcctgc ccctctggga gcaccaggcc tgcctaatgg actgctgtct 1620 ggcgacgagg acttcagctc tatcgccgat atggatttct cagccttgct gggctctggc 1680 agcggcagcc gggattccag ggaagggatg tttttgccga agcctgaggc cggctccgct 1740 attagtgacg tgtttgaggg ccgcgaggtg tgccagccaa aacgaatccg gccatttcat 1800 cctccaggaa gtccatgggc caaccgccca ctccccgcca gcctcgcacc aacaccaacc 1860 ggtccagtac atgagccagt cgggtcactg accccggcac cagtccctca gccactggat 1920 ccagcgcccg cagtgactcc cgaggccagt cacctgttgg aggatcccga tgaagagacg 1980 agccaggctg tcaaagccct tcgggagatg gccgatactg tgattcccca gaaggaagag 2040 gctgcaatct gtggccaaat ggacctttcc catccgcccc caaggggcca tctggatgag 2100 ctgacaacca cacttgagtc catgaccgag gatctgaacc tggactcacc cctgaccccg 2160 gaattgaacg agattctgga taccttcctg aacgacgagt gcctcttgca tgccatgcat 2220 atcagcacag gactgtccat cttcgacaca tctctgttt 2259 <![CDATA[<210> 443]]> <![CDATA[<211> 816]]> <![CDATA[<212> DN]]>A <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 443]]> atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cctcgaacca 60 ggtgaaaaac cttacaaatg tcctgaatgt gggaaatcat tcagtcgcag cgacaacctg 120 gtgagacatc aacgcaccca tacaggagaa aaaccttata aatgtccaga atgtggaaag 180 tccttctcac gagaggataa cttgcacact catcaacgaa cacatactgg tgaaaaacca 240 tacaagtgtc ccgaatgtgg taaaagtttt agccggagcg atgaacttgt ccgacaccaa 300 cgaacccata caggcgagaa gccttacaaa tgtcccgagt gtggcaagag cttctcacaa 360 tcagggaatc tgactgagca tcaacgaact cataccgggg aaaaacctta caagtgtcca 420 gagtgtggga agagcttttc cacaagtgga catctggtac gccaccagag gacacataca 480 ggggagaagc cctacaaatg ccccgaatgc ggtaaaagtt tctctcagaa tagtaccctg 540 accgaacacc agcgaacaca cactgggaaa aaaacgagta aaaggccggc ggccacgaaa 600 aaggccggcc aggcaaaaaa gaaaaaggga tcctacccat acgacgtacc agattacgct 660 ctcgaggacg cgctggacga tttcgatctc gacatgctgg gttctgatgc cctcgatgac 720 tttgacctgg atatgttggg aagcgacgca ttggatgact ttgatctgga catgctcggc 780 tccgatgctc tggacgattt cgatctcgat atgtta 816 <![CDATA[<210> 444]]> <![CDATA[<211> 816]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 444]]> atggccccaa agaagaagcg gaaggtcggt atccacggag tcccagcagc cctcgaacca 60 ggtgaaaaac cttacaaatg tcctgaatgt gggaaatcat tcagtcgcag cgacaacctg 120 gtgagacatc aacgcaccca tacaggagaa aaaccttata aatgtccaga atgtggaaag 180 tccttctcac gagaggataa cttgcacact catcaacgaa cacatactgg tgaaaaacca 240 tacaagtgtc ccgaatgtgg taaaagtttt agccggagcg atgaacttgt ccgacaccaa 300 cgaacccata caggcgagaa gccttacaaa tgtcccgagt gtggcaagag cttctcacaa 360 tcagggaatc tgactgagca tcaacgaact cataccgggg aaaaacctta caagtgtcca 420 gagtgtggga agagcttttc cacaagtgga catctggtac gccaccagag gacacataca 480 ggggagaagc cctacaaatg ccccgaatgc ggtaaaagtt tctctcagaa tagtaccctg 540 accgaacacc agcgaacaca cactgggaaa aaaacgagta aaaggccggc ggccacgaaa 600 aaggccggcc aggcaaaaaa gaaaaaggga tcctacccat acgacgtacc agattacgct 660 ctcgaggacg cgctggacga tttcgatctc gacatgctgg gttctgatgc cctcgatgac 720 tttgacctgg atatgttggg aagcgacgca ttggatgact ttgatctgga catgctcggc 780 tccgatgctc tggacgattt cgatctcgat atgtta 816 <![CDATA[<210> 445]]> <![CDATA[<211> 1893]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描]]>述:合成多核苷酸 <![CDATA[<400> 445]]> atggccgcgg ccaaggccga gatgcagctg atgtccccgc tgcagatctc tgacccgttc 60 ggatcctttc ctcactcgcc caccatggac aactacccta agctggagga gatgatgctg 120 ctgagcaacg gggctcccca gttcctcggc gccgccgggg ccccagaggg cagcggcagc 180 aacagcagca gcagcagcag cgggggcggt ggaggcggcg ggggcggcag caacagcagc 240 agcagcagca gcaccttcaa ccctcaggcg gacacgggcg agcagcccta cgagcacctg 300 accgcagagt cttttcctga catctctctg aacaacgaga aggtgctggt ggagaccagt 360 taccccagcc aaaccactcg actgcccccc atcacctata ctggccgctt ttccctggag 420 cctgcaccca acagtggcaa caccttgtgg cccgagcccc tcttcagctt ggtcagtggc 480 ctagtgagca tgaccaaccc accggcctcc tcgtcctcag caccatctcc agcggcctcc 540 tccgcctccg cctcccagag cccacccctg agctgcgcag tgccatccaa cgacagcagt 600 cccatttact cagcggcacc caccttcccc acgccgaaca ctgacatttt ccctgagcca 660 caaagccagg ccttcccggg ctcggcaggg acagcgctcc agtacccgcc tcctgcctac 720 cctgccgcca agggtggctt ccaggttccc atgatccccg actacctgtt tccacagcag 780 cagggggatc tgggcctggg caccccagac cagaagccct tccagggcct ggagagccgc 840 acccagcagc cttcgctaac ccctctgtct actattaagg cctttgccac tcagtcgggc 900 tcccaggacc tgaaggccct caataccagc taccagtccc agctcatcaa acccagccgc 960 atgcgcaagt accccaaccg gcccagcaag acgccccccc acgaacgccc ttacgcttgc 1020 ccagtggagt cctgtgatcg ccgcttctcc cgcagcgaca acctggtgag acacatccgc 1080 atccacacag gccagaagcc cttccagtgc cgcatctgca tgagaaactt cagccgagag 1140 gataacttgc acactcacat ccgcacccac acaggcgaaa agcccttcgc ctgcgacatc 1200 tgtggaagaa agtttgcccg gagcgatgaa cttgtccgac ataccaagat ccacttgcgg 1260 cagaaggacc gcccttacgc ttgcccagtg gagtcctgtg atcgccgctt ctcccaatca 1320 gggaatctga ctgagcacat ccgcatccac acaggccaga agcccttcca gtgccgcatc 1380 tgcatgagaa acttcagcac aagtggacat ctggtacgcc acatccgcac ccacacaggc 1440 gaaaagccct tcgcctgcga catctgtgga agaaagtttg cccagaatag taccctgacc 1500 gaacatacca agatccactt gcggcagaag gacaagaaag cagacaaaag tgttgtggct 1560 agctcggcca cctcctctct ctcttcctac ccgtccccgg ttgctacctc ttacccgtcc 1620 ccggttacta cctcttatcc atccccggcc accacctcat acccatcccc tgtgcccacc 1680 tccttctcct ctcccggctc ctcgacctac ccatcccctg tgcacagtgg cttcccctcc 1740 ccgtcggtgg ccaccacgta ctcctctgtt ccccctgctt tcccggccca ggtcagcagc 1800 ttcccttcct cagctgtcac caactccttc agcgcctcca cagggctttc ggacatgaca 1860 gcaacctttt ctcccaggac aattgaaatt tgc 1893 <![CDATA[<210> 446]]> <![CDATA[<211> 1740]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成]]>多核苷酸 <![CDATA[<400> 446]]> atggccgccg accacctgat gctcgccgag ggctaccgcc tggtgcagag gccgccgtcc 60 gccgccgccg cccatggccc tcatgcgctc cggactctgc cgccgtacgc gggcccgggc 120 ctggacagtg ggctgaggcc gcggggggct ccgctggggc cgccgccgcc ccgccaaccc 180 ggggccctgg cgtacggggc cttcgggccg ccgtcctcct tccagccctt tccggccgtg 240 cctccgccgg ccgcgggcat cgcgcacctg cagcctgtgg cgacgccgta ccccggccgc 300 gcggccgcgc cccccaacgc tccgggaggc cccccgggcc cgcagccggc cccaagcgcc 360 gcagccccgc cgccgcccgc gcacgccctg ggcggcatgg acgccgaact catcgacgag 420 gaggcgctga cgtcgctgga gctggagctg gggctgcacc gcgtgcgcga gctgcccgag 480 ctgttcctgg gccagagcga gttcgactgc ttctcggact tggggtccgc gccgcccgcc 540 ggctccgtga gctgcggtgg ttctggtggt ggttctggtc agtcccagct catcaaaccc 600 agccgcatgc gcaagtaccc caaccggccc agcaagacgc ccccccacga acgcccttac 660 gcttgcccag tggagtcctg tgatcgccgc ttctcccgca gcgacaacct ggtgagacac 720 atccgcatcc acacaggcca gaagcccttc cagtgccgca tctgcatgag aaacttcagc 780 cgagaggata acttgcacac tcacatccgc acccacacag gcgaaaagcc cttcgcctgc 840 gacatctgtg gaagaaagtt tgcccggagc gatgaacttg tccgacatac caagatccac 900 ttgcggcaga aggaccgccc ttacgcttgc ccagtggagt cctgtgatcg ccgcttctcc 960 caatcaggga atctgactga gcacatccgc atccacacag gccagaagcc cttccagtgc 1020 cgcatctgca tgagaaactt cagcacaagt ggacatctgg tacgccacat ccgcacccac 1080 acaggcgaaa agcccttcgc ctgcgacatc tgtggaagaa agtttgccca gaatagtacc 1140 ctgaccgaac ataccaagat ccacttgcgg cagaaggaca agctcgagat ggccgaccac 1200 ctgatgctcg ccgagggcta ccgcctggtg cagaggccgc cgtccgccgc cgccgcccat 1260 ggccctcatg cgctccggac tctgccgccg tacgcgggcc cgggcctgga cagtgggctg 1320 aggccgcggg gggctccgct ggggccgccg ccgccccgcc aacccggggc cctggcgtac 1380 ggggccttcg ggccgccgtc ctccttccag ccctttccgg ccgtgcctcc gccggccgcg 1440 ggcatcgcgc acctgcagcc tgtggcgacg ccgtaccccg gccgcgcggc cgcgcccccc 1500 aacgctccgg gaggcccccc gggcccgcag ccggccccaa gcgccgcagc cccgccgccg 1560 cccgcgcacg ccctgggcgg catggacgcc gaactcatcg acgaggaggc gctgacgtcg 1620 ctggagctgg agctggggct gcaccgcgtg cgcgagctgc ccgagctgtt cctgggccag 1680 agcgagttcg actgcttctc ggacttgggg tccgcgccgc ccgccggctc cgtgagctgc 1740 <![CDATA[<210> 447]]> <![CDATA[<211> 1881]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 447]]> atggccgcgg ccaaggccga gatgcagctg atgtccccgc tgcagatctc tgacccgttc 60 ggatcctttc ctcactcgcc caccatggac aactacccta agctggagga gatgatgctg 120 ctgagcaacg gggctcccca gttcctcggc gccgccgggg ccccagaggg cagcggcagc 180 aacagcagca gcagcagcag cgggggcggt ggaggcggcg ggggcggcag caacagcagc 240 agcagcagca gcaccttcaa ccctcaggcg gacacgggcg agcagcccta cgagcacctg 300 accgcagagt cttttcctga catctctctg aacaacgaga aggtgctggt ggagaccagt 360 taccccagcc aaaccactcg actgcccccc atcacctata ctggccgctt ttccctggag 420 cctgcaccca acagtggcaa caccttgtgg cccgagcccc tcttcagctt ggtcagtggc 480 ctagtgagca tgaccaaccc accggcctcc tcgtcctcag caccatctcc agcggcctcc 540 tccgcctccg cctcccagag cccacccctg agctgcgcag tgccatccaa cgacagcagt 600 cccatttact cagcggcacc caccttcccc acgccgaaca ctgacatttt ccctgagcca 660 caaagccagg ccttcccggg ctcggcaggg acagcgctcc agtacccgcc tcctgcctac 720 cctgccgcca agggtggctt ccaggttccc atgatccccg actacctgtt tccacagcag 780 cagggggatc tgggcctggg caccccagac cagaagccct tccagggcct ggagagccgc 840 acccagcagc cttcgctaac ccctctgtct actattaagg cctttgccac tcagtcgggc 900 tcccaggacc tgaaggccct caataccagc taccagtccc agctcatcaa acccagccgc 960 atgcgcaagt accccaaccg gcccagcaag acgccccccc acgaacgccc ttacgcttgc 1020 ccagtggagt cctgtgatcg ccgcttctcc cgctcagaca acctcgttcg acacatccgc 1080 atccacacag gccagaagcc cttccagtgc cgcatctgca tgagaaactt cagccaccgg 1140 actacactca cgaaccacat ccgcacccac acaggcgaaa agcccttcgc ctgcgacatc 1200 tgtggaagaa agtttgccag agaagacaat ctccatactc acatccggac acacacggga 1260 gagaagccat tcgcatgtga tatatgtggg agaaagttct ccaccagcca ttctctcact 1320 gaacacatcc gcatccacac aggccagaag cccttccagt gccgcatctg catgagaaac 1380 ttcagccagt ctagctcact ggtgaggcac atccgcaccc acacaggcga aaagcccttc 1440 gcctgcgaca tctgtggaag aaagtttgcc agggaggata acctgcatac gcataccaag 1500 atccacttgc ggcagaagga caagaaagca gacaaaagtg ttgtggctag ctcggccacc 1560 tcctctctct cttcctaccc gtccccggtt gctacctctt acccgtcccc ggttactacc 1620 tcttatccat ccccggccac cacctcatac ccatcccctg tgcccacctc cttctcctct 1680 cccggctcct cgacctaccc atcccctgtg cacagtggct tcccctcccc gtcggtggcc 1740 accacgtact cctctgttcc ccctgctttc ccggcccagg tcagcagctt cccttcctca 1800 gctgtcacca actccttcag cgcctccaca gggctttcgg acatgacagc aaccttttct 1860 cccaggacaa ttgaaatttg c 1881 <![CDATA[<210> 448]]> <![CDATA[<211> 1182]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 448]]> atggccgccg accacctgat gctcgccgag ggctaccgcc tggtgcagag gccgccgtcc 60 gccgccgccg cccatggccc tcatgcgctc cggactctgc cgccgtacgc gggcccgggc 120 ctggacagtg ggctgaggcc gcggggggct ccgctggggc cgccgccgcc ccgccaaccc 180 ggggccctgg cgtacggggc cttcgggccg ccgtcctcct tccagccctt tccggccgtg 240 cctccgccgg ccgcgggcat cgcgcacctg cagcctgtgg cgacgccgta ccccggccgc 300 gcggccgcgc cccccaacgc tccgggaggc cccccgggcc cgcagccggc cccaagcgcc 360 gcagccccgc cgccgcccgc gcacgccctg ggcggcatgg acgccgaact catcgacgag 420 gaggcgctga cgtcgctgga gctggagctg gggctgcacc gcgtgcgcga gctgcccgag 480 ctgttcctgg gccagagcga gttcgactgc ttctcggact tggggtccgc gccgcccgcc 540 ggctccgtga gctgcggtgg ttctggtggt ggttctggtc agtcccagct catcaaaccc 600 agccgcatgc gcaagtaccc caaccggccc agcaagacgc ccccccacga acgcccttac 660 gcttgcccag tggagtcctg tgatcgccgc ttctcccgca gcgacaacct ggtgagacac 720 atccgcatcc acacaggcca gaagcccttc cagtgccgca tctgcatgag aaacttcagc 780 cgagaggata acttgcacac tcacatccgc acccacacag gcgaaaagcc cttcgcctgc 840 gacatctgtg gaagaaagtt tgcccggagc gatgaacttg tccgacatac caagatccac 900 ttgcggcaga aggaccgccc ttacgcttgc ccagtggagt cctgtgatcg ccgcttctcc 960 caatcaggga atctgactga gcacatccgc atccacacag gccagaagcc cttccagtgc 1020 cgcatctgca tgagaaactt cagcacaagt ggacatctgg tacgccacat ccgcacccac 1080 acaggcgaaa agcccttcgc ctgcgacatc tgtggaagaa agtttgccca gaatagtacc 1140 ctgaccgaac ataccaagat ccacttgcgg cagaaggaca ag 1182 <![CDATA[<210> 449]]> <![CDATA[<211> 1740]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 449]]> atggccgccg accacctgat gctcgccgag ggctaccgcc tggtgcagag gccgccgtcc 60 gccgccgccg cccatggccc tcatgcgctc cggactctgc cgccgtacgc gggcccgggc 120 ctggacagtg ggctgaggcc gcggggggct ccgctggggc cgccgccgcc ccgccaaccc 180 ggggccctgg cgtacggggc cttcgggccg ccgtcctcct tccagccctt tccggccgtg 240 cctccgccgg ccgcgggcat cgcgcacctg cagcctgtgg cgacgccgta ccccggccgc 300 gcggccgcgc cccccaacgc tccgggaggc cccccgggcc cgcagccggc cccaagcgcc 360 gcagccccgc cgccgcccgc gcacgccctg ggcggcatgg acgccgaact catcgacgag 420 gaggcgctga cgtcgctgga gctggagctg gggctgcacc gcgtgcgcga gctgcccgag 480 ctgttcctgg gccagagcga gttcgactgc ttctcggact tggggtccgc gccgcccgcc 540 ggctccgtga gctgcggtgg ttctggtggt ggttctggtc agtcccagct catcaaaccc 600 agccgcatgc gcaagtaccc caaccggccc agcaagacgc ccccccacga acgcccttac 660 gcttgcccag tggagtcctg tgatcgccgc ttctcccgct cagacaacct cgttcgacac 720 atccgcatcc acacaggcca gaagcccttc cagtgccgca tctgcatgag aaacttcagc 780 caccggacta cactcacgaa ccacatccgc acccacacag gcgaaaagcc cttcgcctgc 840 gacatctgtg gaagaaagtt tgccagagaa gacaatctcc atactcatac caagatccac 900 ttgcggcaga aggaccgccc ttacgcttgc ccagtggagt cctgtgatcg ccgcttctcc 960 accagccatt ctctcactga acacatccgc atccacacag gccagaagcc cttccagtgc 1020 cgcatctgca tgagaaactt cagccagtct agctcactgg tgaggcacat ccgcacccac 1080 acaggcgaaa agcccttcgc ctgcgacatc tgtggaagaa agtttgccag ggaggataac 1140 ctgcatacgc ataccaagat ccacttgcgg cagaaggaca agctcgagat ggccgaccac 1200 ctgatgctcg ccgagggcta ccgcctggtg cagaggccgc cgtccgccgc cgccgcccat 1260 ggccctcatg cgctccggac tctgccgccg tacgcgggcc cgggcctgga cagtgggctg 1320 aggccgcggg gggctccgct ggggccgccg ccgccccgcc aacccggggc cctggcgtac 1380 ggggccttcg ggccgccgtc ctccttccag ccctttccgg ccgtgcctcc gccggccgcg 1440 ggcatcgcgc acctgcagcc tgtggcgacg ccgtaccccg gccgcgcggc cgcgcccccc 1500 aacgctccgg gaggcccccc gggcccgcag ccggccccaa gcgccgcagc cccgccgccg 1560 cccgcgcacg ccctgggcgg catggacgcc gaactcatcg acgaggaggc gctgacgtcg 1620 ctggagctgg agctggggct gcaccgcgtg cgcgagctgc ccgagctgtt cctgggccag 1680 agcgagttcg actgcttctc ggacttgggg tccgcgccgc ccgccggctc cgtgagctgc 1740 <![CDATA[<210> 450]]> <![CDATA[<211> 1182]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 450]]> atggccgccg accacctgat gctcgccgag ggctaccgcc tggtgcagag gccgccgtcc 60 gccgccgccg cccatggccc tcatgcgctc cggactctgc cgccgtacgc gggcccgggc 120 ctggacagtg ggctgaggcc gcggggggct ccgctggggc cgccgccgcc ccgccaaccc 180 ggggccctgg cgtacggggc cttcgggccg ccgtcctcct tccagccctt tccggccgtg 240 cctccgccgg ccgcgggcat cgcgcacctg cagcctgtgg cgacgccgta ccccggccgc 300 gcggccgcgc cccccaacgc tccgggaggc cccccgggcc cgcagccggc cccaagcgcc 360 gcagccccgc cgccgcccgc gcacgccctg ggcggcatgg acgccgaact catcgacgag 420 gaggcgctga cgtcgctgga gctggagctg gggctgcacc gcgtgcgcga gctgcccgag 480 ctgttcctgg gccagagcga gttcgactgc ttctcggact tggggtccgc gccgcccgcc 540 ggctccgtga gctgcggtgg ttctggtggt ggttctggtc agtcccagct catcaaaccc 600 agccgcatgc gcaagtaccc caaccggccc agcaagacgc ccccccacga acgcccttac 660 gcttgcccag tggagtcctg tgatcgccgc ttctcccgct cagacaacct cgttcgacac 720 atccgcatcc acacaggcca gaagcccttc cagtgccgca tctgcatgag aaacttcagc 780 caccggacta cactcacgaa ccacatccgc acccacacag gcgaaaagcc cttcgcctgc 840 gacatctgtg gaagaaagtt tgccagagaa gacaatctcc atactcatac caagatccac 900 ttgcggcaga aggaccgccc ttacgcttgc ccagtggagt cctgtgatcg ccgcttctcc 960 accagccatt ctctcactga acacatccgc atccacacag gccagaagcc cttccagtgc 1020 cgcatctgca tgagaaactt cagccagtct agctcactgg tgaggcacat ccgcacccac 1080 acaggcgaaa agcccttcgc ctgcgacatc tgtggaagaa agtttgccag ggaggataac 1140 ctgcatacgc ataccaagat ccacttgcgg cagaaggaca ag 1182 <![CDATA[<210> 451]]> <![CDATA[<211> 1893]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 451]]> atggccgcgg ccaaggccga gatgcagctg atgtccccgc tgcagatctc tgacccgttc 60 ggatcctttc ctcactcgcc caccatggac aactacccta agctggagga gatgatgctg 120 ctgagcaacg gggctcccca gttcctcggc gccgccgggg ccccagaggg cagcggcagc 180 aacagcagca gcagcagcag cgggggcggt ggaggcggcg ggggcggcag caacagcagc 240 agcagcagca gcaccttcaa ccctcaggcg gacacgggcg agcagcccta cgagcacctg 300 accgcagagt cttttcctga catctctctg aacaacgaga aggtgctggt ggagaccagt 360 taccccagcc aaaccactcg actgcccccc atcacctata ctggccgctt ttccctggag 420 cctgcaccca acagtggcaa caccttgtgg cccgagcccc tcttcagctt ggtcagtggc 480 ctagtgagca tgaccaaccc accggcctcc tcgtcctcag caccatctcc agcggcctcc 540 tccgcctccg cctcccagag cccacccctg agctgcgcag tgccatccaa cgacagcagt 600 cccatttact cagcggcacc caccttcccc acgccgaaca ctgacatttt ccctgagcca 660 caaagccagg ccttcccggg ctcggcaggg acagcgctcc agtacccgcc tcctgcctac 720 cctgccgcca agggtggctt ccaggttccc atgatccccg actacctgtt tccacagcag 780 cagggggatc tgggcctggg caccccagac cagaagccct tccagggcct ggagagccgc 840 acccagcagc cttcgctaac ccctctgtct actattaagg cctttgccac tcagtcgggc 900 tcccaggacc tgaaggccct caataccagc taccagtccc agctcatcaa acccagccgc 960 atgcgcaagt accccaaccg gcccagcaag acgccccccc acgaacgccc ttacgcttgc 1020 ccagtggagt cctgtgatcg ccgcttctcc cgcagcgaca acctggtgag acacatccgc 1080 atccacacag gccagaagcc cttccagtgc cgcatctgca tgagaaactt cagccgagag 1140 gataacttgc acactcacat ccgcacccac acaggcgaaa agcccttcgc ctgcgacatc 1200 tgtggaagaa agtttgcccg gagcgatgaa cttgtccgac ataccaagat ccacttgcgg 1260 cagaaggacc gcccttacgc ttgcccagtg gagtcctgtg atcgccgctt ctcccaatca 1320 gggaatctga ctgagcacat ccgcatccac acaggccaga agcccttcca gtgccgcatc 1380 tgcatgagaa acttcagcac aagtggacat ctggtacgcc acatccgcac ccacacaggc 1440 gaaaagccct tcgcctgcga catctgtgga agaaagtttg cccagaatag taccctgacc 1500 gaacatacca agatccactt gcggcagaag gacaagaaag cagacaaaag tgttgtggct 1560 agctcggcca cctcctctct ctcttcctac ccgtccccgg ttgctacctc ttacccgtcc 1620 ccggttacta cctcttatcc atccccggcc accacctcat acccatcccc tgtgcccacc 1680 tccttctcct ctcccggctc ctcgacctac ccatcccctg tgcacagtgg cttcccctcc 1740 ccgtcggtgg ccaccacgta ctcctctgtt ccccctgctt tcccggccca ggtcagcagc 1800 ttcccttcct cagctgtcac caactccttc agcgcctcca cagggctttc ggacatgaca 1860 gcaacctttt ctcccaggac aattgaaatt tgc 1893 <![CDATA[<210> 452]]> <![CDATA[<211> 1881]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 452]]> atggccgcgg ccaaggccga gatgcagctg atgtccccgc tgcagatctc tgacccgttc 60 ggatcctttc ctcactcgcc caccatggac aactacccta agctggagga gatgatgctg 120 ctgagcaacg gggctcccca gttcctcggc gccgccgggg ccccagaggg cagcggcagc 180 aacagcagca gcagcagcag cgggggcggt ggaggcggcg ggggcggcag caacagcagc 240 agcagcagca gcaccttcaa ccctcaggcg gacacgggcg agcagcccta cgagcacctg 300 accgcagagt cttttcctga catctctctg aacaacgaga aggtgctggt ggagaccagt 360 taccccagcc aaaccactcg actgcccccc atcacctata ctggccgctt ttccctggag 420 cctgcaccca acagtggcaa caccttgtgg cccgagcccc tcttcagctt ggtcagtggc 480 ctagtgagca tgaccaaccc accggcctcc tcgtcctcag caccatctcc agcggcctcc 540 tccgcctccg cctcccagag cccacccctg agctgcgcag tgccatccaa cgacagcagt 600 cccatttact cagcggcacc caccttcccc acgccgaaca ctgacatttt ccctgagcca 660 caaagccagg ccttcccggg ctcggcaggg acagcgctcc agtacccgcc tcctgcctac 720 cctgccgcca agggtggctt ccaggttccc atgatccccg actacctgtt tccacagcag 780 cagggggatc tgggcctggg caccccagac cagaagccct tccagggcct ggagagccgc 840 acccagcagc cttcgctaac ccctctgtct actattaagg cctttgccac tcagtcgggc 900 tcccaggacc tgaaggccct caataccagc taccagtccc agctcatcaa acccagccgc 960 atgcgcaagt accccaaccg gcccagcaag acgccccccc acgaacgccc ttacgcttgc 1020 ccagtggagt cctgtgatcg ccgcttctcc cgcagcgaca acctggtgag acacatccgc 1080 atccacacag gccagaagcc cttccagtgc cgcatctgca tgagaaactt cagccgagag 1140 gataacttgc acactcacat ccgcacccac acaggcgaaa agcccttcgc ctgcgacatc 1200 tgtggaagaa agtttgcccg gagcgatgaa cttgtccgac acatccggac acacacggga 1260 gagaagccat tcgcatgtga tatatgtggg agaaagttct cccaatcagg gaatctgact 1320 gagcacatcc gcatccacac aggccagaag cccttccagt gccgcatctg catgagaaac 1380 ttcagcacaa gtggacatct ggtacgccac atccgcaccc acacaggcga aaagcccttc 1440 gcctgcgaca tctgtggaag aaagtttgcc cagaatagta ccctgaccga acataccaag 1500 atccacttgc ggcagaagga caagaaagca gacaaaagtg ttgtggctag ctcggccacc 1560 tcctctctct cttcctaccc gtccccggtt gctacctctt acccgtcccc ggttactacc 1620 tcttatccat ccccggccac cacctcatac ccatcccctg tgcccacctc cttctcctct 1680 cccggctcct cgacctaccc atcccctgtg cacagtggct tcccctcccc gtcggtggcc 1740 accacgtact cctctgttcc ccctgctttc ccggcccagg tcagcagctt cccttcctca 1800 gctgtcacca actccttcag cgcctccaca gggctttcgg acatgacagc aaccttttct 1860 cccaggacaa ttgaaatttg c 1881 <![CDATA[<210> 453]]> <![CDATA[<211> 1881]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人工序列]]> <![CDATA[<220>]]> <![CDATA[<223> 人工序列之描述:合成多核苷酸]]> <![CDATA[<400> 453]]> atggccgcgg ccaaggccga gatgcagctg atgtccccgc tgcagatctc tgacccgttc 60 ggatcctttc ctcactcgcc caccatggac aactacccta agctggagga gatgatgctg 120 ctgagcaacg gggctcccca gttcctcggc gccgccgggg ccccagaggg cagcggcagc 180 aacagcagca gcagcagcag cgggggcggt ggaggcggcg ggggcggcag caacagcagc 240 agcagcagca gcaccttcaa ccctcaggcg gacacgggcg agcagcccta cgagcacctg 300 accgcagagt cttttcctga catctctctg aacaacgaga aggtgctggt ggagaccagt 360 taccccagcc aaaccactcg actgcccccc atcacctata ctggccgctt ttccctggag 420 cctgcaccca acagtggcaa caccttgtgg cccgagcccc tcttcagctt ggtcagtggc 480 ctagtgagca tgaccaaccc accggcctcc tcgtcctcag caccatctcc agcggcctcc 540 tccgcctccg cctcccagag cccacccctg agctgcgcag tgccatccaa cgacagcagt 600 cccatttact cagcggcacc caccttcccc acgccgaaca ctgacatttt ccctgagcca 660 caaagccagg ccttcccggg ctcggcaggg acagcgctcc agtacccgcc tcctgcctac 720 cctgccgcca agggtggctt ccaggttccc atgatccccg actacctgtt tccacagcag 780 cagggggatc tgggcctggg caccccagac cagaagccct tccagggcct ggagagccgc 840 acccagcagc cttcgctaac ccctctgtct actattaagg cctttgccac tcagtcgggc 900 tcccaggacc tgaaggccct caataccagc taccagtccc agctcatcaa acccagccgc 960 atgcgcaagt accccaaccg gcccagcaag acgccccccc acgaacgccc ttacgcttgc 1020 ccagtggagt cctgtgatcg ccgcttctcc cgctcagaca acctcgttcg acacatccgc 1080 atccacacag gccagaagcc cttccagtgc cgcatctgca tgagaaactt cagccaccgg 1140 actacactca cgaaccacat ccgcacccac acaggcgaaa agcccttcgc ctgcgacatc 1200 tgtggaagaa agtttgccag agaagacaat ctccatactc acatccggac acacacggga 1260 gagaagccat tcgcatgtga tatatgtggg agaaagttct ccaccagcca ttctctcact 1320 gaacacatcc gcatccacac aggccagaag cccttccagt gccgcatctg catgagaaac 1380 ttcagccagt ctagctcact ggtgaggcac atccgcaccc acacaggcga aaagcccttc 1440 gcctgcgaca tctgtggaag aaagtttgcc agggaggata acctgcatac gcataccaag 1500 atccacttgc ggcagaagga caagaaagca gacaaaagtg ttgtggctag ctcggccacc 1560 tcctctctct cttcctaccc gtccccggtt gctacctctt acccgtcccc ggttactacc 1620 tcttatccat ccccggccac cacctcatac ccatcccctg tgcccacctc cttctcctct 1680 cccggctcct cgacctaccc atcccctgtg cacagtggct tcccctcccc gtcggtggcc 1740 accacgtact cctctgttcc ccctgctttc ccggcccagg tcagcagctt cccttcctca 1800 gctgtcacca actccttcag cgcctccaca gggctttcgg acatgacagc aaccttttct 1860 cccaggacaa ttgaaatttg c 1881
Claims (24)
- 一種聚核苷酸,其包含編碼非天然存在之轉錄因子之核酸序列,該轉錄因子能夠上調細胞中內源性顆粒蛋白前體(PGRN)之表現,其中該非天然存在之轉錄因子包含DNA結合域、轉錄活化域(TAD)及核定位序列(NLS),其中該DNA結合域為包含以下之鋅指DNA結合域:(i)選自由SEQ ID NO: 171、SEQ ID NO: 412、SEQ ID NO: 413、SEQ ID NO: 415及SEQ ID NO: 416組成之群之胺基酸序列,或(ii)與選自由SEQ ID NO: 377及SEQ ID NO: 379組成之群之序列具有至少80%序列一致性之胺基酸序列。
- 如請求項1之聚核苷酸,其中該DNA結合域包含與選自由SEQ ID NO: 165、SEQ ID NO: 166、SEQ ID NO: 167、SEQ ID NO: 169、SEQ ID NO: 170及SEQ ID NO: 384組成之群之序列具有至少80%序列一致性之胺基酸序列。
- 如請求項1之聚核苷酸,其中該DNA結合域包含與選自由SEQ ID NO: 165、SEQ ID NO: 166、SEQ ID NO: 167、SEQ ID NO: 169、SEQ ID NO: 170、SEQ ID NO: 384、SEQ ID NO: 377及SEQ ID NO: 379組成之群之序列具有至少90%序列一致性之胺基酸序列。
- 如請求項1之聚核苷酸,其中該DNA結合域包含與選自由SEQ ID NO: 165、SEQ ID NO: 166、SEQ ID NO: 167、SEQ ID NO: 169、SEQ ID NO: 170、SEQ ID NO: 384、SEQ ID NO: 377及SEQ ID NO: 379組成之群之序列具有至少95%序列一致性之胺基酸序列。
- 如請求項1之聚核苷酸,其中該DNA結合域包含選自由SEQ ID NO: 165、SEQ ID NO: 166、SEQ ID NO: 167、SEQ ID NO: 169、SEQ ID NO: 170、SEQ ID NO: 384、SEQ ID NO: 377及SEQ ID NO: 379組成之群之序列。
- 如請求項1至5中任一項之聚核苷酸,其中該TAD係選自由以下組成之群:SEQ ID NO: 114、SEQ ID NO: 95、SEQ ID NO: 98、SEQ ID NO: 97、與SEQ ID NO: 114、95、98及97中之任一者具有至少80%序列一致性之序列、其功能片段及其任何組合。
- 如請求項6之聚核苷酸,其中該非天然存在之轉錄因子包含與選自由SEQ ID NO: 337、SEQ ID NO: 338、SEQ ID NO: 339及SEQ ID NO: 344組成之群之序列具有至少90%序列一致性之胺基酸序列。
- 如請求項6之聚核苷酸,其中該非天然存在之轉錄因子包含選自由SEQ ID NO: 337、SEQ ID NO: 338、SEQ ID NO: 339及SEQ ID NO: 344組成之群之胺基酸序列。
- 一種表現卡匣,其包含如請求項1至8中任一項之聚核苷酸,其中該表現卡匣包含可操作地連接於該編碼該非天然存在之轉錄因子之核酸序列的調節元件。
- 如請求項9之表現卡匣,其中該調節元件係選自由以下組成之群:內含子、增強子、啟動子、UTR、穩定性元件、WPRE序列、Kozak共同序列、轉譯後反應元件、微RNA結合位點、聚腺苷酸化(polyA)序列,或其任何組合。
- 如請求項10之表現卡匣,其中該調節元件包含與選自由SEQ ID NO: 178、SEQ ID NO: 179、SEQ ID NO: 182、SEQ ID NO: 183、SEQ ID NO: 184、SEQ ID NO: 185、其功能片段及其任何組合組成之群之序列具有至少80%序列一致性之核酸序列。
- 如請求項10之表現卡匣,其中該調節元件包含與選自由SEQ ID NO: 178、SEQ ID NO: 179、SEQ ID NO: 182、SEQ ID NO: 183、SEQ ID NO: 184、SEQ ID NO: 185、其功能片段及其任何組合組成之群之序列具有至少90%序列一致性之核酸序列。
- 如請求項10之表現卡匣,其中該調節元件係選自由SEQ ID NO: 178、SEQ ID NO: 179、SEQ ID NO: 182、SEQ ID NO: 183、SEQ ID NO: 184、SEQ ID NO: 185、其功能片段及其任何組合組成之群。
- 一種表現載體,其包含如請求項9至13中任一項之表現卡匣,其中該表現載體為質體、病毒載體或脂質體。
- 如請求項14之表現載體,其中該表現載體為病毒載體且該病毒載體為腺相關病毒(AAV)載體。
- 如請求項15之表現載體,其中該AAV載體係選自由AAV1、AAV2、AAV3、AAV4、AAV5、AAV6、AAV7、AAV8、AAV9、AAV10、AAV11、AAV12、rh10、禽類AAV、牛類AAV、犬類AAV、馬類AAV、靈長類AAV、綿羊類AAV、scAAV、scAAV1、scAAV2、scAAV5、scAAV8、scAAV9及其雜種(hybrid)組成之群。
- 一種醫藥組合物,其包含如請求項14至16中任一項之表現載體及一或多種醫藥學上可接受之賦形劑。
- 一種用於增加細胞中顆粒蛋白前體(GRN)表現量之活體外方法,其包含使該細胞與如請求項1至8中任一項之聚核苷酸、如請求項9至13中任一項之表現卡匣或如請求項14至16中任一項之表現載體接觸。
- 一種如請求項1至8中任一項之聚核苷酸、如請求項9至13中任一項之表現卡匣或如請求項14至16中任一項之表現載體之用途,其係用於製備增加細胞中GRN表現量之藥物。
- 一種如請求項1至8中任一項之聚核苷酸、如請求項9至13中任一項之表現卡匣或如請求項14至16中任一項之表現載體之用途,其係用於製備調節GRN表現量以治療與GRN相關之疾病或病症之藥物。
- 一種如請求項1至8中任一項之聚核苷酸、如請求項9至13中任一項之表現卡匣或如請求項14至16中任一項之表現載體之用途,其係用於製備治療與GRN相關之中樞神經系統病症之藥物。
- 一種如請求項1至8中任一項之聚核苷酸、如請求項9至13中任一項之表現卡匣或如請求項14至16中任一項之表現載體之用途,其係用於製備治療額顳葉型變性(FTD)、帕金森氏病、阿茲海默氏症或動脈粥樣硬化之藥物。
- 一種宿主細胞,其包含如請求項1至8中任一項之聚核苷酸或如請求項9至13中任一項之表現卡匣。
- 一種製備腺相關病毒(AAV)載體之方法,其包含: a. 在培養基中生產重組AAV病毒粒子之條件下培養如請求項23之宿主細胞; b. 自該宿主細胞之培養物收穫該培養基;及 c. 純化由該宿主細胞生產之AAV病毒粒子。
Applications Claiming Priority (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762593824P | 2017-12-01 | 2017-12-01 | |
US62/593,824 | 2017-12-01 | ||
US201762610014P | 2017-12-22 | 2017-12-22 | |
US62/610,014 | 2017-12-22 | ||
US201862618966P | 2018-01-18 | 2018-01-18 | |
US62/618,966 | 2018-01-18 | ||
US201862641806P | 2018-03-12 | 2018-03-12 | |
US62/641,806 | 2018-03-12 | ||
US201862646198P | 2018-03-21 | 2018-03-21 | |
US62/646,198 | 2018-03-21 | ||
US201862664814P | 2018-04-30 | 2018-04-30 | |
US201862664817P | 2018-04-30 | 2018-04-30 | |
US62/664,817 | 2018-04-30 | ||
US62/664,814 | 2018-04-30 | ||
WOPCT/US18/63498 | 2018-11-30 | ||
PCT/US2018/063498 WO2019109051A1 (en) | 2017-12-01 | 2018-11-30 | Engineered dna binding proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202421790A true TW202421790A (zh) | 2024-06-01 |
Family
ID=66664596
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111138440A TW202319538A (zh) | 2017-12-01 | 2018-12-03 | 工程化dna結合蛋白 |
TW113105374A TW202421790A (zh) | 2017-12-01 | 2018-12-03 | 工程化dna結合蛋白 |
TW107143330A TWI835761B (zh) | 2017-12-01 | 2018-12-03 | 工程化dna結合蛋白 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111138440A TW202319538A (zh) | 2017-12-01 | 2018-12-03 | 工程化dna結合蛋白 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW107143330A TWI835761B (zh) | 2017-12-01 | 2018-12-03 | 工程化dna結合蛋白 |
Country Status (15)
Country | Link |
---|---|
US (2) | US12083188B2 (zh) |
EP (1) | EP3717505A4 (zh) |
JP (3) | JP7401432B2 (zh) |
KR (1) | KR20200107949A (zh) |
CN (2) | CN118345115A (zh) |
AU (2) | AU2018375192B2 (zh) |
BR (1) | BR112020010883A2 (zh) |
CA (1) | CA3083765A1 (zh) |
CL (1) | CL2020001451A1 (zh) |
IL (1) | IL274926A (zh) |
MA (1) | MA50942A (zh) |
MX (1) | MX2020005561A (zh) |
SG (1) | SG11202004926WA (zh) |
TW (3) | TW202319538A (zh) |
WO (1) | WO2019109051A1 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3359685A1 (en) | 2015-10-09 | 2018-08-15 | University Of Southampton | Modulation of gene expression and screening for deregulated protein expression |
SG11201804443UA (en) | 2015-12-14 | 2018-06-28 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
CN118956965A (zh) * | 2017-05-19 | 2024-11-15 | 编码治疗公司 | 高活性调控元件 |
FI3673080T3 (fi) | 2017-08-25 | 2023-11-23 | Stoke Therapeutics Inc | Antisense-oligomeerejä häiriötilojen ja sairauksien hoitoon |
MX2020005561A (es) | 2017-12-01 | 2020-10-12 | Encoded Therapeutics Inc | Proteinas modificadas de union a adn. |
WO2019204766A1 (en) | 2018-04-19 | 2019-10-24 | The Regents Of The University Of California | Compositions and methods for gene editing |
MX2020011695A (es) | 2018-05-04 | 2021-02-26 | Stoke Therapeutics Inc | Métodos y composiciones para el tratamiento de la enfermedad por almacenamiento de éster de colesterilo. |
MX2021014460A (es) | 2019-05-29 | 2022-02-11 | Encoded Therapeutics Inc | Composiciones y metodos para la regulacion genica selectiva. |
JP2022548399A (ja) | 2019-09-23 | 2022-11-18 | オメガ セラピューティクス, インコーポレイテッド | 肝細胞核因子4-アルファ(HNF4α)遺伝子発現をモジュレートするための組成物および方法 |
GB201913974D0 (en) * | 2019-09-27 | 2019-11-13 | King S College London | Vector |
CN115397467A (zh) * | 2020-01-07 | 2022-11-25 | 住友制药株式会社 | Tau蛋白病的治疗剂 |
KR20230022409A (ko) | 2020-05-11 | 2023-02-15 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머 |
CN116096888A (zh) * | 2020-05-13 | 2023-05-09 | 豪夫迈·罗氏有限公司 | 靶向颗粒蛋白前体的寡核苷酸激动剂 |
WO2022020706A1 (en) * | 2020-07-24 | 2022-01-27 | University Of Massachusetts | Dna-binding domain transactivators and uses thereof |
US20240024372A1 (en) * | 2020-12-09 | 2024-01-25 | City Of Hope | Compounds and methods to treat cystic fibrosis |
CN115074389A (zh) * | 2022-06-13 | 2022-09-20 | 华南农业大学 | 稳定表达鸭坦布苏病毒ns1蛋白的细胞系的构建方法及其应用 |
WO2024145499A2 (en) * | 2022-12-29 | 2024-07-04 | Encoded Therapeutics, Inc. | Materials and methods for characterizing potency |
Family Cites Families (148)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
EP0770129B1 (en) | 1994-01-18 | 2005-11-23 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
ATE386131T1 (de) | 1994-04-13 | 2008-03-15 | Univ Rockefeller | Aav-vermittelte überbringung von dna in zellen des nervensystems |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
ATE524545T1 (de) | 1994-08-20 | 2011-09-15 | Gendaq Ltd | Verbesserungen bei oder im zusammenhang mit bindeproteinen zur erkennung von dna |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
WO1998046273A2 (en) | 1997-04-17 | 1998-10-22 | Paola Leone | Delivery system for gene therapy to the brain |
CA2205076A1 (en) | 1997-05-14 | 1998-11-14 | Jim Hu | Episomal expression cassettes for gene therapy |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
EP1060261B1 (en) | 1998-03-02 | 2010-05-05 | Massachusetts Institute of Technology | Poly zinc finger proteins with improved linkers |
US6303370B1 (en) | 1998-03-24 | 2001-10-16 | Mayo Foundation For Medical Education And Research | Tissue-specific regulatory elements |
CA2246005A1 (en) | 1998-10-01 | 2000-04-01 | Hsc Research And Development Limited Partnership | Hybrid genes for gene therapy in erythroid cells |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US20030104526A1 (en) * | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US6649371B1 (en) | 1999-06-11 | 2003-11-18 | Neurosearch A/S | Potassium channel KCNQ5 and sequences encoding the same |
US7329728B1 (en) * | 1999-10-25 | 2008-02-12 | The Scripps Research Institute | Ligand activated transcriptional regulator proteins |
WO2001036620A2 (en) | 1999-11-16 | 2001-05-25 | Genzyme Corporation | Vectors and transgenies with regulatory elements for gene delivery to the liver |
EP1103610A1 (en) | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
WO2001038564A2 (en) | 1999-11-26 | 2001-05-31 | Mcgill University | Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
AU776576B2 (en) | 1999-12-06 | 2004-09-16 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
JP5047437B2 (ja) | 2000-02-08 | 2012-10-10 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 薬物の発見のための細胞 |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
DE60126483T2 (de) | 2000-04-28 | 2007-12-06 | Sangamo BioSciences, Inc., Richmond | Gezielte Modifikation der Chromatinstruktur |
FR2808803B1 (fr) | 2000-05-11 | 2004-12-10 | Agronomique Inst Nat Rech | Cellules es modifiees et gene specifique de cellules es |
AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
CA2411069A1 (en) | 2000-06-07 | 2001-12-13 | Ortho-Mcneil Pharmaceutical, Inc. | The human voltage gated sodium channel .beta.-1a subunit and methods of use |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
US6919204B2 (en) | 2000-09-29 | 2005-07-19 | Sangamo Biosciences, Inc. | Modulation of gene expression using localization domains |
USH2191H1 (en) | 2000-10-24 | 2007-06-05 | Snp Consortium | Identification and mapping of single nucleotide polymorphisms in the human genome |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
AU2002243645A1 (en) * | 2001-01-22 | 2002-07-30 | Sangamo Biosciences, Inc. | Zinc finger proteins for dna binding and gene regulation in plants |
US20030051266A1 (en) | 2001-02-14 | 2003-03-13 | Serafini Tito Andrew | Collections of transgenic animal lines (living library) |
AU2002254903B2 (en) * | 2001-02-21 | 2007-06-21 | The Scripps Research Institute | Zinc finger binding domains for nucleotide sequence ANN |
US7067617B2 (en) | 2001-02-21 | 2006-06-27 | The Scripps Research Institute | Zinc finger binding domains for nucleotide sequence ANN |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
AUPR492201A0 (en) | 2001-05-10 | 2001-06-07 | Bionomics Limited | Novel mutation |
WO2003004660A1 (en) | 2001-07-03 | 2003-01-16 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Methods of administering vectors to synaptically connected neurons |
JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Cnnについての亜鉛フィンガー結合ドメイン |
US6998118B2 (en) | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
EP1481087A4 (en) * | 2002-02-07 | 2005-12-21 | Scripps Research Inst | LIBRARIES IN FINGER GLOVE |
CA2474751A1 (en) | 2002-02-25 | 2003-09-04 | Vanderbilt University | Expression system for human brain-specific voltage-gated sodium channel, type 1 |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
EP2500440B1 (en) | 2002-12-20 | 2015-12-16 | Celera Corporation | Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof |
EP1590467B1 (en) | 2003-01-28 | 2009-10-21 | Ludwig Aigner | Use of regulatory sequences for specific, transient expression in neuronal determined cells |
US20040258666A1 (en) | 2003-05-01 | 2004-12-23 | Passini Marco A. | Gene therapy for neurometabolic disorders |
EP2277996B1 (en) | 2003-05-21 | 2014-09-03 | Genzyme Corporation | Methods for producing preparations of recombinant AAV virions substantially free of empty capsids |
US7094600B2 (en) | 2003-06-26 | 2006-08-22 | The Research Foundation Of State University Of New York | Screen for sodium channel modulators |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
JP2008504803A (ja) | 2004-01-09 | 2008-02-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 遺伝子発現の細胞型特異的パターン |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
AU2005233583B2 (en) | 2004-04-08 | 2011-02-03 | Sangamo Therapeutics, Inc. | Methods and compositions for modulating cardiac contractility |
ES2315859T3 (es) | 2004-04-08 | 2009-04-01 | Sangamo Biosciences, Inc. | Metodos y composiciones para tratar afecciones neuropaticas y neurodegenerativas. |
WO2005100392A2 (en) | 2004-04-08 | 2005-10-27 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
JP2007532639A (ja) | 2004-04-14 | 2007-11-15 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 神経細胞への遺伝子送達方法 |
TWI293307B (en) | 2004-09-30 | 2008-02-11 | Ind Tech Res Inst | A liver-specific chimeric regulatory sequence and use thereof |
WO2006094106A2 (en) | 2005-02-28 | 2006-09-08 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
EP3002330A1 (en) | 2005-05-27 | 2016-04-06 | Ospedale San Raffaele S.r.l. | Gene vector |
JP2009504156A (ja) | 2005-08-11 | 2009-02-05 | ザ スクリップス リサーチ インスティテュート | Cnnに対するジンクフィンガー結合ドメイン |
EP1783645A1 (en) | 2005-11-08 | 2007-05-09 | Actigenics | Methods for the identification of microRNA and their applications in research and human health |
MX352337B (es) | 2005-12-13 | 2017-11-21 | Univ Kyoto | Factor de reprogramacion nuclear. |
US20070161031A1 (en) | 2005-12-16 | 2007-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Functional arrays for high throughput characterization of gene expression regulatory elements |
JP2009519710A (ja) | 2005-12-16 | 2009-05-21 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 遺伝子発現調節エレメントのハイスループットでの特徴付けのための機能性アレイ |
JP4144637B2 (ja) | 2005-12-26 | 2008-09-03 | セイコーエプソン株式会社 | 印刷材収容体、基板、印刷装置および印刷材収容体を準備する方法 |
CN101389290A (zh) | 2006-01-20 | 2009-03-18 | 加利福尼亚大学董事会 | 神经细胞的移植 |
US8685687B2 (en) | 2006-07-05 | 2014-04-01 | The Scripps Research Institute | Chimeric zinc finger recombinases optimized for catalysis by directed evolution |
EP2089398A2 (en) | 2006-10-25 | 2009-08-19 | Polyera Corporation | Organic semiconductor materials and methods of preparing and use thereof |
WO2008073303A2 (en) | 2006-12-07 | 2008-06-19 | Switchgear Genomics | Transcriptional regulatory elements of biological pathways, tools, and methods |
US8440461B2 (en) | 2007-03-23 | 2013-05-14 | Wisconsin Alumni Research Foundation | Reprogramming somatic cells using retroviral vectors comprising Oct-4 and Sox2 genes |
EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
EP2019143A1 (en) | 2007-07-23 | 2009-01-28 | Genethon | CNS gene delivery using peripheral administration of AAV vectors |
WO2009060316A2 (en) * | 2007-09-14 | 2009-05-14 | The Governors Of The University Of Alberta | Hepatitis b virus-binding polypeptides and methods of use thereof |
ITRM20070523A1 (it) | 2007-10-05 | 2009-04-06 | Consiglio Nazionale Ricerche | Acido nucleico codificante per una proteina regolatrice specifica della trascrizione dell'utrofina proteina da esso codificata e sue applicazioni |
WO2009094218A2 (en) | 2008-01-22 | 2009-07-30 | Chromocell Corporation | Novel cell lines expressing nav and methods using them |
WO2009137533A2 (en) | 2008-05-06 | 2009-11-12 | The Regents Of The University Of California | Ameliorating nervous systems disorders |
ES2546732T3 (es) | 2008-08-20 | 2015-09-28 | Brainco Biopharma, S.L. | STXBP1 como biomarcador psiquiátrico en un sistema de modelo murino y sus usos |
WO2010037143A1 (en) | 2008-09-29 | 2010-04-01 | The University Of Montana | Vectors and methods of treating brain seizures |
SI3444335T1 (sl) | 2009-06-16 | 2021-08-31 | Genzyme Corporation | Izboljšani postopki čiščenja vektorjev rekombinantnega AAV |
GB0911870D0 (en) | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
US8815779B2 (en) | 2009-09-16 | 2014-08-26 | SwitchGear Genomics, Inc. | Transcription biomarkers of biological responses and methods |
US20110135611A1 (en) | 2009-12-03 | 2011-06-09 | The J. David Gladstone Institutes | Methods for treating apolipoprotein e4-associated disorders |
US20110203007A1 (en) | 2010-02-16 | 2011-08-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis |
US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
JP5963743B2 (ja) | 2010-04-23 | 2016-08-03 | ユニバーシティ オブ マサチューセッツ | Cnsターゲティングaavベクターおよびその使用方法 |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
CN102959087B (zh) | 2010-05-03 | 2015-04-29 | 桑格摩生物科学股份有限公司 | 用于连接锌指模块的组合物 |
JP6023705B2 (ja) | 2010-06-23 | 2016-11-09 | カッパーアールエヌエー,インコーポレイテッド | ナトリウムチャネル、電位依存性、αサブユニット(SCNA)に対する天然アンチセンス転写物の阻害によるSCNA関連疾患の治療 |
CN107828820B (zh) | 2010-10-27 | 2022-06-07 | 学校法人自治医科大学 | 用于向神经系统细胞导入基因的腺相关病毒粒子 |
EP2635686B1 (en) | 2010-11-05 | 2018-03-28 | The Regents of The University of California | Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord |
DK2638163T3 (en) | 2010-11-12 | 2017-07-24 | Massachusetts Gen Hospital | POLYCOMB-ASSOCIATED NON-CODING RNAs |
WO2012087983A1 (en) | 2010-12-20 | 2012-06-28 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
US10392632B2 (en) | 2011-02-14 | 2019-08-27 | The Children's Hospital Of Philadelphia | AAV8 vector with enhanced functional activity and methods of use thereof |
WO2013033627A2 (en) | 2011-09-01 | 2013-03-07 | The Regents Of The University Of California | Diagnosis and treatment of arthritis using epigenetics |
CA2847811C (en) | 2011-09-06 | 2019-10-22 | Curna, Inc. | Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules |
KR20120087860A (ko) | 2012-02-03 | 2012-08-07 | 주식회사 툴젠 | 신규한 징크 핑거 뉴클레아제 및 이의 용도 |
JP6373763B2 (ja) | 2012-02-17 | 2018-08-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | Aavベクター成分、及び、細胞、臓器並びに組織への遺伝子導入のための方法 |
AU2013201287B2 (en) | 2012-03-06 | 2015-05-14 | Duke University | Synthetic regulation of gene expression |
WO2013155222A2 (en) | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Brain-specific enhancers for cell-based therapy |
PL3494997T3 (pl) * | 2012-07-25 | 2020-04-30 | The Broad Institute, Inc. | Indukowalne białka wiążące dna i narzędzia perturbacji genomu oraz ich zastosowania |
CA2922005A1 (en) | 2012-09-27 | 2014-04-03 | Population Diagnostics, Inc. | Methods and compositions for screening and treating developmental disorders |
US11065311B2 (en) | 2012-10-25 | 2021-07-20 | Denovo Biopharma Llc | Retroviral vector with mini-promoter cassette |
CN105612253A (zh) | 2013-03-15 | 2016-05-25 | 费城儿童医院 | 含有填充者/填充物多核苷酸序列的载体及其制备方法 |
TW201514202A (zh) * | 2013-04-03 | 2015-04-16 | Aliophtha Ag | 經工程改造以克服內體捕獲之人工轉錄因子 |
TW201514201A (zh) * | 2013-04-03 | 2015-04-16 | Aliophtha Ag | 調控核受體之人工轉錄因子及其治療用途 |
RU2692251C2 (ru) | 2013-05-15 | 2019-06-24 | Риджентс Оф Зэ Юниверсити Оф Миннесота | Опосредованный аденоассоциированным вирусом перенос генов в центральную нервную систему |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
PT3060237T (pt) * | 2013-10-25 | 2021-11-09 | Univ Wayne State | Proteína de reprogramação modificada para utilização no tratamento de um cancro |
CA2942762C (en) | 2014-03-18 | 2023-10-17 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
WO2015153760A2 (en) * | 2014-04-01 | 2015-10-08 | Sangamo Biosciences, Inc. | Methods and compositions for prevention or treatment of a nervous system disorder |
EP3151846A4 (en) | 2014-06-05 | 2017-12-27 | Sangamo BioSciences, Inc. | Methods and compositions for nuclease design |
WO2016016119A1 (en) | 2014-07-26 | 2016-02-04 | Consiglio Nazionale Delle Ricerche | Compositions and methods for treatment of muscular dystrophy |
JP6865167B2 (ja) | 2014-12-17 | 2021-04-28 | フンダシオン パラ ラ インベスティガシオン メディカ アプリカダ | ウィルソン病の処置に使用するための核酸構築物及び遺伝子治療ベクター |
TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
CA3019315A1 (en) | 2015-04-23 | 2016-10-27 | University Of Massachusetts | Modulation of aav vector transgene expression |
CN104846015B (zh) | 2015-05-27 | 2018-03-27 | 深圳先进技术研究院 | 特异性兴奋伏隔核中的gaba能神经元的组合物及其在改善精神分裂症异样行为中的应用 |
US20180346531A1 (en) * | 2015-09-15 | 2018-12-06 | Regents Of The University Of California | Compositions and methods for delivering biotherapeutics |
US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
EP3368065A4 (en) | 2015-10-29 | 2019-03-20 | Voyager Therapeutics, Inc. | DISTRIBUTION OF POLYNUCLEOTIDES FOR TARGETING THE CENTRAL NERVOUS SYSTEM |
SG11201804443UA (en) * | 2015-12-14 | 2018-06-28 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome |
AU2017227803B2 (en) * | 2016-03-02 | 2024-05-02 | Defne AMADO | Therapy for frontotemporal dementia |
EP3443081A4 (en) * | 2016-04-13 | 2019-10-30 | Duke University | CRISPR / CAS9-BASED REPRESSORS FOR IN VIVO SHUT-OFF OF GEN-TARGETS AND METHOD OF USE |
EP3510152A4 (en) | 2016-09-07 | 2020-04-29 | Flagship Pioneering, Inc. | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION |
JP2018088888A (ja) | 2016-12-06 | 2018-06-14 | 国立研究開発法人理化学研究所 | Scn1a遺伝子の発現増強法 |
CA3048044A1 (en) | 2016-12-30 | 2018-07-05 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating wilson's disease |
EP3579858A4 (en) | 2017-02-07 | 2020-12-23 | The Regents of The University of California | GENE THERAPY AGAINST HAPLOINSUFFICIENCY |
WO2018187363A1 (en) | 2017-04-03 | 2018-10-11 | Encoded Therapeutics, Inc. | Tissue selective transgene expression |
CN118956965A (zh) | 2017-05-19 | 2024-11-15 | 编码治疗公司 | 高活性调控元件 |
MX2020005561A (es) | 2017-12-01 | 2020-10-12 | Encoded Therapeutics Inc | Proteinas modificadas de union a adn. |
WO2019224864A1 (ja) | 2018-05-21 | 2019-11-28 | 国立研究開発法人理化学研究所 | Scn1a遺伝子の発現増強法とそれによるドラベ症候群の治療法 |
SG11202109362XA (en) | 2019-02-28 | 2021-09-29 | Encoded Therapeutics Inc | Compositions and methods for treating laminopathies |
MX2021014460A (es) | 2019-05-29 | 2022-02-11 | Encoded Therapeutics Inc | Composiciones y metodos para la regulacion genica selectiva. |
-
2018
- 2018-11-30 MX MX2020005561A patent/MX2020005561A/es unknown
- 2018-11-30 EP EP18884285.0A patent/EP3717505A4/en active Pending
- 2018-11-30 AU AU2018375192A patent/AU2018375192B2/en active Active
- 2018-11-30 CN CN202410447378.XA patent/CN118345115A/zh active Pending
- 2018-11-30 CN CN201880088375.4A patent/CN111727259B/zh active Active
- 2018-11-30 KR KR1020207018993A patent/KR20200107949A/ko active Pending
- 2018-11-30 JP JP2020529582A patent/JP7401432B2/ja active Active
- 2018-11-30 WO PCT/US2018/063498 patent/WO2019109051A1/en active Application Filing
- 2018-11-30 CA CA3083765A patent/CA3083765A1/en active Pending
- 2018-11-30 MA MA050942A patent/MA50942A/fr unknown
- 2018-11-30 SG SG11202004926WA patent/SG11202004926WA/en unknown
- 2018-11-30 BR BR112020010883-9A patent/BR112020010883A2/pt unknown
- 2018-12-03 TW TW111138440A patent/TW202319538A/zh unknown
- 2018-12-03 TW TW113105374A patent/TW202421790A/zh unknown
- 2018-12-03 TW TW107143330A patent/TWI835761B/zh active
-
2020
- 2020-05-25 IL IL274926A patent/IL274926A/en unknown
- 2020-05-28 US US16/886,129 patent/US12083188B2/en active Active
- 2020-05-29 CL CL2020001451A patent/CL2020001451A1/es unknown
-
2022
- 2022-09-14 JP JP2022145839A patent/JP7634507B2/ja active Active
-
2023
- 2023-12-20 AU AU2023285810A patent/AU2023285810A1/en active Pending
-
2024
- 2024-03-19 JP JP2024043454A patent/JP2024069591A/ja active Pending
- 2024-07-31 US US18/791,108 patent/US20240408242A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2020001451A1 (es) | 2020-11-06 |
TWI835761B (zh) | 2024-03-21 |
US12083188B2 (en) | 2024-09-10 |
CN111727259B (zh) | 2024-04-19 |
SG11202004926WA (en) | 2020-06-29 |
EP3717505A1 (en) | 2020-10-07 |
EP3717505A4 (en) | 2021-12-01 |
JP2021505133A (ja) | 2021-02-18 |
US20200397917A1 (en) | 2020-12-24 |
KR20200107949A (ko) | 2020-09-16 |
US20240408242A1 (en) | 2024-12-12 |
AU2023285810A1 (en) | 2024-01-18 |
JP2022171792A (ja) | 2022-11-11 |
CA3083765A1 (en) | 2019-06-06 |
MA50942A (fr) | 2020-10-07 |
JP2024069591A (ja) | 2024-05-21 |
TW201925474A (zh) | 2019-07-01 |
CN111727259A (zh) | 2020-09-29 |
AU2018375192B2 (en) | 2023-11-09 |
JP7634507B2 (ja) | 2025-02-21 |
AU2018375192A1 (en) | 2020-07-02 |
IL274926A (en) | 2020-07-30 |
WO2019109051A1 (en) | 2019-06-06 |
MX2020005561A (es) | 2020-10-12 |
BR112020010883A2 (pt) | 2020-11-10 |
TW202319538A (zh) | 2023-05-16 |
JP7401432B2 (ja) | 2023-12-19 |
CN118345115A (zh) | 2024-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW202421790A (zh) | 工程化dna結合蛋白 | |
KR102604159B1 (ko) | 조직 선택적 트랜스진 발현 | |
TW201920679A (zh) | 眼部疾病之細胞模式及用於眼部疾病的療法 | |
KR20220066225A (ko) | 선택적 유전자 조절을 위한 조성물 및 방법 | |
CN116685329B (zh) | 核酸构建体及其用于治疗脊髓性肌肉萎缩症的用途 | |
CN113710693A (zh) | Dna结合结构域反式激活因子及其用途 | |
KR20230002788A (ko) | 신피질 레이어 5 글루타메이트성 뉴런에서 유전자 발현을 선택적으로 조절하기 위한 인공 발현 작제물 | |
CN112639107B (zh) | 治疗clrn1相关的听力损失和/或视力损失的方法 | |
EA046157B1 (ru) | Композиции и способы селективной регуляции экспрессии генов | |
TWI872078B (zh) | 用於選擇性基因調節的組合物和方法 | |
TW202221119A (zh) | Dna結合域轉活化子及其用途 | |
CN117836420A (zh) | 重组tert编码病毒基因组和运载体 | |
EP4291220A2 (en) | Methods and materials for treating tdp-43 proteinopathies |